diff --git a/pharmacogenetics/pharmgkb_phenotypes.json b/pharmacogenetics/pharmgkb_phenotypes.json
index 04cb827..775f615 100644
--- a/pharmacogenetics/pharmgkb_phenotypes.json
+++ b/pharmacogenetics/pharmgkb_phenotypes.json
@@ -1 +1 @@
-[{"genotypeAnnotationText":"Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for gastrointestinal toxicities","increased response to folic acid and methotrexate","increased event free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the GG genotype and severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and two copies of the CYP1A2*1A allele may have increased concentrations of clozapine as compared to patients with two copies of the *1F allele or one copy of the *1F allele in combination with one copy of the *1A allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP1A2 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clozapine concentrations.","phenotypeText":["increased concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs699 GG genotype may have an increased response to irbesartan as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the CG genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom had the CG genotype.","phenotypeText":["higher incidence of toxicity and may tolerate lower doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance and increased exposure to nevirapine"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the GAT\/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT\/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele or a donor with two normal function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["increased risk of drug toxicity and may require dose modification"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["increased dose of atenolol"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have an increased analgesic response to methadone as compared to patients with two decreased function alleles or a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.","phenotypeText":["higher CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["increased cognitive impairment"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased analgesic response to morphine as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AG or GG genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["decreased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the del\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype or may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["increased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have an increased analgesic response to ketorolac as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["shorter period of time before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["higher plasma drug levels"]},{"genotypeAnnotationText":"Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["decreased risk of experiencing adverse events","increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["good response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs72549435 GG genotype may have increased metabolism of nicotine as compared to patients with the CC or CG genotypes. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype have an decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea","increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased QT interval"]},{"genotypeAnnotationText":"No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["less likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin"]},{"genotypeAnnotationText":"Patients with the rs279858 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["less likely to respond to treatment with cholinesterase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have decreased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with thromboembolism and the CT genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the TT genotypes and decreased risk as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants","increased risk for suicide ideation"]},{"genotypeAnnotationText":"Patients with the CYP2C19*25 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*25 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 36% of the clearance ratio of *1 for mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["poorer pain relief response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1042713 AG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol.","phenotypeText":["increased response to salmeterol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["reduced risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the AG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 TT genotype may have a decreased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of developing either heroin or cocaine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["increased likelihood of developing either heroin or cocaine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs121909005 TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and sickle-cell anemia may have increased levels of glucuronidation of morphine as compared to patients with the CC or CT genotypes and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["increased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being ineffective","increased likelihood of treatment being effective"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["decreased risk of developing drug dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the rs3842 CC genotype may have an increased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["increased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype (*17\/*17) and alcoholism may have a decreased response to phenazepam as compared to patients with the CC (*1\/*1) or CT (*1\/*17) genotypes. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs11045995 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require decreased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*29 genotype may have an increased metabolism of dextromethorphan or debrisoquine compared to patients with the *29\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["decreased risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele was only defined by 4110C>G in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin (a higher change in triglycerides)"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["increased survival time","risk for hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.","phenotypeText":["smaller decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["increased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["decreased risk of bone marrow toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the TT genotype or a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs145308399 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["increased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:12 allele may have an decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to esomeprazole (greater % of time with intragastric pH < 4.0, and a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a normal function allele in combination with a no function allele or two no function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["decreased response to esomeprazole"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1381376 CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements","increased dose requirements"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["decreased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Patients with genotype AA and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1\/*1 genotypes. However, one study found that those with the *1\/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":["increased risk for kidney dysfunction","better kidney function"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["decreased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["decreased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Women with the UGT1A1*28\/*28 genotype and osteoporosis may have increased hip bone mineral density when treated with raloxifene as compared to patients with the *1\/*1 or *1\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["increased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["reduced risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with depression and the GG genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ritonavir may have a increased intracellular\/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["increased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["more likely to respond to treatment with selective serotonin-reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["decreased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele may have increased consumption of nicotine as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["increased consumption of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of akathisia when treated with arpiprazole as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["increased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Cells with the CC genotype may have increased enzymatic activity toward SN-38 as compared to cells with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["increased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AA genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the rs1800497 AG genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["increased weight loss response"]},{"genotypeAnnotationText":"Patients with the CC genotype and metastatic colorectal cancer may have increased rapid response to treatment containing irinotecan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["increased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["decreased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CC genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*5) (rs4244285\/rs56337013) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:19 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:19 alleles or negative for the HLA-B*15:19 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the rs527580106 TT genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may experience greater vasodilation as compared to patients with the del\/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with nitroprusside. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 CC genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["increased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["increased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased pain reduction"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["reduced risk for metastasis"]},{"genotypeAnnotationText":"The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["poorer response to treatment with tiotropium"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["increased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["lower levels of morphine"]},{"genotypeAnnotationText":"Patients with the rs12948059 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to flecainide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["increased risk for endometrial neoplasms"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination of a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased simvastatin acid concentration when treated with simvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased simvastatin acid concentration"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test.","phenotypeText":["increased risk of cutaneous adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to methadone in the treatment of heroin dependence as compared to patients with the CT or TT genotypes. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["increased risk of adverse drug reaction","decreased risk of adverse drug reaction"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the CC genotype may have increased clearance of methotrexate as compared to patients with the CT or TT genotypes. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another allele of *1 may have increased metabolism of ibuprofen as compared to patients carrying one or two copies of *3 allele. Other genetic and clinical factors may also influence metabolism of ibuprofen.This annotation only covers the pharmacokinetic relationship between CYP2C8 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1\/*1 diplotype may require increased dose of ibuprofen as compared to patients with CYP2C8*3. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["increased dose of ibuprofen"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another *4 allele (assigned as rapid acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *4 allele in combination with the *5, *6, or *7 allele (assigned as intermediate acetylator phenotype) or patients with the *5\/*5, *5\/*6, *6\/*6, or *6\/*7 genotypes (assigned as slow acetylator phenotype). This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":["increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with the rs1384401 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*4 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the GG genotype on alcohol consumption.","phenotypeText":["effect on alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["lowest dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs3918290 CC genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased concentrations of carbamazepine compared to patients with the AG and GG genotypes when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["increased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have decreased blood alcohol concentrations (BAC) as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":["decreased blood alcohol concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["increased risk of liver failure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["increased area under the curve (AUC) of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have increased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased clearance of 2',2'-difluorodeoxyuridine (dFdU)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*50 allele or one copy of the *50 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype or may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the AG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk","increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["decreased risk for drug toxicity","decreased response to treatment with cisplatin or carboplatin"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["decreased risk of hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5A allele or one copy of the *5A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to treatment with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the GT or TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["less likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16) may have an increased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with two HLA-C alleles from the C2 group (i.e. *02, *04, *05, *06, *15 or *17).","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Cells with the TT genotype may have decreased uptake of catecholamines or metformin as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["decreased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).","phenotypeText":["increased clearance of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the rs3114020 TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype may have increased concentrations of methotrexate as compared to the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["larger reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"The association between the GG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*1 allele in combination with another normal function allele may have decreased lovastatin acid concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["decreased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The CYP2B6*2 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*2 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":["decreased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to corticosteroids compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["increased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with genotype GG and colorectal neoplasms may have a decreased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the AA or AG genotypes. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["decreased response to FOLFOX therapy"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased response when treated with enalapril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*36 allele or one copy of the *36 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the GG genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of folic acid as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased metabolism of folic acid"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["increased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the CC or CG genotypes. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an metabolism of repaglinide as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["decreased heart rate"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have decreased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased plasma concentrations of montelukast as compared to patients with the *2\/*2 or *1\/*2 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *2\/*2 genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *1\/*1 or *1\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["longer post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are smokers and have the GG genotype may have increased lung function as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["increased lung function"]},{"genotypeAnnotationText":"Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects","opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["increased risk for non-immune response to the hepatitis B vaccine"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 TT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with CYP2C19*3\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased fentanyl dose requirements as compared to patients with two decreased function alleles. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.","phenotypeText":["reduced response to losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid or psoriatic arthritis may have a better response when treated with anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2B6*22 allele in combination with a normal function or an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2654754 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["increased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and Arthritis who are treated with methotrexate may have a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Smokers with the TT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["poorer likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Adolescents with the GG genotype may have decreased nicotine cravings as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["decreased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["increased clearance of atazanavir"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["decreased SVR"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with clozapine may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["increased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["increased fentanyl dosage requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["reduced risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*03:01 allele have an increased risk of asthma when treated with aspirin, as compared to patients with no HLA-DPB1*03:01 alleles or negative for the HLA-DPB1*03:01 test. Other genetic and clinical factors may also influence risk of aspirin-induced asthma.","phenotypeText":["increased risk of asthma"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 AG genotype may have an increased response to acamprosate treatment as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the GG genotype may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *18 allele or one copy of the *1 allele in combination with one copy of the *18 allele. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC. The AA genotype may have decreased catalytic activity of DPYD as compared to the GG genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased response to budesonide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["increased risk of Death"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 GG genotype may have an increased response to warfarin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["increased response to warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased survival","risk of severe neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have increased plasma concentrations of triglycerides as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["increased metabolism of zidovudine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["decreased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to topiramate"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular\/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["decreased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"Patients with the rs1800566 AA genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*40 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs111888148 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia or schizoaffective disorder may have less weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["reduced clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["more likely to have complete remission"]},{"genotypeAnnotationText":"Patients with the CYP2D6*17 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity and decreased clearance"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia may have increased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["increased clearance of busulfan"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1128503 GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["better response to treatment with duloxetine"]},{"genotypeAnnotationText":"Patients with the rs997917 CC genotype may be at a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["increased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *7 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["better response to lansoprazole"]},{"genotypeAnnotationText":"Patients with HIV infections and the TT genotype may have increased trough concentrations of amprenavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["increased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with alcoholism and the AG genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Individuals with the CCT\/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT\/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["increased retention rates"]},{"genotypeAnnotationText":"Patients with GSTT1 non-null\/non-null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null\/null. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["decreased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["decreased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["better response to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the *1\/*3C genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CT genotype, (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["increased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["better response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentrations of fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["decreased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype may have a decreased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["decreased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased concentrations of morphine as compared to patients with the AG or GG genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["increased concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C","greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the T\/del or TT genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of carbocisteine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["decreased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["less likely to respond to aspirin"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require a decreased dose of phenprocoumon as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["decreased dose requirement","increased dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of Vitamin K as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["decreased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with cancer pain and the CC genotype may have decreased morphine dose requirements as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["increased risk of developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure)"]},{"genotypeAnnotationText":"Patients with the ATTTGTTCATGCCT\/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del\/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["increased risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["decreased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics..","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving chemotherapy treatment may have increased severity of nausea as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["increased severity of nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with smaller increases in HDL-C levels","better response to treatment with higher increases in HDL-C levels"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["higher plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Cancer patients with the CC genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["require a decreased dose of fentanyl"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["decreased metabolism of doxorubicin","greater tumor reduction","increased severity of neutropenia","increased metabolism of doxorubicin","less tumor reduction","decreased severity of neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with opioid dependence and the GG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["increased risk of sudden death"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal function allele may have increased response to ketoprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to ketoprofen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele may have increased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased severity of diarrhea compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["increased severity of diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["increased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have decreased exposure (Concentration\/Dose) to tacrolimus compared to patients with the AG and AA genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":["lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV)"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease","increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4\/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["decreased risk for side effects","increased dose of drug required"]},{"genotypeAnnotationText":"Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["more effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 CG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["higher likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin (a higher change in triglycerides)"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with \"standard risk cytogenetic profiles\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.","phenotypeText":["shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the TG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3A genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a greater risk for side effects as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["better response to treatment with imatinib","increased risk of developing cytogenetic resistance to imatinib","greater risk for side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to benefit from treatment with atenolol"]},{"genotypeAnnotationText":"Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["increased response to treatment with selective serotonin-reuptake inhibitors (SSRIs)"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk for cardiovascular toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk for Adenoma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to rosuvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically mean arterial pressure, as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs11971167 GT genotype (one copy of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["decreased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the *3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism of imipramine"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to olanzapine as compared to patients with the CC genotype but an increased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with CC genotype and cancer may have an increased risk for toxicity when treated with tegafur as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["increased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*1 diplotype may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":["increased metabolism of cilostazol"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs2736308 CC genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["increased risk of Medication-related osteonecrosis of the jaw (MRONJ)"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["not receive benefit"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["increased response"]},{"genotypeAnnotationText":"African-American patients with the TT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to beta-blockers as compared to patients with deletion of at least one copy of allele A. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["better response to beta-blockers"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*4 allele in combination with a normal function allele may have increased weight gain when treated with olanzapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the rs2239050 GG genotype and response to nimodipine.","phenotypeText":["response to nimodipine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":["decreased concentrations of voriconazole"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs324029 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to atenolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of risperidone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of risperidone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of risperidone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["decreased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*5 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may require a decreased dose of oxycodone as compared to patients with the *3\/*3 genotype. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["decreased dose requirement of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs6275 AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine","decreased clearance of cyclosporine","increased risk in adverse events"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with CYP3A5*3\/*3 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1\/*1 or *1\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["lower granisetron clearance and increased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["increased imatinib clearance"]},{"genotypeAnnotationText":"CYP2D6 *1\/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine and decreased exposure to dextromethorphan as compared to the *1\/*10 or *10\/*10 genotypes. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["increased inhibition of CYP2D6","decreased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*17 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*2) (rs4244285) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nicotine withdrawal as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have a decreased response to olanzapine as compared to patients with the AA genotype but an increased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs5443 CT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["greater reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Women with the AA genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["increased dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["increased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with the rs2654754 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with a *1 or *3 allele may have decreased metabolism of ibuprofen as compared to patients with *1\/*1. Other genetic and clinical factors may also influence metabolism of ibuprofen.This annotation only covers the pharmacokinetic relationship between CYP2C8 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["decreased risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have a worse response, such as shorter survival times, when treated with carboplatin and taxanes as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["worse response, such as shorter survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have increased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G with 100C>T, P34S not considered) was found to have increased intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["increased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allelemay have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs569661196 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*1 genotype may have lower glucuronidation of carvedilol as compared to patients with the *28\/*28 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["lower glucuronidation of carvedilol"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased response","increased risk for stent thrombosis","increased risk for target vessel revascularization","increased risk for cardiovascular secondary events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["decreased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have less severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*4 or *4\/*4 genotypes. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["decreased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased dose-adjusted trough concentrations of phenytoin as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["decreased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["decreased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs11150606 CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased expression of DPYD as compared to the AT or TT genotypes. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["decreased expression of DPYD"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["decreased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["decreased response according to the PANSS negative symptoms scale"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1\/*3 and *3\/*3 genotypes. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs11125039 GG genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["risk of hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["increased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*12A allele or one copy of the *12A allele in combination with *4 or *13A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["increased risk of neutropenia or hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["increased blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the rs1800111 CC genotype (two copies of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["increased abstinence"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *7B or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["increased survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the rs510769 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["less likely to benefit from treatment","increased risk of death or cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["increased severity of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["no significant association with likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 GG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the rs1076560 AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the rs11150606 CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["increased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["decreased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the *13 allele in combination with a normal, decreased or no function function allele may have decreased metabolism of lornoxicam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.","phenotypeText":["decreased dose requirement for methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to respond to antiepileptic drugs"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["increased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the rs371258350 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["increased risk for statin-related myalgia","decreased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs1302192284 CC genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of Esophagitis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["increased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased response","increased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 CC genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["less likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk for stroke"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 CC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may experience less vasodilation when treated with nitroprusside as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["less vasodilation"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs121908755 AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a better response as compared to patients with the ATTTGTTCATGCCT\/del and ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have increased clearance of gemcitabine as compared to patients with the GG genotype, or decreased clearance as compared to patients with the AA genotype. Patients may also have decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to those with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["increased clearance of gemcitabine","decreased elimination clearance of dFdU"]},{"genotypeAnnotationText":"Patients with the *1\/*5 diplotype may have increased exposure of repaglinide as compared to patients with the *37\/*37 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["shorter progression-free survival","decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the TT genotype or an increased risk of coronary artery disease compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with etravirine may have an increased etravirine clearance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["increased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["increased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased response to fluorouracil-containing chemotherapy regimens","increased risk for and an earlier onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["faster analgesic onset"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the GG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"The association between the AG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to develop an addiction to crack cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["more likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the CT or TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:07 allele who are treated with lamotrigine may have an increased risk of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) or Maculopapular Exanthema (MPE) as compared to patients with no HLA-A*02:07 alleles or negative for the HLA-A*02:07 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) or Maculopapular Exanthema (MPE)"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["decreased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3753380 TT genotype and open angle glaucoma, may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 AG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs11045879 CT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience slower desensitization to effects of terbutaline as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["slower desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AA or CC genotypes. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased lovastatin acid concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["increased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["increased stop reaction time, or greater impulsivity"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"The CYP2B6*38 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*38 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with ADHD and the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs62097526 GT genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["gain more weight"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer progression-free survival","increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs662799 AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2C9*55 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *55 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Elderly patients with the *3\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are also CYP2A6 normal metabolizers may have decreased metabolism of nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a worse response when treated with platinum compounds as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with cancer and the CG genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["more likely to benefit from treatment","reduced risk of death or cardiovascular disease events"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased levels of O-desmethylnaproxen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to rosuvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["decreased risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the AA genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"The CYP2B6*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs118192124 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["decreased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["decreased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"No patients with the CC genotype available for analysis.","phenotypeText":["Not available for analysis"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 GG genotype may be more likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2279343 AA genotype may have increased methadone dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["increased risk for toxic liver disease or abnormal liver-function tests"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["decreased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the GT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*10 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have an increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CT and CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs702764 TT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["lower success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["decreased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs3829125 AA genotype may have decreased metabolism of naltrexone as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism of naltrexone"]},{"genotypeAnnotationText":"Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["decreased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype (*1\/*1) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17\/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["decreased severity of nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the CG and CG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. There is currently only available evidence regarding the association between the rs59086055 AG heterozygote and fluorouracil toxicity. However, patients with the rs59086055 AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["smaller risk of relapse"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CC genotype may have a decreased response to methotrexate as compared to patients with the CT and TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AG genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.","phenotypeText":["increased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["increased severity of pain"]},{"genotypeAnnotationText":"Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"There is currently no available evidence regarding any association between the AA genotype and heroin intake in heroin-dependent patients. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Female patients with the wildtype B\/ B diplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["reduced risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of morphine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["increased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*29 allele was found to have decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Pre-menstrual patients with the CC genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["less likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may require a higher dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 TT genotype (CYP3A4*1\/*1) may require a decreased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 CT or CC genotype (CYP3A4*1B). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["require a decreased dose of buprenorphine to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["less inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs3918290 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of desipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of desipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of desipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine","decreased metabolism of desipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["longer period of recurrence-free survival"]},{"genotypeAnnotationText":"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to treatment","reduced response to treatment"]},{"genotypeAnnotationText":"African-American patients with the CT genotype (carriers of E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:04 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DRB1*04:04 alleles or negative for the HLA-DRB1*04:04 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1386493 AA genotype and dosage of methadone. However, patients with heroin dependence and the AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to repaglinide"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs2108622 CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the *28 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller increase or decrease in total cholesterol levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 AG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 GT genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *28\/*28 genotype and HIV may be at increased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *1\/*1 or *1\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["increased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["reduced risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the rs12422149 AA genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["decreased LDL lowering effect"]},{"genotypeAnnotationText":"In vitro, the CG genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the GG genotype and increased expression of TRAF1, decreased expression of MIRLET7I and decreased sensitivity to endoxifen as compared to the CC genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["decreased sensitivity to endoxifen","increased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del\/del genotype. The opposite association is found for females in one study. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1\/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["decreased dose of valproic acid"]},{"genotypeAnnotationText":"Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.","phenotypeText":["lower CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3\/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with post-operative Erectile Dysfunction"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the TTA\/TTA genotype and hypertension may have decreased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["increased trough concentrations of telaprevir"]},{"genotypeAnnotationText":"Patients with the rs2307116 AA genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["lower risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["require a lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 TT genotype and cancers may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype may have increased DPYD activity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with thromboembolism and the TT genotype may have a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*1 genotype may have an increased clearance of doxepin as compared to patients with the CYP2C9*3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.","phenotypeText":["increased clearance of doxepin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*23 allele in combination with one copy of the *20 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1801131 TT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased alcohol consumption as compared to patients with the AG genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of lymphopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["lower thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an improved response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity or increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of pneumonitis"]},{"genotypeAnnotationText":"Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"The AG genotype did not differ significantly in metabolism of repaglinide as compared to patients with the GG or AA genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs1275988 CT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"Patients with the rs75541969 CG genotype (one copy of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AA genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs140989814 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*12 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the genotype AA may have better response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AG or GG, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["better response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.","phenotypeText":["not clear"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A5*3 allele may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia when taking carboplatin and paclitaxel.","phenotypeText":["decreased risk for leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Parkinson's Disease may have an increased risk for adverse events when treated with levodopa as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased fluvastatin concentration when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients with postoperative pain and the TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*3 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentrations of pitavastatin when treated with pitavastatin as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR S977F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for nicotine addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the CG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom were heterozygotes.","phenotypeText":["lower incidence of toxicity"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to olanzapine as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 CC genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.","phenotypeText":["influence on risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs3766951 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically decreased heart rate"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased IGF-I response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["increased response","increased survival times"]},{"genotypeAnnotationText":"No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["reduced plasma concentration","poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with verapamil may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for primary outcome"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["decreased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1\/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["less likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs3829125 AC genotype may have decreased metabolism of naltrexone as compared to patients with the CC genotype, but increased metabolism as compared to the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["reduced risk of abnormal dreams"]},{"genotypeAnnotationText":"Patients with the rs10929302 AG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["increased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased response to corticosteroids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["lower adverse drug reaction scores"]},{"genotypeAnnotationText":"Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 AC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CT genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":["decreased CSF to plasma ratio of ceftriaxone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*40:02 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*40:02 alleles or negative for the HLA-B*40:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["increased risk of oxcarbazepine-induced maculopapular eruption"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 TGGCGCGTCCCGCCCAGGT\/del genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["increased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["increased risk of Drug Toxicity","increased risk of early relapse","decreased progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["good response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["increased fasting triglyceride levels"]},{"genotypeAnnotationText":"Patients with liver cancer and the TT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["phenobarbital resistance"]},{"genotypeAnnotationText":"Patients with the rs10752271 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with TT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs397508513 AC genotype (one copy of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response or decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele (e.g. *1\/*1) may have increased metabolism of esomeprazole as compared to patients with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["increased metabolism of esomeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT or CT genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["minimal 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to smoking and are trying to quit may have a reduced cravings for nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["reduced cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time and decreased likelihood of experiencing remission"]},{"genotypeAnnotationText":"Patients with the AA genotype may have reduced alcohol consumption as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["reduced alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["increased clearance of doxorubicin","decreased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CG or GG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs28358571 T allele (also known as the 1189T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["decreased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased inhibition of KCNH2 by quinidine as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["increased inhibition of KCNH2 by quinidine"]},{"genotypeAnnotationText":"While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.","phenotypeText":["reduced plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["poorer response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the rs4673993 CT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 AA genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the rs2279345 CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism resulting in lower efavirenz plasma levels"]},{"genotypeAnnotationText":"Patients with the null\/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["decreased plasma concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["poorer response to treatment with naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["decreased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["lower reduction in DNA damage"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.","phenotypeText":["no significant effect"]},{"genotypeAnnotationText":"Patients with the rs11030096 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure slower"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of caffeine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"The TT genotype is associated with increased expression of DPYD as compared to the AT or AA genotypes. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["increased expression of DPYD"]},{"genotypeAnnotationText":"Patients with one copy of the *9 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the rs118192172 TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["increased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have a decreased risk for heroin dependence as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["decreased risk for heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs145014075 GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["increased concentrations of nicotine"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have increased survival times when treated with cetuximab as compared to patients with the AA or AG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the GG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Individuals with the *1\/*3C genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the TT genotypes, and increased steady-state levels as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["decreased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased weight gain when treated with rosiglitazone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with anxiety, alcoholism and two copies of the CYP3A4*1 allele may be at a decreased risk of experiencing adverse events when treated with alprazolam as compared to patients with one copy of the *1 allele in combination with one copy of the *22 allele. Other genetic and clinical factors may also influence the risk of experiencing adverse events when treated with alprazolam.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AT genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["more likely to experience myopathy when treated with statins"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 GG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["decreased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"The TPMT*12 allele is assigned as a no function allele by DPWG. Patients with the *12 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*12 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the NUDT15*5 allele in combination with a normal function or no function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7, *9 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1, *14 or *38 alleles, while patients with one copy of the *4 allele in combination with one copy of the *9 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with one copy of the *1 allele. Patients with one copy of the *4 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9, *12, *14 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["decreased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients with genotype AC and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at decreased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["better response and decreased vomiting during the first 24 hours post-cisplatin administration"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance and increased exposure to nevirapine"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG and GT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["lower burden of general side-effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the rs279858 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"No women with the TT genotype were available for analysis, but women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Hepatic cells with the GG genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["less effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs121908751 GG genotype (do not have a copy of the CFTR E92K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patient with TT genotypes may have an increased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased IGF-I response"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have increased concentrations of oxcarbazepine and improved response as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["increased concentrations of oxcarbazepine and improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*2 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["poorer response rate"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with bladder cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patient with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast neoplasms may have increased disease-free survival when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.","phenotypeText":["increased disease-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":["less likely to have a reduction in psoriasis area or disease severity","reduced risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["less likely to have complete remission"]},{"genotypeAnnotationText":"Patients with the rs2884737 CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs193922764 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 TTAAAGTTA\/del genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the CT genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["no significant association with likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to quetiapine as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs397508288 GG genotype (two copies of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["better response to imatinib treatment"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and alcohol dependence may less likely to drink > 36 drinks in 24 hours as compared to patients with the GG genotype. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["less likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["longer time to failure"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the CT or TT genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["lower plasma concentrations"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have higher S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*1 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.","phenotypeText":["higher S-propranolol plasma concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Individuals carrying one or two copies of the *1 allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3, *6, or *7 alleles, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["rapid metabolism of atazanavir"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dosage of morphine as compared to patients with the CC genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.","phenotypeText":["increased dosage of morphine"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *29 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype although evidence is contradictory. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*17 allele may have decreased metabolism of nifedipine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and nifedipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nifedipine metabolism.","phenotypeText":["decreased metabolism of nifedipine"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a lower dose of acenocoumarol as compared to patients with the GG genotype and a higher dose as compared to the AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["better response to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"The CYP2C9*8 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*8 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs121909019 AA genotype (two copies of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased LDL-C responses"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased risk of diabetes"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800497 GG genotype may have a decreased weight loss response to buproprion and naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["decreased weight loss response"]},{"genotypeAnnotationText":"Patients with the rs11881222 GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with CYP2C9*2 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["more time to achieve stable dose"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or AA genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["decreased vitamin e metabolism"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better treatment response"]},{"genotypeAnnotationText":"Children with the null\/null genotype (has no copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have a reduced, but not absent, risk of hearing impairment as compared to children with the non-null\/non-null or non-null\/null genotype. No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["likelihood of myopathy"]},{"genotypeAnnotationText":"Patients with the rs139945292 CC genotype may have decreased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["decreased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["decreased plasma concentrations of morphine"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["increased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs7439366 CT genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 GG genotype may have a decreased response to treatment with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have similar metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *1 allele in combination with an increased function allele may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *1 allele in combination with a decreased function allele or a no function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["similar metabolism","increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["increased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"The AG genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the GG genotypes and increased catalytic activity and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["decreased catalytic activity","increased expression"]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype may have an increased response to antidepressants as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1\/*1 genotypes. However, one study found that those with the *3\/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":["increased risk for kidney dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*20 allele in combination with one copy of the *23 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["may respond to migalastat"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations and decreased clearance of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["less likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["greater risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and psychotic disorders may have a decreased risk for side effects when treated with antipsychotics as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["lower risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["decreased risk for renal dysfunction"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to bupropion treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["less likely to respond to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Male patients with the A genotype (hemizygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["risk for bleeding"]},{"genotypeAnnotationText":"Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":["increased chance of positive treatment response to amlodipine","lower chance of positive treatment response to chlorthalidone","increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone"]},{"genotypeAnnotationText":"Children with the CT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["increased risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with a no function allele may have decreased exposure to olanzapine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["decreased exposure","increased exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3C genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with breast cancer and the del\/del genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del\/CTGGTGAGGAGAGAACC or CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotypes (please note: the del\/del genotype was not observed in this cohort). Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response to cyclophosphamide and doxorubicin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["smaller increases in spine bone mineral density","larger decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism of tenoxicam as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["increased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with venlafaxine may have a decreased, but not absent, risk for agitation and dysphoria as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for agitation and dysphoria"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["decreased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*4\/*15 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["decreased heart rate"]},{"genotypeAnnotationText":"Patients with the rs2236624 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["increased risk for an adverse event"]},{"genotypeAnnotationText":"Pregnant women with the *1F\/*1F (AA; fast metabolizer) genotype who consume caffeine may have an increased likelihood of spontaneous abortion as compared to patients with the *1A\/*1A (CC) or *1A\/*1F (AC) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["increased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype may have increased clinical benefit to fluoxetine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased clinical benefit"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the rs121908757 AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may require lower doses of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or a patients with two normal function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.","phenotypeText":["lower doses of sirolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["decreased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs9620007 CC genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant yperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*1\/*1 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*28\/*28 genotype.","phenotypeText":["increased formation of the clozapine metabolite"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased response to citalopram or escitalopram in people with depression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["higher platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of omeprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of omeprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.","phenotypeText":["reduced response to chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of APOE E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype (non-carriers of APOE E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the CYP2B6*18 allele in combination with a normal function or a decreased function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the G\/del or GG genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["increased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the rs924607 CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["decreased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["increased risk of distant disease progression"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the rs28933396 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG and AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased exposure to pitavastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen"]},{"genotypeAnnotationText":"Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["increased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased catalytic activity of TYMS","increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["increased risk for virological failure"]},{"genotypeAnnotationText":"Patients with the rs9397685 AA genotype may experience an increased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["less likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the rs116855232 CT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs1800566 AG genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the rs145837941 AG genotype and postoperative pain may have decreased consumption of fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["decreased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["lower warfarin dose"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients undergoing a liver transplant who have the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients who have the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["decreased risk for non-immune response to the hepatitis B vaccine"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of warfarin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*1 allele may be at an increased risk of developing neurotoxicity when treated with paclitaxel as compared to patients with two copies of the *3 allele or one copy of the *1 allele in combination with one copy of the *3 allele. Other genetic and clinical factors may also influence risk of developing neurotoxicity when treated with paclitaxel.","phenotypeText":["increased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for allograft loss when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["decreased risk for allograft loss"]},{"genotypeAnnotationText":"Patients with epilepsy and the TT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have a worse response as compared to patients with the CT or CC genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["lower drug toxicity score"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["increased risk for allograft loss"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a normal, decreased or no function allele may have decreased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity score of 2 may have similar imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements","increased imipramine dose requirements","similar imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2C19*9 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*9 allele was found to have a decreased clearance of mephenytoin and decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*9 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. 6% of *1 activity for the substrate mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["decreased abstinence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype (Gly49\/Gly49) were not reported in the studies of metoprolol efficacy.","phenotypeText":["not reported in the studies of metoprolol efficacy"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs16974799 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or \"clinical benefit\" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["increased risk for acute allograft rejection"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Adolescents with the AG genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["smaller, or absent, increase in nicotine cravings"]},{"genotypeAnnotationText":"Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["decreased risk for sinusoidal obstruction syndrome (SOS)"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["decreased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["increased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["decreased plasma drug concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["better response to pantoprazole"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 TT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may have a better response to fluvastatin treatment as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. However, conflicting evidence exists for this association. Other factors may affect concentration of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA genotype, but decreased response compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have longer of progression-free survival as compared to patients with the CC genotype but only in a sub-group of patients with \"standard risk cytogenetic profiles\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.","phenotypeText":["longer progression-free survival"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs16974799 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"There is currently no available evidence concerning an association between the CC genotype and blood concentrations of acetaldehyde, a metabolite of ethanol. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["no observed association"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["decreased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may have show decreased anesthesia efficacy of remifentanil as compared to patients with the AA genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["decreased anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment","longer overall survival time","longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["less likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["increased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["less likely to experience a reduction in systolic blood pressure following fentanyl administration"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs568724445 AC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["lower plasma concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to experience myopathy when treated with statins as compared to patients with the AG or GG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have more severe nicotine dependence as compared to patients with the CC genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with lung cancer and the TT genotype may have a decreased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs1346563 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the rs8099917 GG genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["decreased response to peginterferon alfa and ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the rs3135506 CC genotype and hypertriglyceridemia may have a decreased response to treatment with fenofibrate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["decreased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["less likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Female patients with the B\/B (reference) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or A-202A_376G\/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"The TT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with a decreased risk of leukopenia when treated with methotrexate as compared to the GT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs121918595 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased risk of poorer outcome"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["greater reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have a decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CC genotype and who are treated with cyclosporine following kidney transplantation may have decreased blood concentrations of cyclosporine as compared to patients with the rs2740574 CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["decreased blood concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased CYP2D6 enzyme activity as compared to patients with the CYP2D6*5\/*9 or *4\/*38 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["increased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased lipid-lowering response to simvastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to toxicity as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs112445441 CT genotype (G13D) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be less likely to engage in smoking behaviors as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["less likely to engage in smoking behaviors"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk for aspirin sensitivity","increased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["more favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["decreased response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs696 CT genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *2\/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have higher tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *1\/*1 or *1\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["higher tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["increased exposure to drug"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with CYP2C9*59\/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require significantly decreased dose of warfarin"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["increased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["decreased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 diplotype and chronic pain, or cancer may have increased clearance of ketamine as compared to patients with the CYP2B6 *1\/*6 and *6\/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["increased clearance of ketamine"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["decreased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["greater reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs11971167 TT genotype (two copies of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*1 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the non-null\/ null genotype (has one copy of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer who are treated with temsirolimus may have increased exposure as compared to patients with the AA or AG genotypes and decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["increased exposure","decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with risperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype or may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["better humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Postoperative patients with the GG genotype may have lower morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *9 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol","increased metabolism of tramadol"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatitis C may have an increased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased levels of alcohol consumption as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["decreased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs148693084 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 genotype and depression may have an increased response when treated with mirtazapine as compared to patients with the CYP2B6 *1\/*1, *1\/*4, *1\/*5, *1\/*6, *1\/*7, *4\/*6, *5\/*5 or *5\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["increased response to enalapril in people with Hypertension"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Genotype CT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["decreased uptake of adefovir dipivoxil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.","phenotypeText":["decreased metabolism and clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs193922876 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["less likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the TT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["increased risk for Cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis and 2) a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["increased risk for pneumonitis","decreased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tenoxicam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["decreased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the CT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 TT genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3740563 AC genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs527580106 CT genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Cells with the AA genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may require decreased doses of sufentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *6\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased sustained virological response to ledipasvir and sofosbuvir"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["better response (higher decrease in HbA1c)","poorer response (smaller decrease in HbA1c)"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["decreased risk of addiction to heroin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to sibutramine in terms of weight loss as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["increased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*1a genotype may have decreased metabolism of valproic acid and may need a decreased dose of valproic acid when compared to patients with any of the following genotype combinations: *1a\/*2a,*1a\/*3a,*1a\/*4a,*1a\/*8, *2a\/*2a, *2a\/*3a, *2a\/*4a, *2a\/*8, *3a\/*3a, *3a\/*4a, *3a\/*8 or *4a\/*8 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased metabolism of valproic acid and may need a decreased dose"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the *2\/*2, *2\/*3 or *3\/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["decreased metabolism of brivaracetam"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*4 allele may have reduced metabolism of diclofenac as compared to patients with CYP2C8*1\/*1. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["reduced metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["reduced response to daunorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["lower maintenance dose"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the GG genotype may have a decreased response to liraglutide as compared to women with the AA and AG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the rs4444903 AG genotype may have a poorer response to cetuximab as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["poorer response or better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have an increased risk for weight gain when treated with antipsychotics as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a normal or no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not non-existent, risk for ototoxicity with cisplatin treatment as compared to patients with the GG or GT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["decreased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["increased risk of suicidal ideation","decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall survival and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["more likely to develop colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs2279345 TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz resulting in higher efavirenz plasma levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance","decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3\/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1\/3A and *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["decreased likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with *5\/*5 genotype may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 AA genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.","phenotypeText":["improved response to diuretics, hydrochlorothiazides, or thiazides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased LDL-C reduction"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the rs121908755 GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["increased response","increased remission rate"]},{"genotypeAnnotationText":"Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["increased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of systolic blood pressure","increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["increased risk of Anemia","increased risk of Neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs28933396 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:11 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:11 alleles or negative for the HLA-B*15:11 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["increased risk of developing Cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to simvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require a lower dose of warfarin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G del\/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *6\/*28 genotype and chronic myeloid leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1, *1\/*6, *1\/*28 or *27\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the rs2952768 CC genotype may have a decreased analgesic response to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["poorer response to carvedilol treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia","decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["lower tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the CT or the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2736308 CT genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["increased risk of Medication-related osteonecrosis of the jaw (MRONJ)"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["decreased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Patients with the CT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs4646437 AA genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["decreased platelet inhibition and increased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs193922753 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased dose requirement of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased lipid-lowering response to simvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased dose requirements of sufentanil as compared to patients with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["decreased dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with the rs150212784 GG genotype (two copies of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to citalopram or escitalopram in people with depression as compared to patients with the TT or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*11, *13, *15, *18 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. No significant differences in the clearance of mephenytoin were found during several in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["reduced likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of progression-free survival and increased likelihood of pneumonitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of progression-free survival","increased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased subjective positive effects from oxycodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["increased subjective positive effects from oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased AUC of letermovir as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["decreased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["less improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["decreased response to chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.","phenotypeText":["increased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.","phenotypeText":["not associated with decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["higher triglyceride levels"]},{"genotypeAnnotationText":"Patients with the rs193922803 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AA genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a slower response time but an increased likelihood of experiencing remission as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["slower response time","increased likelihood of experiencing remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["decreased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["increased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AG or GG. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele was only defined as C161S not including 2988G>A in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["increased doses of lamotrigine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs5128 CC genotype and exposure to olanzapine. However, patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs9973653 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs7662029 AG genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["less likely to experience adverse effects","less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and tobacco use disorder may have a worse response (lack of abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["worse response to bupropion and drugs used in nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 CC genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*4 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["lower risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC\/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels as compared to patients with the C\/C genotype, or may have a larger change in apolipoprotein A1 and C3 levels as compared to patients with the del\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["smaller change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the G\/del genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["decreased risk of Thromboembolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Subjects with AA genotypes may have increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["decreased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs4948496 CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with two non-functional CYP2D6 alleles (e.g.*3\/*3, *3\/*4, *4\/*4, *5\/*4) who are treated with aqueous timolol may have increased exposure to timolol and greater excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["increased exposure to timolol and greater exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with alcoholism and the AA genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by an decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, decrease in systolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity score of 0.25 by CPIC. Patients carrying the *10 allele in combination with another decreased function allele or a no function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"The CYP2C9*43 allele has been assigned as a no function allele by CPIC. Patients carrying the *43 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may require a decreased dose of oxycodone as compared to patients with the *3\/*3 genotype. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["decreased risk for clozapine-induced agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with genotype TT may have higher likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["higher likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine","decreased clearance of cyclosporine","increased risk in adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs708272 AA genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the GG genotype but higher platelet aggregation as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation","higher platelet aggregation"]},{"genotypeAnnotationText":"Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.","phenotypeText":["lower CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may have increased plasma concentrations of anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["increased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs80282562 AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["larger mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the rs1954787 CT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the CT genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["decreased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy or myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["increased likelihood of statin-associated myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased risk for Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype TT. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["decreased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["less likely to be tetrahydrocannabinol (THC) dependent"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1127354 AA genotype and liver transplantation may have increased likelihood of rejection when treated with azathioprine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["increased likelihood of rejection"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or AA genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["likelihood of experiencing erythema"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have an increased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may have decreased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["longer recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment, longer overall survival time, and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype (ApoE E4 carriers) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["greater elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter time to progression and overall survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["more weight gain during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of efavirenz toxicity.","phenotypeText":["increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"Patients with the rs4762 GG genotype may have a decreased response to irbesartan as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the AA or AG genotypes. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["decreased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs575853463 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 GG genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased plasma insulin levels and decreased severity of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 GG genotype and Neoplasms may have increased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AA or AG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs755416212 CT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*2 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*2 allele and response to citalopram"]},{"genotypeAnnotationText":"Patients with the *4\/*1XN genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations of galantamine"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the CC genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs1799782 AA genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["lower plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["increased quality of sleep"]},{"genotypeAnnotationText":"Patients with the *5 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["higher likelihood of side effects"]},{"genotypeAnnotationText":"People with the rs2273697 AG genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the TT genotype and stable coronary artery disease who are treated with clopidogrel may have Increased risk of of hemorrhage as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["Increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of nausea as compared to the GG genotype, and a decreased risk of vomiting as compared to the AA genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea","decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 AA genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*81 allele has been assigned as a no function allele by CPIC. Patients carrying the *81 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Women with the CYP2C19 *1\/*1 diplotype may have a decreased exposure to vaginal progesterone as compared to women with the *1\/*2 or *2\/*17 diplotypes. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["decreased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["smaller reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to treatment with tiotropium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus, and require an increased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC> Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CT genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["decreased response to selective beta-2-adrenoreceptor agonists in people with asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["increased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["may respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs6280 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["decreased risk of ADR"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the TT genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of telmisartan as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs924607 CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["decreased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with genotype AA and urticaria may have increased response to desloratadine and mizolastine compared to patients with genotypes AG or GG. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs118192177 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["increased response to simvastatin (higher LDL lowering effect)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["decreased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms may have an increased plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["increased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["decreased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs4961 TT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["increased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may have a decreased risk of hyperbilirubinemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["decreased response to amisulpride"]},{"genotypeAnnotationText":"Patients with the GT genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*16:01-HLA-DQB1-*05:02 haplotype who are treated with flupirtine may have an increased risk of drug-induced liver injury (DILI) as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of flupirtine-induced adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with paroxetine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing an decreased response for the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response","decreased response","no association with the genotype and paroxetine response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["reduced response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased risk for smoking addiction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of acenocoumarol as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["likelihood of resistance"]},{"genotypeAnnotationText":"Patients with *1\/*1 genotypes may have increased pioglitazone metabolism as compared to patients with the *2 or *3 alleles. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["increased pioglitazone metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["lower risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-B*39:01 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C9*5 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *5 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype. Cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["increased risk for anti-TB drug-induced hepatitis"]},{"genotypeAnnotationText":"Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response to paroxetine"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with rs9958628 AT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Female children with lead poisoning and the A- 202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with dimercaprol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1544410 CT genotype who are treated with alendronate have an undocumented response compared to that of patients with the CC or the TT genotype.","phenotypeText":["undocumented response"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and acute respiratory diseases and suspected influenza infection may have decreased risk of side effects when treated with oseltamivir as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have shorter overall survival times when treated with sunitinib as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased resistance to etoposide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["increased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["increased oxidative stress"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["no change in performance in attention-related tasks"]},{"genotypeAnnotationText":"Patients with the UGT1A1*28\/*28 genotype may have higher glucuronidation of carvedilol as compared to patients with the *1\/*1 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["higher glucuronidation of carvedilol"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs397508256 GG genotype (do not have a copy of the CFTR E56K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["decreased response to rocuronium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["reduced plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the CC or CG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs6928499 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 GG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["higher risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of amitriptyline as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of amitriptyline as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response to adalimumab"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["lower methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the GG genotype may have an increased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the AG or AA genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function or no function allele may have increased metabolism of dihydrocodeine as compared to patients with two no function alleles. Other genetic and clinical factors may also affect dihydrocodeine metabolism.","phenotypeText":["increased metabolism of dihydrocodeine"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["less likely to respond to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk of neurological events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require a higher dose when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["decreased metabolism of zidovudine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *3 allele in combination with another no function allele may have a decreased risk of transplant rejection when treated with tacrolimus as compared to patients with a no function allele in combination with a normal function allele or patients with two normal function alleles, while patients with the *3 allele in combination with a normal function allele may have a decreased risk of transplant rejection as compared to patients with two normal function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CYP2D6*61 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*61 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with genotype G\/TT may have decreased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT\/TT. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["increased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.","phenotypeText":["decreased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["decreased risk of lymph node metastases","increased survival rate"]},{"genotypeAnnotationText":"Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may show slower improvement of symptoms when treated with methylphenidate as compared to patients with the CC and CG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["decreased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the rs17004921 CC genotype and rheumatoid arthritis may have a decreased response to methotrextrate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response when treated with methacholine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methacholine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the *6 allele in combination with another decreased function allele may require a decreased dose of methadone as compared to patients carrying two normal function alleles. However, this association was not found to be statistically significant. Other genetic and clinical factors may also affect a patient's methadone dose requirements.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*30 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*30 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with methotrexate may have a decreased risk of leukopenia and neutropenia as compared to the CC genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.","phenotypeText":["decreased risk of leukopenia and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["worse response","decreased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["more sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased creatinine clearance when treated with tenofovir as compared to patients with the CT genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CT genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["decreased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["decreased response and remission rate"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["increased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["reduced survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["better response to treatment with beta-blockers or antihypertensives"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CT genotype may have lower concentrations of lumefantrine as compared to patients with the TT genotype and elevated concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["lower concentrations of lumefantrine","elevated concentrations"]},{"genotypeAnnotationText":"Patients with the AT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["decreased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["decreased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the CC genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the rs4917639 AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased response to nortriptyline in people with Depression"]},{"genotypeAnnotationText":"Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in addition to another decreased function allele with an activity value of 0.25 may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. Other genetic and clinical factors may also affect a patient's tramadol dose requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AT genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype, or decreased risk as compared to patients with the AA genotype. Patients with the AT genotype may also have decreased clearance of isoniazid as compared to patients with the TT genotype. Additionally, cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["increased risk for anti-TB drug-induced hepatitis","decreased clearance of isoniazid"]},{"genotypeAnnotationText":"Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["higher plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["increased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["more benefit from statin treatment in reducing the risk of myocardial infarction","less benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs397508328 GG genotype (two copies of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*3) (rs4244285\/rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*29 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the TTTT\/del genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the del\/del genotype, but an increased risk as compared to patients with the TTTT\/TTTT genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased metabolism of artemether as compared to patients with the *6\/*6 genotype. Other genetic and clinical factors may also affect artemether metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients carrying the GG genotype may have increased pravastatin plasma AUC compared to patients carrying the AA or AG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased pravastatin plasma AUC"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["reduced risk of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele may have increased metabolism of omeprazole as compared to patients with the CYP2C19*23, *29, *30, *31, or *33 allele when assayed with omeprazole. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["increased metabolism of omeprazole"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased hdl cholsterol as compared to women with GG genotypes and increased levels of triglycerides and decreased levels of hdl cholsterol as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides","increased hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["decreased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration\/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with retinal disease and the GG genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CG or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["increased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["smaller decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs12678747 TT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["increased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the rs193922748 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Cells that carry the UGT1A4*3a allele may have increased clearance of testosterone as compared to those with the *1a allele. Other genetic and clinical factors may also influence clearance of testosterone.","phenotypeText":["increased clearance of testosterone"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs186045772 AT genotype (one copy of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["decreased metabolism of hydrocodone"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*18 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["worse response","decreased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of phenprocoumon as compared to patients with two decreased or no function alleles; a normal function allele in combination with a decreased or no function allele; or a decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["increased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["lower warfarin dose"]},{"genotypeAnnotationText":"Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["decreased clearance of voriconazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype who are administered bupropion may have decreased exposure to bupropion as compared to patients with the *1\/*2 and *2\/*2 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["decreased exposure to bupropion"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["not have an increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher expression of SCAP"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of doxepin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and doxepin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence doxepin metabolism.","phenotypeText":["decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*31 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*31 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *1\/*3 diplotype may have increased clearance of tacrolimus as compared to patients with the *3\/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have increased clearance of codeine or decreased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*24 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":["increased clearance of codeine or decreased clearance of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["decreased metabolism of ondansetron"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the AG genotype and response to salbutamol.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["reduced positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["decreased likelihood of neurological adverse reactions and sleepiness"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["increased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 TT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Organ transplant patients with the TT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and CC genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["decreased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AT genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the rs7597593 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["decreased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR E193K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["decreased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["decreased response to bucindolol"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have a decreased response to fluvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["decreased response to fluvastatin"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and the AG genotype may have increased concentrations of alprazolam as compared to patients with the GG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["increased concentrations of alprazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["increased dose of gabapentin"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["decreased response to calcium channel blockers"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pre-menstrual patients with the CG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease","increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["increased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["decreased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["increased severity of alcohol dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 GG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients atrial fibrillation and the GT genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased risk of hypertriglyceridemia","decreased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of tolbutamide as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of developing an addiction to methamphetamines as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and carrying the UGT1A1*28 allele in combination with another decreased function allele or a normal function allele may have an increased risk of developing thrombocytopenia when treated with FOLFIRINOX as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence risk of developing thrombocytopenia when treated with FOLFIRINOX.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response and treatment outcome"]},{"genotypeAnnotationText":"Patients with the rs77409459 CT genotype (one copy of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs10455872 AG genotype may have an improved response to statins as compared to patients with the GG genotypes and a decreased response to statins as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["improved response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["more skin redness"]},{"genotypeAnnotationText":"Patients with the AA genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["more weight gain during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased response to fluorouracil-containing chemotherapy regimens","increased risk for and an earlier onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the null\/null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/non-null or non-null\/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 AG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["increased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["decreased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["decreased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs28358571 T allele (also known as the 1189T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del\/del or del\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["less responsive to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the genotype CG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.","phenotypeText":["decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have decreased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the CC genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Female patients with typhoid fever and the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["smaller reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 TT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/del or A\/A genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients carrying two copies of the 10-repeat allele may report fewer drinking days as compared to patients carrying one or two copies of the 9-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["fewer drinking days"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Postoperative patients with the AA genotype may have higher morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may be less likely to experience nausea when treated with opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["less likely to experience nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased metabolism of gemcitabine"]},{"genotypeAnnotationText":"People with the rs2273697 GG genotype may have decreased clearance of talinolol as compared to people with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the rs324420 AC genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the CC genotype but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["increased risk of experiencing adverse events","decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AA genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["worse response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-A*24:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-A*24:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to tocilizumab as compared to patients with the CC or CT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to respond to antiepileptic drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with the CT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28.Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with two functional CYP2D6 alleles who are treated with aqueous timolol may have decreased exposure to timolol and less excerice heart rate reduction as compared to patients with two non-functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["decreased exposure to timolol and less exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"People with genotype GG may have increased exposure to silibinin compared to people with genotypes AA or AG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["increased exposure to silibinin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del\/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["decreased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may also be at increased risk of over-anticoagulation as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype or may have an increased response as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids","increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["reduced clearance of cyclosporine","decreased dose of cyclosporine","increased risk of infection"]},{"genotypeAnnotationText":"Patients with the rs193922818 AA genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["increased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Migraine with Aura or Chronic Migraine may be less likely to use pharmacological prophylaxis as compared to patients with the ins\/del or del\/del genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["less likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 TTAAAGTTA\/TTAAAGTTA genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"People with the GG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["increased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*3\/*3) (rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with hepatitis B and the CC genotype may have a decreased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["smaller reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 GG genotype may require increased doses of carvedilol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["require increased doses of carvedilol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype may have increased concentrations of methotrexate as compared to the GG genotype but decreased concentrations as compared to the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele or a no function allele may have decreased concentrations of methadone as compared to patients with two no function alleles. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*7 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele may have increased metabolism of clopidogrel as compared to patients with no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["increased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the CC genotype may metabolize nicotine more rapidly as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["metabolize nicotine more rapidly"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with clozapine may have a decreased risk of weight gain as compared to patients with the C genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with hypertensions and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clincial factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the rs140471703 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased metabolism of caffeine as compared to patients with the CC genotype, or decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with the DEL\/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["increased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased antiplatelet effect"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of escitalopram as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the rs11651488 CT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["more likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["better response to losartan in people with hypertension"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response","similar analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have decreased concentrations of methotrexate as compared to the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":["increased exposure to clopidogrel"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC or TT genotypes. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["increased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["reduced risk of adverse effects","increased risk of adverse effects"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response when treated with methacholine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methacholine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased time in therapeutic range when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz","phenotypeText":["increased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype or may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement for warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have an increased response to venlafaxine compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Purified DCK proteins with the AG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["poorer tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*18 allele in combination with a normal or decreased function allele may have decreased metabolism of methadone as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of methadone"]},{"genotypeAnnotationText":"Patients with the rs5882 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer progression-free survival time when treated with sunitinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence sunitinib response.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CC genotype and improved response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*07:27 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*07:27 alleles or negative for the HLA-C*07:27 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the TT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["increased stop reaction time, or greater impulsivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*12A allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension and coronary artery disease who are treated with verapamil may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for the primary outcome"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 CT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["decreased response to azathioprine"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that this genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be more likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients carrying the NAT2*5 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *5 allele in combination with *5 or *6 allele (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *5 allele in combination with the *5 or *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1\/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele may have increased metabolism of risperidone as compared to patients carrying at least one uncertain function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GSTM1 null\/null genotype (no copies of the GSTM1 gene) combined with a NAT2 slow acetylator genotype and AIDs who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of cutaneous reactions as compared to patients with the non-null\/null or non-null\/non-null genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["increased risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased metabolism of nicotine and cotinine as compared to patients with the *1\/*6 genotype. However, this has been partially contradicted by another study. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine and cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to rosuvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs571335587 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased inhibition of KCNH2 by disopyramide as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["increased inhibition of KCNH2 by disopyramide"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["greater positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of becoming addicted to nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["increased risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1\/*3) or TT (*1\/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["increased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["increased methylation at sites within the COMT gene promoter"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased metabolism as compared to patients carrying the *3 allele. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement for warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["less likely to respond to treatment with candesartan"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the rs397508139 TT genotype (do not have a copy of the CFTR I336K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the AC or CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["smaller elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*2 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients with the *3 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*07:01 allele have an increased risk of Pegaspargase Hypersensitivity as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with retinal disease and the CG genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the GG genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 AA genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["poorer response to bumetanide, furosemide or torasemide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*59 allele or one copy of the *59 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the rs67376798 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AT or AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen","decreased rate of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*19 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function may have an increased clearance of mirtazapine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of mirtazapine"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Individuals with the TT genotype may be more likely to experience anxiety when exposed to caffeine as compared to individuals with the CT or CC genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["anxiety"]},{"genotypeAnnotationText":"Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["increased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs5443 TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["greater reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs16974799 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and sacubitril metabolism. However, patients with the CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["decreased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*14:03 allele who are treated with ticlopidine may have an increased risk of toxic liver disease as compared to patients with no HLA-C*14:03 alleles or negative for the HLA-C*14:03 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs118192172 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk of biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["decreased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the rs718656 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["decreased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["increased risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs1800629 GG genotype may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the rs699 AG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*3 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs113100019 GT genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["increased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["increased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the *9 allele in combination with a normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:32 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased risk for Cough"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the GG genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients undergoing a liver transplant who have the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Female patients with the CC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["decreased severity of diarrhea"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment with infliximab"]},{"genotypeAnnotationText":"Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.","phenotypeText":["normal ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a better response when treated with FOLFIRI and bevacizumab as compared to patients with the GG or GT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["decreased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients who carry at least one copy of the HLA-B*08:01 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*08:01 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine.","phenotypeText":["increased dose of codeine"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased metabolism and increased concentrations of nelfinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["longer overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs193922770 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["higher risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["increased clearance and decreased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"The association between the AA genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["increased response to lovastatin"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs397508442 CT genotype (one copy of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype and and Alzheimer Disease may have a worse response to donepezil (faster cognitive decline) as compared to patients with the CT and CC genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["worse response to donepezil"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.","phenotypeText":["intermediate increased risk of poor response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Patient with CT + CC genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 GG genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with less reduction in total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 CC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*2 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["increased metabolism of enalapril"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased subjective positive effects from oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased response","increased risk for stent thrombosis","increased risk for target vessel revascularization","increased risk of cardiovascular secondary events"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["reduced plasma concentration"]},{"genotypeAnnotationText":"Patients with the rs1381376 TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype (CYP3A4 *1\/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the GG genotype who smoke tobacco may have a decreased risk of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["decreased risk of addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs510769 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*14A allele or one copy of the *14A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the GG and less sensitive as compared to PBMCs from individuals with the AA genotype. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["more sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs374527058 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and a GSTT1 null genotype may have a decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with a non-null genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"No significant results have been seen for patients with the CT genotype.","phenotypeText":["No significant results"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["increased response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["lower psoriasis body surface area after treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may have decreased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["decreased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant and have the CYP3A5*1 allele in combination with another normal function allele may require an increased dose of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the CYP3A5*1 allele in combination with a no function allele may require an increased dose of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.","phenotypeText":["decreased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with clozapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with genotype AG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["increased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a increased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele\/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the rs6280 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may at an increased risk of experiencing opioid-induced adverse effects, including nausea and vomiting, as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["increased risk of experiencing opioid-induced adverse effects, including nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["decreased chance of positive erectile response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy","more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of aripiprazole as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of aripiprazole as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of aripiprazole as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 CC genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response to rosuvastatin"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["improved response, longer survival times"]},{"genotypeAnnotationText":"The CYP2C19*19 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*19 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the *1A\/*1A genotype and tuberculosis may have a decreased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*5B genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased sedative response"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["increased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["reduced risk for metastasis"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1x2 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["decreased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["increased severity of intoxication and increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes CC + CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["lesser increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["longer event-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Children with the AA genotype and cancer may have a lower, but not absent, risk for hearing loss with cisplatin treatment compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with AA and AC genotypes. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with a normal allele and cardiovascular disease who are treated with clopidogrel may have a decreased, but not absent, risk for bleeding events as compared to patients with two increased function alleles or the combination of a normal and increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for bleeding events.","phenotypeText":["decreased risk for bleeding events"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AA genotype and improved response as compared to people with the GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["less time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the HLA-A*32:01 allele may be at an increased risk of developing vancomycin-induced DRESS as compared to patients who do not carry any copies of this allele. Other genetic and clinical factors may also affect a patient's risk of developing vancomycin-induced DRESS.","phenotypeText":["increased risk of developing vancomycin-induced DRESS"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["poorer tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs671 AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the CT or TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the rs2874116 GG genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs112445441 CC genotype (reference KRAS with no mutations in codon 13) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the AC or CT genotype (codon 13 mutations). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["diminished response"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["increased survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of clomipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of clomipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of fever"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*2 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the TTTT\/TTTT genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT\/del or del\/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs510769 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Female patients with the B (reference)\/B (reference) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the *2\/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AA genotype may have a decreased response to metformin as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"No patients with del\/del were studied. However, patients with the del\/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to atenolol, hydrochlorothiazide, or metoprolol"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["decreased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs2108622 TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["more likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa in people with cocaine-related disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response","longer progression free survival","greater irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the rs1042713 GG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to salmeterol.","phenotypeText":["increased response to salmeterol"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the CC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have greater elevations of LDL cholesterol concentrations as compared to patients with the AC or AA genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["greater elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["increased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["increased 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Patients with the rs3781727 CT genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["decreased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7, *9A or *10 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with carbamazepine may have an increased likelihood of a good response as compared to patients with the CC or CT genotypes, although most studies have found no association with response. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["increased likelihood of a good response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with clomipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the AA or AT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs5031016 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["decreased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs396991 AC genotype may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["increased risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a worse response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.","phenotypeText":["worse response to diuretics"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:35 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma concentrations of dolutegravir as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with Crohn disease and the TT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may have an increased response to pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["increased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require a reduced dose of catecholamines"]},{"genotypeAnnotationText":"Individuals with the del\/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT\/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["increased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["decreased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs17134592 CT genotype may have increased metabolism of naltrexone as compared to patients with the TT genotype, but decreased metabolism as compared to the CC genotype. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"The TPMT*2 allele has been assigned as a no function allele by CPIC. Patients carrying the *2 allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["decreased response to propofol and remifentanil administered as anesthesia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["increased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["decreased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have increased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["risk for body weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["increased risk of hypokalemia"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["decreased risk of hematologic toxicity, leukopenia, and GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may metabolize nicotine more slowly as compared to patients with the CT CC genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["metabolize nicotine more slowly"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotype. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["increased risk for neutropenia","increased likelihood of dose delay"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs121918595 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs75039782 CC genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["decreased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*52:01 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the *10\/*10 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 allele, but increased metabolism of lovastatin as compared to patients carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["increased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and various cancers may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["decreased risk of resistance"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs3829125 CC genotype may have increased metabolism of naltrexone as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 CC genotype may require decreased doses of methadone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["decreased likelihood of ototoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased serum concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["increased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"The UGT1A1*28 allele has been assigned as a decreased function allele by CPIC. Patients carrying the UGT1A1*28 allele in combination with a normal function allele may have increased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased likelihood of neutropenia compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["increased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["greater weight loss"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with another no function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["decreased clearance of everolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased, but not absent, risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["decreased risk for toxic liver disease or abnormal liver-function tests"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*22 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["improved survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response to morphine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased pain reduction"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of trimipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of trimipramine.","phenotypeText":["decreased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the TT genotype may have a worse response to bevacizumab-based treatment regimens as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["worse response to bevacizumab-based treatment"]},{"genotypeAnnotationText":"Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["increased absorption and higher concentrations of topotecan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["lower blood trough concentrations of cyclosporine and may require dose adjustments"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with interferons and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["no statistically significant different period of recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs2336219 GG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AA genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["increased response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the *15\/*15 genotype may have increased plasma level of olmesartan as compared to patients with SLCO1B1 *37\/*37 genotype. Patients with the increased plasma level may have enhanced therapeutic response to olmesartan, yet may also be at risk of dose-dependent adverse effects of olmesartan. Other genetic and clinical factors may also influence the pharmacokinetics and response to olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma level","enhanced therapeutic response","dose-dependent adverse effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AA genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DQB1*02:01 alleles or negative for the HLA-DQB1*02:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs1760944 TT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased overall survival period"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may require a decreased dose of gabapentin as compared to patients with the aG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of pantoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the TT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["decreased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and alcohol dependence may less likely to drink > 36 drinks in 24 hours as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["less likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"Patients with the rs4140981 AA genotype may have decreased clearance of methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs267606619 T allele (also known as the 1494T allele) may have an increased risk of experiencing hearing loss when treated with micronomicin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with micronomicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the *01:01 haplotype may have reduced risk of statin-related myopathy when taking statins compared to patients with the *04:06 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.","phenotypeText":["reduced risk of statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["increased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["increased residual platelet aggregation","decreased platelet inhibition"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["higher rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["lower reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["increased doses of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["required increased dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["less likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"Males with basal cell carcinoma who are hemizygous for the T allele may have a poorer response to treatment with imiquimod as compared to males hemizygous for the A allele. Other genetic and clinical factors may also influence response to imiquimod treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs1323040 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CYP2C19*8 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*8 allele was found to have decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*8 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the rs568724445 AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the rs2236624 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["decreased risk for an adverse event"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and various cancer may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the A\/A genotype who are treated with clopidogrel may have an average catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["average catalytic activity"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with a normal or no function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased GI toxicity","decreased GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["decreased dose of SN-38"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.","phenotypeText":["decreased dose requirement for carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the rs758649719 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have a decreased response to montelukast as compared to patients with the AA genotype and an increased response to GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["decreased response to montelukast"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.","phenotypeText":["respond better to antidepressant treatments"]},{"genotypeAnnotationText":"Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased clearance of daptomycin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased sufentanil dose requirements as compared to patients with the TT genotype and decreased sufentanil dose requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements","decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have increased exposure to vitamin K1 as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["increased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the rs116855232 CT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["less likely to experience nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Patients with the rs777098658 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs2307116 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 AA genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AG or GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the rs3788853 A genotype may have increased likelihood of angioedema when treated with ace inhibitors as compared to patients with the C or CC genotypes. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["increased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the rs397508435 CT genotype (one copy of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the *14 allele in combination with a *14 or *1 allele may have enhanced lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["enhanced lipid-lowering efficacy"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["increased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the rs193922747 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have a decreased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["increased likelihood of ototoxicity","decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and gout may be more likely to require a 300 mg\/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["more likely to require a 300 mg\/day dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele may be at an increased risk of QT prolongation when treated with methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's risk of QT prolongation when treated with methadone.","phenotypeText":["increased risk of QT prolongation"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*6 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2C19*2 allele in combination with another no function allele or a normal function allele may have decreased metabolism of diazepam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["decreased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have more severe anemia and neutropenia as compared to patients with the AA genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["increased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["increased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the GG or GT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["lower increase in blood glucose"]},{"genotypeAnnotationText":"Patients with tuberculosis and the GG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["decreased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for inflammatory bowel disease"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the G genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the C genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the CC genotype who also carry the CT or TT genotype at rs12979860 may have a decreased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["decreased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of abnormal dreams"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs193922807 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to cytarabine regimens as compared to patients with the AA or AG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["decreased response to cytarabine regimens"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) a decreased, but not absent, risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) increased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["decreased risk of biopsy-proven acute rejection","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["increased risk of Diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype who are treated with platinum-based chemotherapy may have an increased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the AA or AG genotypes. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["increased risk of hematologic toxicity","increased risk of leukopenia","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with a normal function allele may have increased metabolism of SN-38 as compared to patients with one normal function allele and one decreased function allele or two decreased function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the rs116855232 TT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["higher burden of general side-effects","lower burden of general side-effects"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs569661196 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *5\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1 allele in combination with one copy of the *4 or *9 allele may have increased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with the *9 allele, or patients with two copies of the *9 allele. Patients with two copies of the *1 allele may have increased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or or patients with two copies of the *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *24, *27, *28 or *35 alleles or patients with the *4\/*7, *4\/*9 *4\/*17, *9\/*12 *9\/*26 or *17\/*20 diplotypes but may have decreased metabolism as compared to patients with two copies of the *46 allele or one copy of the *1 allele in combination with the *46 or *1x2 alleles. However, conflicting evidence has been reported for *24. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have an increased clearance of amitriptyline as compared to patients with the CYP2D6*87, *88, *89, *90, *91, *93, *94, *95, *97, or *98 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["increased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["decreased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the TPMT*9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 null\/non-null genotype may have an increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the non-null\/non-null genotypes and decreased risk as compared to women with the null\/null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["decreased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["increased AUC and decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["decreased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Pediatric cancer patients with the GG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with HIV infections and the CT genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["increased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["longer period before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the CT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype or may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["increased frequency of relapse","decreased frequency of relapse"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Patients with the rs145837941 AA genotype and postoperative pain may have decreased consumption of fentanyl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["decreased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with epilepsy and the CC genotype may have a worse response to oxcarbazepine as compared to patients with the CT or TT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["worse response to oxcarbazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a poorer response when treated with bevacizumab as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the TT genotype and severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings reporting the opposite association for this genotype with decreased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the rs444904 CT genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of imipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of imipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response","shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["decreased risk for smoking addiction and increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["decreased risk of hypokalemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better response to glucocorticoid treatment and higher lung function in glucocortioid-dependent severe asthma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["better response to glucocorticoid treatment and higher lung function"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting","decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the CTGGTGAGGAGAGAACC\/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["increased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and who are treated with warfarin may require increased dose as compared to patients with the GG genotypes and decreased dose as compared to those with the AA genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require increased dose"]},{"genotypeAnnotationText":"Patients with the *1\/*15 diplotype may be at an increased risk of developing rifampin-induced liver injury as compared to patients who do not carry the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["increased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["greater likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["more likely to respond to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["better response to repaglinide in people with Diabetes Mellitus, Type 2"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*05:02-HLA-DRB1-*15:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.","phenotypeText":["lesser reduction in LDL-C"]},{"genotypeAnnotationText":"Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["decreased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the GG genotype may have a decreased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["decreased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the rs17004921 TT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype, and increased doses as compared to the GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*21 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *2 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype may have increased metabolism of tacrolimus, as compared to patients with the GT or TT genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the C genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs997917 CT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to metoprolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the rs369103276 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the rs121909041 CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs121908751 AG genotype (one copy of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype who have had a stroke may be at increased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["increased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"Patients with the rs3733784 TT genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["higher reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of voriconazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of voriconazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. However some studies showed no association. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the TT genotype may have decreased concentrations of apixaban as compared to patients with the CC and CT genotype and may be associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban","increased clearance of apixaban"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["higher drug toxicity score"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["decreased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors in people with Hyperlipidemias"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["more likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the TT genotype may have lower concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with tobramycin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["longer QTc interval"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin in people with Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs397508256 AA genotype (two copies of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs4752292 TT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["increased risk of emergency department visits"]},{"genotypeAnnotationText":"Evidence conflicts as to whether patients with the GG genotype and psoriasis have decreased response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased plasma insulin levels and increased severity of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["increased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["less likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["decreased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["decreased disease free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the CC genotype and a lower secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype who are smokers may have increased physical responses to smoking as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["decreased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased fentanyl dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["increased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele construct (in this study PMID:26310775 only defined as 3182A>G (D337G) not including 100C>T (P34S)) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["lower or greater body mass index"]},{"genotypeAnnotationText":"Patients with Crohn disease and the CC genotype may have be less likely to develop anti-adalimumab antibodes and therefore may have an increased response to adalimumab therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["less likely to develop anti-adalimumab antibodies and increased response to adalimumab therapy"]},{"genotypeAnnotationText":"Patients with TT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the CC genotype may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["risk for osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the AA genotype were not analyzed in this study, but patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["complete remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["decreased risk of developing treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs139945292 CC genotype may have increased blood pressure reduction after treatment with beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["increased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*15 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["decreased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Postoperative patients with the GG genotype may have higher morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements"]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotypes CC may have decreased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype TT or CT.","phenotypeText":["decreased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *7\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1\/*3 or *1\/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["decreased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have decreased metabolism of cyclosporine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 GG genotype may have decreased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["decreased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"Patients with the rs28360521 CT genotype may have decreased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs12422149 GG genotype may have increased LDL lowering effect as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["increased LDL lowering effect"]},{"genotypeAnnotationText":"Patients with the rs201820739 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["increased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["increased concentrations of atazanavir"]},{"genotypeAnnotationText":"Patients with the rs369103276 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Artery Disease may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have decreased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["decreased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may require decreased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["decreased risk of cardiac or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["increased response to clopidogrel treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["increased risk for diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased response to rocuronium"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the C\/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del\/del genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's Disease may not experience increasing creatinine levels when taking captopril compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["not experience increasing creatinine levels"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have higher clearance of flecainide as compared to patients carrying two no function alleles; two decreased function alleles with an activity value of 0.25; or a no function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["higher clearance of flecainide"]},{"genotypeAnnotationText":"Patients with major thalassemia and the TT genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patient with CC + CT genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with the rs4961 GT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs2654754 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["decreased severity of thrombocytopenia","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["better response to treatment with pemetrexed"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["decreased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg\/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["require a dose equivalent other than 300 mg\/day"]},{"genotypeAnnotationText":"Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 TT genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["decreased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with an increased or normal function allele may have a decreased response to citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying the CYP2D6*1xN allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["better response to pantoprazole"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*1 allele in combination with another normal function allele may have increased clearance of methadone as compared to patients with two decreased function alleles or a decreased function allele in combination with a normal or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs193922876 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for bleeding events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for bleeding events.","phenotypeText":["increased risk for bleeding events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs569661196 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 GG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*7 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["worse response to statin therapy"]},{"genotypeAnnotationText":"Patients who are smokers and have the AG genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["decreased lung function"]},{"genotypeAnnotationText":"Pre-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["decreased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["decreased response to lovastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-B*58:01 allele and risk of severe cutaneous adverse reactions when treated with carbamazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of severe cutaneous adverse reactions when treated with carbamazepine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the CT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.","phenotypeText":["decreased Euphoric and Energetic"]},{"genotypeAnnotationText":"Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 CC genotype may have an increased response to azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["increased response to azathioprine"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.","phenotypeText":["decreased risk of diarrhoea"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require a decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs771237265 AC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the GG genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["increased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["decreased general side-effect burden"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with higher increases in HDL-C levels"]},{"genotypeAnnotationText":"Patients with the rs267606617 G allele (also known as the 1555G allele) may have an increased risk of experiencing hearing loss when treated with neomycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with neomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs780801862 AA genotype may have increased metabolism of flurbiprofen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs708272 AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["greater reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*6 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction)"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTAAAGTTA\/TTAAAGTTA genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with the TTA\/TTAAAGTTA or TTA\/TTA genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["decreased response to tropisetron"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["decreased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with one copy of the *2 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["decreased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the rs2023239 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del\/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased fluvastatin concentration when treated with fluvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the GG or GT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of mephenytoin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and who are treated with warfarin may require increased dose as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require increased dose"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be more likely to experience adverse events following administration of morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["adverse events"]},{"genotypeAnnotationText":"Patients with the rs8050894 CG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*47 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*47 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["increased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["lower concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased concentration-to-dose ratios"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["increased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients with the *3 allele may have decreased plasma concentrations of montelukast as compared to patients carrying *1\/*1. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 TT genotype may have increased clearance of methotrexate as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased response to salbutamol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing drug dependence as compared to patients with the AC or CC genotypes. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["increased risk of developing drug dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better overall survival as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better overall survival"]},{"genotypeAnnotationText":"Patients with the rs77932196 GG genotype (do not have a copy of the CFTR R347H or R347P variants) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"Subjects with AG genotypes may have increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT\/GT. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["decreased dose of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the rs201268750 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Women with the CYP2C19 *2\/*17 diplotype may have an increased exposure to vaginal progesterone as compared to women with the *1\/*1 diplotype. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["increased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["increased risk for renal dysfunction"]},{"genotypeAnnotationText":"Patients with the rs2952768 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["decreased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["increased risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GG genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the CYP2C19*10 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*10 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations. 7% of the clearance ration of *1 for mephenytoin was reported in one study and several studies report significant lower catalytic activity. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased imipramine dose requirements as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased imipramine dose requirements as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased imipramine dose requirements as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["decreased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Children with the TT genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["better response to fluoxetine therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds or radiotherapy"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1\/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3\/*3) genotype who is also a CYP3A4 low or intermediate expresser. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["increased metabolism of cyclosporine resulting in decreased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to quetiapine as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["prolonged time to progression"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":["greater severity of hypotension"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs61605570 AA genotype may have increased metabolism of nicotine as compared to patients with the AT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["increased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of doxepin as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of doxepin as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of doxepin as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin","decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with pravastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the CC genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["lower body mass index"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["increased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs397508435 TT genotype (do not have a copy of the CFTR L927P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a decreased risk of experiencing side effects when treated with imipramine as compared to patients carrying two decreased or no function alleles or a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased adjusted trough concentrations of dabigatran","decreased, but not absent, risk for bleeding"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["higher tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["increased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Males with basal cell carcinoma who are hemizygous for the A allele may have a better response to treatment with imiquimod as compared to males hemizygous for the T allele. Other genetic and clinical factors may also influence response to imiquimod treatment.","phenotypeText":["better response to treatment with imiquimod"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal function allele may have increased response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles, and decreased response as compared to patients with two no function alleles. Patients carrying the *2 allele in combination with another no function allele may have increased response to rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs140039091 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["increased response to trastuzumab and longer progression-free survival in people with Breast cancer"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to quetiapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs)"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["increased risk of oedema"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in the population. However, patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype or may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for Tobacco Use Disorder","decreased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["reduced positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Women with normal metabolizer genotypes, such as *1\/*1, and epilepsy who are taking valproic acid may have decreased risk of becoming overweight compared to patients with intermediate and poor metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["decreased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the rs118192177 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs121918594 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Purified DCK proteins with the AA genotype may have reduced clearance of gemcitabine as compared to those proteins with the AG or GG genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["reduced clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the *62 allele may have decreased clearance of tolbutamide as compared to patients with the *1 allele. CPIC has not yet assigned a functional status to this allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients carrying the AG genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["increased insomnia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with phenytoin may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) or maculopapular exanthema (MPE) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) or maculopapular exanthema (MPE)"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["better response to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele construct (in this study PMID:26310775 only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["increased metabolism of temsirolimus","decreased likelihood of adverse events","increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*4 allele in combination with a normal or decreased function allele may have increased clearance of methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["decreased QTc interval"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased response to salbutamol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with smaller increases in HDL-C levels"]},{"genotypeAnnotationText":"Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["increased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with HIV infections and the *1\/*22 genotype may have increased clearance of lopinavir as compared to patients with the *22\/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["increased clearance of lopinavir"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotype and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["worse response for postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GT genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Men with the null\/null genotype (has no copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have a reduced, but not absent, risk of hearing impairment as compared to patients with the non-null\/null or non-null\/non-null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of hearing impairment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased carvedilol dose requirements as compared to patients carrying two no function alleles or a no function allele in combination with a normal or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["decreased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the rs145157460 GG genotype may have increased metabolism of nicotine as compared to patients with the GT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*16 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *16 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs79910351 CC genotype may have an increased response to remifentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the T\/del genotype may have decreased clearance of rocuronium as compared to patients with the del\/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["decreased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the DEL\/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["increased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the rs121918592 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.","phenotypeText":["increased risk for spontaneous relapse of psychosis"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*6B allele or one copy of the *6B allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is not significant association between the CYP3A4*1 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["not significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AC genotype and solid tumors, may have increased response to gemcitabine compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["decreased overall survival probability"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*3) or a decreased function allele in combination with a no function allele (e.g. *2\/*3) or two no function alleles (e.g. *3\/*3). This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the rs2330951 CC genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and beta-thalassemia may have a better response, but also an increased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["better response","increased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased LDL-C responses and less likely to achieve LDL-C levels of less than 130mg\/dl"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to venlafaxine as compared to patients with two no function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["decreased response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the TT (POR *28\/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the rs121918592 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["decreased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for asthma","increased risk for asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have increased metabolism of cyclosporine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.","phenotypeText":["increased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["increased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the TT genotype may have a decreased response to paroxetine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*3 allele or one copy of the *3 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have decreased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the TT genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival","progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs678849 CC genotype may have a decreased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine"]},{"genotypeAnnotationText":"Patients with ALS and the AA genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["increased response to treatment with creatine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response","less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["increased risk of adverse drug reaction"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have a poorer survival outcomes when treated with fluorouracil as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["poorer survival outcomes"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["more likely to experience adverse effects","more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased risk for Cough"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*1 allele may have increased metabolism of fentanyl as compared to patients with two copies of the *3 or *6 alleles or one copy of the *1 allele in combination with one copy of the *3 or *6 alleles or patients with one copy of the *3 allele in combination with one copy of the *6 allele. Patients with one copy of the *1 allele in combination with one copy of the *3 or *6 allele may have increased metabolism of fentanyl as compared to patients with two copies of the *3 or *6 alleles or those with one copy of the *3 allele in combination with one copy of the *6 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["increased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["decreased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele or a normal function allele may require a decreased dose of clobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["decreased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*13 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["decreased clearance and increased exposure to zafirlukast"]},{"genotypeAnnotationText":"Patients with the (CA)16\/(CA)17 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["increased clinical response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for neutropenia when treated with gemcitabine as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased inhibition of FXIII activation"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.","phenotypeText":["increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["greater increase in fasting glucose"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased IL1B serum levels","less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence","increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with rs16969968 AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype, but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["longer median survival time"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to quetiapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.","phenotypeText":["increased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Children with the CYP2B6*1\/*1 diplotype and B-cell non-Hodgkin's lymphoma may have increased clearance of cyclophosphamide as compared to children with the *1\/*6 or *6\/*6 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["increased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of Mucositis"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs7967354 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require decreased doses of rocuronium"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*35:10 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele who are treated with dapsone may have an increased risk for dapsone hypersensitivity syndrome or dapsone-induced severe cutaneous adverse reactions as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence dapsone-induced toxicities.","phenotypeText":["increased risk for dapsone hypersensitivity syndrome or dapsone-induced severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["better response to haloperidol"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association with risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response to naltrexone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-DRB1*15:01 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*15:01 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased risk of developing chronic lung allograft dysfunction"]},{"genotypeAnnotationText":"Female patients with the CT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["less likely to experience a loss of libido"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["decreased likelihood of developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs2016520 CC genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs10799590 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["decreased risk of hypokalemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the GG genotypes and decreased clearance leading to improved response to metformin as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.","phenotypeText":["increased clearance of metformin","worse response to metformin","decreased clearance leading to improved response to metformin"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CT genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of citalopram as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of citalopram as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs5443 CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["smaller reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes may be more likely to respond to fenofibrate treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["increased antidepressant response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"The CYP2C19*26 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Female patients heterozygous for the G6PD Mediterranean variant with systemic arthritis who are treated with a high dose of aspirin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with homozygous for the G6PD Mediterranean variant or B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["increased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1079596 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs6269 GG genotype may have a decreased analgesic response to butorphanol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have longer progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["decreased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have decreased methadone dose requirements as compared to patients with the GG or GT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["decreased plasma concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["increased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a poorer response to treatment with clonidine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["poorer response to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased risk of poorer outcome"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in addition to a normal or increased function allele may have a similar analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect response to hydrocodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["greater increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele\/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Female patients with the AA genotype (homozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the rs11198893 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["increased isoproterenol-mediated desensitization in the vasculature"]},{"genotypeAnnotationText":"Patients with the rs28358569 A allele (also known as the 827A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and seizures may have increased response to oxcarbazepine compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased glucuronidation of anastrozole as compared to patients with the CT or TT genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["increased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to atorvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the rs1079596 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["increased risk for edema"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer event-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["less likely to develop dizziness"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["better response and decreased vomiting during the first 24 hours post-cisplatin administration"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.","phenotypeText":["reduced disease-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["decreased dose of opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["decreased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["lower concentrations and worse response to lumefantrine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to remifentanil. However, patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased response to remifentanil"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a reduced frequency of asthma exacerbationse when treated with pitrakinra as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["increased risk of biopsy-proven acute rejection","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["greater increases in spine bone mineral density","smaller decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients carrying the *5 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the rs11881222 AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["reduced risk of toxicities"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["reduced accumulation of active methotrexate metabolites","decreased risk for thrombocytopenia"]},{"genotypeAnnotationText":"No significant findings available.","phenotypeText":["No significant findings"]},{"genotypeAnnotationText":"Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor\/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["respond to ivacaftor\/tezacaftor treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of Stevens-Johnson Syndrome when treated with phenytoin as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence the risk of Stevens-Johnson Syndrome.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["decreased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["increased nicotine consumption","decreased neural response to nicotine"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs118192175 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["decreased response to anti-TNF-alpha treatments in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AA or AC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["increased response to latanoprost (as determined by a reduction in intraocular pressure)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs3832043 T\/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT genotype, or increased glucuronidation of SN-38 as compared to patients with the del\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["decreased glucuronidation","increased glucuronidation"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AA genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"This study did not contain individuals with the AA genotype, though individuals with the AA genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["reduced clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the AT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["increased risk for acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["decreased risk for suicide"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the rs570122671 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2273697 GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a shorter overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["shorter overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["increased clearance of doxorubicin","decreased exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the *2 allele may have decreased pioglitazone metabolism as compared to patients with *1\/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["decreased pioglitazone metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["decreased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs3832043 TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T\/del or del\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["decreased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["decreased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have increased metabolism and decreased concentrations of efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["increased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CC genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require increased dose of warfarin compared to patients with the AA and AC genotypes. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *3a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs12948059 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.","phenotypeText":["increased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the rs699 AA genotype may have a decreased response to irbesartan as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["decreased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*18 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Finding reported in case study for *5\/*18 subject. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"There is currently no available evidence on the relationship between the GG genotype and nicotine craving.","phenotypeText":["nicotine craving"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CC genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["longer median survival time"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype, or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["lower plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment OR better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Neoplasms may be at increased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["risk for bone mineral density loss"]},{"genotypeAnnotationText":"Patients with the rs6517442 CT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 CT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased creatine kinase levels and lower risk of adverse events in response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have slightly decreased reduction of systolic blood pressure as compared to patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["slightly decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Male patients with the AG genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased response to nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with CYP2C9*3 in combination with a normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype.or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 GG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response to propranolol"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*100 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Women with the GG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with risperidone may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["decreased metabolism","decreased risk of gastrointestinal toxicity","decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs10799590 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3\/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["increased clearance and decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["increased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs2024627 CT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype who are treated with capecitabine may have a decreased (but not absent) risk of asthenia as compared to patients with the CC and CG genotypes. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs34059508 AA genotype and exposure to olanzapine. However, patients with the AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs764841347 CC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["less likely to respond to rituximab treatment"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased plasma insulin levels","increased severity of weight gain"]},{"genotypeAnnotationText":"Individuals with the CYP2D6*45 allele in combination with a normal, decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the TT genotype (POR *28\/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (POR *1\/*1). Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["lower decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["decreased chance of a prolonged hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["decreased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations and increased clearance of efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["decreased time until response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased antiplatelet effect"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["higher odds of vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Individuals carrying one or two copies of the *1 allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3, *6, or *7 alleles. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["rapid metabolism of atazanavir"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased response to nortriptyline in people with Depression"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*54 allele or one copy of the *54 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs10787959 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may require a lower dose as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)9\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have increased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["decreased chance of survival"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the rs367619008 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*19 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may require an increased dose of oxycodone as compared to patients with the *1\/*1 or *1\/*3 genotypes. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["increased dose of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*37 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*37 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["decreased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Female patients with the AG genotype (heterozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the GG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to citalopram or escitalopram treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs183701923 CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["lesser reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the A allele and HIV may have a lesser decline in adiponectin when treated with antiretroviral therapy as compared to patients with the G allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.","phenotypeText":["lesser decline in adiponectin"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of paroxetine as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of paroxetine as compared to patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of paroxetine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with paroxetine may have a increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing a increased response compared to the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs2874116 AG genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart failure may have increased response to hydralazine and isosorbide dinitrate compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs10787959 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["increased anxiety"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["decreased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 CC genotype (CYP3A4*1B\/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1\/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["increased dose to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"\"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["increased risk for suicide"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["decreased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased IL1B serum levels","less likely to benefit from pravastatin treatment in terms of improvement in coronary function"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine","lower blood trough concentrations of cyclosporine","may require dose adjustments"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["higher levels of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response","increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["higher mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with valproic acid may have a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["decreased likelihood of developing either heroin or cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or more severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":["decreased likelihood of CNS depression"]},{"genotypeAnnotationText":"Patients with the CG genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["poorer response to carvedilol treatment"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of imipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of amitriptyline as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["increased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have increased likelihood of adverse events when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the rs111869995 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.","phenotypeText":["slight decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have decreased survival times when treated with irinotecan-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of mirtazapine"]},{"genotypeAnnotationText":"Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["increased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["increased nicotine consumption","decreased neural response to nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have a poorer response to treatment with interferon beta 1a\/1b as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4762 AA genotype and response to irbesartan. However, patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with escitalopram may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["increased serum creatine kinase levels"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["greater decrease in bone mineral density"]},{"genotypeAnnotationText":"No patients with this genotype were available for analysis, but patients with the *1A\/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["decreased incidence of nausea"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["decreased risk for sinusoidal obstruction syndrome"]},{"genotypeAnnotationText":"Patients with the AC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["lower levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *29 allele may have decreased metabolism of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have decreased oxidative stress in response to treatment with atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["decreased oxidative stress"]},{"genotypeAnnotationText":"Male patients with typhoid fever and the B (reference) haplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Female children with lead poisoning and the B\/B (reference) diplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G diplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the rs75541969 CC genotype (two copies of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*28\/*28 genotype was found to result in the decreased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*1\/*1 orUGT1A1*1\/*28 genotype.","phenotypeText":["decreased formation of clozapine metabolite"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6B allele or one copy of the *6B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association with risk of drug toxicity"]},{"genotypeAnnotationText":"Caucasian patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to Caucasian patients with the AG or GG genotypes. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the A\/del genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del\/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["decreased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["higher levels of toxicity"]},{"genotypeAnnotationText":"Individuals with the AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["decreased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the rs118192168 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to remifentanil as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased analgesic response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype, or an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["methadone dose adjustment"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the CT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require an increased dose of warfarin","no association","associated with a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of bleeding when treated with warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the GG genotype may have a decreased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicityin patients exposed to cisplatin.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1\/*3) or TT (*1\/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["decreased clearance and increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT (POR *28\/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs735668 AC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one copy of the *17 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. However, one study has failed to find this association. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs374515279 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *22 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["decreased risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype who are taking sulfonylureas may have worse response as compared to patients with the CT or TT genotypes, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs7294 CC genotype may require a lower dose of warfarin as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"The CYP2D6*14 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *14 allele in combination with a decreased or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *14 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone","increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["decreased survival","increased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the rs397508139 AT genotype (one copy of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of phenylalanine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"\"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"Patients with the rs185462714 AA genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["decreased risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CYP2D6*14 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*14 allele construct was found to have decreased intrinsic clearance during in vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["decreased risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the CT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["increased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with mesothelioma and the TT genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the GG and GT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs3842 CT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["decreased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other factors may affect concentration of lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["better response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to pregabalin. However, patients with the AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["higher thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/CTT genotype may not respond to treatment with cavosonstat. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["may not respond to treatment with cavosonstat"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased exposure to pitavastatin as compared to patients with two normal function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 genotype and depression may have increased metabolism of mirtazapine as compared to patients with the CYP2B6 *1\/*1, *1\/*4, *1\/*5, *1\/*6, *1\/*7, *4\/*6, *5\/*5 or *5\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["increased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Children with the AG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype or may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of exacerbations","reduced risk of exacerbations"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["decreased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the (CA)17\/(CA)17 genotype and non-small cell lung cancer may have decreased clinical response when treated with gefitinib as compared to patients with the (CA)16\/(CA)16 or (CA)16\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["decreased clinical response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["increased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3\/*3 diplotype may require decreased dose of ibuprofen as compared to patients with CYP2C8*1\/*1. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["decreased dose of ibuprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs4444903 GG genotype may have a better response to cetuximab as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["better response to cetuximab"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased codeine dose requirements as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["decreased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs118192122 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*48 allele or one copy of the *48 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased metabolism of imatinib","increased sensitivity to dasatinib, imatinib, or nilotinib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the CT and TT genotypes, however, no association was found in the majority of studies, and in one study, the CC genotype was associated with an increased dose of warfarin. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs112563513 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype with malaria vivax who are treated with tafenoquine may have decreased likelihood of recurrence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["decreased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. The CYP2D6*87 allele was only defined as AV5 not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"There is currently no available evidence supporting an association between the GG genotype and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["no association with response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["increased risk for endometrial neoplasms"]},{"genotypeAnnotationText":"Patients with the CG genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["increased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may experience an increased response to methotrexate as compared to patients with the GT GG genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*60 allele or one copy of the *60 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["greater percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with one X-chromosome, neuropathic pain and the G genotype may have decreased pain relief when treated with escitalopram as compared to patients with the C genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased pain relief"]},{"genotypeAnnotationText":"Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs2071559 AA genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["decreased overall survival","decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with genotype AA may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["lower rate of sustained virological response (SVR)"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of nortriptyline as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of nortriptyline as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of nortriptyline as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs34545984 GG genotype may be at a decreased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a slower response time as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["slower response time"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.","phenotypeText":["increased risk of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in addition to another no function allele may have decreased metabolism of ethylmorphine as compared to patients carrying one or more normal function alleles. Other genetic and clinical factors may also affect ethylmorphine metabolism.","phenotypeText":["decreased metabolism of ethylmorphine"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*3 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["decreased clearance and increased exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GG genotype, but decreased response as compared to patients with the TT genotype. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of methotrexate response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentration of methadone"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["decreased concentrations of oxcarbazepine","worse response","improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["decreased opioid dose requirements","increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have similar response to treatment with flecainide as to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*1xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the NUDT15*4 allele in combination with a normal function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Cancer patients with the CT genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the *2 in combination with a normal function allele may have a may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying two normal function alleles, while patients carrying the *2 allele in combination with a decreased or no function allele may have an increased risk of drug toxicity when treated with phenytoin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the GG genotype who are receiving methadone maintenance therapy (MMT) may experience decreased insomnia as a side-effect of treatment as compared to patients carrying the AA or AG genotypes. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["decreased insomnia"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["worse response to bupropion and drugs used in nicotine replacement therapy","improved response to bupropion and drugs used in nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["poorer response to imatinib treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["decreased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["increased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance and decreased exposure to nevirapine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*10:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DPB1*10:01 alleles or negative for the HLA-DPB1*10:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["increased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["decreased risk of Death"]},{"genotypeAnnotationText":"Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["decreased metabolism of pantoprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to metformin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["increased risk of nonfatal myocardial infarction with increased coffee consumption"]},{"genotypeAnnotationText":"Patients with the CACATACCATGCAACATACACACTCAGACA\/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response to levodopa"]},{"genotypeAnnotationText":"Patients with the rs4148738 TT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C19*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*5 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.","phenotypeText":["decreased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["decreased risk for drug toxicity","decreased response to treatment with cisplatin or carboplatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the TT genotype may have a decreased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the CC or CT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["decreased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported.","phenotypeText":["increased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype who are administered thiazides may have an increased likelihood of hyponatremia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["increased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4, *12, *26 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele, while patients with two copies of the *9 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele and one copy of the *9 or *12 alleles. Patients with one copy of the *9 allele in combination with one copy of the *4 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *4 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["decreased survival time","increased risk of death","increased survival time","decreased risk for death"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["increased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["not have a change in likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of clomipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CYP2D6*51 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*51 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["less likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["decreased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 CC genotype may have an increased response to anastrozole as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.","phenotypeText":["greater number of bevacizumab injections"]},{"genotypeAnnotationText":"Patients with the rs2016520 CT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*2xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype and epilepsy may have increased clearance of lamotrigine as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the *37\/*37 diplotype may have decreased exposure of repaglinide, including decreased AUC and increased clearance of repaglinide as compared to patients with the *1\/*1, *1\/*37, *37\/*15, *15\/*1 or *5\/*1 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["sensitivity to Alkylating agents"]},{"genotypeAnnotationText":"Patients with the AG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype or may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["decreased clearance of XK469 OR increased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["smaller percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with the rs9973653 GG genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of resistance to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*13 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the GG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Children with the AG genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["reduced risk of neurotoxicity"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*1 genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3\/*3 genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["lower likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs7412 TT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CC genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 AA genotype may have an increased response to propranolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the CC or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["better response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["decreased likelihood of event-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs1125394 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs5128 GG genotype may have decreased exposure to olanzapine as compared to patients with the CG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with efavirenz may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["increased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["poorer response (decreased acute bronchodilation)"]},{"genotypeAnnotationText":"Patients with the rs2236857 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased creatine kinase levels","increased risk of adverse events","lower creatine kinase levels","lower risk of intolerance"]},{"genotypeAnnotationText":"Patients with the rs376073289 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["increased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have increased cyclosporine dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.","phenotypeText":["increased cyclosporine dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*17 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the rs62097526 TT genotype may gain less weight during treatment with antipsychotics as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.","phenotypeText":["decreased risk for psychosis"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["decreased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA genotype but more likely to experience adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["less likely to experience adverse events","more likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["increased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type 2 Diabetes may have increased response to sitagliptin or vildagliptin compared to patients with the AA genotype. Other factors may affect response to sitagliptin and vildagliptin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["increased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["decreased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["decreased risk of resistance"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["lower reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Individuals with the *1\/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["increased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["decreased dose of propofol"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["decreased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["decreased likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"People with poor metabolizer genotypes (e.g. *2\/*2) may have increased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with intermediate and normal metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"In human liver microsomes, the *22\/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1\/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["decreased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to smoking and are trying to quite may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["greater cravings for nicotine"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["smaller elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DRB1*08:03 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DRB1*08:03 alleles or negative for the HLA-DRB1*08:03 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["better pain relief response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2C9*39 allele has been assigned as a no function allele by CPIC. Patients carrying the *39 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced expression of SCAP"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.","phenotypeText":["lower cortisol response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["increased risk of resistance"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response when treated with methadone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of developing sensory neuropathy when taking stavudine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["increased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["higher risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to remifentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of lansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of lansoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased exposure to methotrexate and lower likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*7) (rs4244285\/rs72558186) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["decreased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the rs2236225 GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*3, *1\/*6, *1\/*13) or a decreased function allele in combination with a no function allele (e.g. *5\/*6) or two decreased function alleles (e.g. *5\/*8) or a normal function allele in combination with a decreased function allele (e.g. *1\/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the CYP2D6*26 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*26 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the rs121918594 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this PMID 28087463 study only defined as C161S not including 2988G>A) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1\/*3 diplotype may require decreased dose of ibuprofen as compared to patients with CYP2C8*1\/*1. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["decreased dose of ibuprofen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to efavirenz as compared to patients with the CT or TT genotypes. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs397508513 CC genotype (two copies of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 CC genotype may have an increased response to treatment with interferons as compared to patients with the CT or TT genotypes. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["increased response to treatment with interferons"]},{"genotypeAnnotationText":"Patients with the AA genotype (Ser49\/Ser49) may have increased response to metoproplol than those with the AG genotype (Ser49\/Gly49) although most benefits appear to be only when in haplotype with Arg389. However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["lower triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased risk of drug toxicity when treated with platinum drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["increased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["increased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with *15 allele in combination with another normal function allele may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs374825099 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have significantly decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may be less likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the AA or AG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["less likely to respond to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["increased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["increased metabolism of ondansetron"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and overral survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["decreased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1076560 AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["increased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype and cystic fibrosis may not respond when treated with cysteamine as compared to patients with the CTT\/del or del\/del genotypes. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["not respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["decreased exposure to risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may be at increased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["increased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased clearance of daptomycin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["increased response and survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["higher levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["greater reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and anxiety disorder or major depression may have increased risk of becoming agitated when taking citalopram compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["increased risk of becoming agitated"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased blood pressure","decreased risk for hypertension","faster control of blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the rs368234815 GG genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with a normal, decreased, or no function allele may have increased risk of bleeding when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["increased dose of SN-38"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CYP2D6*71 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*71 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["decreased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients who are smokers and who have the AA genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["increased cigarette consumption"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer progression-free survival","increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Women with the AG genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype, or a lower dose as compared to women with the AA genotype. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["increased dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the rs7270101 AC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/ B diplotype (heterozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["decreased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have increased platelet aggregation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["increased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response according to the Positive and Negative Syndrome Scale"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["increased metabolism of doxorubicin","less tumor reduction","decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have increased risk of anemia as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["lower risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*19 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["decreased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*33 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to tolperisone as compared to patients with the *1\/*4, *1\/*5, *4\/*4 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The CYP2D6*7 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*7 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["increased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["longer event-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["increased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with the rs121918595 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs5882 AG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with another no function or a normal function allele may have increased exposure to dabigatran as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the AG genotype and gout may be more likely to require a 300 mg\/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["more likely to require a 300 mg\/day dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia","increased risk"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["decreased risk for severe neutropenia"]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs2229774 GG genotype may have decreased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 AG or AA. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased alcohol consumption as compared to patients with the AG or GG genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs2229205 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AG genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["decreased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["more likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of poorer outcome"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CC genotype or may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response","reduced response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin","increase efficacy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*18 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter time to therapeutic INR"]},{"genotypeAnnotationText":"Patients with the CC genotype and growth hormone deficiency who are also homozygotes of the full length GHR gene may require an increased dose of recombinant human growth hormone (somatropin) as compared to patients with the AA genotype who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant. Other genetic and clinical factors may also influence dose of somatropin.","phenotypeText":["increased dose of recombinant human growth hormone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with pegloticase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.","phenotypeText":["increased peak cortisol response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*2 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["increased risk of neutropenia","increased risk of leukopenia","decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["greater reductions in diastolic blood pressure","greater reductions in mean arterial pressure","greater reductions in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["decreased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the AG genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype or may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["increased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Stevens-Johnson Syndrome (SJS) when treated with oxcarbazepine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["increased likelihood of smoking cessation","decreased risk of relapse"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CC genotype may have a decreased response to pioglitazone as compared to patients with the CG genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs118192161 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia. T","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1\/*1 or 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4\/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["increased risk of side effects","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the CC genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response (FEV1)"]},{"genotypeAnnotationText":"People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["increased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may be at a decreased risk of experiencing adverse events when treated with paclitaxel as compared to patients with one copy of the *1 allele in combination with one copy of the *8, *20 or *22 alleles. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 TT genotype (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["acquired resistance to gefitinib"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["reduced likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Cells with the AC genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype, or increased activity as compared to those with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with the AG genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CC genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["increased response to methadone maintenance treatment (MMT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased response","decreased risk for sensory neuropathy","later onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"People with GG genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["decreased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Female children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B\/B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs12678747 AT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["increased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the GG genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4906902 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism","increased serum concentration"]},{"genotypeAnnotationText":"Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients who are smokers and who have the AG genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["increased cigarette consumption"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Individuals with the CC genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the rs3804100 TT genotype may have increased morphine dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with *9\/*9 genotype may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["decreased risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["less likely to require rescue analgesic administration","decreased dose of methadone"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of dexlansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["less reduction in LDL"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have a decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["decreased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the rs7297610 TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["decreased risk of neutropenia","decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs2884737 AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response when treated with methacholine as compared to patients with the AA genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs2372536 GG genotype and rheumatoid arthritis may have decreased likelihood of response when treated with methotrexate as compared to patients with the CC or CG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *4 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Several studies assess this association with *4 in combination with other loss-of-function alleles (e.g. *3, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with ADHD and the AG genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["impaired catalytic activity"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*08:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the AC or AA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["decreased likelihood of developing heroin or cocaine dependence"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcohol dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may be more likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["rapid virological response"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *4a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism of nortriptyline"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type II diabetes mellitus may have decreased clearance of metformin leading to improved response to metformin as compared to patients with the CG and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.","phenotypeText":["decreased clearance of metformin leading to improved response"]},{"genotypeAnnotationText":"Patients with the rs4948496 CT genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Post-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["increased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["smoking behaviors"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype who are treated with docetaxel may have a increased severity of neutropenia as compared to patients with the AT or AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and who are receiving methadone for analgesia may required an increased dose as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's methadone dose requirements for analgesia.","phenotypeText":["increased dose requirements for analgesia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["increased likelihood of developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Children with the AA genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of exacerbations"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *1 allele in combination with a normal or no function allele may have increased metabolism of tacrolimus as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for elevated triglycerides"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["poorer response to treatment with gefitinib"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["more likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["decreased risk of cardiovascular events","increased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["increased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["reduced exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["decreased exposure to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1801253 CG genotype and carvedilol dosage requirements. However, patients with heart failure and the CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["decreased doses of carvedilol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["decreased risk of opioid dependence","increased risk of opioid dependence"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*6 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4XN\/*56 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are addicted to methamphetamine may be more likely to experience psychosis when taking methamphetamine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["more likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1\/*3 and *1\/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response","increased risk of myalgia and greater degree of muscle damage"]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less likely to respond to citalopram or escitalopram"]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the non-null\/non-null genotype (has two copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null\/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["increased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department (ED) visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with paroxetine may have an decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, a number of contradictory findings exist showing an increased response for the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype but increased clearance as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2273697 AG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of developing respiratory depression when treated with sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["increased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1 genotype and decreased exposure as compared to the *4\/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["decreased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["increased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype were not part of the study. But patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["decreased response to eculizumab"]},{"genotypeAnnotationText":"Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["increased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"No information is available for the CT genotype.","phenotypeText":["No information available"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["higher ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 AA genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["decreased response to warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with venlafaxine may have an increased risk for agitation and dysphoria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["increased risk for agitation and dysphoria"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have a decreased, but not absent, risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CT or TT genotypes. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["decreased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking clopidogrel may have decreased resistance to clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["decreased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["lower tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Patients with chronic pain and the AA genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["less likely to develop hyperalgesia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have increased response to venlafaxine as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 TT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased clearance and increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Pediatric patients with the *1C\/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may experience less vasodilation when treated with acetylcholine as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["less vasodilation"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus resulting in increased exposure"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 AC genotype may have an increased response to buprenorphine therapy as compared to patients with the CC genotype but a decreased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for neutropenia and a decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 AA genotype may have an increased response to acamprosate treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["increased response to acamprosate treatment"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AC genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2229774 AA genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["decreased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["decreased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs2304016 AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater increase in total cholesterol levels"]},{"genotypeAnnotationText":"Male patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["lower ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs121908753 AA genotype (two copies of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 AG genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["decreased response to warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the GG genotype may have a decreased risk of experiencing adverse events as compared to patients with the AA or AG genotypes. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AG genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the rs11651488 TT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A\/del or A\/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response to ethanol as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["decreased severity of intoxication","decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib response.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["require a decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*1 diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["decreased pravastatin plasma concentrations","increased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["decreased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the AA genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*18:01 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the rs1127354 AC genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to oxycodone as compared to patients with the AG or GG genotypes. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have more favorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["more favorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del\/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the *6 allele in combination with a normal function allele may be at an increased risk of developing neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 CT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dosage of morphine as compared to patients with the TT genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.","phenotypeText":["decreased dosage of morphine"]},{"genotypeAnnotationText":"Patients with the rs75541969 GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the TT genotype may have increased metabolism of mycophenolic acid as compared to patients with the del\/del or del\/T or del\/del genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["increased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may require higher dose of sirolimus as compared to patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may require higher dose of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.","phenotypeText":["higher dose requirement of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["decreased clearance of gemcitabine","increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs10737062 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the CC genotype with response to bupropion.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*69 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["decreased response to insulin supplemented with zinc acetate"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["decreased response to clopidogrel (increased platelet reactivity)"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs80282562 AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["increased dose requirements","conflicting evidence"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have a decreased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["lower maximal rate of ethanol"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs3766951 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del\/del genotype or a decreased risk of venous thrombosis compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the rs11198893 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AA genotype had increased survival times compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["decreased risk for cardiac events"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*17 allele may have decreased metabolism of fluoxetine as compared to patients with the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["not have altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have decreased risk of acute renal toxicity when taking tacrolimus compared to patients with the GT or TT genotypes. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["decreased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"The CYP2D6*21 allele is assigned as a no function allele by CPIC. Patients carrying the *21 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with ADHD and the AT genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["increased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar imipramine dose requirements as compared to patients with other alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["increased imipramine dose requirements"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CYP2C19*3 allele in combination with another no function allele or a normal function allele may have decreased metabolism of diazepam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["decreased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with the rs193922802 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs9679162 TT genotype and Liver Neoplasms may increased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["increased response to cisplatin, fluorouracil, and mitoxantrone chemotherapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a poorer response when treated with rituximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*3 allele in combination with a normal function allele may have increased weight gain when treated with olanzapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*7 or *10 or *12 or *14A or *17 or *18 or *29 or *36 or *37 or *40 or *47 or *49 or *50 or *51 or *54 or *55 or *57 or *62 or *71 or *72 or *75 or *89 or *92 or *93 or *96 allele, 2) similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*27 or *39 or *48 allele when assayed with bufuralol or dextromethorphan, 3) increased clearance of bufuralol as compared to patients with the CYP2D6*10 or *17 or *14B or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98 allele, and 4) decreased clearance of bufuralol as compared to patients with the CYP2D6*53 allele. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased enzyme activity of CYP2D6","similar enzyme activity of CYP2D6","increased clearance of bufuralol","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*13A allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*44:03 allele who are treated with lamotrigine may have an increased risk of maculopapular exanthema as compared to patients with no HLA-A*44:03 alleles or negative for the HLA-A*44:03 test, however this is contradicted in two studies. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular exanthema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*12 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD B (reference) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["decreased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased sedative response"]},{"genotypeAnnotationText":"Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["less likely to have tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["increased bone density"]},{"genotypeAnnotationText":"Patients with the rs6295 CC genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["increased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["increased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs7597593 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit less from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for primary outcome"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to simvastatin (higher LDL lowering effect) as compared to patients withe the AA or AG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["decreased response to simvastatin (higher LDL lowering effect)"]},{"genotypeAnnotationText":"Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":["increased risk of adverse drug reactions","decreased exposure to active mycophenolic acid"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":["decreased metabolism of dexlansoprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with anxiety, alcoholism and one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with alprazolam as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence the risk of experiencing adverse events when treated with alprazolam.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype or may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["better response to omeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5B allele or one copy of the *5B allele in combination with one copy of the *5A, *6A, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*07:02 allele may have an increased risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim as compared to patients with no HLA-B*07:02 alleles or negative for the HLA-B*07:02 test. Other genetic and clinical factors may also influence a patient's risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of respiratory failure"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["increased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["decreased risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs193922878 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CG or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["poorer rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs61767072 GGGGCGGGGCCG\/GGGGCGGGGCCG (ins\/ins) genotype may have a decreased response to beta-blockers as compared to patients with the ins\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["decreased response to beta-blockers"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*13:02-HLA-B*58:01 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with no HLA-DRB1*13:02-HLA-B*58:01 haplotype or negative for the HLA-DRB1*13:02-HLA-B*58:01 test. The HLA-B*58:01 allele has been shown in other studies to have a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients who are HIV-positive and with one or two copies of the HLA-B*67:01 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as DRESS, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with nevirapine as compared to patients with no HLA-B*67:01 alleles or negative for the HLA-B*67:01 test. Other genetic and clinical factors may also influence Severe Cutaneous Adverse Reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["increased AUC of tenofovir"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients who carried the *60 allele with colorectal cancer may have a poorer response when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients who did not carry the allele. Other genetic and clinical factors may also influence response to TIROX treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism","same metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs528152707 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1801131 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["more likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs28379954 CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["decreased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs735668 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4530637 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*03:02 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCARs. Other genetic and clinical factors may also influence risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*24 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Women with the GG genotype who are undergoing cesarean delivery may require a lower dose of phenylephrine as compared to women with the AA genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["lower dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the rs315498 CT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs113993959 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased, but not absent, risk for acute allograft rejection within 3 month after transplantation as compared to patients with the AA genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["decreased risk for acute allograft rejection"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients with breast cancer and carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Female patients with the GG genotype and major depression may have increased response to paroxetine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["decreased risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased reduction in DNA damage"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["increased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["decreased dose of simvastatin and atorvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":["higher risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the T\/T genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del\/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs5031016 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.","phenotypeText":["increased metabolism or clearance of irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AA or AG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA or AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["decreased risk for deep vein thrombosis"]},{"genotypeAnnotationText":"Patients with major thalassemia and the GG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for Torsades de Point"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with citalopram may have decreased, but not absent, risk for treatment related side effects or intolerance as compared to patients with two no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the AG genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have a decreased likelihood of leukopenia and an increased likelihood of hyperglycemia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or hyperglycemia in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of leukopenia","increased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["increased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["decreased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the rs538703919 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*10 genotype may have decreased metabolism of lovastatin as compared to patients with the *1\/*1 genotype, but increased metabolism of lovastatin as compared to patients with the *10\/*10 genotype or who are carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.","phenotypeText":["decreased Euphoric and Energetic after amphetamine exposure"]},{"genotypeAnnotationText":"Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["decreased dose of paroxetine and decreased risk of fatigue"]},{"genotypeAnnotationText":"Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response for fasting and postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who are treated with atorvastatin may have better LDL-C responses and are more likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["better LDL-C responses and more likely to achieve LDL-C levels of less than 130mg\/dl"]},{"genotypeAnnotationText":"Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["more likely to experience neutropenia","decreased progression-free survival"]},{"genotypeAnnotationText":"Individuals with the *28\/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the TT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4\/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["decreased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with rs16969968 AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype (one copy of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["decreased risk for a diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of lansoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["improved response to metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of doxepin as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and doxepin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence doxepin metabolism.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*32 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher levels of morphine as compared to patients with the AA or AG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["higher levels of morphine"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*1 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["increased risk for heroin dependence"]},{"genotypeAnnotationText":"Patients with the v CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["decreased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["decreased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*6 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*5 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Poor metabolizers may also be more likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["reduced clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["lower risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["higher risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA or AG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*65 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*65 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs1806201 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["decreased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the rs2229774 AG genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are smokers may have decreased physical responses to smoking as compared to patients with the AG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["decreased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *4 allele may have increased plasma concentrations of montelukast as compared to patients carrying *1\/*1. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["decreased response to beta-adrenergic inhalants"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["increased risk of toxicity","decreased risk of toxicity"]},{"genotypeAnnotationText":"People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["decreased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["less likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of amitriptyline as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with a combination of alleles that result in ultrarapid metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs2236624 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["increased risk for an adverse event","decreased risk for an adverse event"]},{"genotypeAnnotationText":"Patients with the rs20455 AA genotype may have decreased response to atorvastatin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CC genotype in patients with depressive disorder who are taking citalopram or escitalopram may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CT or TT genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["higher baseline serotonin levels and greater decreases in serotonin levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1801253 CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["risk for myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["lesser increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the GA genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the DEL\/DEL genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/T and TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the GG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The CYP2D6*40 allele is assigned as a no function allele by CPIC. Patients carrying the *40 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *40 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["reduced response to antidepressants"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["increased conversion of the drug to active polyglutamates","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["increased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.","phenotypeText":["greater reduction in LDL-C"]},{"genotypeAnnotationText":"Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype and Parkinson Disease who are treated with levodopa may have increased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa"]},{"genotypeAnnotationText":"The CYP2C6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance and dose requirements of tacrolimus, as compared to patients with the AA or AG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["increased clearance and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs150212784 GT genotype (one copy of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1800629 AA genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs772964366 CG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":["decreased CD4-cell count","decreased virologic response","decreased risk for toxicity-related failure"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CC and CT genotypes. Other factors may affect response to these drugs.","phenotypeText":["decreased response to antipsychotic drugs"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking methadone may have an increased response as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["increased dose of simvastatin and atorvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["decreased blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["lower mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.","phenotypeText":["increased risk of diarrhoea"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *3\/*3 genotype may have a higher likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *1\/*1 or *1\/*3 genotypes. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["higher likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs193922832 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *1\/*3 diplotype may have increased toxicity when treated with indomethacin as compared to patients with *1\/*1 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["increased severity of respiratory depression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may have decreased metabolism of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["lower maximal rate of ethanol"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/del genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/GGAGTC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["average response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a higher dose of acenocoumarol as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["require a higher dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the rs11045995 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the AA genotype may gain less weight during treatment with antipsychotics as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the rs118192178 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of letrozole as compared to patients with any of the following genotypes: one copy of the *1 allele in combination with one copy of the *4 or *9 alleles; one copy of the *46 allele in combination with one copy of the *4, *7 or *9 alleles; one copy of the *4 allele in combination with one copy of the *7 or *9 alleles; one copy of the *7 allele in combination with one copy of the *9 allele; two copies of the *9 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of letrozole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*2 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *7 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the AA or AC genotypes. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.","phenotypeText":["decreased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have increased clearance of mephenytoin as compared to patients with the CYP2C19*1 allele. The CYP2C19*23 allele was found to have an increased clearance of mephenytoin as compared to *1 during one in-vitro characterization study. 235% of the clearance ratio of *1 for mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype, but decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements","decreased opioid dose requirements","conflicting evidence"]},{"genotypeAnnotationText":"Patients with the rs118192162 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AC or CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["larger reduction in LDL"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["increased QTc interval"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of cefotaxime as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["increased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["better response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the rs2952768 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs6275 AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["dose adjustment of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs568367673 AA genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with depressive disorder and the del\/del genotype may have an improved response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["improved response to sertraline"]},{"genotypeAnnotationText":"Patients with the rs1138272 CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["decreased clearance of thiotepa"]},{"genotypeAnnotationText":"Patients with the rs536577604 CC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association with risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with corticosteroids may have increased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the rs372307932 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*18 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs121918596 del\/GAG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GAG\/GAG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the GG genotypes and a decreased likelihood as compared to the AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["increased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*21 allele or one copy of the *21 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 AA genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association between the rs8187710 AA genotype and risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*18 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*70 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*70 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["increased absorption and higher concentrations of topotecan"]},{"genotypeAnnotationText":"Patients with the *1\/*4 diplotype and Hyperlipidemia may have a better response to simvastatin treatment as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to women with TT genotypes and increased triglycerides and decreased hdl cholsterol as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride and hdl cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides","increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["increased response to modafinil"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["shorter recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may at a decreased risk of experiencing adverse effects, including nausea and vomiting, as a result of opioids as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["decreased risk of experiencing adverse effects, including nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1751034 CC genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["decreased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*4 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the TT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["increased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of phenytoin"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the GG genotypes and increased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["decreased risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800629 GG genotype may have increased response to etanercept as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Pre-menstrual patients with the AG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to lansoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, poorer healing or cure rate of gastroesophageal reflux disease, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["reduced response to lansoprazole"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs7412 CC genotype may have decreased response to atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs538703919 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of myelosuppression and neutropenia as compared to the AA and AC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["decreased SVR"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["increased risk of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ketorolac and undergo oral surgery may have a slower analgesic onset as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["slower analgesic onset"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with another normal function allele may have decreased metabolism of oxycodone as compared to patients carrying two increased function alleles or a normal function allele in combination with an increased function allele. However, patients carrying the CYP2D6*2 allele in combination with another normal function allele may have increased metabolism of oxycodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["reduced risk of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa"]},{"genotypeAnnotationText":"Patients with the GT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*54:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the GG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC or CG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs121908753 AG genotype (one copy of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and attention deficit hyperactivity disorder (ADHD) who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score may have a decreased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the TT genotype and response to temozolomide as part of radiochemotherapy.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the A allele may have increased expression of LDLR as compared to patients with the G allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.","phenotypeText":["increased expression of LDLR"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*27 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the rs114558780 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 GG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for having a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the CT genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["risk of diabetes"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing alcoholism.","phenotypeText":["risk of developing alcoholism"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*6 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*56:02 allele may have an increased risk of severe cutaneous adverse reactions when treated with phenytoin as compared to patients with no HLA-B*56:02 alleles or negative for the HLA-B*56:02 test. Other genetic and clinical factors may also influence rick of phenytoin-induced severe cutaneous adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype, or a decreased response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *10 allele may have an increased risk for tardive dyskinesia when treated with antipsychotics as compared to patients with the *1\/*1 genotype. However some studies have found no association with tardive dyskinesia. Additionally, some evidence suggests that this association may only be significant in males. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR R1070W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs17682789 CT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GG genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["increased response to gefitinib"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["increased metabolism of zidovudine"]},{"genotypeAnnotationText":"The CYP2C9*37 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *37 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the CT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the A\/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["average response"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CC. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.","phenotypeText":["decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have worse response to capecitabine or fluorouracil as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["decreased severity of sedation"]},{"genotypeAnnotationText":"Patients carrying the AG genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased pravastatin plasma AUC"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer may have increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["decreased response to platinum compounds and gemcitabine"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["reduced response and reduced likelihood of remission"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*13:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for anemia","decreased, but not absent, risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs137904044 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["decreased area under the concentration-time curve (AUC) of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux.","phenotypeText":["Increased absorption of omeprazole","decreased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs397508442 CC genotype (do not have a copy of the CFTR S945L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response to deferasirox"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["higher risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:18 allele have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*15:18 alleles or negative for the HLA-B*15:18 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["increased risk of ADR"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["increased risk of developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure)"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with HIV infections and the TT genotype may have decreased trough concentrations of lopinavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["decreased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.","phenotypeText":["increased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["decreased clearance of doxorubicin","increased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192122 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*4 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1142345 CT genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AG genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the GG genotypes, and smaller reductions in serotonin as compared to patients with the AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["greater reductions in serotonin concentrations after taking citalopram or escitalopram"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["decreased area under the curve of olanzapine"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*1a allele may have increased clearance of lamotrigine as compared to patients carrying two copies of the *2 allele or one copy of the *1a allele in combination with one copy of the *2 allele. Patients carrying two copies of the UGT1A4*1a allele may have decreased clearance of lamotrigine as compared to patients carrying two copies of the *1b allele or one copy of the *1a allele in combination with one copy of the *1b allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype (ie. have two copies of the GSTM1 gene) and cancer may have decreased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["decreased severity of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs17004921 CT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to hydrochlorothiazide compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association with methotrexate concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have decreased risk of suicidal thoughts when taking antidepressants compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["decreased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the rs368234815 GG genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":["decreased response to pegIFN-alpha\/ribavirin"]},{"genotypeAnnotationText":"Patients with the rs1801253 GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["increased likelihood of event-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype (*1\/*17) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17\/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs3753380 CT genotype and open angle glaucoma may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB3*01:01 allele who are treated with heparin may have an increased risk of heparin-induced thrombocytopenia as compared to patients with no HLA-DRB3*01:01 alleles, or who test negative for the HLA-DRB3*01:01 allele. Other clinical and genetic factors may also influence the risk of developing heparin-induced thrombocytopenia.","phenotypeText":["increased risk of heparin-induced thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["decreased plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*20 allele or one copy of the *20 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the rs3828743 GG genotype may have better response and longer progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["better response and longer progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Women with intermediate metabolizer genotypes, such as *1\/*2, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1A allele or one copy of the *1A allele in combination with one copy of the *1F allele may have a decreased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1C or *1F alleles or one copy of the *1A allele in combination with one copy of the *1C allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["decreased response to repaglinide"]},{"genotypeAnnotationText":"The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["increased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to atenolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["increased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*57:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B*57:01 alleles or negative for the HLA-B*57:01 test. Other genetic and clinical factors may also influence the risk of abacavir-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10737062 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Cancer patients with genotype TT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to topoisomerase I inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["increased risk for osteonecrosis when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["decreased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*14 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 65% of the clearance ratio of *1 for mephenytoin was reported, while a separate study found no differences in catalytic activity compared to CYP2C19*1. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Individuals with the CT genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["less likely to experience anxiety"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with GG genotype and cancer who are treated with fluorouracil and leucovorin may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to varenicline treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["less likely to respond to varenicline treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*37 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*35 allele or one copy of the *35 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with risperidone may have an increased likelihood of cardiovascular adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["increased likelihood of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the rs121918592 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["decreased risk for induction failure"]},{"genotypeAnnotationText":"Transplant recipients with the CT (CYP3A4 *1B\/*1) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["increased dose requirement of sirolimus"]},{"genotypeAnnotationText":"Women with the CT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response to liraglutide"]},{"genotypeAnnotationText":"Patients with the AC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype AA and a decreased response compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a betterr response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["better response to treatment with clonidine"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["faster desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the GT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 AA genotype may have a decreased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["increased severity of toxicity, specifically hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AC and CC genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the GG genotype may be more likely to require treatment for neonatal abstinence syndrome as compared to infants with the GT genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["greater decrease in bone mineral density"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CYP3A5*1\/*1 had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["higher granisetron clearance and reduced exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800111 CG genotype (one copy of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Cancer patients with the TT genotype may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["better response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the CT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4\/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["decreased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["reduced risk of developing myalgia","higher risk of developing myalgia"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism of clomipramine"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of citalopram as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have a decreased risk of developing opioid dependence when treated with tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who have high baseline HDL levels may have a smaller increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased allele, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the CC genotype (also known as ApoE E4\/E4) may have an increased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["increased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs9927200 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*34 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher expression of SCAP"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*49 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"This genotype was not analyzed in this study.","phenotypeText":["not analyzed"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*22 allele or one copy of the *22 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["better anti-inflammatory response"]},{"genotypeAnnotationText":"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["decreased response to cisplatin and irinotecan"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":["increased clearance of methotrexate","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have increased plasma levels of efavirenz as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["increased plasma levels of efavirenz"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"People with an intermediate metabolizer genotype (e.g. *1\/*2) may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with ultra-rapid metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*59 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk of venous thrombosis compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the TT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to topiramate as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*9 genotype may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["decreased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["decreased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["decreased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs2108622 CT genotype may have increased warfarin dosage requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["increased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CG genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs917881 AG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["decreased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with depression and the TT genotype may have a decreased response to escitalopram as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["decreased response to escitalopram"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with risperidone may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for nausea or vomiting and be more likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk for nausea or vomiting","more likely to be responders to treatment"]},{"genotypeAnnotationText":"Patients with the null\/null (has no copies of the GSTT1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null\/ null or the non-null\/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 TT genotype may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the ATGA\/del genotype may have decreased DPYD activity as compared to those with the ATGA\/ATGA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["greater risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["no increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Subjects with the CT genotype may have increased exposure to atorvastatin as compared to subjects with the CC or TT genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with CYP2C19*3 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1\/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.","phenotypeText":["decreased metabolism of icotinib"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs2330951 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have an increased response when treated with lisinopril as compared to patients with the del\/del genotype, or a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AA genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele by CPIC. Patients carrying the *17 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["similar metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["early response to treatment"]},{"genotypeAnnotationText":"Patients with the rs374825099 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 GG genotype may have increased concentrations of temozolomide as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["increased concentrations of temozolomide"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to tropisetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to tropisetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["similar response","decreased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*3 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *1\/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"There is currently no studies which have found an association between the CT genotype and methadone dose requirements in patients with heroin dependence receiving methadone maintenance therapy (MMT).","phenotypeText":["methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["less likely to respond to treatment for methamphetamine dependence"]},{"genotypeAnnotationText":"No information are available for patients with the CT genotype. However, patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with epilepsy and the AG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Mental Disorders who are treated with paroxetine may have an increased risk of nausea as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased risk of nausea"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and colon cancer may have an increased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["increased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Women with the TT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["increased risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 CT genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with CYP2C9*1\/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require significantly decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2236225 GG genotype may have a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and alcohol dependence may more likely to drink > 36 drinks in 24 hours as compared to patients with the del\/del or G\/del genotypes. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["more likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["better response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["increased risk for hematological toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["better pain relief to opioids"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/GGAGTC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/del or del\/del. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the AA genotype and concentrations of alprazolam. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing nicotine dependence when smoking as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*12 allele or one copy of the *12 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the *1\/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *2\/*2 diplotypes and increased exposure as compared to patients with the *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["increased exposure to bupropion"]},{"genotypeAnnotationText":"Patients with the CYP2D6*27 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["increased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["poorer rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AT or TT genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["lower concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["smaller mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype or may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["increased risk for edema"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs578776 AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may be more likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with ALS and the AG genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype and Colorectal Cancer who are treated with fluorouracil-based adjuvant therapy may have a better response as compared to patients with the TTAAAGTTA\/del or del\/del genotype who also have rs45445694 genotype 2R\/2R. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for flucloxacillin-induced liver injury as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["increased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs755416212 CC genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine in men with Epilepsy"]},{"genotypeAnnotationText":"Patients with the rs1065852 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*18 allele was found to have significantly decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["greater prolactin response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["decreased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have show increased anesthesia efficacy of remifentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["increased anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs997917 CT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs708272 AG genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["increased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience an increased severity of sedation during treatment with desloratadine as compared to patients with the CT or TT genotypes. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["increased severity of sedation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine .","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs10306114 GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["better chance of smoking cessation"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the CC genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs702764 CC genotype may have an increased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased response to pazopanib"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype may have increased metabolism of artemether as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect artemether metabolism.","phenotypeText":["increased metabolism of artemether"]},{"genotypeAnnotationText":"Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["decreased likelihood of survival","increased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["reduced metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["better response rate"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["increased dose of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs118192177 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["increased severity of alcoholism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 AG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*11 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs61767072 GGGGCGGGGCCG\/del (ins\/del) genotype may have an increased response to beta-blockers as compared to patients with the ins\/ins genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele)(Short\/Short) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing organ transplantation may have increased metabolism and dose requirements of tacrolimus, as compared to patients with the AA, AC, CT or TT genotypes. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["increased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the non-null\/null genotype (ie. have one copy of the GSTM1 gene and one gene deletion) and cancer may have decreased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["more skin redness"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may have a decreased risk of bleeding when treated with warfarin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["increased withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["decreased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of alopecia","decreased risk of pain"]},{"genotypeAnnotationText":"Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["decreased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the rs121918593 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.","phenotypeText":["decreased response to galantamine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["decreased response to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have longer progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype may be more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*1 genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["clinical benefit from bupropion treatment for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have increased response to serotonin reuptake inhibitors compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["increased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the rs12208357 CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["higher plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with nevirapine may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism of clomipramine"]},{"genotypeAnnotationText":"Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 GG genotype may be at an increased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs4673993 TT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*37 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*37 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["increased general side-effect burden"]},{"genotypeAnnotationText":"Patients with HIV infections and the CT genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["decreased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CYP2B6*30 allele in combination with a normal function allele may have decreased metabolism of bupropion as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the GAT\/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT\/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["increased metabolism of ondansetron"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["decreased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham allele (rs5030868 allele A) who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV)(rs5030868 allele G). Patients with two X-chromosomes and the Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham variant (rs5030868 allele A) in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV)(rs5030868 allele G). Patients with two X-chromosomes and the Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham variant (rs5030868 allele A) in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":["increased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["greater reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs139945292 CT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["increased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of systolic blood pressure as compared to patients with the CC or the CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes TT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["decreased dose of propofol"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["decreased clearance of risperidone"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs145157460 TT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with bladder cancer and the TT genotype may be at a decreased risk of developing neutropenia when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 CG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs139945292 TT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["decreased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response or better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["decreased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with genotype GG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *3\/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased blood alcohol concentration (BAC) as compared to patients with the CC genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.","phenotypeText":["decreased blood alcohol concentration"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7B allele or one copy of the *7B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the GT genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased risk of nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the G\/del or del\/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs76103438 AA genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be more likely to enter remission when treated with antidepressants, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["more likely to enter remission"]},{"genotypeAnnotationText":"Patients with the rs997917 TT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["increased plasma concentrations of triglycerides","decreased hdl cholesterol"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may have increased likelihood of adverse events when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to repaglinide"]},{"genotypeAnnotationText":"Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["decreased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AA genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for gastrointestinal toxicities","decreased response to folic acid and methotrexate","decreased event free survival"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:07 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the GT genotype (one copy of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["reduced risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Children with the CYP2B6*1\/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1\/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["decreased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["decreased response to tropisetron"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["more likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["increased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["increased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Pediatric patients with the *1\/*1 genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1\/*1C or *1C\/*1C genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["decreased response to selective beta-2-adrenoreceptor agonists in people with asthma"]},{"genotypeAnnotationText":"Patients with the rs374825099 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["decreased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT or AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the rs1800111 GG genotype (do not have a copy of the CFTR L997F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Men with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.","phenotypeText":["lower decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with tobramycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"The CYP2C19*26 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased function allele with an activity value of 0.25 or another no function allele who are treated with mianserin may have increased plasma concentration of S-mianserin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["increased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of drug toxicity","decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["less likely to have rapid virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs1760944 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of resistance to treatment"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["increased response to insulin"]},{"genotypeAnnotationText":"Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs121908753 GG genotype (do not have a copy of the CFTR R352Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192172 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 non-null\/non-null genotype may have a decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the null\/null and null\/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1381376 CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 TT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have decreased severity of thrombocytopenia as compared to patients with the CC genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["increased risk of cardiac or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 TT genotype may have increased metabolism of irinotecan as compared to patients with the CT or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["increased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["decreased chance of rehospitalization"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["higher psoriasis body surface area after treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the A allele. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to rosuvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to citalopram or ecitalopram treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to citalopram or ecitalopram treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*3 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["increased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["decreased risk for bone mineral density loss"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["lower stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective positive effects from oxycodone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["increased subjective positive effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to pitavastatin as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with the AC genotype (one copy of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 AT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["increased survival time","risk for hematologic toxicity"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have decreased cyclosporine dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.","phenotypeText":["decreased cyclosporine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["increased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["require longer time to therapeutic INR"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["increased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["increased risk of Angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["decreased risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["better chance of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA genotype, but less likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and may have an increased response when treated with captopril as compared to patients with the del\/del genotype, or a decreased response compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["decreased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["increased risk of adverse drug reactions","neutropenia\/ leukopenia","gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs772964366 CC genotype may have increased metabolism of nicotine as compared to patients with the CG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["improved response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Female patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["decreased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AC or CC genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["poorer response to losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the *2\/*2 genotype who are treated with sipoglitazar may have 1) a better response (as measured by decreased HbgA1c) and 2) decreased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":["better response","decreased clearance"]},{"genotypeAnnotationText":"Patients with the rs2307116 AA genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the *4\/*5 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["better response to lansoprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype (Ser49Gly49) may have decreased response to metoproplol than those with the AA genotype (Ser49\/Ser49). However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the *1\/*2 or *1\/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["better response to omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["decreased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype (homozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["increased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["decreased risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"No patients with the AA genotype are available for analysis, but patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*28 allele in combination with a normal function allele or decreased function allele may have decreased metabolism of SN-38 as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["more likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1611114 TT genotype and heroin dependence may be at a decreased risk of experiencing memory impairment when taking heroin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["decreased risk of experiencing memory impairment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*17 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"People with an intermediate metabolizer genotype (*2\/*17) may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with ultra-rapid metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have poorer response to beta-blockers as compared to patients with the AA genotype. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["poorer response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AC or CC genotypes. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation"]},{"genotypeAnnotationText":"Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["increased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 AG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with GG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 CC genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs3832043 del\/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT or T\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with methylphenidate as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with methylphenidate.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["more likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["increased response to trastuzumab and longer progression-free survival in people with Breast cancer"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs1125394 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["decreased likelihood of hypertension"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs1127354 AC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["decreased likelihood of rejection"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*18 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["decreased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the rs6065 CT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response","decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 AG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele and psoriasis may have a better response to treatment with ustekinumab as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02 test. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DQA1*01:03 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DQA1*01:03 alleles or negative for the HLA-DQA1*01:03 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the rs730012 CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing nicotine dependence.","phenotypeText":["risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Hispanic patients with the AA genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["greater decrease in viral load"]},{"genotypeAnnotationText":"Children with the GG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced risk of exacerbations"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 GG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"People with an ultra-rapid metabolizer genotype (e.g. *1\/*17) may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with intermediate metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased metabolism of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["increased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and cancer when treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["decreased, but not absent, risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["decreased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation compared to patients with two increased function alleles or a combination of a normal function allele with an increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["increased platelet inhibition and decreased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["decreased concentrations of oxcarbazepine and worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["higher plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1065852 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Smokers with the CC genotype who are treated with nicotine gum or nicotine patches may have a greater likelihood of abstinence as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["poorer cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for the primary outcome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["reduced response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 CT genotype may have decreased metabolism of irinotecan as compared to patients with the TT genotype but increased metabolism as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan","increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["decreased risk for body weight gain"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Female patients with the heterozygous for the G6PD Mediterranean variant who are treated with a high dose of chloroquine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B diplotype. Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["decreased isoproterenol-mediated desensitization"]},{"genotypeAnnotationText":"No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["increased risk of developing hyperbilirubinemia during treatment with indinavir"]},{"genotypeAnnotationText":"Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["increased social and clinical needs"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs2359612 GG genotype may require an increased dose of warfarin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 AG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.","phenotypeText":["decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the TT genotypes and an increased likelihood as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["decreased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["better response to bumetanide, furosemide or torasemide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for progression with platinum-based treatments"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["decreased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["decreased risk of drug toxicity","decreased risk of early relapse","increased progression free survival"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with topiramate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CYP2D6*64 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*64 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs397508256 AG genotype (one copy of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["decreased response to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["increased clearance of docetaxel","increased risk of infusion-related reaction","decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype may show a greater QT-interval shortening effect when taking digoxin as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["greater QT-interval shortening effect"]},{"genotypeAnnotationText":"Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. The opposite association is found for females in one study. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["increased risk for metastasis"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs2336219 AA genotype may have a decreased response to cisplatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased GI toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the rs1801131 GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the rs279858 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["less likely to respond to fenofibrate treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["less weight loss"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the rs1054642 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CT genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["less likely to require rescue analgesic administration","decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs1051792 AG genotype and rheumatoid arthritis may have an increased response to TNF inhibitors as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype with high cholesterol may have a better response when treated with pravastatin or simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results and this geneotype was not reported. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["reduced risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs764841347 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to lurasidone as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have decreased response to rosiglitazone as compared to patients with the CYP2C8*1\/*1 genotype. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["decreased response to rosiglitazone"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["decreased risk of remaining on steroids"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*15 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["increased imatinib clearance"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.","phenotypeText":["increased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have increased metabolism of rosiglitazone as compared to patients with the CYP2C8*1\/*1. Other genetic and clinical factors may also influence metabolism of rosiglitazone. This annotation only covers the pharmacokinetic relationship between CYP2C8 and rosiglitazone and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of rosiglitazone"]},{"genotypeAnnotationText":"Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1\/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype or may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects","increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to topoisomerase I inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to oxycodone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["decreased response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response","shorter progression free survival","lower irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*14 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the rs3788853 C genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the A genotype. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and growth hormone deficiency who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant may require a decreased dose of recombinant human growth hormone (somatropin) as compared to patients with the CC genotype who are also homozygotes of the full length GHR gene. Other genetic and clinical factors may also influence dose of somatropin.","phenotypeText":["decreased dose of recombinant human growth hormone"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the CT or CC genotype. Additionally, patients with the TT genotype who are addicted to heroin may require an increased dose of methadone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["more likely to require rescue analgesic administration","increased dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased likelihood of discontinuation of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients with the rs79910351 CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["less likely to have rapid virological response"]},{"genotypeAnnotationText":"Patients with the CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis may have increased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the CTT\/CTT genotype. This association was found in patients carrying one del allele in combination with another cystic fibrosis causative variant. This genotype is not an indication for use of the combination drug of ivacaftor\/tezacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3114020 CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC or CG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["decreased risk for hematological toxicity"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs77932196 CC genotype (two copies of the CFTR R347P variant) and cystic fibrosis may not respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may not respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT\/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT\/GT. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["decreased dose of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype or may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for primary outcome","increased risk for primary outcome"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["reduced risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP2C19 *1\/*1) undergoing transplantation may have decreased metabolism of busulfan as compared to patients with the CT (*1\/*17) or TT (*17\/*17) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["decreased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the rs193922768 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with granisetron or palonosetron may have a lower response and increased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["lower response and increased vomiting"]},{"genotypeAnnotationText":"Patient with CC genotype may have decreased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with olanzapine may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"The CYP2C9*14 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *14 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs7967354 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased metabolism of imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["increased risk for diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["require a decreased dose of valproic acid"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["worse survival"]},{"genotypeAnnotationText":"Patients with the rs2307116 GG genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the rs1065852 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs1384401 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the rs75039782 CT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have an increased response to fluvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and GG genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the rs1868089 CC genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (higher reductions in LDL cholesterol)"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine.","phenotypeText":["decreased dose of codeine"]},{"genotypeAnnotationText":"Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["increased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to treatment with ivacaftor\/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased overall survival period"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["less likely to experience neutropenia","increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of vortioxetine as compared to patients carrying a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["increased metabolism of vortioxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with regorafenib as compared to patients with the AT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased risk of suicide"]},{"genotypeAnnotationText":"Patients with the rs121909013 AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs118192162 AC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased of likelihood of leukopenia or neutropenia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs193922807 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CG or CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and autism spectrum disorders may have a better tolerance for methylphenidate treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["better tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs12885713 CT genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs12471326 TT genotype may have decreased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs10958704 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs148693084 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with CYP2C19*2\/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased survival","decreased risk of severe neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype, or a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased risk for adverse events","decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["decreased metabolism of gemcitabine"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["increased response to diuretics"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the AC and CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased lipid-lowering response to rosuvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["decreased likelihood of recurrence and increased event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *28\/*28 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1 or *1\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*49 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["better response to statin therapy"]},{"genotypeAnnotationText":"Patients the CG genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival","increased overall survival","decreased progression-free survival","decreased overall survival"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the CC genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["increased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["lower risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the rs2279345 CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism resulting in lower efavirenz plasma levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["more likely to experience adverse effects","more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs12948059 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are given amphetamine may have decreased stop reaction time, or reduced impulsivity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["decreased stop reaction time, or reduced impulsivity"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and chronic pain may experience decreased quality of sleep when treated with opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["decreased quality of sleep"]},{"genotypeAnnotationText":"Patients with the del\/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del\/del genotype, or may have a better response to fluvastatin treatment as compared to patients with the insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["less responsive to fluvastatin treatment","better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles, while patients carrying the *4 allele in combination with another no function allele may also have increased carvedilol dose requirements as compared to patients carrying a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["increased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CT genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with hmg coa reductase inhibitors may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["less benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the rs121909041 CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with a decreased function allele with an activity value of 0.25 may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["decreased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14B allele rn one copy of the *14B allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *7B or *14A alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with paroxetine may have increased risk of nausea or sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["increased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["increased severity of alcoholism"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with amikacin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with amikacin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"People with the TT genotype may have increased Anxiety Disorders when exposed to caffeine as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["increased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sufentanil dose requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["decreased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["decreased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["lower risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have an increased response to eculizumab as compared with patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have decreased, but not absent, risk for side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of diazepam as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["increased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with acetylcholine as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["increased likelihood of cough"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["decreased estimated glomerular filtration rate (eGFR)"]},{"genotypeAnnotationText":"Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["increased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the rs6269 AA genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs118192124 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require an increased dose of phenprocoumon as compared to patients with two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["increased dose requirement of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["increased dose of SN-38"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*3A diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3A specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["increased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype, but increased plasma levels as compared to patients with the TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels","increased plasma levels"]},{"genotypeAnnotationText":"Patients with ADHD and the rs71647871 CC genotype may require an increased dose of methylphenidate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the rs187713395 GG genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with a normal or no function allele may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["decreased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*5\/*13 or *4\/*31 or *4\/*69 or *5\/*100 or *2\/*101 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["increased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["decreased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis may have decreased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the del\/del genotype. This genotype is not an indication for use of the combination drug of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination and response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the GG genotype may be more likely to respond to sertraline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment","longer overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of alcoholism compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.","phenotypeText":["decreased risk of alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["increased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with another normal function allele may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two no function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["decreased response to enalapril in people with Hypertension"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC.The AG genotype may have decreased catalytic activity of DPYD as compared to the GG genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may be at an increased risk of developing nicotine dependence as compared to patients with two copies of the *2, *4, *9 or *12 alleles or one copy of the *1 allele in combination with one copy of the *2, *4 or *12 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["increased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the rs368146607 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs62097526 GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["gain more weight"]},{"genotypeAnnotationText":"Patients with the rs1799782 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CC genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["reduced fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["smaller QT-interval shortening effect"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing surgery may have an increased response to propofol and remifentanil administered as anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["increased response to propofol and remifentanil administered as anesthesia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased but not absent risk for rash"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with the rs3219489 CG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may gain less weight during treatment with antipsychotics as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the rs717620 CC genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have increased exposure to mycophenolic acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["increased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs121909020 AA genotype (two copies of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["increased risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["increased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"Patients with the rs758649719 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs3918290 TT genotype and response to fluorouracil. However, the current evidence base suggests that there is no association between the CC or CT genotypes and response to fluorouracil. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association with response to fluorouracil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["decreased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["increased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["lesser reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["increased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of skin rash"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*04:04 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased risk of suicide"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1\/*1 genotype may have increased metabolism of methylphenobarbital as compared to patients with the *2\/*16 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["decreased chance of positive erectile response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["decreased risk of hypersensitivity to asparaginase"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have an increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.","phenotypeText":["increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with tobramycin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["not require a dose reduction or ribavirin"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have a decreased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele by CPIC. Patients carrying the *41 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["similar metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":["increased response or survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["increased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["decreased risk of myopathy"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype may be more likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["loss of libido"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["decreased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the L\/L genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S\/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["less likely to drop out of treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype or may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["decreased efavirenz plasma concentrations","increased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *17 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype (ApoE E4\/E4) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*54 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*54 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*14 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with genotypes AG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["increased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have reduced alcohol consumption as compared to patients with the GG genotype, but an increased level of alcohol consumption compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["reduced alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the del\/del genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the rs187713395 AG genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"African American male patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC or CT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the GG genotype may have a decreased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the CC or CG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["decreased response to carboplatin, lonafarnib, and paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["decreased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["decreased likelihood of acquired resistance to gefitinib"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL)"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with *6 (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *7 allele in combination with the *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["greater percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*55 allele or one copy of the *55 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with CYP1A1*1\/*2A had a significantly higher granisetron clearance and reduced exposure as compared to patients with *1\/*1 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["higher granisetron clearance and reduced exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs9606186 GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["more favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the *4 allele who have a rapid or intermediate acetylator phenotype may have increased metabolism of dipyrone as compared to patients with two slow NAT2 alleles. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["increased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"The CYP2D6*4xN allele (*4x2) is assigned as a no function allele by CPIC. Patients carrying the *4xN allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with HIV infections and the *22\/*22 genotype may have decreased clearance of lopinavir as compared to patients with the *1\/*1 or *1\/*22 genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["decreased clearance of lopinavir"]},{"genotypeAnnotationText":"Patients with the CT genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["worse prognosis"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the TT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia","decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity","increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cannabis dependence as compared to patients with the AG or GG genotypes. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["increased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased likelihood of progression free survival"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["increased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the rs115346678 GG genotype may be at a decreased risk of adverse events when treated with aspirin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *1\/*1 diplotype may have increased clearance of tacrolimus as compared to patients with the *3\/*3 diplotype. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor\/lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["unknown likelihood of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The AG genotype was not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1\/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3\/*3) genotype. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["increased metabolism of cyclosporine resulting in decreased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["worse treatment response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response when treated with oxaliplatin regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["increased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AA genotype may have a decreased response to methotrexate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA genotype, but more likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response","increased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":["increased risk of adverse drug events"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased response to antihypertensives compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a no function allele in combination with a normal function allele or a donor with two normal function alleles, while patients who receive a liver transplant from a donor with the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype or may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele (rs72554665 allele A, assigned as G6PD deficient) who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with the B (reference) allele (non-deficient, class IV). Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with another deficient class II allele who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with two copies of the B allele. Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with a non-deficient allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Male patients with the G genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the A genotype (hemizygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with cardiac arrhythmias and carrying the CYP2D6*1 allele in combination with another normal function allele may have a decreased response to propafenone as compared to patients carrying two decreased function alleles with an activity value of 0.25. Other genetic and clinical factors may also influence response to propafenone.","phenotypeText":["decreased response to propafenone"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the G\/del genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["less likely to respond to tramadol treatment"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs2372536 CG genotype and rheumatoid arthritis may have increased likelihood of response when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*6 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["likelihood of experiencing erythema"]},{"genotypeAnnotationText":"Patients with the rs34911792 TT genotype (do not have a copy of the CFTR S1235R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["increased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AT or TT genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia as compared to patients with the AA genotype, and a decreased likelihood of leukopenia as compared to patients with the GG genotype. In addition, the AG genotype may have an increased likelihood of hyperglycemia as compared to patients with the AA genotype, and a decreased likelihood as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of leukopenia","decreased likelihood of leukopenia","increased likelihood of hyperglycemia","decreased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"People with the rs2273697 AA genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs3918290 CT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["higher reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of rocuronium as compared to patients with the del\/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["decreased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*62 allele or one copy of the *62 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the rs4948496 TT genotype and lymphoblastic leukemia-lymphoma may be at a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the rs510769 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype who are taking gliclazide may have decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (POR *1\/*1) and familial hypercholesterolemia may have a greater decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CT (*1\/*28) or TT (*28\/*28) genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["greater decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.","phenotypeText":["normal ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["decreased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale","better response according to the clinical global impressions (CGI) score"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"The TPMT*6 allele has been assigned as a no function allele by the DPWG. Patients with the *6 allele in combination with a normal function allele may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*6 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*33:03 allele who are treated with lamotrigine may have a decreased risk of maculopapular exanthema as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test, however this is contradicted in one of the two studies. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the rs118192122 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the rs193922802 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs121909019 GG genotype (do not have a copy of the CFTR R1066H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to mirtazapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response to mirtazapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"There is currently no available evidence on the effect of the CC genotype on a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Gastroesphageal reflux who are treated with omeprazole may have decreased absorption rate of omeprazole as compared to patients with the AA or AG genotypes and and decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence Response to and absorption rate of omeprazole in patients gastroesphageal reflux.","phenotypeText":["decreased absorption rate of omeprazole","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["decreased risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 AG genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*13 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of celecoxib.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have an increased risk for drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["drug toxicity","increased response"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of nausea and neutropenia"]},{"genotypeAnnotationText":"Patients with the rs145157460 GT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the genotype TT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*32 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*32 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele have an increased risk of hypersensitivity reactions, such as Stevens-Johnson Syndrome, toxic epidermal necrolysis or maculopapular eruption, when treated with lamotrigine as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have an increased clearance of atomoxetine as compared to patients with the CYP2D6*87, *88, *90, *91, *93, *95, or *97 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["increased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the GG genotype, or patients undergoing a lung transplant, may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel diseases may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*1\/*28 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*28\/*28 genotype.","phenotypeText":["increased formation of the clozapine metabolite"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["greater increase in fasting glucose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may require a decreased dose of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also require a decreased dose of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but an increased dose as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence metoprolol dose requirements.","phenotypeText":["decreased dose of metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype, or a decreased risk and increased activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["increased risk for toxicity and decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*6 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*1 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["increased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the DEL\/T genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*38 allele or one copy of the *38 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles but decreased metabolism as compared to patients carrying two copies of the *46 allele or one copy of the *46 allele in combination with one copy of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of adverse events in response to treatment as compared to patients with the GG or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased creatine kinase levels","increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs4673993 CC genotype and Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*24 allele or one copy of the *24 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *24 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs374515279 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to citalopram or escitalopram treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["less likely to enter remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may require increased doses of sertraline as compared to patients with two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence sertraline dosage requirements.","phenotypeText":["increased doses of sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have decreased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the G\/G genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 CC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with genotype AA may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["lower likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype TT.","phenotypeText":["decreased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*07:02 allele may have an increased risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim as compared to patients with no HLA-C*07:02 alleles or negative for the HLA-C*07:02 test. Other genetic and clinical factors may also influence a patient's risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of respiratory failure"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7A allele or one copy of the *7A allele in combination with one copy of the *5A, *5B, *6A, *6B, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*1 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk fo developing alcohol dependence as compared to patients wit the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also a affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who also have rs45445694 genotype 2R\/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4444903 AA genotype may have a poorer response to cetuximab as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients carrying the *37 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs201268750 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs699 GG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypercholesterolemia may have a smaller increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to metoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with carbamazepine may have increased concentration-to-dose ratios as compared to patients with the AA or AG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased concentration-to-dose ratios"]},{"genotypeAnnotationText":"The CYP2C9*4 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*4 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the rs3778156 GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs10929302 AA genotype may have increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the rs1125394 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs7294 TT genotype may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*39 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*39 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["decreased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased risk of neutropenia, leukopenia, and diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *15\/*15 diplotype may be at an increased risk of developing rifampin-induced liver injury as compared to patients who do not carry the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["increased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia or schizoaffective disorder may have greater weight gain when treated with clozapine or olanzapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele who are treated with fluoxetine may have increased metabolism of fluoxetine as compared to patients with two normal or two no function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the AT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Female patients heterozygous for the G6PD Mediterranean variant who are treated with sulfadoxine may have a varying degree of G6PD deficient red blood cells and an unknown rate of red blood cell survival as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["varying degree of G6PD deficient red blood cells","unknown rate of red blood cell survival"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia who are treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the rs9973653 GT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["increased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype (CYP3A4 *1\/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["increased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.","phenotypeText":["better response to metformin"]},{"genotypeAnnotationText":"Patients with the CT (CYP2C19 *1\/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have increased response to paroxetine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.","phenotypeText":["increased risk of CNS adverse events","increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["longer post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*12:03 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-C*12:03 alleles or negative for the HLA-C*12:03 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 TT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["decreased exposure to silibinin"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer response to treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["increased risk of nicotine dependence","increased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs774072493 del\/del genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC or C\/del genotypes. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the rs11030096 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*28 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*28 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["increased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for elevated triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure to temsirolimus or sirolimus","decreased likelihood of bone marrow and gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["increased serum concentrations","decreased serum concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"The GG genotype is associated with increased catalytic activity and decreased expression of DPYD protein as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*25 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with risperidone may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"The CYP2C9*33 allele has been assigned as a no function allele by CPIC. Patients carrying the *33 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["increased oxidative stress"]},{"genotypeAnnotationText":"Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["decreased absorption and lower concentrations of topotecan"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to bisphosphonate treatment, or may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with nitroprusside as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the rs397508510 GG genotype (do not have a copy of the CFTR H1054D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*49 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["decreased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.","phenotypeText":["improved response to irbesartan"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations and decreased clearance"]},{"genotypeAnnotationText":"The CYP2D6*2xN allele has been assigned as an increased function allele by CPIC. Patients carrying the *2xN allele in combination with another increased function allele, a normal function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs9288993 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying one copy of the 10-repeat allele and one copy of the 9-repeat allele may report more severe negative effects of alcohol as compared to patients carrying two copies of the 10-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["more severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["increased risk for allograft loss"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs548783838 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["better anti-inflammatory response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Pediatric cancer patients with the AG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the AA or AG genotypes. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["increased response to modafinil in the treatment of methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *6\/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk for drug toxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["decreased metabolism of heroin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*47 allele or one copy of the *47 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*31 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["decreased survival time","increased risk of death"]},{"genotypeAnnotationText":"Patients with the rs61605570 TT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs7439366 CC genotype who are treated with sublingual buprenorphine\/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AC genotypes. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the rs1800100 CC genotype (do not have a copy of the CFTR R668C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone","similar metabolism of risperidone","increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["increased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["better response rate"]},{"genotypeAnnotationText":"Female patients with the AC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["decreased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["worse response to rivastigmine"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["decreased response to lovastatin"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 TT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["poorer survival outcomes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["increased risk for nausea","decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele and psoriasis may have a better response to treatment with methotrexate as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab. *Please note: the study tested for presence\/absence of HLA-Cw6 serotype, not the HLA-C*06 alleles.","phenotypeText":["better response to treatment with methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["decreased dose of morphine"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*2 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["increased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs699 AA genotype may have a decreased response to atenolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1303839356 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA genotype, and slightly decreased reduction of systolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["slightly increased reduction of systolic blood pressure and slightly decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR P67L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the CC genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. In a single study, the authors compared outcomes between genotypes between treatments. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs548783838 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"There is currently no evidence regarding the association between the GG genotype and response to folate supplementation in the context of pharmacotherapy for depression.","phenotypeText":["response to folate supplementation"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["lower risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with the rs193922753 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GT and TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["increased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["increased risk of treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the rs397508510 CC genotype (two copies of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["increased risk for smoking addiction and decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"The TT genotype is associated with a decreased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["increased risk of remaining on steroids 1 year after transplantation"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["more likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Female children with typhoid fever and the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with chloramphenicol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A-202A_376G\/A-202A_376G or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["poorer response to glucocorticoid treatment and lower lung function"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have a decreased exposure to dextropropoxyphene as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.","phenotypeText":["decreased exposure to dextropropoxyphene"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AA genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["smaller decrease in glomerular filtration rate"]},{"genotypeAnnotationText":"No information were reported regarding patients with the TT genotype.","phenotypeText":["No phenotype reported"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have an increased risk of anemia as compared to the CT and TT genotypes. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["increased clearance","reduced clearance"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G genotype who are treated with clozapine may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal or no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs2279343 GG genotype may have decreased methadone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased bioavailability of pravastatin as compared to individuals with with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate increased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or CT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["decreased concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have decreased exposure to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["decreased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["smaller drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"Patients carrying the NAT2*6 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *6 allele in combination with *5, *6, or *7 allele (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *6 allele in combination with the *5, *6, or *7 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's hydralazine metabolism.","phenotypeText":["metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*3 genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3\/*3 genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["lower likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a shorter recovery time from general anesthesia as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["shorter recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the rs12422149 AG genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["decreased LDL lowering effect"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*37 allele or one copy of the *37 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"The UGT1A1*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["decreased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs578776 AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["risk for nicotine dependence"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA and stable coronary artery disease who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence risk hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["decreased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the AC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype, or decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with liver cancer and the CC genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype, or a decreased response as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of tolbutamide as compared to patients with the CC or CT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CC or CT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.","phenotypeText":["less bone mineral loss"]},{"genotypeAnnotationText":"Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["worse treatment response"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["reduced exposure to simvastatin"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype who are treated with doxorubcin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have lower weight gain when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs1799971 GG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"The AA genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["decreased CYP4F2 activity and decreased vitamin e metabolism"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["decreased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 (2R\/2R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype with colorectal neoplasms who are treated with celecoxib may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["decreased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*28 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the rs4530637 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs2298383 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may 1) require decreased dose of phenytoin, 2) have increase metabolism of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["require decreased dose of phenytoin","increase metabolism of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["lesser reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.","phenotypeText":["increased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/GGAGTC genotype who receive thiopurine treatment for autoimmune disease may be at a decreased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/del or del\/del genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["decreased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*13 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of phenytoin"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function or a decreased function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may have increased metabolism of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal function or no function allele. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["increased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the rs1801086 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs201268750 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs187713395 AA genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["severe anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["poorer chance at achieving remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival","decreased overall survival"]},{"genotypeAnnotationText":"Patients with the *1\/*3B genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may have decreased metabolism of dihydrocodeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect dihydrocodeine metabolism.","phenotypeText":["decreased metabolism of dihydrocodeine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased likelihood of adverse events when treated with fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the T\/del genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del\/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["decreased risk of lymph node metastases","increased survival rate"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"The CYP2C9*8 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *8 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["decreased response to beta-adrenergic inhalants","increased response to beta-adrenergic inhalants"]},{"genotypeAnnotationText":"Patients with the rs3778156 AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs510769 TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["reduced response","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have a increased severity of anemia as compared to patients with the AA or AG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AG and GG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs771237265 CC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["longer disease-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["decreased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC (POR *1\/*1) genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the CT and TT (*1\/*28 and *28\/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"The UGT1A1*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with a normal or decreased function allele may require an increased dose of irinotecan as compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect irinotecan dose requirements.","phenotypeText":["increased dose requirement of irinotecan"]},{"genotypeAnnotationText":"Patients with the rs140989814 CG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs113993959 GT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the CC genotype. This may be due to increased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the T allele as compared to those with the C allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["decreased risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the rs8099917 GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the rs5186 AC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 AA genotype may have a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have a decreased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["increased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*59 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["better response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the 9,10-repeat genotype (GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/del) may have a decreased response to disulfiram treatment for cocaine dependence. as compared to patients with the 10,10-repeat genotype. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["decreased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs558025 AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-DRB1*16:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*16:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["decreased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the GT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["lower likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the rs396991 AA genotype may have a decreased response to rituximab, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["decreased response to rituximab"]},{"genotypeAnnotationText":"Patients with the rs662799 GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["better response to treatment with adalimumab"]},{"genotypeAnnotationText":"Patients with genotype CC and schizophrenia may have decreased response to olanzapine compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs1806201 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele or a decreased function allele with an activity score of 0.25 may have increased metabolism of tolterodine as compared to patients carrying two no function alleles or two decreased function alleles with an activity value of 0.25 or a no function allele in combination with a a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have increased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["increased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs193922843 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may 1) require increased dose of phenytoin, 2) have decrease metabolism of phenytoin in people with Epilepsy as compared to patients with genotype AA or AG. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["increased dose of phenytoin","decreased metabolism of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2 by quinidine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have higher maximal platelet aggregation as compared to patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["higher maximal platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["lesser response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Type 2 Diabetes may have decreased response to sitagliptin or vildagliptin compared to patients with the GG genotype. Other factors may affect response to sitagliptin and vildagliptin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of dapoxetine as compared to patients with the CYP2D6*10 or *87 or *88 or *91 or *93 or *95 or *97 or *98 allele, and 2) similar clearance compared to CYP2D6*89 or *90 or *94 allele. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["increased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"The AT genotype was not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Purified CDA proteins with the AG genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*4 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs540825 AT genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["decreased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*6 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*59:01 alleles or negative for the HLA-B*59:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["increased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["positive erectile response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CT + TT. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["increased hematologic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (2R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients carrying the AA genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased pravastatin plasma AUC"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of sulfinpyrazone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["increased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Patients with the rs193922818 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs72549435 CC genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Individuals with the TT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically a decreased heart rate"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the AT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"CYP2D6 *10\/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1\/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["decreased inhibition of CYP2D6","increased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["increased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["lower reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of phenprocoumon as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["decreased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the AA genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have decreased likelihood of overall survival in as compared to patients with the AA genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs112563513 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["increased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["poorer response to treatment with tiotropium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased remifentanil requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["increased remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure of repaglinide and decreased response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["decreased exposure and response to repaglinide"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with amikacin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with amikacin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["increased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the GG genotypes and increased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival","increased progression-free survival"]},{"genotypeAnnotationText":"Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["increased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to first remission induction therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["decreased severity of sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a no function or normal function allele may have an increased risk of Stevens-Johnson Syndrome when treated with phenytoin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence the risk of Stevens-Johnson Syndrome.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have an increased analgesic response to ketorolac as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*28 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *1 allele in combination with another normal function allele may have an increased risk of transplant rejection when treated with tacrolimus as compared to patients with a normal function allele in combination with a no function allele or patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may have an increased risk of transplant rejection as compared to patients with two no function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.","phenotypeText":["decreased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer who are treated with capecitabine may have an increased risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs774072493 CC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the del\/del genotype. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have decreased likelihood of drug discontinuation as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the AA genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with *14\/*37 genotype may have decreased transport of atrasentan and increased concentration as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["decreased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the rs558025 GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs3778156 AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*15 allele or one copy of the *15 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine..","phenotypeText":["increased response or decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of severe ototoxicity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function alleles by CPIC. Patients carrying the *4 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["lower risk of relapse"]},{"genotypeAnnotationText":"Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have decreased likelihood of of drug discontinuation as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of drug discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:25 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased formation of gemcitabine triphosphate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["increased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["increased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to smoking may have a better response to treatment with bupropion as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["better response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to anti-depressant treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*29 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the GG genotype may have decreased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["decreased cerebrospinal fluid concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the rs531738678 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele construct (in this study PMID:26310775 only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs145014075 GG genotype may have decreased concentrations of nicotine as compared to patients with the GT genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["decreased concentrations of nicotine"]},{"genotypeAnnotationText":"Patients with the rs77932196 AG genotype (one copy of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"African-American patients with the TT genotype (APOE E2\/E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Male children with lead poisoning and the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2372536 CC genotype and rheumatoid arthritis may have increased likelihood of response when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *29 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and pain who are receiving Opium alkaloids and derivatives may have an increased severity of Substance-Related Disorders as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["increased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the rs17134592 TT genotype may have decreased metabolism of naltrexone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with lung cancer and the CC genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["decreased likelihood of neurological adverse reactions and sleepiness"]},{"genotypeAnnotationText":"Patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a normal function allele in combination with a no function allele or a donor with two no function alleles, while patients who receive a liver transplant from a donor with the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of morphine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"The CYP2D6*29 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*29 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*29 allele in combination with an increased function allele may have similar metabolism of tamoxifen as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AG genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 GG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for Torsades de Point"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*7 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*7 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased metabolism of folic acid"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["decreased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the TT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin","decreased dose of warfarin"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk","increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of caffeine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*9 allele may have decreased clearance of fentanyl as compared to patients with the *1\/*1 diplotype. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["increased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to heroin may have decreased withdrawal symptoms when treated with methadone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["decreased withdrawal symptoms"]},{"genotypeAnnotationText":"\"Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with \"\"standard risk cytogenetic profiles\"\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.\"","phenotypeText":["shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 TT genotype may have a decreased response to naltrexone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the C\/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of lopinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["worse response for fasting and postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["higher maximal rate (Vmax) of ethanol"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of fluvoxamine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["increased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["decreased response to citalopram and escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18\/*21 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine as compared to patients with the CYP2D6*1\/*1 genotype. Finding reported in case study for *18\/*21 subject. Other genetic and clinical factors may also influence the metabolism of debrisoquine.","phenotypeText":["decreased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with the *1\/*2 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*1 genotype who have non-valvular atrial fibrillation may require higher warfarin maintenance dose than patients with *1\/*2 or *1\/*3 or *2\/*2 or *2\/*3 or *3\/*3 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["higher warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2) decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for acute rejection","decreased incidence of lymphopenia"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *13 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["decreased severity of drug toxicity and hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of escitalopram as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of escitalopram as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["decreased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*6 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-A*02:01 allele and risk of severe cutaneous adverse reactions when treated with carbamazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of severe cutaneous adverse reactions when treated with carbamazepine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GTAAGTTG\/GTAAGTTG genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["less improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1800629 AA genotype may have decreased response to etanercept as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["increased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and Neoplasms may have decreased response to cyclophosphamide as compared to patients with AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*27 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["less likely to experience a reduction in systolic blood pressure following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["reduced risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["shorter disease-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to people with the GT or TT genotypes. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with acetazolamide. Other genetic and clinical factors may also influence a patient's risk of acetazolamide-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype who are treated with pravastatin may have a larger reduction in LDL and total cholesterol as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["larger reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype who receive thiopurine treatment for autoimmune disease may be at a decreased risk of developing thiopurine-related cytopenia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["decreased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal function allele or a decreased function allele with an activity score of 0.25 may have decreased metabolism of citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 TT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased clearance of paclitaxel"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Postoperative patients with the AG genotype may have lower morphine requirements as compared to patients with the GG genotype, but higher morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["less response"]},{"genotypeAnnotationText":"Patients with the CCT\/CCT genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the del\/del or del\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs9927200 AC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.","phenotypeText":["poor response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["no changes in mycophenolic acid exposure-related parameters","decreased risk of acute allograft rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["decreased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the AG genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["reduced clearance of risperidone"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["better response (higher decrease in HbA1c)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["improved clearance and metabolism of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["smaller mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*47 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*47 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with phenytoin as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype may have a decreased response to antidepressants as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["lower increase in fasting glucose"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*07:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. This allele is in strong linkage disequilibrium with HLA-DQA1*02:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["increased risk for smoking addiction, and a decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to fentanyl. However, patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not carry a copy of the CFTR R74W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased clinical benefit to fluoxetine"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *1\/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["increased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:03 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased concentration-to-dose ratios"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CYP2B6*6\/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1\/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["decreased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs768416963 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["increased risk of Pancreatitis"]},{"genotypeAnnotationText":"Patients with the rs777098658 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*20 allele or one copy of the *20 allele in combination with one copy of the *1 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles while patients with one copy of the *20 allele in combination with one copy of the *17 allele may have decreased metabolism of nicotine as compared to patients with two copies o the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the rs193922525 AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["increased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may require decreased doses of sertraline as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence sertraline dosage requirements.","phenotypeText":["decreased doses of sertraline"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AA genotype who are treated with azathioprine may have decreased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"The GG genotype is associated with an increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CYP3A5*1 allele in combination with another *1 allele or the *3 allele who are treated with tacrolimus may have a increased risk of nephrotoxicity as compared to patients with two CYP3A5*3 alleles. However, a number of studies show a decreased risk of nephrotoxicity for patients with CYP3A5*1 allele, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CG genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and gout may require a dose of 300 mg\/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["require a higher dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased exposure to methotrexate and lower likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the AA genotype may have increased cocaine cue-reactivity as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and diabetes mellitus may have an increased response when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["increased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs2244613 GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype, but increased oxycodone dose requirements as compared to patients with the AA genotype. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements","increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["increased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs368234815 TT\/TT genotype and chronic hepatitis C infection may have improved response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with G\/TT or GG genotypes. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":["improved response (including sustained virological response (svr))"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with cancer pain and the AC genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*1xN diplotype (ultrarapid metabolizers) may have increased clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or poor metabolizers (*4\/*4, *4\/*5). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["decreased risk for edema"]},{"genotypeAnnotationText":"Hispanic patients with the GG genotype may have a smaller decrease in viral load following the initiation of HAART as compared to Hispanic patients with the AA or AG genotypes. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["smaller decrease in viral load"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AC or CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. A single study reported its association with response to latanoprost by comparing the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism of propafenone"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["decreased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"No cells with the TT genotype were available for analysis, but cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["increased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response to treatment with methadone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":null},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["increased plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["increased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs5031016 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*18 allele or one copy of the *18 allele in combination with one copy of the *1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AT genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and schizophrenia, treated with risperidone may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype G. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["decreased risk of Angioedema"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP3A5*1 allele in combination with a no function allele may have an increased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with two no function alleles. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia when taking carboplatin and paclitaxel.","phenotypeText":["increased risk for leukopenia or neutropenia"]},{"genotypeAnnotationText":"Female patients with the TT genotype may have increased levels of cocaine, ethanol or nicotine use, which may lead to an increased risk of developing substance dependence, as compared to female patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["increased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with the rs77932196 CG genotype (one copy of the CFTR R347P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["increased concentrations of tacrolimus, and require a decreased dose"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["increased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with sulfasalazine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["increased methylation at sites within the COMT gene promoter"]},{"genotypeAnnotationText":"Patients with the GG genotype and who are treated with warfarin may require decreased dose as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2011425 GT genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["decreased serum concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"No patients with the GG genotype were present in the population. However, patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the rs374527058 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["decreased clearance and metabolism"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["smaller elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*45 allele or one copy of the *45 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.","phenotypeText":["no observed effect"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["increased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CYP3A4*1\/*1 genotype and breast cancer may have decreased concentrations of exemestane as compared to patients with the *1\/*22 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["decreased concentrations of exemestane"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to ethanol as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["increased response to ethanol"]},{"genotypeAnnotationText":"Evidence conflicts as to whether patients with the TT genotype and psoriasis have increased response to ustekinumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["conflicting evidence on increased response to ustekinumab"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients with the rs1800566 GG genotype who are treated with platinum chemotherapy regimens may have increased overall survival as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*38 allele or one copy of the *38 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["decreased metabolism of doxorubicin","greater tumor reduction","increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["decreased likelihood of a good response"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs369103276 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol","increased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment OR better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["decreased overall survival probability"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *5 allele or one copy of the *5 allele in combination with the *6 or *7 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the rs397508442 TT genotype (two copies of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*12A allele or one copy of the *12A allele in combination with one copy of any *4 or *13A alleles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["increased likelihood of achieving remission"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk of toxicities as compared to patients with the AG or GG genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AC genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CC genotype, may have a decreased likelihood of weight gain as compared to patients with the CT and TT genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients with ASD or schizophrenia who are taking risperidone, clozapine, or olanzapine.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 GT genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with a normal function allele may have decreased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["decreased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["decreased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased inhibition of FXIII activation by aspirin"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["decreased risk of adverse cognitive effects and sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["require the highest dose"]},{"genotypeAnnotationText":"Patients with the rs2736308 TT genotype may have a decreased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["decreased risk of Medication-related osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and diabetes mellitus may have a decreased response to pioglitazone as compared to patients with the GT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 AG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["decreased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and one or two copies of the HLA-B*15 allele may have a poorer response to interferon beta-1a treatment as compared to patients with no HLA-B*15 alleles or negative for the HLA-B*15 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.","phenotypeText":["poorer response to interferon beta-1a treatment"]},{"genotypeAnnotationText":"Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*3 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["lower ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion) may have decreased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTA\/TTA genotype (also described as 6bp deletion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The TPMT*3B allele has been assigned as a no function allele by CPIC. Patients carrying the *3B allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["decreased risk of adverse drug reaction"]},{"genotypeAnnotationText":"Patients with the rs444904 CC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the rs924607 TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["increased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["increased risk of Angioedema"]},{"genotypeAnnotationText":"Patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["increased risk for new-onset posttransplant diabetes mellitus (PTDM)"]},{"genotypeAnnotationText":"Patients with cardiac arrhythmias and carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have an increased response to propafenone as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to propafenone.","phenotypeText":["increased response to propafenone"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival","decreased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with a normal, decreased, or no function allele may have increased risk of bleeding when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to vitamin K1 as compared to patients with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["decreased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with the rs745364489 AA genotype may have an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the G genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with paroxetine may have an increased risk of adverse drug reactions as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs374515279 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["decreased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["lower response to repaglinide"]},{"genotypeAnnotationText":"Patients with the rs3740563 CC genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP3A4*20 allele in combination with one copy of the *1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele was only defined as C161S not including 2988G>A in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["increased fentanyl dosage requirements"]},{"genotypeAnnotationText":"There is current no available evidence regarding the association between the CYP3A5 *1\/*1 genotype and exposure to dextropropoxyphene.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs20455 GG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased response to citalopram or escitalopram in people with depression"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with another normal function allele may have increased clearance of everolimus as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with a no function allele may have increased clearance of everolimus as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["increased clearance of everolimus"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:09 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the TT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 allele may be at a decreased risk of developing neurotoxicity when treated with paclitaxel as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing neurotoxicity when treated with paclitaxel.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the G allele and HIV may have a greater decline in adiponectin when treated with antiretroviral therapy as compared to patients with the A allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.","phenotypeText":["greater decline in adiponectin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["shorter event-free survival time"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CC or CT genotype (carriers of E4). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["longer duration to reach stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit more from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["improved response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer or HIV may have increased metabolism and decreased concentrations of nelfinavir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased concentrations of nelfinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.","phenotypeText":["require the lowest dose"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response when treated with zileuton as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["decreased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype undergoing organ transplant who received a donor liver with the same genotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CT or TT genotype who received a donor liver heterozygous or homozygous for the variant (T) allele. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["decreased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with any combination of the *5A, *5B, *6A, *6B, *7A, *7B, *14A or *14B alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of addiction to heroin when using heroin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["increased risk of addiction to heroin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["decreased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being ineffective"]},{"genotypeAnnotationText":"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased risk of nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the *6\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["decreased likelihood of complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype may begin using heroin at an earlier age as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["earlier age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["increased risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2B6*26 allele is assigned as a decreased function allele by CPIC. Patients carrying CYP2B6*26 allele in combination with a no, decreased, normal, or increased function allele may require decreased dose of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["decreased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only H463D was considered) was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["similar clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response, decreased concentrations, increased risk of iron overload"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs538336580 AT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*4 allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["increased clearance of cyclosporine","increased dose of cyclosporine","decreased risk of infection"]},{"genotypeAnnotationText":"Caucasian patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*31:01 allele who are treated with carbamazepine may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*31:01 alleles or negative for the HLA-A*31:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["increased conversion of the drug to active polyglutamates","decreased response"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and carrying the UGT1A1*1 allele in combination with another normal function allele may have a decreased risk of developing thrombocytopenia when treated with FOLFIRINOX as compared to patients carrying two decreased function alleles or a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of developing thrombocytopenia when treated with FOLFIRINOX.","phenotypeText":["decreased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["decreased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["decreased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a better response to platinum-based chemotherapy as compared to patients with the AA or AG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["higher accumulation of active methotrexate metabolites","increased risk for thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the rs193922807 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["more severe side effects"]},{"genotypeAnnotationText":"Patients with genotype TT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs3804100 CT genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have decreased metabolism of rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence metabolism of rosiglitazone. This annotation only covers the pharmacokinetic relationship between CYP2C8 and rosiglitazone and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of rosiglitazone"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["decreased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["decreased anxiety"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes GG or GT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased sustained virological response (SVR)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["decreased likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*54 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*54 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype and liver cirrhosis with refractory ascites may be less likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/del or del\/del genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["increased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and diabetes or hypertension may have a better response when treated with benazepril or perindopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to nimodipine as compared to patient with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1128503 AG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["faster improvement in BPRS scores"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have lower S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*10 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.","phenotypeText":["lower S-propranolol plasma concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to drug"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glimepiride as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased metabolism of oxycodone as compared to patients carrying two increased function alleles or a normal function allele in combination with an increased function allele. However, patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of oxycodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.","phenotypeText":["decreased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the rs2874116 AA genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["increased clearance of efavirenz"]},{"genotypeAnnotationText":"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["increased risk for infections"]},{"genotypeAnnotationText":"Patients with the rs118192168 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased QT interval"]},{"genotypeAnnotationText":"Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["later onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.","phenotypeText":["decreased risk of cough"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":["increased exposure to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 CT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["better response to haloperidol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the rs121909020 GG genotype (do not have a copy of the CFTR A1067T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AT genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["decreased likelihood of recurrence and increased event-free and recurrence-free survival"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of vortioxetine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["decreased metabolism of vortioxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["increased risk of developing drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*5\/*8 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased risk for sleep disturbances"]},{"genotypeAnnotationText":"Patients with the AT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["decreased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to atorvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased progression free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time and decreased likelihood of experiencing remission"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:03 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AA genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["increased blood alcohol concentrations and decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a decrease response to risperidone as compared to patients with the CT or TT genotype. Please note this association did not reach statistical significance in one study, while another study failed to find an association. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decrease response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["decreased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with genotypes TT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.","phenotypeText":["increased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the *37 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["decreased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may experience a decreased severity of respiratory depression when treated with alfentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["decreased severity of respiratory depression"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["increased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"The AC genotype may be associated with increased CYP4F2 activity and decreased vitamin e metabolism as compared to the AA genotype and decreased metabolism as compared to the CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["increased CYP4F2 activity","decreased vitamin e metabolism"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased clearance of rocuronium as compared to patients with the del\/T and TT genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["increased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the TT genotype and kidney or lung transplantation may experience increased metabolism of tacrolimus resulting in decreased exposure as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence metabolism of tacrolimus.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs4148738 CT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased clearance of mirtazapine as compared to patients with two no function alleles and a decreased clearance of mirtazapine as compared to patients with an increased function allele in combination with a normal function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.","phenotypeText":["increased absorption rate and response to omeprazole"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["decreased clearance of lorazepam"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["decreased doses of carvedilol"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may require decreased doses of citalopram as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence citalopram dosage.","phenotypeText":["decreased doses of citalopram"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with citalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CC genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["increased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"Patients with the rs571335587 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Individuals with the GG genotype and HIV may have a increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["increased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs118192161 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*14 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*13A allele or one copy of the *13A allele in combination with one copy of any *4 or *12A alleles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*20 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to achieve a target HbA1c level of <7%"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["decreased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["higher dose-adjusted trough concentrations of cyclosporine and lower likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["lower pain relief to opioids"]},{"genotypeAnnotationText":"Patients with the rs193922747 TT genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CT and CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs6065 TT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response","decreased, but not absent, risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the GT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs20455 GG genotype may have increased response to atorvastatin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["less time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a lesser reduction in systolic blood pressure when treated with nifedipine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["lesser reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["increased cognitive impairment"]},{"genotypeAnnotationText":"Patients with the rs1303839356 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have an increased exposure to atorvastatin as compared to individuals with the AA or CC genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["faster improvement in Brief Psychiatric Rating Scale (BPRS) scores"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["better response to carvedilol treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["increased frequency of relapse"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the rs28358572 C allele (also known as the 1520C allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of experiencing aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["decreased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"Patients with the rs997917 TT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs12366035 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with ritonavir may have a increased intracellular\/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["increased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["lower risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["unfavorable prognosis"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 CT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype but decreased concentrations as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate","decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["increased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients with the *3\/*3 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["increased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["increased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["decreased concentrations of temozolomide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["increased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy may have increased metabolism of carbamazepine as compared to patients with the the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["decreased metabolism of escitalopram"]},{"genotypeAnnotationText":"Pre-menopausal women with the CC genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["decreased disease free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"The CYP2D^*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype may have increased activity of DPYD as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects","sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs121909013 GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Female patients with the CT genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["decreased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with TT genotype and breast cancer may have an increased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["risk of vomiting"]},{"genotypeAnnotationText":"Patients with the rs1801131 GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the rs755416212 TT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may be more likely to benefit from pravastatin treatment as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["decreased expression of TCL1A, IL17RA","increased expression of IL17A, IL12RB2, and IL1R2"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["increased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"In healthy volunteers the AA genotype may be associated with increased secretory clearance of metformin and in patients with diabetes mellitus may result in decreased efficacy (increased HbA1c levels), as compared to patients with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["increased secretory clearance of metformin","decreased efficacy (increased HbA1c levels)"]},{"genotypeAnnotationText":"Men with the non-null\/ non-null genotype (has two copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["decreased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the *1\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["decreased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AG genotype may have an increased daily intake of heroin as compared to heroin-dependent patients with the GG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["increased daily intake of heroin"]},{"genotypeAnnotationText":"Patients with the HLA-B*15:05 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*15:05 alleles or negative for the HLA-B*15:05 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["lower rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["increased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with postoperative pain and the CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["better response to statin therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["more inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CC genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*1 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["decreased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["decreased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have decreased exposure to nimodipine as compared to patient with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype who have a high risk of cardiovascular disease may have a poorer anti-inflammatory response when treated with fenofibrate as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["poorer anti-inflammatory response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["decreased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["decreased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the GG genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TPMT *3A\/*3A genotype, may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the *1\/*1 or *1A\/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["increased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentration of lovastatin acid"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have an increased risk of drug toxicity when treated when phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1275988 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["increased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have an lower, but not absent, risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["decreased risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AA genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased response to fluoxetine"]},{"genotypeAnnotationText":"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2244613 GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["increased risk of emergency department visits"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["poorer response to imatinib treatment"]},{"genotypeAnnotationText":"The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Individuals with the GT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype TT\/TT may have increased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype G\/TT or GG. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have increased methadone dose requirements as compared to patients with the TT genotype but decreased dose requirements as compared to the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["increased methadone dose requirements","decreased dose requirements"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for respiratory depression when treated with opioids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["decreased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with CC genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"The TT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with lower baseline serotonin levels and smaller decreases in serotonin levels as compared to the CT or CC genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["lower baseline serotonin levels and smaller decreases in serotonin levels"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and non-small-cell lung cancer may have longer overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the CCGG\/CCGG or CCGG\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["longer overall and progression-free survival times"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal function allele may have decreased metabolism of citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with carbamazepine or oxcarbazepine may have a decreased likelihood of a good response within as compared to patients with the CT or TT genotypes, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["decreased likelihood of a good response"]},{"genotypeAnnotationText":"Patients with the rs137904044 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased risk for depression"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele may have increased metabolism of venlafaxine as compared to patients carrying at least one uncertain function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of venlafaxine.","phenotypeText":["increased metabolism of venlafaxine"]},{"genotypeAnnotationText":"The CC genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased expression of DPYD"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the TT genotype may have an increased risk of leukopenia, as compared to patients with the CC and CT genotypes, but may also experience increased rates of event-free survival, as well as overall survival as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":["increased risk of leukopenia","increased event-free survival","increased overall survival"]},{"genotypeAnnotationText":"Women with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494C allele. However, conflicting evidence has been reported. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *1 allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles, but increased concentrations of methadone as compared to patients carrying a normal function allele in combination with an increased function allele. Patients carrying the *1 allele in combination with a no function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*2 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["increased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["slower reach to target blood pressure"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of lovastatin as compared to patients carrying the *5 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["increased metabolism of lovastatin"]},{"genotypeAnnotationText":"CT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["increased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["increased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response to etanercept treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["decreased response to propofol and remifentanil"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with increased reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs1799782 AG genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.","phenotypeText":["less likely to respond to antidepressant treatments"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GGTCCCACTCTTCCCACA\/GGTCCCACTCTTCCCACA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal function allele may have increased response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles, and decreased response as compared to patients with two no function alleles. Patients carrying the *3 allele in combination with another no function allele may have increased response to rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the CC genotype and mental disorders (excluding schizophrenia) may have smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["smaller weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["increased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Subjects with GG genotypes may have decreased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["decreased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentration of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["increased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to remain abstinent from smoking when treated with placebo as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["more likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["decreased risk of oedema"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and increased fluoxetine response or no association of the variant with response to fluoxetine treatment. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs6280 CC genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs397508513 AA genotype (do not have a copy of the CFTR K1060T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele was only defined by 4110C>G in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the GG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["decreased clearance of imatinib and decreased event-free survival time"]},{"genotypeAnnotationText":"Patients with the rs193922878 GG genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["develop malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["decreased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased serum concentration"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs3740563 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["increased risk for non-response","decreased risk for non-response","contradictory findings for no association of the variation with response"]},{"genotypeAnnotationText":"Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["decreased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*28 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["decreased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the TT genotype may have improved response to oxcarbazepine as compared to patients with the CC and CT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with escitalopram may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram and more severe side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["increased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:05 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["decreased risk of experiencing nausea"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the CC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["increased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.","phenotypeText":["lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs114558780 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with chronic pain and the AG genotype may be more likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["more likely to develop hyperalgesia"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["increased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["decreased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CG genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4 allele in combination with a no function allele and depression may require a lower dose of selective serotonin reuptake inhibitors as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's dose requirement.","phenotypeText":["lower dose requirement of selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of repaglinide as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the TT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["decreased metabolism of nicotine and longer time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may be at an increased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) but a decreased risk as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased catalytic activity of TYMS","increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying and the *28\/*28 genotype when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1\/*1, *1\/*28). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["decreased risk of neutropenia","increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may be more likely to respond to antihypertensives than patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*3 allele in combination with another no function may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4 or *7 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma treated with montelukast may have higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["higher plasma concentration of montelukast and better response to montelukast"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*5 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Female patients with the AA genotype and epilepsy may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["increased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele who are treated with fluoxetine may have increased metabolism of fluoxetine as compared to patients with two no function alleles, and may have increased metabolism of fluoxetine as compared to patients with one increased function allele in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["decreased serum concentrations of simvastatin acid"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the AG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*1 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["decreased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the rs75039782 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased consumption of nicotine as compared to patients with two copies of the *2, *4, *7 or *9 alleles, one copy of the *2 allele in combination with one copy of the *1 allele, one copy of the *4 allele in combination with one copy of the *7 or *9 alleles or one copy of the *7 allele in combination with one copy of the *9 allele. Patients with two copies of the *1 allele may also have decreased nicotine consumption as compared to patients with two copies of the *46 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["increased consumption of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*26 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"Cardiotox was not not found in GG group in this small study. The GG genotype (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.","phenotypeText":["more sensitive to trastuzamab"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["increased response to calcium channel blockers in people with Hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased, but not absent, risk for side effects as compared to the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele in combination with one copy of any *12 or *13 suballeles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["risk of azoospermia"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["faster desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the rs6517442 TT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["increased likelihood of cough"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1751034 CT genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["decreased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["better improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk for stroke"]},{"genotypeAnnotationText":"The TPMT*3C allele has been assigned as a no function allele by CPIC. Patients carrying the *3C allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["prolonged time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["increased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.","phenotypeText":["higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4646437 AG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype, or decreased concentrations as compared to the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["decreased social and clinical needs"]},{"genotypeAnnotationText":"Patients with the CYP2D6*50 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*50 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["increased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy","more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["decreased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"The GG genotype is associated with increased concentrations of UGT1A1 and increased glucoronidation of oxazepam as compared to the AA and AG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["increased concentrations of UGT1A1 and increased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*28 allele or one copy of the *28 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *28 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Has average risk for metabolic syndrome when treated with antipsychotics. Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in people with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may require increased dose of efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["increased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["increased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"The CYP2C9*31 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *31 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs2304016 GG genotype and epilepsy who are treated with antiepileptic drugs may have a decreased, but not absent, risk of drug resistance as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["decreased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs77932196 AC genotype (one copy of the CFTR R347H variant and one copy of the CFTR R347P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. R347P is not on this list of approved variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["increased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["decreased chance of severe hypersensitivity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["increased risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["increased response and decreased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["increased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the CYP2D6*12 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*12 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs671 AA genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["increased risk for heroin dependence"]},{"genotypeAnnotationText":"African-American patients with the CT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Pediatric patients with the AC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased risk for sleep disturbances"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Children with the TT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["increased risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CYP2D6*3\/*4XN genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"Elderly patients with the *2\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["decreased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AC genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD.","phenotypeText":["decreased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5A allele or one copy of the *5A allele in combination with one copy of the *5B, *6A, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["higher risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6 *1 allele may have increased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients carrying at least one copy of the CYP2A6*15, *21 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["increased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["increased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["less likely to experience neutropenia","increased progression-free survival"]},{"genotypeAnnotationText":"Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin","decreased prolactin"]},{"genotypeAnnotationText":"Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk of over-anticoagulation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs112445441 AC genotype (G13V) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the *14 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["increased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["decreased likelihood of cough"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk for aspirin sensitivity","increased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["increased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with the HLA-DRB1*07:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["decreased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["nausea"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["increased blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the rs3135506 GG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the reference B (reference) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and\/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and\/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":["decreased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased tumor response rate","increased risk of grade 3-4 nonhematological toxicity","decreased tumor response rate","decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertensive nephrosclerosis may have a better response to treatment with metoprolol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["better response to treatment with metoprolol"]},{"genotypeAnnotationText":"Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with ADHD and the rs71647871 CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"The CYP2C19*24 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*24 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["increased likelihood of ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["greater risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk for severe cutaneous adverse reactions when receiving lamotrigine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk for severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["increased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*2 allele in combination with a normal function or no function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Cells that carry the UGT1A4*1a allele may have decreased clearance of testosterone as compared to those with the *3a allele. Other genetic and clinical factors may also influence clearance of testosterone.","phenotypeText":["decreased clearance of testosterone"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6B allele or one copy of the *6B allele in combination with one copy of the *5A, *5B, *6A, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["decreased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["decreased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have increased risk for side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of sacubitril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["increased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C19 *17\/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the CYP2D6*62 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*62 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs193922764 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*38 genotype (assigned as a poor metabolizer phenotype) may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["decreased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["rapid nicotine metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity","increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["reduced risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs61742245 AA genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["lower dose-adjusted trough concentrations of cyclosporine and greater likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["lower risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*43 allele or one copy of the *43 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have decreased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response","decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*40:01 allele have a decreased, but not absent, risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*40:01 alleles or negative for the HLA-B*40:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs1800629 AG genotype may have increased response to etanercept as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced developing myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the AG and GG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["decreased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Patients with the TT genotype may also have increased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the CC genotype.Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CC genotype may have lower concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs11198893 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have higher weight gain when treated with antipsychotics as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["higher weight gain"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two functional CYP2C19 alleles (*1\/*1) may have increased metabolism of mephenytoin compared to patients with *2\/*2, *2\/*3, *3\/*3, *2\/5, *2\/*6 and *2\/*7 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["increased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the rs2330951 AC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with genotype TT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs145837941 GG genotype and postoperative pain may have increased consumption of fentanyl as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["increased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have increased dose requirements of sufentanil as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1127354 CC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["decreased likelihood of rejection"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for Adenoma"]},{"genotypeAnnotationText":"Patients with the rs558354142 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs374527058 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":["increased likelihood of CNS depression in breast-feeding infants"]},{"genotypeAnnotationText":"Patients with the rs2023239 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["more time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":["increased CD4-cell count","increased virologic response","increased risk for toxicity-related failure","decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["increased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["decreased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased clearance of imatinib, as well as an increased response and an increased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased clearance of imatinib","increased response","increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the TT genotype may have increased stress-induced alcohol cravings as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["increased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["longer hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may be more likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["more likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased oxycodone dose requirements as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients with the AA genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased response to nicotine"]},{"genotypeAnnotationText":"Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype and decreased response compared to the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["improved response and decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["increased risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["worse response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GT genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["increased response to gefitinib"]},{"genotypeAnnotationText":"Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["lesser response"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer who are treated with antineoplastic agents may be associated with improved survival as compared to women with the AG and GG genotypes. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["improved survival"]},{"genotypeAnnotationText":"Patients with the rs2359612 AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*48:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-B*48:01 alleles or negative for the HLA-B*48:01 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["decreased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["increased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["risk of death"]},{"genotypeAnnotationText":"People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased weight gain and increased risk of edema when treated with rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the toxicity to rosiglitazone.","phenotypeText":["increased weight gain and increased risk of edema"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CC genotype may be at a decreased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["decreased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs121909013 AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*19 allele or one copy of the *19 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased time to relapse"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype and blood cancers may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/3R or 3R\/3R genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have poorer response to beta-blockers as compared to patients with the AA genotype. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["poorer response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*36 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*36 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs778019189 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["increased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the rs10799590 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as E2\/E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 TT genotype may have increased risk of adverse events when treated with mercaptopurine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs10485058 AA genotype who are opioid-dependent may have an increased response to treatment with methadone as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":["increased response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with gemcitabine and platinum compounds may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased subjective response to oxycodone as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["decreased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are heroin dependent may require an increased dose of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the TT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["longer time to failure"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype may have an increased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CC or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have decreased response when treated with enalapril as compared to patients with the del\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the CG genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["higher risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects","decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the AC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with escitalopram may have an increased chance of response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased chance of response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["decreased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR short form (S allele)\/L allele and HTTLPR S allele\/S allele genotypes. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk for depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased inhibition of FXIII activation"]},{"genotypeAnnotationText":"Patients with the CG genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the GG genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients who have genotype TT or CT. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for toxicity when treated with antineoplastic agents as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance","decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 CG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["greater cravings for nicotine"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["decreased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["decreased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with another decreased function allele may have decreased irinotecan dose requirements as compared to patients carrying a normal function allele in combination with a decreased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan dose requirements.","phenotypeText":["decreased irinotecan dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":["decreased risk of adverse drug reactions","increased exposure to active mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with another no function allele may have increased response to sulfonylureas (reduced risk of sulfonylureas treatment failure and better HbA1c response) as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs628031 AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Purified CDA proteins with the AA genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.","phenotypeText":["greater reduction in LDL-C"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/A- 202A_376G haplotype (homozygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["may not respond to treatment for methemoglobinemia","increased risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Patients with the rs139945292 CT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["decreased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the rs397508328 AG genotype (one copy of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype, or decreased as compared to the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with CYP1A1*1\/*1 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1\/*2A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["lower granisetron clearance and increased exposure"]},{"genotypeAnnotationText":"CYP2D6 *1\/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1\/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["decreased inhibition of CYP2D6","increased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*20 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with GSTT1 null\/null genotype may have increased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype non-null\/non-null + non-null\/null. The risk of imatinib failure was increased further if GSTT1del was accompanied by GSTM1 del. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["increased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["increased severity of thrombocytopenia and decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Female children with lead poisoning and the A- 202A_376G\/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*17 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38 allele have an increased likelihood of being a non-responder to therapy when treated with pegylated interferon and ribavirin, as compared to patients with no HLA-B*38 alleles or negative for the HLA-B*38 test. Other genetic and clinical factors may also influence a patient's response to pegylated interferon and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*38 allele. This clinical annotation appears on the HLA-B*38:01 allele page because this was the first *38 allele discovered.","phenotypeText":["increased likelihood of being a non-responder to therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Adolescents with the AA genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["increased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to metoprolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs2952768 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AG and GG genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["may not respond to treatment for methemoglobinemia","increased risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*31 allele has been assigned as a no function allele by CPIC. Patients carrying the *31 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *31 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *31 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to respond to methotrexate"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele was only defined as R388H not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the rs1801252 GG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["increased response to carvedilol"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["less likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia, and neuropathy)"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["greater aromatase inhibition"]},{"genotypeAnnotationText":"Patients with the rs2307116 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["increased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs4917639 CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the *1\/*1 may have increased plasma concentrations of montelukast as compared to patients with the *3 allele, or decreased concentration of the *4 allele. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["decreased imatinib clearance"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["increased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["worse response to fluoxetine therapy"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased HDL-cholesterol)","reduced response (lower increases in HDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have poorer blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CT or TT genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. Other genetic and clinical factors may also influence aripiprazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele or a normal function allele may require a decreased dose of clobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["decreased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*3C diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3C specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["increased plasma concentrations of 6-thioguanine during thiopurine treatment"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["increased risk of cardiovascular events","decreased collagen induced platelet aggregation"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 TT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response to rosuvastatin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["smaller reductions in diastolic blood pressure and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2298383 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs118192168 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for mucositis when treated with methotrexate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["increased risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["increased response to triple therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased progression free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs193922762 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["increased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494C allele. However, conflicting evidence has been reported. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 AT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with gemcitabine may have an increased risk for toxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["decreased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs12208357 CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["lower plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["decreased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["higher likelihood of side effects","reduced likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs11322783 TT\/TT genotype and chronic hepatitis C may have increased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 TT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["less inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*28 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*4 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["decreased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 CC genotype may have an increased response to disulfiram as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased fentanyl dosage requirements as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["decreased fentanyl dosage requirements"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1\/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 GG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["decreased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Male children with the B (reference) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients who receive a kidney with the GG genotype may have increased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AA or AG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["increased estimated glomerular filtration rate (eGFR)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of carbocisteine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the rs200554095 TT genotype may have increased metabolism of nicotine as compared to patients with the AA or AT genotypes. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs12885713 CC genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 TT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["higher LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the CT or CC genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele have an increased risk for maculopapular eruption when treated with carbamazepine as compared to patients with no HLA-DRB1*03:01 alleles or negative for the HLA-DRB1*03:01 test. Other genetic and clinical factors may also influence a patient's risk of maculopapular eruption when treated with carbamazepine.","phenotypeText":["increased risk for maculopapular eruption when treated with carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs267606619 C allele (also known as the 1494C allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with micronomicin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with micronomicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the AA genotype, may have elevated concentrations of lumefantrine as compared to patients with the A\/del or del\/del genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Pre-menopausal women with the AA genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased likelihood of Tobacco Use Disorder","decreased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to corticosteroids compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with methotrexate may have an increased risk of leukopenia and neutropenia as compared to the AA genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.","phenotypeText":["increased risk of leukopenia and neutropenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922816 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)7\/(T)7 genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)8 or (T)8\/(T)8 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased risk of leukopenia","decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["decreased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with any *5, *6 or *7 suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["decreased risk of addiction to heroin","increased risk of heroin addiction"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with metformin may have decreased bioavailability of metformin as compared to patients with the CC or CT genotypes, however the opposite is reported in one study, and no association was reported in two studies . Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["decreased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["decreased clearance and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk of leukopenia"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and who do not carry an activating somatic EGFR mutation, for example the TT genotype at rs121434568 (also known as L858R), may have a decreased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who have an activating EGFR mutation, for example the GG or GT genotypes at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["decreased response to gefitinib"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:01 allele may have an decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs121908757 CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response to candesartan"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.","phenotypeText":["decreased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AG or GG genotype. However, a different study found that the AA genotype was associated with poorer response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have more blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["more blood pressure reduction"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of amitriptyline as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with a combination of alleles that result in ultrarapid metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["decreased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 AG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium or valproic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to pravastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of nevirapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["decreased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*30 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["decreased risk of becoming agitated"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in addition to an increased function allele may have a similar analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect response to hydrocodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs4752292 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and soft tissue sarcoma may have a longer progression-free survival time when treated with doxorubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a shorter median survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["shorter median survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *1xN allele in combination with a normal or increased function allele may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased or no function allele may also have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased or no function allele may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["increased likelihood of disease recurrence"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"The AG genotype was not studied in association with affinity to losartan.","phenotypeText":["affinity to losartan"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased response to tocilizumab as compared to patients with the AC or CC genotypes. Note that an increased response was only seen with one metric at one timepoint from the three analyzed in the study. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["greater methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["increased risk of fatigue"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. Patietns carrying the *1 allele in combination with a no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence","decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower maximal platelet aggregation as compared to patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["lower maximal platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs2253201 AG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["increased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["higher dose-adjusted trough concentrations of cyclosporine and lower likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1\/*1 diplotype and increased clearance of ketamine as compared to patients with the *6\/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["decreased clearance of ketamine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the CYP2C19*22 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*22 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for the substrate mephenytoin was reported in one study, while another study reported reduced protein expression of the *22 allele compared to the WT protein. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity of CYP2C19"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["increased abstinence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of phenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["decreased risk of developing cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the AA genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.","phenotypeText":["decreased levels of the active metabolite"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele may have increased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased likelihood of neutropenia compared to patients with two decreased function alleles. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["increased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with hypertension and the GT genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the TT genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the genotype AA may have increased response to aripiprazole in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus or sirolimus as compared to patients with the AA or AC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.","phenotypeText":["increased metabolism of temsirolimus or sirolimus"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*42 allele or one copy of the *42 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*14:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*14:01 alleles or negative for the HLA-DRB1*14:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"The CYP2C9*42 allele has been assigned as a no function allele by CPIC. Patients carrying the *42 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have reduced alfentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["reduced alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["longer hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["decreased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the non-null\/ non-null genotype (has two copies of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["increased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["decreased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 AG genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*10:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CYP2D6*55 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*55 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs193922809 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs4633 TT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of amlodipine as compared to patients carrying at least one copy of the *3, *6 or *7 alleles. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["increased metabolism of amlodipine"]},{"genotypeAnnotationText":"Women with poor metabolizer genotypes, such as *2\/*3, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["decreased anxiety"]},{"genotypeAnnotationText":"Adolescents with the AG genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["increased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may benefit less from atorvastatin and quinapril treatment (due to less of a reduction in the fibrinolytic marker D-dimer) as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["benefit less from atorvastatin and quinapril treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may havesimilar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["decreased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the rs3781727 CC genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["increased likelihood of complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6A allele or one copy of the *6A allele in combination with one copy of the *5A, *5B, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["decreased response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["decreased retention rates"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs5882 AA genotype may have a decreased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 TT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have low on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["low on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508602 AG genotype (one copy of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs768416963 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["greater methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with the rs116855232 CC genotype may have increased dose of mercaptopurine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["increased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["decreased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["larger changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or less severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["increased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the AT genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["decreased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs115346678 AA genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased risk for smoking addiction"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with olanzapine or risperidone may have increased time until response as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["increased time until response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["higher maintenance dose"]},{"genotypeAnnotationText":"Patients with depression and the GT genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["greater reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["decreased risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*1 genotype. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["increased likelihood of adverse events","worse response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["increased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["lower homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no evidence of a difference in remifentanil requirements between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["no difference in remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased overall survival period"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["more likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the rs7557402 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1\/*2 or *1\/*3A or *1\/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["decreased risk of severe rejection"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["complete response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["more likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["lesser reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*3B or *1\/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6 *1\/*1 diplotype may have increased clearance of fentanyl as compared to patients with the *9 or *29 alleles. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["increased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may experience a greater weight gain when treated with clozapine or olanzapine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence","decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["decreased concentrations of atazanavir"]},{"genotypeAnnotationText":"Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["smaller increases in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2236857 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["decreased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs118192172 CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["decreased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*55:01 allele may have an increased risk of hypersensitivity when treated with penicillin as compared to patients with no HLA-B*55:01 alleles or negative for the HLA-B*55:01 test. Other genetic and clinical factors may also influence risk of hypersensitivity to penicillin.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of clomipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of clomipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of clomipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*01:02 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-C*01:02 alleles or negative for the HLA-C*01:02 test. Other genetic and clinical factors may also influence a patient's risk of methazolamide-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better event-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better event-free survival"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:02 allele have an increased risk of drug-induced liver injury (DILI) when taking minocycline as compared to patients with no HLA-B*35:02 alleles or negative for the HLA-B*35:05 test. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury when taking minocycline.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["less likely to have positive erectile response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CC genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 CC genotype may have decreased metabolism of irinotecan as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":["decreased risk of adverse drug events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a decreased function allele with an activity value of 0.25 may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["lower plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype (CYP3A4*1B allele) may have decreased clearance of fentanyl as compared to patients with the rs2740574 TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms who are treated with methotrexate may have a decreased clearance of methotrexate as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*33 allele or one copy of the *33 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype may have increased metabolism of nicotine and cotinine as compared to patients with the *1\/*1 genotype. However, this has been partially contradicted by another study. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine and cotinine"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs193922748 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins\/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["more likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased time to achieve therapeutic international normalized ratio"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["decreased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the rs193922843 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of cocaine dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of tacrolimus as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs397508328 AA genotype (do not have a copy of the CFTR M1V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs199515342 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the rs2031920 CC genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs118192176 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"The TPMT*3A allele has been assigned as a no function allele by CPIC. Patients carrying the *3A allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs113100019 TT genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the del\/del genotype, may have lower concentrations of lumefantrine as compared to patients with the A\/del or AA genotypes. There is no association with response. Other clinical andgenetic factors may also influence concentrations of lumefantrine in pregnant infected with malaria.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5D allele or one copy of the *5D allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["decreased likelihood of event-free survival"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole","similar metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:27 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:27 alleles or negative for the HLA-B*15:27 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele was only defined as AV5 not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs758649719 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Infants with the rs1799971 AG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with breast cancer and the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del\/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"Healthy individuals with the *1\/*1 genotype may not have decreased concentrations of carisoprodol as compared to those with the *1\/*2 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.","phenotypeText":["not have decreased concentrations of carisoprodol"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*1 genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *1\/*3A or *3A\/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1C allele or one copy of the *1C allele in combination with one copy of the *1A allele may have an increased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1A allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:27 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*15:27 alleles or negative for the HLA-B*15:27 test.","phenotypeText":["increased risk of cutaneous adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the del\/del genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or A\/del genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*1 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*1 allele and response to citalopram"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["less likely to achieve a complete response","less likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission or less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the CYP2C19*6 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*6 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"In human liver microsomes, the TT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients carrying one copy of the 10-repeat allele and one copy of the 9-repeat allele may report more drinking days as compared to patients carrying two copies of the 10-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["more drinking days"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"No information about the AG genotype is reported in the study. However, patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["increased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs28399499 CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the CC (POR *1\/*1) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have decreased metabolism of tacrolimus as compared to patients with the CT and TT (*1\/*28 and *28\/*28) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs34545984 TT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the rs5186 AA genotype may have a decreased response to irbesartan as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["decreased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-B*15:02 allele and risk of maculopapular exanthema when treated with oxcarbazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of maculopapular exanthema when treated with oxcarbazepine.","phenotypeText":["no significant association with risk of maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["increased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the AA or AC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with TT genotype and essential hypertension may have decreased response to telmisartan compared to patients with genotype CC and CT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased analgesic response to sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["not found to have different response to ustekinumab"]},{"genotypeAnnotationText":"Cells with the CC genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["increased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with depressive disorder and the ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["worse response to sertraline"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["decreased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with depressive disorder and the del\/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["worse response to sertraline"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased plasma concentrations of alfentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers, but may not be associated with risk of exanthema.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have increased survival times when treated with oxaliplatin-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients carrying two copies of the 10-repeat allele may report less severe negative effects of alcohol as compared to patients carrying one or two copies of the 9-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["less severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["decreased risk of developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure)"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *1\/*1 diplotype may have decreased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*22 or *22\/*22 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["decreased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs77932196 AA genotype (two copies of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["decreased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 alleles. The CYP2C19*1 allele was found to have an increased clearance of mephenytoin and an increased catalytic activity as compared to CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 during in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["increased enzyme activity of CYP2C19","increased clearance of mephenytoin","increased catalytic activity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["decreased risk of Cough"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["lower plasma drug levels"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs118192176 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele or a donor with two no function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for rash"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*1 genotype who are treated with tamoxifen may have increased metabolism of tamoxifen, but a poorer response to the drug as compared to those with the *1\/*2 or *2\/*2 genotype. Women with breast cancer and the *1\/*1 genotype may have an improved response to the drug as compared to those with the *1\/*17 or *17\/*17 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*1 genotype as compared to those with the *2\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["increased metabolism of tamoxifen","poorer response to the drug","improved response to the drug"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 del\/del genotype may have a decreased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs193922878 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["decreased risk of developing cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to alfentanil as compared to patients with the AG or GG genotypes. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the rs28399499 TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["decreased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet inhibition and better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["reduced severity of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer overall survival"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have increased metabolism of nifedipine as compared to patients with two copies of the *17 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and nifedipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nifedipine metabolism.","phenotypeText":["increased metabolism of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs111888148 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of warfarin as compared to patients with at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the rs9344 AA genotype may be at a decreased but not absent risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and a GSTT1 non-null genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with a null genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with depression and the GG genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients with two copies of the *1 allele may have increased metabolism of metronidazole as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *9 or *17 alleles. However, one study found failed to find this association for the *17 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["increased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased heart rate when treated with Beta Blocking Agents as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AA genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["increased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased pain reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype, or increased clearance as compared to those with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["decreased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["increasing creatinine levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["decreased clearance of 2',2'- difluorodeoxyuridine (dFdU)"]},{"genotypeAnnotationText":"Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response or better response in LDL-cholesterol"]},{"genotypeAnnotationText":"Female patients with the TT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["less likely to experience a loss of libido"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs11615 GG genotype may have an increased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["increased risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["decreased clearance of voriconazole","increased clearance of voriconazole"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have lesser aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["lesser aromatase inhibition"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["better rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["associated with overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the rs708272 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1\/*3 or CYP2C9 *1\/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["increased clearance and decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs10485058 GG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of atomoxetine as compared to patients with two no or decreased function alleles. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of atomoxetine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 CT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response"]},{"genotypeAnnotationText":"Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased beta cell function"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to omeprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["reduced response to omeprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["increased likelihood of ototoxicity"]},{"genotypeAnnotationText":"The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the rs4633 CC genotype may have a decreased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1051266 CC genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*52 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*52 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have decreased metabolism of venlafaxine. This annotation only covers the pharmacokinetic relationship between CYP2C19 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as compared to patients with the CG genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.","phenotypeText":["better response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Individuals with the *2\/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"Male patients with the G genotype may have a better response to risperidone as compared to patients with the A genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype AA or AT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the rs368234815 TT\/TT genotype and chronic hepatitis C may have increased response to sofosbuvir and ribavirin as compared to patients with the TT\/G or G\/G genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["decreased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["increased risk of developing drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 CTT\/CTT genotype (no copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["increased likelihood of adverse events","worse response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the rs10248420 AA genotype may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["decreased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased severity of dyspepsia when treated with ketoprofen as compared to patients carrying a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also influence the severity of dyspepsia.","phenotypeText":["decreased severity of dyspepsia"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 CC genotype may have decreased concentrations of methotrexate as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["lower platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["increased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs1544410 TT genotype who are treated with alendronate may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.","phenotypeText":["less improvement in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"The TT genotype may be associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the TT genotype and depressive disorder may have an increased response to fluvoxamine compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2359612 AG genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response (a higher reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","similar metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["risk of craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["increased risk of oedema"]},{"genotypeAnnotationText":"Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the *9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["smaller reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:27 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["less likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CC genotype may have an increased response to bucindolol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["increased response to bucindolol"]},{"genotypeAnnotationText":"Patients with the rs193922772 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity","increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/non-null or non-null\/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["decreased QTc interval"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/del genotype may not may not respond to treatment with cavosonstat. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["may not respond to treatment with cavosonstat"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["increased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and one or two copies of the HLA-DRB1*04 allele may have a better response to interferon beta-1a treatment as compared to patients with no HLA-DRB1*04 alleles or negative for the HLA-DRB1*04 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.","phenotypeText":["better response to interferon beta-1a treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Individuals with the TC\/TC genotype may have decreased clearance of olanzapine as compared to individuals with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*24 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1806201 AG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"People with intermediate metabolizer genotypes (e.g. *1\/*2) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*13 allele or one copy of the *13 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the TT genotype but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased steady state levels of KDR, possibly leading to decreased metabolism and increased response to pazopanib"]},{"genotypeAnnotationText":"Patients with the rs628031 AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs121918593 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with increased reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have an increased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["increased risk of anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CT or TT genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 AG genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Alzheimer's disease may be more likely to respond to treatment with cholinesterase inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival","decreased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 AA genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3A genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *3A\/*3A genotype, and increased risk of ototoxicity as compared to patients with the *1\/*1 genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["decreased risk of ototoxicity","increased risk of ototoxicity"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs717620 CT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have an increased exposure to tramadol as compared to patients with the GG or GT genotypes. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs371258350 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["more sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *4\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["increased clearance of imatinib","decreased response","decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del (two copies of the CFTR F508del variant) genotype and cystic fibrosis may have increased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["increased chance of eradication failure"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 AA genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["decreased risk of experiencing nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with corticosteroids may have an increased response to corticosteroids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.","phenotypeText":["decreased risk of triglyceride elevation"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs28933397 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1611114 CC genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["risk of experiencing memory impairment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["increased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects","sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Caucasian patients with the TT genotype may have a decreased risk of developing opioid dependence as compared to Caucasian patients with the CC or CT genotypes. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have reduced clearance of efavirenz as compared to patients with the AG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["reduced clearance of efavirenz"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with the AA genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["increased risk of addiction"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs4035887 GG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association between the rs1799971 AA genotype and likelihood of experiencing adverse events when treated with sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are addicted to methamphetamines may have an increased risk for methamphetamine-induced psychosis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["increased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs10929302 GG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have a shorter overall and event-free survival time as compared to patients with the AG or GG genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*30 allele or one copy of the *30 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an unknown function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response","longer overall survival time"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased risk of leukopenia","decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of drug toxicity","decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["increased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype.","phenotypeText":["decreased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["increased doses of anti-Parkinsonian drugs","increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have an increased response to cisplatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as APOE E2\/E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two alleles from the C2 group of HLA-C alleles (i.e. *02, *04, *05, *06, *15 or *17) may have a decreased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16).","phenotypeText":["decreased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time and progression-free survival time, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response, shorter overall survival time, shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*5 allele in combination with a normal function allele (e.g. *1\/*5) or another decreased function allele (e.g.*5\/*8) or a no function allele (e.g. *5\/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["decreased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myeloid leukemia may have increased clearance of imatinib, as well as increased event-free survival time, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["increased clearance of imatinib and increased event-free survival time"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*23 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs7967354 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).","phenotypeText":["decreased clearance of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Myeloid Leukemia who are treated with cytarabine may have an increased survival time and a decreased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased survival time","decreased risk of death"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["higher plasma drug levels"]},{"genotypeAnnotationText":"Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["decreased clearance of doxorubicin","increased exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotypes AA may have decreased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["decreased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the rs10752271 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["increased plasma concentration of atorvastatin"]},{"genotypeAnnotationText":"Patients with the rs6295 GG genotype may have increased response when treated with paroxetine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype who also have rs45445694 genotype 2R\/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele or a normal function allele may have a decreased analgesic response to methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.","phenotypeText":["decreased risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the A\/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["impaired catalytic activity"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the CT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["decreased antidepressant response"]},{"genotypeAnnotationText":"Patients with the rs183701923 TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with genotype GG and epilepsy may have an increased risk of drug toxicity when taking valproic acid as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the del\/T genotype may have decreased metabolism of mycophenolic acid as compared to patients with the TT genotypes but increased metabolism of mycophenolic acid as compared to patients with the del\/del genotype. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["decreased metabolism of mycophenolic acid","increased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with lisinopril as compared to patients with the del\/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CT genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the TT genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.","phenotypeText":["decreased beta cell function"]},{"genotypeAnnotationText":"Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs570122671 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with CT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs77409459 TT genotype (two copies of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and choroidal neovascularization may have a poorer response to anti-VEGF treatment, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["poorer response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased response to rituximab as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["increased response to rituximab"]},{"genotypeAnnotationText":"Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["decreased risk of becoming agitated"]},{"genotypeAnnotationText":"Patients with the CYP2C19*26 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*26 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterizations. 42% of the clearance ratio of *1 for mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["increased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may have improved overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["improved overall survival"]},{"genotypeAnnotationText":"Patients with the rs6269 AG genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the C genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["less of a decrease in bone mineral density"]},{"genotypeAnnotationText":"Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["increased blood pressure","risk for hypertension","slower control of blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.","phenotypeText":["smaller decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs718656 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["increased risk for virological failure"]},{"genotypeAnnotationText":"Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of severe ototoxicity"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with escitalopram may have a decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP2A6*23 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*7 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of Esophagitis"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 CT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotype may have an increased likelihood of hypertension when taking sunitinib as compared to patients with the AA and AT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["increased likelihood of hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["decreased risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["increased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the *1\/*5 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1 genotype and decreased exposure as compared to the *4\/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the AG genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"No patients with the *22\/*22 genotype were available for analysis, but patients with the CYP3A4*1\/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["increased concentrations of exemestane"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["decreased risk of cough"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 1 or 2 decreased function alleles. Patients carrying the *1 allele in combination with a decreased function allele may have increased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 2 normal function alleles. Other genetic and clinical factors may also influence sorafenib-induced hyperbilirubinemia.","phenotypeText":["decreased likelihood of hyperbilirubinemia","increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["decreased risk for myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the *3 allele may have decreased plasma concentration and increased clearance when exposed to pioglitazone as compared to patients with *1\/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["decreased plasma concentration and increased clearance"]},{"genotypeAnnotationText":"Patients with the rs140039091 CG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CT genotype may have a better response to capecitabine or fluorouracil as compared to patients with the CC genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["increased risk of cardiovascular events","decreased collagen induced platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*29 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*9 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*9 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients who are smokers and have the AA genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["decreased lung function"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*16 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the non-null\/ non-null genotype (has two copies of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1544410 CC genotype who are treated with alendronate may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.","phenotypeText":["greater improvement in bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AC genotypes. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs34911792 GT genotype (one copy of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased severity of alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["decreased severity of alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 GG genotype may be at a decreased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CCGG\/del genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs113100019 GG genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["decreased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing neutropenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs118192163 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 CG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["less likely to enter remission"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*1 genotype ((TA)6\/(TA)6) and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the*28\/*28 genotype ((TA)7\/(TA)7) . Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*13 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the TT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a greater chance of achieving complete remission, and a decreased risk of experiencing drug toxicities, as compared to patients with the non-null\/null or null\/null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["greater chance of achieving complete remission","decreased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the rs28933397 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the CYP2D6*75 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*75 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs6269 AA genotype may have a decreased analgesic response to morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"People with normal metabolizer genotypes (e.g. *1\/*1) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AC genotype may have a decreased response to metformin as compared to patients with the CC genotypes and an increased response as compared to patients with the AA genotype. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["decreased response to metformin","increased response to metformin"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have decreased metabolism of N-desmethylclobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia or psychotic disorder may have increased metabolism of antiepileptics compared to patients with the CC or CT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["increased metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["likelihood of toxicity"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*6 allele in combination with a normal function allele (e.g. *1\/*6) or a decreased function allele (e.g. *5\/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require an increased dose of phenprocoumon as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["require an increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["decreased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["increased doses of anti-Parkinsonian drugs","increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["increased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs150212784 TT genotype (do not have a copy of the CFTR F1052V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the CC genotype or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to citalopram as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alcoholism may have decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a dcreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or AA genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype who are receiving methadone maintenance therapy may have increased clearance of methadone, leading to decreased plasma concentration of methadone as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["increased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["increased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["risk for nausea","decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs193922803 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*17 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the rs1560022535 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the A\/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with methotrexate may have increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for toxicity","increased plasma level"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have an increased risk of sadness as a side effect as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["lower risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the rs397508288 AG genotype (one copy of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["decreased clozapine plasma concentrations and decreased risk for agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have shorter overall survival as compared to patients with the CT and TT genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["shorter overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["smaller increases in spine bone mineral density","larger decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of atazanavir as compared to patients with the TT genotype and increased clearance as compared to patients with the CC genotype. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["decreased clearance","increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GTAAGTTG\/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype or may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG\/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["increased risk of hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*13 allele in combination with a normal function allele (e.g. *1\/*13) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased but not absent risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["increased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*24:02 allele may have an increased risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS\/TEN), when treated with phenytoin as compared to patients with no HLA-A*24:02 alleles or negative for the HLA-A*24:02 test. However, this allele was seen in linkage with HLA-A*02:01. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced SJS\/TEN.","phenotypeText":["increased risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Individuals with the TCCTC\/TCCTC genotype may have increased clearance of olanzapine as compared to individuals with the TC\/TC or TC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response or better response to pravastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the rs6517442 CC genotype may have increased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and two copies of the CYP3A4*1 allele may have an increased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with one copy of the *1 allele in combination with one copy of the *22 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*26 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *26 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele in combination with *12A or *13A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with pravastatin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["increased chance of survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["reduced risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased response to antidepressants","decreased, but not absent, risk for suicide ideation"]},{"genotypeAnnotationText":"Colon cancer patients with AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased likelihood of discontinuation of methotrexate in people with Arthritis"]},{"genotypeAnnotationText":"Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for elevated triglycerides"]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations","achieve therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the *5\/*10 genotype may have decreased metabolism of lovastatin as compared to patients without the *5 allele, but increased metabolism of lovastatin as compared to patients with the *5\/*5 genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype but an increased risk as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence","increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a\/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["better response to treatment with interferon beta 1a\/1b"]},{"genotypeAnnotationText":"Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for nicotine addiction"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to rabeprazole (greater % of time with intragastric pH < 4.0, and a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a normal function allele in combination with a no function allele or two no function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["decreased response to rabeprazole"]},{"genotypeAnnotationText":"Patients with the AC genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["poorer response to glucocorticoid treatment and lower lung function"]},{"genotypeAnnotationText":"Patients with rs16969968 GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or AA genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.","phenotypeText":["increased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["increased risk for Alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["lower pain relief to opioids"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["decreased risk of Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*3 allele or one copy of the *3 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["decreased response to treatment with docetaxel and doxorubicin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["decreased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with the rs6686529 CC genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.","phenotypeText":["increased sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of sufentanil"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluoxetine may have increased risk of sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["increased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash","increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["decreased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may experience a high frequency of adverse events when being treated with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["high frequency of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["decreased likelihood of complete response"]},{"genotypeAnnotationText":"The CYP2D6*14 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *14 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *14 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["increased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 CC genotype may have an increased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["increased risk of experiencing nausea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*3 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["less blood pressure (BP) reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["not require a dose reduction of ribavirin"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*114 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*114 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["increased clearance of voriconazole"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs1799752 del\/del genotype may have a decreased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have a decreased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"The TPMT*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["decreased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["decreased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of oseltamivir compared to patients with the TT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.","phenotypeText":["increased concentrations of oseltamivir"]},{"genotypeAnnotationText":"Patients with the rs67376798 AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to gabapentin. However, patients with the AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the CC genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs12777823 AG genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance","increased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["increased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of alcoholism compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.","phenotypeText":["increased risk of alcoholism"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the AA genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with CG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["decreased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CG and GG. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases who are taking anastrozole or letrozole.","phenotypeText":["increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to olanzapine as compared to patients with the AG or GG genotypes. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may require increased doses of citalopram as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence citalopram dosage.","phenotypeText":["require increased doses of citalopram"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7 or *9 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["increased likelihood of neutropenia or leukopenia","decreased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have increased concentrations of methotrexate as compared to patients with the CT and TT genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs28933397 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CYP2D6*63 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*63 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"People with CC genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["decreased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer Disease may have increased response to donepezil, galantamine, or rivastigmine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["increased quality of sleep"]},{"genotypeAnnotationText":"Patients with ALS and the GG genotype may have a decreased response to treatment with creatine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["require a dose reduction of ribavirin"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of zuclopenthixol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of zuclopenthixol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of zuclopenthixol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["decreased metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond better to treatment with flecainide"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decrease in bone density"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Cancer patients with the TT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.","phenotypeText":["decreased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["increased chance of rehospitalization"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking methadone may have an increased response as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs11045995 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["less time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"African American male patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["decreased AUC and increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["decreased likelihood of smoking cessation","increased risk of relapse"]},{"genotypeAnnotationText":"Patients with the TT genotype may have 1) a decreased risk of nicotine dependence and 2) a decreased response to smoking cessation therapies as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["decreased risk of nicotine dependence","decreased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["decreased risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*48:04 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*48:04 alleles or negative for the HLA-B*48:04 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) or HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased blood alcohol concentration (BAC) as compared to patients with the CT genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.","phenotypeText":["increased blood alcohol concentration"]},{"genotypeAnnotationText":"Patients with the TT (CYP3A4 *1G\/*1G genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["more likely to respond to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["increased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["diminished response","improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have an increased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with liver cancer and the TT genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype or may have increased metabolism of trimipramine as compared to patients with the *3\/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["reduced metabolism"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["decreased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["increased response","increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with platinum-based chemotherapy may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["better prognosis"]},{"genotypeAnnotationText":"Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with HIV and the AA genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["risk for nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["later onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may be less likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*6 or *6\/*6 genotypes. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["less likely to experience a clinical benefit from bupropion treatment for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with TT genotype and breast cancer may have an increased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype but a worse response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["improved response","worse response"]},{"genotypeAnnotationText":"Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs9620007 GG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508139 AA genotype (two copies of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["decreased risk of hematologic toxicity, leukopenia, and GI toxicity"]},{"genotypeAnnotationText":"Patients with the rs324420 AA genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who carry the *2a allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *2a allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.","phenotypeText":["increased risk for vomiting"]},{"genotypeAnnotationText":"Patients with postoperative pain and the CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 AA genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs11125039 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["decreased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["higher accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with the rs193922802 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs10958704 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9620007 CG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction and more likely to develop heart palpitations when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["less likely to develop sexual dysfunction","more likely to develop heart palpitations"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GG genotype and decreased likelihood as compared to the AA genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis","decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the rs324029 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["increased risk for suicide"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*31 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"In human liver microsomes, the *1\/*1 genotype is associated with increased metabolism of sirolimus as compared to the *1\/*22 or *22\/*22 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["increased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["decreased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased risk of leukopenia","increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["longer overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the *2 allele in combination with another no function allele may have decreased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have decreased metabolism of N-desmethylclobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association with response to paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype but an increased response compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of sufentanil"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["increased risk of drug toxicities","decreased risk of drug toxicities"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*2 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"The CYP2B6*27 allele may result in decreased expression and enzymatic activity of CYP2B6, as compared to the CYP2B6*1 allele. A patient with the *6\/*27 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy.","phenotypeText":["decreased expression and enzymatic activity of CYP2B6"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Patients with the rs1127354 AA genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of atazanavir as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["decreased clearance of atazanavir"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of vasomotor symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1\/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["decreased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs4148738 CC genotype may have increased risk of bleeding when treated with apixaban as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the rs678849 CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased clearance and increased risk of leukopenia"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["increased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have an increased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT\/del or TTTT\/TTTT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["decreased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to atazanavir as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased simvastatin acid concentration when treated with simvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased simvastatin acid concentration"]},{"genotypeAnnotationText":"No patients with the GG genotype were studied.","phenotypeText":["No phenotype observed"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["decreased risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to metoprolol","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with another decreased function allele may have increased response to sulfonylureas as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs28358569 G allele (also known as the 827G allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:24 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["decreased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["increased likelihood of achieving remission"]},{"genotypeAnnotationText":"Patients with the TC\/TC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia, and neuropathy)"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*51 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*51 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs193922747 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have decreased lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *14\/*14 genotype. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["decreased lipid-lowering efficacy"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have increased clearance of tamoxifen as compared to patients with the CYP2D6*87 or *90 or *91 or *93 or *95 or *98 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["increased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["lower response rate to pramipexole"]},{"genotypeAnnotationText":"Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"No patients with the CC genotype are available for analysis, but patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3\/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["increased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GT and TT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of Mucositis"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.","phenotypeText":["increased peak cortisol response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased exposure to pitavastatin as compared to patients with two normal function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["O-desmethyl-tramadol sulfation"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*4 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["decreased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["increased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *2\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["lower tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of sparteine as compared to patients with the CYP2D6*4\/*11 or *4\/*12 or *4\/*59 or *5\/*7 or *5\/*8 or *41\/*62 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["increased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["increased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the A\/del genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["decreased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the GG genotypes and decreased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Male patients with the GG genotype may have a decreased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the AA or AG genotypes. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased response to nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Patients with the TTAAAGTTA\/del genotype may have a lower response to treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response","lower response"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 CT genotype (CYP3A4*1\/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1\/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["require an increased dose of buprenorphine to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs17134592 CC genotype may have increased metabolism of naltrexone as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["lower plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs28379954 TT genotype and clozapine concentrations. However, patients with schizophrenia and the CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["decreased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype or may have greater weight gain as compared to patients with the TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs28933396 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Epileptic patients with the HLA-A*11:01 allele may be at an increased risk of experiencing psychiatric adverse events when taking levetiracetam as compared to patients who do not carry the HLA-A*11:01 allele. Other genetic and clinical factors may also affect a patient's risk of experiencing psychiatric adverse events when taking levetiracetam.","phenotypeText":["increased risk of experiencing psychiatric adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["require a decreased dose of fentanyl"]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with another decreased function allele may have increased fentanyl dose requirements as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response (decreased disease free survival or overall survival)"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission or more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["decreased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["higher dose requirement for valproic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype or may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased likelihood of treatment-emergent suicidality","decreased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the CYP2D6*27 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*27 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being effective"]},{"genotypeAnnotationText":"Patients with the rs1346563 GG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for anti-TB drug-induced hepatitis as compared to patients with the AA genotype. Patients with the TT genotype may also have increased clearance of isoniazid as compared to patients with the AT genotype. Additionally, cells with the T allele have been shown to result in increased transcription of the NAT2 gene as compared to those with the A allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["decreased risk for anti-TB drug-induced hepatitis","increased clearance of isoniazid","increased transcription of the NAT2 gene"]},{"genotypeAnnotationText":"No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["greater risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["better response to losartan in people with hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["greater elevation in systolic blood pressure and a greater incidence of side effects"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele who are treated with dapsone may have an increased risk for dapsone-induced severe cutaneous adverse reactions as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence a patient's response to dapsone.","phenotypeText":["increased risk for dapsone-induced severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to respond to treatment for methamphetamine dependence as compared to patients with the CT or TT genotypes. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *21 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*15 diplotype may have increased exposure of repaglinide as compared to patients with the *37\/*37 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["increased severity of intoxication and increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*7A allele or one copy of the *7A allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["require decreased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*1 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1303839356 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk for stroke"]},{"genotypeAnnotationText":"Patients with the rs3918290 CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CT or TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hepatitis C or HIV may have an increased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have increased severity of mucositis when receiving methotrexate, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["increased severity of mucositis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may have increased metabolism of thioguanine as compared to patients with two uncertain function or unknown function alleles or an uncertain function or unknown function in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["increased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the TT genotype and bladder cancer may have an increased response to cisplatin-based therapies compared to patients with the CC and CT genotypes. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["decreased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTA\/TTAAAGTTA genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype but a decreased risk as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["decreased response to peginterferon alfa and ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the rs193922748 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["decreased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:07 allele who are treated with zonisamide may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*02:07 alleles or negative for the HLA-A*02:07 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs121918594 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["shorter QTc interval"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Adolescents with the AA genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["smaller, or absent, increase in nicotine cravings"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for the primary outcome","decreased, but not absent, risk for the primary outcome"]},{"genotypeAnnotationText":"Subjects with the TT genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds or radiotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less of a weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs8050894 CC genotype may require a higher dose of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["require a higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the TT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to clopidogrel (increased platelet reactivity) as compared to patients with the AA genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["less likely to respond to treatment for methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD).","phenotypeText":["decreased risk of end-of-induction minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the GA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype, but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["increased response","remission rate"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 null\/null genotype may have an increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the null\/non-null and non-null\/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the TT genotype and stenosis may be more likely to suffer from a transient ischemic attack as compared to patients with the GG or GT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["more likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["decreased response to thalidomide","decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased doses of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin"]},{"genotypeAnnotationText":"Individuals with HIV and the TT genotype may have an increased risk of SJS\/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the GT or GG genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["increased risk of SJS\/TEN and DRESS Syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["increased risk for infections"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a reduced response (a smaller reduction in LDL-cholesterol or change in HDL) as compared to patients with the CT genotype (carriers of E2). Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC (CYP3A4 *1\/*1) genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased exposure of repaglinide, including increased AUC and decreased clearance of repaglinide as compared to patients with the *37\/*37 or *37\/*15 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CYP2D6*23 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*23 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["require a higher dose or a lower dose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the rs1800100 CT genotype (one copy of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["higher platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["greater risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype, or increased clearance or glucuronidation as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["decreased clearance or glucuronidation"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*57:01 allele have an increased risk of drug-induced liver injury when treated with flucloxacillin as compared to patients with no HLA-B*57:01 alleles or negative for the HLA-B*57:01 test. Other genetic and clinical factors may also influence risk of flucloxacillin-induced adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs6686529 GG genotype who are treated with sevoflurane may have decreased sedation as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence sedation.","phenotypeText":["decreased sedation"]},{"genotypeAnnotationText":"Patients with the non-null\/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null\/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["poorer chance of achieving complete remission","increased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or TT genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["increased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["decreased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the rs9288993 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may show an improved performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CT or TT genotypes, who may not show a difference in performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["improved performance in attention-related tasks"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["more likely to respond to treatment for methemoglobinemia","reduced risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["increased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 AG genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the CA or AA genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *12 or *13 allele. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["increased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*2 genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs13210472 AA genotype may be at a decreased risk of developing cancer when taking statins as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["decreased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GT genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar imipramine dose requirements as compared to patients with other alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["increased imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["decreased risk of mortality"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["increased exposure to simvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the rs193922832 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of developing severe cutaneous adverse reactions when treated with antiepileptics as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing severe cutaneous adverse reactions when treated with antiepileptics.","phenotypeText":["increased risk of developing severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs139945292 TT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["increased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with acenocoumarol may have a decreased risk of Hemorrhage as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/GGAGTC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the rs730012 AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["decreased risk of urticaria"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype.","phenotypeText":["increased Euphoric and Energetic"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and methylphenidate dosage requirements. However, patients with ADHD and the CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["decreased dose of methylphenidate"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1, *1\/*4, and *1\/*5 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure to tolperisone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC\/GGAGTC genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the GGAGTC\/del genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.","phenotypeText":["lower incidence of toxicity and may tolerate higher doses of mercaptopurine"]},{"genotypeAnnotationText":"Children with the TT genotype and gating mutations in cystic fibrosis may have decreased response to ivacaftor compared to children with the CC or CT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with AC or CC genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["higher success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["more likely to have complete remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to simvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":["increased concentrations of voriconazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of morphine as compared to patients with the CT or TT genotypes. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["increased plasma concentrations of morphine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":[]},{"genotypeAnnotationText":"Pregnant women with the *1A\/*1A (CC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F\/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["decreased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *7 allele or one copy of the *7 allele in combination with the *5 or *6 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["increased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment (measured by higher decreases in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with genotype AC may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["lower rate of sustained virological response (SVR)"]},{"genotypeAnnotationText":"Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with CYP2C19*2 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1\/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.","phenotypeText":["decreased metabolism of icotinib"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["decreased fasting triglyceride levels"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the TT genotype may have decreased clearance and increased concentrations of apixaban as compared to patients with the GG and GT genotypes. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased clearance and increased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may be at a decreased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *3\/*3 diplotype may have decreased clearance of tacrolimus as compared to patients with the *1\/*1 or *1\/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["decreased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["increased risk of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 del\/del genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association with risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CYP2C19*2\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Women with the TT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["lower risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype or may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased risk of diabetes","decreased risk of diabetes"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5B allele or one copy of the *5B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["decreased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the C\/del or del\/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*27:09 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*27:09 alleles or negative for the HLA-B*27:09 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype.","phenotypeText":["no significant association with breast cancer disease recurrence"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*20 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["increased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["increased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs112563513 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 AA genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["decreased concentrations of temozolomide"]},{"genotypeAnnotationText":"Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["decreased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["decreased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4728709 AG genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["decreased likelihood of developing asthenia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["lower levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs1275988 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depression and the GT genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["lower success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased prolactin when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Women with the CC genotype and obesity and polycystic ovarian syndrome (PCOS) may have an increased response to liraglutide as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sufentanil dose requirements as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the rs4646437 GG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone in Children with Autism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del\/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the rs28358569 A allele (also known as the 827A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with chronic pain and the GG genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["less likely to develop hyperalgesia"]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"The del\/T genotype is associated with decreased catalytic activity of DPYD as compared to the TT genotype and increased catalytic activity as compared to the del\/del genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with genotype CC may have higher rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["higher rate of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["decreased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["increased risk of pneumonitis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*18:01 allele who are treated with amoxicillin-clavulanate may have increased risk of drug-induced liver injury as compared to patients with no HLA-B*18:01 allele. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *27\/*28 genotype and chronic myeloid leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *6\/*6 or *6\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 AA genotype may have an increased response to buprenorphine therapy as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of virological response"]},{"genotypeAnnotationText":"Patients with the CYP2C9*3\/*3 genotype may have a decreased clearance of doxepin as compared to patients with the CYP2C9*1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.","phenotypeText":["decreased clearance of doxepin"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have decreased concentrations of deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the rs1041983 TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of alopecia","decreased risk of pain"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype may be more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*1 genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo"]},{"genotypeAnnotationText":"Patients with the GG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["decreased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with docetaxel may have an increased risk of neuropathy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["increased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with olanzapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 AA genotype may have increased concentrations of methotrexate as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["decreased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["better response to treatment with atomoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the TT genotype may have an increased response to interferon-beta as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["increased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["less likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype may have increased metabolism of trimipramine as compared to patients with the CYP2C9*3\/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["increased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["better response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response","increased time until response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*4 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["decreased response to ustekinumab"]},{"genotypeAnnotationText":"The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate increased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CG genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["increased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CC genotype may have an increased response to pioglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["increased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["greater reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["higher likelihood of developing myalgia","lower likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with valproic acid may have increased bone density as compared to patients with the AA + AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["increased bone density"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"African-American patients with the CC genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["increased response to methadone treatment"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Individuals with the CT (CYP2C8*3\/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for cardiovascular toxicity and symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response","increased time until response"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with carbamazepine may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose of phenprocoumon","increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of neurological events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["reduced survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["not respond as well to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["faster analgesic onset"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["increased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with genotypes GG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased response to daunorubicin"]},{"genotypeAnnotationText":"Patients with the *04:06 haplotype may have increased risk of statin-related myopathy when taking statins compared to patients without the *04:06 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.","phenotypeText":["increased risk of statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.","phenotypeText":["lower risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the rs1751034 TT genotype carriers may have increased concentrations of tenofovir as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["increased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["decreased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the rs193922809 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require higher dose of warfarin as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 CT genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to atorvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*50 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*50 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["increased likelihood of weight gain of more than 7% of baseline body weight"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*10 allele or one copy of the *10 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["decreased time until response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.","phenotypeText":["no effect on exposure"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have an increased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of infection","nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Men with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atrovastatin.","phenotypeText":["lower decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may require an increased dose of thioguanine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Purified DCK proteins with the GG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the rs368146607 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose of thioguanine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["increased time to achieve therapeutic international normalized ratio"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the rs702764 CT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["increased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs708272 AG genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["greater reduction in cardiovascular events","less of a reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs3842 TT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["decreased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of trimipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of trimipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of trimipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 CC genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["increased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the CT and TT genotypes. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["decreased trough concentrations"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["decreased metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the rs1041983 CC genotype and tuberculosis may have a decreased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased metabolism of folic acid"]},{"genotypeAnnotationText":"Individuals with the CYP2D6*46 allele in combination with a normal, decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["decreased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the rs7297610 CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["more likely to respond","less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["phenobarbital resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs10455872 GG genotype may have a decreased response to statins as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *3 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *3 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 CC genotype may have an increased response to abiraterone as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["increased response to abiraterone"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["increased risk for Alcoholism"]},{"genotypeAnnotationText":"Patients with the rs628031 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole","similar metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the CYP2D6*7 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*7 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1695 AG genotype and risk of developing neutropenia when treated with cyclophosphamide and epirubicin. However, patients with breast cancer and the AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["decreased response to amiloride or spironolactone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Male patients with the wildtype B haplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the A-202A_376G haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["reduced risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with CYP3A5*1\/*3 had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["reduced exposure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may show a decreased severity of alcoholism as compared to patients with the AG or GG genotypes. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["decreased severity of alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1868089 TT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["increased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A4 *1\/*1) and epilepsy may have increased concentrations of carbamazepine as compared to patients with the CT (*1\/*1G) or TT (*1G\/*1G) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A\/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A\/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"There is currently no information concerning the effect of the GG genotype on the severity of nausea and vomiting as a result of taking fentanyl. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 TT genotype who are treated with clozapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["decreased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Adolescents with the GG genotype may have a greater increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["greater increase in nicotine cravings"]},{"genotypeAnnotationText":"Patients with rs9958628 TT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may be at a decreased risk of drug toxicity when taking hydrocodone as compared to patients with at least three normal function alleles. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when taking hydrocodone.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin","decreased prolactin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased blood alcohol concentrations (BAC) and increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["decreased blood alcohol concentrations and increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased chance of response"]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *4 or *7 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["risk for progression and decreased survival"]},{"genotypeAnnotationText":"Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["decreased risk for bone mineral density loss"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1560022535 GG genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea following administration of succinylcholine"]},{"genotypeAnnotationText":"Patients with the rs1051792 AA genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AG genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["decreased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.","phenotypeText":["insufficient data"]},{"genotypeAnnotationText":"Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds, or radiotherapy"]},{"genotypeAnnotationText":"Patients with the rs397508602 AA genotype (two copies of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["more likely to be THC dependent"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer time to progression and overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["longer time to progression and overall survival time"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["increased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter time to therapeutic INR"]},{"genotypeAnnotationText":"Patients with the rs20455 AG genotype may have increased response to atorvastatin treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1302192284 TT genotype may have increased metabolism of nicotine as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"Patients with the rs3828743 AG genotype may have better response and longer progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["better response and longer progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have a decreased, but not absent, risk for adverse cardiac and cerebrovascular events as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["decreased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less sensitive to treatment with erlotinib compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["less sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience increased repaglinide exposure and improved response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["increased repaglinide exposure and improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["poorer chance at achieving remission"]},{"genotypeAnnotationText":"The CYP2D6*21 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*21 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have an increased risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR short form (S allele)\/HTTLPR short form (S allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["increased likelihood of Substance-Related Disorders","decreased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the TT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with citalopram may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["decreased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the rs34059508 GG genotype may have decreased exposure to olanzapine as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C4 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of gastrointestinal adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the TTA\/TTA genotype (also described as 6bp deletion) may have increased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have higher adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["higher adverse drug reaction scores"]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GT and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance","decreased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the CC genotype may have decreased response to clopidogrel as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the rs7270101 AA genotype and chronic hepatitis C may have an increased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AC and CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Patients with the GGGGAGCTTTCCCAGAGACCC\/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["more likely to respond to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the AA or AG genotypes. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["decreased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["decreased risk of remaining on steroids"]},{"genotypeAnnotationText":"Patients with the rs193922772 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have increased clearance or glucuronidation of oxazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["increased clearance or glucuronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"The CYP2D6*92 allele has been assigned as a no function allele by CPIC. Patients carrying the *92 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association between the rs4680 AG genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["better response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the TTA\/TTAAAGTTA genotype may have increased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs4948496 TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs78655421 AG genotype (one copy of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with the rs115346678 AG genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the CT genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs1079596 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the GG genotype who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the CT (CYP3A4 *1\/*1G) genotype and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1\/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal function allele (e.g. *1\/*3) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["longer QTc interval"]},{"genotypeAnnotationText":"Patients with the TC\/TCCTC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia and neuropathy)"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the rs116855232 CC genotype and inflammatory bowel diseases who are treated with azathioprine may have a reduced, but not absent risk of myelosuppression as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["reduced risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR R1070Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of experiencing rhabdomyolysis as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["decreased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*2\/*2 genotype may have an increased atorvastatin lactonization as compared to patients with the UGT1A3*1\/*1 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["increased atorvastatin lactonization"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the rs367619008 CC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["decreased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the NUDT15*6 allele in combination with a normal function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["increased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience insomnia as a result of consuming caffeine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["more likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["decreased risk of new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["increased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Cells with the CT genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype, or decreased uptake as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["increased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:02 allele have an increased risk of Pegaspargase Hypersensitivity as compared to patients with no HLA-DQB1*02:02 alleles or negative for the HLA-DQB1*02:02 test. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 AA genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 TT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["decreased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients with the rs4906902 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["decreased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["increased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival","longer disease-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs1800497 AA genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["increased weight loss response"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Women with the TT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["less likely to require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["reduced risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and chronic lymphocytic leukemia may be more likely to achieve a complete response but also more likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*6 or *6\/*6 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["more likely to achieve a complete response","more likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal or no function allele may have increased response to esomeprazole (increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased response to esomeprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission","decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit disorder with hyperactivity may have a decreased, but not absent, risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs2071559 GG genotype may have increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["increased overall survival and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Patients with the rs12366035 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased weight gain when treated with olanzapine as compared to patients carrying a normal function allele in combination with a no function allele. Patients with schizophrenia and carrying the CYP2D6*1 allele in combination with a no function allele may have increased weight gain when treated with olazapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["decreased weight gain","increased weight gain"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele may have decreased metabolism of fluoxetine as compared to patients with the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to flecainide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs140471703 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the HLA-DQA1*02:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk for toxicity when treated with fluoropyrimidines, as well as increased DPYD activity, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["decreased risk for toxicity","increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6A allele or one copy of the *6A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. Other genetic and clinical factors may also influence aripiprazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype CC or AC. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased QT interval"]},{"genotypeAnnotationText":"Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["better response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 GG genotype may have an increased response to combined therapy with morphine and nortriptyline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT (CYP3A4 *1\/*1G) genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["more likely to respond to clopidogrel"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["increased likelihood of neutropenia or leukopenia","decreased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["increased isoproterenol-mediated desensitization"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and increased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure to temsirolimus or sirolimus","increased likelihood of bone marrow and gastrointestinal toxicities or other adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.","phenotypeText":["decreased response to rasagiline"]},{"genotypeAnnotationText":"Patients with the rs193922768 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1, *4, *9 or *10 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["decreased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G6PD B (reference) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.","phenotypeText":["decreased risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of doxepin as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of doxepin as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of doxepin as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin","decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*3 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism of propafenone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CC genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs1603218569 C allele (also known as the 1243C allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT\/TT. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to remifentanil as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs12208357 TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["higher plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs6295 CG genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["decreased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["decreased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["decreased platelet inhibition and increased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["reduced clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the CC genotype on oseltamivir concentrations in patients.","phenotypeText":["no observed effect"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the GG genotype may have an increased overall survival when treated with sorafenib as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with the AC genotype and kidney transplant may have increased risk of neutropenia when treated with valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Women with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with captopril as compared to women with the AA or AG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["decreased hematologic response"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the CC genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["increased concentrations and improved response to lumefantrine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to hydroxyurea treatment"]},{"genotypeAnnotationText":"Patients with the rs3828743 AA genotype may have worse response and shorter progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["worse response","shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the CYP2D6*46 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*46 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 GG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a worse response to methotrexate as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["worse response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["decreased methylation at COMT gene promoter"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 GG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["larger stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *6 allele or one copy of the *6 allele in combination with the *5 or *7 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to simvastatin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require a reduced dose of catecholamines"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of drug toxicity","hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype who are treated with pravastatin may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AG genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings.","phenotypeText":["decreased cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the rs4752292 GT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2011425 GG genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["decreased serum concentrations"]},{"genotypeAnnotationText":"Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["greater prolactin response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk of neurological events"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the TT genotypes, and worse response as compared to CC genotype. This is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["improved response to donepezil (slower cognitive decline)"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the GT genotype may have a decreased response to etanercept as compared to patients with the GG or TT genotypes. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["decreased response to etanercept"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype with diabetes mellitus or polycystic ovarian syndrome who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*11 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity score of 2 may have similar imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements","increased imipramine dose requirements","similar imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["increased risk for more side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["less favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*1\/*1 may have increased metabolism of diclofenac as compared to patients with CYP2C8*3 or *4. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["increased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may require a decreased dose of atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["decreased dose of atenolol"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the TT genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["increased antidepressant response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["less response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6J allele or one copy of the *6J allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the AC or CC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":["reduced dose escalation of morphine"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["decreased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Patients with ADHD and the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs9344 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with gefitinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["better response to treatment with gefitinib"]},{"genotypeAnnotationText":"Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["changes in mycophenolic acid exposure-related parameters","increased risk of acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the rs193922762 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6A allele or one copy of the *6A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/B (reference) haplotype (heterozygous for the G6PD A- variant) who are treated with methylene blue may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with depressive disorder and the CC genotype may have worse response to citalopram or escitalopram as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs735668 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["higher risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing both alcohol and drug dependence as compared to patients with the AA or AG genotypes. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["decreased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["increased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a shorter overall survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing kidney transplantation may have an increased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["increased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*33 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["increased plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*6 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*6 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the rs718656 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype, or increased metabolism compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["decreased metabolism of nicotine","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*3 allele or one copy of the *3 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"CC genotype may be associated with a decreased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the TT or CT genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["decreased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a lower dose of acenocoumarol as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["require a lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT.","phenotypeText":["increased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5A allele or one copy of the *5A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["decreased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the AG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have a decreased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["decreased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs28358572 T allele (also known as the 1520T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 AG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor\/lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["unknown likelihood of experiencing adverse events"]},{"genotypeAnnotationText":"Individuals with the GG genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["decreased estimated glomerular filtration rate (eGFR)","increased eGFR"]},{"genotypeAnnotationText":"Patients with the TT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["improved metformin efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs13210472 CC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["increased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["increased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["decreased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the rs1801086 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the rs699 AG genotype may have an increased response to irbesartan as compared to patients with the AA genotype, but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*1 genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AC genotype who are smokers may have increased physical responses to smoking as compared to patients with the CC genotype, or decreased physical responses as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with the rs10248420 GG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["lower risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["decreased response to amisulpride"]},{"genotypeAnnotationText":"Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["more likely to be tetrahydrocannabinol (THC) dependent"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/del genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/GGAGTC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["increased clearance of imatinib","decreased response","decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.","phenotypeText":["increased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["decreased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Pregnant women with the *1A\/*1F (AC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F\/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["decreased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"Patients with the CG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Female patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype were not studied. But female patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["increased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *5 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Several studies assess this association with *5 in combination with other loss-of-function alleles (e.g. *3, *4). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*1 allele in combination with a normal function allele may have increased exposure of telmisartan as compared to patients with one or more copies of the UGT1A3*2 or *3 allele. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of telmisartan"]},{"genotypeAnnotationText":"Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CT (POR *1\/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["decreased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["increased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response","increased risk of toxicity"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have an increased risk of bone density loss when exposed to letrozole as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 GG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["increased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the CC genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","same metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["less likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["less likely to respond to venlafaxine treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["poorer cardiovascular outcomes"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*20 allele or one copy of the *20 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs11150606 TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["increased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the rs2279343 AG genotype may have increased methadone dose requirements as compared to patients with the GG genotype but decreased dose requirements as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC and CT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["worse response to cisplatin and gemcitabine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the 1494T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may be at a decreased risk of experiencing adverse events when treated with thioguanine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR D110E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased adjusted trough concentrations of dabigatran","decreased, but not absent, risk for bleeding"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["less likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 CC genotype may have increased response to methotrexate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs193922770 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121918596 del\/del genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GAG\/GAG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *12 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require an increased dose of catecholamines"]},{"genotypeAnnotationText":"Individuals with HIV and the GG genotype may have a decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) when treated with nevirapine as compared to patients with the GT or TT genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)"]},{"genotypeAnnotationText":"Patients with HIV infections and the CC genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["decreased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["similar analgesic response to codeine"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 AC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the A or AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer event-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/null genotype (ie. have zero functional copies of the GSTM1 gene) and cancer may have increased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a no function allele (e.g. *2\/*3) may have decreased clearance of tolbutamide as compared to patients with two normal function alleles (e.g. *1\/*1). There is currently no evidence to suggest that tolbutamide clearance is significantly different in patients carrying the * 2 allele in combination with a normal function (e.g. *1\/*2) or another decreased function (e.g. *2\/*2) allele as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs568367673 AC genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and various cancers may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["decreased risk of experiencing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores","late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with opioid dependence and the AA genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying multiple copies of the *2 allele on one chromosome (*2xN) in addition to another normal function allele may be at an increased risk of drug toxicity when taking hydrocodone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when taking hydrocodone.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the rs774072493 C\/del genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the del\/del genotype. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs4906902 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["smaller changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs531738678 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs11322783 G\/TT genotype and chronic hepatitis C may have increased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Hepatic cells with the AC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with genotype AA and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the rs4728709 GG genotype may have an increased likelihood of developing asthenia when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["increased likelihood of developing asthenia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 TT genotype who are treated with olanzapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["increased response to gemcitabine in people with Pancreatic Neoplasms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["decreased risk of Pancreatitis"]},{"genotypeAnnotationText":"Patients with the GG genotype who take methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham variants and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["decreased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*09:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*09:01 alleles or negative for the HLA-DRB1*09:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to quit smoking, regardless of the treatment method, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with AA genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs3135506 CG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["longer period before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying *28, *37 and\/or *6 alleles when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1\/*1). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["higher rate of major cytogenetic response"]},{"genotypeAnnotationText":"Female patients with the AA genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*6 allele or one copy of the *6 allele in combination with one copy of the *1 or *3 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["decreased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased time to relapse"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["decreased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"The del\/del genotype is associated with decreased catalytic activity of DPYD as compared to the del\/T or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*3 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*3 allele and response to citalopram"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with mianserin may have decreased plasma concentration of S-mianserin as compared to patients with a decreased function allele with an activity value of 0.25 in combination with either a normal or no function allele or patients with two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["decreased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the rs121908757 AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with at least one copy of the HLA-A*31:01 allele may have an increased risk of developing DRESS as a result of taking oxcarbazepine as compared to patients who do not carry the HLA-A*31:01 allele. Other genetic and clinical factors may also affect a patient's risk of developing DRESS.","phenotypeText":["increased risk of developing DRESS"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of voriconazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS) when treated with phenytoin as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. However, one study found no association between the allele and adverse reactions. Other genetic and clinical factors may also affect risk for severe cutaneous adverse reactions in patients receiving phenytoin.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype may have an increased response to metformin as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have an increased response to agomelatine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508288 AA genotype (do not have a copy of the CFTR D579G variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with citalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased likelihood of drug toxicity and increased likelihood of overall survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["decreased likelihood of drug toxicity","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the rs397508602 GG genotype (do not have a copy of the CFTR G1249R variant) and cystic fibrosis have an unknown response to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the genotype have not been studied.","phenotypeText":["not been studied"]},{"genotypeAnnotationText":"Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the rs745364489 AG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CYP2D6*25 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*25 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the rs315498 CC genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs10455872 GG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["increased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs575853463 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["decreased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of nicotine as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or one copy of the *2 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a normal function or no function allele who are treated with mianserin may have increased plasma concentration of S-mianserin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["increased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have Increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["Increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["risk of pneumonitis"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased LDL-C reduction"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased alcohol consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GSTM1 non-null\/null genotype (one copy of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole\/trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null\/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["reduced risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements","increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Individuals with HIV and the GT genotype may have a decreased risk of SJS\/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["decreased risk of SJS\/TEN and DRESS Syndrome","increased risk of SJS\/TEN and DRESS Syndrome","not associated with hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of virological response"]},{"genotypeAnnotationText":"Patients carrying the *36 allele in combination with a normal function allele may have decreased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with one or two decreased function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["decreased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["increased SVR"]},{"genotypeAnnotationText":"Female children with the B\/B (reference) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["lower concentrations of topiramate and a better response to treatment with the drug"]},{"genotypeAnnotationText":"Patients with the rs193922753 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["early response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["higher plasma concentrations of the drug"]},{"genotypeAnnotationText":"The AG genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the GG genotypes, and increased concentrations of UGT1A1 and increased glucoronidation of oxazepam. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["decreased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the rs2071559 AG genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["decreased overall survival and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *6 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have a decreased analgesic response to ketorolac as compared to patients carrying two decreased function alleles, two no function alleles, a no function allele in combination with a normal or decreased function allele or a normal function allele in combination with a decreased function allele. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke with the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CC or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["response to paroxetine or antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["increased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CT or TT genotype (carriers of E2). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["longer duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for nicotine addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for nicotine addiction"]},{"genotypeAnnotationText":"Patients with the rs771237265 AA genotype may have increased clearance of tolbutamide as compared to patients with the AC or CC genotypes. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with AA or AG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["decreased risk for non-immune response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have decreased weight gain and decreased risk of edema when treated with rosiglitazone as compared to patients with the CYP2C8*1\/*1. Other genetic and clinical factors may also influence the toxicity to rosiglitazone.","phenotypeText":["decreased weight gain and decreased risk of edema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have Increased likelihood of neutropenia or leukopenia as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["Increased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 may have decreased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *1\/*1 or *1\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["increased risk for diabetes mellitus","decreased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["decreased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs118192124 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the GG genotype although . Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs34545984 GT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require a decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["decreased response to oxcarbazepine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 AA genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CC genotype may have a decreased response to cytarabine and idarubicin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["increased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with TT genotype, but decreased weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Male children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6O allele or one copy of the *6O allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["risk of craniofacial abnormality"]},{"genotypeAnnotationText":"Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["increased risk for induction failure"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["decreased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*28 genotype ((TA)6\/(TA)7) and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the *28\/*28 genotype ((TA)7\/(TA)7). Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype, or less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["more severe side effects","less severe side effects"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to metformin as compared to patients with the GG genotype and an increased response to metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin","increased response to metformin"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["decreased risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5C allele or one copy of the *5C allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as E2\/E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype, although the studies did not have C homozygotes and only reported the effect for the heterozygote. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a poorer response to docetaxel treatment as compared to patients with the AA or AG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["poorer response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may require an increased dose of mercaptopurine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["increased dose of mercaptopurine"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*37 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["decreased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the HLA-B*15:18\/*40:01 genotype have an increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*18 allele may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*1 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1\/*2 and *1\/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1\/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":["increased response to anti-TNFalpha treatment"]},{"genotypeAnnotationText":"The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased exposure to nimodipine as compared to patient with the *1\/*1 or *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["increased exposure to nimodipine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and increased fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased metabolism of clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with depression and the TT genotype may have a decreased response to antidepressants as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs20455 AA genotype may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity"]},{"genotypeAnnotationText":"Individuals with the *1\/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may have a decreased daily intake of heroin as compared to heroin-dependent patients with the AG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["decreased daily intake of heroin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may be more likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["more likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["lower plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with GSTT1 non-null\/null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null\/null. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["decreased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased response to combined acetaminophen and tramadol as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["greater elevation in systolic blood pressure and a greater incidence of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Female patients with the TT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*12 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations","achieve therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms.","phenotypeText":["response to tamoxifen treatment"]},{"genotypeAnnotationText":"Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["more rapid clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the *1 allele in combination with another normal function allele may require an increased dose of methadone as compared to patients carrying two decreased function alleles. However, this association was not found to be statistically significant. Other genetic and clinical factors may also affect a patient's methadone dose requirements.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 GG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents and gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.","phenotypeText":["require an increased dose"]},{"genotypeAnnotationText":"Patients carrying two copies of the 9-repeat allele may report more drinking days as compared to patients carrying two copies of the 10-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["more drinking days"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*3 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["decreased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with the (CA)16\/(CA)16 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["increased clinical response"]},{"genotypeAnnotationText":"Patients with the rs1801252 AA genotype may have a decreased response to carvedilol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the rs193922762 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype have a decreased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["decreased risk for cocaine addiction"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may require decreased dose of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["decreased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with opioid dependence and the TT genotype may have a decreased response to methadone maintenance treatment (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance treatment"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["decreased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a poorer response to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["poorer response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["lower levels of toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["risk for anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*1 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele and Graves Disease may have an increased risk of agranulocytosis when treated with carbimazole or methimazole as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs575853463 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs1051266 TT genotype and rheumatoid arthritis may have decreased likelihood of toxicity when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater increase in total cholesterol levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for rash"]},{"genotypeAnnotationText":"Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have an increased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["increased risk of new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with atomoxetine may have a decreased, but not absent, risk for treatment related side effects as compared to patients with two no function alleles. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["decreased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 GG genotype may have an increased response to treatment with docetaxel and doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["decreased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have poorer response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["poorer response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the AA genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["decreased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["increased response to milnacipran"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 or *6 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["decreased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with thromboembolism and the CC genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTA\/TTA genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with the TTA\/TTAAAGTTA or TTAAAGTTA\/TTAAAGTTA genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response for postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the CC or CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*39:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["increased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease or psoriasis, may have a better response to anti-TNF therapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have a decreased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["greater aromatase (CYP19A1) inhibition"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4x2\/*36 or *4\/*36 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Children with the CC genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the CT or TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["smaller decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*26 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have increased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["risk of Thromboembolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["worse prognosis"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["increased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["smaller QT-interval shortening effect"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC. The GG genotype may have increased catalytic activity of DPYD as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the AT genotype and stable coronary artery disease who are treated with clopidogrel may have increased risk of hemorrhage as compared to patients with the AA genotype and decreased risk as compared to the TT genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["decreased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of Graft vs Host disease"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1 or *35 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 TT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Individuals with the GG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*53 allele or one copy of the *53 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased likelihood of obesity when treated with olanzapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["increased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["increased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G genotype who are treated with risperidone may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*01:01 allele have an increased risk of nevirapine-induced adverse reactions, such as fever, rash or hepatotoxicity, as compared to patients with no HLA-DRB1*01:01 alleles or negative for the HLA-DRB1*01:01 test. Please note that some studies only examined whether patients had the HLA-DRB1*01 type. Other genetic and clinical factors may also influence risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of nevirapine-induced adverse reactions"]},{"genotypeAnnotationText":"Patients with liver cancer and the GG genotype may have increased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response to venlafaxine in people with Anxiety Disorder","decreased response to venlafaxine in people with Depressive Disorders"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AA genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["lower likelihood of experiencing an increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["require decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*12 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have increased clearance of lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["increased clearance of lorazepam"]},{"genotypeAnnotationText":"Individuals with the TT (CYP2C8*1\/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AT genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["decreased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype who are treated with capecitabine may have an increased risk of nausea and vomiting as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to methylphenidate treatment as compared to patients with the CG or GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *15 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"The CYP2D6*14 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*14 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the rs2016520 TT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["poorer improvement in visual acuity","better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["reduced clearance of cyclosporine","increased risk of infection"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with the *3\/*6 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["increased 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased time to relapse"]},{"genotypeAnnotationText":"In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["similar levels of clearance and exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs193922768 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs6275 GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs121918592 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CT genotype may be associated with decreased catalytic activity of DPYD as compared to the TT genotypes and increased catalytic activity as compared to the CC genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["increased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the GG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["decreased risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["decreased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs2307116 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["greater reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["shorter time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)7\/(T)8 genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)7 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["increased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the genotype GG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.","phenotypeText":["decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"Patients with the rs193922816 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs61742245 AC genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased metabolism of repaglinide as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 AA genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":["decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6B allele or one copy of the *6B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1\/*1. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["increased risk of side effects","decreased dose of drug"]},{"genotypeAnnotationText":"Patients with ADHD and the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["lower psoriasis body surface area after treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk of drug toxicity and may not require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["decreased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CT or TT genotypes. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs1302192284 CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["increased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA or AG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with desipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["higher baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["better improvement in visual acuity and poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*1 genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *28\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with *1 allele in combination with another normal function allele may have increased transport and decreased concentration of atrasentan as compared to individuals carrying the *15\/*15, *1\/*15, *15\/*37 or *14\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["increased transport and decreased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with opioid dependence and the TT genotype may be at an increased risk of sudden death when using opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["increased risk of sudden death when using opioids"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and severity of sleep apnea when treated with morphine. However, patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["decreased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*5D allele or one copy of the *5D allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["increased virological response"]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["increased area under the concentration-time curve (AUC) of tenofovir"]},{"genotypeAnnotationText":"Patients with the GG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs3842 CC genotype may have decreased clearance of olanzapine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["decreased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a normal function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 CT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of opioids as compared to patients with the GG genotype, but a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["increased dose of opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone in Children with Autism"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["increased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to respond to methotrexate"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7A allele or one copy of the *7A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.","phenotypeText":["decreased risk for spontaneous relapse of psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased antiplatelet effect"]},{"genotypeAnnotationText":"Patients with the rs1138272 CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["decreased clearance of thiotepa"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with *37 allele in combination with another normal function allele may have increased transport and decreased concentration of atrasentan as compared to individuals carrying the *15\/*15, *1\/*15, *15\/*37 or *14\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["increased transport and decreased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs7557402 CG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["similar levels of clearance of doxorubicin and exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have an increased exposure to dextropropoxyphene as compared to patients with the *1\/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.","phenotypeText":["increased exposure to dextropropoxyphene"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The TT genotype is associated with increased catalytic activity of DPYD as compared to the del\/del or del\/T genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["poorer response to treatment with eculizumab"]},{"genotypeAnnotationText":"In human liver microsomes, the *1\/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1\/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["decreased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may be less likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["less likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, another study did not see an effect of ivacaftor on CFTR-A561E activity. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["decreased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the CG genotype (one copy of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype and epilepsy may require decreased doses of lamotrigine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["decreased doses of lamotrigine"]},{"genotypeAnnotationText":"Patients with glioma and the CC genotype may have increased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CT genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the TT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["less likely to experience nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The CYP2C9*52 allele has been assigned as a no function allele by CPIC. Patients carrying the *52 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have greater increases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the CC or CT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater increases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the rs11125039 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk for hypertension when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["decreased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the L\/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S\/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["less likely to drop out of treatment"]},{"genotypeAnnotationText":"Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["decreased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have a decreased severity of neutropenia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking","decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased clearance of gemcitabine, and decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response to morphine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to olanzapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["decreased risk of neuropathy","increased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of lymphopenia"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["less likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["higher homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the rs113993959 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with Capecitabine may have an increased risk of of nausea and vomiting as compared to patients with the CC or CT genotypes and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["increased risk of nausea and vomiting","decreased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["increased dose of paroxetine","increased risk of fatigue"]},{"genotypeAnnotationText":"Patients with the TT genotype have an unknown response to migalastat as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2024627 TT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased, but not absent, risk of over-anticoagulation, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs121918593 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["similar clearance of atomoxetine"]},{"genotypeAnnotationText":"Genotype TT may be associated with increased dose of warfarin as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction and less likely to develop heart palpitations and when treated with citalopram as compared to patients with the AG or GG genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["more likely to develop sexual dysfunction","less likely to develop heart palpitations"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may be more likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["more likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the AA genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["decreased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AC genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response"]},{"genotypeAnnotationText":"Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have a decreased likelihood of methotrexate response as compared to patients with the GT and TT genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["decreased likelihood of methotrexate response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 AA genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with genotype CC and schizophrenia may have increased response to antipsychotics compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the TT genotype, and a smaller increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*7 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the rs10752271 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Children with the non-null\/null genotype (has one copy of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null\/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*6 genotype and chronic myeloid leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *6\/*6 or *6\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["increased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*5 allele in combination with one copy of the *4D allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased simvastatin acid concentration when treated with simvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased simvastatin acid concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sufentanil dose requirements as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*40 allele or one copy of the *40 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response in people with Depressive Disorder","decreased response in people with Anxiety Disorders"]},{"genotypeAnnotationText":"Patients carrying the AA genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["increased insomnia"]},{"genotypeAnnotationText":"Patients with one X-chromosome, T genotype and psychiatric disorders who are treated with antipsychotics may have a decreased risk of weight gain as compared to patients with the C genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["more sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC or CT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["increased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association between the rs1045642 GG genotype and response to paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of Vitamin K as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["increased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*25 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["decreased chance of survival"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but an increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia","increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA genotype, and greater reduction of diastolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["smaller reduction of diastolic blood pressure and greater reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["increased response to anti-TNF treatments"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs315498 TT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs372307932 AT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["decreased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Genotype CC may be associated with increased uptake of adefovir dipivoxil as compared to genotype TT or CT. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["increased uptake of adefovir dipivoxil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 CT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the HLA-B*39:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["more likely to require a reduction in dose","less likely to require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["decreased response to aripiprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and ANCA-associated vasculitis may have shorter time to failure when treated with rituximab compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["shorter time to failure"]},{"genotypeAnnotationText":"Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["smaller decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response","decreased treatment response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB3*02:02 allele have an increased risk of agranulocytosis when treated with clozapine in people with schizophrenia as compared to patients with no HLA-DRB3*02:02 allele. Other genetic and clinical factors may also influence a patient's risk of agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis who are taking methotrexate may have a decreased risk for adverse events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients with this genotype were not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)","phenotypeText":["better response to antidepressant treatments"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association with risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the CYP2C19*5 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*5 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["better response to treatment with imatinib"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AA genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings.","phenotypeText":["increased cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.","phenotypeText":["decreased risk of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased AUC of letermovir as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["decreased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["increased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the rs121918596 GAG\/GAG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the del\/del or del\/GAG genotypes. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may at a decreased risk of experiencing opioid-induced adverse effects, as compared to patients with the AA genotype, but at an increased risk of experiencing opioid-induced nausea and vomiting as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["decreased risk of opioid-induced adverse effects, increased risk of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs696 CC genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the TT genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the *3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with the AT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 TT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*3 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AG genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["less likely to experience drug toxicity"]},{"genotypeAnnotationText":"In vitro, the GG genotype is associated with increased expression of TRAF1, decreased expression of MIRLET7I, and decreased sensitivity to endoxifen as compared to the CG and CC genotypes. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["decreased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["lower accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["decreased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["increased fasting triglyceride levels and susceptibility to metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["increased risk of neutropenia, leukopenia, and diarrhea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/GGAGTC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol"]},{"genotypeAnnotationText":"Patients with the rs1954787 TT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1384401 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype AC and schizophrenia may have increased response to antipsychotics compared to patients with AA genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the T genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to fluoxetine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs121909019 AG genotype (one copy of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs444904 TT genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the TT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2253201 GG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["increased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["increased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["less likely to respond to treatment with cholinesterase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs118192175 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The AT genotype is associated with increased expression of DPYD as compared to the TT genotypes and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["increased expression of DPYD"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-C*03:01 alleles or negative for the HLA-C*03:01 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan or debrisoquine compared to patients with the *29\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C may have an increased risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["increased blood pressure"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may have increased plasma levels of lopinavir as compared to patients with the CT or TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of lopinavir"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with pravastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT and TT genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*36 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["no increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*4 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the rs28360521 TT genotype may have decreased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs2304016 AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 GG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype or may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased risk for Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastric cancer may have a poorer response when treated with fluorouracil, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CYP3A4*1\/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["increased concentrations of exemestane"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs4140981 GG genotype may have increased clearance of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal function allele (e.g. *1\/*2) may have increased metabolism of rabeprazole as compared to patients with two no function allele (e.g. *2\/*2, *2\/*3), and decreased metabolism of rabeprazole as compared to patients with two normal function alleles. However, a number of studies showed no difference in metabolism. Patients carrying the *2 allele in combination with another no function allele (e.g., *2\/*2, *2\/*3) may have decreased metabolism of rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*5 allele in combination with a no function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["increased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for addiction"]},{"genotypeAnnotationText":"Patients with the CG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the CC genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and gout may require a dose lower than 300 mg\/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*24 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs1386493 AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["require decreased doses of methadone"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*1b allele or one copy of the *1b allele in combination with one copy of the *1a allele may have increased clearance of lamotrigine as compared to patients carrying two copies of the *1a allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.","phenotypeText":["increased risk for psychosis"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs77409459 CC genotype (do not have a copy of the CFTR T338I variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["decreased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs61767072 del\/del genotype may have an increased response to beta-blockers as compared to patients with the ins\/ins genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["increased response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the GG genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["increased response to etanercept"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["decreased, but not absent, likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["increased overall survival probability"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs140989814 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["decreased response to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of Vitamin K as compared to patients with the CC. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["increased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with the AG (i.e. UGT1A1 *1\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation","increased glucuronidation"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 AA genotype may have a decreased response to buprenorphine therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"The CT genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the TT genotype and increased expression, but decreased catalytic activity as compared to the CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased expression of DPYD","increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased likelihood of progression free survival"]},{"genotypeAnnotationText":"Patients with the rs121908755 AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased likelihood of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["higher response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the *1\/*22 genotype and heart failure may have increased concentrations of sildenafil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.","phenotypeText":["increased concentrations of sildenafil"]},{"genotypeAnnotationText":"Patients with the rs708272 GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less of a reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs12777823 GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["worse response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["better response to pravastatin treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["similar analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["decreased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["decreased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in addition to another normal function allele may have increased metabolism of ethylmorphine as compared to patients carrying one or more no function alleles. Other genetic and clinical factors may also affect ethylmorphine metabolism.","phenotypeText":["increased metabolism of ethylmorphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may increased likelihood of toxicity when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["less likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.","phenotypeText":["increased levels of the active metabolite"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs324029 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism and increased plasma concentrations"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and metabolism of enalapril. However, patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["decreased metabolism of enalapril"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*37 allele in combination with another normal function allele may have decreased exposure to pitavastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased exposure to tramadol as compared to patients with the GG genotype, but a decreased exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele have an increased risk of Stevens-Johnson Syndrome when treated with phenobarbital as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["lower homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["shorter disease-free survival time"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs11971167 GG genotype (do not have a copy of the CFTR D1270N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["decreased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CYP2D6*72 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*72 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with epilepsy and the CT genotype may have a worse response to oxcarbazepine as compared to patients with the TT genotype and an improved response as compared to patients with the CC genotype. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["worse response to oxcarbazepine","improved response"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["decreased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the GG genotype and Tobacco Use Disorder who are treated with varenicline may have a decreased response to varenicline as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AC or CC genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["decreased response and survival times"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*1 genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3\/*3 genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["faster clearance rates and increased metabolism of midazolam"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*17 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*17 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Pre-menstrual patients with the AA genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the AG or GG genotypse. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["less likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:02 allele have an increased risk of agranulocytosis when treated with clozapine as compared to patients with no HLA-DRB1*04:02 allele. Other genetic and clinical factors may also influence risk of clozapine-induced agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lowest dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["normal risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with the rs118192172 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*29 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *29 allele in combination with another decreased function allele or a no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *29 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less of a weight gain"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased exposure to fentanyl as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["increased response to acamprosate"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"No patients with the AA genotype are available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["decreased response to clopidogrel (increased platelet reactivity)"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["greater reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["increased risk for nephrotoxicity"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["increased risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:05 allele have an increased risk of skin rash when treated with nevirapine as compared to patients with no HLA-B*35:05 alleles or negative for the HLA-B*35:05 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of skin rash"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CYP2B6*4 allele in combination with a normal function or an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"The CYP2D6*4xN allele (*4x2) is assigned as a no function allele by CPIC. Patients carrying the *4xN allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["poorer response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with the TT genotype and bladder cancer may have decreased metabolism of temsirolimus as compared to patients with the CC or CT genotypes, and an decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["decreased metabolism of temsirolimus","decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may require a dose lower than 300 mg\/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the AA genotype (homozygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["less likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a larger change in apolipoprotein A1 and C3 levels, as compared to patients with the C\/del or del\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["larger change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotype. They also may have a shorter time between waking in the morning and the first cigarette as compared to the AG or GG genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["increased metabolism of nicotine","shorter time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["increased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*35 allele or one copy of the *35 allele in combination with one copy of the *1, *9 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased time to achieve a first INR within therapeutic range and longer time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"Patients with the CT genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs1346563 AA genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of infection or nausea"]},{"genotypeAnnotationText":"Patients with the A\/A genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/del or del\/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["improved response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*29 allele may have decreased clearance of fentanyl as compared to patients with the *1\/*1 diplotype. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["greater reductions in diastolic blood pressure","greater reductions in mean arterial pressure","greater reductions in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*12 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*12 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["may not respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype may have increased DPYD activity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the TT genotype, but decreased binding affinity compared to the CC genotype. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["increased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.","phenotypeText":["decreased metabolism or clearance of irbesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*9 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have increased severity of sleep apnea when treated with morphine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["increased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the CYP2B6*5 allele in combination with an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CG or GG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.","phenotypeText":["decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response when treated with platinum drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["reduced response to haloperidol"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotype, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["increased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an improved response to platinum compounds as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["improved response to platinum compounds"]},{"genotypeAnnotationText":"The CYP2C9*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Caucasian patients with the CC genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["higher burden of general side-effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["earlier onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*23 allele may have decreased clearance of omeprazole as compared to patients with the CYP2C19*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased clearance of omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CC genotype may be more likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-B*38:02 allele may have an increased risk of agranulocytosis when treated with propylthiouracil as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with propylthiouracil.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.","phenotypeText":["decreased response to rasagiline"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs528152707 AC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs140039091 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*1 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["decreased atorvastatin concentrations"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 del\/del genotype (two copies of the F508del variant) may benefit from treatment with the combination drug of ivacaftor\/lumacaftor, as shown by improvement in sweat chloride concentrations and\/or forced expiratory volume in 1 second (FEV1) when compared to treatment with placebo. This genotype is an indication for use of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["benefit from treatment with the combination drug"]},{"genotypeAnnotationText":"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the rs193922770 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with the rs397508510 CG genotype (one copy of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with CT genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the TT genotype and response to nimodipine.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin-dependence who are treated with methadone maintenance therapy may have decreased plasma concentrations of R-methadone compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["decreased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased systolic blood pressure following nimodipine administration as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.","phenotypeText":["increased systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["increased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be less likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 TT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia","increased risk"]},{"genotypeAnnotationText":"Patients with the CYP3A5*3 allele in combination with another *3 allele who are treated with tacrolimus may have a decreased but not absent, risk of nephrotoxicity as compared to patients with two CYP3A5*1 alleles or the combination of the *1 and *3 allele. However, a number of studies show an increased risk of nephrotoxicity for patients with two *3 alleles, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.","phenotypeText":["decreased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["decreased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the AG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs536577604 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["decreased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better overall survival as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better overall survival"]},{"genotypeAnnotationText":"African-American patients with the CT genotype (carriers of E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["decreased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased but not absent risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have less severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the AA or AG genotypes. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the rs6928499 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["less likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["increased expression of TCL1A, IL17RA","decreased expression of IL17A, IL12RB2, and IL1R2"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AA genotype may have decreased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs376073289 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["decreased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Ivacaftor is not recommended in cystic fibrosis patients with this genotype. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association with response to ivacaftor"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["decreased concentrations of morphine"]},{"genotypeAnnotationText":"Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["decreased prolactin response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the rs186045772 AA genotype (two copies of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["require decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased glucuronidation of anastrozole as compared to patients with the AA or AG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["increased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["decreased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs80282562 GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["increased risk of Death"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs2108622 CC genotype may have decreased warfarin dosage requirements as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["decreased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the null\/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null\/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["poorer chance of achieving complete remission","increased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1x2 allele in combination with one copy of the *1 allele may have an increased severity of nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["reduced metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs372307932 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may have a decreased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.","phenotypeText":["decreased response to alprazolam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["increased retention rates"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["reduced exposure to methotrexate and higher likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs3781727 TT genotype may have increased exposure to voriconazole as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["increased exposure to voriconazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 1-4 nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs2031920 TT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Female patients homozygous for the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["increased survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs111869995 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["increased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*11 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of abnormal dreams"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*1 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *2\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["lower tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 AG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 CC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["increased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients carrying the *17 allele in combination with a normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of sedation"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 CC genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA or AC genotypes. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"The TT genotype is associated with increased expression of DPYD, but decreased catalytic activity as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 CC genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a decreased dose as of acenocoumarol compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["require a decreased dose"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["worse response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Male patients with the TT genotype may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the rs34911792 GG genotype (two copies of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (higher decreases in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["increased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be more likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["vomiting"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *4 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["decreased risk of distant disease progression"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and gabapentin dosage requirements. However, patients with the AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["increased dose of gabapentin"]},{"genotypeAnnotationText":"Patients with the CG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the genotype CC who are treated with cytarabine may have reduced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["reduced toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 AA genotype may have a decreased response to anastrozole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone in children with autism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of tolterodine as compared to patients with the CYP2D6*10 or *93 or *94 or *95 allele, 2) may have increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*92 or *96 allele, and 3) similar enzyme activity of CYP2D6 compared to CYP2D6*87 or *88 or *89 or *90 or *91 or *97 or *98 allele. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["increased clearance of tolterodine","increased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["decreased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR short form (S allele) \/ HTTLPR short form (S allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with venlafaxine response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["decreased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype but increased dose requirements as compared to the CC genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the rs1801252 AG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["increased response to carvedilol"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["less blood pressure (BP) reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response","decreased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["less likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer-related pain may require a increased dose escalation of morphine as compared to patients with the AA or AC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":["increased dose escalation of morphine"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["poorer humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["increased exposure to tipifarnib"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the TT genotype or an increased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["decreased risk of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["decreased response to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the G allele may have decreased expression of LDLR as compared to patients with the A allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.","phenotypeText":["decreased expression of LDLR"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["increased response to repaglinide"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the GGTCCCACTCTTCCCACA\/del genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients who carry at least one HLA-B*27:05 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*27:05 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol concentrations as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["increased plasma triglyceride concentrations","decreased HDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *3\/*3 may have a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":["decreased metabolism of cilostazol"]},{"genotypeAnnotationText":"Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type 2 diabetes may have a better response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CT genotype may have elevated concentrations of lumefantrine as compared to patients with the TT genotype, and lower concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["increased risk for treatment-resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype. It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:21 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:21 alleles or negative for the HLA-B*15:21 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence Severe Cutaneous Adverse Reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the rs7270101 CC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have an increased risk of toxicity when compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs570122671 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["better improvement over the first 2 weeks"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CT genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3733784 CT genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*9 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles while patients with two copies of the *9 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["likelihood of quitting smoking"]},{"genotypeAnnotationText":"Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have a decreased response when given bumetanide, furosemide or torasemide as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["increased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CYP2D6*62 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*62 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a lower rate of major cytogenetic response when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["lower rate of major cytogenetic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have decreased response to diuretics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["decreased response to diuretics"]},{"genotypeAnnotationText":"Patients with the rs2108622 CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["require a lower dose or higher dose with conflicting evidence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the *3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["decreased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs578776 GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*7 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or CC genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["decreased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and acetaldehyde concentrations. However, patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["increased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["poorer response to treatment with salvianolate"]},{"genotypeAnnotationText":"Patients with the rs3812718 CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype but a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with warfarin may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Women with the AA genotype were not studied. However, women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin in people with Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["decreased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*6) (rs4244285\/rs72552267) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal or no function allele may have increased response to esomeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the TT genotype. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["decreased trough concentrations of telaprevir"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response to levodopa"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"The CYP2D6*35xN alleles (*35x2) is assigned as an increased function allele by CPIC. Patients carrying a *35xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *35xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *35xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the GG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["decreased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["increased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The CYP2C9*45 allele has been assigned as a no function allele by CPIC. Patients carrying the *45 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may lower weight gain when treated with antipsychotics as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with two functional CYP2C19 alleles (*1\/*1) may have increased metabolism of icotinib as compared to patients with one or two CYP2C19 loss-of-function alleles (*2 or *3). Other genetic and clinical factors may influence a patient's response to icotinib.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["lower risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with the rs558354142 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to the first course of remission induction therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 AG genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*19 allele or one copy of the *19 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["higher biochemical response, optimal cytoreduction, and sensitivity to the treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["decreased clearance of gemcitabine","increased elimination clearance of dFdU"]},{"genotypeAnnotationText":"Patients with the TT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["reduced plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["less improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased response to opioids as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["increased response to opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["decreased risk of calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":["increased response to anti-TNFalpha treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["greater decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["increased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a normal or decreased function allele or two no or decreased function alleles. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying a decreased function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased concentrations of oseltamivir compared to patients with the CT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.","phenotypeText":["decreased concentrations of oseltamivir"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia and a decreased likelihood of hyperglycemia as compared to patients with the AG or AA genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of leukopenia","decreased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3219489 CC genotype and oral squamous cell carcinoma may have an increased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with CYP2C9*14 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["require more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less improvement in left ventricular ejection fraction"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have increased likelihood of drug discontinuation as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence drug discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Hepatic cells with the GG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Women with the UGT1A1*28\/*28 genotype and osteoporosis may have increased metabolism of raloxifene as compared to patients with the *1\/*1 or *1\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["increased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["decreased risk of neutropenia or hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for nausea or vomiting and be less likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.","phenotypeText":["increased risk for nausea or vomiting","less likely to be responders to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of mucositis","decreased likelihood of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for Torsades de Point"]},{"genotypeAnnotationText":"Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["decreased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["decreased risk of hematologic toxicity"]},{"genotypeAnnotationText":"There is currently no evidence regarding the association between the TT genotype and response to folate supplementation in the context of pharmacotherapy for depression.","phenotypeText":["response to folate supplementation"]},{"genotypeAnnotationText":"Patients with alcoholism and the GG genotype may have a longer survival time as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2xN allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between the CYP2D6*2xN allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR G970R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs745364489 GG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 AT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the AA genotype may been more likely to require treatment for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs3812718 TT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 AA genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["decreased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have decreased clearance of rivaroxaban as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased metabolism of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["decreased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*28 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with rs9958628 AA genotype may have a decreased risk of Pegaspargase Hypersensitivity as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["decreased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have increased methadone dose requirements as compared to patients with the GT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["increased risk for toxic liver disease","decreased risk for toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*31 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["altered plasma concentrations and clearance of simvastatin"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the CC genotype may have increased concentrations of apixaban as compared to patients with the TT genotype, although this is contraindicated by another study which found that the CC genotype was associated with increased clearance of apixaban as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["increased concentrations of apixaban"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of nortriptyline as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of nortriptyline as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of nortriptyline as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the AA genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require a decreased dose of phenprocoumon as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["require a decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a decreased function allele with an activity value of 0.25 may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7B allele or one copy of the *7B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["altered gene expression"]},{"genotypeAnnotationText":"Patients with the CYP2D6*114 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*114 allele was found to have a no enzymatic activity during in vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"There is currently no evidence to suggest a difference in anesthesia efficacy between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["no difference in anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs10248420 AG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["increased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:10 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a no function allele or another decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C9*50 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *50 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["no change in performance in attention-related tasks"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*7 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype who are taking buprenorphine for pain may have an increased analgesic response as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["smaller reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["increased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the rs118192178 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["increased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Healthy individuals with the *1\/*2 genotype may have increased concentrations of carisoprodol as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.","phenotypeText":["increased concentrations of carisoprodol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["increased affinity of the AKR1C4 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["decreased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ondansetron may have increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to sulfonylureas (increased risk of sulfonylureas treatment failure and poorer HbA1c response) as compared to patients carrying two no function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["decreased response to sulfonylureas, increased risk of treatment failure, poorer HbA1c response"]},{"genotypeAnnotationText":"Patients with the TT genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Women with the CT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*08:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-B*08:01 alleles or negative for the HLA-B*08:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the rs121908751 AA genotype (two copies of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["higher drug toxicity score","lower drug toxicity score"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10\/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *10\/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["increased likelihood of neurological adverse reactions","sleepiness"]},{"genotypeAnnotationText":"Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["better response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["decreased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["increased risk for sinusoidal obstruction syndrome (SOS)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.","phenotypeText":["decreased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"\"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment.FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs324420 CC genotype may be at a decreased risk of experiencing adverse events when treated with morphine as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["decreased\/increased exposure to drug"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AA genotype, but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["better improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs193922764 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["higher rate of major cytogenetic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["shorter period of recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["increased risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["lower adverse drug reaction scores"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["increased serum concentrations of simvastatin acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.","phenotypeText":["decreased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"The CYP2D6*35xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*35xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*35xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*35xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with an increased or normal function allele may have a decreased response to citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs6065 CC genotype may have a decreased response and an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased response","increased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a normal function allele or another decreased function allele may have increased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least two no function alleles. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs193922772 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased lovastatin acid concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["increased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs28358569 G allele (also known as the 827G allele) may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA, AC, AT, CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have a decreased risk of cocaine dependence as compared to individuals with the GT or TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the genotype AG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["decreased response to aripiprazole in people with Schizophrenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["decreased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased clinical benefit to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C19*19 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*19 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity as compared to *1 during several in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the CYP2B6*1 allele in combination with another normal function allele or an increased function allele may have increased metabolism of bupropion as compared to patients with the following allele combinations: a normal function allele in combination with a decreased function allele; a normal function allele in combination with a no function allele; two decreased function alleles; a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*8 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["increased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele may have an increased risk of carbamazepine-induced adverse reactions as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test. However, some studies find no association between this allele and adverse reactions. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of carbamazepine-induced adverse reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the (AGCCCACCC)12\/(AGCCCACCC)12 genotype and depression who are treated with fluoxetine may be more likely to respond to treatment as compared to patients with the non-(AGCCCACCC)12\/(AGCCCACCC)12 genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs10958704 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs185462714 CC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.","phenotypeText":["poorer response to metformin"]},{"genotypeAnnotationText":"Patients with the rs7557402 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["increased risk of ADR"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["decreased clearance of imatinib and decreased event-free survival time"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *6 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of coumarin as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9A or *10 alleles; patients with two copies of the *4, *7 or *9A alleles; patients carrying the *6, *7, *12, *17, *18, *19 or *20 alleles; or patients with the *4D\/*5, *4\/*7, *4\/*9A, *4\/*10, *4B\/*9A or *4C\/*9A diplotypes. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["increased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased survival","decreased risk of severe neutropenia"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin","phenotypeText":["less LDL-C reduction"]},{"genotypeAnnotationText":"Patients with breast cancer and the del\/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk of biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.","phenotypeText":["decrease in total cholesterol"]},{"genotypeAnnotationText":"Hepatic cells with the CC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*33:03 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCARs. Other genetic and clinical factors may also influence risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["improved metformin efficacy"]},{"genotypeAnnotationText":"The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients with the *2 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with simvastatin may have a reduced response to treatment (measured by a lower reduction in total cholesterol) compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["decreased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["decreased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del\/del genotype, or a decreased risk as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the TT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the GG genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["more likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased response","decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for Malignant Hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for Malignant Hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs76103438 AT genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C19*2\/*16 genotype may have decreased metabolism of methylphenobarbital as compared to patients with the *1\/*1 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.","phenotypeText":["decreased metabolism of methylphenobarbital"]},{"genotypeAnnotationText":"Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the rs1041983 CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1801086 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["increased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["higher risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the GG genotype, and increased plasma levels as compared to those with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["decreased plasma levels","increased plasma levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs6269 AG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["increased risk of Pancreatitis"]},{"genotypeAnnotationText":"Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with AA genotype and HIV may have decreased concentrations of efavirenz in plasma compared to patients with AG or GG genotypes. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["decreased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["increased response (reductions in haemoglobin A1c and fasting plasma glucose levels)"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the AA genotype, and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of sufentanil as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have an increased risk of granulocytopenia when treated with methotrexate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or may have a decreased risk of adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity","decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype with cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["poorer response and treatment outcome"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the TT genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["increased likelihood of statin-associated myopathy and myalgia","decreased likelihood"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"No patients with the TT genotype were present in the population. However, patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["increased risk for new-onset posttransplant diabetes mellitus (PTDM)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["increased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["decreased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the AA or AT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["lower increase in blood glucose"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype who are stopping methadone treatment may have less of an increase in pulse rate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["less of an increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*5 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of heroin as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["increased metabolism of heroin"]},{"genotypeAnnotationText":"Patients with the rs193922832 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs9288993 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele may have increased metabolism of metoprolol as compared to patients with one or two decreased or no function alleles. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater decreases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with epilepsy and the CC genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the CT or TT genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence the response of epileptic patients to anti-epileptic drugs.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the AC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the GG genotype may have a decreased likelihood of adverse events, as well as an improved response to sevoflurane and remifentanil as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["decreased likelihood of adverse events and improved response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to topiramate"]},{"genotypeAnnotationText":"Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond similarily to treatment"]},{"genotypeAnnotationText":"Patients with the rs9927200 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of venlafaxine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of venlafaxine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel and an increased risk of infusion-related reaction as compared to patients with the TT genotype. These patients may experience an increased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["increased clearance of docetaxel","increased risk of infusion-related reaction","increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Individuals who smoke and have the AA genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the AG or GG genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs28360521 CC genotype may have increased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who do not have the rs3745274 TT genotype may have decreased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased exposure to pitavastatin as compared to patients with the TT genotype, but decreased exposure as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*78:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs540825 AA genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["decreased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to sulfonylureas as compared to patients carrying two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["decreased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.","phenotypeText":["decreased exposure of irbesartan"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","similar metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs2229205 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients carrying two copies of the 9-repeat allele may report more severe negative effects of alcohol as compared to patients carrying two copies of the 10-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["more severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"In vitro, the CC genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the CG and GG genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["increased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*8) (rs4244285\/rs41291556) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes GG may need increased dose of propofol as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["increased dose of propofol"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have increased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CC genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotype may have a decreased overall survival as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*4 allele in combination with one copy of the *1, *46, *7 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["increased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the GG genotype may less likely to respond to drugs to treat nicotine dependence as compared to patients with the AA or AG genotypes. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["less likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["better response to treatment with duloxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs199515342 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased sedative response"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the rs116855232 TT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myeloid leukemia may have a 1) a poorer response to treatment with imatinib as compared to patients with the GG or GT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["poorer response to treatment with imatinib","increased risk of developing cytogenetic resistance to imatinib","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*7 allele in combination with one copy of the *46, *4 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a decreased dose of morphine as compared to patients with the GG genotype but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased serum concentrations of sertraline as compared to patients with a decreased function allele in combination with a normal or decreased function allele or may have increased serum concentrations of sertraline as compared to patients with an increased function allele in combination with a normal or increased function allele. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["decreased serum concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may experience greater vasodilation as compared to patients with the del\/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with acetylcholine. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["decreased risk for nausea","increased risk for nausea"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*30 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with CC genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*8 allele in combination with another decreased function allele (e.g. *5\/*8) may have decreased metabolism of losartan as compared to patients with two normal function alleles. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 8 allele in combination with a normal function (e.g. *1\/*8) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A4 *1G\/*1G) and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1\/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["increased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["increased response to calcium channel blockers in people with Hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["decreased hematologic response"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele with another increased function allele may have increased metabolism of clopidogrel compared to two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["decreased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Patients carrying the *28 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 2 normal function alleles. Other genetic and clinical factors may also influence sorafenib-induced hyperbilirubinemia.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["may respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the ATGA\/ATGA genotype may have increased DPYD activity as compared to those with the ATGA\/del or del\/del genotypes. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype and an increased risk of diarrhea as compared to the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased improvement of depression symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*2 allele or one copy of the *2 allele in combination with one copy of the *1a allele may have decreased clearance of lamotrigine as compared to patients carrying two copies of the *1a allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["benefit"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"People with the AA genotype undergoing a kidney transplantation may have increased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["increased risk for aspirin resistance"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased HDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to olanzapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs997917 CC genotype may be at a decreased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Male patients with the A genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the G genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs1611114 CT genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["risk of experiencing memory impairment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["gain more weight during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["less likely to have complete remission"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the TT genotype who are taking letrozole, with or without a statin, may have increased plasma concentrations of triglycerides as compared to women with the CT and CC genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["increased risk for aspirin sensitivity","decreased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the CG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and response to metformin in people with Type II diabetes mellitus.","phenotypeText":["increased clearance of metformin leading to worse response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["increased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["decreased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*71 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*71 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, AA homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to AG or GG subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin.","phenotypeText":["differential induction of HMGCR transcripts upon simvastatin exposure"]},{"genotypeAnnotationText":"Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of an aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["decreased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["decreased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["smoking behaviors"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele (e.g. *1\/*1) may have increased metabolism of rabeprazole as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*2, *1\/*3) or with two no function alleles (e.g.*2\/*2, *2\/*3). However, contradictory findings are reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism of rabeprazole"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to ketoprofen as compared to patients carrying a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence response to ketoprofen.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*20 allele or one copy of the *20 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decreases in triglyceride levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism\/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["increased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with another no function allele (e.g. *2\/*3) may have decreased metabolism of esomeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["increased serum concentrations of digoxin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["decreased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["less likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*39 allele or one copy of the *39 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["lower plasma concentrations and higher clearance of simvastatin"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of imipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of imipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of imipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["increased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["improved clearance of sulfasalazine"]},{"genotypeAnnotationText":"No information were reported regarding patients with the GG genotype.","phenotypeText":["No phenotype reported"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Women with the CG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence","decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the *2\/*2 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*28 genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *28\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["decreased risk of developing treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype (CYP3A4 *18B\/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1\/*1 or *1\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["increased metabolism of cyclosporine"]},{"genotypeAnnotationText":"The CYP2C19*25 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*25 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Postoperative patients with the AA genotype may have lower morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk for stroke"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["decreased likelihood of smoking cessation","increased risk of relapse"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the rs538703919 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["decreased frequency of relapse"]},{"genotypeAnnotationText":"Patients with HIV and the AA genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs396991 CC genotype may have an increased response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response to rituximab"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a decreased dose of acenocoumarol as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["decreased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to atorvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["decreased risk for Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvement"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["decreased response to rivastigmine"]},{"genotypeAnnotationText":"Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["less likely to develop colorectal cancer"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose as compared to the AA genotype, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":["warfarin dose variability"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Children with the GG genotype and acute lymphoblastic leukemia may have increased risk of neurotoxicity when taking methotrexate compared to children with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the CT genotype (POR *1\/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1\/*1). Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["lower decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["reduced likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Patients with the rs7297610 CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the TT genotype may have an increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the CC genotype who are smokers may have a lower chance of smoking cessation when treated with bupropion as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["lower chance of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a better response when treated with docetaxel and epirubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less improvement over the first 2 weeks"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the CT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*7 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Infants with the rs1799971 GG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs12678747 AA genotype may be at a decreased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["decreased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["decreased risk for renal dysfunction"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically decreased heart rate"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with clozapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have decreased toxicity when treated with indomethacin as compared to patients with *1\/*3 or *3\/*3 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["decreased toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["increased risk of mortality"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the AG or GG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutations who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["increased risk for deep vein thrombosis (DVT)"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["more effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"No information are available for the CT genotype. However, patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["higher risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to simvastatin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with methylphenidate as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with methylphenidate.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased risk of suicide","decreased risk of suicide"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["decreased metabolism of pantoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["increased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs11322783 GG genotype and chronic hepatitis C may have decreased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype TT\/TT or G\/TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*41\/*62 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may experience decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["decreased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with sofosbuvir and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GG genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GT or TT genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT (POR *1\/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination one copy of the *1, *46, *2, *4, *7 or *12 alleles may have decreased metabolism of letrozole as compared. to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":["decreased risk of major adverse cardiac events","increased cholesterol efflux response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:13 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS), when treated with phenytoin as compared to patients with no HLA-B*15:13 alleles or negative for the HLA-B*15:13 test. Other genetic and clinical factors, such as HLA-B*15:02, may also influence a patient's risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*11:01 allele who are treated with carbamazepine may have an increased risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), as compared to patients with no HLA-A*11:01 alleles or negative for the HLA-A*11:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)"]},{"genotypeAnnotationText":"Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["increased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to fluvoxamine as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*05:01 allele may have a decreased risk for drug hypersensitivity reactions when treated with nevirapine as compared to patients with no HLA-DQB1*05:01:01 alleles or negative for the HLA-DQB1*05:01:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["decreased risk for drug hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the rs78655421 GG genotype (do not carry a copy of the CFTR R117H variant) have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with warfarin may have an increased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["increased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have increased response to sulfonylureas (reduced risk of sulfonylureas treatment failure and better HbA1c response) as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["decreased metabolism of nicotine and longer time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with epilepsy and the *1 allele in combination with another normal function allele may require an increased dose of clobazam as compared to patients with two no function allele or patients with a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["increased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with the rs1801086 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["increased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["decreased serum concentrations of digoxin"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype CT or CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["decreased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the rs34059508 AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7G allele or one copy of the *7G allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia (ALL) may have an increased risk for hepatotoxicity when treated with asparaginase as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Children with the AA genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["reduced risk of neurotoxicity"]},{"genotypeAnnotationText":"African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*18 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*46:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B*46:01 alleles or negative for the HLA-B*46:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["decreased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the rs118192172 CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["increased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the CC or CT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the rs917881 GG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CC genotype may have an decreased response to cytarabine and idarubicin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may require a increased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*18 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["increased risk of nicotine dependence","increased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Children with the CC genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["better response to fluoxetine therapy"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7B allele or one copy of the *7B allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*13A allele or one copy of the *13A allele in combination with *4 or *12A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6 , *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype and mesothelioma may have shorter progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/del or del\/del genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased concentrations of lovastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 GG genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association between the rs4124874 GG genotype and risk of adverse effects when treated with irinotecan"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 GG genotype may be less sensitive to methotrexate as compared to PBMCs from individuals with the AG and AA genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["less sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 GG genotype may have an increased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["require an decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["decreased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*5 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AG genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of drug toxicity","hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["more likely to have tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of hypersensitivity","decreased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["decreased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs201820739 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased severity of pain"]},{"genotypeAnnotationText":"Patients with Crohn disease and the CT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["decreased response to adalimumab therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased dose of warfarin in African American patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a shorter recovery time from general anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["shorter recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*10 allele in combination with one copy of the *1 or *7 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["less likely to respond to fenofibrate treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["increased risk of Drug Toxicity","increased risk of early relapse","increased progression free survival"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs3918290 CT genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the CT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the AG genotype may be at an increased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["decreased clearance or glucuronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["increased likelihood of weight gain of more than 7% of baseline body weight"]},{"genotypeAnnotationText":"Patients with the GT\/GT genotype may have increased dose of phenytoin in people with Epilepsy as compared to patients with genotype del\/del or GT\/del. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["increased dose of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs61742245 CC genotype may have require a decreased dose of warfarin as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["decreased clearance and increased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.","phenotypeText":["decreased affinity to losartan"]},{"genotypeAnnotationText":"Patients with tuberculosis and the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1, *14 or *38 alleles or patients with one copy of the *1 allele in combination with the *9, *12, *41 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["less response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CC genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the (AGCCCACCC)12\/(AGCCCACCC)12 genotype and depression who are treated with antidepressants may have an increased risk of adverse drug reactions after switching treatment for the second time as compared to non-(AGCCCACCC)12\/(AGCCCACCC)12 genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of adverse drug reactions after switching treatment for the second time"]},{"genotypeAnnotationText":"Patients with the rs11030096 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tenoxicam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["decreased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the non-null\/ null genotype (has one copy of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and two copies of the CYP1A2*1F allele or one copy of the *1F allele in combination with one copy of the *1A allele may have decreased concentrations of clozapine as compared to patients with two copies of the *1A allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP1A2 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clozapine concentrations.","phenotypeText":["decreased concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may have an increased risk of bleeding when treated with warfarin as compared to the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased analgesic response to tramadol as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs17682789 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Patients with the *13 allele in combination with a normal or no function allele may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the rs2952768 TT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with epilepsy the *1 allele in combination with another normal function allele may have a decreased response to clobazam as compared to patients with two no function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *1 allele in combination with a no function allele may have a decreased response as compared to patients with two no function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":["decreased response to clobazam"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or with one copy of the *2 allele in combination with one copy of the *1 allele may have decreased severity of nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter time to progression and overall survival time"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as well as toxic liver disease as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN","toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["not have a change in likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["increased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying two no function alleles. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["decreased conversion of the drug to active polyglutamates and decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["less likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CC genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["decreased response to treatment with docetaxel and doxorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["decreased plasma levels of efavirenz"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) diplotype (heterozygous for the G6PD Mediterranean variant) who are treated with phenazopyridine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*1 genotype (designated as normal metabolizers) may have decreased plasma concentrations of maraviroc as compared to patients with intermediate metabolizer or poor metabolizer genotypes. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found either a lack of association or contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["decreased plasma concentrations of maraviroc"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs1142345 CC genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and hepatitis C or HIV may have an increased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["decreased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of phenprocoumon as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["decreased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["increased risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele was only defined as D337G not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["less likely to respond to nicotine replacement therapy"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs67376798 AT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the HLA-A*24:02 allele may have an increased risk of severe cutaneous adverse reactions (SCARs) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) when treated with carbamazepine as compared to patients with no HLA-A*24:02 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of SCARs or DRESS.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7A allele or one copy of the *7A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater decreases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 GG genotype may experience an increased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["poorer response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*20 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["lower decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["decreased risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the rs2023239 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CC genotype and Cancer who are treated with Capecitabine may have an increased risk of of Diarrhea as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele and acute coronary syndrome who are treated with prasugrel may have a decreased, but not absent, risk for bleeding as compared to patients with two increased function alleles or one increased function allele in combination with a normal function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased risk for bleeding"]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with CYP2C9*1\/*1 may require significantly higher dose of warfarin as compared to patients with CYP2C9 *59\/*59 or CYP2C9 *1\/*59. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["significantly higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased improvement of depression symptoms"]},{"genotypeAnnotationText":"Patients with the rs7597593 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs8050894 GG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 TT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 del\/del genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*7 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor\/tezacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and heart failure may have decreased concentrations of sildenafil as compared to patients with the *1\/*22 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.","phenotypeText":["decreased concentrations of sildenafil"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the rs1051266 CC genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*40 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes CC or CG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["greater increase in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have a decreased response to treatment with anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["decreased response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs371258350 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DQB1*06:01 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DQB1*06:01 alleles or negative for HLA-DQB1*06:01 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["decreased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["increased plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*32 allele or one copy of the *32 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*10 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and cardiovascular disease who are taking a statin may have a decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["decreased likelihood of developing statin-associated myopathy and myalgia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*62 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. CPIC has not yet assigned a functional status to this allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Women with ovarian cancer and the GG genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["more likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*55 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*55 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["decreased response","decreased risk for neutropenia"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with mefloquine 1) may have an increased risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.","phenotypeText":["increased risk of pulmonary damage","similar risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of vortioxetine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["decreased metabolism of vortioxetine"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to pantoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["reduced response to pantoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["lower likelihood of achieving remission"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of pantoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of pantoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with citalopram may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["risk for pneumonitis"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DRB1*03:01 alleles or negative for the HLA-DRB1*03:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:02 allele may have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*13:02 alleles or negative for the HLA-B*13:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["decreased risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["larger changes in systolic and diastolic blood pressures"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have a reduced response to treatment (as measured by a lower reduction in LDL-cholesterol or total cholesterol) as compared to patients with the AG or AA genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*13 allele or one copy of the *13 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson's disease may have an increased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["increased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 AA genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CC genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the CT genotype may have increased concentrations of apixaban as compared to genotype TT, although this is contraindicated by another study which found that the CT and TT genotypes were associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["increased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased response to olanzapine as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["larger stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["better response to treatment with adalimumab"]},{"genotypeAnnotationText":"Patients with the rs678849 TT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result","phenotypeText":["no association with decreased risk of drug toxicity","increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased response to rocuronium"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression who are treated with fluoxetine may have increased response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of trimipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of trimipramine.","phenotypeText":["increased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the S\/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be more likely to drop out of treatment than patients with the L\/L genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["more likely to drop out of treatment"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to atorvastatin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs568367673 CC genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["decreased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the AA or AG genotype. OOther genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*17 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype AA and AG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["decreased risk of anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have more favorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["more favorable progression-free survival"]},{"genotypeAnnotationText":"Transplant recipients with the TT (CYP3A4 *1\/*1) genotype may require a decreased dose of sirolimus as compared to patients with the CC (*1B\/*1B) or CT (*1B\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["decreased dose requirement of sirolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"The TT genotype is associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with tobramycin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["less likely to respond to paroxetine"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of nicotine dependence, as indicated by a lower Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["less sensitive to Alkylating agents"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2xN allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*5 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Pediatric cancer patients with the AA genotype may have a decreased risk for ototoxicity when treated with cisplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["decreased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require increased dose of acenocoumarol as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)8\/(T)8 genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)7 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with glioma and the CT genotype may have decreased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CC genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["decreased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype, or less likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["complete remission"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glipizide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["decreased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["less severe side effects"]},{"genotypeAnnotationText":"Patients with the rs10455872 AA genotype may have a decreased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AG or GG. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["decreased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["higher LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["lower baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1041983 TT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["risk of peripheral neuropathy"]},{"genotypeAnnotationText":"The AA genotype was found less often in smokers as compared to the GG genotype. In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":["increased clearance of methotrexate","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"TT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["increased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["better response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with HIV infections and the *1\/*1 genotype may have increased clearance of lopinavir as compared to patients with the *22\/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["increased clearance of lopinavir"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2C9*8 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["higher risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and and essential hypertension may have an increased response when treated with hypertension as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have more severe anemia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Individuals with the *1\/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma","increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs3813867 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *4\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations of galantamine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["increased response and decreased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["experience nausea"]},{"genotypeAnnotationText":"Patients with the rs528152707 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs3114020 CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["decreased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["more likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*1 genotype. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may have a decreased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["decreased GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["decreased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the *12 allele in combination with a normal or no function allele may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*17 or *17\/*17 genotype who are treated with tamoxifen may have poorer response to tamoxifen as compared to those with the *1\/*1 genotype. However, some studies find no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["poorer response to tamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and kidney transplantation may have increased risk of neutropenia when taking valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect response to valganciclovir.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["more likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele, decreased function allele, or no function allele (e.g. *1\/*3, *2\/*3, *3\/*3) may have decreased clearance of tolbutamide as compared to patients with two normal function alleles (e.g. *1\/*1). This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a poorer response when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have an increased response to treatment with cisplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 CC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 GG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TCCTC\/TCCTC genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TC\/TC or TC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.s","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["increased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with the HLA-B*13:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GT genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity or one study reported reduced risk in heterozygotes. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["decreased risk for induction failure"]},{"genotypeAnnotationText":"Patients with the rs6686529 CG genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.","phenotypeText":["increased sedation"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["increased response to diuretics"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1801086 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1323040 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["increased dose of atenolol"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the CC genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["decreased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["greater decrease in glomerular filtration rate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs1042713 AA genotype and asthma may have a decreased response to salmeterol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol.","phenotypeText":["decreased response to salmeterol"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["decreased response to oxcarbazepine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*53 allele may have increased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*53 allele construct was found to have increased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["increased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"The AG genotype has not been evaluated.","phenotypeText":["not been evaluated"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["increased rapid virological response, complete early virologic response, sustained virological response"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["less likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the AA genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["decreased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["increased response to lovastatin"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["decreased risk for body weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs2336219 AG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for toxicity and decreased plasma level"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["increased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*46 allele or one copy of the *46 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs10455872 AG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["increased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the TTA\/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3813867 CG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs267606617 G allele (also known as the 1555G allele) may have an increased risk of experiencing hearing loss when treated with isepamicin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with isepamicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs10787959 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs1800100 TT genotype (two copies of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["better response to treatment with imatinib","decreased risk of developing cytogenetic resistance to imatinib","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["increased risk of azoospermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":["lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of warfarin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol or bisoprolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*22 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs78655421 AA genotype (two copies of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response to fluorouracil, platinum compounds, or radiotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AT genotype may have worse response to capecitabine or fluorouracil as compared to patients with the TT genotype and improved response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*28 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["decreased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 GG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs2236857 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["decreased risk of azoospermia"]},{"genotypeAnnotationText":"In human liver microsomes, the AC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD B (reference) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.","phenotypeText":["no significant association between the G6PD B variant and risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of skin rash"]},{"genotypeAnnotationText":"Patients with the CCGG\/CCGG genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["decreased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["decreased metabolism of sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.","phenotypeText":["increased affinity to losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) may experience a limited benefit from treatment with the combination drug of ivacaftor\/lumacaftor, as shown by improvement in sweat chloride concentrations CFQ-R questionnaire scores when compared to treatment with placebo. However, ppFEV1, BMI or body weight did not show a significant improvement following ivacaftor\/lumacaftor treatment. This genotype is not an indication for use of the combination drug of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["limited benefit"]},{"genotypeAnnotationText":"Patients with the rs538336580 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC genotype, but more likely to respond than patients with the TT genotype. Other genetic and clincial factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 GG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5B allele or one copy of the *5B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a\/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["better response to treatment with interferon beta 1a\/1b"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the rs11651488 CC genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and tobacco use disorder may have an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["improved response (abstinence from tobacco)"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have an increased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of alopecia","increased risk of pain"]},{"genotypeAnnotationText":"Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have decreased cognitive impairment when taking methamphetamines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["decreased cognitive impairment"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["decreased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs1138272 TT genotype may have increased clearance of thiotepa as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["increased clearance of thiotepa"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["increased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele may have an increased risk of hypersensitivity dermatitis when exposed to trichloroethylene as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence a patient's risk of trichloroethylene-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity dermatitis"]},{"genotypeAnnotationText":"Patients with the *6 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype, or decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for addiction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *36 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["increased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require an increased dose of carbamazepine"]},{"genotypeAnnotationText":"TPatients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["increased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AC genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for gastrointestinal toxicities","decreased response to folic acid and methotrexate","decreased event free survival"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and the GG genotype may have decreased concentrations of alprazolam as compared to patients with the AG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["decreased concentrations of alprazolam"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with another normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["decreased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*11 allele have an increased risk of having an anaphylactoid reaction when receiving nonsteroidal anti-inflammatory drugs (NSAIDs) as compared to patients with no HLA-DRB1*11 alleles or negative for the HLA-DRB1*11 test. Other genetic and clinical factors may also influence a patient's risk of experiencing an anaphylactoid reaction when receiving NSAIDs.","phenotypeText":["increased risk of anaphylactoid reaction"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype (two copies of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with post-operative Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the AC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype or may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for cardiovascular toxicity and symptoms"]},{"genotypeAnnotationText":"Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP2A6*25 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs118192163 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure.","phenotypeText":["decreased risk for having a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs111869995 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with depressive disorder and the GG genotype may have smaller reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["smaller reductions in serotonin concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentration of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["decreased metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond better to treatment with flecainide"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/CTT genotype (no copies of the CFTR F508del variant) have an unknown response to the combination drug ivacaftor\/lumacaftor as this genotype is not an indication for ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the AA genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in patients exposed to cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["higher risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased dose requirements of sufentanil as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["decreased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["poorer pain relief response"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*04:01 allele may have an increased risk of experiencing drug hypersensitivity, including cutaneous adverse reactions, when treated with nevirapine as compared to patients with no HLA-C*04:01 alleles or who are negative for the HLA-C*04:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of nevirapine-induced hypersensitivity.","phenotypeText":["increased risk of experiencing drug hypersensitivity, including cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs3842 TT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["increased severity of respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased response","increased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may begin using heroin at an earlier age as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["earlier age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the AA or AG genotypes. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["increased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*28 genotype may have higher glucuronidation of carvedilol as compared to patients with the *1\/*1 genotype, or lower glucuronidation as compared to patients with the *28\/*28 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["higher glucuronidation"]},{"genotypeAnnotationText":"Patients with the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype may have decreased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/del or del\/del. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["decreased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*6 allele in combination with a normal or decreased function allele may have decreased clearance of methadone as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *22\/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["increased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["increased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Male children with lead poisoning and the B (reference) haplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["increased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["decreased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with TT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":["decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with mirtazapine may have decreased, but not absent, risk of side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles or patients with *1 allele in combination with a no function allele, while patients with the *1 allele in combination with another no function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["decreased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response to etanercept treatment"]},{"genotypeAnnotationText":"Patients with the CYP2B6*2 allele in combination with an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea","decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of clomipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of clomipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of clomipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25.However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels, as compared to patients with the CC or C\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["smaller change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:01 allele may have a decreased, but not absent, risk of severe cutaneous adverse reactions when treated with allopurinol as compared to patients with no HLA-A*02:01 alleles or negative for the HLA-A*02:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["gain more weight during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the GG genotype who are treated with clozapine may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to achieve a HbA1c level of <7%"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may require a decreased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may require a similar dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may require an increased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metoprolol dose requirements.","phenotypeText":["decreased dose of metoprolol"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["risk for nausea"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of vasomotor symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary disease may have decreased response to clopidogrel treatment compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["decreased response to clopidogrel treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the rs267606617 A allele (also known as the 1555A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with neomycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with neomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs4035887 AG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the AC genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*3 genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response to treatment measured by higher reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with hypertension and the GT genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-B*59:01 alleles or negative for the HLA-B*59:01 test. Other genetic and clinical factors may also influence risk of methazolamide-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["increased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*04:01 allele have a decreased risk of asthma when treated with aspirin as compared to patients with no HLA-DPB1*04:01 alleles or negative for the HLA-DPB1*04:01 test. Other genetic and clinical factors may also influence a patient's risk of aspirin-induced asthma.","phenotypeText":["decreased risk of asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["increased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*17 allele in combination with a no or decreased function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*17 allele in combination with an increased function allele may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with clozapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 TT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["benefit from atorvastatin and quinapril treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea","increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["decreased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AC genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the CC genotype and and worse response as compared to the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response","worse response"]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1, *4, *20 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with two copies of the *17 allele or one copy of the *17 allele in combination with the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet reactivity","decreased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores","late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["increased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype who use methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.","phenotypeText":["influence on risk of opioid dependence"]},{"genotypeAnnotationText":"People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs558354142 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs4917639 CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the rs2239050 CG genotype may have an increased response to nimodipine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to nimodipine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation","decreased rate of tapentadol sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["decreased risk of breast cancer occurrence during SERM therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["decreased pain relief"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to metoprolol as compared to patients with the CG or GG genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patient with the TT genotype and Alzheimer's Disease may have an increased response to rivastigmine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*3 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["higher rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *1A\/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence or opioid dependence.","phenotypeText":["increased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The UGT1A1*28 allele has been assigned as decreased function by CPIC. Patients carrying the *28 allele in combination with another decreased function allele may require a decreased dose of irinotecan as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect irinotecan dose requirements.","phenotypeText":["decreased dose requirement of irinotecan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["decreased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for toxicity and decreased plasma level"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 TT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association between the rs717620 TT genotype and clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with timolol may have increased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["increased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs111888148 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["poorer response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have 1) a decreased risk for pneumonitis and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis","increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) (Short\/Short) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2229205 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["likelihood of Lymphopenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs368146607 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["increased severity of alcohol dependence"]},{"genotypeAnnotationText":"Women with the CYP2C19 *1\/*2 diplotype may have an increased exposure to vaginal progesterone as compared to women with the *1\/*1 diplotype. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["increased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["benefit when treated with ivacaftor and curcumin"]},{"genotypeAnnotationText":"Elderly patients with the *2\/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*27 allele or one copy of the *27 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *27 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"The CYP2D6*29 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *29 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *29 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["decreased risk for treatment-resistance"]},{"genotypeAnnotationText":"Individuals with the CCT\/CCT genotype may have increased clearance of olanzapine as compared to individuals with the CCT\/del or del\/del genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased analgesic response to fentanyl as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Male children with typhoid fever and the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"The GT genotype is associated with increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the TT genotype and decreased risk as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased risk for nephrotoxicity"]},{"genotypeAnnotationText":"Patients with cancer and the GT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and rs3212198 T allele who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype in combination with any allele of rs3212198. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["higher dose requirement with warfarin treatment"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"The SLCO1B1*9 allele (defined as consisting of rs59502379) is assigned as a no function allele by CPIC. Patients with *9 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":["increased response","increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased or increased dose requirement of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["better response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with the rs1051792 GG genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*14 allele or one copy of the *14 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs2024627 CC genotype and cancer may have a decreased likelihood of progression-free survival when treated with everolimus as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased exposure to vitamin K1 as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["increased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["decreased risk of Thromboembolism"]},{"genotypeAnnotationText":"Patients with the rs2952768 CT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["less likely to respond to aspirin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["decreased risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the rs185462714 AC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["decreased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele (e.g. *2\/*2) may have decreased metabolism of esomeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["decreased metabolism of esomeprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["decreased response to rosiglitazone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["better response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the rs12366035 TT genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.","phenotypeText":["decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["increased risk of toxicity","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of brivaracetam as compared to patients with the *1\/*2, *1\/*3, *2\/*2, *2\/*3 or *3\/*3 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["decreased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2D6*45 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*45 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["decreased risk for virological failure"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.","phenotypeText":["less likely to have a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["decreased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs118192162 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["decreased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with the rs13210472 AC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["increased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased reduction in DNA damage"]},{"genotypeAnnotationText":"The CYP2D6*36 allele is assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with another no function allele, a normal function allele or a decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism and increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["lower levels of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["reduced risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["higher dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["increased response to amisulpride as measured by the PANSS general"]},{"genotypeAnnotationText":"Patients with the CYP2D6*22 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*22 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the rs28399499 CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["decreased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CT genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["increased response to methadone maintenance treatment (MMT)"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*32 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs558025 AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 GG genotype may have a decreased response to acamprosate treatment as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to hydroxyurea treatment"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have decreased likelihood of drug resistance when treated with phenytoin as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["higher likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs3766951 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea","decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to metformin as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs10737062 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with HIV and the AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to olanzapine as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the AA genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the rs6269 GG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*06:02 allele may be at risk for developing narcolepsy after receiving the vaccination against the H1N1 influenza virus as compared to patients with no HLA-DQB1*06:02 alleles or negative for the HLA-DQB1*06:02 test. However, this allele is also associated with the narcolepsy independent of the H1N1 vaccine, and it is not evident from the literature whether carrying this allele is associated with the development of narcolepsy specifically due to the H1N1 vaccine. Other genetic and clinical factors may also influence a patient's risk of developing narcolepsy.","phenotypeText":["risk of developing narcolepsy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["decreased clearance of docetaxel","decreased risk of infusion-related reaction","decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of hypersensitivity to asparaginase"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs1799971 AA genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["decreased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response","longer progression free survival","greater irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the TT genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["less likely to develop dizziness"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["decreased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192161 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with AC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["increasing creatinine levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 CC genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["higher accumulation of active methotrexate metabolites","increased risk for thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3\/*3 genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["faster clearance rates, and increased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with the rs145308399 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["increased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the rs5186 CC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["increased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs193922803 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["less likely to have reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["decreased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 del\/del genotype may respond to treatment with cavosonstat as measured in reduction of sweat chloride content but not in change of FEV1. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting the opposite effect with a decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype or no association of the variant with response to fluoxetine treatment. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["reduced risk of nephrotoxicity"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased response to caffeine or chlorocresol as compared to individuals with the CT or TT genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*11 allele or one copy of the *11 allele in combination with one copy of the *4 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*13 allele has been assigned as a no function allele by CPIC. Patients carrying the *13 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs28379954 CC genotype may have increased serum concentrations of clozapine as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["increased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of morphine as compared to patients with the TT genotype but an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the (\\UGT1A1*28\/*28 genotype ((TA)7\/(TA)7) and ischemic heart disease may have an increased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the *1\/*1 or *1\/*28 genotype ((TA)6\/(TA)6 or (TA)6\/(TA)7). Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["increased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of phenylalanine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["increased risk for dependence on methamphetamine","decreased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"Patients with CYP2C9*3 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the AA genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the AG genotype and a patient's rick of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fluvoxamine may have a decreased, but not absent, risk of gastrointestinal side effects as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*3 allele in combination with a normal function allele, a decreased function allele, or a no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["increased blood alcohol concentrations and decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require an increased dose of acenocoumarol as compared to patients with the TT and CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["require an increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the G genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype C. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.","phenotypeText":["increased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to successfully quit smoking for at least one year as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["successfully quit smoking"]},{"genotypeAnnotationText":"No individuals with the TT genotype (CYP3A5 *1\/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["increased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the GG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patient with the CT genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["decreased response according to the PANSS negative symptoms scale"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the TT genotype and blood alcohol concentration (BAC). Other genetic and clinical factors may also affect BAC.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["lower elevation in systolic blood pressure","lower incidence of side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["shorter recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart valve replacement may require higher dose of warfarin compared to patients with the AA and AG genotypes. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs118192175 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["increased clearance and decreased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with atorvastatin may have an increased response to treatment as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as comapred to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the del\/del genotype may have decreased DPYD activity as compared to those with the ATGA\/ATGA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["increased metabolism of cyclosporine","increased clearance of cyclosporine","decreased risk in adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased response to nortriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CT and TT genotypes. Other factors may affect response to these drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["decreased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AA genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G del\/del genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/ATTTGTTCATGCCT or ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT or AT. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["decreased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype may have a decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*28 or *28\/*28 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["decreased likelihood of fatigue"]},{"genotypeAnnotationText":"Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs193922809 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["increased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["require higher warfarin dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["no different response to ustekinumab"]},{"genotypeAnnotationText":"Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism of imipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["more benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GA genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*3 allele may have reduced metabolism of diclofenac as compared to patients with CYP2C8*1\/*1. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["reduced metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated gemcitabine and platinum compounds may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have an decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with a high dose of chloroquine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the A-\/A- or B\/B diplotype. Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["better humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"There is currently no available evidence regarding any association between the TT genotype and severity of neonatal abstinence syndrome. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["no available evidence regarding any association"]},{"genotypeAnnotationText":"Patients with the GSTM1 non-null\/non-null genotype (two copies of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole\/trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null\/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["reduced risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased exposure to atazanavir as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"Infants with the rs1799971 GG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["decreased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased remifentanil requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["decreased remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants","increased risk for suicide ideation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs3813867 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the CC genotype and a lower likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["increased risk for resistant hypertension"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AG genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotypes and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["increased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of myelosuppression when treated with mercaptopurine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["decreased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["decreased risk of nausea and vomiting","decreased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with the rs3812718 CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["decreased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["decreased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs193922816 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have an increased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) or HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have an increased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["more likely to respond to paroxetine or antidepressants"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/3R or 3R\/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["decreased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a normal or no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the rs1954787 CC genotype and depressive disorders may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["decreased catalytic activity and increased expression of DPYD protein"]},{"genotypeAnnotationText":"Patients with the rs2244613 TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Individuals with the *2\/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.","phenotypeText":["reduced response to losartan"]},{"genotypeAnnotationText":"Patients with the rs696 TT genotype may require increased doses of sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the TT genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["less likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["lower likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["less likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the GG genotype and who are treated with allopurinol may have a decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA or AG genotypes. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the rs4948496 CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have decreased (but not absent) risk of hyperbilirubinemia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["decreased metabolism of heroin"]},{"genotypeAnnotationText":"People with intermediate metabolizer genotypes (e.g. *2\/*17) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele or one copy of the *1 allele in combination with one copy of the *46 allele may have increased metabolism of letrozole as compared to patients with any of the following genotypes: one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *12 or *17 alleles; one copy of the *46 allele in combination with one copy of the *4, *7 or *9 alleles; two copies of the *9 allele; two copies of the *17 allele; one copy of the *4 allele in combination with one copy of the *7 or *9 alleles; one copy of the *9 allele in combination with one copy of the *2 or *12 allele; one copy of the *17 allele in combination with one copy of the *35 allele; one copy of the *20 allele in combination with one copy of the *23 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["reduced risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs571335587 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["increased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["improved response to cisplatin and gemcitabine"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of lornoxicam as compared to patients with at lease one decreased or no function allele. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of sertraline as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of sertraline as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C or HIV may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased nicotine consumption as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["increased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["greater decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients who are smokers and who have the GG genotype may have decreased cigarette consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["decreased cigarette consumption"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the AG genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with genotype AA and schizophrenia may have decreased response to antipsychotics compared to patients with AC or CC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs118192177 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs10306114 AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs11615 AG genotype and risk of developing mucositis when treated with cisplatin and doxorubicin. However, patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["decreased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the rs4961 GG genotype may have decreased response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["reduced metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the CCT\/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia and neuropathy)"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["reduced risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.","phenotypeText":["require a fewer number of bevacizumab injections"]},{"genotypeAnnotationText":"Patients with cancer pain and the AA genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to adhere to nicotine replacement therapy (NRT) and may consume more NRT at 7 days post quit attempt as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["adherence to nicotine replacement therapy and consumption of NRT"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have decreased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["decreased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *4 or *9 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and an increased likelihood of asthenia as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["decreased risk of nausea and vomiting","increased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the rs121918592 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs121909005 GT genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 AG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["higher risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the rs6928499 CG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of methylphenidate as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["increased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["decreased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AA genotype who are treated with isoniazid and rifampin may have an increased likelihood of drug-induced liver injury as compared to patients with the AG or GG genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["increased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *7 or *9 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have a decreased severity of thrombocytopenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["higher triglyceride levels"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*4 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*1 allele in combination with a normal or no function allele may have increased tacrolimus dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased risk of nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have an increased relative reinforcing value of nicotine as compared to female patients with the AG or GG genotypes. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"In human liver microsomes, the AA genotype was associated with increased glucuronidation of SN-38, as compared to the AC or CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require a lower dose of warfarin as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients with a normal function allele in combination with a decreased function allele or patients with a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or GG genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["greater reductions in serotonin concentrations"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["increased serum concentrations"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele or decreased function allele may have decreased metabolism of SN-38 as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and alcoholism may have a decreased response to acamprosate as compared to patients with the AA or AT genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["decreased response to acamprosate"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["less weight loss","greater weight loss"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to achieve a target HbA1c level of <7%"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 AA genotype may have increased likelihood of angioedema when treated with ace inhibitors as compared to patients with the CC genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["increased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["better response (increased acute bronchodilation)"]},{"genotypeAnnotationText":"Patients with the *7 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs6280 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the A\/del genotype, may have elevated concentrations of lumefantrine as compared to patients with the del\/del genotypes, and lower concentrations of lumefantrine as compared to patients with the AA genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["increased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs118192177 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT, CT, CG, or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to quetiapine as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["higher risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with gemcitabine may have an increased risk of side effects including neutropenia as compared to patients with the AA or AG genotype combined with the G allele at rs9937. This association was not seen in a seperate study in patients with pancreatic cancer.Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less likely to respond to citalopram or escitalopram"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the GG genotype, and may be at decreased risk of toxicity compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC (CYP2C9 *1\/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1\/*2) or TT (*2\/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased blood pressure response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA\/AA genotypes (P=0.03; GG vs GA\/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.","phenotypeText":["larger tamoxifen-induced decrease in total cholesterol","tamoxifen-induced increase in triglycerides","decrease in high density lipoprotein"]},{"genotypeAnnotationText":"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the AA genotype and kidney transplantation may have increased exposure (Concentration\/Dose) to tacrolimus compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels","increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Men with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a greater decrease in triglycerides as compared to men with either the CT or TT genotypes. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["increased exposure to risperidone"]},{"genotypeAnnotationText":"The CT genotype is associated with decreased catalytic activity of DPYD as compared to the CC and increased catalytic activity as compared to the TT genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower IL1B serum levels","more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"The CYP2C19*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*6 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased risk for sleep disturbances"]},{"genotypeAnnotationText":"Patients with CG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have an increased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the AA or AG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["increased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response when compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Cancer patients with the AT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2253201 AA genotype may be at a decreased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["decreased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC> Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["increased risk for hematological toxicity"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism","increased serum concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["increased clearance of the drug"]},{"genotypeAnnotationText":"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CYP2C19*16 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*16 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations.The CYP2C19*16 allele was catalytic inactive toward mephenytoin during one in-vitro characterization with 4% of *1 activity for the substrate mephenytoin. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity of CYP2C19"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["increased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and treated with long-term opioids may be more likely to develop dizziness as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["more likely to develop dizziness"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 and increased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*14 and *23 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":["increased enzyme activity and clearance of clopidogrel"]},{"genotypeAnnotationText":"Individuals with the *1\/*3A genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["lower risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["decreased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["more likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele may have an increased clearance of methadone as compared to patients carrying two decreased or uncertain function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele construct (in this study PMID:26310775 only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have decreased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the GG and GT genotypes. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["decreased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["decreased likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with the rs3753380 CC genotype and open angle glaucoma may have an increased response to latanoprost compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of paroxetine as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of paroxetine as compared to patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of paroxetine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have decreased response to citalopram as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["reduced risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["increased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have increased metabolism of etoposide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["increased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with CC genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*6 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*3 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs137904044 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["less reduction in LDL"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal function allele (e.g. *1\/*3) may have increased metabolism of rabeprazole as compared to patients with two no function allele (e.g. *3\/*3, *2\/*3), and decreased metabolism of rabeprazole as compared to patients with two normal function alleles. However, a number of studies showed no difference in metabolism. Patients carrying the *3 allele in combination with another no function allele (e.g., *3\/*3, *2\/*3) may have decreased metabolism of rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have less severe anemia and neutropenia as compared to patients with the AG genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["decreased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG\/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one X-chromosome, neuropathic pain and the C genotype may have increased pain relief when treated with escitalopram as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased weight gain","decreased weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["decreased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to quetiapine as compared to patients with two copies of the *3 allele or one copy of the *1 allele in combination with one copy of the *3 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype who are treated with atorvastatin may have a increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele was only defined as D337G not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["increased general side-effect burden"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the TT genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the CG or GG genotypes. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["decreased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the rs4530637 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["increased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"The TPMT*6 allele has been assigned as a no function allele by the DPWG. Patients carrying the *6 allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased and decreased response to rocuronium"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AG genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["increased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have increased blood alcohol concentrations (BAC) as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":["increased blood alcohol concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*44:03 allele have an increased risk of toxic liver disease when treated with ticlopidine as compared to patients with no HLA-B*44:03 allele. Other genetic and clinical factors may also influence a patient's risk of toxic liver disease.","phenotypeText":["increased risk of toxic liver disease"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying and the *1\/*1 extensive metabolizer genotype when treated with pazopanib may have decreased risk but not absence of hyperbilirubinemia as compared to those with the *28, *37, *6 alleles. Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["increased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the TT genotype who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking","decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the AG genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype; patients with the AG genotype may have an increased likelihood of weight gain as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["decreased likelihood of weight gain","increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1F allele or one copy of the *1F allele in combination with one copy of the *1A allele may have an increased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1A allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 CT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Male patients with the B haplotype (wildtype, associated with normal G6PD activity) who are treated with mefloquine 1) may have a reduced risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.","phenotypeText":["reduced risk of pulmonary damage","similar risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of omeprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["decreased likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs510769 CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The CYP2D6*11 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*11 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit less from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the rs193922525 AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may be less likely to develop side effects when treated with venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["less likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":["reduction in psoriasis area or disease severity","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["increased chance of positive erectile response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*1 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due to an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased reduction in the fibrinolytic marker D-dimer"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["not have an increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["decreased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype TT. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["increased time in therapeutic range (TTR)"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["increased risk of biopsy-proven acute rejection","decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["increased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may be at an increased risk of toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["require a decreased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["decreased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased risk of biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who undergo kidney transplant may have a decreased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["decreased risk for new-onset posttransplant diabetes mellitus"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AA genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["less likely to experience drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["decreased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 GG genotype may have an increased response to buprenorphine therapy as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 or *1\/2 genotype may have an increased metabolism of debrisoquine or dextromethorphan or sparteine as compared to patients with the CYP2D6*18\/*21 or *5\/*18 or *1\/*21 or *10\/*21 or *2\/*44 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or dextromethorphan or sparteine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3\/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["increased clearance and decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["increased metabolism","increased risk of gastrointestinal toxicity","increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["decreased risk of bone marrow toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs1386493 GG genotype may require increased doses of methadone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with docetaxel may have an increased clearance and decreased risk of leukopenia as compared to patients with the GG genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased clearance and decreased risk of leukopenia"]},{"genotypeAnnotationText":"The CC genotype is associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 TT genotype may have an increased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["smaller decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and rs2501873 TT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased levels of acetaminophen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased exposure to dabigatran compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["worse response to enalapril"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs3733784 CC genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*23 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["increased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the G\/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del\/del or G\/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response","decreased time until response"]},{"genotypeAnnotationText":"Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs10455872 AA genotype may have an improved response to statins as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["improved response to statins"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CG genotype may have an increased response to pioglitazone as compared to patients with the CC genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele was only defined as R388H not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["increased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have increased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["increased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased metabolism as compared to patients carrying the *2 allele . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the CC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs3842 CT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["higher accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased metabolism and increased concentrations of nelfinavir"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["higher risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*96 allele has been assigned as a no function allele by CPIC. Patients carrying the *96 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the AG genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in pediatric patients exposed to cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["decreased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with CYP2C9*13 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["require more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["decreased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Patients with the rs777098658 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with two non-functional CYP2D6 alleles (e.g.*3\/*3, *3\/*4, *4\/*4, *5\/*4) who are treated with aqueous timolol may have increased exposure to timolol and increased excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["increased exposure to timolol and increased exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["slower improvement in Brief Psychiatric Rating Scale (BPRS) scores"]},{"genotypeAnnotationText":"Patients with the rs193922843 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs118192163 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["changes in mycophenolic acid exposure-related parameters and increased risk of acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased likelihood of discontinuation of methotrexate in people with Arthritis"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["increased clearance of gemcitabine","decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of morphine as compared to patients with the CC genotype, but increased metabolism of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["decreased metabolism of morphine","increased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["increased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the rs186045772 TT genotype (do not have a copy of the CFTR F1074L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["increased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the *5\/*5 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with nortriptyline may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CYP2D6*14 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*14 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["increased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with a normal function allele in combination with a no function allele or patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may have increased metabolism of N-desmethylclobazam as compared to patients with two no function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients who carry the *3 allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *3 allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.","phenotypeText":["increased risk for vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 1-4 nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["decreased risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *6\/*6 genotype and chronic myeloid leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1, *1\/*6, *1\/*28 or *27\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype may be at a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["lower decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*48 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*12 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["increased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1323040 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and Crohn Disease who are treated with corticosteroids may have a decreased likelihood of responsiveness as compared to patients with AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["less likely to have positive erectile response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["decreased risk for myalgia"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension have decreased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*3A or *1\/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["decreased likelihood of fatigue"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*4 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Poor metabolizers may also be more likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["reduced clearance of donepezil"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant and have have the CYP3A5*3 allele in combination with another no function allele may require a decreased dose of tacrolimus as compared to patients with a no function allele in combination with a normal function allele or two normal function alleles, while patients who have the CYP3A5*3 allele in combination with a normal function allele may require a decreased dose of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased dose requirement of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased nicotine consumption and an increased neural response to nicotine, as measured by MRI, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["decreased nicotine consumption","increased neural response to nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association between the rs6313 GG genotype and response to sertraline"]},{"genotypeAnnotationText":"Patients with the GG genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 GG genotype may have an increased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function alleles by CPIC. Patients carrying the *3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the CT and TT genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2075572 GG genotype and severity of sleep disorders when treated with methadone. However, patients with the CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may have a decreased response to gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response to gabapentin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.","phenotypeText":["increased concentrations of S-EDDP"]},{"genotypeAnnotationText":"\"Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or \"\"clinical benefit\"\" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.\"","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs548783838 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism of clomipramine"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["higher maintenance dose"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the GG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["smaller elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["increased risk for bleeding"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the AA or AG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["overall survival"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["decreased response to treatment with interferons"]},{"genotypeAnnotationText":"Individuals with the AG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GG genotype but may have and an improved response as compared to individuals with the AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CYP2D6*43 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*43 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the GG genotype who are treated with risperidone may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC\/del genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GGAGTC\/GGAGTC genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.","phenotypeText":["higher incidence of toxicity","tolerate lower doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased doses of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the rs7662029 GG genotype who are treated with sublingual buprenorphine\/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype may have and increased response to antidepressants as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["lower thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["decreased risk of nonfatal myocardial infarction"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype, or increased severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["reduced severity of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["increased withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["more likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have decreased response when treated with enalapril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["higher response rates to triple therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patient with the CC genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["increased risk of cardiac arrest or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with hepatitis B and the TT genotype may have an increased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the CC or CT genotypes. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have decreased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the rs1051266 TT genotype and rheumatoid arthritis may have increased response when treated with methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the CC genotype and breast or ovarian cancer may have a decreased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["decreased risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["decreased risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["increased concentrations of atazanavir"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 GG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["decreased but not absent risk for endometrial neoplasms"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CT genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*2\/*101 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CT or TT genotypes. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic"]},{"genotypeAnnotationText":"Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the CT genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["improved response to bevacizumab-based treatment regimens"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the AA genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["increased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"People with an ultra-rapid metabolizer genotype (e.g. *17\/*17) may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with intermediate metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased metabolism of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin","decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["less sensitive to Alkylating agents"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*12 allele or one copy of the *12 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of mephenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/ A-202A_376G diplotype (homozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["lack of early response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["increased dose of opioids"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["decreased risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal function allele may have an increased severity of dyspepsia when treated with ketoprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence the severity of dyspepsia.","phenotypeText":["increased severity of dyspepsia"]},{"genotypeAnnotationText":"Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *4 allele in combination with a normal function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence","increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4948496 CC genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may be at an increased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["decreased severity of thrombocytopenia","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["lower response to repaglinide"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["lower plasma concentrations of metoprolol and smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and response to opioids. However, patients with the AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["decreased response to opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers","phenotypeText":["smaller tamoxifen-induced decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CYP2C9*3\/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["reduced metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs780801862 AT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype were not studied but patients with the GAT\/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT\/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"Patients with the rs397508435 CC genotype (two copies of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["increased alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype who are undergoing hematopoietic stem cell transplantation may have increased clearance of busulfan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["increased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission","increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CT genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CT or TT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1142345 TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["decreased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["decreased severity of nausea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*6 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*6 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the rs267606617 A allele (also known as the 1555A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with isepamicin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with isepamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs2239050 CC genotype may have a decreased response to nimodipine as compared to patients with the CG genotype. Other genetic and clinical factors may also affect response to nimodipine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype and postoperative pain may require an increased dose when treated with fentanyl as compared to patients with the AG+GG genotype. Other genetic and clinical factors may also influence the required dose of fentanyl.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:01 allele may have an increased risk of experiencing nevirapine-related adverse events when treated with the drug as compared to patients with no HLA-B*35:01 alleles or negative for the HLA-B*35:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of experiencing nevirapine-related adverse events"]},{"genotypeAnnotationText":"Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the rs376073289 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *3\/*3 genotype who are administered midazolam may have slower clearance rates, and decreased metabolism of midazolam as compared to patients with the CYP3A5 *1\/*3 or *1\/*1 genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["slower clearance rates and decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with another no function allele may have increased response to sulfonylureas as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the del\/del genotype may have decreased metabolism of mycophenolic acid as compared to patients with the de\/T or TT genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["decreased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["decreased risk of emergency department visits"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the A genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["decreased likelihood of hypertension"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs4633 CT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A\/*1B) may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A\/*1A). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.","phenotypeText":["decreased likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype or those who are not taking oral contraceptives and a decreased risk of DVT as compared to patients with the AA genotype. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["increased risk for deep vein thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["increased clozapine plasma concentrations","increased risk for clozapine-induced agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins\/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["more likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["better response to antidepressant treatment"]},{"genotypeAnnotationText":"Individuals who smoke and have the GG genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the AG or AA genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":["decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*24 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may be at a decreased risk of QT prolongation when treated with methadone as compared to patients with two decreased function alleles. Other genetic and clinical factors may also affect a patient's risk of QT prolongation when treated with methadone.","phenotypeText":["decreased risk of QT prolongation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles or a decreased function allele in combination with a no function allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased inhibition of platelet aggregation","decreased risk of high on-clopidogrel platelet reactivity and poor responder status"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CC genotype may have an increased response to treatment with either aripiprazole or risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*57:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["decreased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the rs1603218569 T allele (also known as the 1243T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of severe ototoxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["decreased response","decreased exposure"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may have an increased risk of hyperbilirubinemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the CC genotype and increased reduction of diastolic blood pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan"]},{"genotypeAnnotationText":"The CYP2B6*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*9 allele in combination with a normal function allele or another decreased function allele may have increased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AG genotypes. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*35 allele in combination with one copy of the *17 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may be less likely to benefit from pravastatin treatment as compared to patients with the AA or A\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have increased overall survival time when treated with cetuximab as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG or GT genotypes. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the null\/null (has no copies of the GSTM1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null\/ null or the non-null\/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["decreased likelihood to be phenobarbital resistant"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["increased risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk for venous thrombosis compared to the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis","decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypertension who are treated with hydrochlorothiazide may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["decreased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1\/*3 or *1\/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["decreased risk for infections"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["increased blood concentrations"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GT or TT genotypes. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["decreased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["higher plasma concentrations and reduced clearance of simvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias"]},{"genotypeAnnotationText":"Patients with the rs568724445 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["decreased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to treatment with ivacaftor\/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to quetiapine as compared to patients with two copies of the *20 or *22 alleles or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["decreased exposure to quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["decreased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with nortriptyline may have more improvement in neurovegetative symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["more improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["better response","reduced response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 AG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response to propranolol"]},{"genotypeAnnotationText":"Patients with the CC genotype (two copies of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype or may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["increased dose of warfarin","decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with a decreased function allele may have increased irinotecan dose requirements as compared to patients carrying two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan dose requirements.","phenotypeText":["increased irinotecan dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["increased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response to venlafaxine in people with Anxiety Disorder","decreased response to venlafaxine in people with Depressive Disorders"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may be at a decreased risk of developing rifampin-induced liver injury as compared to patients carrying one or more copies of the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["decreased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to hydrochlorothiazide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the rs3804100 CC genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the TT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["no significant differences in progression-free survival time","reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*11 allele or one copy of the *11 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for nausea","increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["increased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs536577604 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["increased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40\/*42 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to experience myopathy when treated with statins as compared to patients with the AA or AG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a poorer response to treatment with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["poorer response to treatment with imatinib"]},{"genotypeAnnotationText":"The CYP2C9*11 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *11 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["increased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["increased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["decreased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["increased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["increased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["decreased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the G\/del genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1\/*6 and *1\/*1 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["decreased clearance of ketamine"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 TT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["decreased response to treatment with interferons"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["decreased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs7662029 AA genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["increased chance of rehospitalization"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["improved response, longer survival times"]},{"genotypeAnnotationText":"Patients with the rs527580106 CC genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs2031920 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["decreased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol","similar metabolism of haloperidol","increased metabolism of haloperidol"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of infection or nausea"]},{"genotypeAnnotationText":"Patients with the rs1800629 AG genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs4728709 AA genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["decreased likelihood of developing asthenia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment.","phenotypeText":["poorer response to metformin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1127354 CC genotype and chronic hepatitis C may have an increased risk of anemia as compared to patients with the AA or AC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*28 allele in combination with a normal function allele may have increased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased severity of diarrhea compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["increased severity of diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.","phenotypeText":["greater decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*34 allele or one copy of the *34 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the AC genotype and diabetes mellitus may have a worse response to sulfonylureas as compared to the AA and CC genotypes. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["worse response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["average risk for progression"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal or no function allele may require a decreased dose of tramadol as compared to patients carrying two no function alleles while patients carrying the *1 allele in combination with a decreased function allele with an activity value of 0.25 may require a decreased dose of tramadol as compared to patients carrying two decreased function alleles with an activity value of 0.25. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["decreased dose of tramadol"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 AG genotype may have a decreased response to buprenorphine therapy as compared to patients GG genotype but an increased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["smaller decrease in glomerular filtration rate (GFR)"]},{"genotypeAnnotationText":"In healthy volunteers the AG genotype may be associated with decreased secretory clearance of metformin and in patients with diabetes mellitus may result in an increase in efficacy (decreased HbA1c levels) as compared to patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin","increase in efficacy (decreased HbA1c levels)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.","phenotypeText":["decreased concentrations of S-EDDP"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs193922876 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism of nortriptyline"]},{"genotypeAnnotationText":"Patients with the rs367619008 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 CC genotype may have increased response when treated with platinum-based therapies as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the *2\/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *1\/*2 and *1\/*1 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["increased exposure to bupropion"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and colon cancer may have a shorter time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["shorter time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the CT genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the TT genotypes and lower concentrations and worse response to lumefantrine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["increased concentrations and an improved response to lumefantrine"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["more likely to respond to tramadol treatment"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["acquired resistance to erlotinib"]},{"genotypeAnnotationText":"Patients with the AA genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["increased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["higher mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["decreased doses of anti-Parkinsonian drugs","decreased risk of mortality"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["increased risk of hematologic toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AA genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*03:02 allele and chronic renal insufficiency who are treated with allopurinol may have an increased risk of simple rash as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of simple rash"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience adverse events as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the *3\/*3 diplotype may have increased toxicity when treated with indomethacin as compared to patients with *1\/*1 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["decreased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with escitalopram may have an increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["higher baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients the CC genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival","decreased progression-free survival","increased overall survival","decreased overall survival"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the TT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of lornoxicam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["decreased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have decreased severity of nicotine dependence as compared to patients with one copy of the *1 allele in combination with one copy of the *1x2 allele, but increased severity as compared to patients with two copies of the *2 allele or one copy of the *1 allele in combination with one copy of the *2 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["increased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs121909005 GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs9397685 AG genotype may experience a decreased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"African-American patients with the CC genotype (E4\/E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration to reach stable warfarin dose"]},{"genotypeAnnotationText":"Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["smaller increases in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs2108622 TT genotype may have increased warfarin dosage requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["increased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased systolic blood pressure following nimodipine administration as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.","phenotypeText":["decreased systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*2 allele or one copy of the *2 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to pitavastatin as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["decreased clearance of gemcitabine","increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Healthy males with the del\/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and pulmonary fibrosis may have increased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["increased response to N-acetylcysteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype TT or AT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["increased risk of Esophagitis"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["less likely to experience anxiety"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with risperidone may have a reduced, but not absent, risk of side effects as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["reduced risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or AT. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 2 allele in combination with a normal function allele (e.g. *1\/*2) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Cells with the CC genotype may have decreased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CT genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["decreased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the AG genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["risk of addiction"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4, *4B or *4C alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with nitrofurantoin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of mortality after myocardial infarction as compared to the CC or CT genotypes (ApoE E2 carriers), which may be mitigated by simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["decreased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the rs17682789 TT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:09 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of gemcitabine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 AA genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1805087 AA genotype and risk of toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentration of lovastatin acid as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentration of lovastatin acid"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs121909020 AG genotype (one copy of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"Female children with typhoid fever and the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"The SLCO1B1*14 allele (defined as consisting of rs2306283 and rs11045819) is assigned as an increased function allele by CPIC. Patients with the *14 allele in combination with another increased or normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1XN genotype (carriers of more than two functional CYP2D6 alleles) may have a reduced response to dolasetron as compared to patients with the same genotype who were administered granisetron. Other clinical and genetic factors may also influence response to dolasetron in patients with postoperative nausea and vomiting.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with antiepileptics as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test.","phenotypeText":["decreased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3\/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1\/*3 or *1\/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["decreased metabolism of cyclosporine resulting in increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the TT genotype who smoke tobacco may have a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["greater body mass index"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the AG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have an increased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["risk of bone marrow toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is not significant association between the CYP3A4*22 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["not significant association"]},{"genotypeAnnotationText":"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the CYP2D6*33 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*33 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Pediatric patients with the *1\/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors, may have increased response to gemcitabine compared to the CC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL\/A or DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["decreased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased chance of response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["decreased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["increased risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have improved response to citalopram or escitalopram as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["poorer likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart conditions may have a poorer response to treatment with beta-blockers or antihypertensives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of desipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of desipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of desipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25.This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine","decreased metabolism of desipramine"]},{"genotypeAnnotationText":"Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms compared to TT carriers, and more likely to have improvement in symptoms as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less likely to have an improvement in symptoms"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased fluvastatin concentration when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response according to the Positive and Negative Syndrome Scale"]},{"genotypeAnnotationText":"Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"It is currently unclear how the CT genotype affects a patient's risk of developing heroin dependence.","phenotypeText":["risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/A genotype, but a decreased risk as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:02 allele who are treated with acetaminophen may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-DQB1*02:02 alleles or negative for the HLA-DQB1*02:02 test. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["increased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the C\/del or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs12471326 CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor\/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["respond to ivacaftor\/tezacaftor treatment"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype (two copies of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Infants with the rs1799971 AG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs10306114 AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["better chance at achieving remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype, but decreased morphine dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs118192176 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of methotrexate response"]},{"genotypeAnnotationText":"The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["better response to treatment with salvianolate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["decreased social and clinical needs"]},{"genotypeAnnotationText":"The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotypes, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["increased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased improvement of depression symptoms"]},{"genotypeAnnotationText":"Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["increased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["increased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *4\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response","decreased concentrations of deferasirox","increased risk of iron overload"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["less likely to achieve a complete response but also less likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele in combination with a normal function allele and depression may require a higher dose of selective serotonin reuptake inhibitors as compared to patients with two no function alleles. Other genetic and clinical factors may also influence a patient's dose requirement.","phenotypeText":["higher dose requirement of selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or one copy of the *2 allele in combination with one copy of the *1 allele may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of naproxen as compared to patients with the AT or TT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["increased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Hispanic patients with the AG genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["greater decrease in viral load"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["increased alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["increased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQA1*02:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. This allele is in strong linkage disequilibrium with HLA-DRB1*07:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype, and an increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["increased metabolism of temsirolimus","increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Postoperative patients with the AG genotype may have higher morphine requirements as compared to patients with the GG genotype, but lower morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements","lower morphine requirements","interaction with ethnicity"]},{"genotypeAnnotationText":"Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["reduced risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and tobacco use disorder may have a decreased risk for nicotine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer may have decreased exposure to sirolimus and temsirolimus as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of citalopram as compared to patients with a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["increased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["increased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["increased risk of nonfatal myocardial infarction"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["decreased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The TT genotype was not analyzed, but patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CT genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the rs2011425 TT genotype may have increased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["increased serum concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GT genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the TT genotype and a decreased likelihood as compared to the GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["decreased risk of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["higher plasma concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["decreased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*4 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.","phenotypeText":["increased beta cell function"]},{"genotypeAnnotationText":"Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["reduced response or better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["decreased dose of phenytoin"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:01 allele who are treated with lamotrigine may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) as compared to patients with no HLA-B*38:01 alleles or negative for the HLA-B*38:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 CC genotype may have decreased methadone dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.","phenotypeText":["increased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have decreased survival time and a decreased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*10 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT, and increased dose as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["associated with decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*7 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with genotype GG and depressive disorder may have increased response to venlafaxine compared to patients with genotype AA or AG. Patients with GG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*44 allele have an increased likelihood of having a sustained response to interferon-alpha and ribavirin therapy, as compared to patients with no HLA-B*44 alleles or negative for the HLA-B*44 test. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to interferon-alpha and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*44 allele. This clinical annotation appears on the HLA-B*44:02 allele page because this was the first *44 allele discovered.","phenotypeText":["increased likelihood of having a sustained response to interferon-alpha and ribavirin therapy"]},{"genotypeAnnotationText":"The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:01 allele may have a decreased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*15:01 alleles or negative for the HLA-B*15:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["decreased risk of oxcarbazepine-induced maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*41 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["better response to treatment with imatinib"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1868089 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with opioid dependence and the AG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["increased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the AG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs76103438 TT genotype may be at a decreased risk of experiencing adverse events when treated with simvastatin as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["decreased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the CT (CYP2C9 *1\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["increased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 TT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["decreased response to azathioprine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["decreased risk of myocardial infarction"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response","similar analgesic response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["less likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Genotype TT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["decreased uptake"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.","phenotypeText":["decreased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["decreased likelihood of developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["decreased risk of developing drug dependence"]},{"genotypeAnnotationText":"People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AG or GG genotypes. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with intermediate metabolizer genotypes, such as *1\/*3, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype (carriers of E2 or E2\/E2). Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/3R or 3R\/3R genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate in people with Rheumatoid Arthritis"]},{"genotypeAnnotationText":"Patients with the rs4035887 AA genotype may have an increased risk of toxicity when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","decreased endoxifen concentrations","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2D6*2\/*44 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *2\/*44 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CGG genotype may be at an increased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs2075572 CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.","phenotypeText":["decreased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["association with serotonin levels"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to peginterferon alpha and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs538336580 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["greater reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["increased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the rs9606186 CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Individuals with the TC\/TCCTC genotype may have decreased clearance of olanzapine as compared to individuals with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of sertraline as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GGTCCCACTCTTCCCACA\/GGTCCCACTCTTCCCACA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*8 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs12885713 TT genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["increased response to cyclosporine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype may have increased activity of DPYD as compared to patients with the AT or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["better response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the 9,9-repeat genotype (del\/del) may have a decreased response to disulfiram treatment for cocaine dependence. as compared to patients with the 10,10-repeat genotype. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["increased risk for treatment-resistance"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*9 or *25 or *26 or *28 or *32 or *39 or *43 or *45 or *48 or *70 allele, 2) similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*22 or *23 or *24 or *27 or *33 or *49 allele, and 3) increased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*7 or *10 or *12 or *14A or *14B or *17 or *18 or *29 or *30 or *31 or *36 or *37 or *40 or *46 or *47 or *50 or *51 or *52 or *54 or *55 or *61 or *62 or *63 or *64 or *65 or *71 or *72 or *75 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["increased clearance of n-desmethyltamoxifen","similar clearance of n-desmethyltamoxifen","increased activity of CYP2D6"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["increased area under the curve (AUC) of olanzapine"]},{"genotypeAnnotationText":"Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["more likely to develop colorectal cancer"]},{"genotypeAnnotationText":"The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*29 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting","decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the rs61605570 AT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs9679162 GG genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["decreased response to chemotherapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14 allele or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":["greater bone mineral loss"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased metabolism of imatinib","decreased sensitivity to dasatinib, imatinib, or nilotinib"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1 allele in combination with one copy of the *4 or *9 allele may have increased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with the *9 allele, or patients with two copies of the *9 allele. Patients with two copies of the *1 allele may have increased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *23, *24, *25, *26, *27, *28, *35, *39, *41 or *55 alleles or or patients with two copies of the *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *24, *27, *28, *35, *39, *41 or *55 alleles or patients with the *4\/*7, *4\/*9 *4\/*17, *9\/*12 *9\/*26 or *17\/*20 diplotypes but may have decreased metabolism as compared to patients with two copies of the *46 allele or one copy of the *1 allele in combination with the *46 or *1x2 alleles. However, conflicting evidence has been reported for *24. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have a decreased response to antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["reduced risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol","similar metabolism of tramadol","increased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have an increased response to statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["increased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and carrying one or two copies of the NAT2*1 allele (formerly *12A, B, C) may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of two *5, *6 or *7 suballeles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["require a decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the CC genotype may have improved response to antidepressants as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["improved response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 CC genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["increased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["decreased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*14 allele or one copy of the *14 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs72547516 AT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir in people with HIV"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with the *6, *7, or *14 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another fast acetylator allele may have increased metabolism of dipyrone as compared to patients carrying the *4 allele in combination with the *6, *7, *14, or *16 allele or patients with the any two *6, *7, *14, or *16 alleles. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of dipyrone"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism","reduced metabolism"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*14 allele or one copy of the *14 allele in combination with the *6, *7, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5 allele or one copy of the *5 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 CT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients carrying the NAT2*6 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AG genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele (*13A now also mapped under *4) in combination with the *1 allele (formerly *12A, B, C) may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7, *14, or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have decreased clearance of pravastatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased plasma concentrations of aripiprazole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of aripiprazole"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*41 allele or one copy of the *41 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and carrying one or two copies of the NAT2*4 allele (*13A now also mapped under *4) may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of two *5, *6 or *7 suballeles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*39 allele or one copy of the *39 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14 allele or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["better response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 CT genotype may have increased clearance of tenofovir as compared to patients with the TT genotype but decreased clearance compared to the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["increased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 TT genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *6 allele or one copy of the *6 allele in combination with any of the *5, *6, *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients with the rs895819 CC genotype may have increased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["increased risk of severe toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7 allele or one copy of the *7 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7 allele or one copy of the *7 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association between the rs2306283 AA genotype and response to pravastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have an increased response to antidepressants as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*5 allele or one copy of *5 in combination with the *6, *7, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*5 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *5 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects","increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["less likely to have a complete response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure","increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*55 allele or one copy of the *55 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["increased risk of oxcarbazepine-induced maculopapular eruption (MPE)"]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have increased clearance of pravastatin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["decreased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*7 allele or one copy of the *7 allele in combination with the *6, *14, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":["decreased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["increased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*6 allele or one copy of *6 in combination with the *5, *7, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*6 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *6 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of hydralazine","increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs11045819 CC genotype may have a decreased response to statins as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["increased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 CC genotype may have increased clearance of tenofovir as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["increased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5 allele or one copy of the *5 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["increased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs11045819 AA genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["decreased progression-free survival","decreased overall survival","increased progression-free survival","increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir in people with HIV"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele (*13A now also mapped under *4) or one copy of the *4 allele in combination with one copy of any *1 allele (formerly *12A, B, C) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele; any combination of the *5, *6, *7, *14, *16 or *39 allele; two copies of *5, *6, *7, *14, *16 or *39 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6 allele or one copy of the *6 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have an increased response to statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*6 allele or one copy of the *6 allele in combination with the *7, *14, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have an increased response to simvastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5 allele or one copy of the *5 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for Adenoma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of myalgia and lower degree of muscle damage"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 TT genotype may have decreased clearance of tenofovir as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["decreased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*7 allele or one copy of the *7 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["more likely to respond to hydralazine treatment"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *7 allele or one copy of the *7 allele in combination with any of the *5, *6 *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 GG genotype may be at a decreased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the AC genotype may have decreased response to antidepressants as compared to patients with the CC genotypes and imporved response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["decreased response to antidepressants","improved response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AA genotype may have a decreased response to metformin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*16 allele or one copy of *16 in combination with the *5, *6, or *7 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*16 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *16 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72547516 TT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 CC genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the rs895819 CT genotype may have increased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["increased risk of severe toxicity"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["decreased metabolism of sertraline"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7 allele or one copy of the *7 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7G allele or one copy of the *7G allele in combination with one of the *5, *6, *7, *14, *16 or *39 may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The *7G allele was not transitioned into the PharmVar database and remains with the arylamine N-acetyltransferases (NATs) site.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs72547516 GG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*14 allele or one copy of the *14 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have an increased response to antidepressants as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*6 allele or one copy of the *6 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["more likely to respond to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy","consume less NRT at 7 days post quit attempt","more likely to adhere to NRT","consume more NRT at 7 days post quit attempt"]},{"genotypeAnnotationText":"Patients with the rs895819 TT genotype may have decreased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["decreased risk of severe toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs11045819 AC genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism of venlafaxine","similar metabolism of venlafaxine","increased metabolism of venlafaxine"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response in men","increased response in women"]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6J allele or one copy of the *6J allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The *6J allele was not transitioned into the PharmVar database and remains with the arylamine N-acetyltransferases (NATs) site.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*16 allele (formerly *5A, *5D) in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2306283 AG genotype and response to statins. However, patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation of carvedilol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["decreased atorvastatin lactonization"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["stronger aggregation","increased risk of non-response"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*1 allele (formerly *12A, B, C) may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two of the *5, *6, *7, *14, or *16 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with any combination of the *5, *6, *7, *14 or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*39 allele (formerly *6O) or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*7 allele or one copy of *7 in combination with the *5, *6, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*7 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of hydralazine","increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1805128 CC genotype may have increased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["increased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6 allele or one copy of the *6 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 CT genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with tenofovir concentrations"]},{"genotypeAnnotationText":"Patients with the rs1805128 TT genotype may have decreased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["decreased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["decreased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin serum concentration","decreased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the rs1803155 AA genotype and tuberculosis may have decreased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AA genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":["decreased clearance of fesoterodine"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["less skin redness"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1803155 AG genotype and tuberculosis may have increased clearance of rifampin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72547516 AA genotype and may have increased metabolism of clozapine as compared to patients with the AG, AT, TT or GG genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron","no recommendation for CYP2D6 intermediate and poor metabolizers"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association between the rs2306283 GG genotype and response to pravastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*4 allele (*13A now also mapped under *4) may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two of the *5, *6, *7, *14, or *16 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 TT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response and increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the rs72547516 AG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*1 allele (formerly *12A, B, C) or one copy of the *1 allele in combination with one copy of *4 allele (*13A now also mapped under *4) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele; any combination of the *5, *6, *7, *14, *16 or *39 allele; two copies of the *5, *6, *7, *14, *16 or *39 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 GG genotype may have an increased response to metformin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":["decreased clearance of codeine"]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6 allele or one copy of the *6 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs2306283 AG genotype may have increased clearance of pravastatin as compared to patients with the GG genotype but decreased clearance as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of aripiprazole"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AG genotype may have a decreased response to metformin as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["increased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*1 allele or one copy of the *1 allele (formerly *12A, B, C) in combination with *4 allele (*13A now also mapped under *4) may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7, *14, or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["improved response to the drug"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *4 allele in combination with the *5, *6, *7, or *16 allele or patients with two of the *5, *6, *7, or *16 alleles. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any of the *5, *6 *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":["worse response","increased clearance"]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["better response to metoprolol"]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs1805128 CT genotype may have increased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["increased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have decreased response to antidepressants as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["increased metabolism of oxycodone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["increased concentrations of nicotine"]},{"genotypeAnnotationText":"Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the NAT2*14 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1803155 GG genotype and tuberculosis may have increased clearance of rifampin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["reduced risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["increased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["decreased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism","reduced metabolism"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for neutropenia and a decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure","increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["decreased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with *6 (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *7 allele in combination with the *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["increased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["decreased progression-free survival","decreased overall survival","increased progression-free survival","increased overall survival"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["decreased dose requirement of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of myalgia","lower degree of muscle damage"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response","no association of the genotype with fluvoxamine response","the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response","Other genetic and clinical factors may also influence a patient's response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy","consume less NRT at 7 days post quit attempt","more likely to adhere to NRT","consume more NRT at 7 days post quit attempt"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response in men","increased response in women"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation of carvedilol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["decreased atorvastatin lactonization"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["decreased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron","no recommendation for CYP2D6 intermediate and poor metabolizers"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response and an increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["increased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":["No information available"]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide","decreased risk of gastrointestinal toxicity","decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]}]
\ No newline at end of file
+[{"genotypeAnnotationText":"Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for gastrointestinal toxicities","increased response to folic acid and methotrexate","increased event free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the GG genotype and severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and two copies of the CYP1A2*1A allele may have increased concentrations of clozapine as compared to patients with two copies of the *1F allele or one copy of the *1F allele in combination with one copy of the *1A allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP1A2 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clozapine concentrations.","phenotypeText":["increased concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs699 GG genotype may have an increased response to irbesartan as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the CG genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom had the CG genotype.","phenotypeText":["higher incidence of toxicity and may tolerate lower doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)9 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance and increased exposure to nevirapine"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the GAT\/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT\/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele or a donor with two normal function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["increased risk of drug toxicity and may require dose modification"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["increased dose of atenolol"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have an increased analgesic response to methadone as compared to patients with two decreased function alleles or a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.","phenotypeText":["higher CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["increased cognitive impairment"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased analgesic response to morphine as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AG or GG genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["decreased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the del\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype or may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["increased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have an increased analgesic response to ketorolac as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["shorter period of time before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["higher plasma drug levels"]},{"genotypeAnnotationText":"Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["decreased risk of experiencing adverse events","increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["good response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs72549435 GG genotype may have increased metabolism of nicotine as compared to patients with the CC or CG genotypes. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype have an decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea","increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased QT interval"]},{"genotypeAnnotationText":"No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["less likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin"]},{"genotypeAnnotationText":"Patients with the rs279858 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["less likely to respond to treatment with cholinesterase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have decreased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with thromboembolism and the CT genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the TT genotypes and decreased risk as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants","increased risk for suicide ideation"]},{"genotypeAnnotationText":"Patients with the CYP2C19*25 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*25 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 36% of the clearance ratio of *1 for mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["poorer pain relief response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1042713 AG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol.","phenotypeText":["increased response to salmeterol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["reduced risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the AG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 TT genotype may have a decreased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of developing either heroin or cocaine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["increased likelihood of developing either heroin or cocaine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs121909005 TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and sickle-cell anemia may have increased levels of glucuronidation of morphine as compared to patients with the CC or CT genotypes and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["increased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being ineffective","increased likelihood of treatment being effective"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["decreased risk of developing drug dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the rs3842 CC genotype may have an increased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["increased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype (*17\/*17) and alcoholism may have a decreased response to phenazepam as compared to patients with the CC (*1\/*1) or CT (*1\/*17) genotypes. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs11045995 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require decreased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*29 genotype may have an increased metabolism of dextromethorphan or debrisoquine compared to patients with the *29\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["decreased risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele was only defined by 4110C>G in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin (a higher change in triglycerides)"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["increased survival time","risk for hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.","phenotypeText":["smaller decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["increased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["decreased risk of bone marrow toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the TT genotype or a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs145308399 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["increased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:12 allele may have an decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to esomeprazole (greater % of time with intragastric pH < 4.0, and a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a normal function allele in combination with a no function allele or two no function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["decreased response to esomeprazole"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1381376 CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements","increased dose requirements"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["decreased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Patients with genotype AA and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1\/*1 genotypes. However, one study found that those with the *1\/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":["increased risk for kidney dysfunction","better kidney function"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["decreased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["decreased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Women with the UGT1A1*28\/*28 genotype and osteoporosis may have increased hip bone mineral density when treated with raloxifene as compared to patients with the *1\/*1 or *1\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["increased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["reduced risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with depression and the GG genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ritonavir may have a increased intracellular\/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["increased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["more likely to respond to treatment with selective serotonin-reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["decreased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele may have increased consumption of nicotine as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["increased consumption of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of akathisia when treated with arpiprazole as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["increased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Cells with the CC genotype may have increased enzymatic activity toward SN-38 as compared to cells with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["increased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AA genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the rs1800497 AG genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["increased weight loss response"]},{"genotypeAnnotationText":"Patients with the CC genotype and metastatic colorectal cancer may have increased rapid response to treatment containing irinotecan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["increased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["decreased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CC genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*5) (rs4244285\/rs56337013) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:19 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:19 alleles or negative for the HLA-B*15:19 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the rs527580106 TT genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may experience greater vasodilation as compared to patients with the del\/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with nitroprusside. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 CC genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["increased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["increased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased pain reduction"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["reduced risk for metastasis"]},{"genotypeAnnotationText":"The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["poorer response to treatment with tiotropium"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["increased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["lower levels of morphine"]},{"genotypeAnnotationText":"Patients with the rs12948059 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to flecainide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["increased risk for endometrial neoplasms"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination of a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased simvastatin acid concentration when treated with simvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased simvastatin acid concentration"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test.","phenotypeText":["increased risk of cutaneous adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to methadone in the treatment of heroin dependence as compared to patients with the CT or TT genotypes. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["increased risk of adverse drug reaction","decreased risk of adverse drug reaction"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the CC genotype may have increased clearance of methotrexate as compared to patients with the CT or TT genotypes. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another allele of *1 may have increased metabolism of ibuprofen as compared to patients carrying one or two copies of *3 allele. Other genetic and clinical factors may also influence metabolism of ibuprofen.This annotation only covers the pharmacokinetic relationship between CYP2C8 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1\/*1 diplotype may require increased dose of ibuprofen as compared to patients with CYP2C8*3. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["increased dose of ibuprofen"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another *4 allele (assigned as rapid acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *4 allele in combination with the *5, *6, or *7 allele (assigned as intermediate acetylator phenotype) or patients with the *5\/*5, *5\/*6, *6\/*6, or *6\/*7 genotypes (assigned as slow acetylator phenotype). This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":["increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with the rs1384401 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*4 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the GG genotype on alcohol consumption.","phenotypeText":["effect on alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["lowest dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs3918290 CC genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased concentrations of carbamazepine compared to patients with the AG and GG genotypes when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["increased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have decreased blood alcohol concentrations (BAC) as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":["decreased blood alcohol concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["increased risk of liver failure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["increased area under the curve (AUC) of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have increased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased clearance of 2',2'-difluorodeoxyuridine (dFdU)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*50 allele or one copy of the *50 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype or may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the AG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk","increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["decreased risk for drug toxicity","decreased response to treatment with cisplatin or carboplatin"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["decreased risk of hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5A allele or one copy of the *5A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to treatment with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the GT or TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["less likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16) may have an increased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with two HLA-C alleles from the C2 group (i.e. *02, *04, *05, *06, *15 or *17).","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Cells with the TT genotype may have decreased uptake of catecholamines or metformin as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["decreased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).","phenotypeText":["increased clearance of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the rs3114020 TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype may have increased concentrations of methotrexate as compared to the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["larger reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"The association between the GG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*1 allele in combination with another normal function allele may have decreased lovastatin acid concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["decreased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The CYP2B6*2 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*2 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":["decreased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to corticosteroids compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["increased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with genotype GG and colorectal neoplasms may have a decreased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the AA or AG genotypes. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["decreased response to FOLFOX therapy"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased response when treated with enalapril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*36 allele or one copy of the *36 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the GG genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of folic acid as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased metabolism of folic acid"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["increased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the CC or CG genotypes. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an metabolism of repaglinide as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["decreased heart rate"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have decreased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased plasma concentrations of montelukast as compared to patients with the *2\/*2 or *1\/*2 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *2\/*2 genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *1\/*1 or *1\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["longer post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are smokers and have the GG genotype may have increased lung function as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["increased lung function"]},{"genotypeAnnotationText":"Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects","opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["increased risk for non-immune response to the hepatitis B vaccine"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 TT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with CYP2C19*3\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased fentanyl dose requirements as compared to patients with two decreased function alleles. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.","phenotypeText":["reduced response to losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid or psoriatic arthritis may have a better response when treated with anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2B6*22 allele in combination with a normal function or an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2654754 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["increased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and Arthritis who are treated with methotrexate may have a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Smokers with the TT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["poorer likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Adolescents with the GG genotype may have decreased nicotine cravings as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["decreased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["increased clearance of atazanavir"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["decreased SVR"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with clozapine may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["increased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["increased fentanyl dosage requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["reduced risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*03:01 allele have an increased risk of asthma when treated with aspirin, as compared to patients with no HLA-DPB1*03:01 alleles or negative for the HLA-DPB1*03:01 test. Other genetic and clinical factors may also influence risk of aspirin-induced asthma.","phenotypeText":["increased risk of asthma"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 AG genotype may have an increased response to acamprosate treatment as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the GG genotype may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *18 allele or one copy of the *1 allele in combination with one copy of the *18 allele. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC. The AA genotype may have decreased catalytic activity of DPYD as compared to the GG genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased response to budesonide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["increased risk of Death"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 GG genotype may have an increased response to warfarin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["increased response to warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased survival","risk of severe neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have increased plasma concentrations of triglycerides as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["increased metabolism of zidovudine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["decreased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to topiramate"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular\/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["decreased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"Patients with the rs1800566 AA genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*40 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs111888148 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia or schizoaffective disorder may have less weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["reduced clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["more likely to have complete remission"]},{"genotypeAnnotationText":"Patients with the CYP2D6*17 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity and decreased clearance"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia may have increased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["increased clearance of busulfan"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1128503 GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["better response to treatment with duloxetine"]},{"genotypeAnnotationText":"Patients with the rs997917 CC genotype may be at a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["increased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *7 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["better response to lansoprazole"]},{"genotypeAnnotationText":"Patients with HIV infections and the TT genotype may have increased trough concentrations of amprenavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["increased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10 allele and depression who are treated with sertraline may have a less response to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with alcoholism and the AG genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Individuals with the CCT\/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT\/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["increased retention rates"]},{"genotypeAnnotationText":"Patients with GSTT1 non-null\/non-null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null\/null. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["decreased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["decreased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["better response to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the *1\/*3C genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CT genotype, (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["increased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["better response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentrations of fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["decreased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype may have a decreased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["decreased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased concentrations of morphine as compared to patients with the AG or GG genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["increased concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C","greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the T\/del or TT genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of carbocisteine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["decreased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["less likely to respond to aspirin"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require a decreased dose of phenprocoumon as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["decreased dose requirement","increased dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of Vitamin K as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["decreased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with cancer pain and the CC genotype may have decreased morphine dose requirements as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["increased risk of developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure)"]},{"genotypeAnnotationText":"Patients with the ATTTGTTCATGCCT\/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del\/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["increased risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["decreased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics..","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving chemotherapy treatment may have increased severity of nausea as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["increased severity of nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with smaller increases in HDL-C levels","better response to treatment with higher increases in HDL-C levels"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["higher plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Cancer patients with the CC genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["require a decreased dose of fentanyl"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["decreased metabolism of doxorubicin","greater tumor reduction","increased severity of neutropenia","increased metabolism of doxorubicin","less tumor reduction","decreased severity of neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with opioid dependence and the GG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["increased risk of sudden death"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal function allele may have increased response to ketoprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to ketoprofen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele may have increased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased severity of diarrhea compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["increased severity of diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["increased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have decreased exposure (Concentration\/Dose) to tacrolimus compared to patients with the AG and AA genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":["lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV)"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease","increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4\/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["decreased risk for side effects","increased dose of drug required"]},{"genotypeAnnotationText":"Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["more effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 CG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["higher likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin (a higher change in triglycerides)"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with \"standard risk cytogenetic profiles\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.","phenotypeText":["shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the TG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3A genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a greater risk for side effects as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["better response to treatment with imatinib","increased risk of developing cytogenetic resistance to imatinib","greater risk for side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to benefit from treatment with atenolol"]},{"genotypeAnnotationText":"Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["increased response to treatment with selective serotonin-reuptake inhibitors (SSRIs)"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk for cardiovascular toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk for Adenoma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to rosuvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically mean arterial pressure, as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs11971167 GT genotype (one copy of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["decreased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the *3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism of imipramine"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to olanzapine as compared to patients with the CC genotype but an increased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with CC genotype and cancer may have an increased risk for toxicity when treated with tegafur as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["increased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*1 diplotype may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":["increased metabolism of cilostazol"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs2736308 CC genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["increased risk of Medication-related osteonecrosis of the jaw (MRONJ)"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["not receive benefit"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["increased response"]},{"genotypeAnnotationText":"African-American patients with the TT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to beta-blockers as compared to patients with deletion of at least one copy of allele A. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["better response to beta-blockers"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*4 allele in combination with a normal function allele may have increased weight gain when treated with olanzapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the rs2239050 GG genotype and response to nimodipine.","phenotypeText":["response to nimodipine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":["decreased concentrations of voriconazole"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs324029 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to atenolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of risperidone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of risperidone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of risperidone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["decreased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*5 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may require a decreased dose of oxycodone as compared to patients with the *3\/*3 genotype. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["decreased dose requirement of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs6275 AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine","decreased clearance of cyclosporine","increased risk in adverse events"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with CYP3A5*3\/*3 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1\/*1 or *1\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["lower granisetron clearance and increased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["increased imatinib clearance"]},{"genotypeAnnotationText":"CYP2D6 *1\/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine and decreased exposure to dextromethorphan as compared to the *1\/*10 or *10\/*10 genotypes. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["increased inhibition of CYP2D6","decreased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*17 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*2) (rs4244285) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nicotine withdrawal as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have a decreased response to olanzapine as compared to patients with the AA genotype but an increased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs5443 CT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["greater reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Women with the AA genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["increased dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["increased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with the rs2654754 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with a *1 or *3 allele may have decreased metabolism of ibuprofen as compared to patients with *1\/*1. Other genetic and clinical factors may also influence metabolism of ibuprofen.This annotation only covers the pharmacokinetic relationship between CYP2C8 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["decreased risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["decreased risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have a worse response, such as shorter survival times, when treated with carboplatin and taxanes as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["worse response, such as shorter survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have increased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G with 100C>T, P34S not considered) was found to have increased intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["increased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allelemay have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs569661196 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*1 genotype may have lower glucuronidation of carvedilol as compared to patients with the *28\/*28 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["lower glucuronidation of carvedilol"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased response","increased risk for stent thrombosis","increased risk for target vessel revascularization","increased risk for cardiovascular secondary events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["decreased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have less severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*4 or *4\/*4 genotypes. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["decreased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased dose-adjusted trough concentrations of phenytoin as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["decreased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["decreased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs11150606 CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased expression of DPYD as compared to the AT or TT genotypes. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["decreased expression of DPYD"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["decreased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["decreased response according to the PANSS negative symptoms scale"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1\/*3 and *3\/*3 genotypes. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs11125039 GG genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["risk of hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["increased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*12A allele or one copy of the *12A allele in combination with *4 or *13A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["increased risk of neutropenia or hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["increased blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the rs1800111 CC genotype (two copies of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["increased abstinence"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *7B or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["increased survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the rs510769 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["less likely to benefit from treatment","increased risk of death or cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["increased severity of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["no significant association with likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 GG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the rs1076560 AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the rs11150606 CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["increased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["decreased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the *13 allele in combination with a normal, decreased or no function function allele may have decreased metabolism of lornoxicam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.","phenotypeText":["decreased dose requirement for methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to respond to antiepileptic drugs"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["increased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the rs371258350 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["increased risk for statin-related myalgia","decreased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs1302192284 CC genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of Esophagitis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["increased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased response","increased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 CC genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["less likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk for stroke"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 CC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may experience less vasodilation when treated with nitroprusside as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["less vasodilation"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs121908755 AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a better response as compared to patients with the ATTTGTTCATGCCT\/del and ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have increased clearance of gemcitabine as compared to patients with the GG genotype, or decreased clearance as compared to patients with the AA genotype. Patients may also have decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to those with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["increased clearance of gemcitabine","decreased elimination clearance of dFdU"]},{"genotypeAnnotationText":"Patients with the *1\/*5 diplotype may have increased exposure of repaglinide as compared to patients with the *37\/*37 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["shorter progression-free survival","decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the TT genotype or an increased risk of coronary artery disease compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with etravirine may have an increased etravirine clearance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["increased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["increased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased response to fluorouracil-containing chemotherapy regimens","increased risk for and an earlier onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["faster analgesic onset"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the GG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"The association between the AG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to develop an addiction to crack cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["more likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the CT or TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:07 allele who are treated with lamotrigine may have an increased risk of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) or Maculopapular Exanthema (MPE) as compared to patients with no HLA-A*02:07 alleles or negative for the HLA-A*02:07 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR), Stevens-Johnson Syndrome (SJS) or Maculopapular Exanthema (MPE)"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["decreased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3753380 TT genotype and open angle glaucoma, may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 AG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs11045879 CT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience slower desensitization to effects of terbutaline as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["slower desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AA or CC genotypes. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased lovastatin acid concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["increased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["increased stop reaction time, or greater impulsivity"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"The CYP2B6*38 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*38 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with ADHD and the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs62097526 GT genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["gain more weight"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer progression-free survival","increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs662799 AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2C9*55 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *55 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Elderly patients with the *3\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are also CYP2A6 normal metabolizers may have decreased metabolism of nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a worse response when treated with platinum compounds as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with cancer and the CG genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["more likely to benefit from treatment","reduced risk of death or cardiovascular disease events"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased levels of O-desmethylnaproxen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to rosuvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["decreased risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the AA genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"The CYP2B6*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs118192124 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["decreased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["decreased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"No patients with the CC genotype available for analysis.","phenotypeText":["Not available for analysis"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 GG genotype may be more likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2279343 AA genotype may have increased methadone dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["increased risk for toxic liver disease or abnormal liver-function tests"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["decreased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the GT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*10 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have an increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CT and CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs702764 TT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["lower success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["decreased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs3829125 AA genotype may have decreased metabolism of naltrexone as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism of naltrexone"]},{"genotypeAnnotationText":"Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["decreased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype (*1\/*1) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17\/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["decreased severity of nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the CG and CG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. There is currently only available evidence regarding the association between the rs59086055 AG heterozygote and fluorouracil toxicity. However, patients with the rs59086055 AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["smaller risk of relapse"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CC genotype may have a decreased response to methotrexate as compared to patients with the CT and TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AG genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.","phenotypeText":["increased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["increased severity of pain"]},{"genotypeAnnotationText":"Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"There is currently no available evidence regarding any association between the AA genotype and heroin intake in heroin-dependent patients. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Female patients with the wildtype B\/ B diplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["reduced risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of morphine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["increased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*29 allele was found to have decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Pre-menstrual patients with the CC genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["less likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may require a higher dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 TT genotype (CYP3A4*1\/*1) may require a decreased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 CT or CC genotype (CYP3A4*1B). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["require a decreased dose of buprenorphine to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["less inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs3918290 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of desipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of desipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of desipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine","decreased metabolism of desipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["longer period of recurrence-free survival"]},{"genotypeAnnotationText":"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to treatment","reduced response to treatment"]},{"genotypeAnnotationText":"African-American patients with the CT genotype (carriers of E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:04 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DRB1*04:04 alleles or negative for the HLA-DRB1*04:04 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1386493 AA genotype and dosage of methadone. However, patients with heroin dependence and the AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to repaglinide"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs2108622 CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the *28 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller increase or decrease in total cholesterol levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 AG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 GT genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *28\/*28 genotype and HIV may be at increased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *1\/*1 or *1\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["increased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["reduced risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the rs12422149 AA genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["decreased LDL lowering effect"]},{"genotypeAnnotationText":"In vitro, the CG genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the GG genotype and increased expression of TRAF1, decreased expression of MIRLET7I and decreased sensitivity to endoxifen as compared to the CC genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["decreased sensitivity to endoxifen","increased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del\/del genotype. The opposite association is found for females in one study. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1\/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["decreased dose of valproic acid"]},{"genotypeAnnotationText":"Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.","phenotypeText":["lower CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3\/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with post-operative Erectile Dysfunction"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the TTA\/TTA genotype and hypertension may have decreased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["increased trough concentrations of telaprevir"]},{"genotypeAnnotationText":"Patients with the rs2307116 AA genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["lower risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["require a lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 TT genotype and cancers may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype may have increased DPYD activity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with thromboembolism and the TT genotype may have a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*1 genotype may have an increased clearance of doxepin as compared to patients with the CYP2C9*3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.","phenotypeText":["increased clearance of doxepin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*23 allele in combination with one copy of the *20 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1801131 TT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased alcohol consumption as compared to patients with the AG genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of lymphopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["lower thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an improved response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity or increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of pneumonitis"]},{"genotypeAnnotationText":"Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"The AG genotype did not differ significantly in metabolism of repaglinide as compared to patients with the GG or AA genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs1275988 CT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"Patients with the rs75541969 CG genotype (one copy of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AA genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs140989814 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*12 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the genotype AA may have better response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AG or GG, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["better response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.","phenotypeText":["not clear"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A5*3 allele may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia when taking carboplatin and paclitaxel.","phenotypeText":["decreased risk for leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Parkinson's Disease may have an increased risk for adverse events when treated with levodopa as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased fluvastatin concentration when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients with postoperative pain and the TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*3 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentrations of pitavastatin when treated with pitavastatin as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR S977F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for nicotine addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the CG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom were heterozygotes.","phenotypeText":["lower incidence of toxicity"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to olanzapine as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 CC genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.","phenotypeText":["influence on risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs3766951 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically decreased heart rate"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased IGF-I response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["increased response","increased survival times"]},{"genotypeAnnotationText":"No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["reduced plasma concentration","poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with verapamil may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for primary outcome"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["decreased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1\/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["less likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs3829125 AC genotype may have decreased metabolism of naltrexone as compared to patients with the CC genotype, but increased metabolism as compared to the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["reduced risk of abnormal dreams"]},{"genotypeAnnotationText":"Patients with the rs10929302 AG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["increased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased response to corticosteroids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["lower adverse drug reaction scores"]},{"genotypeAnnotationText":"Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 AC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CT genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":["decreased CSF to plasma ratio of ceftriaxone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*40:02 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*40:02 alleles or negative for the HLA-B*40:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["increased risk of oxcarbazepine-induced maculopapular eruption"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 TGGCGCGTCCCGCCCAGGT\/del genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["increased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["increased risk of Drug Toxicity","increased risk of early relapse","decreased progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["good response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["increased fasting triglyceride levels"]},{"genotypeAnnotationText":"Patients with liver cancer and the TT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["phenobarbital resistance"]},{"genotypeAnnotationText":"Patients with the rs10752271 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with TT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs397508513 AC genotype (one copy of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response or decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele (e.g. *1\/*1) may have increased metabolism of esomeprazole as compared to patients with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["increased metabolism of esomeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT or CT genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["minimal 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to smoking and are trying to quit may have a reduced cravings for nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["reduced cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time and decreased likelihood of experiencing remission"]},{"genotypeAnnotationText":"Patients with the AA genotype may have reduced alcohol consumption as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["reduced alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["increased clearance of doxorubicin","decreased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CG or GG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs28358571 T allele (also known as the 1189T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["decreased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased inhibition of KCNH2 by quinidine as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["increased inhibition of KCNH2 by quinidine"]},{"genotypeAnnotationText":"While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.","phenotypeText":["reduced plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["poorer response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the rs4673993 CT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 AA genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the rs2279345 CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism resulting in lower efavirenz plasma levels"]},{"genotypeAnnotationText":"Patients with the null\/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["decreased plasma concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["poorer response to treatment with naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["decreased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["lower reduction in DNA damage"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.","phenotypeText":["no significant effect"]},{"genotypeAnnotationText":"Patients with the rs11030096 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure slower"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of caffeine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"The TT genotype is associated with increased expression of DPYD as compared to the AT or AA genotypes. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["increased expression of DPYD"]},{"genotypeAnnotationText":"Patients with one copy of the *9 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the rs118192172 TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["increased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have a decreased risk for heroin dependence as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["decreased risk for heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs145014075 GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["increased concentrations of nicotine"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have increased survival times when treated with cetuximab as compared to patients with the AA or AG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the GG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Individuals with the *1\/*3C genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the TT genotypes, and increased steady-state levels as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["decreased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased weight gain when treated with rosiglitazone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with anxiety, alcoholism and two copies of the CYP3A4*1 allele may be at a decreased risk of experiencing adverse events when treated with alprazolam as compared to patients with one copy of the *1 allele in combination with one copy of the *22 allele. Other genetic and clinical factors may also influence the risk of experiencing adverse events when treated with alprazolam.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AT genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["more likely to experience myopathy when treated with statins"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 GG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["decreased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"The TPMT*12 allele is assigned as a no function allele by DPWG. Patients with the *12 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*12 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the NUDT15*5 allele in combination with a normal function or no function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7, *9 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1, *14 or *38 alleles, while patients with one copy of the *4 allele in combination with one copy of the *9 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with one copy of the *1 allele. Patients with one copy of the *4 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9, *12, *14 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["decreased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients with genotype AC and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at decreased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["better response and decreased vomiting during the first 24 hours post-cisplatin administration"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance and increased exposure to nevirapine"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG and GT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["lower burden of general side-effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the rs279858 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"No women with the TT genotype were available for analysis, but women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Hepatic cells with the GG genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["less effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs121908751 GG genotype (do not have a copy of the CFTR E92K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patient with TT genotypes may have an increased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased IGF-I response"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have increased concentrations of oxcarbazepine and improved response as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["increased concentrations of oxcarbazepine and improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*2 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["poorer response rate"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with bladder cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patient with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast neoplasms may have increased disease-free survival when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.","phenotypeText":["increased disease-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":["less likely to have a reduction in psoriasis area or disease severity","reduced risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["less likely to have complete remission"]},{"genotypeAnnotationText":"Patients with the rs2884737 CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs193922764 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 TTAAAGTTA\/del genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the CT genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["no significant association with likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to quetiapine as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs397508288 GG genotype (two copies of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["better response to imatinib treatment"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and alcohol dependence may less likely to drink > 36 drinks in 24 hours as compared to patients with the GG genotype. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["less likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["longer time to failure"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the CT or TT genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["lower plasma concentrations"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have higher S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*1 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.","phenotypeText":["higher S-propranolol plasma concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Individuals carrying one or two copies of the *1 allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3, *6, or *7 alleles, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["rapid metabolism of atazanavir"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dosage of morphine as compared to patients with the CC genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.","phenotypeText":["increased dosage of morphine"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *29 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype although evidence is contradictory. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*17 allele may have decreased metabolism of nifedipine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and nifedipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nifedipine metabolism.","phenotypeText":["decreased metabolism of nifedipine"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a lower dose of acenocoumarol as compared to patients with the GG genotype and a higher dose as compared to the AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["better response to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"The CYP2C9*8 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*8 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs121909019 AA genotype (two copies of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased LDL-C responses"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased risk of diabetes"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800497 GG genotype may have a decreased weight loss response to buproprion and naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["decreased weight loss response"]},{"genotypeAnnotationText":"Patients with the rs11881222 GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with CYP2C9*2 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["more time to achieve stable dose"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or AA genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["decreased vitamin e metabolism"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better treatment response"]},{"genotypeAnnotationText":"Children with the null\/null genotype (has no copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have a reduced, but not absent, risk of hearing impairment as compared to children with the non-null\/non-null or non-null\/null genotype. No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["likelihood of myopathy"]},{"genotypeAnnotationText":"Patients with the rs139945292 CC genotype may have decreased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["decreased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["decreased plasma concentrations of morphine"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["increased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs7439366 CT genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 GG genotype may have a decreased response to treatment with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have similar metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *1 allele in combination with an increased function allele may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *1 allele in combination with a decreased function allele or a no function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["similar metabolism","increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["increased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"The AG genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the GG genotypes and increased catalytic activity and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["decreased catalytic activity","increased expression"]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype may have an increased response to antidepressants as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are undergoing kidney transplantation may have an increased risk for kidney dysfunction as compared to patients with the *1\/*1 genotypes. However, one study found that those with the *3\/*3 variant had increased estimated glomerular filtration rate, or better kidney function, as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":["increased risk for kidney dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*20 allele in combination with one copy of the *23 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["may respond to migalastat"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations and decreased clearance of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["less likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["greater risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and psychotic disorders may have a decreased risk for side effects when treated with antipsychotics as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["lower risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["decreased risk for renal dysfunction"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to bupropion treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["less likely to respond to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Male patients with the A genotype (hemizygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["risk for bleeding"]},{"genotypeAnnotationText":"Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":["increased chance of positive treatment response to amlodipine","lower chance of positive treatment response to chlorthalidone","increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone"]},{"genotypeAnnotationText":"Children with the CT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["increased risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with a no function allele may have decreased exposure to olanzapine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["decreased exposure","increased exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3C genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with breast cancer and the del\/del genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del\/CTGGTGAGGAGAGAACC or CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotypes (please note: the del\/del genotype was not observed in this cohort). Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response to cyclophosphamide and doxorubicin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["smaller increases in spine bone mineral density","larger decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism of tenoxicam as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["increased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with venlafaxine may have a decreased, but not absent, risk for agitation and dysphoria as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for agitation and dysphoria"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["decreased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*4\/*15 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["decreased heart rate"]},{"genotypeAnnotationText":"Patients with the rs2236624 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["increased risk for an adverse event"]},{"genotypeAnnotationText":"Pregnant women with the *1F\/*1F (AA; fast metabolizer) genotype who consume caffeine may have an increased likelihood of spontaneous abortion as compared to patients with the *1A\/*1A (CC) or *1A\/*1F (AC) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["increased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype may have increased clinical benefit to fluoxetine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased clinical benefit"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the rs121908757 AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may require lower doses of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or a patients with two normal function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.","phenotypeText":["lower doses of sirolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["decreased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs9620007 CC genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant yperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*1\/*1 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*28\/*28 genotype.","phenotypeText":["increased formation of the clozapine metabolite"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased response to citalopram or escitalopram in people with depression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["higher platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of omeprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of omeprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.","phenotypeText":["reduced response to chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of APOE E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype (non-carriers of APOE E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the CYP2B6*18 allele in combination with a normal function or a decreased function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the G\/del or GG genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["increased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the rs924607 CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["decreased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["increased risk of distant disease progression"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the rs28933396 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG and AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased exposure to pitavastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen"]},{"genotypeAnnotationText":"Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["increased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased catalytic activity of TYMS","increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["increased risk for virological failure"]},{"genotypeAnnotationText":"Patients with the rs9397685 AA genotype may experience an increased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["less likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the rs116855232 CT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs1800566 AG genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the rs145837941 AG genotype and postoperative pain may have decreased consumption of fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["decreased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["lower warfarin dose"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients undergoing a liver transplant who have the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients who have the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["decreased risk for non-immune response to the hepatitis B vaccine"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of warfarin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*1 allele may be at an increased risk of developing neurotoxicity when treated with paclitaxel as compared to patients with two copies of the *3 allele or one copy of the *1 allele in combination with one copy of the *3 allele. Other genetic and clinical factors may also influence risk of developing neurotoxicity when treated with paclitaxel.","phenotypeText":["increased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for allograft loss when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["decreased risk for allograft loss"]},{"genotypeAnnotationText":"Patients with epilepsy and the TT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have a worse response as compared to patients with the CT or CC genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["lower drug toxicity score"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["increased risk for allograft loss"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a normal, decreased or no function allele may have decreased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity score of 2 may have similar imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements","increased imipramine dose requirements","similar imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2C19*9 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*9 allele was found to have a decreased clearance of mephenytoin and decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*9 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. 6% of *1 activity for the substrate mephenytoin were reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["decreased abstinence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype (Gly49\/Gly49) were not reported in the studies of metoprolol efficacy.","phenotypeText":["not reported in the studies of metoprolol efficacy"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs16974799 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or \"clinical benefit\" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["increased risk for acute allograft rejection"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Adolescents with the AG genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["smaller, or absent, increase in nicotine cravings"]},{"genotypeAnnotationText":"Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["decreased risk for sinusoidal obstruction syndrome (SOS)"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["decreased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["increased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["decreased plasma drug concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["better response to pantoprazole"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 TT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may have a better response to fluvastatin treatment as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. However, conflicting evidence exists for this association. Other factors may affect concentration of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA genotype, but decreased response compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have longer of progression-free survival as compared to patients with the CC genotype but only in a sub-group of patients with \"standard risk cytogenetic profiles\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.","phenotypeText":["longer progression-free survival"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs16974799 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"There is currently no available evidence concerning an association between the CC genotype and blood concentrations of acetaldehyde, a metabolite of ethanol. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["no observed association"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["decreased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may have show decreased anesthesia efficacy of remifentanil as compared to patients with the AA genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["decreased anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment","longer overall survival time","longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["less likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["increased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["less likely to experience a reduction in systolic blood pressure following fentanyl administration"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs568724445 AC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["lower plasma concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to experience myopathy when treated with statins as compared to patients with the AG or GG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have more severe nicotine dependence as compared to patients with the CC genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with lung cancer and the TT genotype may have a decreased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs1346563 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the rs8099917 GG genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["decreased response to peginterferon alfa and ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the rs3135506 CC genotype and hypertriglyceridemia may have a decreased response to treatment with fenofibrate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["decreased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["less likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Female patients with the B\/B (reference) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or A-202A_376G\/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"The TT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with a decreased risk of leukopenia when treated with methotrexate as compared to the GT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs121918595 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased risk of poorer outcome"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["greater reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have a decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CC genotype and who are treated with cyclosporine following kidney transplantation may have decreased blood concentrations of cyclosporine as compared to patients with the rs2740574 CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["decreased blood concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased CYP2D6 enzyme activity as compared to patients with the CYP2D6*5\/*9 or *4\/*38 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["increased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased lipid-lowering response to simvastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to toxicity as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs112445441 CT genotype (G13D) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be less likely to engage in smoking behaviors as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["less likely to engage in smoking behaviors"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk for aspirin sensitivity","increased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["more favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["decreased response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs696 CT genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *2\/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have higher tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *1\/*1 or *1\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["higher tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["increased exposure to drug"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with CYP2C9*59\/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require significantly decreased dose of warfarin"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["increased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["decreased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 diplotype and chronic pain, or cancer may have increased clearance of ketamine as compared to patients with the CYP2B6 *1\/*6 and *6\/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["increased clearance of ketamine"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["decreased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["greater reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs11971167 TT genotype (two copies of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*1 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the non-null\/ null genotype (has one copy of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer who are treated with temsirolimus may have increased exposure as compared to patients with the AA or AG genotypes and decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["increased exposure","decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with risperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype or may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["better humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Postoperative patients with the GG genotype may have lower morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *9 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol","increased metabolism of tramadol"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatitis C may have an increased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased levels of alcohol consumption as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["decreased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs148693084 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 genotype and depression may have an increased response when treated with mirtazapine as compared to patients with the CYP2B6 *1\/*1, *1\/*4, *1\/*5, *1\/*6, *1\/*7, *4\/*6, *5\/*5 or *5\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["increased response to enalapril in people with Hypertension"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Genotype CT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["decreased uptake of adefovir dipivoxil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.","phenotypeText":["decreased metabolism and clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs193922876 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["less likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the TT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["increased risk for Cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis and 2) a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["increased risk for pneumonitis","decreased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tenoxicam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["decreased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the CT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 TT genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3740563 AC genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs527580106 CT genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Cells with the AA genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may require decreased doses of sufentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *6\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased sustained virological response to ledipasvir and sofosbuvir"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["better response (higher decrease in HbA1c)","poorer response (smaller decrease in HbA1c)"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["decreased risk of addiction to heroin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to sibutramine in terms of weight loss as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["increased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*1a genotype may have decreased metabolism of valproic acid and may need a decreased dose of valproic acid when compared to patients with any of the following genotype combinations: *1a\/*2a,*1a\/*3a,*1a\/*4a,*1a\/*8, *2a\/*2a, *2a\/*3a, *2a\/*4a, *2a\/*8, *3a\/*3a, *3a\/*4a, *3a\/*8 or *4a\/*8 genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased metabolism of valproic acid and may need a decreased dose"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the *2\/*2, *2\/*3 or *3\/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["decreased metabolism of brivaracetam"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*4 allele may have reduced metabolism of diclofenac as compared to patients with CYP2C8*1\/*1. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["reduced metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["reduced response to daunorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["lower maintenance dose"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the GG genotype may have a decreased response to liraglutide as compared to women with the AA and AG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the rs4444903 AG genotype may have a poorer response to cetuximab as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["poorer response or better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have an increased risk for weight gain when treated with antipsychotics as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a normal or no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not non-existent, risk for ototoxicity with cisplatin treatment as compared to patients with the GG or GT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["decreased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["increased risk of suicidal ideation","decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall survival and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["more likely to develop colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs2279345 TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz resulting in higher efavirenz plasma levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance","decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3\/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1\/3A and *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["decreased likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with *5\/*5 genotype may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan.This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 AA genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.","phenotypeText":["improved response to diuretics, hydrochlorothiazides, or thiazides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased LDL-C reduction"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the rs121908755 GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["increased response","increased remission rate"]},{"genotypeAnnotationText":"Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["increased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of systolic blood pressure","increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["increased risk of Anemia","increased risk of Neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs28933396 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:11 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:11 alleles or negative for the HLA-B*15:11 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["increased risk of developing Cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to simvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require a lower dose of warfarin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G del\/ATTTGTTCATGCCT genotype may have better response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/del genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *6\/*28 genotype and chronic myeloid leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1, *1\/*6, *1\/*28 or *27\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the rs2952768 CC genotype may have a decreased analgesic response to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["poorer response to carvedilol treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia","decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["lower tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the CT or the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2736308 CT genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["increased risk of Medication-related osteonecrosis of the jaw (MRONJ)"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["decreased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Patients with the CT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs4646437 AA genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["decreased platelet inhibition and increased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs193922753 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased dose requirement of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased lipid-lowering response to simvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased dose requirements of sufentanil as compared to patients with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["decreased dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with the rs150212784 GG genotype (two copies of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to citalopram or escitalopram in people with depression as compared to patients with the TT or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*11, *13, *15, *18 allele may have similar enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. No significant differences in the clearance of mephenytoin were found during several in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["reduced likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of progression-free survival and increased likelihood of pneumonitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of progression-free survival","increased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased subjective positive effects from oxycodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["increased subjective positive effects from oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased AUC of letermovir as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["decreased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["less improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["decreased response to chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.","phenotypeText":["increased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.","phenotypeText":["not associated with decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["higher triglyceride levels"]},{"genotypeAnnotationText":"Patients with the rs193922803 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AA genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a slower response time but an increased likelihood of experiencing remission as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["slower response time","increased likelihood of experiencing remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["decreased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["increased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AG or GG. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele was only defined as C161S not including 2988G>A in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["increased doses of lamotrigine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs5128 CC genotype and exposure to olanzapine. However, patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs9973653 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs7662029 AG genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["less likely to experience adverse effects","less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and tobacco use disorder may have a worse response (lack of abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["worse response to bupropion and drugs used in nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 CC genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*4 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["lower risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC\/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels as compared to patients with the C\/C genotype, or may have a larger change in apolipoprotein A1 and C3 levels as compared to patients with the del\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["smaller change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the G\/del genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["decreased risk of Thromboembolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Subjects with AA genotypes may have increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["decreased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs4948496 CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with two non-functional CYP2D6 alleles (e.g.*3\/*3, *3\/*4, *4\/*4, *5\/*4) who are treated with aqueous timolol may have increased exposure to timolol and greater excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["increased exposure to timolol and greater exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with alcoholism and the AA genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by an decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, decrease in systolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity score of 0.25 by CPIC. Patients carrying the *10 allele in combination with another decreased function allele or a no function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"The CYP2C9*43 allele has been assigned as a no function allele by CPIC. Patients carrying the *43 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may require a decreased dose of oxycodone as compared to patients with the *3\/*3 genotype. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["decreased risk for clozapine-induced agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with genotype TT may have higher likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["higher likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine","decreased clearance of cyclosporine","increased risk in adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs708272 AA genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the GG genotype but higher platelet aggregation as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation","higher platelet aggregation"]},{"genotypeAnnotationText":"Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.","phenotypeText":["lower CYP3A4 activity induced by rifampin"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may have increased plasma concentrations of anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["increased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs80282562 AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["larger mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the rs1954787 CT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the CT genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["decreased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy or myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["increased likelihood of statin-associated myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased risk for Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype TT. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["decreased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["less likely to be tetrahydrocannabinol (THC) dependent"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1127354 AA genotype and liver transplantation may have increased likelihood of rejection when treated with azathioprine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["increased likelihood of rejection"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or AA genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["likelihood of experiencing erythema"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have an increased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may have decreased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["longer recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment, longer overall survival time, and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype (ApoE E4 carriers) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["greater elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter time to progression and overall survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["more weight gain during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of efavirenz toxicity.","phenotypeText":["increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"Patients with the rs4762 GG genotype may have a decreased response to irbesartan as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the AA or AG genotypes. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["decreased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs575853463 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 GG genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased plasma insulin levels and decreased severity of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 GG genotype and Neoplasms may have increased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AA or AG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs755416212 CT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*2 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*2 allele and response to citalopram"]},{"genotypeAnnotationText":"Patients with the *4\/*1XN genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations of galantamine"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the CC genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs1799782 AA genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["lower plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["increased quality of sleep"]},{"genotypeAnnotationText":"Patients with the *5 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["higher likelihood of side effects"]},{"genotypeAnnotationText":"People with the rs2273697 AG genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased, but not absent, risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the TT genotype and stable coronary artery disease who are treated with clopidogrel may have Increased risk of of hemorrhage as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["Increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of nausea as compared to the GG genotype, and a decreased risk of vomiting as compared to the AA genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea","decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 AA genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*81 allele has been assigned as a no function allele by CPIC. Patients carrying the *81 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Women with the CYP2C19 *1\/*1 diplotype may have a decreased exposure to vaginal progesterone as compared to women with the *1\/*2 or *2\/*17 diplotypes. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["decreased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["smaller reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to treatment with tiotropium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus, and require an increased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC> Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CT genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["decreased response to selective beta-2-adrenoreceptor agonists in people with asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["increased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["may respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs6280 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["decreased risk of ADR"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the TT genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of telmisartan as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs924607 CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["decreased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with genotype AA and urticaria may have increased response to desloratadine and mizolastine compared to patients with genotypes AG or GG. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs118192177 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["increased response to simvastatin (higher LDL lowering effect)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["decreased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms may have an increased plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["increased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["decreased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs4961 TT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["increased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may have a decreased risk of hyperbilirubinemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["decreased response to amisulpride"]},{"genotypeAnnotationText":"Patients with the GT genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*16:01-HLA-DQB1-*05:02 haplotype who are treated with flupirtine may have an increased risk of drug-induced liver injury (DILI) as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of flupirtine-induced adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with paroxetine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing an decreased response for the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response","decreased response","no association with the genotype and paroxetine response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["reduced response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased risk for smoking addiction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of acenocoumarol as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["likelihood of resistance"]},{"genotypeAnnotationText":"Patients with *1\/*1 genotypes may have increased pioglitazone metabolism as compared to patients with the *2 or *3 alleles. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["increased pioglitazone metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["lower risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-B*39:01 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C9*5 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *5 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype. Cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["increased risk for anti-TB drug-induced hepatitis"]},{"genotypeAnnotationText":"Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response to paroxetine"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with rs9958628 AT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Female children with lead poisoning and the A- 202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with dimercaprol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1544410 CT genotype who are treated with alendronate have an undocumented response compared to that of patients with the CC or the TT genotype.","phenotypeText":["undocumented response"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and acute respiratory diseases and suspected influenza infection may have decreased risk of side effects when treated with oseltamivir as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have shorter overall survival times when treated with sunitinib as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased resistance to etoposide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["increased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["increased oxidative stress"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["no change in performance in attention-related tasks"]},{"genotypeAnnotationText":"Patients with the UGT1A1*28\/*28 genotype may have higher glucuronidation of carvedilol as compared to patients with the *1\/*1 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["higher glucuronidation of carvedilol"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs397508256 GG genotype (do not have a copy of the CFTR E56K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["decreased response to rocuronium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["reduced plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the CC or CG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs6928499 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 GG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["higher risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of amitriptyline as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of amitriptyline as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response to adalimumab"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["lower methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the GG genotype may have an increased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the AG or AA genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function or no function allele may have increased metabolism of dihydrocodeine as compared to patients with two no function alleles. Other genetic and clinical factors may also affect dihydrocodeine metabolism.","phenotypeText":["increased metabolism of dihydrocodeine"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["less likely to respond to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk of neurological events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require a higher dose when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["decreased metabolism of zidovudine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *3 allele in combination with another no function allele may have a decreased risk of transplant rejection when treated with tacrolimus as compared to patients with a no function allele in combination with a normal function allele or patients with two normal function alleles, while patients with the *3 allele in combination with a normal function allele may have a decreased risk of transplant rejection as compared to patients with two normal function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CYP2D6*61 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*61 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with genotype G\/TT may have decreased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT\/TT. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and diabetes or hypertension may have a poorer response when treated with benazepril or perindopril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["increased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.","phenotypeText":["decreased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["decreased risk of lymph node metastases","increased survival rate"]},{"genotypeAnnotationText":"Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may show slower improvement of symptoms when treated with methylphenidate as compared to patients with the CC and CG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["decreased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the rs17004921 CC genotype and rheumatoid arthritis may have a decreased response to methotrextrate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response when treated with methacholine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methacholine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the *6 allele in combination with another decreased function allele may require a decreased dose of methadone as compared to patients carrying two normal function alleles. However, this association was not found to be statistically significant. Other genetic and clinical factors may also affect a patient's methadone dose requirements.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*30 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*30 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with methotrexate may have a decreased risk of leukopenia and neutropenia as compared to the CC genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.","phenotypeText":["decreased risk of leukopenia and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["worse response","decreased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["more sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased creatinine clearance when treated with tenofovir as compared to patients with the CT genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CT genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["decreased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["decreased response and remission rate"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["increased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["reduced survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["better response to treatment with beta-blockers or antihypertensives"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CT genotype may have lower concentrations of lumefantrine as compared to patients with the TT genotype and elevated concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["lower concentrations of lumefantrine","elevated concentrations"]},{"genotypeAnnotationText":"Patients with the AT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["decreased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["decreased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the CC genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the rs4917639 AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased response to nortriptyline in people with Depression"]},{"genotypeAnnotationText":"Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in addition to another decreased function allele with an activity value of 0.25 may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. Other genetic and clinical factors may also affect a patient's tramadol dose requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AT genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype, or decreased risk as compared to patients with the AA genotype. Patients with the AT genotype may also have decreased clearance of isoniazid as compared to patients with the TT genotype. Additionally, cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["increased risk for anti-TB drug-induced hepatitis","decreased clearance of isoniazid"]},{"genotypeAnnotationText":"Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["higher plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["increased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["more benefit from statin treatment in reducing the risk of myocardial infarction","less benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs397508328 GG genotype (two copies of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*3) (rs4244285\/rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*29 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the TTTT\/del genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the del\/del genotype, but an increased risk as compared to patients with the TTTT\/TTTT genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased metabolism of artemether as compared to patients with the *6\/*6 genotype. Other genetic and clinical factors may also affect artemether metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients carrying the GG genotype may have increased pravastatin plasma AUC compared to patients carrying the AA or AG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased pravastatin plasma AUC"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["reduced risk of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele may have increased metabolism of omeprazole as compared to patients with the CYP2C19*23, *29, *30, *31, or *33 allele when assayed with omeprazole. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["increased metabolism of omeprazole"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased hdl cholsterol as compared to women with GG genotypes and increased levels of triglycerides and decreased levels of hdl cholsterol as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides","increased hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["decreased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration\/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with retinal disease and the GG genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CG or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["increased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["smaller decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs12678747 TT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["increased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the rs193922748 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Cells that carry the UGT1A4*3a allele may have increased clearance of testosterone as compared to those with the *1a allele. Other genetic and clinical factors may also influence clearance of testosterone.","phenotypeText":["increased clearance of testosterone"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs186045772 AT genotype (one copy of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["decreased metabolism of hydrocodone"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*18 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["worse response","decreased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of phenprocoumon as compared to patients with two decreased or no function alleles; a normal function allele in combination with a decreased or no function allele; or a decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["increased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["lower warfarin dose"]},{"genotypeAnnotationText":"Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["decreased clearance of voriconazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype who are administered bupropion may have decreased exposure to bupropion as compared to patients with the *1\/*2 and *2\/*2 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["decreased exposure to bupropion"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["not have an increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher expression of SCAP"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of doxepin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and doxepin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence doxepin metabolism.","phenotypeText":["decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*31 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*31 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *1\/*3 diplotype may have increased clearance of tacrolimus as compared to patients with the *3\/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have increased clearance of codeine or decreased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*24 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":["increased clearance of codeine or decreased clearance of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["decreased metabolism of ondansetron"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the AG genotype and response to salbutamol.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["reduced positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["decreased likelihood of neurological adverse reactions and sleepiness"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["increased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 TT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Organ transplant patients with the TT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and CC genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["decreased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AT genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the rs7597593 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["decreased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR E193K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["decreased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["decreased response to bucindolol"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have a decreased response to fluvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["decreased response to fluvastatin"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and the AG genotype may have increased concentrations of alprazolam as compared to patients with the GG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["increased concentrations of alprazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["increased dose of gabapentin"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["decreased response to calcium channel blockers"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pre-menstrual patients with the CG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease","increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.","phenotypeText":["increased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["decreased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["increased severity of alcohol dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 GG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients atrial fibrillation and the GT genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["increased risk of hypertriglyceridemia","decreased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of tolbutamide as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of developing an addiction to methamphetamines as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and carrying the UGT1A1*28 allele in combination with another decreased function allele or a normal function allele may have an increased risk of developing thrombocytopenia when treated with FOLFIRINOX as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence risk of developing thrombocytopenia when treated with FOLFIRINOX.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response and treatment outcome"]},{"genotypeAnnotationText":"Patients with the rs77409459 CT genotype (one copy of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs10455872 AG genotype may have an improved response to statins as compared to patients with the GG genotypes and a decreased response to statins as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["improved response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["more skin redness"]},{"genotypeAnnotationText":"Patients with the AA genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["more weight gain during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased response to fluorouracil-containing chemotherapy regimens","increased risk for and an earlier onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the null\/null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/non-null or non-null\/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 AG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["increased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["decreased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["decreased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs28358571 T allele (also known as the 1189T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del\/del or del\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["less responsive to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the genotype CG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.","phenotypeText":["decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have decreased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the CC genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Female patients with typhoid fever and the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["smaller reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 TT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/del or A\/A genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients carrying two copies of the 10-repeat allele may report fewer drinking days as compared to patients carrying one or two copies of the 9-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["fewer drinking days"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Postoperative patients with the AA genotype may have higher morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may be less likely to experience nausea when treated with opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["less likely to experience nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased metabolism of gemcitabine"]},{"genotypeAnnotationText":"People with the rs2273697 GG genotype may have decreased clearance of talinolol as compared to people with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the rs324420 AC genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the CC genotype but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["increased risk of experiencing adverse events","decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AA genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["worse response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-A*24:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-A*24:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to tocilizumab as compared to patients with the CC or CT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to respond to antiepileptic drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with the CT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28.Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with two functional CYP2D6 alleles who are treated with aqueous timolol may have decreased exposure to timolol and less excerice heart rate reduction as compared to patients with two non-functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["decreased exposure to timolol and less exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"People with genotype GG may have increased exposure to silibinin compared to people with genotypes AA or AG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["increased exposure to silibinin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del\/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["decreased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may also be at increased risk of over-anticoagulation as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype or may have an increased response as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids","increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["reduced clearance of cyclosporine","decreased dose of cyclosporine","increased risk of infection"]},{"genotypeAnnotationText":"Patients with the rs193922818 AA genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["increased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Migraine with Aura or Chronic Migraine may be less likely to use pharmacological prophylaxis as compared to patients with the ins\/del or del\/del genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["less likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 TTAAAGTTA\/TTAAAGTTA genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"People with the GG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["increased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*3\/*3) (rs4986893) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with hepatitis B and the CC genotype may have a decreased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["smaller reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 GG genotype may require increased doses of carvedilol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["require increased doses of carvedilol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype may have increased concentrations of methotrexate as compared to the GG genotype but decreased concentrations as compared to the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele or a no function allele may have decreased concentrations of methadone as compared to patients with two no function alleles. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*7 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele may have increased metabolism of clopidogrel as compared to patients with no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["increased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the CC genotype may metabolize nicotine more rapidly as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["metabolize nicotine more rapidly"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with clozapine may have a decreased risk of weight gain as compared to patients with the C genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with hypertensions and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clincial factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the rs140471703 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased metabolism of caffeine as compared to patients with the CC genotype, or decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with the DEL\/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["increased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased antiplatelet effect"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of escitalopram as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the rs11651488 CT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["more likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["better response to losartan in people with hypertension"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response","similar analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have decreased concentrations of methotrexate as compared to the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":["increased exposure to clopidogrel"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC or TT genotypes. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["increased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["reduced risk of adverse effects","increased risk of adverse effects"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response when treated with methacholine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methacholine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased time in therapeutic range when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz","phenotypeText":["increased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype or may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement for warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have an increased response to venlafaxine compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Purified DCK proteins with the AG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["poorer tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*18 allele in combination with a normal or decreased function allele may have decreased metabolism of methadone as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of methadone"]},{"genotypeAnnotationText":"Patients with the rs5882 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer progression-free survival time when treated with sunitinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence sunitinib response.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CC genotype and improved response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*07:27 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*07:27 alleles or negative for the HLA-C*07:27 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the TT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["increased stop reaction time, or greater impulsivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*12A allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension and coronary artery disease who are treated with verapamil may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for the primary outcome"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 CT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["decreased response to azathioprine"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that this genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be more likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients carrying the NAT2*5 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *5 allele in combination with *5 or *6 allele (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *5 allele in combination with the *5 or *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Elderly patients with the *1\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are homozygous for the *2 or *3 allele and an increased risk of hypoglycemia as compared to patients who are *1\/*1. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele may have increased metabolism of risperidone as compared to patients carrying at least one uncertain function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GSTM1 null\/null genotype (no copies of the GSTM1 gene) combined with a NAT2 slow acetylator genotype and AIDs who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of cutaneous reactions as compared to patients with the non-null\/null or non-null\/non-null genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["increased risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased metabolism of nicotine and cotinine as compared to patients with the *1\/*6 genotype. However, this has been partially contradicted by another study. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine and cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to rosuvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs571335587 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience increased inhibition of KCNH2 by disopyramide as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["increased inhibition of KCNH2 by disopyramide"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["greater positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of becoming addicted to nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["increased risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1\/*3) or TT (*1\/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["increased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["increased methylation at sites within the COMT gene promoter"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased metabolism as compared to patients carrying the *3 allele. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement for warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["less likely to respond to treatment with candesartan"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the rs397508139 TT genotype (do not have a copy of the CFTR I336K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the AC or CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["smaller elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*2 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients with the *3 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*07:01 allele have an increased risk of Pegaspargase Hypersensitivity as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with retinal disease and the CG genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the GG genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 AA genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["poorer response to bumetanide, furosemide or torasemide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*59 allele or one copy of the *59 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the rs67376798 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AT or AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen","decreased rate of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*19 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function may have an increased clearance of mirtazapine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of mirtazapine"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Individuals with the TT genotype may be more likely to experience anxiety when exposed to caffeine as compared to individuals with the CT or CC genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["anxiety"]},{"genotypeAnnotationText":"Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["increased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the rs5443 TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["greater reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs16974799 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and sacubitril metabolism. However, patients with the CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["decreased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*14:03 allele who are treated with ticlopidine may have an increased risk of toxic liver disease as compared to patients with no HLA-C*14:03 alleles or negative for the HLA-C*14:03 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs118192172 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk of biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["decreased risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the rs718656 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["decreased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["decreased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["increased risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs1800629 GG genotype may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the rs699 AG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*3 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs113100019 GT genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["increased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["increased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the *9 allele in combination with a normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:32 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased risk for Cough"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the GG genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients undergoing a liver transplant who have the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Female patients with the CC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["decreased severity of diarrhea"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment with infliximab"]},{"genotypeAnnotationText":"Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.","phenotypeText":["normal ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a better response when treated with FOLFIRI and bevacizumab as compared to patients with the GG or GT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["decreased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients who carry at least one copy of the HLA-B*08:01 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*08:01 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine.","phenotypeText":["increased dose of codeine"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased metabolism and increased concentrations of nelfinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["longer overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs193922770 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["higher risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["increased clearance and decreased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"The association between the AA genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["severity of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["increased response to lovastatin"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs397508442 CT genotype (one copy of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype and and Alzheimer Disease may have a worse response to donepezil (faster cognitive decline) as compared to patients with the CT and CC genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["worse response to donepezil"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.","phenotypeText":["intermediate increased risk of poor response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Patient with CT + CC genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 GG genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with less reduction in total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 CC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*2 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["increased metabolism of enalapril"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased subjective positive effects from oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased response","increased risk for stent thrombosis","increased risk for target vessel revascularization","increased risk of cardiovascular secondary events"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["reduced plasma concentration"]},{"genotypeAnnotationText":"Patients with the rs1381376 TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype (CYP3A4 *1\/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the GG genotype who smoke tobacco may have a decreased risk of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["decreased risk of addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs510769 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*14A allele or one copy of the *14A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the GG and less sensitive as compared to PBMCs from individuals with the AA genotype. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["more sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs374527058 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and a GSTT1 null genotype may have a decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with a non-null genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"No significant results have been seen for patients with the CT genotype.","phenotypeText":["No significant results"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["increased response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["lower psoriasis body surface area after treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AA genotype may have decreased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["decreased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant and have the CYP3A5*1 allele in combination with another normal function allele may require an increased dose of tacrolimus as compared to patients with a normal function allele in combination with a no function allele or two no function alleles, while patients who have the CYP3A5*1 allele in combination with a no function allele may require an increased dose of tacrolimus as compared to patients with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.","phenotypeText":["decreased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with clozapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with genotype AG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["increased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a increased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele\/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the rs6280 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may at an increased risk of experiencing opioid-induced adverse effects, including nausea and vomiting, as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["increased risk of experiencing opioid-induced adverse effects, including nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["decreased chance of positive erectile response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy","more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of aripiprazole as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of aripiprazole as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of aripiprazole as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 CC genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response to rosuvastatin"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["improved response, longer survival times"]},{"genotypeAnnotationText":"The CYP2C19*19 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*19 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the *1A\/*1A genotype and tuberculosis may have a decreased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*5B genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased sedative response"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["increased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["reduced risk for metastasis"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1x2 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["decreased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["increased severity of intoxication and increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes CC + CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["lesser increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["longer event-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Children with the AA genotype and cancer may have a lower, but not absent, risk for hearing loss with cisplatin treatment compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with AA and AC genotypes. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with a normal allele and cardiovascular disease who are treated with clopidogrel may have a decreased, but not absent, risk for bleeding events as compared to patients with two increased function alleles or the combination of a normal and increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for bleeding events.","phenotypeText":["decreased risk for bleeding events"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AA genotype and improved response as compared to people with the GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["less time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the HLA-A*32:01 allele may be at an increased risk of developing vancomycin-induced DRESS as compared to patients who do not carry any copies of this allele. Other genetic and clinical factors may also affect a patient's risk of developing vancomycin-induced DRESS.","phenotypeText":["increased risk of developing vancomycin-induced DRESS"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["poorer tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs671 AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the CT or TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the rs2874116 GG genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs112445441 CC genotype (reference KRAS with no mutations in codon 13) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the AC or CT genotype (codon 13 mutations). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["diminished response"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["increased survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of clomipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of clomipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of fever"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*2 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the TTTT\/TTTT genotype may have a decreased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT\/del or del\/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs510769 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Female patients with the B (reference)\/B (reference) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the *2\/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AA genotype may have a decreased response to metformin as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"No patients with del\/del were studied. However, patients with the del\/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to atenolol, hydrochlorothiazide, or metoprolol"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["decreased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs2108622 TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["more likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa in people with cocaine-related disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response","longer progression free survival","greater irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the rs1042713 GG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to salmeterol.","phenotypeText":["increased response to salmeterol"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the CC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have greater elevations of LDL cholesterol concentrations as compared to patients with the AC or AA genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["greater elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["increased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["increased 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Patients with the rs3781727 CT genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["decreased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7, *9A or *10 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with carbamazepine may have an increased likelihood of a good response as compared to patients with the CC or CT genotypes, although most studies have found no association with response. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["increased likelihood of a good response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with clomipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the AA or AT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs5031016 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["decreased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs396991 AC genotype may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["increased risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a worse response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.","phenotypeText":["worse response to diuretics"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:35 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma concentrations of dolutegravir as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with Crohn disease and the TT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may have an increased response to pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["increased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require a reduced dose of catecholamines"]},{"genotypeAnnotationText":"Individuals with the del\/del genotype may have decreased clearance of olanzapine as compared to individuals with the CCT\/CCT genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["increased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["decreased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs17134592 CT genotype may have increased metabolism of naltrexone as compared to patients with the TT genotype, but decreased metabolism as compared to the CC genotype. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"The TPMT*2 allele has been assigned as a no function allele by CPIC. Patients carrying the *2 allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["decreased response to propofol and remifentanil administered as anesthesia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["increased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["decreased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have increased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["risk for body weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["increased risk of hypokalemia"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["decreased risk of hematologic toxicity, leukopenia, and GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may metabolize nicotine more slowly as compared to patients with the CT CC genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["metabolize nicotine more slowly"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotype. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["increased risk for neutropenia","increased likelihood of dose delay"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs121918595 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs75039782 CC genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["decreased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*52:01 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the *10\/*10 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 allele, but increased metabolism of lovastatin as compared to patients carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["increased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and various cancers may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["decreased risk of resistance"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs3829125 CC genotype may have increased metabolism of naltrexone as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 CC genotype may require decreased doses of methadone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["decreased likelihood of ototoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased serum concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["increased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"The UGT1A1*28 allele has been assigned as a decreased function allele by CPIC. Patients carrying the UGT1A1*28 allele in combination with a normal function allele may have increased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased likelihood of neutropenia compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["increased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["greater weight loss"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with another no function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["decreased clearance of everolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased, but not absent, risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["decreased risk for toxic liver disease or abnormal liver-function tests"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*22 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["improved survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response to morphine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased pain reduction"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of trimipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of trimipramine.","phenotypeText":["decreased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the TT genotype may have a worse response to bevacizumab-based treatment regimens as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["worse response to bevacizumab-based treatment"]},{"genotypeAnnotationText":"Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["increased absorption and higher concentrations of topotecan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["lower blood trough concentrations of cyclosporine and may require dose adjustments"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with interferons and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["no statistically significant different period of recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs2336219 GG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AA genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["increased response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the *15\/*15 genotype may have increased plasma level of olmesartan as compared to patients with SLCO1B1 *37\/*37 genotype. Patients with the increased plasma level may have enhanced therapeutic response to olmesartan, yet may also be at risk of dose-dependent adverse effects of olmesartan. Other genetic and clinical factors may also influence the pharmacokinetics and response to olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma level","enhanced therapeutic response","dose-dependent adverse effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AA genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DQB1*02:01 alleles or negative for the HLA-DQB1*02:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs1760944 TT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased overall survival period"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may require a decreased dose of gabapentin as compared to patients with the aG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of pantoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the TT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["decreased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and alcohol dependence may less likely to drink > 36 drinks in 24 hours as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["less likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"Patients with the rs4140981 AA genotype may have decreased clearance of methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs267606619 T allele (also known as the 1494T allele) may have an increased risk of experiencing hearing loss when treated with micronomicin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with micronomicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the *01:01 haplotype may have reduced risk of statin-related myopathy when taking statins compared to patients with the *04:06 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.","phenotypeText":["reduced risk of statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["increased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["increased residual platelet aggregation","decreased platelet inhibition"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["higher rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["lower reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["increased doses of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["required increased dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["less likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"Males with basal cell carcinoma who are hemizygous for the T allele may have a poorer response to treatment with imiquimod as compared to males hemizygous for the A allele. Other genetic and clinical factors may also influence response to imiquimod treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs1323040 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CYP2C19*8 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*8 allele was found to have decreased activity of CYP2C19 as compared to *1 during several in-vitro characterizations. The CYP2C19*8 allele was catalytic inactive toward mephenytoin during one in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the rs568724445 AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the rs2236624 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["decreased risk for an adverse event"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and various cancer may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the A\/A genotype who are treated with clopidogrel may have an average catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["average catalytic activity"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with a normal or no function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased GI toxicity","decreased GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["decreased dose of SN-38"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.","phenotypeText":["decreased dose requirement for carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the rs758649719 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have a decreased response to montelukast as compared to patients with the AA genotype and an increased response to GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["decreased response to montelukast"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.","phenotypeText":["respond better to antidepressant treatments"]},{"genotypeAnnotationText":"Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased clearance of daptomycin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased sufentanil dose requirements as compared to patients with the TT genotype and decreased sufentanil dose requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements","decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have increased exposure to vitamin K1 as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["increased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the rs116855232 CT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["less likely to experience nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Patients with the rs777098658 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs2307116 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 AA genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AG or GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the rs3788853 A genotype may have increased likelihood of angioedema when treated with ace inhibitors as compared to patients with the C or CC genotypes. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["increased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the rs397508435 CT genotype (one copy of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the *14 allele in combination with a *14 or *1 allele may have enhanced lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["enhanced lipid-lowering efficacy"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["increased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the rs193922747 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to cetuximab.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have a decreased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["increased likelihood of ototoxicity","decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and gout may be more likely to require a 300 mg\/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["more likely to require a 300 mg\/day dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele may be at an increased risk of QT prolongation when treated with methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's risk of QT prolongation when treated with methadone.","phenotypeText":["increased risk of QT prolongation"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*6 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2C19*2 allele in combination with another no function allele or a normal function allele may have decreased metabolism of diazepam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["decreased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have more severe anemia and neutropenia as compared to patients with the AA genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["increased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["increased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the GG or GT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["lower increase in blood glucose"]},{"genotypeAnnotationText":"Patients with tuberculosis and the GG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["decreased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for inflammatory bowel disease"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the G genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the C genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the CC genotype who also carry the CT or TT genotype at rs12979860 may have a decreased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["decreased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of abnormal dreams"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs193922807 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to cytarabine regimens as compared to patients with the AA or AG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["decreased response to cytarabine regimens"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) a decreased, but not absent, risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) increased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["decreased risk of biopsy-proven acute rejection","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["increased risk of Diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype who are treated with platinum-based chemotherapy may have an increased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the AA or AG genotypes. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["increased risk of hematologic toxicity","increased risk of leukopenia","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with a normal function allele may have increased metabolism of SN-38 as compared to patients with one normal function allele and one decreased function allele or two decreased function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the rs116855232 TT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["higher burden of general side-effects","lower burden of general side-effects"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs569661196 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *5\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1 allele in combination with one copy of the *4 or *9 allele may have increased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with the *9 allele, or patients with two copies of the *9 allele. Patients with two copies of the *1 allele may have increased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or or patients with two copies of the *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *24, *27, *28 or *35 alleles or patients with the *4\/*7, *4\/*9 *4\/*17, *9\/*12 *9\/*26 or *17\/*20 diplotypes but may have decreased metabolism as compared to patients with two copies of the *46 allele or one copy of the *1 allele in combination with the *46 or *1x2 alleles. However, conflicting evidence has been reported for *24. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have an increased clearance of amitriptyline as compared to patients with the CYP2D6*87, *88, *89, *90, *91, *93, *94, *95, *97, or *98 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["increased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["decreased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the TPMT*9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 null\/non-null genotype may have an increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the non-null\/non-null genotypes and decreased risk as compared to women with the null\/null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["decreased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["increased AUC and decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["decreased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Pediatric cancer patients with the GG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with HIV infections and the CT genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["increased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["longer period before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the CT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype or may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["increased frequency of relapse","decreased frequency of relapse"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Patients with the rs145837941 AA genotype and postoperative pain may have decreased consumption of fentanyl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["decreased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with epilepsy and the CC genotype may have a worse response to oxcarbazepine as compared to patients with the CT or TT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["worse response to oxcarbazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a poorer response when treated with bevacizumab as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the TT genotype and severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings reporting the opposite association for this genotype with decreased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the rs444904 CT genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of imipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of imipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response","shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["decreased risk for smoking addiction and increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["decreased risk of hypokalemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better response to glucocorticoid treatment and higher lung function in glucocortioid-dependent severe asthma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["better response to glucocorticoid treatment and higher lung function"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting","decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the CTGGTGAGGAGAGAACC\/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["increased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and who are treated with warfarin may require increased dose as compared to patients with the GG genotypes and decreased dose as compared to those with the AA genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require increased dose"]},{"genotypeAnnotationText":"Patients with the *1\/*15 diplotype may be at an increased risk of developing rifampin-induced liver injury as compared to patients who do not carry the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["increased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["greater likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["more likely to respond to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["better response to repaglinide in people with Diabetes Mellitus, Type 2"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*05:02-HLA-DRB1-*15:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.","phenotypeText":["lesser reduction in LDL-C"]},{"genotypeAnnotationText":"Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["decreased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the GG genotype may have a decreased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["decreased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the rs17004921 TT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype, and increased doses as compared to the GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*21 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *2 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype may have increased metabolism of tacrolimus, as compared to patients with the GT or TT genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the C genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs997917 CT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to metoprolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the rs369103276 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the rs121909041 CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs121908751 AG genotype (one copy of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype who have had a stroke may be at increased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["increased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"Patients with the rs3733784 TT genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["higher reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a normal, decreased, no, or increased function allele may have increased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence toxicity of efavirenz.","phenotypeText":["increased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of voriconazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of voriconazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. However some studies showed no association. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the TT genotype may have decreased concentrations of apixaban as compared to patients with the CC and CT genotype and may be associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban","increased clearance of apixaban"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["higher drug toxicity score"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.","phenotypeText":["decreased risk of developing veno-occlusive disease of the liver"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors in people with Hyperlipidemias"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["more likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the TT genotype may have lower concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with tobramycin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["longer QTc interval"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin in people with Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs397508256 AA genotype (two copies of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs4752292 TT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["increased risk of emergency department visits"]},{"genotypeAnnotationText":"Evidence conflicts as to whether patients with the GG genotype and psoriasis have decreased response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased plasma insulin levels and increased severity of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["increased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["less likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["decreased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["decreased disease free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the CC genotype and a lower secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype who are smokers may have increased physical responses to smoking as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["decreased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased fentanyl dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["increased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele construct (in this study PMID:26310775 only defined as 3182A>G (D337G) not including 100C>T (P34S)) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["lower or greater body mass index"]},{"genotypeAnnotationText":"Patients with Crohn disease and the CC genotype may have be less likely to develop anti-adalimumab antibodes and therefore may have an increased response to adalimumab therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["less likely to develop anti-adalimumab antibodies and increased response to adalimumab therapy"]},{"genotypeAnnotationText":"Patients with TT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the CC genotype may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["risk for osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the AA genotype were not analyzed in this study, but patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["complete remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["decreased risk of developing treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs139945292 CC genotype may have increased blood pressure reduction after treatment with beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["increased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*15 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["decreased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Postoperative patients with the GG genotype may have higher morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements"]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotypes CC may have decreased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype TT or CT.","phenotypeText":["decreased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *7\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1\/*3 or *1\/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["decreased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have decreased metabolism of cyclosporine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 GG genotype may have decreased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["decreased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"Patients with the rs28360521 CT genotype may have decreased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs12422149 GG genotype may have increased LDL lowering effect as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["increased LDL lowering effect"]},{"genotypeAnnotationText":"Patients with the rs201820739 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["increased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["increased concentrations of atazanavir"]},{"genotypeAnnotationText":"Patients with the rs369103276 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Artery Disease may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have decreased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["decreased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may require decreased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["decreased risk of cardiac or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["increased response to clopidogrel treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["increased risk for diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased response to rocuronium"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the C\/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del\/del genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's Disease may not experience increasing creatinine levels when taking captopril compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["not experience increasing creatinine levels"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have higher clearance of flecainide as compared to patients carrying two no function alleles; two decreased function alleles with an activity value of 0.25; or a no function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["higher clearance of flecainide"]},{"genotypeAnnotationText":"Patients with major thalassemia and the TT genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patient with CC + CT genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with the rs4961 GT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs2654754 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["decreased severity of thrombocytopenia","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["better response to treatment with pemetrexed"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["decreased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg\/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["require a dose equivalent other than 300 mg\/day"]},{"genotypeAnnotationText":"Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 TT genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.","phenotypeText":["decreased triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.","phenotypeText":["increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with an increased or normal function allele may have a decreased response to citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying the CYP2D6*1xN allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to pantoprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["better response to pantoprazole"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*1 allele in combination with another normal function allele may have increased clearance of methadone as compared to patients with two decreased function alleles or a decreased function allele in combination with a normal or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs193922876 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele and cardiovascular disease who are treated with clopidogrel may have an increased risk for bleeding events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for bleeding events.","phenotypeText":["increased risk for bleeding events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs569661196 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 GG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*7 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["worse response to statin therapy"]},{"genotypeAnnotationText":"Patients who are smokers and have the AG genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["decreased lung function"]},{"genotypeAnnotationText":"Pre-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["decreased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["decreased response to lovastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-B*58:01 allele and risk of severe cutaneous adverse reactions when treated with carbamazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of severe cutaneous adverse reactions when treated with carbamazepine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the CT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.","phenotypeText":["decreased Euphoric and Energetic"]},{"genotypeAnnotationText":"Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 CC genotype may have an increased response to azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["increased response to azathioprine"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.","phenotypeText":["decreased risk of diarrhoea"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require a decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs771237265 AC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the GG genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["increased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["decreased general side-effect burden"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with higher increases in HDL-C levels"]},{"genotypeAnnotationText":"Patients with the rs267606617 G allele (also known as the 1555G allele) may have an increased risk of experiencing hearing loss when treated with neomycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with neomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs780801862 AA genotype may have increased metabolism of flurbiprofen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs708272 AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["greater reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*6 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction)"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTAAAGTTA\/TTAAAGTTA genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with the TTA\/TTAAAGTTA or TTA\/TTA genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["decreased response to tropisetron"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["decreased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with one copy of the *2 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["decreased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the rs2023239 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype and early stage Rheumatoid Arthritis who are treated with methotrexate may have a poorer response as compared to patients with the del\/del genotype. This association was not seen in a separate study of long-term RA patients. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have decreased fluvastatin concentration when treated with fluvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the GG or GT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of mephenytoin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and who are treated with warfarin may require increased dose as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require increased dose"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be more likely to experience adverse events following administration of morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["adverse events"]},{"genotypeAnnotationText":"Patients with the rs8050894 CG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*47 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*47 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["increased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["lower concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased concentration-to-dose ratios"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["increased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients with the *3 allele may have decreased plasma concentrations of montelukast as compared to patients carrying *1\/*1. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 TT genotype may have increased clearance of methotrexate as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased response to salbutamol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing drug dependence as compared to patients with the AC or CC genotypes. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["increased risk of developing drug dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better overall survival as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better overall survival"]},{"genotypeAnnotationText":"Patients with the rs77932196 GG genotype (do not have a copy of the CFTR R347H or R347P variants) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"Subjects with AG genotypes may have increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["increased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT\/GT. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["decreased dose of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the rs201268750 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Women with the CYP2C19 *2\/*17 diplotype may have an increased exposure to vaginal progesterone as compared to women with the *1\/*1 diplotype. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["increased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["increased risk for renal dysfunction"]},{"genotypeAnnotationText":"Patients with the rs2952768 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["decreased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["increased risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GG genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the CYP2C19*10 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*10 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations. 7% of the clearance ration of *1 for mephenytoin was reported in one study and several studies report significant lower catalytic activity. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased imipramine dose requirements as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased imipramine dose requirements as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased imipramine dose requirements as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["decreased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Children with the TT genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["better response to fluoxetine therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds or radiotherapy"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1\/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3\/*3) genotype who is also a CYP3A4 low or intermediate expresser. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["increased metabolism of cyclosporine resulting in decreased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to quetiapine as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["prolonged time to progression"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":["greater severity of hypotension"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs61605570 AA genotype may have increased metabolism of nicotine as compared to patients with the AT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["increased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of doxepin as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of doxepin as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of doxepin as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin","decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with pravastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the CC genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["lower body mass index"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["increased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs397508435 TT genotype (do not have a copy of the CFTR L927P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a decreased risk of experiencing side effects when treated with imipramine as compared to patients carrying two decreased or no function alleles or a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased adjusted trough concentrations of dabigatran","decreased, but not absent, risk for bleeding"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["higher tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["increased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Males with basal cell carcinoma who are hemizygous for the A allele may have a better response to treatment with imiquimod as compared to males hemizygous for the T allele. Other genetic and clinical factors may also influence response to imiquimod treatment.","phenotypeText":["better response to treatment with imiquimod"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal function allele may have increased response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles, and decreased response as compared to patients with two no function alleles. Patients carrying the *2 allele in combination with another no function allele may have increased response to rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs140039091 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["increased response to trastuzumab and longer progression-free survival in people with Breast cancer"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to quetiapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.","phenotypeText":["less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs)"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["increased risk of oedema"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in the population. However, patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype or may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for Tobacco Use Disorder","decreased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["reduced positive symptom improvement and positive symptom remission"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Women with normal metabolizer genotypes, such as *1\/*1, and epilepsy who are taking valproic acid may have decreased risk of becoming overweight compared to patients with intermediate and poor metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["decreased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the rs118192177 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs121918594 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Purified DCK proteins with the AA genotype may have reduced clearance of gemcitabine as compared to those proteins with the AG or GG genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["reduced clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the *62 allele may have decreased clearance of tolbutamide as compared to patients with the *1 allele. CPIC has not yet assigned a functional status to this allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients carrying the AG genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["increased insomnia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with phenytoin may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) or maculopapular exanthema (MPE) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) or maculopapular exanthema (MPE)"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["better response to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele construct (in this study PMID:26310775 only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["increased metabolism of temsirolimus","decreased likelihood of adverse events","increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*4 allele in combination with a normal or decreased function allele may have increased clearance of methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["decreased QTc interval"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased response to salbutamol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced response to treatment with smaller increases in HDL-C levels"]},{"genotypeAnnotationText":"Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["increased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with HIV infections and the *1\/*22 genotype may have increased clearance of lopinavir as compared to patients with the *22\/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["increased clearance of lopinavir"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotype and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs806368 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["worse response for postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GT genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Men with the null\/null genotype (has no copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have a reduced, but not absent, risk of hearing impairment as compared to patients with the non-null\/null or non-null\/non-null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of hearing impairment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased carvedilol dose requirements as compared to patients carrying two no function alleles or a no function allele in combination with a normal or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["decreased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the rs145157460 GG genotype may have increased metabolism of nicotine as compared to patients with the GT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*16 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *16 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs79910351 CC genotype may have an increased response to remifentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the T\/del genotype may have decreased clearance of rocuronium as compared to patients with the del\/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["decreased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the DEL\/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["increased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the rs121918592 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.","phenotypeText":["increased risk for spontaneous relapse of psychosis"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*6B allele or one copy of the *6B allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is not significant association between the CYP3A4*1 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["not significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AC genotype and solid tumors, may have increased response to gemcitabine compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["decreased overall survival probability"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*3) or a decreased function allele in combination with a no function allele (e.g. *2\/*3) or two no function alleles (e.g. *3\/*3). This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the rs2330951 CC genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and beta-thalassemia may have a better response, but also an increased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.","phenotypeText":["better response","increased risk for experiencing adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased LDL-C responses and less likely to achieve LDL-C levels of less than 130mg\/dl"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to venlafaxine as compared to patients with two no function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["decreased response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the TT (POR *28\/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the rs121918592 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["decreased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for asthma","increased risk for asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have increased metabolism of cyclosporine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.","phenotypeText":["increased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["increased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the TT genotype may have a decreased response to paroxetine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*3 allele or one copy of the *3 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have decreased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the TT genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival","progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs678849 CC genotype may have a decreased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine"]},{"genotypeAnnotationText":"Patients with ALS and the AA genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["increased response to treatment with creatine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response","less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["increased risk of adverse drug reaction"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have a poorer survival outcomes when treated with fluorouracil as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["poorer survival outcomes"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["more likely to experience adverse effects","more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased risk for Cough"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*1 allele may have increased metabolism of fentanyl as compared to patients with two copies of the *3 or *6 alleles or one copy of the *1 allele in combination with one copy of the *3 or *6 alleles or patients with one copy of the *3 allele in combination with one copy of the *6 allele. Patients with one copy of the *1 allele in combination with one copy of the *3 or *6 allele may have increased metabolism of fentanyl as compared to patients with two copies of the *3 or *6 alleles or those with one copy of the *3 allele in combination with one copy of the *6 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["increased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["decreased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele or a normal function allele may require a decreased dose of clobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["decreased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*13 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["decreased clearance and increased exposure to zafirlukast"]},{"genotypeAnnotationText":"Patients with the (CA)16\/(CA)17 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["increased clinical response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for neutropenia when treated with gemcitabine as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased inhibition of FXIII activation"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.","phenotypeText":["increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["greater increase in fasting glucose"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased IL1B serum levels","less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence","increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with rs16969968 AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype, but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["longer median survival time"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to quetiapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.","phenotypeText":["increased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Children with the CYP2B6*1\/*1 diplotype and B-cell non-Hodgkin's lymphoma may have increased clearance of cyclophosphamide as compared to children with the *1\/*6 or *6\/*6 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["increased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of Mucositis"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs7967354 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require decreased doses of rocuronium"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*35:10 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele who are treated with dapsone may have an increased risk for dapsone hypersensitivity syndrome or dapsone-induced severe cutaneous adverse reactions as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence dapsone-induced toxicities.","phenotypeText":["increased risk for dapsone hypersensitivity syndrome or dapsone-induced severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["better response to haloperidol"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association with risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response to naltrexone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-DRB1*15:01 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*15:01 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased risk of developing chronic lung allograft dysfunction"]},{"genotypeAnnotationText":"Female patients with the CT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["less likely to experience a loss of libido"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["decreased likelihood of developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs2016520 CC genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs10799590 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.","phenotypeText":["decreased risk of hypokalemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the GG genotypes and decreased clearance leading to improved response to metformin as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.","phenotypeText":["increased clearance of metformin","worse response to metformin","decreased clearance leading to improved response to metformin"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CT genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of citalopram as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of citalopram as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.","phenotypeText":["decreased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs5443 CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antihypertensive drugs.","phenotypeText":["smaller reduction in risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes may be more likely to respond to fenofibrate treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["increased antidepressant response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"The CYP2C19*26 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Female patients heterozygous for the G6PD Mediterranean variant with systemic arthritis who are treated with a high dose of aspirin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with homozygous for the G6PD Mediterranean variant or B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["increased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1079596 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs6269 GG genotype may have a decreased analgesic response to butorphanol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have longer progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["decreased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have decreased methadone dose requirements as compared to patients with the GG or GT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["decreased plasma concentration"]},{"genotypeAnnotationText":"Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["increased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a poorer response to treatment with clonidine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["poorer response to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased risk of poorer outcome"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in addition to a normal or increased function allele may have a similar analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect response to hydrocodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["greater increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR L allele\/L allele genotype. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Female patients with the AA genotype (homozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the rs11198893 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["increased isoproterenol-mediated desensitization in the vasculature"]},{"genotypeAnnotationText":"Patients with the rs28358569 A allele (also known as the 827A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and seizures may have increased response to oxcarbazepine compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased glucuronidation of anastrozole as compared to patients with the CT or TT genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["increased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the rs2230806 CC genotype may have an increased response to atorvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the rs1079596 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["increased risk for edema"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer event-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["less likely to develop dizziness"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["better response and decreased vomiting during the first 24 hours post-cisplatin administration"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.","phenotypeText":["reduced disease-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["decreased dose of opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["decreased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["lower concentrations and worse response to lumefantrine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to remifentanil. However, patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased response to remifentanil"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a reduced frequency of asthma exacerbationse when treated with pitrakinra as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["increased risk of biopsy-proven acute rejection","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["greater increases in spine bone mineral density","smaller decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients carrying the *5 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the rs11881222 AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.","phenotypeText":["likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["reduced risk of toxicities"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["reduced accumulation of active methotrexate metabolites","decreased risk for thrombocytopenia"]},{"genotypeAnnotationText":"No significant findings available.","phenotypeText":["No significant findings"]},{"genotypeAnnotationText":"Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor\/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["respond to ivacaftor\/tezacaftor treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of Stevens-Johnson Syndrome when treated with phenytoin as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence the risk of Stevens-Johnson Syndrome.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["decreased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["increased nicotine consumption","decreased neural response to nicotine"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs118192175 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["decreased response to anti-TNF-alpha treatments in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AA or AC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["increased response to latanoprost (as determined by a reduction in intraocular pressure)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs3832043 T\/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT genotype, or increased glucuronidation of SN-38 as compared to patients with the del\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["decreased glucuronidation","increased glucuronidation"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AA genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"This study did not contain individuals with the AA genotype, though individuals with the AA genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["reduced clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the AT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["increased risk for acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["decreased risk for suicide"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the rs570122671 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2273697 GG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a shorter overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["shorter overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["increased clearance of doxorubicin","decreased exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the *2 allele may have decreased pioglitazone metabolism as compared to patients with *1\/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["decreased pioglitazone metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["decreased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs3832043 TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T\/del or del\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["decreased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["decreased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have increased metabolism and decreased concentrations of efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["increased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CC genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require increased dose of warfarin compared to patients with the AA and AC genotypes. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *3a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs12948059 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.","phenotypeText":["increased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the rs699 AA genotype may have a decreased response to irbesartan as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["decreased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the TT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*18 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Finding reported in case study for *5\/*18 subject. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"There is currently no available evidence on the relationship between the GG genotype and nicotine craving.","phenotypeText":["nicotine craving"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CC genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["longer median survival time"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype, or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["lower plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment OR better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Neoplasms may be at increased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["risk for bone mineral density loss"]},{"genotypeAnnotationText":"Patients with the rs6517442 CT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 CT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased creatine kinase levels and lower risk of adverse events in response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have slightly decreased reduction of systolic blood pressure as compared to patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["slightly decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Male patients with the AG genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased response to nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with CYP2C9*3 in combination with a normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype.or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 GG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response to propranolol"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*100 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Women with the GG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with risperidone may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["decreased metabolism","decreased risk of gastrointestinal toxicity","decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs10799590 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3\/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["increased clearance and decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["increased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs2024627 CT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype who are treated with capecitabine may have a decreased (but not absent) risk of asthenia as compared to patients with the CC and CG genotypes. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs34059508 AA genotype and exposure to olanzapine. However, patients with the AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs764841347 CC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["less likely to respond to rituximab treatment"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased plasma insulin levels","increased severity of weight gain"]},{"genotypeAnnotationText":"Individuals with the CYP2D6*45 allele in combination with a normal, decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the TT genotype (POR *28\/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (POR *1\/*1). Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["lower decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["decreased chance of a prolonged hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["decreased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations and increased clearance of efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["decreased time until response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased antiplatelet effect"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["higher odds of vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Individuals carrying one or two copies of the *1 allele may metabolize atazanavir more rapidly as compared to individuals with the one or more copies of the *3, *6, or *7 alleles. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["rapid metabolism of atazanavir"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased response to nortriptyline in people with Depression"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*54 allele or one copy of the *54 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs10787959 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may require a lower dose as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)9\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have increased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["decreased chance of survival"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with amitriptyline may have decreased likelihood of side effects as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["decreased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the rs367619008 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*19 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may require an increased dose of oxycodone as compared to patients with the *1\/*1 or *1\/*3 genotypes. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.","phenotypeText":["increased dose of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*37 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*37 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["decreased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Female patients with the AG genotype (heterozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the GG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to citalopram or escitalopram treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs183701923 CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["lesser reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the A allele and HIV may have a lesser decline in adiponectin when treated with antiretroviral therapy as compared to patients with the G allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.","phenotypeText":["lesser decline in adiponectin"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of paroxetine as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of paroxetine as compared to patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of paroxetine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with paroxetine may have a increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, a number of contradictory findings exist showing a increased response compared to the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs2874116 AG genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart failure may have increased response to hydralazine and isosorbide dinitrate compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs10787959 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["increased anxiety"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["decreased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 CC genotype (CYP3A4*1B\/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1\/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["increased dose to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"\"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["increased risk for suicide"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["decreased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased IL1B serum levels","less likely to benefit from pravastatin treatment in terms of improvement in coronary function"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine","lower blood trough concentrations of cyclosporine","may require dose adjustments"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["higher levels of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response","increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["higher mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with valproic acid may have a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["decreased likelihood of developing either heroin or cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or more severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":["decreased likelihood of CNS depression"]},{"genotypeAnnotationText":"Patients with the CG genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["poorer response to carvedilol treatment"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of imipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of amitriptyline as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["increased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have increased likelihood of adverse events when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the rs111869995 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.","phenotypeText":["slight decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have decreased survival times when treated with irinotecan-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of mirtazapine"]},{"genotypeAnnotationText":"Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["increased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["increased nicotine consumption","decreased neural response to nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have a poorer response to treatment with interferon beta 1a\/1b as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4762 AA genotype and response to irbesartan. However, patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with escitalopram may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["increased serum creatine kinase levels"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["greater decrease in bone mineral density"]},{"genotypeAnnotationText":"No patients with this genotype were available for analysis, but patients with the *1A\/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["decreased incidence of nausea"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["decreased risk for sinusoidal obstruction syndrome"]},{"genotypeAnnotationText":"Patients with the AC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["lower levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *29 allele may have decreased metabolism of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have decreased oxidative stress in response to treatment with atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["decreased oxidative stress"]},{"genotypeAnnotationText":"Male patients with typhoid fever and the B (reference) haplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Female children with lead poisoning and the B\/B (reference) diplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G diplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the rs75541969 CC genotype (two copies of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*28\/*28 genotype was found to result in the decreased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*1\/*1 orUGT1A1*1\/*28 genotype.","phenotypeText":["decreased formation of clozapine metabolite"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6B allele or one copy of the *6B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association with risk of drug toxicity"]},{"genotypeAnnotationText":"Caucasian patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to Caucasian patients with the AG or GG genotypes. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the A\/del genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del\/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["decreased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["higher levels of toxicity"]},{"genotypeAnnotationText":"Individuals with the AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["decreased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the rs118192168 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to remifentanil as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased analgesic response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype, or an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["methadone dose adjustment"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the CT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require an increased dose of warfarin","no association","associated with a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of bleeding when treated with warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the GG genotype may have a decreased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicityin patients exposed to cisplatin.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1\/*3) or TT (*1\/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["decreased clearance and increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT (POR *28\/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs735668 AC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one copy of the *17 allele in combination with one copy of the *1 allele may have decreased metabolism of metronidazole as compared to patients with two copies of the *1 allele. However, one study has failed to find this association. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs374515279 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *22 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["decreased risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype who are taking sulfonylureas may have worse response as compared to patients with the CT or TT genotypes, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs7294 CC genotype may require a lower dose of warfarin as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"The CYP2D6*14 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *14 allele in combination with a decreased or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *14 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone","increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["decreased survival","increased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the rs397508139 AT genotype (one copy of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of phenylalanine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"\"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"Patients with the rs185462714 AA genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.","phenotypeText":["decreased risk for cough"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["decreased risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CYP2D6*14 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*14 allele construct was found to have decreased intrinsic clearance during in vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["decreased risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the CT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["increased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with mesothelioma and the TT genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the GG and GT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs3842 CT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["decreased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other factors may affect concentration of lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased resistance to etoposide"]},{"genotypeAnnotationText":"Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["better response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*94 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele (in this study only defined as D337G not including 100C>T, P34S) was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to pregabalin. However, patients with the AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["higher thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/CTT genotype may not respond to treatment with cavosonstat. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["may not respond to treatment with cavosonstat"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased exposure to pitavastatin as compared to patients with two normal function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 genotype and depression may have increased metabolism of mirtazapine as compared to patients with the CYP2B6 *1\/*1, *1\/*4, *1\/*5, *1\/*6, *1\/*7, *4\/*6, *5\/*5 or *5\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["increased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Children with the AG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype or may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of exacerbations","reduced risk of exacerbations"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["decreased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the (CA)17\/(CA)17 genotype and non-small cell lung cancer may have decreased clinical response when treated with gefitinib as compared to patients with the (CA)16\/(CA)16 or (CA)16\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["decreased clinical response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["increased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3\/*3 diplotype may require decreased dose of ibuprofen as compared to patients with CYP2C8*1\/*1. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["decreased dose of ibuprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs4444903 GG genotype may have a better response to cetuximab as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["better response to cetuximab"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased codeine dose requirements as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["decreased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs118192122 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*48 allele or one copy of the *48 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased metabolism of imatinib","increased sensitivity to dasatinib, imatinib, or nilotinib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the CT and TT genotypes, however, no association was found in the majority of studies, and in one study, the CC genotype was associated with an increased dose of warfarin. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs112563513 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype with malaria vivax who are treated with tafenoquine may have decreased likelihood of recurrence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["decreased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. The CYP2D6*87 allele was only defined as AV5 not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"There is currently no available evidence supporting an association between the GG genotype and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["no association with response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["increased risk for endometrial neoplasms"]},{"genotypeAnnotationText":"Patients with the CG genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["increased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may experience an increased response to methotrexate as compared to patients with the GT GG genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*60 allele or one copy of the *60 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["greater percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with one X-chromosome, neuropathic pain and the G genotype may have decreased pain relief when treated with escitalopram as compared to patients with the C genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased pain relief"]},{"genotypeAnnotationText":"Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs2071559 AA genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["decreased overall survival","decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with genotype AA may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["lower rate of sustained virological response (SVR)"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of nortriptyline as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of nortriptyline as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of nortriptyline as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs34545984 GG genotype may be at a decreased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a slower response time as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["slower response time"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.","phenotypeText":["increased risk of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in addition to another no function allele may have decreased metabolism of ethylmorphine as compared to patients carrying one or more normal function alleles. Other genetic and clinical factors may also affect ethylmorphine metabolism.","phenotypeText":["decreased metabolism of ethylmorphine"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*3 genotype may have decreased clearance and increased exposure to zafirlukast as compared to CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["decreased clearance and increased exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GG genotype, but decreased response as compared to patients with the TT genotype. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of methotrexate response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentration of methadone"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["decreased concentrations of oxcarbazepine","worse response","improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["decreased opioid dose requirements","increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have similar response to treatment with flecainide as to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["increased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*1xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the NUDT15*4 allele in combination with a normal function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Cancer patients with the CT genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the *2 in combination with a normal function allele may have a may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying two normal function alleles, while patients carrying the *2 allele in combination with a decreased or no function allele may have an increased risk of drug toxicity when treated with phenytoin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the GG genotype who are receiving methadone maintenance therapy (MMT) may experience decreased insomnia as a side-effect of treatment as compared to patients carrying the AA or AG genotypes. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["decreased insomnia"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["worse response to bupropion and drugs used in nicotine replacement therapy","improved response to bupropion and drugs used in nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["poorer response to imatinib treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["decreased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["increased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance and decreased exposure to nevirapine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*10:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DPB1*10:01 alleles or negative for the HLA-DPB1*10:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["increased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["decreased risk of Death"]},{"genotypeAnnotationText":"Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["decreased metabolism of pantoprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to metformin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["increased risk of nonfatal myocardial infarction with increased coffee consumption"]},{"genotypeAnnotationText":"Patients with the CACATACCATGCAACATACACACTCAGACA\/del genotype and Parkinson Disease who are treated with levodopa may have decreased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response to levodopa"]},{"genotypeAnnotationText":"Patients with the rs4148738 TT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C19*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*5 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.","phenotypeText":["decreased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["decreased risk for drug toxicity","decreased response to treatment with cisplatin or carboplatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the TT genotype may have a decreased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the CC or CT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["decreased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported.","phenotypeText":["increased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype who are administered thiazides may have an increased likelihood of hyponatremia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["increased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4, *12, *26 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele, while patients with two copies of the *9 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele and one copy of the *9 or *12 alleles. Patients with one copy of the *9 allele in combination with one copy of the *4 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *4 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["decreased survival time","increased risk of death","increased survival time","decreased risk for death"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["increased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["not have a change in likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of clomipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CYP2D6*51 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*51 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["less likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["decreased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 CC genotype may have an increased response to anastrozole as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.","phenotypeText":["greater number of bevacizumab injections"]},{"genotypeAnnotationText":"Patients with the rs2016520 CT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*2xN allele in combination with a normal function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype and epilepsy may have increased clearance of lamotrigine as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the *37\/*37 diplotype may have decreased exposure of repaglinide, including decreased AUC and increased clearance of repaglinide as compared to patients with the *1\/*1, *1\/*37, *37\/*15, *15\/*1 or *5\/*1 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["sensitivity to Alkylating agents"]},{"genotypeAnnotationText":"Patients with the AG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype or may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["decreased clearance of XK469 OR increased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["smaller percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with the rs9973653 GG genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of resistance to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*13 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the GG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Children with the AG genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["reduced risk of neurotoxicity"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*1 genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3\/*3 genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["lower likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs7412 TT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CC genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 AA genotype may have an increased response to propranolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the CC or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["better response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["decreased likelihood of event-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs1125394 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs5128 GG genotype may have decreased exposure to olanzapine as compared to patients with the CG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with efavirenz may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["increased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["poorer response (decreased acute bronchodilation)"]},{"genotypeAnnotationText":"Patients with the rs2236857 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased creatine kinase levels","increased risk of adverse events","lower creatine kinase levels","lower risk of intolerance"]},{"genotypeAnnotationText":"Patients with the rs376073289 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["increased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *1 allele in combination with a normal or no function allele may have increased cyclosporine dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.","phenotypeText":["increased cyclosporine dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*17 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*17 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the rs62097526 TT genotype may gain less weight during treatment with antipsychotics as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.","phenotypeText":["decreased risk for psychosis"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["decreased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA genotype but more likely to experience adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["less likely to experience adverse events","more likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["increased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type 2 Diabetes may have increased response to sitagliptin or vildagliptin compared to patients with the AA genotype. Other factors may affect response to sitagliptin and vildagliptin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["increased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["decreased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["decreased risk of resistance"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["lower reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Individuals with the *1\/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["increased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["decreased dose of propofol"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["decreased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs1695 AA genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["decreased likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"People with poor metabolizer genotypes (e.g. *2\/*2) may have increased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with intermediate and normal metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"In human liver microsomes, the *22\/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1\/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["decreased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to smoking and are trying to quite may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["greater cravings for nicotine"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["smaller elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DRB1*08:03 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DRB1*08:03 alleles or negative for the HLA-DRB1*08:03 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["better pain relief response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2C9*39 allele has been assigned as a no function allele by CPIC. Patients carrying the *39 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced expression of SCAP"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.","phenotypeText":["lower cortisol response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.","phenotypeText":["increased risk of resistance"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype and blood cancers may have a decreased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response when treated with methadone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of developing sensory neuropathy when taking stavudine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["increased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["higher risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs2066702 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to remifentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of lansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of lansoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased exposure to methotrexate and lower likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*7) (rs4244285\/rs72558186) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["decreased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the rs2236225 GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*3, *1\/*6, *1\/*13) or a decreased function allele in combination with a no function allele (e.g. *5\/*6) or two decreased function alleles (e.g. *5\/*8) or a normal function allele in combination with a decreased function allele (e.g. *1\/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the CYP2D6*26 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*26 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the rs121918594 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this PMID 28087463 study only defined as C161S not including 2988G>A) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1\/*3 diplotype may require decreased dose of ibuprofen as compared to patients with CYP2C8*1\/*1. Other Other genetic and clinical factors may also influence the dose of ibuprofen.","phenotypeText":["decreased dose of ibuprofen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["increased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to efavirenz as compared to patients with the CT or TT genotypes. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs397508513 CC genotype (two copies of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 CC genotype may have an increased response to treatment with interferons as compared to patients with the CT or TT genotypes. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["increased response to treatment with interferons"]},{"genotypeAnnotationText":"Patients with the AA genotype (Ser49\/Ser49) may have increased response to metoproplol than those with the AG genotype (Ser49\/Gly49) although most benefits appear to be only when in haplotype with Arg389. However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["lower triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased risk of drug toxicity when treated with platinum drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["increased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["increased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with *15 allele in combination with another normal function allele may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs374825099 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol or dextromethorphan as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have significantly decreased enzymatic activity and decreased clearance during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may be less likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the AA or AG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["less likely to respond to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["increased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["increased metabolism of ondansetron"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and overral survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["decreased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1076560 AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["increased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype and cystic fibrosis may not respond when treated with cysteamine as compared to patients with the CTT\/del or del\/del genotypes. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["not respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["decreased exposure to risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may be at increased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["increased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased clearance of daptomycin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["increased response and survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["higher levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["greater reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and anxiety disorder or major depression may have increased risk of becoming agitated when taking citalopram compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["increased risk of becoming agitated"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased blood pressure","decreased risk for hypertension","faster control of blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the rs368234815 GG genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*3 in combination with a normal, decreased, or no function allele may have increased risk of bleeding when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["increased dose of SN-38"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["decreased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CYP2D6*71 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*71 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["decreased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting IL-2"]},{"genotypeAnnotationText":"Patients who are smokers and who have the AA genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["increased cigarette consumption"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer progression-free survival","increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Women with the AG genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype, or a lower dose as compared to women with the AA genotype. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["increased dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the rs7270101 AC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/ B diplotype (heterozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["decreased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have increased platelet aggregation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to clopidogrel.","phenotypeText":["increased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response according to the Positive and Negative Syndrome Scale"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["increased metabolism of doxorubicin","less tumor reduction","decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have increased risk of anemia as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["lower risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*19 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["decreased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*33 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to tolperisone as compared to patients with the *1\/*4, *1\/*5, *4\/*4 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The CYP2D6*7 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*7 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.","phenotypeText":["increased risk for statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["longer event-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["increased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 2-4 anemia"]},{"genotypeAnnotationText":"Patients with the rs121918595 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs5882 AG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with another no function or a normal function allele may have increased exposure to dabigatran as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the AG genotype and gout may be more likely to require a 300 mg\/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["more likely to require a 300 mg\/day dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only defined by 4110C>G) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia","increased risk"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["decreased risk for severe neutropenia"]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the rs2229774 GG genotype may have decreased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 AG or AA. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased alcohol consumption as compared to patients with the AG or GG genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs2229205 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AG genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["decreased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["more likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of poorer outcome"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CC genotype or may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response","reduced response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin","increase efficacy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*18 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter time to therapeutic INR"]},{"genotypeAnnotationText":"Patients with the CC genotype and growth hormone deficiency who are also homozygotes of the full length GHR gene may require an increased dose of recombinant human growth hormone (somatropin) as compared to patients with the AA genotype who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant. Other genetic and clinical factors may also influence dose of somatropin.","phenotypeText":["increased dose of recombinant human growth hormone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with pegloticase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.","phenotypeText":["increased peak cortisol response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*2 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["increased risk of neutropenia","increased risk of leukopenia","decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["greater reductions in diastolic blood pressure","greater reductions in mean arterial pressure","greater reductions in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["decreased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the AG genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype or may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["increased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Stevens-Johnson Syndrome (SJS) when treated with oxcarbazepine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["increased likelihood of smoking cessation","decreased risk of relapse"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CC genotype may have a decreased response to pioglitazone as compared to patients with the CG genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs118192161 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia. T","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1\/*1 or 1) may have a decreased, but not absent, risk for side effects, 2) may require an increased dose of drug compared to patients with CYP2D6*4\/*4. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["increased risk of side effects","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the CC genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response (FEV1)"]},{"genotypeAnnotationText":"People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["increased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may be at a decreased risk of experiencing adverse events when treated with paclitaxel as compared to patients with one copy of the *1 allele in combination with one copy of the *8, *20 or *22 alleles. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 TT genotype (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["acquired resistance to gefitinib"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["reduced likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Cells with the AC genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype, or increased activity as compared to those with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with the AG genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CC genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["increased response to methadone maintenance treatment (MMT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased response","decreased risk for sensory neuropathy","later onset of sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"People with GG genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["decreased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Female children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B\/B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs12678747 AT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["increased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the GG genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4906902 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism","increased serum concentration"]},{"genotypeAnnotationText":"Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients who are smokers and who have the AG genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["increased cigarette consumption"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Individuals with the CC genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the rs3804100 TT genotype may have increased morphine dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with *9\/*9 genotype may have decreased transport and increased concentration of atrasentan as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["decreased risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["less likely to require rescue analgesic administration","decreased dose of methadone"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of dexlansoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["less reduction in LDL"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have a decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["decreased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the rs7297610 TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["decreased risk of neutropenia","decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs2884737 AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response when treated with methacholine as compared to patients with the AA genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs2372536 GG genotype and rheumatoid arthritis may have decreased likelihood of response when treated with methotrexate as compared to patients with the CC or CG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *4 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Several studies assess this association with *4 in combination with other loss-of-function alleles (e.g. *3, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with ADHD and the AG genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["impaired catalytic activity"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*08:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the AC or AA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.","phenotypeText":["decreased likelihood of developing heroin or cocaine dependence"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcohol dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may be more likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["rapid virological response"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *4a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism of nortriptyline"]},{"genotypeAnnotationText":"Patients with the GG genotype and Type II diabetes mellitus may have decreased clearance of metformin leading to improved response to metformin as compared to patients with the CG and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus.","phenotypeText":["decreased clearance of metformin leading to improved response"]},{"genotypeAnnotationText":"Patients with the rs4948496 CT genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Post-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["increased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["smoking behaviors"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype who are treated with docetaxel may have a increased severity of neutropenia as compared to patients with the AT or AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and who are receiving methadone for analgesia may required an increased dose as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's methadone dose requirements for analgesia.","phenotypeText":["increased dose requirements for analgesia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["increased likelihood of developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Children with the AA genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of exacerbations"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *1 allele in combination with a normal or no function allele may have increased metabolism of tacrolimus as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for elevated triglycerides"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["poorer response to treatment with gefitinib"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["more likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["decreased risk of cardiovascular events","increased platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.","phenotypeText":["increased dose-adjusted trough concentrations of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["reduced exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["decreased exposure to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1801253 CG genotype and carvedilol dosage requirements. However, patients with heart failure and the CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["decreased doses of carvedilol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["decreased risk of opioid dependence","increased risk of opioid dependence"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*6 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4XN\/*56 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are addicted to methamphetamine may be more likely to experience psychosis when taking methamphetamine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["more likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1\/*3 and *1\/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response","increased risk of myalgia and greater degree of muscle damage"]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less likely to respond to citalopram or escitalopram"]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the non-null\/non-null genotype (has two copies of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null\/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["increased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department (ED) visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with paroxetine may have an decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, a number of contradictory findings exist showing an increased response for the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Further, studies exist reporting no association with the genotype and paroxetine response. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype but increased clearance as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2273697 AG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of developing respiratory depression when treated with sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["increased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1 genotype and decreased exposure as compared to the *4\/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["decreased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["increased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype were not part of the study. But patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["decreased response to eculizumab"]},{"genotypeAnnotationText":"Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["increased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"The TPMT*3B allele is assigned as a no function allele by CPIC. Patients with the TPMT*3B allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"No information is available for the CT genotype.","phenotypeText":["No information available"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["higher ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 AA genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["decreased response to warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with venlafaxine may have an increased risk for agitation and dysphoria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["increased risk for agitation and dysphoria"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have a decreased, but not absent, risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CT or TT genotypes. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["decreased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking clopidogrel may have decreased resistance to clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["decreased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.","phenotypeText":["lower tamoxifen-induced increase in triglycerides"]},{"genotypeAnnotationText":"Patients with chronic pain and the AA genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["less likely to develop hyperalgesia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have increased response to venlafaxine as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 TT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased clearance and increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Pediatric patients with the *1C\/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may experience less vasodilation when treated with acetylcholine as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["less vasodilation"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.","phenotypeText":["decreased metabolism of tacrolimus resulting in increased exposure"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 AC genotype may have an increased response to buprenorphine therapy as compared to patients with the CC genotype but a decreased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for neutropenia and a decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of pitavastatin"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 AA genotype may have an increased response to acamprosate treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["increased response to acamprosate treatment"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AC genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2229774 AA genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["decreased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["decreased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs2304016 AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater increase in total cholesterol levels"]},{"genotypeAnnotationText":"Male patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["lower ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs121908753 AA genotype (two copies of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with thrombosis and the rs1800566 AG genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.","phenotypeText":["decreased response to warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the GG genotype may have a decreased risk of experiencing adverse events as compared to patients with the AA or AG genotypes. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AG genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the rs11651488 TT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A\/del or A\/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response to ethanol as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["decreased severity of intoxication","decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib response.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["require a decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*1 diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["decreased pravastatin plasma concentrations","increased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["decreased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the AA genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*18:01 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the rs1127354 AC genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to oxycodone as compared to patients with the AG or GG genotypes. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have more favorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["more favorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del\/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the *6 allele in combination with a normal function allele may be at an increased risk of developing neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 CT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dosage of morphine as compared to patients with the TT genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements.","phenotypeText":["decreased dosage of morphine"]},{"genotypeAnnotationText":"Patients with the rs75541969 GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the TT genotype may have increased metabolism of mycophenolic acid as compared to patients with the del\/del or del\/T or del\/del genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["increased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may require higher dose of sirolimus as compared to patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may require higher dose of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.","phenotypeText":["higher dose requirement of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["decreased clearance of gemcitabine","increased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs10737062 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["smaller decrease in blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the CC genotype with response to bupropion.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*69 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["decreased response to insulin supplemented with zinc acetate"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["decreased response to clopidogrel (increased platelet reactivity)"]},{"genotypeAnnotationText":"Patients with the AA genotype undergoing percutaneous coronary intervention who are CYP2C19*1\/*1 carriers may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk for high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs80282562 AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["increased dose requirements","conflicting evidence"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have a decreased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["lower maximal rate of ethanol"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs3766951 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["risk of gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the del\/del genotype or a decreased risk of venous thrombosis compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the rs11198893 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AA genotype had increased survival times compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.","phenotypeText":["decreased risk for cardiac events"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*17 allele may have decreased metabolism of fluoxetine as compared to patients with the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["not have altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have decreased risk of acute renal toxicity when taking tacrolimus compared to patients with the GT or TT genotypes. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["decreased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"The CYP2D6*21 allele is assigned as a no function allele by CPIC. Patients carrying the *21 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with ADHD and the AT genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["increased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar imipramine dose requirements as compared to patients with other alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["increased imipramine dose requirements"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CYP2C19*3 allele in combination with another no function allele or a normal function allele may have decreased metabolism of diazepam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["decreased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with the rs193922802 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs9679162 TT genotype and Liver Neoplasms may increased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["increased response to cisplatin, fluorouracil, and mitoxantrone chemotherapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a poorer response when treated with rituximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*3 allele in combination with a normal function allele may have increased weight gain when treated with olanzapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*7 or *10 or *12 or *14A or *17 or *18 or *29 or *36 or *37 or *40 or *47 or *49 or *50 or *51 or *54 or *55 or *57 or *62 or *71 or *72 or *75 or *89 or *92 or *93 or *96 allele, 2) similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*27 or *39 or *48 allele when assayed with bufuralol or dextromethorphan, 3) increased clearance of bufuralol as compared to patients with the CYP2D6*10 or *17 or *14B or *87 or *88 or *89 or *90 or *91 or *93 or *94 or *95 or *97 or *98 allele, and 4) decreased clearance of bufuralol as compared to patients with the CYP2D6*53 allele. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased enzyme activity of CYP2D6","similar enzyme activity of CYP2D6","increased clearance of bufuralol","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*13A allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*44:03 allele who are treated with lamotrigine may have an increased risk of maculopapular exanthema as compared to patients with no HLA-A*44:03 alleles or negative for the HLA-A*44:03 test, however this is contradicted in two studies. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular exanthema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*12 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD B (reference) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.","phenotypeText":["decreased risk for capecitabine-induced toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased sedative response"]},{"genotypeAnnotationText":"Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["less likely to have tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["increased bone density"]},{"genotypeAnnotationText":"Patients with the rs6295 CC genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["increased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["increased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs7597593 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit less from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for primary outcome"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to simvastatin (higher LDL lowering effect) as compared to patients withe the AA or AG genotype. Other genetic or clinical factors may also influence the response to simvastatin.","phenotypeText":["decreased response to simvastatin (higher LDL lowering effect)"]},{"genotypeAnnotationText":"Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":["increased risk of adverse drug reactions","decreased exposure to active mycophenolic acid"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":["decreased metabolism of dexlansoprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with anxiety, alcoholism and one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with alprazolam as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence the risk of experiencing adverse events when treated with alprazolam.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype or may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["better response to omeprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5B allele or one copy of the *5B allele in combination with one copy of the *5A, *6A, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*07:02 allele may have an increased risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim as compared to patients with no HLA-B*07:02 alleles or negative for the HLA-B*07:02 test. Other genetic and clinical factors may also influence a patient's risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of respiratory failure"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["increased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["decreased risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs193922878 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CG or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["poorer rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs61767072 GGGGCGGGGCCG\/GGGGCGGGGCCG (ins\/ins) genotype may have a decreased response to beta-blockers as compared to patients with the ins\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["decreased response to beta-blockers"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*13:02-HLA-B*58:01 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with no HLA-DRB1*13:02-HLA-B*58:01 haplotype or negative for the HLA-DRB1*13:02-HLA-B*58:01 test. The HLA-B*58:01 allele has been shown in other studies to have a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients who are HIV-positive and with one or two copies of the HLA-B*67:01 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as DRESS, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with nevirapine as compared to patients with no HLA-B*67:01 alleles or negative for the HLA-B*67:01 test. Other genetic and clinical factors may also influence Severe Cutaneous Adverse Reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["increased AUC of tenofovir"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["increased risk of nonfatal myocardial infarction and fatal coronary heart disease"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients who carried the *60 allele with colorectal cancer may have a poorer response when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients who did not carry the allele. Other genetic and clinical factors may also influence response to TIROX treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism","same metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs528152707 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1801131 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["more likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs28379954 CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["decreased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs735668 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4530637 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*03:02 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCARs. Other genetic and clinical factors may also influence risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*24 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Women with the GG genotype who are undergoing cesarean delivery may require a lower dose of phenylephrine as compared to women with the AA genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine.","phenotypeText":["lower dose of phenylephrine"]},{"genotypeAnnotationText":"Patients with the rs315498 CT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs113993959 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["not have improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased, but not absent, risk for acute allograft rejection within 3 month after transplantation as compared to patients with the AA genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection.","phenotypeText":["decreased risk for acute allograft rejection"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients with breast cancer and carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Female patients with the GG genotype and major depression may have increased response to paroxetine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["decreased risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased reduction in DNA damage"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["increased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["decreased dose of simvastatin and atorvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":["higher risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the T\/T genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del\/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs5031016 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.","phenotypeText":["increased metabolism or clearance of irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AA or AG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA or AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["decreased risk for deep vein thrombosis"]},{"genotypeAnnotationText":"Patients with major thalassemia and the GG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for Torsades de Point"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with citalopram may have decreased, but not absent, risk for treatment related side effects or intolerance as compared to patients with two no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the AG genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have a decreased likelihood of leukopenia and an increased likelihood of hyperglycemia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or hyperglycemia in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of leukopenia","increased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["increased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["decreased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the rs538703919 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*10 genotype may have decreased metabolism of lovastatin as compared to patients with the *1\/*1 genotype, but increased metabolism of lovastatin as compared to patients with the *10\/*10 genotype or who are carrying the *5 allele. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.","phenotypeText":["decreased Euphoric and Energetic after amphetamine exposure"]},{"genotypeAnnotationText":"Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["decreased dose of paroxetine and decreased risk of fatigue"]},{"genotypeAnnotationText":"Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response for fasting and postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia who are treated with atorvastatin may have better LDL-C responses and are more likely to achieve LDL-C levels of less than 130mg\/dl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["better LDL-C responses and more likely to achieve LDL-C levels of less than 130mg\/dl"]},{"genotypeAnnotationText":"Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["more likely to experience neutropenia","decreased progression-free survival"]},{"genotypeAnnotationText":"Individuals with the *28\/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the TT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4\/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["decreased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with rs16969968 AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype (one copy of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["decreased risk for a diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of lansoprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["improved response to metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of doxepin as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and doxepin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence doxepin metabolism.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*32 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher levels of morphine as compared to patients with the AA or AG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["higher levels of morphine"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*1 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["increased risk for heroin dependence"]},{"genotypeAnnotationText":"Patients with the v CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.","phenotypeText":["decreased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["decreased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*6 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*5 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Poor metabolizers may also be more likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["reduced clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["lower risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["higher risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA or AG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*65 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*65 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs1806201 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["decreased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["decreased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the rs2229774 AG genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased risk of anthracycline-induced cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are smokers may have decreased physical responses to smoking as compared to patients with the AG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["decreased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *4 allele may have increased plasma concentrations of montelukast as compared to patients carrying *1\/*1. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["decreased response to beta-adrenergic inhalants"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["increased risk of toxicity","decreased risk of toxicity"]},{"genotypeAnnotationText":"People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["decreased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.","phenotypeText":["less likely to develop an addiction to crack cocaine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of amitriptyline as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with a combination of alleles that result in ultrarapid metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs2236624 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.","phenotypeText":["increased risk for an adverse event","decreased risk for an adverse event"]},{"genotypeAnnotationText":"Patients with the rs20455 AA genotype may have decreased response to atorvastatin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CC genotype in patients with depressive disorder who are taking citalopram or escitalopram may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CT or TT genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["higher baseline serotonin levels and greater decreases in serotonin levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1801253 CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["risk for myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.","phenotypeText":["lesser increase in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the GA genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the DEL\/DEL genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/T and TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the GG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The CYP2D6*40 allele is assigned as a no function allele by CPIC. Patients carrying the *40 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *40 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["reduced response to antidepressants"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["increased conversion of the drug to active polyglutamates","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["increased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.","phenotypeText":["greater reduction in LDL-C"]},{"genotypeAnnotationText":"Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CACATACCATGCAACATACACACTCAGACA\/CACATACCATGCAACATACACACTCAGACA genotype and Parkinson Disease who are treated with levodopa may have increased response to levodopa as compared to patients with the CACATACCATGCAACATACACACTCAGACA\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa"]},{"genotypeAnnotationText":"The CYP2C6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance and dose requirements of tacrolimus, as compared to patients with the AA or AG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["increased clearance and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs150212784 GT genotype (one copy of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1800629 AA genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs772964366 CG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":["decreased CD4-cell count","decreased virologic response","decreased risk for toxicity-related failure"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CC and CT genotypes. Other factors may affect response to these drugs.","phenotypeText":["decreased response to antipsychotic drugs"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking methadone may have an increased response as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.","phenotypeText":["increased dose of simvastatin and atorvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["decreased blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["lower mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea.","phenotypeText":["increased risk of diarrhoea"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *3\/*3 genotype may have a higher likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *1\/*1 or *1\/*3 genotypes. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["higher likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs193922832 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *1\/*3 diplotype may have increased toxicity when treated with indomethacin as compared to patients with *1\/*1 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["increased severity of respiratory depression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may have decreased metabolism of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["lower maximal rate of ethanol"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/del genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/GGAGTC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["average response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["increased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG\/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a higher dose of acenocoumarol as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["require a higher dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["increased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the rs11045995 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the AA genotype may gain less weight during treatment with antipsychotics as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the rs118192178 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of letrozole as compared to patients with any of the following genotypes: one copy of the *1 allele in combination with one copy of the *4 or *9 alleles; one copy of the *46 allele in combination with one copy of the *4, *7 or *9 alleles; one copy of the *4 allele in combination with one copy of the *7 or *9 alleles; one copy of the *7 allele in combination with one copy of the *9 allele; two copies of the *9 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of letrozole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*2 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *7 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the AA or AC genotypes. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.","phenotypeText":["decreased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have increased clearance of mephenytoin as compared to patients with the CYP2C19*1 allele. The CYP2C19*23 allele was found to have an increased clearance of mephenytoin as compared to *1 during one in-vitro characterization study. 235% of the clearance ratio of *1 for mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype, but decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements","decreased opioid dose requirements","conflicting evidence"]},{"genotypeAnnotationText":"Patients with the rs118192162 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AC or CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["larger reduction in LDL"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["increased QTc interval"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of cefotaxime as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["increased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["better response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the rs2952768 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs6275 AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["dose adjustment of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs568367673 AA genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with depressive disorder and the del\/del genotype may have an improved response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["improved response to sertraline"]},{"genotypeAnnotationText":"Patients with the rs1138272 CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["decreased clearance of thiotepa"]},{"genotypeAnnotationText":"Patients with the rs536577604 CC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2273697 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association with risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with corticosteroids may have increased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the rs372307932 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*18 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs121918596 del\/GAG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GAG\/GAG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the GG genotypes and a decreased likelihood as compared to the AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["increased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*21 allele or one copy of the *21 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs8187710 AA genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.","phenotypeText":["no significant association between the rs8187710 AA genotype and risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*18 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*70 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*70 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["increased absorption and higher concentrations of topotecan"]},{"genotypeAnnotationText":"Patients with the *1\/*4 diplotype and Hyperlipidemia may have a better response to simvastatin treatment as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to women with TT genotypes and increased triglycerides and decreased hdl cholsterol as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride and hdl cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides","increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["increased response to modafinil"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["shorter recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may at a decreased risk of experiencing adverse effects, including nausea and vomiting, as a result of opioids as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["decreased risk of experiencing adverse effects, including nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1751034 CC genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["decreased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*4 diplotype (heterozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the TT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["increased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of phenytoin"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["decreased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the GG genotypes and increased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["decreased risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800629 GG genotype may have increased response to etanercept as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Pre-menstrual patients with the AG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to lansoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, poorer healing or cure rate of gastroesophageal reflux disease, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["reduced response to lansoprazole"]},{"genotypeAnnotationText":"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs7412 CC genotype may have decreased response to atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs538703919 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of myelosuppression and neutropenia as compared to the AA and AC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["decreased SVR"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["increased risk of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with ketorolac and undergo oral surgery may have a slower analgesic onset as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["slower analgesic onset"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with another normal function allele may have decreased metabolism of oxycodone as compared to patients carrying two increased function alleles or a normal function allele in combination with an increased function allele. However, patients carrying the CYP2D6*2 allele in combination with another normal function allele may have increased metabolism of oxycodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["reduced risk of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["increased response to levodopa"]},{"genotypeAnnotationText":"Patients with the GT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*54:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the GG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC or CG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs121908753 AG genotype (one copy of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and attention deficit hyperactivity disorder (ADHD) who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score may have a decreased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the TT genotype and response to temozolomide as part of radiochemotherapy.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the A allele may have increased expression of LDLR as compared to patients with the G allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.","phenotypeText":["increased expression of LDLR"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*27 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the rs114558780 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 GG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for having a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the CT genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["risk of diabetes"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing alcoholism.","phenotypeText":["risk of developing alcoholism"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*6 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*56:02 allele may have an increased risk of severe cutaneous adverse reactions when treated with phenytoin as compared to patients with no HLA-B*56:02 alleles or negative for the HLA-B*56:02 test. Other genetic and clinical factors may also influence rick of phenytoin-induced severe cutaneous adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype, or a decreased response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *10 allele may have an increased risk for tardive dyskinesia when treated with antipsychotics as compared to patients with the *1\/*1 genotype. However some studies have found no association with tardive dyskinesia. Additionally, some evidence suggests that this association may only be significant in males. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR R1070W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs17682789 CT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GG genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["increased response to gefitinib"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.","phenotypeText":["increased metabolism of zidovudine"]},{"genotypeAnnotationText":"The CYP2C9*37 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *37 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the CT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the A\/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["average response"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CC. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.","phenotypeText":["decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have worse response to capecitabine or fluorouracil as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["decreased severity of sedation"]},{"genotypeAnnotationText":"Patients carrying the AG genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased pravastatin plasma AUC"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer may have increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of docetaxel.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["decreased response to platinum compounds and gemcitabine"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a lower dose of methadone"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["reduced response and reduced likelihood of remission"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*13:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for anemia","decreased, but not absent, risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs137904044 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["decreased area under the concentration-time curve (AUC) of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux.","phenotypeText":["Increased absorption of omeprazole","decreased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs397508442 CC genotype (do not have a copy of the CFTR S945L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response to deferasirox"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have a higher risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["higher risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:18 allele have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*15:18 alleles or negative for the HLA-B*15:18 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["increased risk of ADR"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["increased risk of developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure)"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with HIV infections and the TT genotype may have decreased trough concentrations of lopinavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["decreased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.","phenotypeText":["increased response to photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["improved response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["decreased clearance of doxorubicin","increased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192122 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*4 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1142345 CT genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AG genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the GG genotypes, and smaller reductions in serotonin as compared to patients with the AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["greater reductions in serotonin concentrations after taking citalopram or escitalopram"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["decreased area under the curve of olanzapine"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*1a allele may have increased clearance of lamotrigine as compared to patients carrying two copies of the *2 allele or one copy of the *1a allele in combination with one copy of the *2 allele. Patients carrying two copies of the UGT1A4*1a allele may have decreased clearance of lamotrigine as compared to patients carrying two copies of the *1b allele or one copy of the *1a allele in combination with one copy of the *1b allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype (ie. have two copies of the GSTM1 gene) and cancer may have decreased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["decreased severity of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs17004921 CT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrextrate"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to hydrochlorothiazide compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association with methotrexate concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may have decreased risk of suicidal thoughts when taking antidepressants compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["decreased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the rs368234815 GG genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":["decreased response to pegIFN-alpha\/ribavirin"]},{"genotypeAnnotationText":"Patients with the rs1801253 GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["increased likelihood of event-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype (*1\/*17) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17\/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs3753380 CT genotype and open angle glaucoma may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB3*01:01 allele who are treated with heparin may have an increased risk of heparin-induced thrombocytopenia as compared to patients with no HLA-DRB3*01:01 alleles, or who test negative for the HLA-DRB3*01:01 allele. Other clinical and genetic factors may also influence the risk of developing heparin-induced thrombocytopenia.","phenotypeText":["increased risk of heparin-induced thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["decreased plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*20 allele or one copy of the *20 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the rs3828743 GG genotype may have better response and longer progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["better response and longer progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Women with intermediate metabolizer genotypes, such as *1\/*2, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1A allele or one copy of the *1A allele in combination with one copy of the *1F allele may have a decreased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1C or *1F alleles or one copy of the *1A allele in combination with one copy of the *1C allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["decreased response to repaglinide"]},{"genotypeAnnotationText":"The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["increased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to atenolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["increased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*57:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B*57:01 alleles or negative for the HLA-B*57:01 test. Other genetic and clinical factors may also influence the risk of abacavir-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10737062 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Cancer patients with genotype TT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to topoisomerase I inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["increased risk for osteonecrosis when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["decreased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*14 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterization. 65% of the clearance ratio of *1 for mephenytoin was reported, while a separate study found no differences in catalytic activity compared to CYP2C19*1. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Individuals with the CT genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["less likely to experience anxiety"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with GG genotype and cancer who are treated with fluorouracil and leucovorin may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to varenicline treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["less likely to respond to varenicline treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*37 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*35 allele or one copy of the *35 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with risperidone may have an increased likelihood of cardiovascular adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.","phenotypeText":["increased likelihood of cardiovascular adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the rs121918592 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["decreased risk for induction failure"]},{"genotypeAnnotationText":"Transplant recipients with the CT (CYP3A4 *1B\/*1) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["increased dose requirement of sirolimus"]},{"genotypeAnnotationText":"Women with the CT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response to liraglutide"]},{"genotypeAnnotationText":"Patients with the AC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype AA and a decreased response compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a betterr response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["better response to treatment with clonidine"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["faster desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the GT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 AA genotype may have a decreased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.","phenotypeText":["increased severity of toxicity, specifically hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AC and CC genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the GG genotype may be more likely to require treatment for neonatal abstinence syndrome as compared to infants with the GT genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["greater decrease in bone mineral density"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CYP3A5*1\/*1 had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["higher granisetron clearance and reduced exposure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800111 CG genotype (one copy of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Cancer patients with the TT genotype may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["better response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the CT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4\/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["decreased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["reduced risk of developing myalgia","higher risk of developing myalgia"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism of clomipramine"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of citalopram as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have a decreased risk of developing opioid dependence when treated with tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia who have high baseline HDL levels may have a smaller increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased allele, or no function allele may have decreased metabolism of ibuprofen as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Patients with Alzheimer's disease and the CC genotype (also known as ApoE E4\/E4) may have an increased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease.","phenotypeText":["increased response to treatment with statins"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs9927200 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*34 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher expression of SCAP"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*49 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"This genotype was not analyzed in this study.","phenotypeText":["not analyzed"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*22 allele or one copy of the *22 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["better anti-inflammatory response"]},{"genotypeAnnotationText":"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["decreased response to cisplatin and irinotecan"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":["increased clearance of methotrexate","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have increased plasma levels of efavirenz as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["increased plasma levels of efavirenz"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with dihydrostreptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with dihydrostreptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"People with an intermediate metabolizer genotype (e.g. *1\/*2) may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with ultra-rapid metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*59 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk of venous thrombosis compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the TT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to topiramate as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*9 genotype may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["decreased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["decreased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["decreased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs2108622 CT genotype may have increased warfarin dosage requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["increased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CG genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs917881 AG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["decreased likelihood of acquired resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with depression and the TT genotype may have a decreased response to escitalopram as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["decreased response to escitalopram"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with risperidone may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for nausea or vomiting and be more likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk for nausea or vomiting","more likely to be responders to treatment"]},{"genotypeAnnotationText":"Patients with the null\/null (has no copies of the GSTT1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null\/ null or the non-null\/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 TT genotype may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the ATGA\/del genotype may have decreased DPYD activity as compared to those with the ATGA\/ATGA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["greater risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["no increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased severity of triglyceride elevation"]},{"genotypeAnnotationText":"Subjects with the CT genotype may have increased exposure to atorvastatin as compared to subjects with the CC or TT genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with CYP2C19*3 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1\/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.","phenotypeText":["decreased metabolism of icotinib"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs2330951 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have an increased response when treated with lisinopril as compared to patients with the del\/del genotype, or a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AA genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele by CPIC. Patients carrying the *17 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["similar metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["early response to treatment"]},{"genotypeAnnotationText":"Patients with the rs374825099 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 GG genotype may have increased concentrations of temozolomide as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["increased concentrations of temozolomide"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to tropisetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to tropisetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["similar response","decreased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*3 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *1\/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"There is currently no studies which have found an association between the CT genotype and methadone dose requirements in patients with heroin dependence receiving methadone maintenance therapy (MMT).","phenotypeText":["methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["less likely to respond to treatment for methamphetamine dependence"]},{"genotypeAnnotationText":"No information are available for patients with the CT genotype. However, patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with epilepsy and the AG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Mental Disorders who are treated with paroxetine may have an increased risk of nausea as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased risk of nausea"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and colon cancer may have an increased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["increased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Women with the TT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["increased risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 CT genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with CYP2C9*1\/*59 may require significantly decreased dose of warfarin as compared to patients with CYP2C9 *1\/*1. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require significantly decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2236225 GG genotype may have a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and alcohol dependence may more likely to drink > 36 drinks in 24 hours as compared to patients with the del\/del or G\/del genotypes. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["more likely to drink > 36 drinks in 24 hours"]},{"genotypeAnnotationText":"People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["better response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["increased risk for hematological toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["better pain relief to opioids"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/GGAGTC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/del or del\/del. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the AA genotype and concentrations of alprazolam. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing nicotine dependence when smoking as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*12 allele or one copy of the *12 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the *1\/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *2\/*2 diplotypes and increased exposure as compared to patients with the *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["increased exposure to bupropion"]},{"genotypeAnnotationText":"Patients with the CYP2D6*27 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["increased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["poorer rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AT or TT genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["lower concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["smaller mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype or may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["increased risk for edema"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs578776 AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression may be more likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with ALS and the AG genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype and Colorectal Cancer who are treated with fluorouracil-based adjuvant therapy may have a better response as compared to patients with the TTAAAGTTA\/del or del\/del genotype who also have rs45445694 genotype 2R\/2R. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for flucloxacillin-induced liver injury as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["increased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs755416212 CC genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine in men with Epilepsy"]},{"genotypeAnnotationText":"Patients with the rs1065852 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["decreased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*18 allele was found to have significantly decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["greater prolactin response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["decreased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have show increased anesthesia efficacy of remifentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["increased anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs997917 CT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs708272 AG genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["increased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience an increased severity of sedation during treatment with desloratadine as compared to patients with the CT or TT genotypes. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["increased severity of sedation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine .","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the rs10306114 GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["better chance of smoking cessation"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the CC genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs702764 CC genotype may have an increased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased response to pazopanib"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype may have increased metabolism of artemether as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect artemether metabolism.","phenotypeText":["increased metabolism of artemether"]},{"genotypeAnnotationText":"Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["decreased likelihood of survival","increased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["reduced metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["better response rate"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["increased dose of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs118192177 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["increased severity of alcoholism"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 AG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*11 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs61767072 GGGGCGGGGCCG\/del (ins\/del) genotype may have an increased response to beta-blockers as compared to patients with the ins\/ins genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele)(Short\/Short) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing organ transplantation may have increased metabolism and dose requirements of tacrolimus, as compared to patients with the AA, AC, CT or TT genotypes. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["increased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the non-null\/null genotype (ie. have one copy of the GSTM1 gene and one gene deletion) and cancer may have decreased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["more skin redness"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may have a decreased risk of bleeding when treated with warfarin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["increased withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["decreased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of alopecia","decreased risk of pain"]},{"genotypeAnnotationText":"Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["decreased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the rs121918593 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.","phenotypeText":["decreased response to galantamine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["decreased response to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have longer progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype may be more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*1 genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["clinical benefit from bupropion treatment for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have increased response to serotonin reuptake inhibitors compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["increased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the rs12208357 CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["higher plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with nevirapine may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["decreased clearance of nevirapine"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism of clomipramine"]},{"genotypeAnnotationText":"Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 GG genotype may be at an increased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs4673993 TT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*37 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*37 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["increased general side-effect burden"]},{"genotypeAnnotationText":"Patients with HIV infections and the CT genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["decreased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CYP2B6*30 allele in combination with a normal function allele may have decreased metabolism of bupropion as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the GAT\/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT\/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.","phenotypeText":["increased metabolism of ondansetron"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["decreased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham allele (rs5030868 allele A) who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV)(rs5030868 allele G). Patients with two X-chromosomes and the Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham variant (rs5030868 allele A) in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV)(rs5030868 allele G). Patients with two X-chromosomes and the Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham variant (rs5030868 allele A) in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":["increased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["greater reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs139945292 CT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["increased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of systolic blood pressure as compared to patients with the CC or the CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes TT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["decreased dose of propofol"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["decreased clearance of risperidone"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs145157460 TT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with bladder cancer and the TT genotype may be at a decreased risk of developing neutropenia when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 CG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs139945292 TT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["decreased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response or better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["decreased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with genotype GG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *3\/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased blood alcohol concentration (BAC) as compared to patients with the CC genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.","phenotypeText":["decreased blood alcohol concentration"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7B allele or one copy of the *7B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with bipolar disorder and the GT genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased risk of nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have similar metabolism of hydrocodone as compared to patients carrying two increased function alleles or two decreased function alleles or a normal function allele in combination with a increased or no function allele or a decreased function allele in combination with an increased or no function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of hydrocodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence hydrocodone metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the G\/del or del\/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs76103438 AA genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be more likely to enter remission when treated with antidepressants, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["more likely to enter remission"]},{"genotypeAnnotationText":"Patients with the rs997917 TT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["increased plasma concentrations of triglycerides","decreased hdl cholesterol"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may have increased likelihood of adverse events when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to repaglinide"]},{"genotypeAnnotationText":"Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased treatment response"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.","phenotypeText":["decreased serum concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AA genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for gastrointestinal toxicities","decreased response to folic acid and methotrexate","decreased event free survival"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:07 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the GT genotype (one copy of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["reduced risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Children with the CYP2B6*1\/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1\/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["decreased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to tropisetron.","phenotypeText":["decreased response to tropisetron"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["more likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["increased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["increased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Pediatric patients with the *1\/*1 genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus as compared to patients with the *1\/*1C or *1C\/*1C genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["decreased response to selective beta-2-adrenoreceptor agonists in people with asthma"]},{"genotypeAnnotationText":"Patients with the rs374825099 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.","phenotypeText":["decreased plasma concentrations of anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT or AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the rs1800111 GG genotype (do not have a copy of the CFTR L997F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele may have increased concentrations of methadone as compared to patients with two normal function alleles. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Men with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.","phenotypeText":["lower decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with tobramycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"The CYP2C19*26 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*26 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased function allele with an activity value of 0.25 or another no function allele who are treated with mianserin may have increased plasma concentration of S-mianserin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["increased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of drug toxicity","decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["less likely to have rapid virological response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the rs1760944 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of piroxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of piroxicam"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of resistance to treatment"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["increased response to insulin"]},{"genotypeAnnotationText":"Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs121908753 GG genotype (do not have a copy of the CFTR R352Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192172 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 non-null\/non-null genotype may have a decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the null\/null and null\/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1381376 CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 TT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have decreased severity of thrombocytopenia as compared to patients with the CC genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["increased risk of cardiac or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["decreased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 TT genotype may have increased metabolism of irinotecan as compared to patients with the CT or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin in people with type 2 Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs3749187 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["increased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["decreased chance of rehospitalization"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patient harbors the rs63749869 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs63749869 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["higher psoriasis body surface area after treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the A allele. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to rosuvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to citalopram or ecitalopram treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to citalopram or ecitalopram treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*3 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["increased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["decreased risk for bone mineral density loss"]},{"genotypeAnnotationText":"Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["lower stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased subjective positive effects from oxycodone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["increased subjective positive effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to pitavastatin as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with the AC genotype (one copy of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 AT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["increased survival time","risk for hematologic toxicity"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have decreased cyclosporine dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.","phenotypeText":["decreased cyclosporine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["increased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["require longer time to therapeutic INR"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["increased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["increased risk of Angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["decreased risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["better chance of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA genotype, but less likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype and may have an increased response when treated with captopril as compared to patients with the del\/del genotype, or a decreased response compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["decreased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["increased risk of adverse drug reactions","neutropenia\/ leukopenia","gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs772964366 CC genotype may have increased metabolism of nicotine as compared to patients with the CG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["improved response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Female patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["decreased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AC or CC genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["poorer response to losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the *2\/*2 genotype who are treated with sipoglitazar may have 1) a better response (as measured by decreased HbgA1c) and 2) decreased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":["better response","decreased clearance"]},{"genotypeAnnotationText":"Patients with the rs2307116 AA genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the *4\/*5 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have a better response to lansoprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, better healing or cure rate of gastroesophageal reflux disease, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to lansoprazole.","phenotypeText":["better response to lansoprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype (Ser49Gly49) may have decreased response to metoproplol than those with the AA genotype (Ser49\/Ser49). However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253).","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patient harbors the rs118192116 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192116 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the *1\/*2 or *1\/*3 genotype may have decreased metabolism of brivaracetam as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have a better response to omeprazole (smaller % of time with intragastric pH < 4.0, a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["better response to omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["decreased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype (homozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["increased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["decreased risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"No patients with the AA genotype are available for analysis, but patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["decreased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*28 allele in combination with a normal function allele or decreased function allele may have decreased metabolism of SN-38 as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["more likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1611114 TT genotype and heroin dependence may be at a decreased risk of experiencing memory impairment when taking heroin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["decreased risk of experiencing memory impairment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*17 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"People with an intermediate metabolizer genotype (*2\/*17) may have decreased metabolism of 3,4-methylenedioxymethamphetamine compared to people with ultra-rapid metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have poorer response to beta-blockers as compared to patients with the AA genotype. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["poorer response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AC or CC genotypes. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["lower platelet aggregation"]},{"genotypeAnnotationText":"Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["increased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 AG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with GG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 CC genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs3832043 del\/del genotype and non-small cell lung cancer may have decreased glucuronidation of SN-38 as compared to patients with the TT or T\/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal function allele may be at an increased risk of experiencing adverse events when treated with methylphenidate as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with methylphenidate.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["more likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["increased response to trastuzumab and longer progression-free survival in people with Breast cancer"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs1125394 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["decreased likelihood of hypertension"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs1127354 AC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["decreased likelihood of rejection"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the AC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*18 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["decreased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the rs6065 CT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response","decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 AG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele and psoriasis may have a better response to treatment with ustekinumab as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02 test. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DQA1*01:03 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DQA1*01:03 alleles or negative for the HLA-DQA1*01:03 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the rs730012 CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["increased risk of urticaria"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing nicotine dependence.","phenotypeText":["risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs7668258 TT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Hispanic patients with the AA genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["greater decrease in viral load"]},{"genotypeAnnotationText":"Children with the GG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["reduced risk of exacerbations"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 GG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"People with an ultra-rapid metabolizer genotype (e.g. *1\/*17) may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with intermediate metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased metabolism of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["increased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and cancer when treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.","phenotypeText":["decreased, but not absent, risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["decreased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have increased platelet inhibition and decreased residual platelet aggregation as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation compared to patients with two increased function alleles or a combination of a normal function allele with an increased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["increased platelet inhibition and decreased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.","phenotypeText":["decreased concentrations of oxcarbazepine and worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["higher plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1065852 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Smokers with the CC genotype who are treated with nicotine gum or nicotine patches may have a greater likelihood of abstinence as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["poorer cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for the primary outcome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["reduced response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 CT genotype may have decreased metabolism of irinotecan as compared to patients with the TT genotype but increased metabolism as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan","increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["decreased risk for body weight gain"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Female patients with the heterozygous for the G6PD Mediterranean variant who are treated with a high dose of chloroquine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B diplotype. Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["decreased isoproterenol-mediated desensitization"]},{"genotypeAnnotationText":"No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["increased risk of developing hyperbilirubinemia during treatment with indinavir"]},{"genotypeAnnotationText":"Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["increased social and clinical needs"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs2359612 GG genotype may require an increased dose of warfarin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 AG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.","phenotypeText":["decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the TT genotypes and an increased likelihood as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["decreased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["better response to bumetanide, furosemide or torasemide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for progression with platinum-based treatments"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["decreased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["decreased risk of drug toxicity","decreased risk of early relapse","increased progression free survival"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with topiramate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CYP2D6*64 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*64 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs397508256 AG genotype (one copy of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["decreased response to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["increased clearance of docetaxel","increased risk of infusion-related reaction","decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype may show a greater QT-interval shortening effect when taking digoxin as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["greater QT-interval shortening effect"]},{"genotypeAnnotationText":"Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. The opposite association is found for females in one study. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.","phenotypeText":["increased risk for metastasis"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs2336219 AA genotype may have a decreased response to cisplatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["increased GI toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the rs1801131 GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["decreased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the rs279858 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["less likely to respond to fenofibrate treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["less weight loss"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"Patients with the rs1054642 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CT genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["less likely to require rescue analgesic administration","decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs1051792 AG genotype and rheumatoid arthritis may have an increased response to TNF inhibitors as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype with high cholesterol may have a better response when treated with pravastatin or simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results and this geneotype was not reported. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["reduced risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs764841347 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to lurasidone as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have decreased response to rosiglitazone as compared to patients with the CYP2C8*1\/*1 genotype. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["decreased response to rosiglitazone"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["decreased risk of remaining on steroids"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*15 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) or debrisoquine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["increased imatinib clearance"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.","phenotypeText":["increased risk for resistance"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have increased metabolism of rosiglitazone as compared to patients with the CYP2C8*1\/*1. Other genetic and clinical factors may also influence metabolism of rosiglitazone. This annotation only covers the pharmacokinetic relationship between CYP2C8 and rosiglitazone and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of rosiglitazone"]},{"genotypeAnnotationText":"Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1\/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype or may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects","increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to topoisomerase I inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to oxycodone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to oxycodone.","phenotypeText":["decreased response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response","shorter progression free survival","lower irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*14 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the rs3788853 C genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the A genotype. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and growth hormone deficiency who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant may require a decreased dose of recombinant human growth hormone (somatropin) as compared to patients with the CC genotype who are also homozygotes of the full length GHR gene. Other genetic and clinical factors may also influence dose of somatropin.","phenotypeText":["decreased dose of recombinant human growth hormone"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the CT or CC genotype. Additionally, patients with the TT genotype who are addicted to heroin may require an increased dose of methadone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.","phenotypeText":["more likely to require rescue analgesic administration","increased dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased likelihood of discontinuation of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients with the rs79910351 CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.","phenotypeText":["less likely to have rapid virological response"]},{"genotypeAnnotationText":"Patients with the CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis may have increased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the CTT\/CTT genotype. This association was found in patients carrying one del allele in combination with another cystic fibrosis causative variant. This genotype is not an indication for use of the combination drug of ivacaftor\/tezacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3114020 CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC or CG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["decreased risk for hematological toxicity"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs77932196 CC genotype (two copies of the CFTR R347P variant) and cystic fibrosis may not respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may not respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT\/del genotype may have decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GT\/GT. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["decreased dose of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype or may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["decreased risk for primary outcome","increased risk for primary outcome"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["reduced risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP2C19 *1\/*1) undergoing transplantation may have decreased metabolism of busulfan as compared to patients with the CT (*1\/*17) or TT (*17\/*17) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.","phenotypeText":["decreased metabolism of doxorubicin"]},{"genotypeAnnotationText":"Patients with the rs193922768 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with granisetron or palonosetron may have a lower response and increased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.","phenotypeText":["lower response and increased vomiting"]},{"genotypeAnnotationText":"Patient with CC genotype may have decreased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased IGF-I response"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the T genotype and psychiatric disorders who are treated with olanzapine may have a decreased risk of weight gain as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"The CYP2C9*14 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *14 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CC genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs7967354 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased metabolism of imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["increased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.","phenotypeText":["increased risk for diminished estimated glomerular filtration rate and transient proteinuria"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["require a decreased dose of valproic acid"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["worse survival"]},{"genotypeAnnotationText":"Patients with the rs2307116 GG genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the rs1065852 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide, decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs1384401 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the rs75039782 CT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have an increased response to fluvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and GG genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the rs1868089 CC genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (higher reductions in LDL cholesterol)"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine.","phenotypeText":["decreased dose of codeine"]},{"genotypeAnnotationText":"Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["increased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to treatment with ivacaftor\/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased overall survival period"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["less likely to experience neutropenia","increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of vortioxetine as compared to patients carrying a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["increased metabolism of vortioxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with regorafenib as compared to patients with the AT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["decreased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased risk of suicide"]},{"genotypeAnnotationText":"Patients with the rs121909013 AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs118192162 AC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased of likelihood of leukopenia or neutropenia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs193922807 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CG or CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and autism spectrum disorders may have a better tolerance for methylphenidate treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.","phenotypeText":["better tolerance for methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs12885713 CT genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["increased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs12471326 TT genotype may have decreased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs10958704 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs148693084 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with CYP2C19*2\/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased survival","decreased risk of severe neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype, or a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased risk for adverse events","decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["decreased metabolism of gemcitabine"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["increased response to diuretics"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the AC and CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased lipid-lowering response to rosuvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*21 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["decreased likelihood of recurrence and increased event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *28\/*28 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1 or *1\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*49 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["better response to statin therapy"]},{"genotypeAnnotationText":"Patients the CG genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival","increased overall survival","decreased progression-free survival","decreased overall survival"]},{"genotypeAnnotationText":"No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the CC genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["increased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["lower risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.","phenotypeText":["not experience a reduced risk of developing colonic cancer"]},{"genotypeAnnotationText":"Patients with the rs2279345 CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism resulting in lower efavirenz plasma levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.","phenotypeText":["more likely to experience adverse effects","more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs12948059 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are given amphetamine may have decreased stop reaction time, or reduced impulsivity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence stop reaction time.","phenotypeText":["decreased stop reaction time, or reduced impulsivity"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and chronic pain may experience decreased quality of sleep when treated with opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["decreased quality of sleep"]},{"genotypeAnnotationText":"Patients with the del\/insert genotype and Coronary Artery Disease may be less responsive to fluvastatin treatment as compared to patients with the del\/del genotype, or may have a better response to fluvastatin treatment as compared to patients with the insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["less responsive to fluvastatin treatment","better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal or no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles, while patients carrying the *4 allele in combination with another no function allele may also have increased carvedilol dose requirements as compared to patients carrying a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["increased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CT genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with hmg coa reductase inhibitors may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["less benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the rs121909041 CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with a decreased function allele with an activity value of 0.25 may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.","phenotypeText":["decreased risk for experiencing fatigue"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14B allele rn one copy of the *14B allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *7B or *14A alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with paroxetine may have increased risk of nausea or sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["increased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["increased severity of alcoholism"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with amikacin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with amikacin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"People with the TT genotype may have increased Anxiety Disorders when exposed to caffeine as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["increased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the GT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sufentanil dose requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["decreased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the 961delT+C(n) allele (represented here by the rs1556422499 CCCCCCC allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["decreased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.","phenotypeText":["lower risk for adverse effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have an increased response to eculizumab as compared with patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have decreased, but not absent, risk for side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of diazepam as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and diazepam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence diazepam metabolism.","phenotypeText":["increased metabolism of diazepam"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with acetylcholine as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["increased likelihood of cough"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["decreased estimated glomerular filtration rate (eGFR)"]},{"genotypeAnnotationText":"Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["increased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the rs6269 AA genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs118192124 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require an increased dose of phenprocoumon as compared to patients with two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["increased dose requirement of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.","phenotypeText":["increased dose of SN-38"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*3A diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3A specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["increased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype, but increased plasma levels as compared to patients with the TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels","increased plasma levels"]},{"genotypeAnnotationText":"Patients with ADHD and the rs71647871 CC genotype may require an increased dose of methylphenidate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the rs187713395 GG genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["increased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*3 allele in combination with a normal or no function allele may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["decreased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*5\/*13 or *4\/*31 or *4\/*69 or *5\/*100 or *2\/*101 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["increased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["decreased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis may have decreased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the del\/del genotype. This genotype is not an indication for use of the combination drug of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination and response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the GG genotype may be more likely to respond to sertraline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to sertraline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment","longer overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of alcoholism compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.","phenotypeText":["decreased risk of alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["increased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with another normal function allele may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two no function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["decreased response to enalapril in people with Hypertension"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC.The AG genotype may have decreased catalytic activity of DPYD as compared to the GG genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may be at an increased risk of developing nicotine dependence as compared to patients with two copies of the *2, *4, *9 or *12 alleles or one copy of the *1 allele in combination with one copy of the *2, *4 or *12 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["increased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the rs368146607 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs62097526 GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.","phenotypeText":["gain more weight"]},{"genotypeAnnotationText":"Patients with the rs1799782 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CC genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["reduced fasting glucose levels"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["smaller QT-interval shortening effect"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing surgery may have an increased response to propofol and remifentanil administered as anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["increased response to propofol and remifentanil administered as anesthesia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased but not absent risk for rash"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with the rs3219489 CG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may gain less weight during treatment with antipsychotics as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the rs717620 CC genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have increased exposure to mycophenolic acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["increased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs121909020 AA genotype (two copies of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["increased risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["increased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"Patients with the rs758649719 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs3918290 TT genotype and response to fluorouracil. However, the current evidence base suggests that there is no association between the CC or CT genotypes and response to fluorouracil. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association with response to fluorouracil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.","phenotypeText":["decreased likelihood of hyponatremia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.","phenotypeText":["increased risk of treatment-emergent suicidal ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["lesser reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["increased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of skin rash"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*04:04 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased risk of suicide"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1\/*1 genotype may have increased metabolism of methylphenobarbital as compared to patients with the *2\/*16 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["decreased chance of positive erectile response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["decreased risk of hypersensitivity to asparaginase"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have an increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.","phenotypeText":["increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with tobramycin as compared to patients with the G allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["not require a dose reduction or ribavirin"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have a decreased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele by CPIC. Patients carrying the *41 allele in combination with an increased, normal, decreased or no function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["similar metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":["increased response or survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["increased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["decreased risk of myopathy"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype may be more likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["loss of libido"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["decreased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the L\/L genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S\/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["less likely to drop out of treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype or may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["decreased efavirenz plasma concentrations","increased efavirenz plasma concentrations"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *17 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype (ApoE E4\/E4) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*54 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*54 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"The TPMT*3C allele is assigned as a no function allele by CPIC. Patients with the TPMT*3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*14 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with genotypes AG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["increased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have reduced alcohol consumption as compared to patients with the GG genotype, but an increased level of alcohol consumption compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["reduced alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased concentrations of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the del\/del genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the rs187713395 AG genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"African American male patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC or CT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the GG genotype may have a decreased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the CC or CG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["decreased response to carboplatin, lonafarnib, and paclitaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["decreased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["decreased likelihood of acquired resistance to gefitinib"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (3R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL)"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with *6 (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *7 allele in combination with the *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.","phenotypeText":["greater percent reduction in left ventricular mass index"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*55 allele or one copy of the *55 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with CYP1A1*1\/*2A had a significantly higher granisetron clearance and reduced exposure as compared to patients with *1\/*1 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["higher granisetron clearance and reduced exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs9606186 GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["more favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with the *4 allele who have a rapid or intermediate acetylator phenotype may have increased metabolism of dipyrone as compared to patients with two slow NAT2 alleles. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["increased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"The CYP2D6*4xN allele (*4x2) is assigned as a no function allele by CPIC. Patients carrying the *4xN allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with HIV infections and the *22\/*22 genotype may have decreased clearance of lopinavir as compared to patients with the *1\/*1 or *1\/*22 genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["decreased clearance of lopinavir"]},{"genotypeAnnotationText":"Patients with the CT genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["worse prognosis"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the TT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia","decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity","increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cannabis dependence as compared to patients with the AG or GG genotypes. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence.","phenotypeText":["increased risk of developing cannabis dependence"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased likelihood of progression free survival"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["increased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the rs115346678 GG genotype may be at a decreased risk of adverse events when treated with aspirin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *1\/*1 diplotype may have increased clearance of tacrolimus as compared to patients with the *3\/*3 diplotype. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["increased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor\/lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["unknown likelihood of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The AG genotype was not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Male patients with the CC genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1\/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3\/*3) genotype. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["increased metabolism of cyclosporine resulting in decreased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["worse treatment response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response when treated with oxaliplatin regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.","phenotypeText":["increased resistance to clopidogrel"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AA genotype may have a decreased response to methotrexate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA genotype, but more likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased response","increased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":["increased risk of adverse drug events"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased response to antihypertensives compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a no function allele in combination with a normal function allele or a donor with two normal function alleles, while patients who receive a liver transplant from a donor with the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype or may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele (rs72554665 allele A, assigned as G6PD deficient) who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with the B (reference) allele (non-deficient, class IV). Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with another deficient class II allele who are treated with sulfamethoxazole may have an increased risk of hemolysis as compared to patients with two copies of the B allele. Patients with two X-chromosomes and the Canton, Taiwan-Hakka, Gifu-like, Agrigento-like allele in combination with a non-deficient allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Male patients with the G genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the A genotype (hemizygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with cardiac arrhythmias and carrying the CYP2D6*1 allele in combination with another normal function allele may have a decreased response to propafenone as compared to patients carrying two decreased function alleles with an activity value of 0.25. Other genetic and clinical factors may also influence response to propafenone.","phenotypeText":["decreased response to propafenone"]},{"genotypeAnnotationText":"The del allele of rs72549303 is assigned no function by CPIC. Patients with the G\/del genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["less likely to respond to tramadol treatment"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs2372536 CG genotype and rheumatoid arthritis may have increased likelihood of response when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*6 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["likelihood of experiencing erythema"]},{"genotypeAnnotationText":"Patients with the rs34911792 TT genotype (do not have a copy of the CFTR S1235R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["increased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AT or TT genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia as compared to patients with the AA genotype, and a decreased likelihood of leukopenia as compared to patients with the GG genotype. In addition, the AG genotype may have an increased likelihood of hyperglycemia as compared to patients with the AA genotype, and a decreased likelihood as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of leukopenia","decreased likelihood of leukopenia","increased likelihood of hyperglycemia","decreased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"People with the rs2273697 AA genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.","phenotypeText":["increased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs3918290 CT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.","phenotypeText":["higher reduction in the risk of colon cancer"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of rocuronium as compared to patients with the del\/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["decreased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*62 allele or one copy of the *62 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the rs4948496 TT genotype and lymphoblastic leukemia-lymphoma may be at a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the rs510769 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype who are taking gliclazide may have decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype (POR *1\/*1) and familial hypercholesterolemia may have a greater decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CT (*1\/*28) or TT (*28\/*28) genotype. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["greater decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.","phenotypeText":["normal ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["decreased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale","better response according to the clinical global impressions (CGI) score"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"The TPMT*6 allele has been assigned as a no function allele by the DPWG. Patients with the *6 allele in combination with a normal function allele may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*6 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*33:03 allele who are treated with lamotrigine may have a decreased risk of maculopapular exanthema as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test, however this is contradicted in one of the two studies. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the rs118192122 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the rs193922802 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs121909019 GG genotype (do not have a copy of the CFTR R1066H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to mirtazapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response to mirtazapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"There is currently no available evidence on the effect of the CC genotype on a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Gastroesphageal reflux who are treated with omeprazole may have decreased absorption rate of omeprazole as compared to patients with the AA or AG genotypes and and decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence Response to and absorption rate of omeprazole in patients gastroesphageal reflux.","phenotypeText":["decreased absorption rate of omeprazole","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.","phenotypeText":["decreased risk for diarrhea and skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the rs7853758 AG genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*13 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of celecoxib as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of celecoxib.","phenotypeText":["decreased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have an increased risk for drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.","phenotypeText":["drug toxicity","increased response"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of nausea and neutropenia"]},{"genotypeAnnotationText":"Patients with the rs145157460 GT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the genotype TT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*32 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*32 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele have an increased risk of hypersensitivity reactions, such as Stevens-Johnson Syndrome, toxic epidermal necrolysis or maculopapular eruption, when treated with lamotrigine as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have an increased clearance of atomoxetine as compared to patients with the CYP2D6*87, *88, *90, *91, *93, *95, or *97 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["increased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the GG genotype, or patients undergoing a lung transplant, may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel diseases may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"In human liver microsomes, the UGT1A1*1\/*28 genotype was found to result in the increased formation of the clozapine metabolite clozapine N+-glucuronide as compared to the UGT1A1*28\/*28 genotype.","phenotypeText":["increased formation of the clozapine metabolite"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["greater increase in fasting glucose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may require a decreased dose of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also require a decreased dose of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but an increased dose as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence metoprolol dose requirements.","phenotypeText":["decreased dose of metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype, or a decreased risk and increased activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["increased risk for toxicity and decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*6 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*1 allele in addition to an increased function allele may have a decreased response to methadone maintenance therapy (MMT) as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["decreased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["increased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the DEL\/T genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.","phenotypeText":["decreased metabolism of mycophenolate mofetil"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*38 allele or one copy of the *38 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles but decreased metabolism as compared to patients carrying two copies of the *46 allele or one copy of the *46 allele in combination with one copy of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of adverse events in response to treatment as compared to patients with the GG or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased creatine kinase levels","increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs4673993 CC genotype and Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*24 allele or one copy of the *24 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *24 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs374515279 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to citalopram or escitalopram treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["less likely to enter remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may require increased doses of sertraline as compared to patients with two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence sertraline dosage requirements.","phenotypeText":["increased doses of sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have decreased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the G\/G genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 CC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with genotype AA may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["lower likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype TT.","phenotypeText":["decreased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*07:02 allele may have an increased risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim as compared to patients with no HLA-C*07:02 alleles or negative for the HLA-C*07:02 test. Other genetic and clinical factors may also influence a patient's risk of respiratory failure when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of respiratory failure"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7A allele or one copy of the *7A allele in combination with one copy of the *5A, *5B, *6A, *6B, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*1 genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk fo developing alcohol dependence as compared to patients wit the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also a affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who also have rs45445694 genotype 2R\/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4444903 AA genotype may have a poorer response to cetuximab as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients carrying the *37 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs201268750 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs699 GG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypercholesterolemia may have a smaller increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to metoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with carbamazepine may have increased concentration-to-dose ratios as compared to patients with the AA or AG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased concentration-to-dose ratios"]},{"genotypeAnnotationText":"The CYP2C9*4 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*4 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the rs3778156 GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs10929302 AA genotype may have increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the rs1125394 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs7294 TT genotype may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*39 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*39 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["decreased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased risk of neutropenia, leukopenia, and diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *15\/*15 diplotype may be at an increased risk of developing rifampin-induced liver injury as compared to patients who do not carry the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["increased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia or schizoaffective disorder may have greater weight gain when treated with clozapine or olanzapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele who are treated with fluoxetine may have increased metabolism of fluoxetine as compared to patients with two normal or two no function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the AT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Female patients heterozygous for the G6PD Mediterranean variant who are treated with sulfadoxine may have a varying degree of G6PD deficient red blood cells and an unknown rate of red blood cell survival as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["varying degree of G6PD deficient red blood cells","unknown rate of red blood cell survival"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia who are treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the rs9973653 GT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["increased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype (CYP3A4 *1\/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["decreased metabolism of cyclosporine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["increased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.","phenotypeText":["better response to metformin"]},{"genotypeAnnotationText":"Patients with the CT (CYP2C19 *1\/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have increased response to paroxetine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.","phenotypeText":["increased risk of CNS adverse events","increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["longer post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*12:03 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-C*12:03 alleles or negative for the HLA-C*12:03 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 TT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["decreased exposure to silibinin"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer response to treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["increased risk of nicotine dependence","increased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs774072493 del\/del genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC or C\/del genotypes. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the rs11030096 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["increased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 2R\/3R genotype may have an increased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*28 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*28 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["increased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for elevated triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure to temsirolimus or sirolimus","decreased likelihood of bone marrow and gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["increased serum concentrations","decreased serum concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"The GG genotype is associated with increased catalytic activity and decreased expression of DPYD protein as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*25 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with risperidone may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"The CYP2C9*33 allele has been assigned as a no function allele by CPIC. Patients carrying the *33 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.","phenotypeText":["increased oxidative stress"]},{"genotypeAnnotationText":"Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.","phenotypeText":["decreased absorption and lower concentrations of topotecan"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to bisphosphonate treatment, or may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with nitroprusside as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. Other genetic and clinical factors may also influence a patient's response to nitroprusside.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the rs397508510 GG genotype (do not have a copy of the CFTR H1054D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*49 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*49 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["decreased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.","phenotypeText":["improved response to irbesartan"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations and decreased clearance"]},{"genotypeAnnotationText":"The CYP2D6*2xN allele has been assigned as an increased function allele by CPIC. Patients carrying the *2xN allele in combination with another increased function allele, a normal function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs9288993 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying one copy of the 10-repeat allele and one copy of the 9-repeat allele may report more severe negative effects of alcohol as compared to patients carrying two copies of the 10-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["more severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.","phenotypeText":["increased risk for allograft loss"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs548783838 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["better anti-inflammatory response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Pediatric cancer patients with the AG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the AA or AG genotypes. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["increased response to modafinil in the treatment of methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *6\/*6 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk for drug toxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["decreased metabolism of heroin"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*47 allele or one copy of the *47 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*31 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["decreased survival time","increased risk of death"]},{"genotypeAnnotationText":"Patients with the rs61605570 TT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs7439366 CC genotype who are treated with sublingual buprenorphine\/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AC genotypes. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with the rs1800100 CC genotype (do not have a copy of the CFTR R668C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["decreased metabolism of risperidone","similar metabolism of risperidone","increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["increased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX\/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.","phenotypeText":["better response rate"]},{"genotypeAnnotationText":"Female patients with the AC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["decreased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["worse response to rivastigmine"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["decreased response to lovastatin"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["increased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6311 TT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["poorer survival outcomes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["increased risk for nausea","decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele and psoriasis may have a better response to treatment with methotrexate as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02. Other genetic and clinical factors may also influence a patient's response to treatment with ustekinumab. *Please note: the study tested for presence\/absence of HLA-Cw6 serotype, not the HLA-C*06 alleles.","phenotypeText":["better response to treatment with methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["decreased dose of morphine"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*2 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg\/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.","phenotypeText":["increased cardiomyopathy risk"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk of death"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs699 AA genotype may have a decreased response to atenolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1303839356 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA genotype, and slightly decreased reduction of systolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["slightly increased reduction of systolic blood pressure and slightly decreased reduction of systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR P67L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with ovarian cancer and the CC genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. In a single study, the authors compared outcomes between genotypes between treatments. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs548783838 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"There is currently no evidence regarding the association between the GG genotype and response to folate supplementation in the context of pharmacotherapy for depression.","phenotypeText":["response to folate supplementation"]},{"genotypeAnnotationText":"Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["lower risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with the rs193922753 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GT and TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.","phenotypeText":["increased concentrations of erlotinib"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["increased risk of treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the rs397508510 CC genotype (two copies of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["increased risk for smoking addiction and decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"The TT genotype is associated with a decreased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["increased risk of remaining on steroids 1 year after transplantation"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["more likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Female children with typhoid fever and the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with chloramphenicol may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to children with the A-202A_376G\/A-202A_376G or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["poorer response to glucocorticoid treatment and lower lung function"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have a decreased exposure to dextropropoxyphene as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.","phenotypeText":["decreased exposure to dextropropoxyphene"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AA genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["smaller decrease in glomerular filtration rate"]},{"genotypeAnnotationText":"No information were reported regarding patients with the TT genotype.","phenotypeText":["No phenotype reported"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have an increased risk of anemia as compared to the CT and TT genotypes. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["increased clearance","reduced clearance"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G genotype who are treated with clozapine may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal or no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs2279343 GG genotype may have decreased methadone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased bioavailability of pravastatin as compared to individuals with with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate increased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or CT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["decreased concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have decreased exposure to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["decreased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have a decreased response when treated with lisinopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["smaller drop in LDL-C levels and rise in HDL-C levels"]},{"genotypeAnnotationText":"Patients carrying the NAT2*6 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *6 allele in combination with *5, *6, or *7 allele (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *6 allele in combination with the *5, *6, or *7 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's hydralazine metabolism.","phenotypeText":["metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*3 genotype may have a lower likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *3\/*3 genotype. Other clinical and genetic factors may also influence risk of nephrotoxicity.","phenotypeText":["lower likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a shorter recovery time from general anesthesia as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["shorter recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the rs12422149 AG genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.","phenotypeText":["decreased LDL lowering effect"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*37 allele or one copy of the *37 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"The UGT1A1*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["decreased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs578776 AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["risk for nicotine dependence"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["increased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA and stable coronary artery disease who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence risk hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["decreased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the AC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype, or decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with liver cancer and the CC genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype, or a decreased response as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of tolbutamide as compared to patients with the CC or CT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CC or CT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.","phenotypeText":["less bone mineral loss"]},{"genotypeAnnotationText":"Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["worse treatment response"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["reduced exposure to simvastatin"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype who are treated with doxorubcin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have lower weight gain when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs1799971 GG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"The AA genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["decreased CYP4F2 activity and decreased vitamin e metabolism"]},{"genotypeAnnotationText":"The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["decreased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 (2R\/2R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype with colorectal neoplasms who are treated with celecoxib may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.","phenotypeText":["decreased risk of adenoma recurrence"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*28 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the rs4530637 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs2298383 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may 1) require decreased dose of phenytoin, 2) have increase metabolism of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["require decreased dose of phenytoin","increase metabolism of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.","phenotypeText":["lesser reduction in pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.","phenotypeText":["increased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/GGAGTC genotype who receive thiopurine treatment for autoimmune disease may be at a decreased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/del or del\/del genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["decreased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"The CYP2C9*13 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*13 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of phenytoin"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function or a decreased function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may have increased metabolism of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal function or no function allele. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["increased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["decreased response to acetaminophen (paracetamol)"]},{"genotypeAnnotationText":"Patients with the rs1801086 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs201268750 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs187713395 AA genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["severe anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["poorer chance at achieving remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival","decreased overall survival"]},{"genotypeAnnotationText":"Patients with the *1\/*3B genotype and cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may have decreased metabolism of dihydrocodeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect dihydrocodeine metabolism.","phenotypeText":["decreased metabolism of dihydrocodeine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased likelihood of adverse events when treated with fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the T\/del genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del\/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of celecoxib"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["decreased risk of lymph node metastases","increased survival rate"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"The CYP2C9*8 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *8 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma.","phenotypeText":["decreased response to beta-adrenergic inhalants","increased response to beta-adrenergic inhalants"]},{"genotypeAnnotationText":"Patients with the rs3778156 AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs510769 TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["reduced response","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have a increased severity of anemia as compared to patients with the AA or AG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["increased severity of anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AG and GG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs771237265 CC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["longer disease-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["decreased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CT genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC (POR *1\/*1) genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the CT and TT (*1\/*28 and *28\/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"The UGT1A1*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with a normal or decreased function allele may require an increased dose of irinotecan as compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect irinotecan dose requirements.","phenotypeText":["increased dose requirement of irinotecan"]},{"genotypeAnnotationText":"Patients with the rs140989814 CG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs113993959 GT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the CC genotype. This may be due to increased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the T allele as compared to those with the C allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["decreased risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the rs8099917 GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the rs5186 AC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 AA genotype may have a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["decreased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have a decreased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["increased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*59 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype may have decreased plasma concentrations of montelukast as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["better response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the 9,10-repeat genotype (GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/del) may have a decreased response to disulfiram treatment for cocaine dependence. as compared to patients with the 10,10-repeat genotype. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["decreased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the T genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs558025 AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying one or two copies of the HLA-DRB1*16:02 allele in addition to carrying the HLA-B*13:01 allele may be at an increased risk of experiencing dapsone hypersensitivity as compared to HLA-B*13:01-positive patients who do not carry any copies of the HLA-DRB1*16:02 allele. However, this association lost significance following Bonferroni correction. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing dapsone hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["decreased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the GT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV\/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.","phenotypeText":["lower likelihood of achieving successful virologic response"]},{"genotypeAnnotationText":"Patients with the rs396991 AA genotype may have a decreased response to rituximab, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["decreased response to rituximab"]},{"genotypeAnnotationText":"Patients with the rs662799 GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less reduction in LDL-cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["better response to treatment with adalimumab"]},{"genotypeAnnotationText":"Patients with genotype CC and schizophrenia may have decreased response to olanzapine compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs1806201 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele or a decreased function allele with an activity score of 0.25 may have increased metabolism of tolterodine as compared to patients carrying two no function alleles or two decreased function alleles with an activity value of 0.25 or a no function allele in combination with a a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have increased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["increased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs193922843 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may 1) require increased dose of phenytoin, 2) have decrease metabolism of phenytoin in people with Epilepsy as compared to patients with genotype AA or AG. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["increased dose of phenytoin","decreased metabolism of phenytoin in people with Epilepsy"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.","phenotypeText":["decreased inhibition of KCNH2 by quinidine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have higher maximal platelet aggregation as compared to patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["higher maximal platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["lesser response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Type 2 Diabetes may have decreased response to sitagliptin or vildagliptin compared to patients with the GG genotype. Other factors may affect response to sitagliptin and vildagliptin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of dapoxetine as compared to patients with the CYP2D6*10 or *87 or *88 or *91 or *93 or *95 or *97 or *98 allele, and 2) similar clearance compared to CYP2D6*89 or *90 or *94 allele. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["increased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"The AT genotype was not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Purified CDA proteins with the AG genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*4 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs540825 AT genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["decreased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*6 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to patients with no HLA-B*59:01 alleles or negative for the HLA-B*59:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["increased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["positive erectile response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CT + TT. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["increased hematologic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 (2R\/3R) genotype and concentrations of methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs45445694 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients carrying the AA genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased pravastatin plasma AUC"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of sulfinpyrazone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["increased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Patients with the rs193922818 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the rs72549435 CC genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Individuals with the TT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically a decreased heart rate"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the AT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"CYP2D6 *10\/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1\/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["decreased inhibition of CYP2D6","increased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["increased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["lower reduction in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of phenprocoumon as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["decreased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the AA genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer may have decreased likelihood of overall survival in as compared to patients with the AA genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.","phenotypeText":["decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs112563513 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["increased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.","phenotypeText":["poorer response to treatment with tiotropium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased remifentanil requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["increased remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure of repaglinide and decreased response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["decreased exposure and response to repaglinide"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with amikacin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with amikacin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["increased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the GG genotypes and increased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival","increased progression-free survival"]},{"genotypeAnnotationText":"Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["increased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to first remission induction therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to first remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.","phenotypeText":["decreased severity of sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a no function or normal function allele may have an increased risk of Stevens-Johnson Syndrome when treated with phenytoin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence the risk of Stevens-Johnson Syndrome.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have an increased analgesic response to ketorolac as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2B6*18 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2B6*28 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with mirtazapine may have increased risk of side effects as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *1 allele in combination with another normal function allele may have an increased risk of transplant rejection when treated with tacrolimus as compared to patients with a normal function allele in combination with a no function allele or patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may have an increased risk of transplant rejection as compared to patients with two no function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.","phenotypeText":["decreased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer who are treated with capecitabine may have an increased risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs774072493 CC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the del\/del genotype. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have decreased likelihood of drug discontinuation as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the AA genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with *14\/*37 genotype may have decreased transport of atrasentan and increased concentration as compared to individuals carrying the *1\/*1, *1\/*37 or *37\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["decreased transport and increased concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.","phenotypeText":["decreased metabolism of quetiapine"]},{"genotypeAnnotationText":"Patients with the rs558025 GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients with the rs3778156 AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*15 allele or one copy of the *15 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine..","phenotypeText":["increased response or decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of severe ototoxicity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function alleles by CPIC. Patients carrying the *4 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["lower risk of relapse"]},{"genotypeAnnotationText":"Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["decreased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have decreased likelihood of of drug discontinuation as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of drug discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:25 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased formation of gemcitabine triphosphate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["increased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["increased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with CC genotype and breast cancer may have a decreased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response to atenolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to smoking may have a better response to treatment with bupropion as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["better response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to anti-depressant treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.","phenotypeText":["increased exposure to olanzapine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*29 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the GG genotype may have decreased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["decreased cerebrospinal fluid concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the rs531738678 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele construct (in this study PMID:26310775 only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs145014075 GG genotype may have decreased concentrations of nicotine as compared to patients with the GT genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["decreased concentrations of nicotine"]},{"genotypeAnnotationText":"Patients with the rs77932196 AG genotype (one copy of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"African-American patients with the TT genotype (APOE E2\/E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased risk for toxicity when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for fluorouracil toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Male children with lead poisoning and the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2372536 CC genotype and rheumatoid arthritis may have increased likelihood of response when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *29 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and pain who are receiving Opium alkaloids and derivatives may have an increased severity of Substance-Related Disorders as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["increased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the rs17134592 TT genotype may have decreased metabolism of naltrexone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["decreased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with lung cancer and the CC genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["decreased likelihood of neurological adverse reactions and sleepiness"]},{"genotypeAnnotationText":"Patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a normal function allele in combination with a no function allele or a donor with two no function alleles, while patients who receive a liver transplant from a donor with the *1 allele in combination with a no function allele may have increased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of morphine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"The CYP2D6*29 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*29 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*29 allele in combination with an increased function allele may have similar metabolism of tamoxifen as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AG genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 GG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for Torsades de Point"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs7997012 GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*7 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*7 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased metabolism of folic acid"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with another normal function allele may have decreased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["decreased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the TT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin","decreased dose of warfarin"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk","increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of caffeine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*9 allele may have decreased clearance of fentanyl as compared to patients with the *1\/*1 diplotype. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["increased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are addicted to heroin may have decreased withdrawal symptoms when treated with methadone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["decreased withdrawal symptoms"]},{"genotypeAnnotationText":"\"Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with \"\"standard risk cytogenetic profiles\"\". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.\"","phenotypeText":["shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 TT genotype may have a decreased response to naltrexone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the C\/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of lopinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["worse response for fasting and postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.","phenotypeText":["higher maximal rate (Vmax) of ethanol"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of fluvoxamine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["increased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.","phenotypeText":["decreased response to citalopram and escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*18\/*21 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine as compared to patients with the CYP2D6*1\/*1 genotype. Finding reported in case study for *18\/*21 subject. Other genetic and clinical factors may also influence the metabolism of debrisoquine.","phenotypeText":["decreased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with the *1\/*2 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*1 genotype who have non-valvular atrial fibrillation may require higher warfarin maintenance dose than patients with *1\/*2 or *1\/*3 or *2\/*2 or *2\/*3 or *3\/*3 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["higher warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2) decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk for acute rejection","decreased incidence of lymphopenia"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *13 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["decreased severity of drug toxicity and hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of escitalopram as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of escitalopram as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["decreased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*6 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-A*02:01 allele and risk of severe cutaneous adverse reactions when treated with carbamazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of severe cutaneous adverse reactions when treated with carbamazepine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GTAAGTTG\/GTAAGTTG genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["less improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1800629 AA genotype may have decreased response to etanercept as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.","phenotypeText":["increased risk for new-onset diabetes mellitus (NODM)"]},{"genotypeAnnotationText":"Patients with the rs1695 GG genotype and Neoplasms may have decreased response to cyclophosphamide as compared to patients with AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*27 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["less likely to experience a reduction in systolic blood pressure following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["reduced risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["shorter disease-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to people with the GT or TT genotypes. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of Stevens-Johnson Syndrome when treated with acetazolamide. Other genetic and clinical factors may also influence a patient's risk of acetazolamide-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype who are treated with pravastatin may have a larger reduction in LDL and total cholesterol as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["larger reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype who receive thiopurine treatment for autoimmune disease may be at a decreased risk of developing thiopurine-related cytopenia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["decreased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a normal function allele or a decreased function allele with an activity score of 0.25 may have decreased metabolism of citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 TT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["increased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased clearance of paclitaxel"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Postoperative patients with the AG genotype may have lower morphine requirements as compared to patients with the GG genotype, but higher morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["less response"]},{"genotypeAnnotationText":"Patients with the CCT\/CCT genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the del\/del or del\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs9927200 AC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.","phenotypeText":["poor response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of myelosuppression and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["no changes in mycophenolic acid exposure-related parameters","decreased risk of acute allograft rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.","phenotypeText":["decreased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the AG genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["reduced clearance of risperidone"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1801394 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["better response (higher decrease in HbA1c)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["improved clearance and metabolism of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.","phenotypeText":["smaller mean changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*47 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*47 allele was found to have no or drastic decrease in enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with phenytoin as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype may have a decreased response to antidepressants as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["decreased emergency department visits and hospital utilization"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["lower increase in fasting glucose"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*07:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. This allele is in strong linkage disequilibrium with HLA-DQA1*02:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation.","phenotypeText":["increased risk for smoking addiction, and a decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to fentanyl. However, patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not carry a copy of the CFTR R74W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased clinical benefit to fluoxetine"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *1\/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["increased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs7997012 AA genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:03 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased concentration-to-dose ratios"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CYP2B6*6\/*6 diplotype and B-cell non-Hodgkin's lymphoma may have decreased clearance of cyclophosphamide as compared to children with the *1\/*1 diplotype. Other genetic and clinical factors may also influence a patient's clearance of cyclophosphamide.","phenotypeText":["decreased clearance of cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs768416963 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["increased risk of Pancreatitis"]},{"genotypeAnnotationText":"Patients with the rs777098658 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*20 allele or one copy of the *20 allele in combination with one copy of the *1 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles while patients with one copy of the *20 allele in combination with one copy of the *17 allele may have decreased metabolism of nicotine as compared to patients with two copies o the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the rs193922525 AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["increased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may require decreased doses of sertraline as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence sertraline dosage requirements.","phenotypeText":["decreased doses of sertraline"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AA genotype who are treated with azathioprine may have decreased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":["decreased likelihood of adverse events"]},{"genotypeAnnotationText":"The GG genotype is associated with an increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CYP3A5*1 allele in combination with another *1 allele or the *3 allele who are treated with tacrolimus may have a increased risk of nephrotoxicity as compared to patients with two CYP3A5*3 alleles. However, a number of studies show a decreased risk of nephrotoxicity for patients with CYP3A5*1 allele, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CG genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and gout may require a dose of 300 mg\/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["require a higher dose of allopurinol or febuxostat"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["increased exposure to methotrexate and lower likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the AA genotype may have increased cocaine cue-reactivity as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and diabetes mellitus may have an increased response when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.","phenotypeText":["increased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the rs2244613 GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype, but increased oxycodone dose requirements as compared to patients with the AA genotype. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements","increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["increased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"Patients with the rs368234815 TT\/TT genotype and chronic hepatitis C infection may have improved response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with G\/TT or GG genotypes. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":["improved response (including sustained virological response (svr))"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with cancer pain and the AC genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *1\/*1xN diplotype (ultrarapid metabolizers) may have increased clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or poor metabolizers (*4\/*4, *4\/*5). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["increased clearance of donepezil"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.","phenotypeText":["decreased risk for edema"]},{"genotypeAnnotationText":"Hispanic patients with the GG genotype may have a smaller decrease in viral load following the initiation of HAART as compared to Hispanic patients with the AA or AG genotypes. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["smaller decrease in viral load"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AC or CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. A single study reported its association with response to latanoprost by comparing the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism of propafenone"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype who are treated with Ace Inhibitors may have a decreased, but not absent, risk for major cardiovascular events or mortality as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["decreased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"No cells with the TT genotype were available for analysis, but cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["increased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response to treatment with methadone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":null},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["increased plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["increased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the rs5031016 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*18 allele or one copy of the *18 allele in combination with one copy of the *1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AT genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and schizophrenia, treated with risperidone may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype G. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["decreased risk of Angioedema"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP3A5*1 allele in combination with a no function allele may have an increased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with two no function alleles. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia when taking carboplatin and paclitaxel.","phenotypeText":["increased risk for leukopenia or neutropenia"]},{"genotypeAnnotationText":"Female patients with the TT genotype may have increased levels of cocaine, ethanol or nicotine use, which may lead to an increased risk of developing substance dependence, as compared to female patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["increased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with the rs77932196 CG genotype (one copy of the CFTR R347P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["increased concentrations of tacrolimus, and require a decreased dose"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["increased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with sulfasalazine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["increased methylation at sites within the COMT gene promoter"]},{"genotypeAnnotationText":"Patients with the GG genotype and who are treated with warfarin may require decreased dose as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["require decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2011425 GT genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["decreased serum concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"No patients with the GG genotype were present in the population. However, patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the rs374527058 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["decreased clearance and metabolism"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.","phenotypeText":["smaller elevations of LDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*45 allele or one copy of the *45 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.","phenotypeText":["no observed effect"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["increased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CYP3A4*1\/*1 genotype and breast cancer may have decreased concentrations of exemestane as compared to patients with the *1\/*22 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["decreased concentrations of exemestane"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["increased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to ethanol as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["increased response to ethanol"]},{"genotypeAnnotationText":"Evidence conflicts as to whether patients with the TT genotype and psoriasis have increased response to ustekinumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["conflicting evidence on increased response to ustekinumab"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients with the rs1800566 GG genotype who are treated with platinum chemotherapy regimens may have increased overall survival as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*38 allele or one copy of the *38 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.","phenotypeText":["decreased metabolism of doxorubicin","greater tumor reduction","increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["decreased likelihood of a good response"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs369103276 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs2231142 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol","increased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment OR better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["decreased overall survival probability"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *5 allele or one copy of the *5 allele in combination with the *6 or *7 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the rs397508442 TT genotype (two copies of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*12A allele or one copy of the *12A allele in combination with one copy of any *4 or *13A alleles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["increased likelihood of achieving remission"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk of toxicities as compared to patients with the AG or GG genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AC genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CC genotype, may have a decreased likelihood of weight gain as compared to patients with the CT and TT genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients with ASD or schizophrenia who are taking risperidone, clozapine, or olanzapine.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 GT genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with a normal function allele may have decreased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with one or two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["decreased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["decreased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased inhibition of FXIII activation by aspirin"]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["decreased risk of adverse cognitive effects and sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["require the highest dose"]},{"genotypeAnnotationText":"Patients with the rs2736308 TT genotype may have a decreased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.","phenotypeText":["decreased risk of Medication-related osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and diabetes mellitus may have a decreased response to pioglitazone as compared to patients with the GT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 AG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["decreased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and one or two copies of the HLA-B*15 allele may have a poorer response to interferon beta-1a treatment as compared to patients with no HLA-B*15 alleles or negative for the HLA-B*15 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.","phenotypeText":["poorer response to interferon beta-1a treatment"]},{"genotypeAnnotationText":"Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*3 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["lower ADP-induced peak platelet aggregation"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion) may have decreased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTA\/TTA genotype (also described as 6bp deletion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The TPMT*3B allele has been assigned as a no function allele by CPIC. Patients carrying the *3B allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.","phenotypeText":["decreased risk of adverse drug reaction"]},{"genotypeAnnotationText":"Patients with the rs444904 CC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the rs924607 TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.","phenotypeText":["increased risk of peripheral nervous system diseases"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema.","phenotypeText":["increased risk of Angioedema"]},{"genotypeAnnotationText":"Patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["increased risk for new-onset posttransplant diabetes mellitus (PTDM)"]},{"genotypeAnnotationText":"Patients with cardiac arrhythmias and carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have an increased response to propafenone as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to propafenone.","phenotypeText":["increased response to propafenone"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival","decreased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*2 in combination with a normal, decreased, or no function allele may have increased risk of bleeding when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to vitamin K1 as compared to patients with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["decreased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with the rs745364489 AA genotype may have an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the C genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the G genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with paroxetine may have an increased risk of adverse drug reactions as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs374515279 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["decreased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["lower response to repaglinide"]},{"genotypeAnnotationText":"Patients with the rs3740563 CC genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP3A4*20 allele in combination with one copy of the *1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele was only defined as C161S not including 2988G>A in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["increased fentanyl dosage requirements"]},{"genotypeAnnotationText":"There is current no available evidence regarding the association between the CYP3A5 *1\/*1 genotype and exposure to dextropropoxyphene.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs20455 GG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased response to citalopram or escitalopram in people with depression"]},{"genotypeAnnotationText":"Patients carrying the CYP3A5*1 allele in combination with another normal function allele may have increased clearance of everolimus as compared to patients carrying two no function alleles or a no function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with a no function allele may have increased clearance of everolimus as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["increased clearance of everolimus"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:09 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the TT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 allele may be at a decreased risk of developing neurotoxicity when treated with paclitaxel as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing neurotoxicity when treated with paclitaxel.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the G allele and HIV may have a greater decline in adiponectin when treated with antiretroviral therapy as compared to patients with the A allele. Other genetic and clinical factors may also influence adiponectin response to antiretroviral therapy.","phenotypeText":["greater decline in adiponectin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.","phenotypeText":["shorter event-free survival time"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk for cardiotoxicity"]},{"genotypeAnnotationText":"African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CC or CT genotype (carriers of E4). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["longer duration to reach stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit more from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["improved response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer or HIV may have increased metabolism and decreased concentrations of nelfinavir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased concentrations of nelfinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.","phenotypeText":["require the lowest dose"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the rs2230806 TT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a poorer response when treated with zileuton as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to zileuton treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["decreased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["poorer response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype undergoing organ transplant who received a donor liver with the same genotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CT or TT genotype who received a donor liver heterozygous or homozygous for the variant (T) allele. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["decreased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with any combination of the *5A, *5B, *6A, *6B, *7A, *7B, *14A or *14B alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of addiction to heroin when using heroin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["increased risk of addiction to heroin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["decreased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being ineffective"]},{"genotypeAnnotationText":"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased risk of nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of amitriptyline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C19 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the *6\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["decreased likelihood of complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype may begin using heroin at an earlier age as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["earlier age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["increased risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2B6*26 allele is assigned as a decreased function allele by CPIC. Patients carrying CYP2B6*26 allele in combination with a no, decreased, normal, or increased function allele may require decreased dose of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["decreased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response to naltrexone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*98 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele (in this study only H463D was considered) was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["similar clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response, decreased concentrations, increased risk of iron overload"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs538336580 AT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*4 allele may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two suballeles of *5, *6, *7 or *14. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["increased clearance of cyclosporine","increased dose of cyclosporine","decreased risk of infection"]},{"genotypeAnnotationText":"Caucasian patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*31:01 allele who are treated with carbamazepine may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*31:01 alleles or negative for the HLA-A*31:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["increased conversion of the drug to active polyglutamates","decreased response"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and carrying the UGT1A1*1 allele in combination with another normal function allele may have a decreased risk of developing thrombocytopenia when treated with FOLFIRINOX as compared to patients carrying two decreased function alleles or a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of developing thrombocytopenia when treated with FOLFIRINOX.","phenotypeText":["decreased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.","phenotypeText":["decreased risk of hyperbilirubinemia and bilirubin-related drug discontinuation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["decreased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a better response to platinum-based chemotherapy as compared to patients with the AA or AG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response to platinum-based chemotherapy"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["higher accumulation of active methotrexate metabolites","increased risk for thrombocytopenia"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the rs193922807 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["more severe side effects"]},{"genotypeAnnotationText":"Patients with genotype TT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs3804100 CT genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patient harbors the rs118204423 CC genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118204423 G>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the TT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["increased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have decreased metabolism of rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence metabolism of rosiglitazone. This annotation only covers the pharmacokinetic relationship between CYP2C8 and rosiglitazone and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of rosiglitazone"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["decreased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["decreased anxiety"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes GG or GT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased sustained virological response (SVR)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["decreased likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*54 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*54 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype and liver cirrhosis with refractory ascites may be less likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/del or del\/del genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.","phenotypeText":["increased on-treatment platelet activity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and diabetes or hypertension may have a better response when treated with benazepril or perindopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to benazepril or perindopril.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to nimodipine as compared to patient with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1128503 AG genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["faster improvement in BPRS scores"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have lower S-propranolol plasma concentration when treated with propranolol as compared to patients with the CYP2D6*10 allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's metabolism of propranolol.","phenotypeText":["lower S-propranolol plasma concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to drug"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glimepiride as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased metabolism of oxycodone as compared to patients carrying two increased function alleles or a normal function allele in combination with an increased function allele. However, patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of oxycodone as compared to patients carrying two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.","phenotypeText":["decreased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the rs2874116 AA genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["increased clearance of efavirenz"]},{"genotypeAnnotationText":"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["increased risk for infections"]},{"genotypeAnnotationText":"Patients with the rs118192168 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased QT interval"]},{"genotypeAnnotationText":"Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["later onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.","phenotypeText":["decreased risk of cough"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":["increased exposure to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 CT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["better response to haloperidol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["decreased likelihood of remission at 8 weeks"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the rs121909020 GG genotype (do not have a copy of the CFTR A1067T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AT genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased likelihood of recurrence and increased event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["decreased likelihood of recurrence and increased event-free and recurrence-free survival"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of vortioxetine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["decreased metabolism of vortioxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["increased risk of developing drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*5\/*8 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased risk for sleep disturbances"]},{"genotypeAnnotationText":"Patients with the AT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["decreased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to atorvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased progression free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time and decreased likelihood of experiencing remission"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:03 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AA genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["increased blood alcohol concentrations and decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a decrease response to risperidone as compared to patients with the CT or TT genotype. Please note this association did not reach statistical significance in one study, while another study failed to find an association. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decrease response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["decreased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with genotypes TT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.","phenotypeText":["increased likelihood of virological relapse"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the *37 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.","phenotypeText":["decreased risk of developing hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may experience a decreased severity of respiratory depression when treated with alfentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["decreased severity of respiratory depression"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["increased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"The AC genotype may be associated with increased CYP4F2 activity and decreased vitamin e metabolism as compared to the AA genotype and decreased metabolism as compared to the CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.","phenotypeText":["increased CYP4F2 activity","decreased vitamin e metabolism"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased clearance of rocuronium as compared to patients with the del\/T and TT genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.","phenotypeText":["increased clearance of rocuronium"]},{"genotypeAnnotationText":"Patients with the TT genotype and kidney or lung transplantation may experience increased metabolism of tacrolimus resulting in decreased exposure as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence metabolism of tacrolimus.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs4148738 CT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["decreased risk of bleeding"]},{"genotypeAnnotationText":"Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased clearance of mirtazapine as compared to patients with two no function alleles and a decreased clearance of mirtazapine as compared to patients with an increased function allele in combination with a normal function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.","phenotypeText":["increased absorption rate and response to omeprazole"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["decreased clearance of lorazepam"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.","phenotypeText":["decreased doses of carvedilol"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may require decreased doses of citalopram as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence citalopram dosage.","phenotypeText":["decreased doses of citalopram"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with citalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CC genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["increased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"Patients with the rs571335587 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Individuals with the GG genotype and HIV may have a increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.","phenotypeText":["increased risk of developing Kidney disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs118192161 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*14 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*13A allele or one copy of the *13A allele in combination with one copy of any *4 or *12A alleles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*20 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to achieve a target HbA1c level of <7%"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["increased risk of occurrence of breast cancer during SERM therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.","phenotypeText":["decreased risk for flucloxacillin-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["higher dose-adjusted trough concentrations of cyclosporine and lower likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["lower pain relief to opioids"]},{"genotypeAnnotationText":"Patients with the rs193922747 TT genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CT and CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs6065 TT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased response","decreased, but not absent, risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the GT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs20455 GG genotype may have increased response to atorvastatin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["less time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a lesser reduction in systolic blood pressure when treated with nifedipine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["lesser reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["increased cognitive impairment"]},{"genotypeAnnotationText":"Patients with the rs1303839356 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs7205113 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.","phenotypeText":["increased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have an increased exposure to atorvastatin as compared to individuals with the AA or CC genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["faster improvement in Brief Psychiatric Rating Scale (BPRS) scores"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["better response to carvedilol treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["increased frequency of relapse"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the rs28358572 C allele (also known as the 1520C allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of experiencing aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["decreased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs.","phenotypeText":["better response","poorer response"]},{"genotypeAnnotationText":"Patients with the rs997917 TT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs12366035 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with ritonavir may have a increased intracellular\/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.","phenotypeText":["increased intracellular\/plasma trough concentration"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["lower risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.","phenotypeText":["unfavorable prognosis"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 CT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype but decreased concentrations as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate","decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["increased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients with the *3\/*3 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["increased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["increased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["decreased concentrations of temozolomide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["increased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy may have increased metabolism of carbamazepine as compared to patients with the the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["decreased metabolism of escitalopram"]},{"genotypeAnnotationText":"Pre-menopausal women with the CC genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["decreased disease free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"The CYP2D^*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype may have increased activity of DPYD as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects","sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs121909013 GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Female patients with the CT genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["decreased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with TT genotype and breast cancer may have an increased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy.","phenotypeText":["risk of vomiting"]},{"genotypeAnnotationText":"Patients with the rs1801131 GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of drug toxicity and adverse events"]},{"genotypeAnnotationText":"Patients with the rs755416212 TT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may be more likely to benefit from pravastatin treatment as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["decreased expression of TCL1A, IL17RA","increased expression of IL17A, IL12RB2, and IL1R2"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["increased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"In healthy volunteers the AA genotype may be associated with increased secretory clearance of metformin and in patients with diabetes mellitus may result in decreased efficacy (increased HbA1c levels), as compared to patients with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["increased secretory clearance of metformin","decreased efficacy (increased HbA1c levels)"]},{"genotypeAnnotationText":"Men with the non-null\/ non-null genotype (has two copies of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.","phenotypeText":["decreased plasma predose concentration"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the *1\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["decreased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AG genotype may have an increased daily intake of heroin as compared to heroin-dependent patients with the GG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["increased daily intake of heroin"]},{"genotypeAnnotationText":"Patients with the HLA-B*15:05 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*15:05 alleles or negative for the HLA-B*15:05 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["lower rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["increased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with postoperative pain and the CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.","phenotypeText":["better response to statin therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["more inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CC genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*1 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["decreased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.","phenotypeText":["decreased pravastatin plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may have decreased exposure to nimodipine as compared to patient with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype who have a high risk of cardiovascular disease may have a poorer anti-inflammatory response when treated with fenofibrate as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.","phenotypeText":["poorer anti-inflammatory response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["decreased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["decreased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the GG genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the TPMT *3A\/*3A genotype, may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the *1\/*1 or *1A\/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir\/sofosbuvir therapy.","phenotypeText":["increased likelihood of relapse"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentration of lovastatin acid"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have an increased risk of drug toxicity when treated when phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1275988 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["increased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have an lower, but not absent, risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["decreased risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AA genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased response to fluoxetine"]},{"genotypeAnnotationText":"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2244613 GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["increased risk of emergency department visits"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["poorer response to imatinib treatment"]},{"genotypeAnnotationText":"The TPMT*2 allele is assigned as a no function allele by CPIC. Patients with the TPMT*2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Individuals with the GT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype TT\/TT may have increased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype G\/TT or GG. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["increased risk of developing chronic lung allograft dysfunction (CLAD)"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the CT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of telmisartan"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have increased methadone dose requirements as compared to patients with the TT genotype but decreased dose requirements as compared to the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["increased methadone dose requirements","decreased dose requirements"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for respiratory depression when treated with opioids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["decreased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with CC genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"The TT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with lower baseline serotonin levels and smaller decreases in serotonin levels as compared to the CT or CC genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["lower baseline serotonin levels and smaller decreases in serotonin levels"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and non-small-cell lung cancer may have longer overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the CCGG\/CCGG or CCGG\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["longer overall and progression-free survival times"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with a normal function allele may have decreased metabolism of citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with carbamazepine or oxcarbazepine may have a decreased likelihood of a good response within as compared to patients with the CT or TT genotypes, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.","phenotypeText":["decreased likelihood of a good response"]},{"genotypeAnnotationText":"Patients with the rs137904044 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased risk for depression"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele may have increased metabolism of venlafaxine as compared to patients carrying at least one uncertain function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of venlafaxine.","phenotypeText":["increased metabolism of venlafaxine"]},{"genotypeAnnotationText":"The CC genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased expression of DPYD"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the TT genotype may have an increased risk of leukopenia, as compared to patients with the CC and CT genotypes, but may also experience increased rates of event-free survival, as well as overall survival as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":["increased risk of leukopenia","increased event-free survival","increased overall survival"]},{"genotypeAnnotationText":"Women with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494C allele. However, conflicting evidence has been reported. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *1 allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles, but increased concentrations of methadone as compared to patients carrying a normal function allele in combination with an increased function allele. Patients carrying the *1 allele in combination with a no function allele may have decreased concentrations of methadone as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*2 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["increased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["slower reach to target blood pressure"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of lovastatin as compared to patients carrying the *5 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["increased metabolism of lovastatin"]},{"genotypeAnnotationText":"CT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["increased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Female patients homozygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["increased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response to etanercept treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.","phenotypeText":["decreased response to propofol and remifentanil"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with increased reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-\/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the rs1799782 AG genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.","phenotypeText":["less likely to respond to antidepressant treatments"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the GGTCCCACTCTTCCCACA\/GGTCCCACTCTTCCCACA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal function allele may have increased response to rabeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles, and decreased response as compared to patients with two no function alleles. Patients carrying the *3 allele in combination with another no function allele may have increased response to rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the CC genotype and mental disorders (excluding schizophrenia) may have smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["smaller weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["increased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Subjects with GG genotypes may have decreased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.","phenotypeText":["decreased ratio of (R)-warfarin \/ (S)-warfarin AUC prothrombin time"]},{"genotypeAnnotationText":"Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentration of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["increased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to remain abstinent from smoking when treated with placebo as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's success at smoking cessation.","phenotypeText":["more likely to remain abstinent from smoking"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["decreased risk of oedema"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluoxetine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and increased fluoxetine response or no association of the variant with response to fluoxetine treatment. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs6280 CC genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs397508513 AA genotype (do not have a copy of the CFTR K1060T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*98 allele was only defined by 4110C>G in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the GG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["decreased clearance of imatinib and decreased event-free survival time"]},{"genotypeAnnotationText":"Patients with the rs193922878 GG genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["develop malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["decreased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of vomiting"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased serum concentration"]},{"genotypeAnnotationText":"Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs3740563 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["increased risk for non-response","decreased risk for non-response","contradictory findings for no association of the variation with response"]},{"genotypeAnnotationText":"Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["decreased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*28 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["decreased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the TT genotype may have improved response to oxcarbazepine as compared to patients with the CC and CT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with escitalopram may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram and more severe side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["increased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *1a\/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:05 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["decreased risk of experiencing nausea"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the CC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of breast cancer recurrence"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["increased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.","phenotypeText":["increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.","phenotypeText":["lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs114558780 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with chronic pain and the AG genotype may be more likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["more likely to develop hyperalgesia"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["increased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["decreased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CG genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4 allele in combination with a no function allele and depression may require a lower dose of selective serotonin reuptake inhibitors as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's dose requirement.","phenotypeText":["lower dose requirement of selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of repaglinide as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the TT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["decreased metabolism of nicotine and longer time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may be at an increased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) but a decreased risk as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased catalytic activity of TYMS","increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying and the *28\/*28 genotype when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1\/*1, *1\/*28). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["decreased risk of neutropenia","increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may be more likely to respond to antihypertensives than patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["increased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"The NUDT15*3 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*3 allele in combination with another no function may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4 or *7 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["decreased likelihood of response"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma treated with montelukast may have higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["higher plasma concentration of montelukast and better response to montelukast"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the NAT2*5\/*5 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Female patients with the AA genotype and epilepsy may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antiepileptics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["increased risk for cocaine addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele who are treated with fluoxetine may have increased metabolism of fluoxetine as compared to patients with two no function alleles, and may have increased metabolism of fluoxetine as compared to patients with one increased function allele in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["decreased serum concentrations of simvastatin acid"]},{"genotypeAnnotationText":"The A allele of rs1801266 is assigned no function by CPIC. Patients with the AG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*1 genotype and osteoporosis may have decreased hip bone mineral density when treated with raloxifene as compared to patients with the *28\/*28 genotype. Other genetic and clinical factors may also influence bone mineral density.","phenotypeText":["decreased hip bone mineral density"]},{"genotypeAnnotationText":"Patients with the rs75039782 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased consumption of nicotine as compared to patients with two copies of the *2, *4, *7 or *9 alleles, one copy of the *2 allele in combination with one copy of the *1 allele, one copy of the *4 allele in combination with one copy of the *7 or *9 alleles or one copy of the *7 allele in combination with one copy of the *9 allele. Patients with two copies of the *1 allele may also have decreased nicotine consumption as compared to patients with two copies of the *46 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["increased consumption of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.","phenotypeText":["increased risk of renal proximal tubulopathy"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*26 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"Cardiotox was not not found in GG group in this small study. The GG genotype (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.","phenotypeText":["more sensitive to trastuzamab"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["increased response to calcium channel blockers in people with Hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased, but not absent, risk for side effects as compared to the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele in combination with one copy of any *12 or *13 suballeles may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *4, *12 or *13 suballeles in combination with one copy of the *5, *6, *7 or *14 suballeles; any combination of the *5, *6, *7 or *14 alleles; two copies of any suballeles of *5, *6, *7 or *14. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["risk of azoospermia"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.","phenotypeText":["faster desensitization to effects of terbutaline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the rs6517442 TT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["increased likelihood of cough"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1751034 CT genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["decreased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["better improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk for stroke"]},{"genotypeAnnotationText":"The TPMT*3C allele has been assigned as a no function allele by CPIC. Patients carrying the *3C allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["prolonged time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["increased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.","phenotypeText":["higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4646437 AG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype, or decreased concentrations as compared to the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["decreased social and clinical needs"]},{"genotypeAnnotationText":"Patients with the CYP2D6*50 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*50 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["increased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy","more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.","phenotypeText":["decreased response to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"The GG genotype is associated with increased concentrations of UGT1A1 and increased glucoronidation of oxazepam as compared to the AA and AG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["increased concentrations of UGT1A1 and increased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*28 allele or one copy of the *28 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *28 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Has average risk for metabolic syndrome when treated with antipsychotics. Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of debrisoquine or sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or sparteine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in people with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["increased concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*8 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may require increased dose of efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["increased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["increased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"The CYP2C9*31 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *31 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs2304016 GG genotype and epilepsy who are treated with antiepileptic drugs may have a decreased, but not absent, risk of drug resistance as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["decreased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with the rs77932196 AC genotype (one copy of the CFTR R347H variant and one copy of the CFTR R347P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. R347P is not on this list of approved variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.","phenotypeText":["increased risk for CNS depression"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["decreased chance of severe hypersensitivity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["increased risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["increased response and decreased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["increased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the CYP2D6*12 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*12 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs671 AA genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.","phenotypeText":["increased risk for heroin dependence"]},{"genotypeAnnotationText":"African-American patients with the CT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased response to methadone"]},{"genotypeAnnotationText":"Pediatric patients with the AC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased risk for sleep disturbances"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Children with the TT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["increased risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CYP2D6*3\/*4XN genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from treatment"]},{"genotypeAnnotationText":"Elderly patients with the *2\/*3 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1\/*3 or *3\/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations.","phenotypeText":["decreased trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the AC genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD.","phenotypeText":["decreased risk of end-of-induction minimal residual disease (MRD)"]},{"genotypeAnnotationText":"Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5A allele or one copy of the *5A allele in combination with one copy of the *5B, *6A, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of atorvastatin-related myopathy when treated with atorvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of atorvastatin.","phenotypeText":["higher risk of atorvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6 *1 allele may have increased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients carrying at least one copy of the CYP2A6*15, *21 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["increased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["increased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*7 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.","phenotypeText":["less likely to experience neutropenia","increased progression-free survival"]},{"genotypeAnnotationText":"Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin","decreased prolactin"]},{"genotypeAnnotationText":"Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk of over-anticoagulation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the rs112445441 AC genotype (G13V) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["similar response"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the *14 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.","phenotypeText":["increased clearance of vardenafil"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.","phenotypeText":["decreased likelihood of cough"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk for aspirin sensitivity","increased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["increased exposure to methotrexate"]},{"genotypeAnnotationText":"Patients with the HLA-DRB1*07:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DRB1*07:01 alleles or negative for the HLA-DRB1*07:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["decreased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["nausea"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["increased blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the rs3135506 GG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the reference B (reference) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and\/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and\/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":["decreased risk of methemoglobinemia and\/or hemolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased tumor response rate","increased risk of grade 3-4 nonhematological toxicity","decreased tumor response rate","decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Women with the CC genotype and hypertensive nephrosclerosis may have a better response to treatment with metoprolol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to metoprolol.","phenotypeText":["better response to treatment with metoprolol"]},{"genotypeAnnotationText":"Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with ADHD and the rs71647871 CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"The CYP2C19*24 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*24 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["increased likelihood of ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.","phenotypeText":["greater risk for haloperidol-induced toxicities"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk for severe cutaneous adverse reactions when receiving lamotrigine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk for severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["increased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients carrying the NUDT15*2 allele in combination with a normal function or no function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Cells that carry the UGT1A4*1a allele may have decreased clearance of testosterone as compared to those with the *3a allele. Other genetic and clinical factors may also influence clearance of testosterone.","phenotypeText":["decreased clearance of testosterone"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6B allele or one copy of the *6B allele in combination with one copy of the *5A, *5B, *6A, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.","phenotypeText":["decreased clearance of memantine"]},{"genotypeAnnotationText":"Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["decreased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have increased risk for side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of sacubitril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.","phenotypeText":["increased metabolism of sacubitril"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C19 *17\/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the CYP2D6*62 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*62 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs193922764 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*38 genotype (assigned as a poor metabolizer phenotype) may have a decreased CYP2D6 enzyme activity as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence CYP2D6 enzyme activity.","phenotypeText":["decreased CYP2D6 enzyme activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.","phenotypeText":["rapid nicotine metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity","increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.","phenotypeText":["reduced risk of adverse effects"]},{"genotypeAnnotationText":"Patients with the rs61742245 AA genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["lower dose-adjusted trough concentrations of cyclosporine and greater likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["lower risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*43 allele or one copy of the *43 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have decreased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response","decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*40:01 allele have a decreased, but not absent, risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*40:01 alleles or negative for the HLA-B*40:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs1800629 AG genotype may have increased response to etanercept as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced developing myalgia"]},{"genotypeAnnotationText":"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the AG and GG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["decreased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Patients with the TT genotype may also have increased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the CC genotype.Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CC genotype may have lower concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs11198893 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have higher weight gain when treated with antipsychotics as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["higher weight gain"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two functional CYP2C19 alleles (*1\/*1) may have increased metabolism of mephenytoin compared to patients with *2\/*2, *2\/*3, *3\/*3, *2\/5, *2\/*6 and *2\/*7 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["increased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with the rs2330951 AC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with genotype TT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs145837941 GG genotype and postoperative pain may have increased consumption of fentanyl as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fentanyl dose.","phenotypeText":["increased consumption of fentanyl"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have increased dose requirements of sufentanil as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1127354 CC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.","phenotypeText":["decreased likelihood of rejection"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for Adenoma"]},{"genotypeAnnotationText":"Patients with the rs558354142 AG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs374527058 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":["increased likelihood of CNS depression in breast-feeding infants"]},{"genotypeAnnotationText":"Patients with the rs2023239 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["more time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":["increased CD4-cell count","increased virologic response","increased risk for toxicity-related failure","decreased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.","phenotypeText":["increased risk of acute cellular rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["decreased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["increased reduction in total cholesterol or LDL cholesterol levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased clearance of imatinib, as well as an increased response and an increased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased clearance of imatinib","increased response","increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the TT genotype may have increased stress-induced alcohol cravings as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["increased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["longer hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AA genotype may be more likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["more likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased oxycodone dose requirements as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.","phenotypeText":["decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients with the AA genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased response to nicotine"]},{"genotypeAnnotationText":"Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["higher plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype and decreased response compared to the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.","phenotypeText":["improved response and decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["increased risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["worse response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GT genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["increased response to gefitinib"]},{"genotypeAnnotationText":"Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["lesser response"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer who are treated with antineoplastic agents may be associated with improved survival as compared to women with the AG and GG genotypes. Other clinical and genetic factors may also influence survival rates in women with breast cancer.","phenotypeText":["improved survival"]},{"genotypeAnnotationText":"Patients with the rs2359612 AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*48:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-B*48:01 alleles or negative for the HLA-B*48:01 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["decreased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["increased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["risk of death"]},{"genotypeAnnotationText":"People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased weight gain and increased risk of edema when treated with rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the toxicity to rosiglitazone.","phenotypeText":["increased weight gain and increased risk of edema"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CC genotype may be at a decreased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.","phenotypeText":["decreased risk of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs121909013 AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*19 allele or one copy of the *19 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"The CYP2C19*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*9 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased time to relapse"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype and blood cancers may have an increased risk for drug toxicity when treated with methotrexate as compared to patients with the 2R\/3R or 3R\/3R genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have poorer response to beta-blockers as compared to patients with the AA genotype. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.","phenotypeText":["poorer response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*4a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*36 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*36 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs778019189 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["increased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the rs10799590 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as E2\/E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 TT genotype may have increased risk of adverse events when treated with mercaptopurine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs10485058 AA genotype who are opioid-dependent may have an increased response to treatment with methadone as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":["increased response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with gemcitabine and platinum compounds may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have a decreased subjective response to oxycodone as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["decreased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype who are heroin dependent may require an increased dose of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the TT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["longer time to failure"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype may have an increased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CC or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have decreased response when treated with enalapril as compared to patients with the del\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplant and receive a liver with the CG genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["higher risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects","decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the AC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with escitalopram may have an increased chance of response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased chance of response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["decreased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the HTTLPR short form (S allele)\/L allele and HTTLPR S allele\/S allele genotypes. Other genetic and clinical factors may also influence risk for depression in patients receiving peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk for depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased risk for Tobacco Use Disorder"]},{"genotypeAnnotationText":"Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased inhibition of FXIII activation"]},{"genotypeAnnotationText":"Patients with the CG genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the GG genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients who have genotype TT or CT. Other Genetic and clinical factors may also influence the response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"The A allele of rs1801268 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk for toxicity when treated with antineoplastic agents as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance","decreased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 CG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.","phenotypeText":["greater cravings for nicotine"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.","phenotypeText":["decreased etravirine clearance"]},{"genotypeAnnotationText":"Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.","phenotypeText":["increased risk of hand-foot syndrome","not associated with decreased clinical outcome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["decreased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with another decreased function allele may have decreased irinotecan dose requirements as compared to patients carrying a normal function allele in combination with a decreased function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan dose requirements.","phenotypeText":["decreased irinotecan dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":["decreased risk of adverse drug reactions","increased exposure to active mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.","phenotypeText":["smaller reduction in HDL-C"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with another no function allele may have increased response to sulfonylureas (reduced risk of sulfonylureas treatment failure and better HbA1c response) as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs628031 AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Purified CDA proteins with the AA genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.","phenotypeText":["greater reduction in LDL-C"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/A- 202A_376G haplotype (homozygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["may not respond to treatment for methemoglobinemia","increased risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Patients with the rs139945292 CT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.","phenotypeText":["decreased blood pressure reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the rs397508328 AG genotype (one copy of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype, or decreased as compared to the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["increased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.","phenotypeText":["risk of thiopurine-induced Leukopenia"]},{"genotypeAnnotationText":"Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["less likely to develop hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with CYP1A1*1\/*1 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1\/*2A in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["lower granisetron clearance and increased exposure"]},{"genotypeAnnotationText":"CYP2D6 *1\/*10 is associated with decreased inhibition of CYP2D6 when exposed to berberine and coptisine and increased exposure to dextromethorphan as compared to the *1\/*1 genotype. Other clinical and genetic factors may also influence inhibition of CYP2D6 and exposure to dextromethorphan.","phenotypeText":["decreased inhibition of CYP2D6","increased exposure to dextromethorphan"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*20 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.","phenotypeText":["decreased risk of hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with GSTT1 null\/null genotype may have increased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype non-null\/non-null + non-null\/null. The risk of imatinib failure was increased further if GSTT1del was accompanied by GSTM1 del. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["increased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["increased severity of thrombocytopenia and decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Female children with lead poisoning and the A- 202A_376G\/A- 202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with dimercaprol may have an increased risk of hemolysis as compared to children with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*17 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38 allele have an increased likelihood of being a non-responder to therapy when treated with pegylated interferon and ribavirin, as compared to patients with no HLA-B*38 alleles or negative for the HLA-B*38 test. Other genetic and clinical factors may also influence a patient's response to pegylated interferon and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*38 allele. This clinical annotation appears on the HLA-B*38:01 allele page because this was the first *38 allele discovered.","phenotypeText":["increased likelihood of being a non-responder to therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.","phenotypeText":["decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid"]},{"genotypeAnnotationText":"Adolescents with the AA genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["increased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and hypertension may have increased response to metoprolol compared to patients with genotype CC. Other genetic and clinical factors may influence the patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs2952768 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AG and GG genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with methylene blue 1) may not respond to treatment for methemoglobinemia 2) may have an increased risk of drug-induced hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["may not respond to treatment for methemoglobinemia","increased risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion in the treatment of major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*31 allele has been assigned as a no function allele by CPIC. Patients carrying the *31 allele in combination with a decreased, normal or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *31 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *31 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol","similar metabolism of metoprolol","increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to respond to methotrexate"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele was only defined as R388H not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the rs1801252 GG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["increased response to carvedilol"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 AG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["less likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with CYP2C19*1\/*2 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia, and neuropathy)"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["greater aromatase inhibition"]},{"genotypeAnnotationText":"Patients with the rs2307116 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.","phenotypeText":["increased risk of developing endometrial cancer following tamoxifen treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs4917639 CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the *1\/*1 may have increased plasma concentrations of montelukast as compared to patients with the *3 allele, or decreased concentration of the *4 allele. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.","phenotypeText":["decreased imatinib clearance"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["increased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["worse response to fluoxetine therapy"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased HDL-cholesterol)","reduced response (lower increases in HDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have poorer blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CT or TT genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. Other genetic and clinical factors may also influence aripiprazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele or a normal function allele may require a decreased dose of clobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["decreased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*3C diplotype may have increased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*1 diplotype. It should be noted that the study only genotyped participants for the *3 haplotype and not *3C specifically. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["increased plasma concentrations of 6-thioguanine during thiopurine treatment"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["decreased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["increased risk of cardiovascular events","decreased collagen induced platelet aggregation"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 TT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response to rosuvastatin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["smaller reductions in diastolic blood pressure and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2298383 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":["increased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs118192168 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for mucositis when treated with methotrexate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["decreased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased risk for treatment related side effects or intolerance"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.","phenotypeText":["increased risk for developing prostate cancer"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["increased response to triple therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["decreased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased progression free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the rs193922762 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["increased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494C allele. However, conflicting evidence has been reported. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 AT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with gemcitabine may have an increased risk for toxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["decreased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.","phenotypeText":["decreased response to sibutramine in terms of weight loss"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs12208357 CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["lower plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.","phenotypeText":["decreased trough concentrations of sirolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.","phenotypeText":["higher likelihood of side effects","reduced likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs11322783 TT\/TT genotype and chronic hepatitis C may have increased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 TT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["decreased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.","phenotypeText":["less inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*28 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*4 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["decreased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the rs678849 CC genotype may have an increased response to disulfiram as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to disulfiram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased fentanyl dosage requirements as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements.","phenotypeText":["decreased fentanyl dosage requirements"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1\/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 GG genotype and risk of adverse events when treated with oxycodone"]},{"genotypeAnnotationText":"Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["decreased risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Male children with the B (reference) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients who receive a kidney with the GG genotype may have increased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AA or AG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["increased estimated glomerular filtration rate (eGFR)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of carbocisteine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["increased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the rs200554095 TT genotype may have increased metabolism of nicotine as compared to patients with the AA or AT genotypes. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs12885713 CC genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["decreased response to cyclosporine"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 TT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["higher LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the CT or CC genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele have an increased risk for maculopapular eruption when treated with carbamazepine as compared to patients with no HLA-DRB1*03:01 alleles or negative for the HLA-DRB1*03:01 test. Other genetic and clinical factors may also influence a patient's risk of maculopapular eruption when treated with carbamazepine.","phenotypeText":["increased risk for maculopapular eruption when treated with carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs267606619 C allele (also known as the 1494C allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with micronomicin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with micronomicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the AA genotype, may have elevated concentrations of lumefantrine as compared to patients with the A\/del or del\/del genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Pre-menopausal women with the AA genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased likelihood of Tobacco Use Disorder","decreased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to corticosteroids compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with methotrexate may have an increased risk of leukopenia and neutropenia as compared to the AA genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.","phenotypeText":["increased risk of leukopenia and neutropenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922816 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)7\/(T)7 genotype may have decreased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)8 or (T)8\/(T)8 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased risk of leukopenia","decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.","phenotypeText":["decreased risk of adverse effects"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with any *5, *6 or *7 suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.","phenotypeText":["decreased risk of addiction to heroin","increased risk of heroin addiction"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with metformin may have decreased bioavailability of metformin as compared to patients with the CC or CT genotypes, however the opposite is reported in one study, and no association was reported in two studies . Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["decreased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.","phenotypeText":["decreased clearance and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk of leukopenia"]},{"genotypeAnnotationText":"Patients with advanced non-small-cell lung cancer and who do not carry an activating somatic EGFR mutation, for example the TT genotype at rs121434568 (also known as L858R), may have a decreased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who have an activating EGFR mutation, for example the GG or GT genotypes at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib.","phenotypeText":["decreased response to gefitinib"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:01 allele may have an decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs121908757 CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response to candesartan"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.","phenotypeText":["decreased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AG or GG genotype. However, a different study found that the AA genotype was associated with poorer response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have more blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["more blood pressure reduction"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of amitriptyline as compared to patients with a combination of alleles that result in intermediate or poor metabolizer phenotype. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with a combination of alleles that result in ultrarapid metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["decreased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 AG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium or valproic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response to pravastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of nevirapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.","phenotypeText":["decreased concentrations of nevirapine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.","phenotypeText":["decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*30 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele when assayed with omeprazole. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["decreased risk of becoming agitated"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in addition to an increased function allele may have a similar analgesic response when treated with hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect response to hydrocodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs4752292 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and soft tissue sarcoma may have a longer progression-free survival time when treated with doxorubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a shorter median survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival.","phenotypeText":["shorter median survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *1xN allele in combination with a normal or increased function allele may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased or no function allele may also have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased or no function allele may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":["increased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["increased likelihood of disease recurrence"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":["decreased clearance"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"The AG genotype was not studied in association with affinity to losartan.","phenotypeText":["affinity to losartan"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased response to tocilizumab as compared to patients with the AC or CC genotypes. Note that an increased response was only seen with one metric at one timepoint from the three analyzed in the study. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["greater methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["increased risk of fatigue"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. Patietns carrying the *1 allele in combination with a no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence","decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower maximal platelet aggregation as compared to patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["lower maximal platelet aggregation"]},{"genotypeAnnotationText":"Patients with the rs2253201 AG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["increased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.","phenotypeText":["higher dose-adjusted trough concentrations of cyclosporine and lower likelihood of experiencing biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1\/*1 diplotype and increased clearance of ketamine as compared to patients with the *6\/*6 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["decreased clearance of ketamine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["greater reduction in HDL-C"]},{"genotypeAnnotationText":"Patients with the CYP2C19*22 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*22 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for the substrate mephenytoin was reported in one study, while another study reported reduced protein expression of the *22 allele compared to the WT protein. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity of CYP2C19"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.","phenotypeText":["decreased risk for rapid rise of motor side effects at the beginning of the treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.","phenotypeText":["increased abstinence"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of phenytoin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["decreased risk of developing cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the AA genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.","phenotypeText":["decreased levels of the active metabolite"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele may have increased likelihood of neutropenia when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased likelihood of neutropenia compared to patients with two decreased function alleles. Other genetic and clinical factors may also influence irinotecan related neutropenia.","phenotypeText":["increased likelihood of neutropenia"]},{"genotypeAnnotationText":"Patients with hypertension and the GT genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the TT genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the genotype AA may have increased response to aripiprazole in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a no function allele may have increased carvedilol dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a increased or decreased function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect carvedilol dose requirements.","phenotypeText":["increased carvedilol dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus or sirolimus as compared to patients with the AA or AC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.","phenotypeText":["increased metabolism of temsirolimus or sirolimus"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*42 allele or one copy of the *42 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*14:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*14:01 alleles or negative for the HLA-DRB1*14:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"The CYP2C9*42 allele has been assigned as a no function allele by CPIC. Patients carrying the *42 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have reduced alfentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["reduced alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.","phenotypeText":["longer hospital stay due to respiratory depression"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["decreased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the non-null\/ non-null genotype (has two copies of the GSTM1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.","phenotypeText":["increased risk for drug hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["decreased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["decreased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*8 genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs2236225 AG genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*10:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CYP2D6*55 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*55 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs193922809 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs4633 TT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of amlodipine as compared to patients carrying at least one copy of the *3, *6 or *7 alleles. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["increased metabolism of amlodipine"]},{"genotypeAnnotationText":"Women with poor metabolizer genotypes, such as *2\/*3, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.","phenotypeText":["decreased anxiety"]},{"genotypeAnnotationText":"Adolescents with the AG genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["increased nicotine cravings"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may benefit less from atorvastatin and quinapril treatment (due to less of a reduction in the fibrinolytic marker D-dimer) as compared to patients with the insert\/del or insert\/insert genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["benefit less from atorvastatin and quinapril treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may havesimilar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["decreased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the rs3781727 CC genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["increased likelihood of complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6A allele or one copy of the *6A allele in combination with one copy of the *5A, *5B, *6B, *7A, *7B, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["decreased response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["decreased retention rates"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs6973474 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs5882 AA genotype may have a decreased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 TT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have low on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["low on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508602 AG genotype (one copy of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs768416963 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.","phenotypeText":["greater methotrexate polyglutamate accumulation"]},{"genotypeAnnotationText":"Patients with the rs116855232 CC genotype may have increased dose of mercaptopurine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence mercaptopurine dose.","phenotypeText":["increased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["decreased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.","phenotypeText":["risk of death from cocaine intoxication"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["larger changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or less severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["increased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the AT genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["decreased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs115346678 AA genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased risk for smoking addiction"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with olanzapine or risperidone may have increased time until response as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["increased time until response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["higher maintenance dose"]},{"genotypeAnnotationText":"Patients with depression and the GT genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.","phenotypeText":["greater reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["decreased risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*1 genotype. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["increased likelihood of adverse events","worse response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["increased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["lower homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no evidence of a difference in remifentanil requirements between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["no difference in remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased overall survival period"]},{"genotypeAnnotationText":"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["more likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the rs7557402 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1\/*2 or *1\/*3A or *1\/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["decreased risk of severe rejection"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["complete response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["more likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["decreased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["lesser reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1\/*3B or *1\/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6 *1\/*1 diplotype may have increased clearance of fentanyl as compared to patients with the *9 or *29 alleles. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["increased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution \"the relevance of these data is uncertain, given the low number of rare alleles\". Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may experience a greater weight gain when treated with clozapine or olanzapine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence","decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["decreased concentrations of atazanavir"]},{"genotypeAnnotationText":"Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["smaller increases in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs2236857 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.","phenotypeText":["decreased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs118192172 CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["decreased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["increased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*55:01 allele may have an increased risk of hypersensitivity when treated with penicillin as compared to patients with no HLA-B*55:01 alleles or negative for the HLA-B*55:01 test. Other genetic and clinical factors may also influence risk of hypersensitivity to penicillin.","phenotypeText":["increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of clomipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of clomipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of clomipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*01:02 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-C*01:02 alleles or negative for the HLA-C*01:02 test. Other genetic and clinical factors may also influence a patient's risk of methazolamide-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better event-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better event-free survival"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:02 allele have an increased risk of drug-induced liver injury (DILI) when taking minocycline as compared to patients with no HLA-B*35:02 alleles or negative for the HLA-B*35:05 test. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury when taking minocycline.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["less likely to have positive erectile response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CC genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with metastatic colorectal cancer and the rs11574077 CC genotype may have decreased metabolism of irinotecan as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.","phenotypeText":["decreased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":["decreased risk of adverse drug events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association with response to methotrexate"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a decreased function allele with an activity value of 0.25 may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.","phenotypeText":["lower plasma total homocysteine concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2740574 CT genotype (CYP3A4*1B allele) may have decreased clearance of fentanyl as compared to patients with the rs2740574 TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with the CC genotype and neoplasms who are treated with methotrexate may have a decreased clearance of methotrexate as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*33 allele or one copy of the *33 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype may have increased metabolism of nicotine and cotinine as compared to patients with the *1\/*1 genotype. However, this has been partially contradicted by another study. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine and cotinine"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs193922748 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins\/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["more likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased time to achieve therapeutic international normalized ratio"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["decreased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have decreased clearance of tamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with tamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["decreased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.","phenotypeText":["higher blood trough concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the rs193922843 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs3762555 CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of cocaine dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of tacrolimus as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs397508328 AA genotype (do not have a copy of the CFTR M1V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs199515342 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the rs2031920 CC genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs118192176 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"The TPMT*3A allele has been assigned as a no function allele by CPIC. Patients carrying the *3A allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs113100019 TT genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the del\/del genotype, may have lower concentrations of lumefantrine as compared to patients with the A\/del or AA genotypes. There is no association with response. Other clinical andgenetic factors may also influence concentrations of lumefantrine in pregnant infected with malaria.","phenotypeText":["lower concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5D allele or one copy of the *5D allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.","phenotypeText":["decreased likelihood of event-free survival"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole","similar metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:27 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*15:27 alleles or negative for the HLA-B*15:27 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*87 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele was only defined as AV5 not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["decreased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["decreased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the rs758649719 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.","phenotypeText":["better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Infants with the rs1799971 AG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with breast cancer and the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the del\/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"Healthy individuals with the *1\/*1 genotype may not have decreased concentrations of carisoprodol as compared to those with the *1\/*2 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.","phenotypeText":["not have decreased concentrations of carisoprodol"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*1 genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *1\/*3A or *3A\/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["decreased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1C allele or one copy of the *1C allele in combination with one copy of the *1A allele may have an increased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1A allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:27 allele may have an increased risk of cutaneous adverse drug reactions when treated with clindamycin as compared to patients with no HLA-B*15:27 alleles or negative for the HLA-B*15:27 test.","phenotypeText":["increased risk of cutaneous adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the del\/del genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or A\/del genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*1 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*1 allele and response to citalopram"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation with the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["less likely to achieve a complete response","less likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission or less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the CYP2C19*6 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*6 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"In human liver microsomes, the TT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients carrying one copy of the 10-repeat allele and one copy of the 9-repeat allele may report more drinking days as compared to patients carrying two copies of the 10-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["more drinking days"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"No information about the AG genotype is reported in the study. However, patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["increased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs28399499 CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the CC (POR *1\/*1) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have decreased metabolism of tacrolimus as compared to patients with the CT and TT (*1\/*28 and *28\/*28) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs34545984 TT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the rs5186 AA genotype may have a decreased response to irbesartan as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["decreased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the HLA-B*15:02 allele and risk of maculopapular exanthema when treated with oxcarbazepine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of maculopapular exanthema when treated with oxcarbazepine.","phenotypeText":["no significant association with risk of maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with Ace Inhibitors may have an increased risk for major cardiovascular events or mortality as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors.","phenotypeText":["increased risk for major cardiovascular events or mortality"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the AA or AC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with TT genotype and essential hypertension may have decreased response to telmisartan compared to patients with genotype CC and CT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased analgesic response to sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["not found to have different response to ustekinumab"]},{"genotypeAnnotationText":"Cells with the CC genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["increased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.","phenotypeText":["increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with depressive disorder and the ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["worse response to sertraline"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.","phenotypeText":["decreased rifampicin exposure"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["increased risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with depressive disorder and the del\/ATTTGTTCATGCCT genotype may have a worse response to sertraline as compared to fluoxetine. Other clinical and genetic factors may also influence response to sertraline in people with depressive disorder.","phenotypeText":["worse response to sertraline"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased plasma concentrations of alfentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*38:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers, but may not be associated with risk of exanthema.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have increased survival times when treated with oxaliplatin-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["increased survival times"]},{"genotypeAnnotationText":"Patients carrying two copies of the 10-repeat allele may report less severe negative effects of alcohol as compared to patients carrying one or two copies of the 9-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["less severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.","phenotypeText":["decreased risk of developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure)"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *1\/*1 diplotype may have decreased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*22 or *22\/*22 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["decreased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs77932196 AA genotype (two copies of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.","phenotypeText":["decreased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 alleles. The CYP2C19*1 allele was found to have an increased clearance of mephenytoin and an increased catalytic activity as compared to CYP2C19*5, *6, *8, *9, *10, *14, *16, *19, *22, *23, *24, *25, *26 during in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["increased enzyme activity of CYP2C19","increased clearance of mephenytoin","increased catalytic activity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["decreased risk of Cough"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele, a decreased function allele or a normal function allele may have decreased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tropisetron as compared to patients with other alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity score of 3 or greater may have increased metabolism of tropisetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for tropisetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tropisetron and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tropisetron metabolism.","phenotypeText":["decreased metabolism of tropisetron","similar metabolism of tropisetron","increased metabolism of tropisetron"]},{"genotypeAnnotationText":"Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["lower plasma drug levels"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs118192176 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with another normal function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele or a donor with two no function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*1 allele in combination with a no function allele may require increased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two no function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for rash"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["shorter overall survival time"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*1 genotype who are treated with tamoxifen may have increased metabolism of tamoxifen, but a poorer response to the drug as compared to those with the *1\/*2 or *2\/*2 genotype. Women with breast cancer and the *1\/*1 genotype may have an improved response to the drug as compared to those with the *1\/*17 or *17\/*17 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*1 genotype as compared to those with the *2\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["increased metabolism of tamoxifen","poorer response to the drug","improved response to the drug"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 del\/del genotype may have a decreased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs193922878 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *2 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.","phenotypeText":["decreased risk of developing cardiomyopathies"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased analgesic response to alfentanil as compared to patients with the AG or GG genotypes. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the rs28399499 TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["decreased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet inhibition and better response"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["reduced severity of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["longer overall survival"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have increased metabolism of nifedipine as compared to patients with two copies of the *17 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and nifedipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nifedipine metabolism.","phenotypeText":["increased metabolism of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs111888148 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of warfarin as compared to patients with at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the rs9344 AA genotype may be at a decreased but not absent risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and a GSTT1 non-null genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with a null genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with depression and the GG genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients with two copies of the *1 allele may have increased metabolism of metronidazole as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *9 or *17 alleles. However, one study found failed to find this association for the *17 allele. Other genetic and clinical factors may also affect metronidazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and metronidazole and does not include evidence on clinical outcomes.","phenotypeText":["increased metabolism of metronidazole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased heart rate when treated with Beta Blocking Agents as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AA genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1042713 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["increased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased pain reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype, or increased clearance as compared to those with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.","phenotypeText":["decreased clearance of sulfinpyrazone"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["increasing creatinine levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.","phenotypeText":["increased metabolism of olanzapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["decreased clearance of 2',2'- difluorodeoxyuridine (dFdU)"]},{"genotypeAnnotationText":"Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response or better response in LDL-cholesterol"]},{"genotypeAnnotationText":"Female patients with the TT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.","phenotypeText":["less likely to experience a loss of libido"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs11615 GG genotype may have an increased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["increased risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["decreased clearance of voriconazole","increased clearance of voriconazole"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have lesser aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["lesser aromatase inhibition"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon\/RBV therapy.","phenotypeText":["better rapid virological response and sustained virological response"]},{"genotypeAnnotationText":"No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["associated with overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.","phenotypeText":["higher dose requirement"]},{"genotypeAnnotationText":"Patients with the rs708272 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with CYP2C9 *1\/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1\/*3 or CYP2C9 *1\/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.","phenotypeText":["increased clearance and decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs10485058 GG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":["decreased response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of atomoxetine as compared to patients with two no or decreased function alleles. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of atomoxetine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs4149056 CT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["no association with LDL-lowering response"]},{"genotypeAnnotationText":"Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased beta cell function"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to omeprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to omeprazole.","phenotypeText":["reduced response to omeprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.","phenotypeText":["increased likelihood of ototoxicity"]},{"genotypeAnnotationText":"The CYP2C19*10 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*10 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the rs4633 CC genotype may have a decreased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs1051266 CC genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*52 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*52 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of rosuvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have decreased metabolism of venlafaxine. This annotation only covers the pharmacokinetic relationship between CYP2C19 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less severe nicotine dependence as compared to patients with the CG genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.","phenotypeText":["better response to inhaled glucocorticoids"]},{"genotypeAnnotationText":"Individuals with the *2\/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"Male patients with the G genotype may have a better response to risperidone as compared to patients with the A genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype AA or AT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin"]},{"genotypeAnnotationText":"Patients with the rs368234815 TT\/TT genotype and chronic hepatitis C may have increased response to sofosbuvir and ribavirin as compared to patients with the TT\/G or G\/G genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["decreased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["increased risk of developing drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 CTT\/CTT genotype (no copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Indication of ivacaftor in cystic fibrosis patients with this genotype is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["increased likelihood of adverse events","worse response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the rs10248420 AA genotype may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["decreased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased severity of dyspepsia when treated with ketoprofen as compared to patients carrying a decreased function allele in combination with a normal function allele. Other genetic and clinical factors may also influence the severity of dyspepsia.","phenotypeText":["decreased severity of dyspepsia"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1544105 CC genotype may have decreased concentrations of methotrexate as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["lower platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["increased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs1544410 TT genotype who are treated with alendronate may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.","phenotypeText":["less improvement in bone mineral density"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"The TT genotype may be associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the TT genotype and depressive disorder may have an increased response to fluvoxamine compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2359612 AG genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response (a higher reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may have a decreased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["decreased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.","phenotypeText":["risk for GI toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","similar metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["risk of craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.","phenotypeText":["increased risk of oedema"]},{"genotypeAnnotationText":"Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"The TPMT*9 allele is assigned as a no function allele by DPWG. Patients with the *9 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that CPIC assigned TPMT*9 as an uncertain function allele. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["smaller reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:27 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["increased risk for suicidal ideation"]},{"genotypeAnnotationText":"Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["less likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.","phenotypeText":["decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 CC genotype may have an increased response to bucindolol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["increased response to bucindolol"]},{"genotypeAnnotationText":"Patients with the rs193922772 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity","increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/non-null or non-null\/non-null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC . Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.","phenotypeText":["decreased QTc interval"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/del genotype may not may not respond to treatment with cavosonstat. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["may not respond to treatment with cavosonstat"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["reduced risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["increased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and one or two copies of the HLA-DRB1*04 allele may have a better response to interferon beta-1a treatment as compared to patients with no HLA-DRB1*04 alleles or negative for the HLA-DRB1*04 test. Other genetic and clinical factors may also influence a patient's response to interferon beta-1a treatment.","phenotypeText":["better response to interferon beta-1a treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Individuals with the TC\/TC genotype may have decreased clearance of olanzapine as compared to individuals with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*24 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1806201 AG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"People with intermediate metabolizer genotypes (e.g. *1\/*2) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*13 allele or one copy of the *13 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the TT genotype but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.","phenotypeText":["decreased steady state levels of KDR, possibly leading to decreased metabolism and increased response to pazopanib"]},{"genotypeAnnotationText":"Patients with the rs628031 AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the rs121918593 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment with increased reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have an increased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["increased risk of anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*08:01 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*08:01 alleles or negative for the HLA-C*08:01 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CT or TT genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 AG genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and Alzheimer's disease may be more likely to respond to treatment with cholinesterase inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival","decreased likelihood of pneumonitis"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 AA genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*3A genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *3A\/*3A genotype, and increased risk of ototoxicity as compared to patients with the *1\/*1 genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.","phenotypeText":["decreased risk of ototoxicity","increased risk of ototoxicity"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs717620 CT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs3745274 TT genotype may have an increased exposure to tramadol as compared to patients with the GG or GT genotypes. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs371258350 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["more sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *4\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["increased clearance of imatinib","decreased response","decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the del\/del (two copies of the CFTR F508del variant) genotype and cystic fibrosis may have increased response when treated with ivacaftor\/tezacaftor combination as compared to patients with the CTT\/CTT genotype. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["increased chance of eradication failure"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 AA genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["decreased risk of experiencing nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with corticosteroids may have an increased response to corticosteroids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased response to corticosteroids"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.","phenotypeText":["decreased risk of triglyceride elevation"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs28933397 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1611114 CC genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["risk of experiencing memory impairment"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["increased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects","sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Caucasian patients with the TT genotype may have a decreased risk of developing opioid dependence as compared to Caucasian patients with the CC or CT genotypes. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have reduced clearance of efavirenz as compared to patients with the AG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.","phenotypeText":["reduced clearance of efavirenz"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with the AA genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["increased risk of addiction"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["increased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with the rs4035887 GG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association between the rs1799971 AA genotype and likelihood of experiencing adverse events when treated with sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are addicted to methamphetamines may have an increased risk for methamphetamine-induced psychosis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["increased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs10929302 GG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype may have a shorter overall and event-free survival time as compared to patients with the AG or GG genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*30 allele or one copy of the *30 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an unknown function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response","longer overall survival time"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased risk of leukopenia","decreased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased likelihood of drug toxicity","decreased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["increased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype.","phenotypeText":["decreased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.","phenotypeText":["decreased concentrations of cotinine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["increased doses of anti-Parkinsonian drugs","increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the rs11615 GG genotype may have an increased response to cisplatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as APOE E2\/E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased reduction in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two alleles from the C2 group of HLA-C alleles (i.e. *02, *04, *05, *06, *15 or *17) may have a decreased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients as compared to patients with one or more HLA-C alleles from the C1 group (i.e. *01, *03, *07, *08, *12, *14 or *16).","phenotypeText":["decreased response to peginterferon alfa-2b and ribavirin therapy in hepatitis C patients"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing heroin or opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time and progression-free survival time, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response, shorter overall survival time, shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*5 allele in combination with a normal function allele (e.g. *1\/*5) or another decreased function allele (e.g.*5\/*8) or a no function allele (e.g. *5\/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["decreased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myeloid leukemia may have increased clearance of imatinib, as well as increased event-free survival time, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["increased clearance of imatinib and increased event-free survival time"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*23 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs7967354 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["require increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).","phenotypeText":["decreased clearance of sulfasalazine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Myeloid Leukemia who are treated with cytarabine may have an increased survival time and a decreased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased survival time","decreased risk of death"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["increased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.","phenotypeText":["higher plasma drug levels"]},{"genotypeAnnotationText":"Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["decreased clearance of doxorubicin","increased exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["decreased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with genotypes AA may have decreased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["decreased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the rs10752271 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.","phenotypeText":["increased plasma concentration of atorvastatin"]},{"genotypeAnnotationText":"Patients with the rs6295 GG genotype may have increased response when treated with paroxetine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype who also have rs45445694 genotype 2R\/2R and Colorectal Cancer who are treated with fluorouracil may have a decreased response as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele or a normal function allele may have a decreased analgesic response to methadone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.","phenotypeText":["decreased risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the A\/del genotype who are treated with clopidogrel may have impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["impaired catalytic activity"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the CT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["decreased antidepressant response"]},{"genotypeAnnotationText":"Patients with the rs183701923 TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with genotype GG and epilepsy may have an increased risk of drug toxicity when taking valproic acid as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the del\/T genotype may have decreased metabolism of mycophenolic acid as compared to patients with the TT genotypes but increased metabolism of mycophenolic acid as compared to patients with the del\/del genotype. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["decreased metabolism of mycophenolic acid","increased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response when treated with lisinopril as compared to patients with the del\/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence response to lisinopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CT genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the TT genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.","phenotypeText":["decreased beta cell function"]},{"genotypeAnnotationText":"Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs570122671 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with CT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs77409459 TT genotype (two copies of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and choroidal neovascularization may have a poorer response to anti-VEGF treatment, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["poorer response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased response to rituximab as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["increased response to rituximab"]},{"genotypeAnnotationText":"Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.","phenotypeText":["decreased risk of becoming agitated"]},{"genotypeAnnotationText":"Patients with the CYP2C19*26 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*26 allele was found to have a decreased clearance of mephenytoin as compared to *1 during in-vitro characterizations. 42% of the clearance ratio of *1 for mephenytoin was reported in one study. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.","phenotypeText":["increased likelihood of hemorrhage"]},{"genotypeAnnotationText":"Patients with the GG genotype may have improved overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["improved overall survival"]},{"genotypeAnnotationText":"Patients with the rs6269 AG genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the C genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs2231142 GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.","phenotypeText":["less of a decrease in bone mineral density"]},{"genotypeAnnotationText":"Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives.","phenotypeText":["increased blood pressure","risk for hypertension","slower control of blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.","phenotypeText":["smaller decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs718656 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["decreased rapid response"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["increased risk for virological failure"]},{"genotypeAnnotationText":"Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of severe ototoxicity"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with escitalopram may have a decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP2A6*23 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*7 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["decreased risk of Esophagitis"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs7439366 CT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.","phenotypeText":["no significant association with valproic acid concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotype may have an increased likelihood of hypertension when taking sunitinib as compared to patients with the AA and AT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["increased likelihood of hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["decreased risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["increased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["increased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["decreased response to treatment with interferon-beta"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the *1\/*5 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1 genotype and decreased exposure as compared to the *4\/*4 genotype. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the AG genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"No patients with the *22\/*22 genotype were available for analysis, but patients with the CYP3A4*1\/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["increased concentrations of exemestane"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["decreased risk of cough"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 1 or 2 decreased function alleles. Patients carrying the *1 allele in combination with a decreased function allele may have increased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 2 normal function alleles. Other genetic and clinical factors may also influence sorafenib-induced hyperbilirubinemia.","phenotypeText":["decreased likelihood of hyperbilirubinemia","increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["decreased risk for myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the *3 allele may have decreased plasma concentration and increased clearance when exposed to pioglitazone as compared to patients with *1\/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone.","phenotypeText":["decreased plasma concentration and increased clearance"]},{"genotypeAnnotationText":"Patients with the rs140039091 CG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CT genotype may have a better response to capecitabine or fluorouracil as compared to patients with the CC genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["better response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel.","phenotypeText":["increased risk of cardiovascular events","decreased collagen induced platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*29 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*9 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*9 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients who are smokers and have the AA genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.","phenotypeText":["decreased lung function"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer survival times"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*16 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the non-null\/ non-null genotype (has two copies of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1544410 CC genotype who are treated with alendronate may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.","phenotypeText":["greater improvement in bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AC genotypes. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs34911792 GT genotype (one copy of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased severity of alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["decreased severity of alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 GG genotype may be at a decreased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CCGG\/del genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs113100019 GG genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["decreased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["better response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing neutropenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs118192163 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 CG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.","phenotypeText":["less likely to enter remission"]},{"genotypeAnnotationText":"Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*1 genotype ((TA)6\/(TA)6) and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the*28\/*28 genotype ((TA)7\/(TA)7) . Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*13 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the TT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a greater chance of achieving complete remission, and a decreased risk of experiencing drug toxicities, as compared to patients with the non-null\/null or null\/null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["greater chance of achieving complete remission","decreased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the rs28933397 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the CYP2D6*75 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*75 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs6269 AA genotype may have a decreased analgesic response to morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"People with normal metabolizer genotypes (e.g. *1\/*1) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AC genotype may have a decreased response to metformin as compared to patients with the CC genotypes and an increased response as compared to patients with the AA genotype. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["decreased response to metformin","increased response to metformin"]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have decreased metabolism of N-desmethylclobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.","phenotypeText":["increased emergency department utilization"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia or psychotic disorder may have increased metabolism of antiepileptics compared to patients with the CC or CT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["increased metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["likelihood of toxicity"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*6 allele in combination with a normal function allele (e.g. *1\/*6) or a decreased function allele (e.g. *5\/*6) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require an increased dose of phenprocoumon as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["require an increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["decreased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["greater response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["increased doses of anti-Parkinsonian drugs","increased risk of mortality"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine.","phenotypeText":["increased risk of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["increased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs150212784 TT genotype (do not have a copy of the CFTR F1052V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the CC genotype or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to citalopram as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype and depression who are treated with paroxetine may have a better response to treatment as compared to other genotypes. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alcoholism may have decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a dcreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or AA genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype who are receiving methadone maintenance therapy may have increased clearance of methadone, leading to decreased plasma concentration of methadone as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["increased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.","phenotypeText":["increased chance of severe hypersensitivity to carbamazepine treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["risk for nausea","decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs193922803 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*17 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence","lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the rs1560022535 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Patients with the A\/del genotype and hypertension may have a decreased risk of stroke when treated with lisinopril as compared to patients with the AA genotype who are treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["decreased risk of stroke"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with methotrexate may have increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for toxicity","increased plasma level"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV infection who are treated with efavirenz may have an increased risk of sadness as a side effect as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.","phenotypeText":["lower risk of dependence on methamphetamine or heroin"]},{"genotypeAnnotationText":"Patients with the rs397508288 AG genotype (one copy of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["decreased clozapine plasma concentrations and decreased risk for agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have shorter overall survival as compared to patients with the CT and TT genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.","phenotypeText":["shorter overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.","phenotypeText":["decreased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density.","phenotypeText":["smaller increases in spine bone mineral density","larger decreases in spine bone mineral density"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of atazanavir as compared to patients with the TT genotype and increased clearance as compared to patients with the CC genotype. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["decreased clearance","increased clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GTAAGTTG\/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have increased risk for gastrointestinal side effects as compared to patients with the deldel genotype or may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG\/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["increased risk of hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*13 allele in combination with a normal function allele (e.g. *1\/*13) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased but not absent risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["increased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*24:02 allele may have an increased risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS\/TEN), when treated with phenytoin as compared to patients with no HLA-A*24:02 alleles or negative for the HLA-A*24:02 test. However, this allele was seen in linkage with HLA-A*02:01. Other genetic and clinical factors may also influence a patient's risk of phenytoin-induced SJS\/TEN.","phenotypeText":["increased risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Individuals with the TCCTC\/TCCTC genotype may have increased clearance of olanzapine as compared to individuals with the TC\/TC or TC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the rs2032582 CT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["reduced response or better response to pravastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the rs6517442 CC genotype may have increased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and two copies of the CYP3A4*1 allele may have an increased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with one copy of the *1 allele in combination with one copy of the *22 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*26 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *26 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele in combination with *12A or *13A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with pravastatin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["increased chance of survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["reduced risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased response to antidepressants","decreased, but not absent, risk for suicide ideation"]},{"genotypeAnnotationText":"Colon cancer patients with AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased likelihood of discontinuation of methotrexate in people with Arthritis"]},{"genotypeAnnotationText":"Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for elevated triglycerides"]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations","achieve therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the *5\/*10 genotype may have decreased metabolism of lovastatin as compared to patients without the *5 allele, but increased metabolism of lovastatin as compared to patients with the *5\/*5 genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype but an increased risk as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["decreased risk of opioid dependence","increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a\/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["better response to treatment with interferon beta 1a\/1b"]},{"genotypeAnnotationText":"Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["decreased risk for nicotine addiction"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency) who are treated with phenazopyridine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to rabeprazole (greater % of time with intragastric pH < 4.0, and a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a normal function allele in combination with a no function allele or two no function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to rabeprazole.","phenotypeText":["decreased response to rabeprazole"]},{"genotypeAnnotationText":"Patients with the AC genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.","phenotypeText":["poorer response to glucocorticoid treatment and lower lung function"]},{"genotypeAnnotationText":"Patients with rs16969968 GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or AA genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.","phenotypeText":["increased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["increased risk for Alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["lower pain relief to opioids"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.","phenotypeText":["decreased risk of Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*3 allele or one copy of the *3 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["decreased response to treatment with docetaxel and doxorubicin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["decreased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with the rs6686529 CC genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.","phenotypeText":["increased sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of sufentanil"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluoxetine may have increased risk of sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine.","phenotypeText":["increased risk of sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash","increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.","phenotypeText":["decreased risk of in-stent restenosis"]},{"genotypeAnnotationText":"Women with the GG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and cystic fibrosis may experience a high frequency of adverse events when being treated with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["high frequency of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.","phenotypeText":["decreased likelihood of complete response"]},{"genotypeAnnotationText":"The CYP2D6*14 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the *14 allele in combination with a decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *14 allele in combination with an increased function allele may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine","increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["increased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["longer time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the rs2072671 CC genotype may have an increased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.","phenotypeText":["increased risk of experiencing nausea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*3 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["less blood pressure (BP) reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["not require a dose reduction of ribavirin"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*114 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*114 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.","phenotypeText":["increased clearance of voriconazole"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["increased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the rs1799752 del\/del genotype may have a decreased response when treated with captopril as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The rs267606618 C allele (also known as the 1095C allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Hypertensive patients with the rs1799752 ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have an increased response to irbesartan as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del or del\/del genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have a decreased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"The TPMT*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["decreased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["decreased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of oseltamivir compared to patients with the TT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.","phenotypeText":["increased concentrations of oseltamivir"]},{"genotypeAnnotationText":"Patients with the rs67376798 AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to gabapentin. However, patients with the AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the CC genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs12777823 AG genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["require a lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance","increased clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may require an increased dose of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["increased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of alcoholism compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.","phenotypeText":["increased risk of alcoholism"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the AA genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) concentrations of ceftriaxone"]},{"genotypeAnnotationText":"Patients with CG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*8 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*8 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["decreased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CG and GG. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases who are taking anastrozole or letrozole.","phenotypeText":["increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to olanzapine as compared to patients with the AG or GG genotypes. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["decreased platelet aggregation"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may require increased doses of citalopram as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence citalopram dosage.","phenotypeText":["require increased doses of citalopram"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *1, *7 or *9 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["increased likelihood of neutropenia or leukopenia","decreased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["require increased doses of methadone"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have increased concentrations of methotrexate as compared to patients with the CT and TT genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs28933397 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CYP2D6*63 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*63 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"People with CC genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.","phenotypeText":["decreased clearance of quetiapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer Disease may have increased response to donepezil, galantamine, or rivastigmine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.","phenotypeText":["increased quality of sleep"]},{"genotypeAnnotationText":"Patients with ALS and the GG genotype may have a decreased response to treatment with creatine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to creatine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.","phenotypeText":["require a dose reduction of ribavirin"]},{"genotypeAnnotationText":"Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of zuclopenthixol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of zuclopenthixol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of zuclopenthixol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["decreased metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond better to treatment with flecainide"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decrease in bone density"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["increased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Cancer patients with the TT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.","phenotypeText":["decreased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["increased chance of rehospitalization"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking methadone may have an increased response as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs11045995 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.","phenotypeText":["increased doses of rocuronium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["decreased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["less time in INR therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the GG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"African American male patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.","phenotypeText":["decreased AUC and increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["decreased likelihood of smoking cessation","increased risk of relapse"]},{"genotypeAnnotationText":"Patients with the TT genotype may have 1) a decreased risk of nicotine dependence and 2) a decreased response to smoking cessation therapies as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["decreased risk of nicotine dependence","decreased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["decreased risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*48:04 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*48:04 alleles or negative for the HLA-B*48:04 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) or HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AC genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased blood alcohol concentration (BAC) as compared to patients with the CT genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.","phenotypeText":["increased blood alcohol concentration"]},{"genotypeAnnotationText":"Patients with the TT (CYP3A4 *1G\/*1G genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["more likely to respond to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.","phenotypeText":["increased risk of Coronary Disease"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.","phenotypeText":["diminished response","improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have an increased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with liver cancer and the TT genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype or may have increased metabolism of trimipramine as compared to patients with the *3\/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["reduced metabolism"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["decreased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["increased response","increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with platinum-based chemotherapy may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["better prognosis"]},{"genotypeAnnotationText":"Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with HIV and the AA genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28\/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.","phenotypeText":["likelihood of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["risk for nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["later onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["increased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may be less likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*6 or *6\/*6 genotypes. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["less likely to experience a clinical benefit from bupropion treatment for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with TT genotype and breast cancer may have an increased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea and neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the rs7754840 CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype but a worse response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.","phenotypeText":["improved response","worse response"]},{"genotypeAnnotationText":"Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs9620007 GG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of dermatitis"]},{"genotypeAnnotationText":"Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508139 AA genotype (two copies of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy.","phenotypeText":["decreased risk of hematologic toxicity, leukopenia, and GI toxicity"]},{"genotypeAnnotationText":"Patients with the rs324420 AA genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients who carry the *2a allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *2a allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.","phenotypeText":["increased risk for vomiting"]},{"genotypeAnnotationText":"Patients with postoperative pain and the CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.","phenotypeText":["require a higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*2a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs4680 AA genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs11125039 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.","phenotypeText":["decreased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["higher accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with the rs193922802 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs10958704 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9620007 CG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction and more likely to develop heart palpitations when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["less likely to develop sexual dysfunction","more likely to develop heart palpitations"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GG genotype and decreased likelihood as compared to the AA genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis","decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the rs324029 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram.","phenotypeText":["increased risk for suicide"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*31 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"In human liver microsomes, the *1\/*1 genotype is associated with increased metabolism of sirolimus as compared to the *1\/*22 or *22\/*22 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["increased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["decreased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased risk of leukopenia","increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment.","phenotypeText":["longer overall survival time and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the *2 allele in combination with another no function allele may have decreased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have decreased metabolism of N-desmethylclobazam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association with response to paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs7668258 CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype but an increased response compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of sufentanil"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.","phenotypeText":["increased risk of drug toxicities","decreased risk of drug toxicities"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*2 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"The CYP2B6*27 allele may result in decreased expression and enzymatic activity of CYP2B6, as compared to the CYP2B6*1 allele. A patient with the *6\/*27 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy.","phenotypeText":["decreased expression and enzymatic activity of CYP2B6"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["decreased risk of severe hypersensitivity"]},{"genotypeAnnotationText":"Patients with the rs1127354 AA genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of atazanavir as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence clearance of atazanavir.","phenotypeText":["decreased clearance of atazanavir"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of vasomotor symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["greater likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype and bipolar disorder and other psychotic disorders may have decreased dose of valproic acid compared to patients with the *1\/*1 genotype. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["decreased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["improved overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs4148738 CC genotype may have increased risk of bleeding when treated with apixaban as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the rs678849 CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["decreased clearance and increased risk of leukopenia"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["increased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["increased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have an increased risk of agranulocytosis when treated with antithyroid preparations as compared to patients with the TTTT\/del or TTTT\/TTTT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["decreased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to atazanavir as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased simvastatin acid concentration when treated with simvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased simvastatin acid concentration"]},{"genotypeAnnotationText":"No patients with the GG genotype were studied.","phenotypeText":["No phenotype observed"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.","phenotypeText":["decreased risk of becoming addicted to nicotine"]},{"genotypeAnnotationText":"Patients with the C\/del genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del\/del. Other genetic and clinical factors may influence the patient's response to metoprolol","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with another decreased function allele may have increased response to sulfonylureas as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs28358569 G allele (also known as the 827G allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["poorer response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) and colorectal cancer may have an increased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["increased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased risk for leukopenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*15:24 allele may have a decreased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["decreased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":["risk for severe neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["decreased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["reduced response to fluvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["increased likelihood of achieving remission"]},{"genotypeAnnotationText":"Patients with the TC\/TC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia, and neuropathy)"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*51 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*51 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, conflicting evidence regarding an association with side effects has been reported. Other genetic and clinical factors may also influence likelihood of developing side effects when treated with sertraline.","phenotypeText":["develop sexual dysfunction"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the rs193922747 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have decreased lipid-lowering efficacy to fluvastatin in elderly hypercholesterolemic patients as compared to patients with the *14\/*14 genotype. Other genetic and clinical factors may also influence response to fluvastatin.","phenotypeText":["decreased lipid-lowering efficacy"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"non-responder\" phenotype from the \"responder\" phenotype when using a logistic regression multivariate model.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have increased clearance of tamoxifen as compared to patients with the CYP2D6*87 or *90 or *91 or *93 or *95 or *98 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of tamoxifen.","phenotypeText":["increased clearance of tamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["lower response rate to pramipexole"]},{"genotypeAnnotationText":"Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"No patients with the CC genotype are available for analysis, but patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3\/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["increased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GT and TT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of Mucositis"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of drug toxicities"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.","phenotypeText":["increased peak cortisol response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased exposure to pitavastatin as compared to patients with two normal function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["O-desmethyl-tramadol sulfation"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*4 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.","phenotypeText":["decreased Anxiety Disorders"]},{"genotypeAnnotationText":"Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["increased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*2 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *2\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["lower tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of sparteine as compared to patients with the CYP2D6*4\/*11 or *4\/*12 or *4\/*59 or *5\/*7 or *5\/*8 or *41\/*62 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["increased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["increased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the A\/del genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["complete response"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.","phenotypeText":["decreased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the GG genotypes and decreased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Male patients with the GG genotype may have a decreased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the AA or AG genotypes. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["decreased response to nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Patients with the TTAAAGTTA\/del genotype may have a lower response to treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response","lower response"]},{"genotypeAnnotationText":"Patients with opioid-related disorders and the rs2740574 CT genotype (CYP3A4*1\/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1\/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.","phenotypeText":["require an increased dose of buprenorphine to prevent withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the rs17134592 CC genotype may have increased metabolism of naltrexone as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.","phenotypeText":["increased metabolism of naltrexone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.","phenotypeText":["lower plasma concentrations of atorvastatin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs28379954 TT genotype and clozapine concentrations. However, patients with schizophrenia and the CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["decreased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype or may have greater weight gain as compared to patients with the TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.","phenotypeText":["increased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs28933396 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Epileptic patients with the HLA-A*11:01 allele may be at an increased risk of experiencing psychiatric adverse events when taking levetiracetam as compared to patients who do not carry the HLA-A*11:01 allele. Other genetic and clinical factors may also affect a patient's risk of experiencing psychiatric adverse events when taking levetiracetam.","phenotypeText":["increased risk of experiencing psychiatric adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.","phenotypeText":["require a decreased dose of fentanyl"]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with another decreased function allele may have increased fentanyl dose requirements as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.","phenotypeText":["improved response (decreased disease free survival or overall survival)"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["less likely to experience remission or more likely to experience remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["decreased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.","phenotypeText":["higher dose requirement for valproic acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype or may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased likelihood of treatment-emergent suicidality","decreased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the CYP2D6*27 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*27 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of treatment being effective"]},{"genotypeAnnotationText":"Patients with the rs1346563 GG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with GG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and nephrotoxicity"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for anti-TB drug-induced hepatitis as compared to patients with the AA genotype. Patients with the TT genotype may also have increased clearance of isoniazid as compared to patients with the AT genotype. Additionally, cells with the T allele have been shown to result in increased transcription of the NAT2 gene as compared to those with the A allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.","phenotypeText":["decreased risk for anti-TB drug-induced hepatitis","increased clearance of isoniazid","increased transcription of the NAT2 gene"]},{"genotypeAnnotationText":"No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["greater risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["better response to losartan in people with hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["greater elevation in systolic blood pressure and a greater incidence of side effects"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele who are treated with dapsone may have an increased risk for dapsone-induced severe cutaneous adverse reactions as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. Other genetic and clinical factors may also influence a patient's response to dapsone.","phenotypeText":["increased risk for dapsone-induced severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to respond to treatment for methamphetamine dependence as compared to patients with the CT or TT genotypes. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *21 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity of CYP2A6"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*15 diplotype may have increased exposure of repaglinide as compared to patients with the *37\/*37 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol.","phenotypeText":["increased severity of intoxication and increased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*06:02 allele who are treated with sulfamethoxazole\/trimethoprim may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-C*06:02 alleles or negative for the HLA-C*06:02 test. Other genetic and clinical factors may also influence risk of sulfamethoxazole\/trimethoprim-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs74569896 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*7A allele or one copy of the *7A allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["better response when treated with corticosteroids"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["decreased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["require decreased dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*1 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1303839356 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk for stroke"]},{"genotypeAnnotationText":"Patients with the rs3918290 CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CT or TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hepatitis C or HIV may have an increased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have increased severity of mucositis when receiving methotrexate, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["increased severity of mucositis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may have increased metabolism of thioguanine as compared to patients with two uncertain function or unknown function alleles or an uncertain function or unknown function in combination with a normal function allele. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["increased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the TT genotype and bladder cancer may have an increased response to cisplatin-based therapies compared to patients with the CC and CT genotypes. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapies"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["decreased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTA\/TTAAAGTTA genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype but a decreased risk as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.","phenotypeText":["less likely to experience remission"]},{"genotypeAnnotationText":"Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["decreased response to peginterferon alfa and ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the rs193922748 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.","phenotypeText":["decreased risk for severe emesis"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased likelihood of response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose.","phenotypeText":["decreased dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["increased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:07 allele who are treated with zonisamide may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-A*02:07 alleles or negative for the HLA-A*02:07 test. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the rs121918594 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["shorter QTc interval"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Adolescents with the AA genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["smaller, or absent, increase in nicotine cravings"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil.","phenotypeText":["increased risk for the primary outcome","decreased, but not absent, risk for the primary outcome"]},{"genotypeAnnotationText":"Subjects with the TT genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds or radiotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less of a weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs8050894 CC genotype may require a higher dose of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["require a higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with schizophrenia, or autism spectrum disorder (ASD) and the TT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to clopidogrel (increased platelet reactivity) as compared to patients with the AA genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.","phenotypeText":["less likely to respond to treatment for methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD).","phenotypeText":["decreased risk of end-of-induction minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the GA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype, but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.","phenotypeText":["increased response","remission rate"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with HIV who have the GSTM1 null\/null genotype may have an increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) as compared to patients with the null\/non-null and non-null\/non-null genotypes when treated with nevirapine. However, the genotype may not be associated with likelihood of hepatotoxicity. Other clinical and genetic factors may also influence the likelihood of SJS\/TEN in women with HIV who are administered nevirapine.","phenotypeText":["increased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to treatment with anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the TT genotype and stenosis may be more likely to suffer from a transient ischemic attack as compared to patients with the GG or GT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.","phenotypeText":["more likely to suffer from a transient ischemic attack"]},{"genotypeAnnotationText":"Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["decreased response to thalidomide","decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased doses of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin"]},{"genotypeAnnotationText":"Individuals with HIV and the TT genotype may have an increased risk of SJS\/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the GT or GG genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["increased risk of SJS\/TEN and DRESS Syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["increased risk for infections"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a reduced response (a smaller reduction in LDL-cholesterol or change in HDL) as compared to patients with the CT genotype (carriers of E2). Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC (CYP3A4 *1\/*1) genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased exposure of repaglinide, including increased AUC and decreased clearance of repaglinide as compared to patients with the *37\/*37 or *37\/*15 diplotype. Other genetic and clinical factors may also influence a patient's repaglinide pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and repaglinide and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of repaglinide"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CYP2D6*23 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*23 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.","phenotypeText":["require a higher dose or a lower dose"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have 1) a decreased enzyme activity of CYP2D6 and 2) decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele construct was found to exhibited >90% decreases in catalytic activity than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan and decreased clearance with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6","decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.","phenotypeText":["increased risk of coronary artery disease"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the rs1800100 CT genotype (one copy of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.","phenotypeText":["higher platelet reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.","phenotypeText":["greater risk of diarrhea and vomiting"]},{"genotypeAnnotationText":"Subjects with the AC genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype, or increased clearance or glucuronidation as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["decreased clearance or glucuronidation"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*57:01 allele have an increased risk of drug-induced liver injury when treated with flucloxacillin as compared to patients with no HLA-B*57:01 alleles or negative for the HLA-B*57:01 test. Other genetic and clinical factors may also influence risk of flucloxacillin-induced adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs6686529 GG genotype who are treated with sevoflurane may have decreased sedation as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence sedation.","phenotypeText":["decreased sedation"]},{"genotypeAnnotationText":"Patients with the non-null\/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null\/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["poorer chance of achieving complete remission","increased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or TT genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["increased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["decreased risk of urticaria"]},{"genotypeAnnotationText":"Patients with the rs9288993 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may show an improved performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CT or TT genotypes, who may not show a difference in performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["improved performance in attention-related tasks"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":["more likely to respond to treatment for methemoglobinemia","reduced risk of drug-induced hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["increased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 AG genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the CA or AA genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *12 or *13 allele. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["increased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the TPMT *1\/*2 genotype and heart transplantation who are treated with azathioprine may have an increased risk of severe rejection as compared to patients with the TPMT *1\/*1 genotype. Other genetic and clinical factors may also impact the risk for organ rejection.","phenotypeText":["increased risk of severe rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["require decreased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs13210472 AA genotype may be at a decreased risk of developing cancer when taking statins as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["decreased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GT genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar imipramine dose requirements as compared to patients with other alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["increased imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["decreased risk of mortality"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.","phenotypeText":["increased exposure to simvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.","phenotypeText":["decreased inhibition of KCNH2"]},{"genotypeAnnotationText":"Patients with the rs193922832 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of developing severe cutaneous adverse reactions when treated with antiepileptics as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing severe cutaneous adverse reactions when treated with antiepileptics.","phenotypeText":["increased risk of developing severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a\/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs139945292 TT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.","phenotypeText":["increased adverse cardiovascular risk"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with acenocoumarol may have a decreased risk of Hemorrhage as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the GGAGTC\/GGAGTC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the rs730012 AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for urticaria.","phenotypeText":["decreased risk of urticaria"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with a high dose of chloroquine may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype.","phenotypeText":["increased Euphoric and Energetic"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and methylphenidate dosage requirements. However, patients with ADHD and the CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.","phenotypeText":["decreased dose of methylphenidate"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype may have increased exposure to tolperisone as compared to patients with the *1\/*1, *1\/*4, and *1\/*5 genotypes. Other clinical and genetic factors may also influence patient exposure to tolperisone.","phenotypeText":["increased exposure to tolperisone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC\/GGAGTC genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the GGAGTC\/del genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.","phenotypeText":["lower incidence of toxicity and may tolerate higher doses of mercaptopurine"]},{"genotypeAnnotationText":"Children with the TT genotype and gating mutations in cystic fibrosis may have decreased response to ivacaftor compared to children with the CC or CT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with AC or CC genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["higher success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["more likely to have complete remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to simvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":["increased concentrations of voriconazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of morphine as compared to patients with the CT or TT genotypes. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.","phenotypeText":["increased plasma concentrations of morphine"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":[]},{"genotypeAnnotationText":"Pregnant women with the *1A\/*1A (CC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F\/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["decreased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *7 allele or one copy of the *7 allele in combination with the *5 or *6 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["increased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment (measured by higher decreases in LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with genotype AC may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["lower rate of sustained virological response (SVR)"]},{"genotypeAnnotationText":"Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with CYP2C19*2 may have may have decreased metabolism of icotinib as compared to patients with two functional alleles (*1\/*1). Other genetic and clinical factors may also influence a patient's response to icotinib.","phenotypeText":["decreased metabolism of icotinib"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["decreased fasting triglyceride levels"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the TT genotype may have decreased clearance and increased concentrations of apixaban as compared to patients with the GG and GT genotypes. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased clearance and increased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may be at a decreased risk of experiencing adverse events when treated with mercaptopurine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with mercaptopurine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Pediatric patients with nephrotic syndrome and the *3\/*3 diplotype may have decreased clearance of tacrolimus as compared to patients with the *1\/*1 or *1\/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.","phenotypeText":["decreased clearance of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":["increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["increased risk of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs11280056 del\/del genotype and risk of side effects when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["no significant association with risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CYP2C19*2\/*3 genotype who have non-valvular atrial fibrillation may require lower warfarin maintenance dose than patients with *1\/*1 genotype. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["lower warfarin maintenance dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Women with the TT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["lower risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype or may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased risk of diabetes","decreased risk of diabetes"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5B allele or one copy of the *5B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["decreased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the C\/del or del\/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["less likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["poorer response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*27:09 allele have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*27:09 alleles or negative for the HLA-B*27:09 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype.","phenotypeText":["no significant association with breast cancer disease recurrence"]},{"genotypeAnnotationText":"Patients carrying the CYP2A6*20 allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["increased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.","phenotypeText":["increased risk for QTc interval prolongation"]},{"genotypeAnnotationText":"Patients with the rs112563513 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with glioma and the rs1128503 AA genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.","phenotypeText":["decreased concentrations of temozolomide"]},{"genotypeAnnotationText":"Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["decreased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with genotype CT may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.","phenotypeText":["decreased likelihood of Drug Hypersensitivity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4728709 AG genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["decreased likelihood of developing asthenia"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["lower levels of morphine-3-glucuronide formation"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the rs1275988 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depression and the GT genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.","phenotypeText":["lower success rate in achieving short-term remission"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have decreased prolactin when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Women with the CC genotype and obesity and polycystic ovarian syndrome (PCOS) may have an increased response to liraglutide as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sufentanil dose requirements as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the rs4646437 GG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*5 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone in Children with Autism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del\/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the rs28358569 A allele (also known as the 827A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with chronic pain and the GG genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.","phenotypeText":["less likely to develop hyperalgesia"]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *35 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*88 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"The del\/T genotype is associated with decreased catalytic activity of DPYD as compared to the TT genotype and increased catalytic activity as compared to the del\/del genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with genotype CC may have higher rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN\/RBV) therapy as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["higher rate of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.","phenotypeText":["increased risk of aspirin-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["decreased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["increased risk of pneumonitis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*18:01 allele who are treated with amoxicillin-clavulanate may have increased risk of drug-induced liver injury as compared to patients with no HLA-B*18:01 allele. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased prolactin"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *27\/*28 genotype and chronic myeloid leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *6\/*6 or *6\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs756770 AA genotype may have an increased response to buprenorphine therapy as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of virological response"]},{"genotypeAnnotationText":"Patients with the CYP2C9*3\/*3 genotype may have a decreased clearance of doxepin as compared to patients with the CYP2C9*1\/*1 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.","phenotypeText":["decreased clearance of doxepin"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have decreased concentrations of deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["decreased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the rs1041983 TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of alopecia","decreased risk of pain"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype may be more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo than patients with the *1\/*1 genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["more likely to experience a clinical benefit from bupropion treatment for nicotine dependence compared to placebo"]},{"genotypeAnnotationText":"Patients with the GG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.","phenotypeText":["decreased clearance of XK469"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with docetaxel may have an increased risk of neuropathy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["increased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with olanzapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 AA genotype may have increased concentrations of methotrexate as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.","phenotypeText":["decreased likelihood of treatment interruptions"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["better response to treatment with atomoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN\/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN\/RBV therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the TT genotype may have an increased response to interferon-beta as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["increased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.","phenotypeText":["less likely to require a decrease in dose or switch to a different drug"]},{"genotypeAnnotationText":"Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype may have increased metabolism of trimipramine as compared to patients with the CYP2C9*3\/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["increased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["better response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response","increased time until response"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*4 allele in combination with a normal function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["decreased response to ustekinumab"]},{"genotypeAnnotationText":"The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate increased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CG genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.","phenotypeText":["increased absolute leucocyte and neutrophil counts"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CC genotype may have an increased response to pioglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["increased response to pioglitazone"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["greater reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["higher likelihood of developing myalgia","lower likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with valproic acid may have increased bone density as compared to patients with the AA + AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["increased bone density"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"African-American patients with the CC genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone.","phenotypeText":["increased response to methadone treatment"]},{"genotypeAnnotationText":"The rs267606617 A allele (also known as the 1555A allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the A allele may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Individuals with the CT (CYP2C8*3\/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.","phenotypeText":["increased metabolism of repaglinide"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for cardiovascular toxicity and symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and Schizophrenia who are treated with antipsychotics 1) may have decreased response 2) may have increased time until response, compared to patients with the GG genotype. Please note that there is contradictory evidence from studies that report no association with these alleles and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased response","increased time until response"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with carbamazepine may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose of phenprocoumon","increased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of neurological events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with sulfadoxine may have reduced survival of red blood cells as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["reduced survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["increased heart rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["not respond as well to treatment with escitalopram"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.","phenotypeText":["faster analgesic onset"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["increased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with genotypes GG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["increased response to daunorubicin"]},{"genotypeAnnotationText":"Patients with the *04:06 haplotype may have increased risk of statin-related myopathy when taking statins compared to patients without the *04:06 haplotype. Other clinical and genetic factors affect risk of myopathy when taking statins.","phenotypeText":["increased risk of statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.","phenotypeText":["lower risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the rs1751034 TT genotype carriers may have increased concentrations of tenofovir as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations.","phenotypeText":["increased concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.","phenotypeText":["decreased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the rs193922809 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require higher dose of warfarin as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs3745274 GT genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5\/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol"]},{"genotypeAnnotationText":"Patient harbors the rs118192170 CT genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192170 T>C variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["less likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to atorvastatin as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*50 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*50 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["increased likelihood of weight gain of more than 7% of baseline body weight"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*10 allele or one copy of the *10 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.","phenotypeText":["decreased time until response"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.","phenotypeText":["no effect on exposure"]},{"genotypeAnnotationText":"Patients with testicular cancer and the GG genotype may have an increased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of infection","nausea"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Men with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atrovastatin.","phenotypeText":["lower decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["increased sustained virological response (svr)"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may require an increased dose of thioguanine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Purified DCK proteins with the GG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the rs368146607 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose of thioguanine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with warfarin may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["increased time to achieve therapeutic international normalized ratio"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the rs702764 CT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["increased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs708272 AG genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["greater reduction in cardiovascular events","less of a reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs3842 TT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.","phenotypeText":["decreased likelihood of developing palpitations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of trimipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of trimipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of trimipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs698 CC genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.","phenotypeText":["increased area under the curve of irinotecan-based therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the CT and TT genotypes. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["decreased trough concentrations"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with another no function allele may have decreased metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with a decreased, normal or increased function allele may have similar metabolism of hydrocodone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and hydrocodone and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for hydrocodone and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also affect hydrocodone metabolism.","phenotypeText":["decreased metabolism of hydrocodone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response to acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the rs1041983 CC genotype and tuberculosis may have a decreased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased metabolism of folic acid"]},{"genotypeAnnotationText":"Individuals with the CYP2D6*46 allele in combination with a normal, decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with two normal function alleles. Note that this allele has been assigned as a normal function allele by CPIC. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the CG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["decreased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the rs7297610 CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["more likely to respond","less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of fever"]},{"genotypeAnnotationText":"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["phenobarbital resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs10455872 GG genotype may have a decreased response to statins as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *3 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *3 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients with prostate cancer and the rs523349 CC genotype may have an increased response to abiraterone as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to abiraterone.","phenotypeText":["increased response to abiraterone"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CYP2D6*92 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*92 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have a similar analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have an increased analgesic response when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["decreased analgesic response","similar analgesic response","increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["increased risk for Alcoholism"]},{"genotypeAnnotationText":"Patients with the rs628031 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.","phenotypeText":["decreased concentrations of lamotrigine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence aripiprazole metabolism.","phenotypeText":["decreased metabolism of aripiprazole","similar metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the CYP2D6*7 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*7 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1695 AG genotype and risk of developing neutropenia when treated with cyclophosphamide and epirubicin. However, patients with breast cancer and the AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone.","phenotypeText":["decreased response to amiloride or spironolactone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["less severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Male patients with the wildtype B haplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the A-202A_376G haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["reduced risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with CYP3A5*1\/*3 had a significantly higher granisetron clearance and reduced exposure as compared to patients with *3\/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.","phenotypeText":["reduced exposure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may show a decreased severity of alcoholism as compared to patients with the AG or GG genotypes. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism.","phenotypeText":["decreased severity of alcoholism"]},{"genotypeAnnotationText":"Patients with the rs1868089 TT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["increased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["decreased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A4 *1\/*1) and epilepsy may have increased concentrations of carbamazepine as compared to patients with the CT (*1\/*1G) or TT (*1G\/*1G) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["increased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A\/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A\/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"There is currently no information concerning the effect of the GG genotype on the severity of nausea and vomiting as a result of taking fentanyl. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response (higher reductions in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*5 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 TT genotype who are treated with clozapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["decreased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Adolescents with the GG genotype may have a greater increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.","phenotypeText":["greater increase in nicotine cravings"]},{"genotypeAnnotationText":"Patients with rs9958628 TT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may be at a decreased risk of drug toxicity when taking hydrocodone as compared to patients with at least three normal function alleles. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when taking hydrocodone.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin","decreased prolactin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased blood alcohol concentrations (BAC) and increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["decreased blood alcohol concentrations and increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased chance of response"]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *4 or *7 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["risk for progression and decreased survival"]},{"genotypeAnnotationText":"Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and\/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.","phenotypeText":["decreased risk for bone mineral density loss"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1560022535 GG genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea following administration of succinylcholine"]},{"genotypeAnnotationText":"Patients with the rs1051792 AA genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AG genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["decreased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.","phenotypeText":["insufficient data"]},{"genotypeAnnotationText":"Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["worse response to fluorouracil, platinum compounds, or radiotherapy"]},{"genotypeAnnotationText":"Patients with the rs397508602 AA genotype (two copies of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects","increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["more likely to be THC dependent"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer time to progression and overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["longer time to progression and overall survival time"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["increased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["longer recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter time to therapeutic INR"]},{"genotypeAnnotationText":"Patients with the rs20455 AG genotype may have increased response to atorvastatin treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1302192284 TT genotype may have increased metabolism of nicotine as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"Patients with the rs3828743 AG genotype may have better response and longer progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["better response and longer progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with clopidogrel may have a decreased, but not absent, risk for adverse cardiac and cerebrovascular events as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["decreased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may be less sensitive to treatment with erlotinib compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["less sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience increased repaglinide exposure and improved response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["increased repaglinide exposure and improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["poorer chance at achieving remission"]},{"genotypeAnnotationText":"The CYP2D6*21 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*21 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have an increased risk for presence of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to patients with HTTLPR short form (S allele)\/HTTLPR short form (S allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting an association of SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) with increased risk of side effects. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased risk for presence of sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["increased likelihood of Substance-Related Disorders","decreased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with chronic hepatitis C genotype 1 and the TT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with citalopram may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.","phenotypeText":["decreased risk for suicidal ideation"]},{"genotypeAnnotationText":"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the rs34059508 GG genotype may have decreased exposure to olanzapine as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C4 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.","phenotypeText":["increased risk of gastrointestinal adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the TTA\/TTA genotype (also described as 6bp deletion) may have increased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.","phenotypeText":["increased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have higher adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["higher adverse drug reaction scores"]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GT and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance","decreased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the CC genotype may have decreased response to clopidogrel as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the rs7270101 AA genotype and chronic hepatitis C may have an increased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AC and CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["better response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Patients with the GGGGAGCTTTCCCAGAGACCC\/del genotype and liver cirrhosis with refractory ascites may be more likely to respond to treatment with clonidine as compared to patients with the GGGGAGCTTTCCCAGAGACCC\/GGGGAGCTTTCCCAGAGACCC genotype. Other genetic and clinical factors may also influence response to clonidine.","phenotypeText":["more likely to respond to treatment with clonidine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the AA or AG genotypes. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["decreased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.","phenotypeText":["decreased risk of remaining on steroids"]},{"genotypeAnnotationText":"Patients with the rs193922772 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have increased clearance or glucuronidation of oxazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["increased clearance or glucuronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["decreased metabolism of caffeine"]},{"genotypeAnnotationText":"The CYP2D6*92 allele has been assigned as a no function allele by CPIC. Patients carrying the *92 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association between the rs4680 AG genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["better response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the TTA\/TTAAAGTTA genotype may have increased severity of toxicity when treated with fluorouracil-based chemotherapy regimens as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype (also described as 6bp insertion). Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["risk of Hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs4948496 TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs78655421 AG genotype (one copy of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with the rs115346678 AG genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.","phenotypeText":["more likely to require a dose reduction of imatinib due to drug toxicity"]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the AC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Peptic Ulcer Hemorrhage"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the CT genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with infections and the rs1799930 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs1079596 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the GG genotype who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the CT (CYP3A4 *1\/*1G) genotype and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1\/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal function allele (e.g. *1\/*3) may have decreased metabolism of losartan as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.","phenotypeText":["decreased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment.","phenotypeText":["increased risk of adverse drug reactions, in particular neutropenia\/ leukopenia and gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.","phenotypeText":["longer QTc interval"]},{"genotypeAnnotationText":"Patients with the TC\/TCCTC genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia and neuropathy)"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.","phenotypeText":["increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the rs116855232 CC genotype and inflammatory bowel diseases who are treated with azathioprine may have a reduced, but not absent risk of myelosuppression as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["reduced risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR R1070Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of experiencing rhabdomyolysis as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["decreased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*2\/*2 genotype may have an increased atorvastatin lactonization as compared to patients with the UGT1A3*1\/*1 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["increased atorvastatin lactonization"]},{"genotypeAnnotationText":"Patients with the CC genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the rs367619008 CC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["decreased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.","phenotypeText":["higher risk of simvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the NUDT15*6 allele in combination with a normal function allele may be at an increased risk of developing leukopenia when treated with mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["increased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype may be more likely to experience insomnia as a result of consuming caffeine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["more likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["decreased risk of new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.","phenotypeText":["increased risk of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Cells with the CT genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype, or decreased uptake as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.","phenotypeText":["increased uptake of catecholamines or metformin"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.","phenotypeText":["increased metabolism of irinotecan"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:02 allele have an increased risk of Pegaspargase Hypersensitivity as compared to patients with no HLA-DQB1*02:02 alleles or negative for the HLA-DQB1*02:02 test. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["increased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 AA genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 TT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.","phenotypeText":["increased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["decreased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients with the rs4906902 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.","phenotypeText":["decreased response to selective beta blockers"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.","phenotypeText":["increased concentrations of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["shorter disease-free survival","longer disease-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs1800497 AA genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.","phenotypeText":["increased weight loss response"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Women with the TT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["less likely to require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs75750968 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["reduced risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased event free survival"]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.","phenotypeText":["increased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and chronic lymphocytic leukemia may be more likely to achieve a complete response but also more likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*6 or *6\/*6 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["more likely to achieve a complete response","more likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal or no function allele may have increased response to esomeprazole (increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased response to esomeprazole"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission","decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit disorder with hyperactivity may have a decreased, but not absent, risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs2071559 GG genotype may have increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["increased overall survival and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G\/del or del\/del genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Patients with the rs12366035 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and carrying the CYP2D6*1 allele in combination with another normal function allele may have decreased weight gain when treated with olanzapine as compared to patients carrying a normal function allele in combination with a no function allele. Patients with schizophrenia and carrying the CYP2D6*1 allele in combination with a no function allele may have increased weight gain when treated with olazapine as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence weight gain when treated with olanzapine.","phenotypeText":["decreased weight gain","increased weight gain"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele may have decreased metabolism of fluoxetine as compared to patients with the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients carrying the *6 allele in combination with another decreased function allele may have increased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to flecainide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*91 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs140471703 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the HLA-DQA1*02:01 allele with inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a decreased risk for toxicity when treated with fluoropyrimidines, as well as increased DPYD activity, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["decreased risk for toxicity","increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6A allele or one copy of the *6A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["increased bronchodilator response"]},{"genotypeAnnotationText":"The CYP2D6*41 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *41 allele in combination with a decreased or no function allele may have decreased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *41 allele in combination with an increased function allele may have increased metabolism of aripiprazole as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for aripiprazole and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid and intermediate metabolizers. Other genetic and clinical factors may also influence aripiprazole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of aripiprazole","increased metabolism of aripiprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype CC or AC. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased QT interval"]},{"genotypeAnnotationText":"Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["better response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with neuropathic pain and the rs1045642 GG genotype may have an increased response to combined therapy with morphine and nortriptyline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to morphine and nortriptyline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT (CYP3A4 *1\/*1G) genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["more likely to respond to clopidogrel"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["increased likelihood of neutropenia or leukopenia","decreased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.","phenotypeText":["increased isoproterenol-mediated desensitization"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["lower on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and increased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure to temsirolimus or sirolimus","increased likelihood of bone marrow and gastrointestinal toxicities or other adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.","phenotypeText":["decreased response to rasagiline"]},{"genotypeAnnotationText":"Patients with the rs193922768 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1, *4, *9 or *10 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["decreased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G6PD B (reference) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.","phenotypeText":["decreased risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*35 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of doxepin as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of doxepin as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*35 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of doxepin as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin","decreased metabolism of doxepin"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*3 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of propafenone as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of propafenone as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of propafenone as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism of propafenone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CC genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs1603218569 C allele (also known as the 1243C allele) may have an increased risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (svr) when treated with simeprevir\/peginterferon\/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT\/TT. Other genetic and clinical factors may also influence the response to simeprevir\/peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to remifentanil as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs12208357 TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.","phenotypeText":["higher plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs6295 CG genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.","phenotypeText":["decreased metabolism of verapamil"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["increased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["decreased likelihood of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["increased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*91 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*91 allele (in this study only defined as C161S not including 2988G>A) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have decreased platelet inhibition and increased residual platelet aggregation as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence platelet inhibition.","phenotypeText":["decreased platelet inhibition and increased residual platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["reduced clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["increased risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure to tramadol"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the CC genotype on oseltamivir concentrations in patients.","phenotypeText":["no observed effect"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the GG genotype may have an increased overall survival when treated with sorafenib as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of recurrent clinical events"]},{"genotypeAnnotationText":"Patients with the AC genotype and kidney transplant may have increased risk of neutropenia when treated with valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype (carriers of E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Women with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with captopril as compared to women with the AA or AG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.","phenotypeText":["greater decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["decreased hematologic response"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the CC genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["increased concentrations and improved response to lumefantrine"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["increased clearance of paclitaxel"]},{"genotypeAnnotationText":"Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to hydroxyurea treatment"]},{"genotypeAnnotationText":"Patients with the rs3828743 AA genotype may have worse response and shorter progression-free survival when treated with abiraterone\/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence the response to abiraterone\/prednisolone.","phenotypeText":["worse response","shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the CYP2D6*46 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*46 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The current evidence base suggests there that is no significant association between the rs6313 GG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["no significant association with response to antidepressants"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a worse response to methotrexate as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["worse response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.","phenotypeText":["decreased methylation at COMT gene promoter"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs13181 GG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["larger stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *6 allele or one copy of the *6 allele in combination with the *5 or *7 alleles may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *4, *12 or *13 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele or a normal function allele may have a decreased response to simvastatin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require a reduced dose of catecholamines"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of drug toxicity","hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype who are treated with pravastatin may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["fewer adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AG genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings.","phenotypeText":["decreased cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the rs4752292 GT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2011425 GG genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["decreased serum concentrations"]},{"genotypeAnnotationText":"Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["greater prolactin response"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased risk of neurological events"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the TT genotypes, and worse response as compared to CC genotype. This is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["improved response to donepezil (slower cognitive decline)"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the GT genotype may have a decreased response to etanercept as compared to patients with the GG or TT genotypes. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["decreased response to etanercept"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["less likely to respond to treatment with clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype with diabetes mellitus or polycystic ovarian syndrome who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*11 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity score of 2 may have similar imipramine dose requirements as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence imipramine dose requirements.","phenotypeText":["decreased imipramine dose requirements","increased imipramine dose requirements","similar imipramine dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.","phenotypeText":["increased risk for more side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["decreased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the TT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.","phenotypeText":["less favorable event-free and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*1\/*1 may have increased metabolism of diclofenac as compared to patients with CYP2C8*3 or *4. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["increased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may require a decreased dose of atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["decreased dose of atenolol"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs2449598 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the TT genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["increased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["increased antidepressant response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["less response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["decreased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6J allele or one copy of the *6J allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the AC or CC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":["reduced dose escalation of morphine"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to spironolactone.","phenotypeText":["decreased response to spironolactone"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.","phenotypeText":["poorer response to treatment with interferons and ribavirin"]},{"genotypeAnnotationText":"Patients with ADHD and the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs9344 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with gefitinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to gefitinib.","phenotypeText":["better response to treatment with gefitinib"]},{"genotypeAnnotationText":"Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["changes in mycophenolic acid exposure-related parameters","increased risk of acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the rs193922762 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6A allele or one copy of the *6A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Female patients with the A- 202A_376G\/B (reference) haplotype (heterozygous for the G6PD A- variant) who are treated with methylene blue may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A- 202A_376G\/A- 202A_376G or B\/B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with depressive disorder and the CC genotype may have worse response to citalopram or escitalopram as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs735668 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of rosuvastatin-related myopathy when treated with rosuvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of rosuvastatin.","phenotypeText":["higher risk of rosuvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing both alcohol and drug dependence as compared to patients with the AA or AG genotypes. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence.","phenotypeText":["decreased risk of developing alcohol and drug dependence"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["increased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.","phenotypeText":["decreased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.","phenotypeText":["decreased TPMT activity toward mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a shorter overall survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival times.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing kidney transplantation may have an increased risk for nausea and\/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and\/or vomiting.","phenotypeText":["increased risk for nausea and\/or vomiting"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*33 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["increased plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*6 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*6 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["lower risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the rs718656 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype, or increased metabolism compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["decreased metabolism of nicotine","increased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*3 allele or one copy of the *3 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["decreased risk for experiencing drug toxicity, particularly diarrhea"]},{"genotypeAnnotationText":"CC genotype may be associated with a decreased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the TT or CT genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["decreased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a lower dose of acenocoumarol as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.","phenotypeText":["require a lower dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT.","phenotypeText":["increased risk of hematological toxicity"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5A allele or one copy of the *5A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.","phenotypeText":["risk for osteonecrosis of the jaw"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["decreased risk for cardiovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the AG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with epilepsy and the GG genotype may have a decreased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["decreased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs28358572 T allele (also known as the 1520T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 AG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.","phenotypeText":["decreased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs113993960 CTT\/CTT genotype (do not have a copy of the CFTR F508del variant) and cystic fibrosis have an unknown likelihood of experiencing adverse events while being treated with ivacaftor\/lumacaftor, as the frequency of adverse events may be influenced by the presence of other CFTR variants. Other genetic and clinical factors may also influence the frequency of adverse events experienced during treatment with ivacaftor\/lumacaftor.","phenotypeText":["unknown likelihood of experiencing adverse events"]},{"genotypeAnnotationText":"Individuals with the GG genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["improved response to lithium"]},{"genotypeAnnotationText":"Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.","phenotypeText":["decreased estimated glomerular filtration rate (eGFR)","increased eGFR"]},{"genotypeAnnotationText":"Patients with the TT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["improved metformin efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["decreased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs13210472 CC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["increased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of cerivastatin-associated rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*55:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.","phenotypeText":["increased risk of virological failure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["decreased risk of Nevirapine-induced rash"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["reduced frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the rs1801086 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the rs699 AG genotype may have an increased response to irbesartan as compared to patients with the AA genotype, but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*1 genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the AC genotype who are smokers may have increased physical responses to smoking as compared to patients with the CC genotype, or decreased physical responses as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["increased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with the rs10248420 GG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1494T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["lower risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["decreased response to amisulpride"]},{"genotypeAnnotationText":"Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.","phenotypeText":["more likely to be tetrahydrocannabinol (THC) dependent"]},{"genotypeAnnotationText":"Patients with the GGAGTC\/del genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/GGAGTC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.","phenotypeText":["increased clearance of imatinib","decreased response","decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.","phenotypeText":["increased Stimulation and Euphoria scores"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT.","phenotypeText":["decreased risk for new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Pregnant women with the *1A\/*1F (AC; slow metabolizer) genotype who consume caffeine may have a decreased likelihood of spontaneous abortion as compared to patients with the *1F\/*1F (AA) genotype. Other genetic and clinical factors may also influence likelihood of spontaneous abortion.","phenotypeText":["decreased likelihood of spontaneous abortion"]},{"genotypeAnnotationText":"Patients with the CG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Female patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype were not studied. But female patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have increased clomipramine-induced prolactin release when exposed to clomipramine as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine.","phenotypeText":["increased clomipramine-induced prolactin release"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *5 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Several studies assess this association with *5 in combination with other loss-of-function alleles (e.g. *3, *4). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":["increased risk for tardive dyskinesia or parkinsonism"]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*1 allele in combination with a normal function allele may have increased exposure of telmisartan as compared to patients with one or more copies of the UGT1A3*2 or *3 allele. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure of telmisartan"]},{"genotypeAnnotationText":"Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CT (POR *1\/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1\/*1 or *1\/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine.","phenotypeText":["decreased risk of nausea or sexual dysfunctions"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["increased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response","increased risk of toxicity"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have an increased risk of bone density loss when exposed to letrozole as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with colonic neoplasms and the rs9344 GG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["increased time-to-tumor recurrence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the CC genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","same metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["less likely to respond to diuretic treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["less likely to respond to venlafaxine treatment"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["poorer cardiovascular outcomes"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*20 allele or one copy of the *20 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs11150606 TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["increased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the rs2279343 AG genotype may have increased methadone dose requirements as compared to patients with the GG genotype but decreased dose requirements as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC and CT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["worse response to cisplatin and gemcitabine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the 1494T allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may be at a decreased risk of experiencing adverse events when treated with thioguanine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with thioguanine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR D110E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased adjusted trough concentrations of dabigatran","decreased, but not absent, risk for bleeding"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["decreased virological response"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.","phenotypeText":["less likely to experience psychosis"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs2292596 CC genotype may have increased response to methotrexate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the rs193922770 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased risk for depression"]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121918596 del\/del genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GAG\/GAG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *12 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.","phenotypeText":["require an increased dose of catecholamines"]},{"genotypeAnnotationText":"Individuals with HIV and the GG genotype may have a decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) when treated with nevirapine as compared to patients with the GT or TT genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)"]},{"genotypeAnnotationText":"Patients with HIV infections and the CC genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.","phenotypeText":["decreased trough concentrations of amprenavir"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["similar analgesic response to codeine"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 AC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the A or AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["decreased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer event-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/null genotype (ie. have zero functional copies of the GSTM1 gene) and cancer may have increased response when treated with platinum compounds as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with a no function allele (e.g. *2\/*3) may have decreased clearance of tolbutamide as compared to patients with two normal function alleles (e.g. *1\/*1). There is currently no evidence to suggest that tolbutamide clearance is significantly different in patients carrying the * 2 allele in combination with a normal function (e.g. *1\/*2) or another decreased function (e.g. *2\/*2) allele as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs568367673 AC genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter survival times"]},{"genotypeAnnotationText":"Patients with the rs1695 AG genotype and various cancers may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["decreased risk of experiencing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores","late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with opioid dependence and the AA genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the rs6311 CC genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.","phenotypeText":["increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have an increased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying multiple copies of the *2 allele on one chromosome (*2xN) in addition to another normal function allele may be at an increased risk of drug toxicity when taking hydrocodone as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when taking hydrocodone.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the rs774072493 C\/del genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the del\/del genotype. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs4906902 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["smaller changes in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs531738678 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs11322783 G\/TT genotype and chronic hepatitis C may have increased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Hepatic cells with the AC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*5 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Patients with genotype AA and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the rs4728709 GG genotype may have an increased likelihood of developing asthenia when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["increased likelihood of developing asthenia"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 TT genotype who are treated with olanzapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to gemcitabine.","phenotypeText":["increased response to gemcitabine in people with Pancreatic Neoplasms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased metformin efficacy"]},{"genotypeAnnotationText":"Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["decreased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["decreased risk of Pancreatitis"]},{"genotypeAnnotationText":"Patients with the GG genotype who take methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham variants and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["decreased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*09:01 allele who are treated with allopurinol may have an increased risk of hypersensitivity reactions as compared to patients with no HLA-DRB1*09:01 alleles or negative for the HLA-DRB1*09:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to quit smoking, regardless of the treatment method, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's ability to quit smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with AA genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs3135506 CG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response to treatment with fenofibrate"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.","phenotypeText":["longer period before chemotherapy-induced ovarian failure"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying *28, *37 and\/or *6 alleles when treated with pazopanib may have increased risk of hyperbilirubinemia as compared to those with the extensive metabolizer genotype (*1\/*1). Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["higher rate of major cytogenetic response"]},{"genotypeAnnotationText":"Female patients with the AA genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity toward SN-38"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*6 allele or one copy of the *6 allele in combination with one copy of the *1 or *3 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["decreased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased time to relapse"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.","phenotypeText":["decreased reduction in ambulatory blood pressure"]},{"genotypeAnnotationText":"The del\/del genotype is associated with decreased catalytic activity of DPYD as compared to the del\/T or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C19*3 allele and response to citalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no significant association between the CYP2C19*3 allele and response to citalopram"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with mianserin may have decreased plasma concentration of S-mianserin as compared to patients with a decreased function allele with an activity value of 0.25 in combination with either a normal or no function allele or patients with two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["decreased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the rs121908757 AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with at least one copy of the HLA-A*31:01 allele may have an increased risk of developing DRESS as a result of taking oxcarbazepine as compared to patients who do not carry the HLA-A*31:01 allele. Other genetic and clinical factors may also affect a patient's risk of developing DRESS.","phenotypeText":["increased risk of developing DRESS"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of voriconazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS) when treated with phenytoin as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. However, one study found no association between the allele and adverse reactions. Other genetic and clinical factors may also affect risk for severe cutaneous adverse reactions in patients receiving phenytoin.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the CC genotype may have an increased response to metformin as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and depressive disorder may have an increased response to agomelatine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to agomelatine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs397508288 AA genotype (do not have a copy of the CFTR D579G variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with citalopram may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased likelihood of drug toxicity and increased likelihood of overall survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["decreased likelihood of drug toxicity","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the rs397508602 GG genotype (do not have a copy of the CFTR G1249R variant) and cystic fibrosis have an unknown response to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the genotype have not been studied.","phenotypeText":["not been studied"]},{"genotypeAnnotationText":"Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the rs745364489 AG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the CYP2D6*25 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*25 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the rs315498 CC genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs10455872 GG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["increased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs575853463 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.","phenotypeText":["decreased risk of statin-related myalgia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of nicotine as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or one copy of the *2 allele in combination with one copy of the *1 allele may be at a decreased risk of developing nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a normal function or no function allele who are treated with mianserin may have increased plasma concentration of S-mianserin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mianserin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of mianserin.","phenotypeText":["increased plasma concentration of S-mianserin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have Increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["Increased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["risk of pneumonitis"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased LDL-C reduction"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased alcohol consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.","phenotypeText":["decreased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GSTM1 non-null\/null genotype (one copy of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole\/trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null\/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["reduced risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements","increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Individuals with HIV and the GT genotype may have a decreased risk of SJS\/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS\/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.","phenotypeText":["decreased risk of SJS\/TEN and DRESS Syndrome","increased risk of SJS\/TEN and DRESS Syndrome","not associated with hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of virological response"]},{"genotypeAnnotationText":"Patients carrying the *36 allele in combination with a normal function allele may have decreased likelihood of hyperbilirubinemia when treated with atazanavir (in most studies boosted with low dose of ritonavir) as compared to patients with one or two decreased function alleles. Other genetic and clinical factors may also influence likelihood of hyperbilirubinemia in response to atazanavir.","phenotypeText":["decreased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.","phenotypeText":["increased SVR"]},{"genotypeAnnotationText":"Female children with the B\/B (reference) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["lower concentrations of topiramate and a better response to treatment with the drug"]},{"genotypeAnnotationText":"Patients with the rs193922753 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["early response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["higher plasma concentrations of the drug"]},{"genotypeAnnotationText":"The AG genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the GG genotypes, and increased concentrations of UGT1A1 and increased glucoronidation of oxazepam. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.","phenotypeText":["decreased glucoronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the rs2071559 AG genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib.","phenotypeText":["decreased overall survival and progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["shorter survival time"]},{"genotypeAnnotationText":"The CYP3A5*6 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *6 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.","phenotypeText":["decreased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have a decreased analgesic response to ketorolac as compared to patients carrying two decreased function alleles, two no function alleles, a no function allele in combination with a normal or decreased function allele or a normal function allele in combination with a decreased function allele. Other genetic and clinical factors may also influence response to ketorolac.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke with the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CC or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["response to paroxetine or antidepressants"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.","phenotypeText":["increased risk of experiencing cognitive dysfunction"]},{"genotypeAnnotationText":"African-American patients with the CC genotype (especially those who are APOE E3\/E3, also having rs429358 TT) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CT or TT genotype (carriers of E2). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["longer duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for nicotine addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for nicotine addiction"]},{"genotypeAnnotationText":"Patients with the rs771237265 AA genotype may have increased clearance of tolbutamide as compared to patients with the AC or CC genotypes. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["increased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with AA or AG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.","phenotypeText":["decreased risk for non-immune response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased progression-free survival and decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have decreased weight gain and decreased risk of edema when treated with rosiglitazone as compared to patients with the CYP2C8*1\/*1. Other genetic and clinical factors may also influence the toxicity to rosiglitazone.","phenotypeText":["decreased weight gain and decreased risk of edema"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have Increased likelihood of neutropenia or leukopenia as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["Increased likelihood of neutropenia or leukopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased likelihood of treatment-emergent suicidality"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 may have decreased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *1\/*1 or *1\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["increased risk for diabetes mellitus","decreased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.","phenotypeText":["decreased risk for an immediate reaction to beta-lactam antibiotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs118192124 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the GG genotype although . Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs34545984 GT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require a decreased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["decreased response to oxcarbazepine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 AA genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["decreased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CC genotype may have a decreased response to cytarabine and idarubicin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["increased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with TT genotype, but decreased weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Male children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency) with systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children with the B (reference) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6O allele or one copy of the *6O allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response to fluoxetine treatment"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["risk of craniofacial abnormality"]},{"genotypeAnnotationText":"Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["increased risk for induction failure"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["decreased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*28 genotype ((TA)6\/(TA)7) and ischemic heart disease may have a decreased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the *28\/*28 genotype ((TA)7\/(TA)7). Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype, or less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["more severe side effects","less severe side effects"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to metformin as compared to patients with the GG genotype and an increased response to metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin","increased response to metformin"]},{"genotypeAnnotationText":"Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.","phenotypeText":["decreased risk for hemorrhagic cystitis"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5C allele or one copy of the *5C allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype (also known as E2\/E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype, although the studies did not have C homozygotes and only reported the effect for the heterozygote. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a poorer response to docetaxel treatment as compared to patients with the AA or AG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["poorer response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*1 allele may require an increased dose of mercaptopurine as compared to patients with one uncertain function allele in combination with a normal function allele. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["increased dose of mercaptopurine"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*37 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["decreased atorvastatin concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the HLA-B*15:18\/*40:01 genotype have an increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*18 allele may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*1 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1\/*2 and *1\/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.","phenotypeText":["increased dose of valproic acid"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1\/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.","phenotypeText":["increased risk of transplant rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":["increased response to anti-TNFalpha treatment"]},{"genotypeAnnotationText":"The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased exposure to nimodipine as compared to patient with the *1\/*1 or *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.","phenotypeText":["increased exposure to nimodipine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting the opposite effect with an association of the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and increased fluoxetine response. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["increased sulfation of acetaminophen"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased metabolism of clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with depression and the TT genotype may have a decreased response to antidepressants as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the rs20455 AA genotype may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.","phenotypeText":["decreased enzymatic activity"]},{"genotypeAnnotationText":"Individuals with the *1\/*28 genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with heroin dependence and the GG genotype may have a decreased daily intake of heroin as compared to heroin-dependent patients with the AG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.","phenotypeText":["decreased daily intake of heroin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype may be more likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["more likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["lower plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with GSTT1 non-null\/null genotype may have decreased likelihood of imatinib failure in chronic myeloid leukemia patients as compared to patients with genotype null\/null. Other genetic and clinical factors may also influence the response to imatinib.","phenotypeText":["decreased likelihood of imatinib failure"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased response to combined acetaminophen and tramadol as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["greater elevation in systolic blood pressure and a greater incidence of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":["higher risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with infections and the rs1799931 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Female patients with the TT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*12 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations","achieve therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms.","phenotypeText":["response to tamoxifen treatment"]},{"genotypeAnnotationText":"Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.","phenotypeText":["more rapid clearance rates of mycophenolic acid"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the *1 allele in combination with another normal function allele may require an increased dose of methadone as compared to patients carrying two decreased function alleles. However, this association was not found to be statistically significant. Other genetic and clinical factors may also affect a patient's methadone dose requirements.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 GG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents and gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema.","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.","phenotypeText":["require an increased dose"]},{"genotypeAnnotationText":"Patients carrying two copies of the 9-repeat allele may report more drinking days as compared to patients carrying two copies of the 10-repeat allele. However, there was no significant association between this variant and the number of heavy drinking days reported or the number of drinks consumed per drinking day. Other genetic or clinical factors may also affect alcohol consumption.","phenotypeText":["more drinking days"]},{"genotypeAnnotationText":"Patients with the CG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.","phenotypeText":["decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*3 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["decreased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements"]},{"genotypeAnnotationText":"Patients with the (CA)16\/(CA)16 genotype and non-small cell lung cancer may have increased clinical response when treated with gefitinib as compared to patients with the (CA)17\/(CA)17. Other genetic and clinical factors may also influence gefitinib response.","phenotypeText":["increased clinical response"]},{"genotypeAnnotationText":"Patients with the rs1801252 AA genotype may have a decreased response to carvedilol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the rs193922762 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["required decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs4736529 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["decreased risk of experiencing major adverse cardiac events"]},{"genotypeAnnotationText":"Patients with the TT genotype have a decreased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.","phenotypeText":["decreased risk for cocaine addiction"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may require decreased dose of efavirenz as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the dose of efavirenz.","phenotypeText":["decreased dose of efavirenz"]},{"genotypeAnnotationText":"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with opioid dependence and the TT genotype may have a decreased response to methadone maintenance treatment (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["decreased response to methadone maintenance treatment"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["decreased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have a poorer response to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["poorer response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.","phenotypeText":["lower levels of toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["risk for anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*1 allele and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.","phenotypeText":["better response to treatment with methadone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:02 allele and Graves Disease may have an increased risk of agranulocytosis when treated with carbimazole or methimazole as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the rs575853463 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs1051266 TT genotype and rheumatoid arthritis may have decreased likelihood of toxicity when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["decreased likelihood of toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater increase in total cholesterol levels"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for rash"]},{"genotypeAnnotationText":"Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing kidney transplantation may have an increased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.","phenotypeText":["increased risk of new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with atomoxetine may have a decreased, but not absent, risk for treatment related side effects as compared to patients with two no function alleles. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["decreased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 GG genotype may have an increased response to treatment with docetaxel and doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.","phenotypeText":["decreased response to lenalidomide and thalidomide treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have poorer response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.","phenotypeText":["poorer response to controlled ovarian hyperstimulation"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.","phenotypeText":["more likely to experience remission"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["decreased metabolism of omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the AA genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["decreased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["increased response to milnacipran"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 or *6 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.","phenotypeText":["decreased metabolism of fentanyl"]},{"genotypeAnnotationText":"Patients with thromboembolism and the CC genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.","phenotypeText":["increased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11280056 TTA\/TTA genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with the TTA\/TTAAAGTTA or TTAAAGTTA\/TTAAAGTTA genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["better response for postprandial plasma glucose"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the CC or CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*39:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["increased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease or psoriasis, may have a better response to anti-TNF therapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have a decreased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.","phenotypeText":["greater aromatase (CYP19A1) inhibition"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4x2\/*36 or *4\/*36 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Children with the CC genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the CT or TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["smaller decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*26 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have increased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["risk of Thromboembolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Breast Neoplasms who are ER-ve\/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.","phenotypeText":["worse prognosis"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["increased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the rs10494366 TT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.","phenotypeText":["smaller QT-interval shortening effect"]},{"genotypeAnnotationText":"The A allele of rs59086055 is assigned as no function by CPIC. The GG genotype may have increased catalytic activity of DPYD as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity of DPYD"]},{"genotypeAnnotationText":"Patients with the AT genotype and stable coronary artery disease who are treated with clopidogrel may have increased risk of hemorrhage as compared to patients with the AA genotype and decreased risk as compared to the TT genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.","phenotypeText":["risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.","phenotypeText":["decreased risk for developing extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["decreased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the rs6311 CT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of Graft vs Host disease"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1 or *35 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6981827 TT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience sexual dysfunction or reproductive system disorders"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Individuals with the GG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*53 allele or one copy of the *53 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased likelihood of obesity when treated with olanzapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.","phenotypeText":["increased likelihood of obesity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["decreased response to adalimumab"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["increased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma","decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with one X-chromosome and the G genotype who are treated with risperidone may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*01:01 allele have an increased risk of nevirapine-induced adverse reactions, such as fever, rash or hepatotoxicity, as compared to patients with no HLA-DRB1*01:01 alleles or negative for the HLA-DRB1*01:01 test. Please note that some studies only examined whether patients had the HLA-DRB1*01 type. Other genetic and clinical factors may also influence risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of nevirapine-induced adverse reactions"]},{"genotypeAnnotationText":"Patients with liver cancer and the GG genotype may have increased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response to venlafaxine in people with Anxiety Disorder","decreased response to venlafaxine in people with Depressive Disorders"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AA genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["lower likelihood of experiencing an increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["require decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*12 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["less likely to quit smoking"]},{"genotypeAnnotationText":"Subjects with the CC genotype may have increased clearance of lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.","phenotypeText":["increased clearance of lorazepam"]},{"genotypeAnnotationText":"Individuals with the TT (CYP2C8*1\/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3\/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs2268639 AT genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.","phenotypeText":["decreased risk for experiencing severe cutaneous adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in addition to another no function allele may require an increased dose of tramadol as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["increased dose of tramadol"]},{"genotypeAnnotationText":"Patients with cancer and the TT genotype who are treated with capecitabine may have an increased risk of nausea and vomiting as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["increased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients (mainly pediatric patients) with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to methylphenidate treatment as compared to patients with the CG or GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response to methylphenidate treatment"]},{"genotypeAnnotationText":"Patients with at least one copy of the CYP2A6 *15 allele may have decreased enzyme activity of CYP2A6 when treated with methoxsalen as compared to patients with two copies of the CYP2A6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and methoxsalen and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect enzyme activity of CYP2A6.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients with CYP2C9*11 in combination with another normal, decreased, or no function allele may have increased risk of over-anticoagulation when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"The CYP2D6*14 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*14 allele in combination with a no or decreased function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"Patients with the rs2016520 TT genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["poorer improvement in visual acuity","better improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.","phenotypeText":["reduced clearance of cyclosporine","increased risk of infection"]},{"genotypeAnnotationText":"Patients with the AA genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with the *3\/*6 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.","phenotypeText":["increased 7-hydroxylation of coumarin"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased time to relapse"]},{"genotypeAnnotationText":"In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.","phenotypeText":["similar levels of clearance and exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["poorer overall survival times"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.","phenotypeText":["decreased likelihood of experiencing constipation"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs193922768 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs6275 GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased dose of methadone"]},{"genotypeAnnotationText":"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs121918592 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CT genotype may be associated with decreased catalytic activity of DPYD as compared to the TT genotypes and increased catalytic activity as compared to the CC genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.","phenotypeText":["increased risk for drug-resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the GG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.","phenotypeText":["decreased risk of cisplatin-induced ototoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["decreased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the rs2307116 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.","phenotypeText":["greater reduction in blood pressure and pulse wave velocity"]},{"genotypeAnnotationText":"Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.","phenotypeText":["shorter time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)7\/(T)8 genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)7 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["increased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with breast cancer and the genotype GG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype.","phenotypeText":["decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis"]},{"genotypeAnnotationText":"Patients with the rs193922816 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs61742245 AC genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require an increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased metabolism of repaglinide as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.","phenotypeText":["decreased metabolism of repaglinide"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs6269 AA genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["no significant association with morphine dose requirements"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":["decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6B allele or one copy of the *6B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*4 and depression who are treated with opipramol or maprotiline or tricyclic antidepressants 1) may have an increased risk of side effects, 2) may require a decreased dose of drug compared to patients with CYP2D6*1\/*1. Other genetic and clinical factors may also influence a patient's metabolism of opipramol or maprotiline or tricyclic antidepressants and risk of adverse effects.","phenotypeText":["increased risk of side effects","decreased dose of drug"]},{"genotypeAnnotationText":"Patients with ADHD and the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["lower psoriasis body surface area after treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk of drug toxicity and may not require dose modification when administered capecitabine and\/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.","phenotypeText":["decreased risk for anemia and thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased reduction in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CT or TT genotypes. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs1302192284 CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.","phenotypeText":["increased risk of acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the GG genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA or AG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with desipramine may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["higher baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.","phenotypeText":["better improvement in visual acuity and poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*1 genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *28\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with *1 allele in combination with another normal function allele may have increased transport and decreased concentration of atrasentan as compared to individuals carrying the *15\/*15, *1\/*15, *15\/*37 or *14\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["increased transport and decreased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with opioid dependence and the TT genotype may be at an increased risk of sudden death when using opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["increased risk of sudden death when using opioids"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and severity of sleep apnea when treated with morphine. However, patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["decreased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*5D allele or one copy of the *5D allele in combination with any *5, *6, *7 or *14A suballeles may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.","phenotypeText":["increased virological response"]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.","phenotypeText":["increased area under the concentration-time curve (AUC) of tenofovir"]},{"genotypeAnnotationText":"Patients with the GG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs3842 CC genotype may have decreased clearance of olanzapine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["decreased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.","phenotypeText":["increased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a normal function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799722 CT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of opioids as compared to patients with the GG genotype, but a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["increased dose of opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone in Children with Autism"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype may be less likely to benefit from pravastatin treatment as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.","phenotypeText":["increased risk of resistance to cyclosporine"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to respond to methotrexate"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7A allele or one copy of the *7A allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.","phenotypeText":["decreased risk for spontaneous relapse of psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased antiplatelet effect"]},{"genotypeAnnotationText":"Patients with the rs1138272 CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["decreased clearance of thiotepa"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["increased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with *37 allele in combination with another normal function allele may have increased transport and decreased concentration of atrasentan as compared to individuals carrying the *15\/*15, *1\/*15, *15\/*37 or *14\/*37 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atrasentan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atrasentan and does not include evidence about clinical outcomes.","phenotypeText":["increased transport and decreased concentration of atrasentan"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs7557402 CG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response to clozapine"]},{"genotypeAnnotationText":"Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.","phenotypeText":["similar levels of clearance of doxorubicin and exposure to doxorubicin and its metabolite doxorubicinol"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have an increased exposure to dextropropoxyphene as compared to patients with the *1\/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.","phenotypeText":["increased exposure to dextropropoxyphene"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The TT genotype is associated with increased catalytic activity of DPYD as compared to the del\/del or del\/T genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["poorer response to treatment with eculizumab"]},{"genotypeAnnotationText":"In human liver microsomes, the *1\/*22 genotype is associated with decreased metabolism of sirolimus as compared to the *1\/*1 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.","phenotypeText":["decreased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["increased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased risk of statin-related muscle symptoms"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may be less likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["less likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, another study did not see an effect of ivacaftor on CFTR-A561E activity. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["decreased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the CG genotype (one copy of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype and epilepsy may require decreased doses of lamotrigine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence lamotrigine dosage requirements.","phenotypeText":["decreased doses of lamotrigine"]},{"genotypeAnnotationText":"Patients with glioma and the CC genotype may have increased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CT genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the TT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["less likely to experience nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The CYP2C9*52 allele has been assigned as a no function allele by CPIC. Patients carrying the *52 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have greater increases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the CC or CT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater increases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the rs11125039 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk for hypertension when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.","phenotypeText":["decreased risk for hypertension"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response to paroxetine"]},{"genotypeAnnotationText":"Patients with the L\/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be less likely to drop out of treatment than patients with the S\/S genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["less likely to drop out of treatment"]},{"genotypeAnnotationText":"Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["decreased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have a decreased severity of neutropenia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking","decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased clearance of gemcitabine, and decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["increased analgesic response to morphine"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have a decreased response to olanzapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.","phenotypeText":["decreased risk of neuropathy","increased risk of neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["decreased likelihood of lymphopenia"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["less likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3\u20134 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["increased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["decreased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["higher homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the rs113993959 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.","phenotypeText":["improvement in chloride transport"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with Capecitabine may have an increased risk of of nausea and vomiting as compared to patients with the CC or CT genotypes and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["increased risk of nausea and vomiting","decreased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.","phenotypeText":["increased dose of paroxetine","increased risk of fatigue"]},{"genotypeAnnotationText":"Patients with the TT genotype have an unknown response to migalastat as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2024627 TT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased, but not absent, risk of over-anticoagulation, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.","phenotypeText":["decreased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.","phenotypeText":["decreased bone density"]},{"genotypeAnnotationText":"Patients with the rs121918593 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["similar clearance of atomoxetine"]},{"genotypeAnnotationText":"Genotype TT may be associated with increased dose of warfarin as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction and less likely to develop heart palpitations and when treated with citalopram as compared to patients with the AG or GG genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.","phenotypeText":["more likely to develop sexual dysfunction","less likely to develop heart palpitations"]},{"genotypeAnnotationText":"Patients with nicotine dependence and the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may be more likely to achieve smoking abstinence with bupropion treatment as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also affect a patient's response to bupropion treatment for nicotine dependence.","phenotypeText":["more likely to achieve smoking abstinence"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Alcohol-dependent patients with the AA genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.","phenotypeText":["decreased stress-induced alcohol cravings"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AC genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response"]},{"genotypeAnnotationText":"Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have a decreased likelihood of methotrexate response as compared to patients with the GT and TT genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["decreased likelihood of methotrexate response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs4673 AA genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["smaller increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with genotype CC and schizophrenia may have increased response to antipsychotics compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the TT genotype, and a smaller increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"The CYP3A5*7 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*7 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the rs10752271 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Children with the non-null\/null genotype (has one copy of the GSTM1 gene) and cancer who are treated with a cisplatin-based chemotherapy may have an increased risk of hearing impairment as compared to children with the null\/null genotype (no copies of the GSTM1 gene). No association was seen with severe hearing impairment in a separate study of adult patients receiving a cisplatin-containing regimen for testicular cancer treatment unless other genetic variants were taken into account. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["increased risk of hearing impairment"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*6 genotype and chronic myeloid leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *6\/*6 or *6\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["increased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*5 allele in combination with one copy of the *4D allele may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased simvastatin acid concentration when treated with simvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the metabolism of simvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and simvastatin acid or simvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased simvastatin acid concentration"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sufentanil dose requirements as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["decreased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*40 allele or one copy of the *40 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response in people with Depressive Disorder","decreased response in people with Anxiety Disorders"]},{"genotypeAnnotationText":"Patients carrying the AA genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.","phenotypeText":["increased insomnia"]},{"genotypeAnnotationText":"Patients with one X-chromosome, T genotype and psychiatric disorders who are treated with antipsychotics may have a decreased risk of weight gain as compared to patients with the C genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["decreased risk of edema"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["better response to treatment with lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.","phenotypeText":["more sensitive to treatment with erlotinib"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.","phenotypeText":["increased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC or CT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["increased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.","phenotypeText":["longer overall survival time"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.","phenotypeText":["no significant association between the rs1045642 GG genotype and response to paclitaxel"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased concentrations of Vitamin K as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["increased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*25 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.","phenotypeText":["decreased chance of survival"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but an increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia","increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.","phenotypeText":["increased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA genotype, and greater reduction of diastolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["smaller reduction of diastolic blood pressure and greater reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.","phenotypeText":["increased response to anti-TNF treatments"]},{"genotypeAnnotationText":"Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs315498 TT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs372307932 AT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["decreased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.","phenotypeText":["decreased risk for residual platelet reactivity"]},{"genotypeAnnotationText":"Genotype CC may be associated with increased uptake of adefovir dipivoxil as compared to genotype TT or CT. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["increased uptake of adefovir dipivoxil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 CT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["increased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the HLA-B*39:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*39:01 alleles or negative for the HLA-B*39:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["increased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.","phenotypeText":["more likely to require a reduction in dose","less likely to require a reduction in dose"]},{"genotypeAnnotationText":"Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["decreased response to aripiprazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and ANCA-associated vasculitis may have shorter time to failure when treated with rituximab compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to rituximab.","phenotypeText":["shorter time to failure"]},{"genotypeAnnotationText":"Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["smaller decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["increased treatment response","decreased treatment response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB3*02:02 allele have an increased risk of agranulocytosis when treated with clozapine in people with schizophrenia as compared to patients with no HLA-DRB3*02:02 allele. Other genetic and clinical factors may also influence a patient's risk of agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis who are taking methotrexate may have a decreased risk for adverse events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["decreased risk for adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.","phenotypeText":["decreased response to modafinil"]},{"genotypeAnnotationText":"Patients with this genotype were not studied.","phenotypeText":["not studied"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.","phenotypeText":["reach target blood pressure faster"]},{"genotypeAnnotationText":"Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)","phenotypeText":["better response to antidepressant treatments"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["no significant association with risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the CYP2C19*5 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*5 allele was catalytic inactive toward mephenytoin during in-vitro characterization. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["better response to treatment with imatinib"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["decreased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AA genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings.","phenotypeText":["increased cravings for nicotine"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation.","phenotypeText":["decreased risk of triglyceride elevation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased AUC of letermovir as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["decreased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.","phenotypeText":["increased systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the rs121918596 GAG\/GAG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the del\/del or del\/GAG genotypes. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may at a decreased risk of experiencing opioid-induced adverse effects, as compared to patients with the AA genotype, but at an increased risk of experiencing opioid-induced nausea and vomiting as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects.","phenotypeText":["decreased risk of opioid-induced adverse effects, increased risk of opioid-induced nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs696 CC genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["decreased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the TT genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the *3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.","phenotypeText":["decreased response to ethanol"]},{"genotypeAnnotationText":"Patients with the AT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs17222723 TT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*3 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AG genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["less likely to experience drug toxicity"]},{"genotypeAnnotationText":"In vitro, the GG genotype is associated with increased expression of TRAF1, decreased expression of MIRLET7I, and decreased sensitivity to endoxifen as compared to the CG and CC genotypes. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["decreased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["lower accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["decreased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.","phenotypeText":["increased fasting triglyceride levels and susceptibility to metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["decreased response to treatment with platinum-based chemotherapy"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["increased risk of neutropenia, leukopenia, and diarrhea"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype GGAGTC\/GGAGTC. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol"]},{"genotypeAnnotationText":"Patients with the rs1954787 TT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1384401 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with genotype AC and schizophrenia may have increased response to antipsychotics compared to patients with AA genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs12749274 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the T genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to fluoxetine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the rs121909019 AG genotype (one copy of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs444904 TT genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["decreased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased renal and secretory clearance of metformin"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the TT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2253201 GG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["increased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["increased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.","phenotypeText":["less likely to respond to treatment with cholinesterase inhibitors"]},{"genotypeAnnotationText":"Patients with the rs118192175 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The AT genotype is associated with increased expression of DPYD as compared to the TT genotypes and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence DPYD protein expression.","phenotypeText":["increased expression of DPYD"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-C*03:01 alleles or negative for the HLA-C*03:01 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCAR. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14A allele or one copy of the *14A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan or debrisoquine compared to patients with the *29\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hepatitis C may have an increased risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.","phenotypeText":["increased blood pressure"]},{"genotypeAnnotationText":"Patients with HIV and the CC genotype may have increased plasma levels of lopinavir as compared to patients with the CT or TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of lopinavir"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with pravastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT and TT genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*36 allele was found to have no activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["no increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with opioid dependence and carrying the CYP2D6*4 allele in addition to another no function allele may have an increased response to methadone maintenance therapy (MMT) as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to MMT.","phenotypeText":["increased response to methadone maintenance therapy (MMT)"]},{"genotypeAnnotationText":"Patients with the rs28360521 TT genotype may have decreased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["decreased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["require a higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["longer time to progression"]},{"genotypeAnnotationText":"Patients with the rs2304016 AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801394 GG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype or may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["increased risk for Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and gastric cancer may have a poorer response when treated with fluorouracil, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CYP3A4*1\/*22 genotype and breast cancer may have increased concentrations of exemestane as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence exemestane concentrations.","phenotypeText":["increased concentrations of exemestane"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs4140981 GG genotype may have increased clearance of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal function allele (e.g. *1\/*2) may have increased metabolism of rabeprazole as compared to patients with two no function allele (e.g. *2\/*2, *2\/*3), and decreased metabolism of rabeprazole as compared to patients with two normal function alleles. However, a number of studies showed no difference in metabolism. Patients carrying the *2 allele in combination with another no function allele (e.g., *2\/*2, *2\/*3) may have decreased metabolism of rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients carrying the NUDT15*5 allele in combination with a no function allele may tolerate decreased doses of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also affect mercaptopurine dosing.","phenotypeText":["tolerate decreased doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.","phenotypeText":["increased risk for elevated plasma lipids"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["less likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for addiction"]},{"genotypeAnnotationText":"Patients with the CG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the CC genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype and gout may require a dose lower than 300 mg\/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*24 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs1386493 AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["require decreased doses of methadone"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*1b allele or one copy of the *1b allele in combination with one copy of the *1a allele may have increased clearance of lamotrigine as compared to patients carrying two copies of the *1a allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["increased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar enzyme activity as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.","phenotypeText":["increased risk for psychosis"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the rs77409459 CC genotype (do not have a copy of the CFTR T338I variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.","phenotypeText":["decreased response to cyclophosphamide"]},{"genotypeAnnotationText":"Patients with the rs61767072 del\/del genotype may have an increased response to beta-blockers as compared to patients with the ins\/ins genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["increased response to beta-blockers"]},{"genotypeAnnotationText":"Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the GG genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["increased response to etanercept"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.","phenotypeText":["decreased, but not absent, likelihood to develop postural hypotension"]},{"genotypeAnnotationText":"Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.","phenotypeText":["increased overall survival probability"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the rs140989814 GG genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["decreased response to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*6 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of Vitamin K as compared to patients with the CC. Other clinical and genetic factors may also influence concentrations of Vitamin K.","phenotypeText":["increased concentrations of Vitamin K"]},{"genotypeAnnotationText":"Patients with the AG (i.e. UGT1A1 *1\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation","increased glucuronidation"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 AA genotype may have a decreased response to buprenorphine therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response to buprenorphine therapy"]},{"genotypeAnnotationText":"The CT genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the TT genotype and increased expression, but decreased catalytic activity as compared to the CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased expression of DPYD","increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":["decreased likelihood of progression free survival"]},{"genotypeAnnotationText":"Patients with the rs121908755 AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["decreased likelihood of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["higher response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the *1\/*22 genotype and heart failure may have increased concentrations of sildenafil as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.","phenotypeText":["increased concentrations of sildenafil"]},{"genotypeAnnotationText":"Patients with the rs708272 GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to statin treatment.","phenotypeText":["less of a reduction in cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.","phenotypeText":["increased response to selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.","phenotypeText":["longer progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs12777823 GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dosage.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.","phenotypeText":["worse response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["better response to pravastatin treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with tramadol.","phenotypeText":["similar analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.","phenotypeText":["decreased risk of developing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.","phenotypeText":["decreased risk for aspirin hypersensitivity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in addition to another normal function allele may have increased metabolism of ethylmorphine as compared to patients carrying one or more no function alleles. Other genetic and clinical factors may also affect ethylmorphine metabolism.","phenotypeText":["increased metabolism of ethylmorphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may increased likelihood of toxicity when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sunitinib toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*04:06 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["less likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone.","phenotypeText":["increased levels of the active metabolite"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the rs324029 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism and increased plasma concentrations"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs71647871 TT genotype and metabolism of enalapril. However, patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.","phenotypeText":["decreased metabolism of enalapril"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["decreased clearance of dapoxetine"]},{"genotypeAnnotationText":"The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*37 allele in combination with another normal function allele may have decreased exposure to pitavastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pitavastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to pitavastatin"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased exposure to tramadol as compared to patients with the GG genotype, but a decreased exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele have an increased risk of Stevens-Johnson Syndrome when treated with phenobarbital as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test.","phenotypeText":["increased risk of Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.","phenotypeText":["lower homocysteine levels after nitrous oxide anesthesia"]},{"genotypeAnnotationText":"Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time.","phenotypeText":["shorter disease-free survival time"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs11971167 GG genotype (do not have a copy of the CFTR D1270N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs71647871 TT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["decreased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CYP2D6*72 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*72 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with epilepsy and the CT genotype may have a worse response to oxcarbazepine as compared to patients with the TT genotype and an improved response as compared to patients with the CC genotype. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.","phenotypeText":["worse response to oxcarbazepine","improved response"]},{"genotypeAnnotationText":"Patients with the AT genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.","phenotypeText":["decreased risk for worsening of working memory"]},{"genotypeAnnotationText":"Patients with the GG genotype and Tobacco Use Disorder who are treated with varenicline may have a decreased response to varenicline as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a decreased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AC or CC genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab.","phenotypeText":["decreased response and survival times"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*1 genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3\/*3 genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["faster clearance rates and increased metabolism of midazolam"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*17 allele in combination with a no, decreased function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*17 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations similar to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Pre-menstrual patients with the AA genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the AG or GG genotypse. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["less likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:02 allele have an increased risk of agranulocytosis when treated with clozapine as compared to patients with no HLA-DRB1*04:02 allele. Other genetic and clinical factors may also influence risk of clozapine-induced agranulocytosis.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.","phenotypeText":["lowest dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["normal risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.","phenotypeText":["decreased dose requirements of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with the rs118192172 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*29 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *29 allele in combination with another decreased function allele or a no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *29 allele in combination with an increased function allele may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["greater chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.","phenotypeText":["less of a weight gain"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased exposure to fentanyl as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AA genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["increased response to acamprosate"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"No patients with the AA genotype are available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.","phenotypeText":["decreased response to clopidogrel (increased platelet reactivity)"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.","phenotypeText":["greater reduction in LDL and total cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["increased risk for nephrotoxicity"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AG genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.","phenotypeText":["increased risk of clozapine-induced Neutropenia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:05 allele have an increased risk of skin rash when treated with nevirapine as compared to patients with no HLA-B*35:05 alleles or negative for the HLA-B*35:05 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of skin rash"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CYP2B6*4 allele in combination with a normal function or an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"The CYP2D6*4xN allele (*4x2) is assigned as a no function allele by CPIC. Patients carrying the *4xN allele in combination with another no function allele who are treated with atomoxetine may have an increased risk for treatment related side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to atomoxetine.","phenotypeText":["increased risk for treatment related side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["poorer response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with the TT genotype and bladder cancer may have decreased metabolism of temsirolimus as compared to patients with the CC or CT genotypes, and an decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["decreased metabolism of temsirolimus","decreased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and gout may require a dose lower than 300 mg\/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.","phenotypeText":["lower dose requirement"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the AA genotype (homozygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.","phenotypeText":["greater risk of relapse"]},{"genotypeAnnotationText":"Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["less likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluvastatin may have a larger change in apolipoprotein A1 and C3 levels, as compared to patients with the C\/del or del\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["larger change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["decreased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotype. They also may have a shorter time between waking in the morning and the first cigarette as compared to the AG or GG genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["increased metabolism of nicotine","shorter time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["increased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*35 allele or one copy of the *35 allele in combination with one copy of the *1, *9 or *17 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*33 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased time to achieve a first INR within therapeutic range and longer time to have over-anticoagulation risk"]},{"genotypeAnnotationText":"Patients with the CT genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the rs1346563 AA genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.","phenotypeText":["increased risk of hypertension"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AA genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of infection or nausea"]},{"genotypeAnnotationText":"Patients with the A\/A genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/del or del\/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.","phenotypeText":["improved response to metformin"]},{"genotypeAnnotationText":"Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*29 allele may have decreased clearance of fentanyl as compared to patients with the *1\/*1 diplotype. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":["decreased clearance of fentanyl"]},{"genotypeAnnotationText":"Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.","phenotypeText":["increased likelihood of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype may be at a decreased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.","phenotypeText":["greater reductions in diastolic blood pressure","greater reductions in mean arterial pressure","greater reductions in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*12 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*12 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the rs77010898 GG genotype and cystic fibrosis may not respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["may not respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["decreased risk of developing hypertension"]},{"genotypeAnnotationText":"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype may have increased DPYD activity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the TT genotype, but decreased binding affinity compared to the CC genotype. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["increased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension.","phenotypeText":["decreased metabolism or clearance of irbesartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*9 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response to lithium"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have increased severity of sleep apnea when treated with morphine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.","phenotypeText":["increased severity of sleep apnea"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased metabolism of naproxen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence naproxen metabolism. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the CYP2B6*5 allele in combination with an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CG or GG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["decreased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.","phenotypeText":["decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.","phenotypeText":["decreased risk of nephrolithiasis"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and mesothelioma may have longer progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/TTAAAGTTA genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["increased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response when treated with platinum drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["reduced response to haloperidol"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotype, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["increased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of doxepin as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have an improved response to platinum compounds as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["improved response to platinum compounds"]},{"genotypeAnnotationText":"The CYP2C9*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Caucasian patients with the CC genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.","phenotypeText":["higher burden of general side-effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy.","phenotypeText":["earlier onset of bortezomib-induced peripheral neuropathy"]},{"genotypeAnnotationText":"Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.","phenotypeText":["increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*23 allele may have decreased clearance of omeprazole as compared to patients with the CYP2C19*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of omeprazole.","phenotypeText":["decreased clearance of omeprazole"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the CC genotype may be more likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects.","phenotypeText":["nausea, vomiting, or sexual dysfunction"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-B*38:02 allele may have an increased risk of agranulocytosis when treated with propylthiouracil as compared to patients with no HLA-B*38:02 alleles or negative for the HLA-B*38:02 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with propylthiouracil.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["smaller decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.","phenotypeText":["decreased response to rasagiline"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk for gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs528152707 AC genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs140039091 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*1 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and atorvastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence atorvastatin pharmacokinetics.","phenotypeText":["decreased atorvastatin concentrations"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 del\/del genotype (two copies of the F508del variant) may benefit from treatment with the combination drug of ivacaftor\/lumacaftor, as shown by improvement in sweat chloride concentrations and\/or forced expiratory volume in 1 second (FEV1) when compared to treatment with placebo. This genotype is an indication for use of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["benefit from treatment with the combination drug"]},{"genotypeAnnotationText":"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the rs193922770 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with decreased, normal or no function allele or an increased function allele with an activity value of 2 may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased allele with an activity value of 3 or greater may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with the rs397508510 CG genotype (one copy of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with CT genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the TT genotype and response to nimodipine.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin-dependence who are treated with methadone maintenance therapy may have decreased plasma concentrations of R-methadone compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["decreased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients with the AG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased systolic blood pressure following nimodipine administration as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.","phenotypeText":["increased systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib.","phenotypeText":["lower chance of achieving major molecular response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 AA genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.","phenotypeText":["increased metabolism of caffeine"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.","phenotypeText":["increased metabolism of itopride"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may be less likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs140410716 TT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia","increased risk"]},{"genotypeAnnotationText":"Patients with the CYP3A5*3 allele in combination with another *3 allele who are treated with tacrolimus may have a decreased but not absent, risk of nephrotoxicity as compared to patients with two CYP3A5*1 alleles or the combination of the *1 and *3 allele. However, a number of studies show an increased risk of nephrotoxicity for patients with two *3 alleles, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.","phenotypeText":["decreased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["increased risk for post-operative nausea and vomiting (PONV)"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.","phenotypeText":["decreased metabolism of digoxin"]},{"genotypeAnnotationText":"Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of ibuprofen"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the AG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs536577604 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with the CYP2D6*96 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*96 allele construct was found catalytically inactive during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and Parkinson's Disease may have a decreased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.","phenotypeText":["decreased risk for gastrointestinal toxicities"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better overall survival as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better overall survival"]},{"genotypeAnnotationText":"African-American patients with the CT genotype (carriers of E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration of time to reach a stable warfarin dose"]},{"genotypeAnnotationText":"Patients with the GG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.","phenotypeText":["improved response to pharmacotherapy for depression"]},{"genotypeAnnotationText":"Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["decreased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased but not absent risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have less severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the AA or AG genotypes. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["less severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the rs6928499 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["less likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["increased expression of TCL1A, IL17RA","decreased expression of IL17A, IL12RB2, and IL1R2"]},{"genotypeAnnotationText":"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AA genotype may have decreased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs376073289 CC genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of acute kidney transplant rejection"]},{"genotypeAnnotationText":"The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.","phenotypeText":["decreased likelihood of experiencing weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs113993960 del\/del genotype (two copies of the CFTR F508del variant) and response to ivacaftor. However, conflicting evidence has been reported. Ivacaftor is not recommended in cystic fibrosis patients with this genotype. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["no significant association with response to ivacaftor"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.","phenotypeText":["decreased concentrations of morphine"]},{"genotypeAnnotationText":"Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.","phenotypeText":["decreased prolactin response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk for cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the rs186045772 AA genotype (two copies of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab.","phenotypeText":["decreased survival times"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["require decreased dose"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased glucuronidation of anastrozole as compared to patients with the AA or AG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["increased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["decreased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs80282562 GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.","phenotypeText":["increased risk of Death"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the rs2108622 CC genotype may have decreased warfarin dosage requirements as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["decreased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the null\/null genotype and Hodgkin lymphoma who are on the ABVD chemotherapy regimen may have a poorer chance of achieving complete remission, and an increased risk of experiencing drug toxicities, as compared to patients with the non-null\/non-null genotype. Other genetic and clinical factors may also influence chance of remission or risk of drug toxicities when treated with the ABVD regimen.","phenotypeText":["poorer chance of achieving complete remission","increased risk of experiencing drug toxicities"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response to risperidone"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1x2 allele in combination with one copy of the *1 allele may have an increased severity of nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["increased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["increased risk of DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["reduced metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["no significant association with nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs372307932 AA genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and one copy of the CYP3A4*22 allele in combination with one copy of the *1 allele may have a decreased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.","phenotypeText":["decreased response to alprazolam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.","phenotypeText":["increased retention rates"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.","phenotypeText":["reduced exposure to methotrexate and higher likelihood of minimal residual disease"]},{"genotypeAnnotationText":"Patients with the rs3781727 TT genotype may have increased exposure to voriconazole as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.","phenotypeText":["increased exposure to voriconazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 1-4 nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs2031920 TT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Female patients homozygous for the B (reference) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.","phenotypeText":["increased survival of red blood cells"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs111869995 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["increased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.","phenotypeText":["better survival outcomes"]},{"genotypeAnnotationText":"The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*11 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["increased risk of abnormal dreams"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with gentamicin as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"Patients with the CYP2C19 *1\/*1 genotype who underwent kidney transplantation and are treated with tacrolimus may have lower tacrolimus dose-normalized trough blood concentrations (C0\/D) as compared to patients with the *2\/*2 genotype. Please note that this was studied exclusively in patients with the CYP3A5 *3\/*3 (also known as rs776746 CC) non-expresser genotype. Additionally, no significant association was seen between the donor kidney genotype and tacrolimus C0\/D. Other genetic and clinical factors may also influence a patient's tacrolimus dose-normalized trough blood concentrations.","phenotypeText":["lower tacrolimus dose-normalized trough blood concentrations"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 AG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2231142 TT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin.","phenotypeText":["increased risk of drug-induced toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3212986 CC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["increased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients carrying the *17 allele in combination with a normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of sedation"]},{"genotypeAnnotationText":"People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["decreased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs17064642 CC genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the CC genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA or AC genotypes. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"The TT genotype is associated with increased expression of DPYD, but decreased catalytic activity as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased clearance of mycophenolate mofetil"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 CC genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less likely to have improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may require a decreased dose as of acenocoumarol compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["require a decreased dose"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["worse response to dipeptidyl peptidase 4 inhibitors"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of sorafenib-induced grade 2 diarrhea"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Male patients with the TT genotype may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased likelihood of Tobacco Use Disorder"]},{"genotypeAnnotationText":"Patients with the rs34911792 GG genotype (two copies of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*98 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (higher decreases in total cholesterol)"]},{"genotypeAnnotationText":"Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.","phenotypeText":["increased major cardiovascular events rate"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may be more likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["vomiting"]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with at least one copy of the *4 allele may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of the *5, *6 or *7 alleles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.","phenotypeText":["decreased risk of distant disease progression"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and gabapentin dosage requirements. However, patients with the AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.","phenotypeText":["increased dose of gabapentin"]},{"genotypeAnnotationText":"Patients with the CG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the genotype CC who are treated with cytarabine may have reduced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.","phenotypeText":["reduced toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs6990851 AA genotype may have a decreased response to anastrozole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs.","phenotypeText":["increased likelihood of Toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["poorer response to risperidone in children with autism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of tolterodine as compared to patients with the CYP2D6*10 or *93 or *94 or *95 allele, 2) may have increased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*92 or *96 allele, and 3) similar enzyme activity of CYP2D6 compared to CYP2D6*87 or *88 or *89 or *90 or *91 or *97 or *98 allele. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["increased clearance of tolterodine","increased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.","phenotypeText":["decreased plasma concentrations of (R)-lansoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR short form (S allele) \/ HTTLPR short form (S allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with venlafaxine response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["decreased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype but increased dose requirements as compared to the CC genotype. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the rs1801252 AG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.","phenotypeText":["increased response to carvedilol"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.","phenotypeText":["less blood pressure (BP) reduction"]},{"genotypeAnnotationText":"Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response","decreased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["smaller decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["less likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs25531 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer-related pain may require a increased dose escalation of morphine as compared to patients with the AA or AC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":["increased dose escalation of morphine"]},{"genotypeAnnotationText":"Female patients with the AA genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["poorer humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with nitrofurantoin may have an increased risk of hemolysis as compared to patients with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.","phenotypeText":["increased exposure to tipifarnib"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the TT genotype or an increased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["decreased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["decreased risk of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.","phenotypeText":["decreased response to nicotine replacement therapy"]},{"genotypeAnnotationText":"Patients with the G allele may have decreased expression of LDLR as compared to patients with the A allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.","phenotypeText":["decreased expression of LDLR"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Male patients with the B (reference) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.","phenotypeText":["poorer response to the pertussis vaccine"]},{"genotypeAnnotationText":"Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["increased response to repaglinide"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.","phenotypeText":["decreased severity of heroin dependence"]},{"genotypeAnnotationText":"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Current literature evidence finds no significant effect of the GGTCCCACTCTTCCCACA\/del genotype on progression-free survival time in patients taking docetaxel.","phenotypeText":["no significant effect on progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients who carry at least one HLA-B*27:05 allele may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with no HLA-B*27:05 alleles. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol concentrations as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["increased plasma triglyceride concentrations","decreased HDL cholesterol concentrations"]},{"genotypeAnnotationText":"Patients with the AC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CT genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["later age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *3\/*3 may have a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":["decreased metabolism of cilostazol"]},{"genotypeAnnotationText":"Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type 2 diabetes may have a better response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to OADs.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CT genotype may have elevated concentrations of lumefantrine as compared to patients with the TT genotype, and lower concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["increased risk for treatment-resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype. It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:21 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:21 alleles or negative for the HLA-B*15:21 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence Severe Cutaneous Adverse Reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the rs7270101 CC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with gemcitabine may have an increased risk of toxicity when compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs570122671 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["better improvement over the first 2 weeks"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CT genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3733784 CT genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*9 allele in combination with one copy of the *1 allele may be less likely to quit smoking as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *17, *20, *23, *24, *25, *26, *27, *28 or *35 alleles or patients with two copies of the *9, *17, *20 or *35 alleles while patients with two copies of the *9 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["likelihood of quitting smoking"]},{"genotypeAnnotationText":"Healthy males with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may have a decreased response when given bumetanide, furosemide or torasemide as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.","phenotypeText":["increased inhibition of platelet aggregation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the CYP2D6*62 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*62 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have a lower rate of major cytogenetic response when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["lower rate of major cytogenetic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypertension may have decreased response to diuretics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["decreased response to diuretics"]},{"genotypeAnnotationText":"Patients with the rs2108622 CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose.","phenotypeText":["require a lower dose or higher dose with conflicting evidence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the *3C allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.","phenotypeText":["decreased risk of statin intolerance"]},{"genotypeAnnotationText":"Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk of death"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs578776 GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["unfavorable progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*7 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or CC genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.","phenotypeText":["decreased binding affinity of salbutamol to ADRB2"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and acetaldehyde concentrations. However, patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.","phenotypeText":["increased likelihood of experiencing rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["decreased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["poorer response to treatment with salvianolate"]},{"genotypeAnnotationText":"Patients with the rs3812718 CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype but a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["dose requirement"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with warfarin may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Women with the AA genotype were not studied. However, women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin in people with Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.","phenotypeText":["decreased likelihood of adverse reactions"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*6) (rs4244285\/rs72552267) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with a normal or no function allele may have increased response to esomeprazole (smaller % of time with intragastric pH < 4.0, and a higher intragastric pH during a 24-hour time period, increased likelihood of H. pylori eradication, among other parameters) as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to esomeprazole.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the TT genotype. Other factors may affect trough concentrations of telaprevir.","phenotypeText":["decreased trough concentrations of telaprevir"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.","phenotypeText":["decreased response to levodopa"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with Erectile Dysfunction"]},{"genotypeAnnotationText":"The CYP2D6*35xN alleles (*35x2) is assigned as an increased function allele by CPIC. Patients carrying a *35xN allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *35xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have a decreased response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *35xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have a similar response to ondansetron as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the GG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["decreased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["increased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["increased response to clopidogrel"]},{"genotypeAnnotationText":"Patients with the TT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"The CYP2C9*45 allele has been assigned as a no function allele by CPIC. Patients carrying the *45 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may lower weight gain when treated with antipsychotics as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"Patients with two functional CYP2C19 alleles (*1\/*1) may have increased metabolism of icotinib as compared to patients with one or two CYP2C19 loss-of-function alleles (*2 or *3). Other genetic and clinical factors may influence a patient's response to icotinib.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.","phenotypeText":["lower risk of chemotherapy-induced amenorrhea"]},{"genotypeAnnotationText":"Patients with the rs558354142 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to the first course of remission induction therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["less likely to have a complete response to the first course of remission induction therapy"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 AG genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel.","phenotypeText":["decreased metabolism of paclitaxel"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes. Other genetic and clinical factors may influence also a patient's atorvastatin response.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*19 allele or one copy of the *19 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.","phenotypeText":["higher biochemical response, optimal cytoreduction, and sensitivity to the treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.","phenotypeText":["decreased clearance of gemcitabine","increased elimination clearance of dFdU"]},{"genotypeAnnotationText":"Patients with the TT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.","phenotypeText":["reduced plasma concentrations of repaglinide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.","phenotypeText":["decreased likelihood of experiencing respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["reduced risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["less improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have an increased response to opioids as compared to patients with the AG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["increased response to opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1\/*3 or *1\/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.","phenotypeText":["decreased risk of calcineurin-inhibitor induced hepatic toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of haloperidol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of haloperidol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of haloperidol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":["increased response to anti-TNFalpha treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["greater decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.","phenotypeText":["increased risk of acute renal toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["increased median zidovudine-triphosphate concentration"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a normal or decreased function allele or two no or decreased function alleles. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying a decreased function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased concentrations of oseltamivir compared to patients with the CT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.","phenotypeText":["decreased concentrations of oseltamivir"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia and a decreased likelihood of hyperglycemia as compared to patients with the AG or AA genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of leukopenia","decreased likelihood of hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3219489 CC genotype and oral squamous cell carcinoma may have an increased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["less likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["decreased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["increased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with CYP2C9*14 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["require more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less improvement in left ventricular ejection fraction"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with everolimus may have increased likelihood of drug discontinuation as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence drug discontinuation in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of drug discontinuation"]},{"genotypeAnnotationText":"Hepatic cells with the GG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Women with the UGT1A1*28\/*28 genotype and osteoporosis may have increased metabolism of raloxifene as compared to patients with the *1\/*1 or *1\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["increased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.","phenotypeText":["decreased risk of neutropenia or hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for nausea or vomiting and be less likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy.","phenotypeText":["increased risk for nausea or vomiting","less likely to be responders to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the rs2032582 AT genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["reduced risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.","phenotypeText":["increased likelihood of mucositis","decreased likelihood of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk for Torsades de Point"]},{"genotypeAnnotationText":"Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["decreased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["decreased risk of hematologic toxicity"]},{"genotypeAnnotationText":"There is currently no evidence regarding the association between the TT genotype and response to folate supplementation in the context of pharmacotherapy for depression.","phenotypeText":["response to folate supplementation"]},{"genotypeAnnotationText":"Patients with alcoholism and the GG genotype may have a longer survival time as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence survival time in patients with alcoholism.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.","phenotypeText":["less weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2xN allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between the CYP2D6*2xN allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR G970R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs745364489 GG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 AT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Infants who have been been exposed to methadone in utero and who have the AA genotype may been more likely to require treatment for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the rs3812718 TT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["require a higher dose"]},{"genotypeAnnotationText":"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity","reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 AA genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["decreased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have decreased clearance of rivaroxaban as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":["increased metabolism of gemcitabine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation of O-desmethyl-tramadol"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["decreased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in addition to another no function allele may be at a decreased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least one normal function allele. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["decreased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*28 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["increased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with rs9958628 AA genotype may have a decreased risk of Pegaspargase Hypersensitivity as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.","phenotypeText":["decreased risk of Pegaspargase Hypersensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the G\/del genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking cessation.","phenotypeText":["lower likelihood of abstinence"]},{"genotypeAnnotationText":"Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have increased methadone dose requirements as compared to patients with the GT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.","phenotypeText":["increased risk for toxic liver disease","decreased risk for toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*4\/*31 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["altered plasma concentrations and clearance of simvastatin"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the CC genotype may have increased concentrations of apixaban as compared to patients with the TT genotype, although this is contraindicated by another study which found that the CC genotype was associated with increased clearance of apixaban as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["increased concentrations of apixaban"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of nortriptyline as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of nortriptyline as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of nortriptyline as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the AA genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the rs9934438 AA genotype may require a decreased dose of phenprocoumon as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.","phenotypeText":["require a decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with a decreased function allele with an activity value of 0.25 may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles or a normal function allele in combination with a decreased function allele with an activity value of 0.25. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7B allele or one copy of the *7B allele in combination with any suballele of *5, *6, *7 or *14 may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *4, *12A or *13A alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.","phenotypeText":["altered gene expression"]},{"genotypeAnnotationText":"Patients with the CYP2D6*114 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*114 allele was found to have a no enzymatic activity during in vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"There is currently no evidence to suggest a difference in anesthesia efficacy between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.","phenotypeText":["no difference in anesthesia efficacy"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["decreased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs10248420 AG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.","phenotypeText":["increased likelihood of developing somnolence"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["increased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*39:10 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a no function allele or another decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C9*50 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *50 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["no change in performance in attention-related tasks"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*7 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype who are taking buprenorphine for pain may have an increased analgesic response as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence analgesic response to buprenorphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["smaller reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.","phenotypeText":["increased steady-state levels of vitamin E"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["decreased response to treatment with atenolol and hydrochlorothiazide resulting in increased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the rs118192178 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the del\/del genotype may have increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["increased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["lower levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Healthy individuals with the *1\/*2 genotype may have increased concentrations of carisoprodol as compared to those with the *1\/*1 genotype. Other genetic and clinical factors may also influence pharmacokinetics of carisoprodol in an individual.","phenotypeText":["increased concentrations of carisoprodol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["increased affinity of the AKR1C4 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["decreased response to metoprolol"]},{"genotypeAnnotationText":"Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.","phenotypeText":["decreased lumbar bone loss"]},{"genotypeAnnotationText":"Patients with the CG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.","phenotypeText":["increased trough plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with ondansetron may have increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long\/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased response to sulfonylureas (increased risk of sulfonylureas treatment failure and poorer HbA1c response) as compared to patients carrying two no function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["decreased response to sulfonylureas, increased risk of treatment failure, poorer HbA1c response"]},{"genotypeAnnotationText":"Patients with the TT genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Women with the CT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*08:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-B*08:01 alleles or negative for the HLA-B*08:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["increased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the rs121908751 AA genotype (two copies of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.","phenotypeText":["higher drug toxicity score","lower drug toxicity score"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10\/*21 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *10\/*21 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.","phenotypeText":["increased likelihood of neurological adverse reactions","sleepiness"]},{"genotypeAnnotationText":"Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["better response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CC genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.","phenotypeText":["decreased risk for hemorrhagic transformation"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS.","phenotypeText":["increased risk for sinusoidal obstruction syndrome (SOS)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the rs3745274 GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.","phenotypeText":["decreased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["increased risk of asthma exacerbations"]},{"genotypeAnnotationText":"\"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution \"\"the relevance of these data is uncertain, given the low number of rare alleles\"\". Other clinical or genetic factors may also influence a patient's response.\"","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment.FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs324420 CC genotype may be at a decreased risk of experiencing adverse events when treated with morphine as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["decreased\/increased exposure to drug"]},{"genotypeAnnotationText":"Patients with acute coronary syndrome and the rs11640115 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.","phenotypeText":["increased risk of experiencing major adverse cardiac events (MACE)"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AA genotype, but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.","phenotypeText":["better improvement in disease symptoms at 3 months"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AA genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs193922764 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.","phenotypeText":["higher rate of major cytogenetic response"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["shorter period of recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["increased risk of major adverse cardiac events (mace)"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["increased risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.","phenotypeText":["decreased response to trastuzumab and shorter progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["lower adverse drug reaction scores"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["increased serum concentrations of simvastatin acid"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 3-4 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.","phenotypeText":["decreased likelihood of emerging viral drug resistance"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.","phenotypeText":["increased risk of pancreatitis"]},{"genotypeAnnotationText":"Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response to treatment with repaglinide"]},{"genotypeAnnotationText":"The CYP2D6*35xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*35xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*35xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*35xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["increased metabolism of doxepin"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*51:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2xN allele in combination with an increased or normal function allele may have a decreased response to citalopram as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs6065 CC genotype may have a decreased response and an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased response","increased risk for aspirin resistance"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a normal function allele or another decreased function allele may have increased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking hydrocodone as compared to patients carrying at least two no function alleles. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs193922772 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased lovastatin acid concentrations as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and lovastatin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence a patient's lovastatin pharmacokinetics.","phenotypeText":["increased lovastatin acid concentrations"]},{"genotypeAnnotationText":"Patients with the rs28358569 G allele (also known as the 827G allele) may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA, AC, AT, CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Individuals with the GG genotype may have a decreased risk of cocaine dependence as compared to individuals with the GT or TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the genotype AG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.","phenotypeText":["decreased response to aripiprazole in people with Schizophrenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.","phenotypeText":["decreased risk of experiencing a hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased clinical benefit to fluoxetine"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C19*19 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*19 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity as compared to *1 during several in-vitro characterizations. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the CYP2B6*1 allele in combination with another normal function allele or an increased function allele may have increased metabolism of bupropion as compared to patients with the following allele combinations: a normal function allele in combination with a decreased function allele; a normal function allele in combination with a no function allele; two decreased function alleles; a decreased function allele in combination with a no function allele. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with one copy of the CYP3A4*8 allele in combination with one copy of the *1 allele may be at an increased risk of experiencing adverse events when treated with paclitaxel as compared to patients with two copies of the *1 allele. This drug-gene pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.","phenotypeText":["increased likelihood of asthma-related exacerbations"]},{"genotypeAnnotationText":"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*51:01 allele may have an increased risk of carbamazepine-induced adverse reactions as compared to patients with no HLA-B*51:01 alleles or negative for the HLA-B*51:01 test. However, some studies find no association between this allele and adverse reactions. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of carbamazepine-induced adverse reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis"]},{"genotypeAnnotationText":"Patients with the (AGCCCACCC)12\/(AGCCCACCC)12 genotype and depression who are treated with fluoxetine may be more likely to respond to treatment as compared to patients with the non-(AGCCCACCC)12\/(AGCCCACCC)12 genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["more likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs10958704 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the rs185462714 CC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.","phenotypeText":["poorer response to metformin"]},{"genotypeAnnotationText":"Patients with the rs7557402 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs.","phenotypeText":["increased risk of ADR"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of methadone"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.","phenotypeText":["decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.","phenotypeText":["decreased clearance of imatinib and decreased event-free survival time"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the *2a\/*3a genotype may have increased metabolism of valproic acid and may need an increased dose when treated with valproic acid when compared to patients with the *1a\/*1a genotype. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["increased metabolism of valproic acid"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *6 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of coumarin as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9A or *10 alleles; patients with two copies of the *4, *7 or *9A alleles; patients carrying the *6, *7, *12, *17, *18, *19 or *20 alleles; or patients with the *4D\/*5, *4\/*7, *4\/*9A, *4\/*10, *4B\/*9A or *4C\/*9A diplotypes. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["increased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.","phenotypeText":["decreased survival","decreased risk of severe neutropenia"]},{"genotypeAnnotationText":"The rs267606618 T allele (also known as the 1095T allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin","phenotypeText":["less LDL-C reduction"]},{"genotypeAnnotationText":"Patients with breast cancer and the del\/CTGGTGAGGAGAGAACC genotype may have an improved response to cyclophosphamide and doxorubicin as compared to patients with the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype. Other clinical and genetic factors may also influence response to cyclophosphamide and doxorubicin in women with breast cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also impact the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["increased risk of biopsy-proven acute rejection at 12 month post-transplant"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.","phenotypeText":["decrease in total cholesterol"]},{"genotypeAnnotationText":"Hepatic cells with the CC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the TT genotype (two copies of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*33:03 allele who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions (SCARs) as compared to patients with no HLA-A*33:03 alleles or negative for the HLA-A*33:03 test. This allele has been shown to be in linkage disequilibrium with the HLA-B*58:01 allele in some populations, which has a strong association with allopurinol-induced SCARs. Other genetic and clinical factors may also influence risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs)"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["ACE inhibitor induced cough"]},{"genotypeAnnotationText":"In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["improved metformin efficacy"]},{"genotypeAnnotationText":"The NUDT15*2 allele is assigned as a no function allele by CPIC. Patients with the *2 allele in combination with a normal or no function allele may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["lower dose of methadone required"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with simvastatin may have a reduced response to treatment (measured by a lower reduction in total cholesterol) compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["decreased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["decreased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the G\/del genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del\/del genotype, or a decreased risk as compared to patients with the GG genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the TT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the GG genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["more likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased response","decreased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for Malignant Hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for Malignant Hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs76103438 AT genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CYP2C19*2\/*16 genotype may have decreased metabolism of methylphenobarbital as compared to patients with the *1\/*1 genotype. Other clinical and genetic factors may also affect metabolism of methylphenobarbital.","phenotypeText":["decreased metabolism of methylphenobarbital"]},{"genotypeAnnotationText":"Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.","phenotypeText":["increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with the rs1041983 CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1801086 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["increased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid\/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["higher risk of cardiovascular events"]},{"genotypeAnnotationText":"Patients with the AG genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the GG genotype, and increased plasma levels as compared to those with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["decreased plasma levels","increased plasma levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs6269 AG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.","phenotypeText":["increased risk of Pancreatitis"]},{"genotypeAnnotationText":"Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.","phenotypeText":["more likely to resume menses following chemotherapy"]},{"genotypeAnnotationText":"Patients with AA genotype and HIV may have decreased concentrations of efavirenz in plasma compared to patients with AG or GG genotypes. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.","phenotypeText":["decreased concentrations of efavirenz in plasma"]},{"genotypeAnnotationText":"Patients with the GG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.","phenotypeText":["decreased risk of liver failure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.","phenotypeText":["increased response (reductions in haemoglobin A1c and fasting plasma glucose levels)"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of suicide ideation"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the AA genotype, and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of sufentanil as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have an increased risk of granulocytopenia when treated with methotrexate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or may have a decreased risk of adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity","decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype with cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":["poorer response and treatment outcome"]},{"genotypeAnnotationText":"Patients with ankylosing spondylitis and the TT genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["increased likelihood of statin-associated myopathy and myalgia","decreased likelihood"]},{"genotypeAnnotationText":"Patients with the TT genotype may require increased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"No patients with the TT genotype were present in the population. However, patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["increased risk for new-onset posttransplant diabetes mellitus (PTDM)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["increased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.","phenotypeText":["decreased risk of developing respiratory depression"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the AA or AT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["lower increase in blood glucose"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype who are stopping methadone treatment may have less of an increase in pulse rate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["less of an increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*5 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of heroin as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["increased metabolism of heroin"]},{"genotypeAnnotationText":"Patients with the rs193922832 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs9288993 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele may have increased metabolism of metoprolol as compared to patients with one or two decreased or no function alleles. Other genetic and clinical factors may also influence metoprolol metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["decreased severity of neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater decreases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with epilepsy and the CC genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the CT or TT genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence the response of epileptic patients to anti-epileptic drugs.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the AC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Pediatric patients undergoing surgery with the GG genotype may have a decreased likelihood of adverse events, as well as an improved response to sevoflurane and remifentanil as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.","phenotypeText":["decreased likelihood of adverse events and improved response to sevoflurane and remifentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response to topiramate"]},{"genotypeAnnotationText":"Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond similarily to treatment"]},{"genotypeAnnotationText":"Patients with the rs9927200 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of dose reduction when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.","phenotypeText":["increased likelihood of dose reduction"]},{"genotypeAnnotationText":"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.","phenotypeText":["decreased response to deferasirox"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["increased severity of opioid overdose"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of venlafaxine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of venlafaxine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a decreased or no function allele but increased metabolism of venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of docetaxel and an increased risk of infusion-related reaction as compared to patients with the TT genotype. These patients may experience an increased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["increased clearance of docetaxel","increased risk of infusion-related reaction","increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["increase in systolic blood pressure and increased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Individuals who smoke and have the AA genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the AG or GG genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["decreased rates of nicotine clearance"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs28360521 CC genotype may have increased risk of gastrointestinal bleeding when treated with aspirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence gastrointestinal bleeding.","phenotypeText":["increased risk of gastrointestinal bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV who do not have the rs3745274 TT genotype may have decreased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["decreased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased exposure to pitavastatin as compared to patients with the TT genotype, but decreased exposure as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*78:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the rs540825 AA genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["decreased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to sulfonylureas as compared to patients carrying two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["decreased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.","phenotypeText":["decreased exposure of irbesartan"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine","similar metabolism of codeine","increased metabolism of codeine"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["less likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs2229205 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients carrying two copies of the 9-repeat allele may report more severe negative effects of alcohol as compared to patients carrying two copies of the 10-repeat allele. However, this association was only observed using certain scoring systems. Other genetic or clinical factors may also affect a patient's response to alcohol.","phenotypeText":["more severe negative effects of alcohol"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.","phenotypeText":["increased risk of weight gain"]},{"genotypeAnnotationText":"In vitro, the CC genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the CG and GG genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen.","phenotypeText":["increased sensitivity to endoxifen"]},{"genotypeAnnotationText":"Patients with two no function CYP2C19 alleles (*2\/*8) (rs4244285\/rs41291556) may have decreased metabolism of mephenytoin compared to patients with *1\/*1 genotype. Other genetic and clinical factors may influence a patient's metabolism of mephenytoin.","phenotypeText":["decreased metabolism of mephenytoin"]},{"genotypeAnnotationText":"Patients under general anaesthesia with genotypes GG may need increased dose of propofol as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence the dose of propofol.","phenotypeText":["increased dose of propofol"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have increased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.","phenotypeText":["increased concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CC genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotype may have a decreased overall survival as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*4 allele in combination with one copy of the *1, *46, *7 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the rs6313 AG genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone.","phenotypeText":["increased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the GG genotype may less likely to respond to drugs to treat nicotine dependence as compared to patients with the AA or AG genotypes. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["less likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["better response to treatment with duloxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["increased sulfation of tapentadol"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*56:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the rs199515342 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.","phenotypeText":["decreased sedative response"]},{"genotypeAnnotationText":"Patients with the AG genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.","phenotypeText":["decreased severity of nicotine withdrawal"]},{"genotypeAnnotationText":"Patients with the rs116855232 TT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.","phenotypeText":["increased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myeloid leukemia may have a 1) a poorer response to treatment with imatinib as compared to patients with the GG or GT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["poorer response to treatment with imatinib","increased risk of developing cytogenetic resistance to imatinib","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*7 allele in combination with one copy of the *46, *4 or *9 alleles may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may require a decreased dose of morphine as compared to patients with the GG genotype but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the CC genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.","phenotypeText":["decreased response to fluvoxamine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased serum concentrations of sertraline as compared to patients with a decreased function allele in combination with a normal or decreased function allele or may have increased serum concentrations of sertraline as compared to patients with an increased function allele in combination with a normal or increased function allele. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["decreased serum concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["risk for metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may experience greater vasodilation as compared to patients with the del\/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype when treated with acetylcholine. Other genetic and clinical factors may also influence a patient's response to acetylcholine.","phenotypeText":["greater vasodilation"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["decreased risk for nausea","increased risk for nausea"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*30 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with CC genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*8 allele in combination with another decreased function allele (e.g. *5\/*8) may have decreased metabolism of losartan as compared to patients with two normal function alleles. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 8 allele in combination with a normal function (e.g. *1\/*8) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A4 *1G\/*1G) and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1\/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.","phenotypeText":["increased intracellular and blood concentrations of cyclosporine"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tocilizumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.","phenotypeText":["increased response to calcium channel blockers in people with Hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.","phenotypeText":["decreased hematologic response"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele with another increased function allele may have increased metabolism of clopidogrel compared to two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.","phenotypeText":["decreased risk for antipsychotic-induced parkinsonism"]},{"genotypeAnnotationText":"Patients carrying the *28 allele in combination with a normal or decreased function allele may have increased likelihood of hyperbilirubinemia when treated with sorafenib as compared to patients with 2 normal function alleles. Other genetic and clinical factors may also influence sorafenib-induced hyperbilirubinemia.","phenotypeText":["increased likelihood of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["decreased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.","phenotypeText":["may respond to lumacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the ATGA\/ATGA genotype may have increased DPYD activity as compared to those with the ATGA\/del or del\/del genotypes. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype and an increased risk of diarrhea as compared to the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["increased improvement of depression symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.","phenotypeText":["risk of drug-induced ventricular arrhythmia and QT prolongation"]},{"genotypeAnnotationText":"Patients carrying two copies of the UGT1A4*2 allele or one copy of the *2 allele in combination with one copy of the *1a allele may have decreased clearance of lamotrigine as compared to patients carrying two copies of the *1a allele. This annotation only covers the pharmacokinetic relationship between UGT1A4 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.","phenotypeText":["decreased clearance of lamotrigine"]},{"genotypeAnnotationText":"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["less likely to develop sexual dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["faster response time"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["benefit"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine.","phenotypeText":["no association with response to fluvoxamine"]},{"genotypeAnnotationText":"People with the AA genotype undergoing a kidney transplantation may have increased exposure to tacrolimus, as measured by concentration\/distribution, compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.","phenotypeText":["increased risk for aspirin resistance"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron"]},{"genotypeAnnotationText":"Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["better response (increased HDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have an increased response to olanzapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["decreased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs997917 CC genotype may be at a decreased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the CC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Male patients with the A genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the G genotype in autistic children. This gene is on the X chromosome and male patients only have one allele. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["worse symptoms and a poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["decreased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the rs1611114 CT genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.","phenotypeText":["risk of experiencing memory impairment"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele who are treated with fluoxetine may have decreased metabolism of fluoxetine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluoxetine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["decreased metabolism of fluoxetine"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.","phenotypeText":["increased disease free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["gain more weight during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["less likely to have complete remission"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the TT genotype who are taking letrozole, with or without a statin, may have increased plasma concentrations of triglycerides as compared to women with the CT and CC genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["increased risk for aspirin sensitivity","decreased risk for aspirin sensitivity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the CG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and response to metformin in people with Type II diabetes mellitus.","phenotypeText":["increased clearance of metformin leading to worse response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.","phenotypeText":["increased risk of resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.","phenotypeText":["decreased incidence of adverse events, including hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.","phenotypeText":["poorer response to anti-EGFR plus irinotecan treatment"]},{"genotypeAnnotationText":"Patients with the CYP2D6*71 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*71 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"The CYP2D6*41 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*41 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*41 allele in combination with an increased function allele may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, AA homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to AG or GG subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin.","phenotypeText":["differential induction of HMGCR transcripts upon simvastatin exposure"]},{"genotypeAnnotationText":"Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of an aspirin-resistant phenotype"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["decreased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.","phenotypeText":["decreased risk of discontinuation of therapy due to severe toxicity"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors.","phenotypeText":["smoking behaviors"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele (e.g. *1\/*1) may have increased metabolism of rabeprazole as compared to patients with a normal function allele in combination with a no function allele (e.g. *1\/*2, *1\/*3) or with two no function alleles (e.g.*2\/*2, *2\/*3). However, contradictory findings are reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism of rabeprazole"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to ketoprofen as compared to patients carrying a no function allele in combination with a normal function allele. Other genetic and clinical factors may also influence response to ketoprofen.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*1 may have increased risk of drug-induced liver injury when treated with anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide and rifampin) in men with Tuberculosis as compared to patients with CYP2B6 *6\/*6. Other genetic and clinical factors may also influence the response to anti-tuberculosis drugs.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP3A4*20 allele or one copy of the *20 allele in combination with one copy of the *1 allele may have increased exposure to quetiapine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["greater decreases in triglyceride levels"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism\/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["increased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with another no function allele (e.g. *2\/*3) may have decreased metabolism of esomeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["no increased response to montelukast treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["increased serum concentrations of digoxin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["decreased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.","phenotypeText":["less likely to become addicted to alcohol"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*39 allele or one copy of the *39 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["lower plasma concentrations and higher clearance of simvastatin"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of imipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of imipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of imipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["increased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.","phenotypeText":["improved clearance of sulfasalazine"]},{"genotypeAnnotationText":"No information were reported regarding patients with the GG genotype.","phenotypeText":["No phenotype reported"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Women with the CG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.","phenotypeText":["increased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.","phenotypeText":["increased likelihood of Acute coronary syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.","phenotypeText":["increased sustained virological response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence","decreased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the *2\/*2 diplotype may have decreased metabolism as compared to patients carrying the *1\/*1 . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *1\/*28 genotype and HIV may be at decreased risk for hyperbilirubinemia when treated with indinavir as compared to patients with the *28\/*28 genotype. However, results are contradictory. Other genetic and clinical factors may also influence a patient's risk of hyperbilirubinemia when treated with indinavir.","phenotypeText":["decreased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence duloxetine response.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.","phenotypeText":["decreased risk of developing treatment emergent suicidal ideation (TESI)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the GG genotype (CYP3A4 *18B\/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1\/*1 or *1\/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.","phenotypeText":["increased metabolism of cyclosporine"]},{"genotypeAnnotationText":"The CYP2C19*25 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C19*25 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clopidogrel as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of clopidogrel.","phenotypeText":["decreased metabolism of clopidogrel"]},{"genotypeAnnotationText":"Postoperative patients with the AA genotype may have lower morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["lower morphine requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.","phenotypeText":["increased risk for stroke"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.","phenotypeText":["decreased likelihood of smoking cessation","increased risk of relapse"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype and response to venlafaxine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["decreased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the rs538703919 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.","phenotypeText":["decreased frequency of relapse"]},{"genotypeAnnotationText":"Patients with HIV and the AA genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["decreased risk of non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the rs396991 CC genotype may have an increased response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab.","phenotypeText":["increased response to rituximab"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased change in forced expiratory volume in 1 s (FEV1)"]},{"genotypeAnnotationText":"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["less likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a decreased dose of acenocoumarol as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["decreased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased response to atorvastatin as compared to patients carrying two no function alleles or one normal function allele in combination with a no function allele. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics.","phenotypeText":["decreased risk for Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvement"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.","phenotypeText":["decreased response to rivastigmine"]},{"genotypeAnnotationText":"Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["less likely to develop colorectal cancer"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose as compared to the AA genotype, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":["warfarin dose variability"]},{"genotypeAnnotationText":"Patients with the rs489693 AA genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["increased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Children with the GG genotype and acute lymphoblastic leukemia may have increased risk of neurotoxicity when taking methotrexate compared to children with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster response"]},{"genotypeAnnotationText":"Patients with the CT genotype (POR *1\/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1\/*1). Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["lower decrease in total cholesterol and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.","phenotypeText":["reduced likelihood of being overanticoagulated"]},{"genotypeAnnotationText":"Patients with the rs7297610 CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the TT genotype may have an increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":["increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone"]},{"genotypeAnnotationText":"Patients with the CC genotype who are smokers may have a lower chance of smoking cessation when treated with bupropion as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.","phenotypeText":["lower chance of smoking cessation"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a better response when treated with docetaxel and epirubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less improvement over the first 2 weeks"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the CT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs958804 CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*7 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Infants with the rs1799971 GG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with methadone for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs12678747 AA genotype may be at a decreased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.","phenotypeText":["decreased risk of developing peptic ulcers"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3\/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.","phenotypeText":["decreased risk for renal dysfunction"]},{"genotypeAnnotationText":"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically decreased heart rate"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with clozapine.","phenotypeText":["increased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation whose donor livers have the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have decreased toxicity when treated with indomethacin as compared to patients with *1\/*3 or *3\/*3 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["decreased toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.","phenotypeText":["increased risk of mortality"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with desipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the AG or GG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutations who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["increased risk for deep vein thrombosis (DVT)"]},{"genotypeAnnotationText":"Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["more effective lowering of systolic blood pressure"]},{"genotypeAnnotationText":"No information are available for the CT genotype. However, patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":["decreased affinity of the AKR1C3 enzyme for exemestane"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of fluvastatin"]},{"genotypeAnnotationText":"Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.","phenotypeText":["decreased risk of osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.","phenotypeText":["higher risk of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele or a normal function allele may have a decreased response to simvastatin as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.","phenotypeText":["decreased creatinine clearance"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1\/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.","phenotypeText":["decreased metabolism of amlodipine"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*2 allele in combination with a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with methylphenidate as compared to patients carrying two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with methylphenidate.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased risk of suicide","decreased risk of suicide"]},{"genotypeAnnotationText":"Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["decreased risk for drug toxicity"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of pantoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["decreased metabolism of pantoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["increased likelihood of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the rs11322783 GG genotype and chronic hepatitis C may have decreased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype TT\/TT or G\/TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*41\/*62 genotype (assigned as intermediate metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine.","phenotypeText":["less likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may experience decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.","phenotypeText":["decreased risk of musculoskeletal pain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with sofosbuvir and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GG genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GT or TT genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of metoprolol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of metoprolol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele but increased metabolism of metoprolol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CT (POR *1\/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the CC (*1\/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus.","phenotypeText":["increased risk for developing new-onset diabetes after transplantation"]},{"genotypeAnnotationText":"Patient harbors the rs118192178 CG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192178 C>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination one copy of the *1, *46, *2, *4, *7 or *12 alleles may have decreased metabolism of letrozole as compared. to patients with two copies of the *1 allele, two copies of the *46 allele or one copy of the *1 allele in combination with one copy of the *46 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.","phenotypeText":["better response to treatment with anti-TNF drugs"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":["decreased risk of major adverse cardiac events","increased cholesterol efflux response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:13 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS), when treated with phenytoin as compared to patients with no HLA-B*15:13 alleles or negative for the HLA-B*15:13 test. Other genetic and clinical factors, such as HLA-B*15:02, may also influence a patient's risk of phenytoin-induced adverse reactions.","phenotypeText":["increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*11:01 allele who are treated with carbamazepine may have an increased risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), as compared to patients with no HLA-A*11:01 alleles or negative for the HLA-A*11:01 test. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)"]},{"genotypeAnnotationText":"Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.","phenotypeText":["increased risk for a drug hypersensitivity reaction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to fluvoxamine as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may require a decreased dose of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence mercaptopurine dose requirements.","phenotypeText":["decreased dose requirement of mercaptopurine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*05:01 allele may have a decreased risk for drug hypersensitivity reactions when treated with nevirapine as compared to patients with no HLA-DQB1*05:01:01 alleles or negative for the HLA-DQB1*05:01:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["decreased risk for drug hypersensitivity reactions"]},{"genotypeAnnotationText":"Patients with the rs78655421 GG genotype (do not carry a copy of the CFTR R117H variant) have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with warfarin may have an increased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.","phenotypeText":["increased total and low-density lipoprotein cholesterol"]},{"genotypeAnnotationText":"Patient harbors the rs118192167 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs118192167 A>G variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele may have increased response to sulfonylureas (reduced risk of sulfonylureas treatment failure and better HbA1c response) as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.","phenotypeText":["decreased metabolism of nicotine and longer time between waking and first cigarette"]},{"genotypeAnnotationText":"Patients with epilepsy and the *1 allele in combination with another normal function allele may require an increased dose of clobazam as compared to patients with two no function allele or patients with a normal function allele in combination with a no function allele. Other genetic and clinical factors may also affect a patient's clobazam dose requirements.","phenotypeText":["increased dose requirement of clobazam"]},{"genotypeAnnotationText":"Patients with the rs1801086 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.","phenotypeText":["increased response to haloperidol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.","phenotypeText":["decreased serum concentrations of digoxin"]},{"genotypeAnnotationText":"Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["decreased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype CT or CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.","phenotypeText":["decreased risk of statin-related myopathy or myalgia"]},{"genotypeAnnotationText":"Patients with the rs34059508 AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7G allele or one copy of the *7G allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia (ALL) may have an increased risk for hepatotoxicity when treated with asparaginase as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Children with the AA genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.","phenotypeText":["reduced risk of neurotoxicity"]},{"genotypeAnnotationText":"African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*18 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.","phenotypeText":["poorer response to treatment with lithium"]},{"genotypeAnnotationText":"Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["increased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the GG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*46:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B*46:01 alleles or negative for the HLA-B*46:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["decreased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients with the rs118192172 CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.","phenotypeText":["increased risk to statin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele (in this study only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the CC or CT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["decreased response to fentanyl"]},{"genotypeAnnotationText":"Patients with the rs917881 GG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with acute myeloid leukemia and the CC genotype may have an decreased response to cytarabine and idarubicin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["decreased severity of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may require a increased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*18 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.","phenotypeText":["increased dose of fentanyl to manage postoperative pain"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.","phenotypeText":["increased risk for side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["improved symptoms and response to risperidone"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.","phenotypeText":["increased risk of nicotine dependence","increased response to smoking cessation therapies"]},{"genotypeAnnotationText":"Children with the CC genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.","phenotypeText":["better response to fluoxetine therapy"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7B allele or one copy of the *7B allele in combination with one copy of the *5A, *5B, *6A, *6B, *7A, *14A or *14B alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["require higher dose of warfarin"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.","phenotypeText":["increased survival rates"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*13A allele or one copy of the *13A allele in combination with *4 or *12A alleles may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6 , *7 or *14A suballeles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype and mesothelioma may have shorter progression-free survival time when treated with pemetrexed as compared to patients with the TTAAAGTTA\/del or del\/del genotype. Other genetic and clinical factors may also influence response to pemetrexed.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased concentrations of lovastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine.","phenotypeText":["no significant association with plasma concentrations of morphine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 GG genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association between the rs4124874 GG genotype and risk of adverse effects when treated with irinotecan"]},{"genotypeAnnotationText":"Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 GG genotype may be less sensitive to methotrexate as compared to PBMCs from individuals with the AG and AA genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.","phenotypeText":["less sensitive to methotrexate"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the rs1695 GG genotype may have an increased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["require an decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["decreased plasma concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*5 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the AG genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of drug toxicity","hematologic toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["more likely to have tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.","phenotypeText":["decreased metabolism of carbocisteine"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of hypersensitivity","decreased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.","phenotypeText":["decreased risk of urticaria and Angioedema"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["lower weight gain"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs201820739 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased severity of pain"]},{"genotypeAnnotationText":"Patients with Crohn disease and the CT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.","phenotypeText":["decreased response to adalimumab therapy"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased dose of warfarin in African American patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["decreased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a shorter recovery time from general anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.","phenotypeText":["shorter recovery time from general anesthesia"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*10 allele in combination with one copy of the *1 or *7 alleles may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CC genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["less likely to respond to fenofibrate treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin.","phenotypeText":["increased risk of Drug Toxicity","increased risk of early relapse","increased progression free survival"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of vomiting"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs3918290 CT genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["no association"]},{"genotypeAnnotationText":"Patients with the CT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the AG genotype may be at an increased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.","phenotypeText":["risk of developing thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased weight gain"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.","phenotypeText":["decreased clearance or glucuronidation of oxazepam"]},{"genotypeAnnotationText":"Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.","phenotypeText":["increased likelihood of weight gain of more than 7% of baseline body weight"]},{"genotypeAnnotationText":"Patients with the GT\/GT genotype may have increased dose of phenytoin in people with Epilepsy as compared to patients with genotype del\/del or GT\/del. Other genetic and clinical factors may also influence the dose of phenytoin.","phenotypeText":["increased dose of phenytoin"]},{"genotypeAnnotationText":"Patients with the rs61742245 CC genotype may have require a decreased dose of warfarin as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["require a decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["shorter overall survival times"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["decreased clearance and increased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.","phenotypeText":["decreased affinity to losartan"]},{"genotypeAnnotationText":"Patients with tuberculosis and the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the null\/non-null genotype may have a decreased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the AT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1, *14 or *38 alleles or patients with one copy of the *1 allele in combination with the *9, *12, *41 or *38 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.","phenotypeText":["less response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CC genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.","phenotypeText":["decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the (AGCCCACCC)12\/(AGCCCACCC)12 genotype and depression who are treated with antidepressants may have an increased risk of adverse drug reactions after switching treatment for the second time as compared to non-(AGCCCACCC)12\/(AGCCCACCC)12 genotypes. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased risk of adverse drug reactions after switching treatment for the second time"]},{"genotypeAnnotationText":"Patients with the rs11030096 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of tenoxicam as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.","phenotypeText":["decreased metabolism of tenoxicam"]},{"genotypeAnnotationText":"Patients with the non-null\/ null genotype (has one copy of the GSTT1 gene) and Tuberculosis may have a decreased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the null\/ null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["decreased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with schizophrenia and two copies of the CYP1A2*1F allele or one copy of the *1F allele in combination with one copy of the *1A allele may have decreased concentrations of clozapine as compared to patients with two copies of the *1A allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP1A2 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clozapine concentrations.","phenotypeText":["decreased concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may have an increased risk of bleeding when treated with warfarin as compared to the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have a decreased analgesic response to tramadol as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs17682789 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.","phenotypeText":["decrease in ability to efflux fluorescently labelled paclitaxel"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["decreased response to bupropion"]},{"genotypeAnnotationText":"Patients with the *13 allele in combination with a normal or no function allele may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the rs2952768 TT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with epilepsy the *1 allele in combination with another normal function allele may have a decreased response to clobazam as compared to patients with two no function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *1 allele in combination with a no function allele may have a decreased response as compared to patients with two no function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":["decreased response to clobazam"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or with one copy of the *2 allele in combination with one copy of the *1 allele may have decreased severity of nicotine dependence as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["decreased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation of acetaminophen"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1800566 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.","phenotypeText":["shorter time to progression and overall survival time"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with tramadol as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with tramadol as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with tramadol as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-DRB1*01:02 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as well as toxic liver disease as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN","toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["not have a change in likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone.","phenotypeText":["increased subjective response to oxycodone"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele or a no function allele may be at an increased risk of developing opioid dependence as a result of taking codeine as compared to patients carrying two no function alleles. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.","phenotypeText":["decreased conversion of the drug to active polyglutamates and decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["less likely to respond to citalopram treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1937840 CC genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.","phenotypeText":["decreased response to treatment with docetaxel and doxorubicin"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels.","phenotypeText":["decreased plasma levels of efavirenz"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) diplotype (heterozygous for the G6PD Mediterranean variant) who are treated with phenazopyridine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*1 genotype (designated as normal metabolizers) may have decreased plasma concentrations of maraviroc as compared to patients with intermediate metabolizer or poor metabolizer genotypes. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found either a lack of association or contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["decreased plasma concentrations of maraviroc"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the rs1142345 CC genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and hepatitis C or HIV may have an increased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["decreased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have decreased metabolism of phenprocoumon as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.","phenotypeText":["decreased metabolism of phenprocoumon"]},{"genotypeAnnotationText":"The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.","phenotypeText":["increased risk of aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele was only defined as D337G not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Female patients with the GG genotype may be less likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.","phenotypeText":["less likely to respond to nicotine replacement therapy"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the rs67376798 AT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the HLA-A*24:02 allele may have an increased risk of severe cutaneous adverse reactions (SCARs) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) when treated with carbamazepine as compared to patients with no HLA-A*24:02 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of SCARs or DRESS.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCARs) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7A allele or one copy of the *7A allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab.","phenotypeText":["greater decreases in central subfield macular thickness (CSMT)"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 GG genotype may experience an increased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["increased severity of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.","phenotypeText":["poorer response to treatment with bupropion"]},{"genotypeAnnotationText":"Patients with hypertension and the CG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["increased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the CYP3A4*20 allele may have increased exposure to fentanyl as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.","phenotypeText":["increased exposure to fentanyl"]},{"genotypeAnnotationText":"Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["lower decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["decreased risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with the rs2023239 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the CG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CC genotype and Cancer who are treated with Capecitabine may have an increased risk of of Diarrhea as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*1 allele in combination with another normal function allele and acute coronary syndrome who are treated with prasugrel may have a decreased, but not absent, risk for bleeding as compared to patients with two increased function alleles or one increased function allele in combination with a normal function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["decreased risk for bleeding"]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with CYP2C9*1\/*1 may require significantly higher dose of warfarin as compared to patients with CYP2C9 *59\/*59 or CYP2C9 *1\/*59. Other genetic and clinical factors may also influence the dose of warfarin.","phenotypeText":["significantly higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased improvement of depression symptoms"]},{"genotypeAnnotationText":"Patients with the rs7597593 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs8050894 GG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 TT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 del\/del genotype may have a decreased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs6311 TT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.","phenotypeText":["decreased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the CYP2D6*5\/*7 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of sparteine as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of sparteine.","phenotypeText":["decreased metabolism of sparteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment"]},{"genotypeAnnotationText":"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor\/tezacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype and heart failure may have decreased concentrations of sildenafil as compared to patients with the *1\/*22 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.","phenotypeText":["decreased concentrations of sildenafil"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the rs1051266 CC genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*40 allele was found to have significantly decreased enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.","phenotypeText":["more likely to require postoperative intervention with opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes CC or CG. Other genetic and clinical factors may also influence peginterferon response.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["increased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*93 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["greater increase in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype and rheumatoid arthritis may have a decreased response to treatment with anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["decreased response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.","phenotypeText":["decreased severity of opioid overdose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs77010898 AA genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs371258350 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with Graves disease and one or two copies of the HLA-DQB1*06:01 allele may have an increased risk of agranulocytosis when treated with antithyroid drugs as compared to patients with no HLA-DQB1*06:01 alleles or negative for HLA-DQB1*06:01 test. Other genetic and clinical factors may also influence risk of agranulocytosis when treated with antithyroid drugs.","phenotypeText":["increased risk of agranulocytosis"]},{"genotypeAnnotationText":"Female patients with the CC genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence.","phenotypeText":["decreased risk of developing substance dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for mucositis.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.","phenotypeText":["increased plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":["metabolize atazanavir more rapidly"]},{"genotypeAnnotationText":"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*32 allele or one copy of the *32 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*10 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/2R genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["no significant association with response to naltrexone"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased metabolism of oxycodone as compared to patients carrying two normal function alleles, two increased function alleles or a normal function allele in combination with an increased function allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["decreased metabolism of oxycodone"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of hypersensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and cardiovascular disease who are taking a statin may have a decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.","phenotypeText":["decreased likelihood of developing statin-associated myopathy and myalgia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*62 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. CPIC has not yet assigned a functional status to this allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Women with ovarian cancer and the GG genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["more likely to experience arthralgia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*55 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*55 allele construct was found to have catalytic activity but less than CYP2D6*1 during in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity of CYP2D6"]},{"genotypeAnnotationText":"Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.","phenotypeText":["decreased response","decreased risk for neutropenia"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency) who are treated with mefloquine 1) may have an increased risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the B haplotype (wildtype). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.","phenotypeText":["increased risk of pulmonary damage","similar risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of vortioxetine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and vortioxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence vortioxetine metabolism.","phenotypeText":["decreased metabolism of vortioxetine"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have a reduced response to pantoprazole (greater % of time with intragastric pH < 4.0, a lower intragastric pH during a 24-hour time period, decreased likelihood of H. pylori eradication, among other parameters) as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Patients who are infected with Helicobacter pylori (H. pylori) also received amoxicillin and\/or clarithromycin. Other genetic and clinical factors may also influence response to pantoprazole.","phenotypeText":["reduced response to pantoprazole"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.","phenotypeText":["lower likelihood of achieving remission"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of pantoprazole as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of pantoprazole as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and pantoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of pantoprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with citalopram may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting no association with the genotype and citalopram response. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["risk for pneumonitis"]},{"genotypeAnnotationText":"Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.","phenotypeText":["increased concentrations of plasma HDL cholesterol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.","phenotypeText":["decreased likelihood of Diabetes Mellitus"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*03:01 allele may have an increased risk of drug-induced liver injury when treated with infliximab as compared to patients with no HLA-DRB1*03:01 alleles or negative for the HLA-DRB1*03:01 test. Other genetic and clinical factors may also influence risk of drug-induced liver injury when treated with infliximab.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:02 allele may have an increased risk of maculopapular eruption when treated with oxcarbazepine as compared to patients with no HLA-B*13:02 alleles or negative for the HLA-B*13:02 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced adverse reactions.","phenotypeText":["increased risk of maculopapular eruption"]},{"genotypeAnnotationText":"Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.","phenotypeText":["decreased intraocular pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain.","phenotypeText":["decreased risk of Myocardial Infarction"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.","phenotypeText":["decreased risk of aspirin induced asthma"]},{"genotypeAnnotationText":"Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.","phenotypeText":["larger changes in systolic and diastolic blood pressures"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased progression-free survival and increased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have a reduced response to treatment (as measured by a lower reduction in LDL-cholesterol or total cholesterol) as compared to patients with the AG or AA genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3\u20134 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3\u20134 severe diarrhea.","phenotypeText":["decreased risk for grade 3\u20134 severe diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*13 allele or one copy of the *13 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism and decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson's disease may have an increased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.","phenotypeText":["increased risk for adverse reactions, including hallucinations and dyskinesia"]},{"genotypeAnnotationText":"Patients with breast cancer as the rs1695 AA genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the CC genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["increased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. However, patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["reduced progression-free survival"]},{"genotypeAnnotationText":"Patients with atrial fibrillation and the CT genotype may have increased concentrations of apixaban as compared to genotype TT, although this is contraindicated by another study which found that the CT and TT genotypes were associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.","phenotypeText":["increased concentrations of apixaban"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have an increased response to olanzapine as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.","phenotypeText":["larger stable dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.","phenotypeText":["better response to treatment with adalimumab"]},{"genotypeAnnotationText":"Patients with the rs678849 TT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result","phenotypeText":["no association with decreased risk of drug toxicity","increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased response to rocuronium"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression who are treated with fluoxetine may have increased response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of trimipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of trimipramine.","phenotypeText":["increased metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the S\/S genotype who are receiving methadone or buprenorphine treatment for opioid dependence may be more likely to drop out of treatment than patients with the L\/L genotype. Other genetic and clinical factors may also affect a patient's adherence to treatment with methadone or buprenorphine.","phenotypeText":["more likely to drop out of treatment"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the GG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased response to lithium"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased exposure to atorvastatin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs568367673 CC genotype may have decreased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["higher risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.","phenotypeText":["decreased risk for Neutropenia"]},{"genotypeAnnotationText":"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the AA or AG genotype. OOther genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["slower response"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of lansoprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and lansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of lansoprazole.","phenotypeText":["decreased metabolism of lansoprazole"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*17 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype AA and AG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds.","phenotypeText":["decreased risk of anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have more favorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["more favorable progression-free survival"]},{"genotypeAnnotationText":"Transplant recipients with the TT (CYP3A4 *1\/*1) genotype may require a decreased dose of sirolimus as compared to patients with the CC (*1B\/*1B) or CT (*1B\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["decreased dose requirement of sirolimus"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["increased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"The TT genotype is associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["increased catalytic activity"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The rs267606619 T allele (also known as the 1494T allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the T allele may have an increased risk of experiencing hearing loss when treated with tobramycin as compared to patients with the 1494C allele. Almost all individuals studied were homoplasmic for the T allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with tobramycin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["less likely to respond to paroxetine"]},{"genotypeAnnotationText":"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["decreased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased severity of nicotine dependence, as indicated by a lower Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.","phenotypeText":["decreased severity of nicotine dependence"]},{"genotypeAnnotationText":"Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["less sensitive to Alkylating agents"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*2xN allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased sustained virological response (svr) when treated with peginterferon\/ribavirin therapy in people with Hepatitis C as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon\/ribavirin therapy.","phenotypeText":["decreased sustained virological response"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*5 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Pediatric cancer patients with the AA genotype may have a decreased risk for ototoxicity when treated with cisplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.","phenotypeText":["decreased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with the rs9934438 GG genotype may require increased dose of acenocoumarol as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the rs140989814 (T)8\/(T)8 genotype may have increased risk of toxicity when treated with fluoropyrimidine regimens as compared to patients with the (T)7\/(T)7 genotype. Other genetic and clinical factors may also influence fluoropyrimidine toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with glioma and the CT genotype may have decreased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CC genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.","phenotypeText":["decreased response to serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["decreased risk for thiopurine-induced myelosuppression"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rivaroxaban"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype, or less likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.","phenotypeText":["complete remission"]},{"genotypeAnnotationText":"Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glipizide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.","phenotypeText":["decreased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.","phenotypeText":["decreased response to treatment with interferon alfa (IFN-alpha) therapy"]},{"genotypeAnnotationText":"No patients with the CC genotype were available for analysis, but patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["increased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.","phenotypeText":["less severe side effects"]},{"genotypeAnnotationText":"Patients with the rs10455872 AA genotype may have a decreased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AG or GG. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["decreased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.","phenotypeText":["higher LDL-C reduction"]},{"genotypeAnnotationText":"Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["lower baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs1041983 TT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.","phenotypeText":["risk of peripheral neuropathy"]},{"genotypeAnnotationText":"The AA genotype was found less often in smokers as compared to the GG genotype. In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["nicotine dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association with response to sertraline"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":["increased clearance of methotrexate","increased risk of GI toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"TT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir.","phenotypeText":["increased affinity for nucleoside phosphonate analogs"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["decreased clearance of the drug"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.","phenotypeText":["better response to docetaxel treatment"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *1 or *4 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with HIV infections and the *1\/*1 genotype may have increased clearance of lopinavir as compared to patients with the *22\/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.","phenotypeText":["increased clearance of lopinavir"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2C9*8 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["higher risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and and essential hypertension may have an increased response when treated with hypertension as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have more severe anemia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Individuals with the *1\/*2 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma","increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with the rs1801133 AA genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs3813867 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["increased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the *4\/*41 genotype and dementia may have decreased dose-adjusted plasma concentrations of galantamine as compared to patients with the *3\/*4, *4\/*4 or *4\/*5 genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["decreased dose-adjusted plasma concentrations of galantamine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.","phenotypeText":["increased response and decreased risk of uncontrolled blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the TT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.","phenotypeText":["experience nausea"]},{"genotypeAnnotationText":"Patients with the rs528152707 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs3114020 CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine.","phenotypeText":["increased concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.","phenotypeText":["decreased risk of Hemorrhage"]},{"genotypeAnnotationText":"Patients with the AG genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.","phenotypeText":["more likely to smoke when pregnant"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the *1\/*4 genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the *1\/*1 genotype. However, analysis of other measurements failed to find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.","phenotypeText":["more severe nicotine dependence"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may have a decreased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.","phenotypeText":["poorer overall survival"]},{"genotypeAnnotationText":"Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["decreased GI toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.","phenotypeText":["decreased likelihood of developing hyperglycemia"]},{"genotypeAnnotationText":"Patients with the *12 allele in combination with a normal or no function allele may have decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and conjugated estrogens and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the pharmacokinetics of estrone sulfate and estradiol 17beta-d-glucuronide.","phenotypeText":["decreased uptake of estrone sulfate and estradiol 17beta-d-glucuronide"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*17 or *17\/*17 genotype who are treated with tamoxifen may have poorer response to tamoxifen as compared to those with the *1\/*1 genotype. However, some studies find no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["poorer response to tamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CT genotype and kidney transplantation may have increased risk of neutropenia when taking valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect response to valganciclovir.","phenotypeText":["risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["more likely to be resistant to treatment"]},{"genotypeAnnotationText":"Patients carrying the *3 allele in combination with a normal function allele, decreased function allele, or no function allele (e.g. *1\/*3, *2\/*3, *3\/*3) may have decreased clearance of tolbutamide as compared to patients with two normal function alleles (e.g. *1\/*1). This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.","phenotypeText":["decreased clearance of tolbutamide"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have a poorer response when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the rs11615 AA genotype may have an increased response to treatment with cisplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 CC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.","phenotypeText":["decreased survival rates"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 GG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.","phenotypeText":["decreased risk for anemia"]},{"genotypeAnnotationText":"Patients with the TCCTC\/TCCTC genotype may have decreased but not non-existent risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide chemotherapy regimens as compared to patients with the TC\/TC or TC\/TCCTC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.s","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.","phenotypeText":["increased metabolism of deferasirox"]},{"genotypeAnnotationText":"Patients with the HLA-B*13:01 allele may have an increased risk of DRESS when treated with sulfasalazine as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence a patient's risk of sulfasalazine-induced adverse reactions.","phenotypeText":["increased risk of DRESS"]},{"genotypeAnnotationText":"Patients with bladder cancer and the GT genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity or one study reported reduced risk in heterozygotes. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.","phenotypeText":["decreased risk for induction failure"]},{"genotypeAnnotationText":"Patients with the rs6686529 CG genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.","phenotypeText":["increased sedation"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.","phenotypeText":["increased response to diuretics"]},{"genotypeAnnotationText":"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs1801086 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs1323040 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.","phenotypeText":["increased dose of atenolol"]},{"genotypeAnnotationText":"Patients with multiple sclerosis and the CC genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.","phenotypeText":["decreased response to interferon-beta"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a greater decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["greater decrease in glomerular filtration rate"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response to atenolol in hypertensive patients"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin.","phenotypeText":["increased concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the AG genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the rs1042713 AA genotype and asthma may have a decreased response to salmeterol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol.","phenotypeText":["decreased response to salmeterol"]},{"genotypeAnnotationText":"Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.","phenotypeText":["decreased response to oxcarbazepine"]},{"genotypeAnnotationText":"Patients with the CYP2D6*53 allele may have increased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*53 allele construct was found to have increased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["increased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the rs2230806 CT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response to simvastatin"]},{"genotypeAnnotationText":"The AG genotype has not been evaluated.","phenotypeText":["not been evaluated"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2\/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2\/RBV.","phenotypeText":["increased rapid virological response, complete early virologic response, sustained virological response"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.","phenotypeText":["less likely to reach target LDL levels"]},{"genotypeAnnotationText":"Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the AA genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["require decreased doses of warfarin","increased doses of warfarin"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.","phenotypeText":["decreased plasma drug levels of phenytoin"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.","phenotypeText":["increased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.","phenotypeText":["increased response to lovastatin"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.","phenotypeText":["decreased risk for body weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.","phenotypeText":["increased clearance of risperidone"]},{"genotypeAnnotationText":"Patients with the rs2336219 AG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.","phenotypeText":["decreased risk for extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for toxicity and decreased plasma level"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.","phenotypeText":["decreased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.","phenotypeText":["increased risk for acute rejection after kidney transplantation"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["decreased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*46 allele or one copy of the *46 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol)"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs10455872 AG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.","phenotypeText":["increased risk of Coronary Artery Disease"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.","phenotypeText":["increased likelihood of response"]},{"genotypeAnnotationText":"Patients with the TTA\/del genotype and hypertension may have increased response to atenolol, hydrochlorothiazide, or metoprolol as compared to patients with the TTA\/TTA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs3813867 CG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs267606617 G allele (also known as the 1555G allele) may have an increased risk of experiencing hearing loss when treated with isepamicin as compared to patients with the A allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with isepamicin.","phenotypeText":["increased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs10787959 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs1800100 TT genotype (two copies of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.","phenotypeText":["better response to treatment with imatinib","decreased risk of developing cytogenetic resistance to imatinib","decreased risk for side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["increased risk of azoospermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":["lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV)"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of warfarin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["decreased response to atenolol or bisoprolol in hypertensive patients"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*22 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*95 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs78655421 AA genotype (two copies of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response to fluorouracil, platinum compounds, or radiotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with metastasized cancer and the AT genotype may have worse response to capecitabine or fluorouracil as compared to patients with the TT genotype and improved response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Women with the UGT1A1*1\/*28 genotype and osteoporosis may have decreased metabolism of raloxifene as compared to patients with the *28\/*28 genotype as measured by formation of raloxifene 6-glucuronide and raloxifene 4'-glucuronide. However, an in vitro study found the metabolite raloxifene 6-glucuronide was increased in *1 microsomes compared to the *28 microsomes . Other genetic and clinical factors may also influence metabolism of raloxifene.","phenotypeText":["decreased metabolism of raloxifene"]},{"genotypeAnnotationText":"Patients with the CYP2D6*89 allele may have similar clearance of dapoxetine as compared to patients with the CYP2D6*1 allele. The CYP2D6*89 allele was found to have similar intrinsic clearance during in-vitro characterization with dapoxetine. Other genetic and clinical factors may also influence the metabolism of dapoxetine.","phenotypeText":["similar clearance of dapoxetine"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1800566 GG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the rs2236857 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["unlikely to be resistant to warfarin and may require a decreased dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.","phenotypeText":["decreased risk of azoospermia"]},{"genotypeAnnotationText":"In human liver microsomes, the AC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["decreased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["increased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the G6PD B (reference) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.","phenotypeText":["no significant association between the G6PD B variant and risk of hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.","phenotypeText":["increased risk of developing hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of skin rash"]},{"genotypeAnnotationText":"Patients with the CCGG\/CCGG genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["shorter overall and progression-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.","phenotypeText":["decreased progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.","phenotypeText":["increased response to anti-TNF drugs"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["decreased metabolism of sertraline"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.","phenotypeText":["increased affinity to losartan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity.","phenotypeText":["increased DPYD activity"]},{"genotypeAnnotationText":"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/del genotype (one copy of the CFTR F508del variant) may experience a limited benefit from treatment with the combination drug of ivacaftor\/lumacaftor, as shown by improvement in sweat chloride concentrations CFQ-R questionnaire scores when compared to treatment with placebo. However, ppFEV1, BMI or body weight did not show a significant improvement following ivacaftor\/lumacaftor treatment. This genotype is not an indication for use of the combination drug of ivacaftor\/lumacaftor according to the FDA-approved drug label for this drug combination. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["limited benefit"]},{"genotypeAnnotationText":"Patients with the rs538336580 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC genotype, but more likely to respond than patients with the TT genotype. Other genetic and clincial factors may also affect a patient's response to antihypertensives.","phenotypeText":["less likely to respond to antihypertensives"]},{"genotypeAnnotationText":"Patients with the TT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.","phenotypeText":["increase in pulse rate"]},{"genotypeAnnotationText":"Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*10 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the CYP2D6*10 allele in combination with a no or decreased function allele may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with HIV and the rs9349256 GG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with kanamycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5B allele or one copy of the *5B allele in combination with one copy of any suballeles of *5, *6, *7 or *14 alleles may have decreased metabolism of isoniazid as compared to patients with any *4, *12A or *13A alleles. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.","phenotypeText":["decreased risk of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.","phenotypeText":["decreased response to salbutamol in people with Asthma"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a\/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.","phenotypeText":["better response to treatment with interferon beta 1a\/1b"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with with alleles that result in intermediate or poor metabolizer phenotype who are treated with amitriptyline may have increased likelihood of side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence response to amitriptyline.","phenotypeText":["increased likelihood of side effects"]},{"genotypeAnnotationText":"Patients with the rs11651488 CC genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["risk of diarrhea"]},{"genotypeAnnotationText":"Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and tobacco use disorder may have an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.","phenotypeText":["improved response (abstinence from tobacco)"]},{"genotypeAnnotationText":"Patients with testicular cancer and the CC genotype may have an increased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of alopecia","increased risk of pain"]},{"genotypeAnnotationText":"Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.","phenotypeText":["decreased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have decreased cognitive impairment when taking methamphetamines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.","phenotypeText":["decreased cognitive impairment"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.","phenotypeText":["decreased severity of social withdrawal or nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the rs1138272 TT genotype may have increased clearance of thiotepa as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.","phenotypeText":["increased clearance of thiotepa"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.","phenotypeText":["increased risk for respiratory depression"]},{"genotypeAnnotationText":"Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*13:01 allele may have an increased risk of hypersensitivity dermatitis when exposed to trichloroethylene as compared to patients with no HLA-B*13:01 alleles or negative for the HLA-B*13:01 test. Other genetic and clinical factors may also influence a patient's risk of trichloroethylene-induced adverse reactions.","phenotypeText":["increased risk of hypersensitivity dermatitis"]},{"genotypeAnnotationText":"Patients with the *6 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype, or decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.","phenotypeText":["increased risk for addiction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels.","phenotypeText":["increased fasting glucose levels"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *36 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.","phenotypeText":["increased likelihood of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":["require an increased dose of carbamazepine"]},{"genotypeAnnotationText":"TPatients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.","phenotypeText":["increased risk of lovastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AC genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["increased risk for gastrointestinal toxicities","decreased response to folic acid and methotrexate","decreased event free survival"]},{"genotypeAnnotationText":"Patients with alcoholism, anxiety and the GG genotype may have decreased concentrations of alprazolam as compared to patients with the AG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.","phenotypeText":["decreased concentrations of alprazolam"]},{"genotypeAnnotationText":"Patients carrying the *2 allele in combination with another normal function allele may have a decreased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two decreased function alleles or a no function allele in combination with a decreased function or a normal function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["decreased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.","phenotypeText":["decreased chance of response to risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["less resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*11 allele have an increased risk of having an anaphylactoid reaction when receiving nonsteroidal anti-inflammatory drugs (NSAIDs) as compared to patients with no HLA-DRB1*11 alleles or negative for the HLA-DRB1*11 test. Other genetic and clinical factors may also influence a patient's risk of experiencing an anaphylactoid reaction when receiving NSAIDs.","phenotypeText":["increased risk of anaphylactoid reaction"]},{"genotypeAnnotationText":"Male patients with the A-202A_376G haplotype (hemizygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the CC genotype (two copies of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.","phenotypeText":["increased response to sildenafil in men with post-operative Erectile Dysfunction"]},{"genotypeAnnotationText":"Patients with the AC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype or may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for cardiovascular toxicity and symptoms"]},{"genotypeAnnotationText":"Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying one copy of the CYP2A6*25 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele or patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs118192163 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure.","phenotypeText":["decreased risk for having a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["decreased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs111869995 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with depressive disorder and the GG genotype may have smaller reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["smaller reductions in serotonin concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentration of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.","phenotypeText":["better cardiovascular outcomes"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of escitalopram as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and escitalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of escitalopram.","phenotypeText":["decreased metabolism of escitalopram"]},{"genotypeAnnotationText":"Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*97 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele construct was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["respond better to treatment with flecainide"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 CTT\/CTT genotype (no copies of the CFTR F508del variant) have an unknown response to the combination drug ivacaftor\/lumacaftor as this genotype is not an indication for ivacaftor\/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the AA genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in patients exposed to cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased international normalized ratio variability (INR-var)"]},{"genotypeAnnotationText":"Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.","phenotypeText":["higher risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased dose requirements of sufentanil as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.","phenotypeText":["decreased dose requirements of sufentanil"]},{"genotypeAnnotationText":"Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.","phenotypeText":["poorer pain relief response"]},{"genotypeAnnotationText":"Patients with the rs7668258 CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.","phenotypeText":["increased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*04:01 allele may have an increased risk of experiencing drug hypersensitivity, including cutaneous adverse reactions, when treated with nevirapine as compared to patients with no HLA-C*04:01 alleles or who are negative for the HLA-C*04:01 test. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of nevirapine-induced hypersensitivity.","phenotypeText":["increased risk of experiencing drug hypersensitivity, including cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the rs3842 TT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil.","phenotypeText":["increased severity of respiratory depression"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin.","phenotypeText":["increased response","increased progression-free survival and overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may begin using heroin at an earlier age as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.","phenotypeText":["earlier age at first use of heroin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the AA or AG genotypes. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.","phenotypeText":["increased risk of developing neurotoxicity"]},{"genotypeAnnotationText":"Patients with the UGT1A1*1\/*28 genotype may have higher glucuronidation of carvedilol as compared to patients with the *1\/*1 genotype, or lower glucuronidation as compared to patients with the *28\/*28 genotype. However, this does not appear to affect carvedilol dosing. Other genetic and clinical factors may also influence glucuronidation of carvedilol.","phenotypeText":["higher glucuronidation"]},{"genotypeAnnotationText":"Patients with the CTGGTGAGGAGAGAACC\/CTGGTGAGGAGAGAACC genotype may have decreased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC\/del or del\/del. Other genetic and clinical factors may also influence the risk of toxicity to carboplatin, cyclophosphamide and thiotepa.","phenotypeText":["decreased severity of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2B6*6 allele in combination with a normal or decreased function allele may have decreased clearance of methadone as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the CYP3A4 *22\/*22 diplotype may have increased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1\/*1 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.","phenotypeText":["increased plasma concentrations of simvastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.","phenotypeText":["increased pitavastatin plasma concentrations"]},{"genotypeAnnotationText":"Male children with lead poisoning and the B (reference) haplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["increased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.","phenotypeText":["decreased risk of sadness as a side effect"]},{"genotypeAnnotationText":"Patients with TT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":["decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic"]},{"genotypeAnnotationText":"Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["decreased risk for kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with mirtazapine may have decreased, but not absent, risk of side effects as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's response to mirtazapine.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with alleles that result in intermediate or poor metabolizer phenotype may have decreased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of amitriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of amitriptyline.","phenotypeText":["decreased metabolism of amitriptyline","increased metabolism of amitriptyline"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles or patients with *1 allele in combination with a no function allele, while patients with the *1 allele in combination with another no function allele may have increased metabolism of sirolimus as compared to patients with two no function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of sirolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.","phenotypeText":["decreased overall and progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.","phenotypeText":["increased response to etanercept treatment"]},{"genotypeAnnotationText":"Patients with the CYP2B6*2 allele in combination with an increased function allele may have increased metabolism of bupropion as compared to patients with two normal function alleles or one normal function allele in combination with a decreased function allele or two decreased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine concentrations"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence from smoking"]},{"genotypeAnnotationText":"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.","phenotypeText":["more likely to require glucarpidase treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["increased risk of post anesthesia apnea","decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of clomipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of clomipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of clomipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25.However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein A1 and C3 levels, as compared to patients with the CC or C\/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["smaller change in apolipoprotein A1 and C3 levels"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-A*02:01 allele may have a decreased, but not absent, risk of severe cutaneous adverse reactions when treated with allopurinol as compared to patients with no HLA-A*02:01 alleles or negative for the HLA-A*02:01 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["decreased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.","phenotypeText":["gain more weight during treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["decreased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the GG genotype who are treated with clozapine may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["more likely to achieve a HbA1c level of <7%"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*3, *2\/*3 or *3\/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["less likely to experience hypotension"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may require a decreased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may require a similar dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may require an increased dose of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metoprolol dose requirements.","phenotypeText":["decreased dose of metoprolol"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.","phenotypeText":["risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["decreased risk for diarrhea"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["risk for nausea"]},{"genotypeAnnotationText":"Patients with the AG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of vasomotor symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary disease may have decreased response to clopidogrel treatment compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect clopidogrel response.","phenotypeText":["decreased response to clopidogrel treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.","phenotypeText":["more likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the rs267606617 A allele (also known as the 1555A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with neomycin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with neomycin.","phenotypeText":["decreased risk of experiencing hearing loss"]},{"genotypeAnnotationText":"Patients with the rs4035887 AG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of meloxicam as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of meloxicam"]},{"genotypeAnnotationText":"Patients with the AC genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.","phenotypeText":["decreased response to latanoprost"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"No patients with the GG genotype were available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.","phenotypeText":["better overall survival times"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *1\/*3 genotype may have a greater likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *3\/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.","phenotypeText":["greater likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of lovastatin acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["better response to treatment measured by higher reductions in total cholesterol"]},{"genotypeAnnotationText":"Patients with hypertension and the GT genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*59:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, when treated with methazolamide as compared to patients with no HLA-B*59:01 alleles or negative for the HLA-B*59:01 test. Other genetic and clinical factors may also influence risk of methazolamide-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.","phenotypeText":["increased risk of experiencing transplant rejection"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DPB1*04:01 allele have a decreased risk of asthma when treated with aspirin as compared to patients with no HLA-DPB1*04:01 alleles or negative for the HLA-DPB1*04:01 test. Other genetic and clinical factors may also influence a patient's risk of aspirin-induced asthma.","phenotypeText":["decreased risk of asthma"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["increased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"The CYP2D6*17 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*17 allele in combination with a no or decreased function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*17 allele in combination with an increased function allele may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with clozapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2230345 TT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["benefit from atorvastatin and quinapril treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea","increased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.","phenotypeText":["decreased risk for cardiac events"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AC genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the CC genotype and and worse response as compared to the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response","worse response"]},{"genotypeAnnotationText":"Female patients with the AG genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*17 allele or one copy of the *17 allele in combination with one copy of the *1, *4, *20 or *35 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with two copies of the *17 allele or one copy of the *17 allele in combination with the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet reactivity","decreased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores","late decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["increased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with the TT genotype who use methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.","phenotypeText":["influence on risk of opioid dependence"]},{"genotypeAnnotationText":"People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.","phenotypeText":["increased exposure to rivaroxaban"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with the rs558354142 GG genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs4917639 CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.","phenotypeText":["increased risk of developing myopathy"]},{"genotypeAnnotationText":"Patients with the rs2239050 CG genotype may have an increased response to nimodipine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to nimodipine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s","phenotypeText":["increased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation","decreased rate of tapentadol sulfation"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.","phenotypeText":["decreased risk of breast cancer occurrence during SERM therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.","phenotypeText":["higher levels of platelet aggregation inhibition"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.","phenotypeText":["decreased pain relief"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to metoprolol as compared to patients with the CG or GG genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.","phenotypeText":["increased response to metoprolol"]},{"genotypeAnnotationText":"Patient with the TT genotype and Alzheimer's Disease may have an increased response to rivastigmine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C8*3 allele and response to ibuprofen. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ibuprofen.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.","phenotypeText":["higher rate of high on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the *1A\/*5B genotype and tuberculosis may have an increased risk for hepatotoxicity when treated with antitubercular agents as compared to those with the *1A\/*1A genotype. However, multiple studies have shown contradictory or negative evidence for this association. Other genetic and clinical factors, such as variants in the NAT2 gene, may also affect risk for hepatotoxicity in patients taking antitubercular agents.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence or opioid dependence.","phenotypeText":["increased risk of developing heroin dependence or opioid dependence"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The UGT1A1*28 allele has been assigned as decreased function by CPIC. Patients carrying the *28 allele in combination with another decreased function allele may require a decreased dose of irinotecan as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect irinotecan dose requirements.","phenotypeText":["decreased dose requirement of irinotecan"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.","phenotypeText":["decreased metabolic ratio of midazolam"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate.","phenotypeText":["decreased risk of developing cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased risk for toxicity and decreased plasma level"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs717620 TT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.","phenotypeText":["no significant association between the rs717620 TT genotype and clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with timolol may have increased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to timolol.","phenotypeText":["increased systolic and diastolic arterial pressure responses"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased metabolism of tolterodine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tolterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tolterodine metabolism.","phenotypeText":["decreased metabolism of tolterodine"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs111888148 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["poorer response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol.","phenotypeText":["decreased response to atenolol or metoprolol"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["longer overall survival times"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range (TTR)"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung cancer may have 1) a decreased risk for pneumonitis and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":["decreased risk for pneumonitis","increased risk for adverse events related to drug toxicities"]},{"genotypeAnnotationText":"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of weight gain"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with risperidone may have an increased risk of side effects as compared to patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) (Short\/Short) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism.","phenotypeText":["no significant association with risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.","phenotypeText":["decreased sulfation of tapentadol"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2229205 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased metabolism of clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.","phenotypeText":["likelihood of Lymphopenia"]},{"genotypeAnnotationText":"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with the rs368146607 GT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.","phenotypeText":["increased severity of alcohol dependence"]},{"genotypeAnnotationText":"Women with the CYP2C19 *1\/*2 diplotype may have an increased exposure to vaginal progesterone as compared to women with the *1\/*1 diplotype. Other genetic and clinical factors may also affect a patient's exposure to progesterone.","phenotypeText":["increased exposure to vaginal progesterone"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*46 allele or one copy of the *46 allele in combination with one copy of the *1 allele may have increased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the rs77010898 AG genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.","phenotypeText":["benefit when treated with ivacaftor and curcumin"]},{"genotypeAnnotationText":"Elderly patients with the *2\/*2 genotype and Type II diabetes mellitus who are administered sulfonylureas may have an increased risk of hypoglycemia as compared to patients with the *1\/*1, *1\/*2 or *1\/*3 genotypes. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.","phenotypeText":["increased risk of hypoglycemia"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*27 allele or one copy of the *27 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele while patients with one copy of the *27 allele in combination with one copy of the *1 allele may also have decreased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with the *9 or *12 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"The CYP2D6*29 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *29 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *29 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["decreased risk for treatment-resistance"]},{"genotypeAnnotationText":"Individuals with the CCT\/CCT genotype may have increased clearance of olanzapine as compared to individuals with the CCT\/del or del\/del genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased analgesic response to fentanyl as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with HIV and the CT genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["decreased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Male children with typhoid fever and the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B haplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"The GT genotype is associated with increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the TT genotype and decreased risk as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.","phenotypeText":["risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["decreased risk for nephrotoxicity"]},{"genotypeAnnotationText":"Patients with cancer and the GT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and rs3212198 T allele who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype in combination with any allele of rs3212198. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.","phenotypeText":["higher dose requirement with warfarin treatment"]},{"genotypeAnnotationText":"Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs13169373 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"The SLCO1B1*9 allele (defined as consisting of rs59502379) is assigned as a no function allele by CPIC. Patients with *9 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":["increased response","increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.","phenotypeText":["decreased or increased dose requirement of warfarin"]},{"genotypeAnnotationText":"Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.","phenotypeText":["better response to anti-VEGF treatment"]},{"genotypeAnnotationText":"Patients with the rs1051792 GG genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.","phenotypeText":["decreased response to TNF inhibitors"]},{"genotypeAnnotationText":"Patients carrying two copies of the CYP2A6*14 allele or one copy of the *14 allele in combination with one copy of the *1 allele may have increased metabolism of nicotine as compared to patients carrying any combination of the *2 or *4 alleles. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*88 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs2024627 CC genotype and cancer may have a decreased likelihood of progression-free survival when treated with everolimus as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.","phenotypeText":["decreased likelihood of progression-free survival"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may have increased exposure to vitamin K1 as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.","phenotypeText":["increased exposure to vitamin K1"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["early decrease in the percentage of HAMD scores"]},{"genotypeAnnotationText":"Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.","phenotypeText":["decreased risk of Thromboembolism"]},{"genotypeAnnotationText":"Patients with the rs2952768 CT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.","phenotypeText":["increased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["less likely to respond to aspirin"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["decreased risk of hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.","phenotypeText":["risk for angiotensin-converting enzyme inhibitors-induced cough"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.","phenotypeText":["decreased risk of sensory peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the rs185462714 AC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis.","phenotypeText":["decreased risk of experiencing thrombosis"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*2 allele in combination with another no function allele (e.g. *2\/*2) may have decreased metabolism of esomeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and esomeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of esomeprazole.","phenotypeText":["decreased metabolism of esomeprazole"]},{"genotypeAnnotationText":"Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area or severity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["decreased response to rosiglitazone"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics.","phenotypeText":["better response to treatment with loop diuretics"]},{"genotypeAnnotationText":"Patients with the rs12366035 TT genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["increased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.","phenotypeText":["decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.","phenotypeText":["increased risk of toxicity","decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have increased metabolism of brivaracetam as compared to patients with the *1\/*2, *1\/*3, *2\/*2, *2\/*3 or *3\/*3 genotype. Other genetic and clinical factors may also influence metabolism of brivaracetam.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.","phenotypeText":["decreased risk of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["increased risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased clearance of L-tryptophan"]},{"genotypeAnnotationText":"Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the CYP2D6*45 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*45 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.","phenotypeText":["decreased risk for virological failure"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.","phenotypeText":["less likely to have a child with a craniofacial abnormality"]},{"genotypeAnnotationText":"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.","phenotypeText":["decreased sensitivity to tamoxifen"]},{"genotypeAnnotationText":"Patients with the rs118192162 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["decreased likelihood of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["less likely to respond to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.","phenotypeText":["decreased hearing and vision-related side-effects"]},{"genotypeAnnotationText":"Patients with the rs13210472 AC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.","phenotypeText":["increased risk of developing cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.","phenotypeText":["more severe side effects and opioid withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["decreased rate of sulfation of tapentadol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["increased international normalized ratio variability"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["increased reduction in DNA damage"]},{"genotypeAnnotationText":"The CYP2D6*36 allele is assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with another no function allele, a normal function allele or a decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.","phenotypeText":["lower clearance of flecainide"]},{"genotypeAnnotationText":"Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism and increased plasma concentrations of siponimod as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism and increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["higher on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.","phenotypeText":["increased opioid dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased or no function allele may have an increased risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have a similar risk of experiencing side effects when treated with imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of side effects when treated with imipramine.","phenotypeText":["increased risk of experiencing side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.","phenotypeText":["lower levels of morphine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.","phenotypeText":["reduced risk of neurological adverse drug reactions"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["higher dose requirement of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["reduced response to simvastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*97 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.","phenotypeText":["increased response to amisulpride as measured by the PANSS general"]},{"genotypeAnnotationText":"Patients with the CYP2D6*22 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*22 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.","phenotypeText":["increased reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the rs28399499 CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS\/TEN when receiving nevirapine.","phenotypeText":["increased risk for Stevens-Johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.","phenotypeText":["increased risk for mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.","phenotypeText":["decreased formation of gemcitabine triphosphate"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CT genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.","phenotypeText":["increased response to methadone maintenance treatment (MMT)"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["reduced risk of late stage toxicity"]},{"genotypeAnnotationText":"People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["increased exposure to dabigatran"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*32 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.","phenotypeText":["increased risk of developing skin rash"]},{"genotypeAnnotationText":"Patients with the CT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the rs558025 AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone"]},{"genotypeAnnotationText":"Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the AT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["decreased response to methotrexate"]},{"genotypeAnnotationText":"Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.","phenotypeText":["decreased risk of hemorrhage"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs77583603 GG genotype may have a decreased response to acamprosate treatment as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to acamprosate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to hydroxyurea treatment"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["worse response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased likelihood of Drug Toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have decreased likelihood of drug resistance when treated with phenytoin as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.","phenotypeText":["decreased likelihood of drug resistance"]},{"genotypeAnnotationText":"Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["higher likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the rs3766951 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["reduced risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of nausea","decreased risk of neutropenia"]},{"genotypeAnnotationText":"The CYP2D6*17 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism of metoprolol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to metformin as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs10737062 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.","phenotypeText":["greater decrease in blood pressure"]},{"genotypeAnnotationText":"Patients with HIV and the AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.","phenotypeText":["increased severity of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["increased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the rs4240803 AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to olanzapine as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["decreased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the AA genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["decreased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the rs6269 GG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*06:02 allele may be at risk for developing narcolepsy after receiving the vaccination against the H1N1 influenza virus as compared to patients with no HLA-DQB1*06:02 alleles or negative for the HLA-DQB1*06:02 test. However, this allele is also associated with the narcolepsy independent of the H1N1 vaccine, and it is not evident from the literature whether carrying this allele is associated with the development of narcolepsy specifically due to the H1N1 vaccine. Other genetic and clinical factors may also influence a patient's risk of developing narcolepsy.","phenotypeText":["risk of developing narcolepsy"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.","phenotypeText":["decreased clearance of docetaxel","decreased risk of infusion-related reaction","decreased risk of neurotoxicity"]},{"genotypeAnnotationText":"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.","phenotypeText":["decreased risk of developing osteonecrosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of hypersensitivity to asparaginase"]},{"genotypeAnnotationText":"Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.","phenotypeText":["decreased reduction in fasting LDL-C"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association between the rs1799971 AA genotype and risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AA genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.","phenotypeText":["decreased risk for oral mucositis"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.","phenotypeText":["increased rapid response","longer progression free survival","greater irinotecan-related time to treatment failure"]},{"genotypeAnnotationText":"Patients with the TT genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["less likely to develop dizziness"]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable.","phenotypeText":["decreased risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.","phenotypeText":["decreased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs118192161 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with AC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.","phenotypeText":["increasing creatinine levels"]},{"genotypeAnnotationText":"Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801253 CC genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.","phenotypeText":["higher accumulation of active methotrexate metabolites","increased risk for thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 genotype who are administered midazolam may have faster clearance rates, and increased metabolism of midazolam as compared to patients with the CYP3A5 *3\/*3 genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["faster clearance rates, and increased metabolism of midazolam"]},{"genotypeAnnotationText":"Patients with the rs145308399 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.","phenotypeText":["increased risk for Coronary Disease"]},{"genotypeAnnotationText":"Patients with the rs5186 CC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["increased response to irbesartan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.","phenotypeText":["decreased analgesic response to opioids"]},{"genotypeAnnotationText":"Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.","phenotypeText":["poorer response to treatment with infliximab"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.","phenotypeText":["increased metabolism of tolbutamide"]},{"genotypeAnnotationText":"Patients with the rs193922803 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.","phenotypeText":["less likely to have reduced pain or attack frequency"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.","phenotypeText":["decreased metabolism of indinavir"]},{"genotypeAnnotationText":"Patients with cystic fibrosis and the rs113993960 del\/del genotype may respond to treatment with cavosonstat as measured in reduction of sweat chloride content but not in change of FEV1. However, conflicting evidence has been reported. Other clinical and genetic factors may also affect response to cavosonstat.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotype who are treated with fluoxetine may have decreased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings exist reporting the opposite effect with a decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype or no association of the variant with response to fluoxetine treatment. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["reduced risk of nephrotoxicity"]},{"genotypeAnnotationText":"Individuals with the CC genotype may have a decreased response to caffeine or chlorocresol as compared to individuals with the CT or TT genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.","phenotypeText":["decreased concentrations of ticagrelor"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*11 allele or one copy of the *11 allele in combination with one copy of the *4 allele may have decreased metabolism of tegafur as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with schizophrenia and the GG genotype may have a decreased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"The CYP2C9*13 allele has been assigned as a no function allele by CPIC. Patients carrying the *13 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.","phenotypeText":["increased risk of cough"]},{"genotypeAnnotationText":"Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs28379954 CC genotype may have increased serum concentrations of clozapine as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.","phenotypeText":["increased serum concentrations of clozapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.","phenotypeText":["decreased risk of experiencing drug resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype may require a decreased dose of morphine as compared to patients with the TT genotype but an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.","phenotypeText":["require a decreased dose of morphine"]},{"genotypeAnnotationText":"Patients with the (\\UGT1A1*28\/*28 genotype ((TA)7\/(TA)7) and ischemic heart disease may have an increased risk for hyperbilirubinemia when treated with tranilast as compared to patients with the *1\/*1 or *1\/*28 genotype ((TA)6\/(TA)6 or (TA)6\/(TA)7). Other genetic and clinical factors may also influence risk for hyperbilirubinemia.","phenotypeText":["increased risk for hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of phenylalanine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Pediatric patients with the TT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.","phenotypeText":["increased risk for dependence on methamphetamine","decreased risk for dependence on methamphetamine"]},{"genotypeAnnotationText":"Patients with CYP2C9*3 allele in combination with a normal, decreased or no function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with the AA genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.","phenotypeText":["decreased risk for hyperprolactinemia"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the AG genotype and a patient's rick of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with fluvoxamine may have a decreased, but not absent, risk of gastrointestinal side effects as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["decreased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients carrying CYP2C9*3 allele in combination with a normal function allele, a decreased function allele, or a no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.","phenotypeText":["lower dose required"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism.","phenotypeText":["increased blood alcohol concentrations and decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with the rs9923231 CC genotype may require an increased dose of acenocoumarol as compared to patients with the TT and CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.","phenotypeText":["require an increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with one X-chromosome, the G genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype C. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.","phenotypeText":["increased likelihood of antipsychotic-induced weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to successfully quit smoking for at least one year as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["successfully quit smoking"]},{"genotypeAnnotationText":"No individuals with the TT genotype (CYP3A5 *1\/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1\/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.","phenotypeText":["increased risk for neurotoxicity"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the GG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["increased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patient with the CT genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to amisulpride.","phenotypeText":["decreased response according to the PANSS negative symptoms scale"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the TT genotype and blood alcohol concentration (BAC). Other genetic and clinical factors may also affect BAC.","phenotypeText":["no available evidence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.","phenotypeText":["lower elevation in systolic blood pressure","lower incidence of side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.","phenotypeText":["shorter recurrence-free survival times"]},{"genotypeAnnotationText":"Patients with the GG genotype and heart valve replacement may require higher dose of warfarin compared to patients with the AA and AG genotypes. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs118192175 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.","phenotypeText":["increased clearance and decreased exposure to cotinine"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with atorvastatin may have an increased response to treatment as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response to treatment"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as comapred to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.","phenotypeText":["risk of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the TT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.","phenotypeText":["less likely to successfully quit smoking"]},{"genotypeAnnotationText":"The del allele of rs72549309 is assigned no function by CPIC. Patients with the del\/del genotype may have decreased DPYD activity as compared to those with the ATGA\/ATGA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine.","phenotypeText":["increased metabolism of cyclosporine","increased clearance of cyclosporine","decreased risk in adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased response to nortriptyline"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CT and TT genotypes. Other factors may affect response to these drugs.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["decreased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CYP2D6*90 allele may have a decreased clearance of atomoxetine as compared to patients with the CYP2D6*1 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of atomoxetine.","phenotypeText":["decreased clearance of atomoxetine"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.","phenotypeText":["decreased alanine aminotransferase levels"]},{"genotypeAnnotationText":"Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with heroin dependence and the AA genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the HLA-G del\/del genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the HLA-G del\/ATTTGTTCATGCCT or ATTTGTTCATGCCT\/ATTTGTTCATGCCT genotypes. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.","phenotypeText":["worse response to capecitabine or fluorouracil"]},{"genotypeAnnotationText":"Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT or AT. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of desipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of desipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.","phenotypeText":["decreased likelihood of drug toxicity"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype may have a decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*28 or *28\/*28 genotype. Other genetic and clinical factors may also influence likelihood of fatigue when receiving olanzapine.","phenotypeText":["decreased likelihood of fatigue"]},{"genotypeAnnotationText":"Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs193922809 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe\/unsafe hemoglobin decreases as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone.","phenotypeText":["increased risk of hemolysis and severe\/unsafe hemoglobin decreases"]},{"genotypeAnnotationText":"Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.","phenotypeText":["require higher warfarin dose"]},{"genotypeAnnotationText":"Patients with the CC genotype may have lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sunitinib.","phenotypeText":["lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.","phenotypeText":["no different response to ustekinumab"]},{"genotypeAnnotationText":"Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response to citalopram"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.","phenotypeText":["decreased metabolism of imipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["more benefit from statin treatment in reducing the risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers.","phenotypeText":["better blood pressure response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response to allopurinol"]},{"genotypeAnnotationText":"Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GA genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.","phenotypeText":["decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying CYP2C8*3 allele may have reduced metabolism of diclofenac as compared to patients with CYP2C8*1\/*1. Other genetic and clinical factors may also impact the metabolism of diclofenac.","phenotypeText":["reduced metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.","phenotypeText":["increased risk for dose reductions due to toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated gemcitabine and platinum compounds may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.","phenotypeText":["increased risk for nausea"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have an decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with a high dose of chloroquine may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the A-\/A- or B\/B diplotype. Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["better response to risperidone"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.","phenotypeText":["increased response to olanzapine"]},{"genotypeAnnotationText":"Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.","phenotypeText":["better humoral and renal hemodynamic responses"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response to treatment with duloxetine for major depressive disorder"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased likelihood of osteonecrosis"]},{"genotypeAnnotationText":"Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.","phenotypeText":["worse overall and progression-free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"There is currently no available evidence regarding any association between the TT genotype and severity of neonatal abstinence syndrome. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["no available evidence regarding any association"]},{"genotypeAnnotationText":"Patients with the GSTM1 non-null\/non-null genotype (two copies of the GSTM1 gene) and AIDs who are treated with sulfamethoxazole\/trimethoprim may have a reduced, but not absent risk, of cutaneous reactions as compared to patients with the null\/null genotype combined with a NAT2 slow acetylator genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced cutaneous reactions.","phenotypeText":["reduced risk of cutaneous reactions"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["poorer blood pressure response"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV may have increased exposure to atazanavir as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.","phenotypeText":["increased exposure to atazanavir"]},{"genotypeAnnotationText":"Infants with the rs1799971 GG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.","phenotypeText":["increased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.","phenotypeText":["decreased likelihood of myelosuppression"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased remifentanil requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.","phenotypeText":["decreased remifentanil requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased response to antidepressants","increased risk for suicide ideation"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.","phenotypeText":["increased plasma concentrations of O-desmethyltramadol"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs3813867 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.","phenotypeText":["decreased risk of adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the CC genotype and a lower likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.","phenotypeText":["increase in serum creatine kinase"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["decreased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["increased risk for resistant hypertension"]},{"genotypeAnnotationText":"Pediatric patients with epilepsy and the AG genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotypes and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with genotype TT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.","phenotypeText":["increased severity of opioid withdrawal symptoms and side effects"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of myelosuppression when treated with mercaptopurine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.","phenotypeText":["decreased risk of myelosuppression"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["decreased risk of nausea and vomiting","decreased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with the rs3812718 CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["require a lower dose"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.","phenotypeText":["decreased clearance of cefotaxime"]},{"genotypeAnnotationText":"Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.","phenotypeText":["decreased response to duloxetine"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.","phenotypeText":["decreased risk for adverse cardiovascular outcomes"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.","phenotypeText":["increased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.","phenotypeText":["smaller decrease in diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with genotype GG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs17708472 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs193922816 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype may have an increased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron as compared to patients with the HTTLPR long form (L allele)\/HTTLPR short form (S allele) or HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.","phenotypeText":["increased percentage of days abstinent and lower number of drinks per drinking day"]},{"genotypeAnnotationText":"Patients with testicular cancer and the TT genotype may have an increased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.","phenotypeText":["more likely to respond to paroxetine or antidepressants"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) and colorectal cancer may have a decreased risk of asthenia when treated with irinotecan and raltitrexed as compared to patients with the 2R\/3R or 3R\/3R genotype. Other genetic and clinical factors may also influence risk of asthenia.","phenotypeText":["decreased risk of asthenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*5 allele in combination with a normal or no function allele may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":["decreased metabolism of carvedilol"]},{"genotypeAnnotationText":"Patients with the rs1954787 CC genotype and depressive disorders may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.","phenotypeText":["decreased catalytic activity and increased expression of DPYD protein"]},{"genotypeAnnotationText":"Patients with the rs2244613 TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["decreased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Individuals with the *2\/*3 genotype were more likely to experience hypotension when receiving olanzapine as compared to individuals with the *1\/*1, *1\/*2 or *2\/*2 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.","phenotypeText":["hypotension"]},{"genotypeAnnotationText":"Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine.","phenotypeText":["decreased risk of Stevens-Johnson syndrome"]},{"genotypeAnnotationText":"Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.","phenotypeText":["reduced response to losartan"]},{"genotypeAnnotationText":"Patients with the rs696 TT genotype may require increased doses of sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence sufentanil dosage requirements.","phenotypeText":["require increased doses of sufentanil"]},{"genotypeAnnotationText":"Patients with the CC genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the TT genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["decreased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.","phenotypeText":["less likely to achieve target LDL levels"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.","phenotypeText":["lower likelihood of developing myalgia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.","phenotypeText":["less likely to experience insomnia"]},{"genotypeAnnotationText":"Patients with the GG genotype and who are treated with allopurinol may have a decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA or AG genotypes. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.","phenotypeText":["decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome"]},{"genotypeAnnotationText":"Patients with the rs4948496 CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate.","phenotypeText":["increased concentrations of methotrexate"]},{"genotypeAnnotationText":"Patients with cancer and the CC genotype who are treated with capecitabine may have decreased (but not absent) risk of hyperbilirubinemia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs71647871 CT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.","phenotypeText":["decreased metabolism of heroin"]},{"genotypeAnnotationText":"People with intermediate metabolizer genotypes (e.g. *2\/*17) may have decreased risk of hypertension when taking 3,4-methylenedioxymethamphetamine compared to people with poor metabolizer genotypes. Other clinical and genetic factors may affect side effects to 3,4-methylenedioxymethamphetamine.","phenotypeText":["decreased risk of hypertension"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele or one copy of the *1 allele in combination with one copy of the *46 allele may have increased metabolism of letrozole as compared to patients with any of the following genotypes: one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *12 or *17 alleles; one copy of the *46 allele in combination with one copy of the *4, *7 or *9 alleles; two copies of the *9 allele; two copies of the *17 allele; one copy of the *4 allele in combination with one copy of the *7 or *9 alleles; one copy of the *9 allele in combination with one copy of the *2 or *12 allele; one copy of the *17 allele in combination with one copy of the *35 allele; one copy of the *20 allele in combination with one copy of the *23 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.","phenotypeText":["reduced risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the rs571335587 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.","phenotypeText":["increased risk of drug induced liver injury"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine\/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.","phenotypeText":["improved response to cisplatin and gemcitabine"]},{"genotypeAnnotationText":"The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of lornoxicam as compared to patients with at lease one decreased or no function allele. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["increased risk for toxicity"]},{"genotypeAnnotationText":"The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of sertraline as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of sertraline as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and chronic hepatitis C or HIV may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["increased likelihood of sustained virological response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased nicotine consumption as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption.","phenotypeText":["increased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.","phenotypeText":["greater decrease of hepatic venous pressure gradient"]},{"genotypeAnnotationText":"Patients who are smokers and who have the GG genotype may have decreased cigarette consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect cigarette consumption.","phenotypeText":["decreased cigarette consumption"]},{"genotypeAnnotationText":"Postmenopausal women with HR+breast cancer and the AG genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.","phenotypeText":["increased likelihood of experiencing arthralgia"]},{"genotypeAnnotationText":"Patients with the rs4680 AA genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with genotype AA and schizophrenia may have decreased response to antipsychotics compared to patients with AC or CC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.","phenotypeText":["decreased response to antipsychotics"]},{"genotypeAnnotationText":"Patients with the rs118192177 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs10306114 AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["increased risk for non-response to aspirin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs11615 AG genotype and risk of developing mucositis when treated with cisplatin and doxorubicin. However, patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.","phenotypeText":["risk of developing mucositis"]},{"genotypeAnnotationText":"Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.","phenotypeText":["decreased risk for bradycardia"]},{"genotypeAnnotationText":"Patients with the rs4961 GG genotype may have decreased response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone.","phenotypeText":["decreased analgesic response"]},{"genotypeAnnotationText":"Patients with the CG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.","phenotypeText":["decreased risk of diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.","phenotypeText":["reduced metabolism of antiepileptics"]},{"genotypeAnnotationText":"Patients with the CCT\/del genotype may have increased risk of side effects (thrombocytopenia, anemia and neuropathy) with cisplatin and cyclophosphamide therapy as compared to patients with the CCT\/CCT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events.","phenotypeText":["increased risk of side effects (thrombocytopenia, anemia and neuropathy)"]},{"genotypeAnnotationText":"Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.","phenotypeText":["reduced risk of distant disease progression"]},{"genotypeAnnotationText":"Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.","phenotypeText":["require a fewer number of bevacizumab injections"]},{"genotypeAnnotationText":"Patients with cancer pain and the AA genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to adhere to nicotine replacement therapy (NRT) and may consume more NRT at 7 days post quit attempt as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["adherence to nicotine replacement therapy and consumption of NRT"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":["decreased risk of leukopenia"]},{"genotypeAnnotationText":"Women with the AA genotype and breast cancer may have decreased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["decreased progression-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.","phenotypeText":["lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs)"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*7 allele or one copy of the *7 allele in combination with one copy of the *4 or *9 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["increased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and an increased likelihood of asthenia as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.","phenotypeText":["decreased risk of nausea and vomiting","increased likelihood of asthenia"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["reduced response to atorvastatin treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.","phenotypeText":["increased risk of bone density loss"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.","phenotypeText":["greater resistance to treatment with antipsychotics"]},{"genotypeAnnotationText":"Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["increased chance of response to treatment with docetaxel and thalidomide"]},{"genotypeAnnotationText":"Patients with the rs121918592 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with at least two medications for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs121909005 GT genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["may respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["increased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs28365063 AG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.","phenotypeText":["no significant association with concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.","phenotypeText":["higher risk of cerivastatin-related rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the CG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.","phenotypeText":["shorter time to progression"]},{"genotypeAnnotationText":"Patients with the rs6928499 CG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with hypertension and the AC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["decreased response to hydrochlorothiazide"]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype may have increased metabolism of methylphenidate as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.","phenotypeText":["increased metabolism of methylphenidate"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.","phenotypeText":["decreased trough concentrations of imatinib"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.","phenotypeText":["less likely to experience ACE inhibitor induced cough"]},{"genotypeAnnotationText":"Patients with tuberculosis and the AA genotype who are treated with isoniazid and rifampin may have an increased likelihood of drug-induced liver injury as compared to patients with the AG or GG genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury.","phenotypeText":["increased likelihood of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*4 allele or one copy of the *4 allele in combination with one copy of the *7 or *9 alleles may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have a decreased severity of thrombocytopenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["higher triglyceride levels"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*4 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.","phenotypeText":["decreased risk of toxicities"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["increased likelihood of sexual adverse events"]},{"genotypeAnnotationText":"The CYP3A5*1 allele has been assigned as a normal function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*1 allele in combination with a normal or no function allele may have increased tacrolimus dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["increased tacrolimus dose requirements"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased risk of nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Female patients with the AA genotype may have an increased relative reinforcing value of nicotine as compared to female patients with the AG or GG genotypes. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.","phenotypeText":["increased relative reinforcing value of nicotine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["decreased rate of sulfation"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"In human liver microsomes, the AA genotype was associated with increased glucuronidation of SN-38, as compared to the AC or CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.","phenotypeText":["increased glucuronidation of SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the rs9934438 AG genotype may require a lower dose of warfarin as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence warfarin dose requirements.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients with a normal function allele in combination with a decreased function allele or patients with a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or GG genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder.","phenotypeText":["greater reductions in serotonin concentrations"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.","phenotypeText":["increased serum concentrations"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*6 allele in combination with a normal function allele or decreased function allele may have decreased metabolism of SN-38 as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of SN-38. This annotation only covers the pharmacokinetic relationship between UGT1A1 and SN-38 and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of SN-38"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and alcoholism may have a decreased response to acamprosate as compared to patients with the AA or AT genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.","phenotypeText":["decreased response to acamprosate"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.","phenotypeText":["decreased risk for toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.","phenotypeText":["less weight loss","greater weight loss"]},{"genotypeAnnotationText":"Patients with alcoholism and the rs671 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to achieve a target HbA1c level of <7%"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the rs3788853 AA genotype may have increased likelihood of angioedema when treated with ace inhibitors as compared to patients with the CC genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.","phenotypeText":["increased likelihood of angioedema"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.","phenotypeText":["better response (increased acute bronchodilation)"]},{"genotypeAnnotationText":"Patients with the *7 allele (assigned as slow acetylator phenotype) may have decreased metabolism of dipyrone as compared to patients with one or two NAT2 alleles conferring a rapid acetylator phenotype. Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with the rs6280 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the A\/del genotype, may have elevated concentrations of lumefantrine as compared to patients with the del\/del genotypes, and lower concentrations of lumefantrine as compared to patients with the AA genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.","phenotypeText":["increased clearance of nifedipine"]},{"genotypeAnnotationText":"Patients with the rs118192177 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the TT, CT, CG, or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"Patients with schizophrenia and the CT genotype may have an increased response to quetiapine as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of pravastatin-related myopathy when treated with pravastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of pravastatin.","phenotypeText":["higher risk of pravastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.","phenotypeText":["higher dose of warfarin"]},{"genotypeAnnotationText":"Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer who are treated with gemcitabine may have an increased risk of side effects including neutropenia as compared to patients with the AA or AG genotype combined with the G allele at rs9937. This association was not seen in a seperate study in patients with pancreatic cancer.Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":["less likely to respond to citalopram or escitalopram"]},{"genotypeAnnotationText":"Patients with the AT genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of developing an addiction to methamphetamines"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.","phenotypeText":["decreased bronchodilator response"]},{"genotypeAnnotationText":"Patients with the rs1801133 AG genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the GG genotype, and may be at decreased risk of toxicity compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC (CYP2C9 *1\/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1\/*2) or TT (*2\/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["increased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["increased blood pressure response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA\/AA genotypes (P=0.03; GG vs GA\/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.","phenotypeText":["larger tamoxifen-induced decrease in total cholesterol","tamoxifen-induced increase in triglycerides","decrease in high density lipoprotein"]},{"genotypeAnnotationText":"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["increased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the AA genotype and kidney transplantation may have increased exposure (Concentration\/Dose) to tacrolimus compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.","phenotypeText":["increased exposure to tacrolimus"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels","increased serum bicarbonate levels"]},{"genotypeAnnotationText":"Men with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a greater decrease in triglycerides as compared to men with either the CT or TT genotypes. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.","phenotypeText":["greater decrease in triglycerides"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.","phenotypeText":["increased exposure to risperidone"]},{"genotypeAnnotationText":"The CT genotype is associated with decreased catalytic activity of DPYD as compared to the CC and increased catalytic activity as compared to the TT genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["lower IL1B serum levels","more likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["increased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients with CYP2C9*6 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of bleeding when treated with warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.","phenotypeText":["increased risk of bleeding"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"The CYP2C19*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*6 allele in combination with a no, decreased, normal, or increased function allele who are treated with clopidogrel may have an increased risk for adverse cardiac and cerebrovascular events as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk for adverse cardiovascular events.","phenotypeText":["increased risk for adverse cardiac and cerebrovascular events"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.","phenotypeText":["risk for diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["increased likelihood of smoking addiction"]},{"genotypeAnnotationText":"Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["decreased risk for sleep disturbances"]},{"genotypeAnnotationText":"Patients with CG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy.","phenotypeText":["increased risk of anemia and leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T\/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.","phenotypeText":["increased clearance of docetaxel"]},{"genotypeAnnotationText":"Patients with the GG genotype and chronic myeloid leukemia may have an increased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the AA or AG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.","phenotypeText":["increased likelihood of achieving complete molecular response"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*2 allele in combination with one copy of the *1 allele may be more likely to quit smoking as compared to patients with two copies of the *1 or *46 alleles or one copy of the *1 allele in combination with one copy of the *46, *9 or *12 alleles. Other genetic and clinical factors may also influence likelihood of quitting smoking.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response when compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["decreased response to lithium","increased response"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Cancer patients with the AT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.","phenotypeText":["increased risk for drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs2253201 AA genotype may be at a decreased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.","phenotypeText":["decreased risk of developing angioedema"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to corticosteroids.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC> Patients carrying a *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["increased metabolism of paroxetine"]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.","phenotypeText":["increased risk for hematological toxicity"]},{"genotypeAnnotationText":"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.","phenotypeText":["greater decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism","increased serum concentration"]},{"genotypeAnnotationText":"Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.","phenotypeText":["increased clearance of the drug"]},{"genotypeAnnotationText":"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the CYP2C19*16 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*1 allele. The CYP2C19*16 allele was found to have a decreased clearance of mephenytoin and decreased catalytic activity of CYP2C19 as compared to *1 during several in-vitro characterizations.The CYP2C19*16 allele was catalytic inactive toward mephenytoin during one in-vitro characterization with 4% of *1 activity for the substrate mephenytoin. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":["decreased enzyme activity of CYP2C19"]},{"genotypeAnnotationText":"Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.","phenotypeText":["increased risk for cardiovascular and all-cause mortality"]},{"genotypeAnnotationText":"Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.","phenotypeText":["increased risk of experiencing hypersensitivity to dapsone"]},{"genotypeAnnotationText":"Patients with the CC genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and treated with long-term opioids may be more likely to develop dizziness as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.","phenotypeText":["more likely to develop dizziness"]},{"genotypeAnnotationText":"Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["increased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CYP2C19*1 allele may have an increased enzyme activity of CYP2C19 and increased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*14 and *23 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":["increased enzyme activity and clearance of clopidogrel"]},{"genotypeAnnotationText":"Individuals with the *1\/*3A genotype may have an increased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*1 genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["increased likelihood of fatigue"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.","phenotypeText":["lower risk for resistant hypertension"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.","phenotypeText":["decreased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.","phenotypeText":["more likely to respond to treatment with rituximab"]},{"genotypeAnnotationText":"Patients with the rs1801394 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal function allele may have an increased clearance of methadone as compared to patients carrying two decreased or uncertain function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["increased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*87 allele may have a decreased clearance of bufuralol as compared to patients with the CYP2D6*1 allele. The CYP2D6*87 allele construct (in this study PMID:26310775 only defined as AV5 not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["decreased clearance of bufuralol"]},{"genotypeAnnotationText":"Patients with the TT genotype and breast cancer may have decreased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the GG and GT genotypes. Other clinical and genetic factors may affect the metabolism of tamoxifen.","phenotypeText":["decreased concentrations of tamoxifen-n-glucuronide"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+\/-gemcitabine).","phenotypeText":["decreased likelihood of leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the TT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.","phenotypeText":["decreased severity of drug-induced toxicity"]},{"genotypeAnnotationText":"Patients with the rs3753380 CC genotype and open angle glaucoma may have an increased response to latanoprost compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost.","phenotypeText":["increased response to latanoprost"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of paroxetine as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of paroxetine as compared to patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but increased metabolism of paroxetine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism of paroxetine"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have decreased response to citalopram as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.","phenotypeText":["reduced risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.","phenotypeText":["decreased likelihood of sustained virological response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may may be more likely to develop side effects when treated with venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["more likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["increased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram.","phenotypeText":["no association with response to escitalopram"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.","phenotypeText":["increased risk of extreme weight gain"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have increased metabolism of etoposide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.","phenotypeText":["increased metabolism of etoposide"]},{"genotypeAnnotationText":"Patients with CC genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the NAT2*6\/*6 genotype (assigned as slow acetylator phenotype) and hypertension may be more likely to develop adverse effects to hydralazine treatment as compared to patients with other acetylator phenotypes. Please note, the findings were reported as within the slow acetylator group not per specific NAT2 genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["more likely to develop adverse effects to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*3 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*3 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs137904044 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["less reduction in LDL"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*3 allele in combination with a normal function allele (e.g. *1\/*3) may have increased metabolism of rabeprazole as compared to patients with two no function allele (e.g. *3\/*3, *2\/*3), and decreased metabolism of rabeprazole as compared to patients with two normal function alleles. However, a number of studies showed no difference in metabolism. Patients carrying the *3 allele in combination with another no function allele (e.g., *3\/*3, *2\/*3) may have decreased metabolism of rabeprazole as compared to patients with two normal function alleles or one normal function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C19 and rabeprazole and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of rabeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.","phenotypeText":["increased risk of experiencing a hypersensitivity reaction to NSAIDs"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AA genotype may have less severe anemia and neutropenia as compared to patients with the AG genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia and neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["decreased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have decreased, but not absent, risk for gastrointestinal side effects as compared to patients with the GTAAGTTG\/GTAAGTTG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with one X-chromosome, neuropathic pain and the C genotype may have increased pain relief when treated with escitalopram as compared to patients with the G genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased pain relief"]},{"genotypeAnnotationText":"Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.","phenotypeText":["increased weight gain","decreased weight gain"]},{"genotypeAnnotationText":"Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["decreased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to quetiapine as compared to patients with two copies of the *3 allele or one copy of the *1 allele in combination with one copy of the *3 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the rs2032582 TT genotype who are treated with atorvastatin may have a increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["no association with response to fluoxetine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*94 allele may have decreased metabolism of venlafaxine as compared to patients with the CYP2D6*1 allele. The CYP2D6*94 allele was only defined as D337G not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of venlafaxine. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of venlafaxine.","phenotypeText":["decreased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.","phenotypeText":["increased general side-effect burden"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole.","phenotypeText":["decreased glucuronidation of anastrozole"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the TT genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the CG or GG genotypes. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.","phenotypeText":["decreased cocaine cue-reactivity"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AC genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.","phenotypeText":["poorer response to capecitabine-based chemoradiotherapy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.","phenotypeText":["decreased reduction in mean blood pressure"]},{"genotypeAnnotationText":"Patients with the rs4530637 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine.","phenotypeText":["increased dose of carbamazepine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption.","phenotypeText":["increased alcohol consumption"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"The TPMT*6 allele has been assigned as a no function allele by the DPWG. Patients carrying the *6 allele in combination with a normal or a no function allele may have increased likelihood of experiencing toxicity when treated with azathioprine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence azathioprine toxicity.","phenotypeText":["increased likelihood of experiencing toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rocuronium.","phenotypeText":["increased and decreased response to rocuronium"]},{"genotypeAnnotationText":"Patients with mood disorders and the rs4713916 AG genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.","phenotypeText":["increased exposure to doxorubicin"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have increased blood alcohol concentrations (BAC) as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":["increased blood alcohol concentrations"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*44:03 allele have an increased risk of toxic liver disease when treated with ticlopidine as compared to patients with no HLA-B*44:03 allele. Other genetic and clinical factors may also influence a patient's risk of toxic liver disease.","phenotypeText":["increased risk of toxic liver disease"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma carrying and the *1\/*1 extensive metabolizer genotype when treated with pazopanib may have decreased risk but not absence of hyperbilirubinemia as compared to those with the *28, *37, *6 alleles. Other genetic and clinical factors may also influence adverse events associated with pazopanib in an individual.","phenotypeText":["decreased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.","phenotypeText":["increased trough concentrations of lopinavir"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.","phenotypeText":["increased risk for ototoxicity"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the TT genotype who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["decreased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CYP2D6*10 allele may have decreased clearance of tolterodine as compared to patients with the CYP2D6*1 allele. The CYP2D6*10 allele was found to have decreased intrinsic clearance during in-vitro characterization with tolterodine. Other genetic and clinical factors may also influence the metabolism of tolterodine.","phenotypeText":["decreased clearance of tolterodine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking","decreased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients with autism spectrum disorder (ASD), or mood disorders and the AG genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype; patients with the AG genotype may have an increased likelihood of weight gain as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone.","phenotypeText":["decreased likelihood of weight gain","increased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with two copies of the CYP1A2*1F allele or one copy of the *1F allele in combination with one copy of the *1A allele may have an increased risk of experiencing adverse events when treated with clozapine as compared to patients with two copies of the *1A allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the risk of adverse events when treated with clozapine.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1051266 CT genotype and risk of drug toxicity"]},{"genotypeAnnotationText":"Male patients with the B haplotype (wildtype, associated with normal G6PD activity) who are treated with mefloquine 1) may have a reduced risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.","phenotypeText":["reduced risk of pulmonary damage","similar risk of hemolysis"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of omeprazole as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of omeprazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and omeprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of omeprazole.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the CC genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and\/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and\/or non-steroidal anti-inflammatory agents.","phenotypeText":["decreased likelihood of colorectal cancer"]},{"genotypeAnnotationText":"Patients with the rs510769 CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"The CYP2D6*11 allele is assigned as a no function allele by CPIC. Patients with breast cancer and carrying the CYP2D6*11 allele in combination with a no, decreased or normal function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["benefit less from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the rs193922525 AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may be less likely to develop side effects when treated with venlafaxine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of experiencing side effects when treated with venlafaxine.","phenotypeText":["less likely to develop side effects"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.","phenotypeText":["increased risk of developing methamphetamine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":["reduction in psoriasis area or disease severity","increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.","phenotypeText":["faster improvement of symptoms"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.","phenotypeText":["decreased risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["increased chance of positive erectile response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*1 allele and analgesic response to oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to oxycodone.","phenotypeText":["no significant association between CYP2D6*1 allele and analgesic response to oxycodone"]},{"genotypeAnnotationText":"Patients with the insert\/insert genotype and Coronary Artery Disease may be more likely to benefit from atorvastatin and quinapril treatment (due to an increased reduction in the fibrinolytic marker D-dimer) as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["increased reduction in the fibrinolytic marker D-dimer"]},{"genotypeAnnotationText":"Patients with the CC genotype were not studied. Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["not have an increase in lumbar bone marrow density"]},{"genotypeAnnotationText":"Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["decreased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.","phenotypeText":["decreased response to botulinum toxin A"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype TT. Other genetic and clinical factors may influence the response to warfarin.","phenotypeText":["increased time in therapeutic range (TTR)"]},{"genotypeAnnotationText":"Subjects with the AA genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.","phenotypeText":["decreased exposure to atorvastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.","phenotypeText":["increased response to antidepressant treatment"]},{"genotypeAnnotationText":"Patients with postoperative pain and the rs7858836 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.","phenotypeText":["decreased fentanyl dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant.","phenotypeText":["increased risk of biopsy-proven acute rejection","decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["increased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond","more likely to respond"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.","phenotypeText":["increased metabolism of debrisoquine"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the rs1805087 GG genotype may be at an increased risk of toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.","phenotypeText":["require a decreased dose of valproic acid"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["decreased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)","phenotypeText":["increased risk of developing maculopapular exanthema"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["decreased risk of biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Infants who have been exposed to buprenorphine in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype who undergo kidney transplant may have a decreased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for PTDM.","phenotypeText":["decreased risk for new-onset posttransplant diabetes mellitus"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AA genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.","phenotypeText":["less likely to experience drug toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.","phenotypeText":["decreased activity of UGT1A proteins"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 GG genotype may have an increased response to buprenorphine therapy as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["increased response to buprenorphine therapy"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 or *1\/2 genotype may have an increased metabolism of debrisoquine or dextromethorphan or sparteine as compared to patients with the CYP2D6*18\/*21 or *5\/*18 or *1\/*21 or *10\/*21 or *2\/*44 genotype. Other genetic and clinical factors may also influence the metabolism of debrisoquine or dextromethorphan or sparteine.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.","phenotypeText":["greater increase in blood glucose"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*22 allele or one copy of the *22 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":["decreased dose of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype (CYP3A5 *1\/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3\/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.","phenotypeText":["increased clearance and decreased concentrations of carbamazepine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["increased metabolism","increased risk of gastrointestinal toxicity","increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["decreased risk of bone marrow toxicity"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs1386493 GG genotype may require increased doses of methadone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.","phenotypeText":["increased doses of methadone"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["no association with response to citalopram"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased sulfation of acetaminophen"]},{"genotypeAnnotationText":"Patients with the CT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with docetaxel may have an increased clearance and decreased risk of leukopenia as compared to patients with the GG genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.","phenotypeText":["increased clearance and decreased risk of leukopenia"]},{"genotypeAnnotationText":"The CC genotype is associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased catalytic activity"]},{"genotypeAnnotationText":"Patients with acute lymphblastic leukemia (ALL) and the rs1544105 TT genotype may have an increased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.","phenotypeText":["increased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.","phenotypeText":["increased risk for aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["smaller decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.","phenotypeText":["increased risk of adverse cognitive effects"]},{"genotypeAnnotationText":"Patients with the CC genotype and rs2501873 TT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased levels of acetaminophen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.","phenotypeText":["decreased levels of acetaminophen sulfation"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.","phenotypeText":["decreased plasma drug exposure"]},{"genotypeAnnotationText":"Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.","phenotypeText":["decreased risk of anemia"]},{"genotypeAnnotationText":"People with the CC genotype may have decreased exposure to dabigatran compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.","phenotypeText":["worse response to enalapril"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs3733784 CC genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.","phenotypeText":["increased vol% end-tidal sevoflurane concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for aspirin intolerance"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*23 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["decreased chance of response to bupropion treatment for smoking cessation"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.","phenotypeText":["increased glucuronidation metabolic ratios"]},{"genotypeAnnotationText":"Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.","phenotypeText":["decreased dose-adjusted trough concentrations of tacrolimus"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with clomipramine may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["increased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the G\/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del\/del or G\/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased response","decreased time until response"]},{"genotypeAnnotationText":"Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.","phenotypeText":["overall survival and progression free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the rs10455872 AA genotype may have an improved response to statins as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to statins.","phenotypeText":["improved response to statins"]},{"genotypeAnnotationText":"Patients with Type II diabetes and the CG genotype may have an increased response to pioglitazone as compared to patients with the CC genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele was only defined as R388H not including 100C>T (P34S) in the in-vitro study assaying the intrinsic clearance of risperidone. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":["decreased metabolism of risperidone"]},{"genotypeAnnotationText":"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":["decreased risk of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.","phenotypeText":["decreased risk for biopsy-proven acute rejection"]},{"genotypeAnnotationText":"Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.","phenotypeText":["increased warfarin dose requirement"]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have increased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.","phenotypeText":["increased severity of neurotoxicity syndromes"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.","phenotypeText":["decreased clearance of talinolol"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.","phenotypeText":["decreased risk of Heroin Dependence","increased risk of Heroin Dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may have increased metabolism as compared to patients carrying the *2 allele . Other genetic and clinical factors may also influence the metabolism of dipyrone.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the CC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.","phenotypeText":["decreased response to tocilizumab"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the rs3842 CT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["increased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.","phenotypeText":["higher accumulation of lopinavir in peripheral blood mononuclear cells"]},{"genotypeAnnotationText":"Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.","phenotypeText":["decreased metabolism and increased concentrations of nelfinavir"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of fluvastatin-related myopathy when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.","phenotypeText":["higher risk of fluvastatin-related myopathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of gemcitabine"]},{"genotypeAnnotationText":"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"The CYP2D6*96 allele has been assigned as a no function allele by CPIC. Patients carrying the *96 allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of atomoxetine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.","phenotypeText":["decreased subjective positive effects"]},{"genotypeAnnotationText":"Patients with brain tumors, osteosarcoma, and other cancers and the AG genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in pediatric patients exposed to cisplatin.","phenotypeText":["increased risk of ototoxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype (CYP3A5 *1\/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3\/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.","phenotypeText":["decreased chance of achieving remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with CYP2C9*13 allele in combination with a normal function allele may require more time to achieve stable dose when treated with warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.","phenotypeText":["require more time to achieve stable dose"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.","phenotypeText":["increased risk for paradoxical psoriasiform reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.","phenotypeText":["decreased risk for methamphetamine-induced psychosis"]},{"genotypeAnnotationText":"Patients with the rs777098658 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with two non-functional CYP2D6 alleles (e.g.*3\/*3, *3\/*4, *4\/*4, *5\/*4) who are treated with aqueous timolol may have increased exposure to timolol and increased excerice heart rate reduction as compared to patients with two or one functional CYP2D6 allele. Other genetic and clinical factors may also influence a patient's response to aqueous timolol.","phenotypeText":["increased exposure to timolol and increased exercise heart rate reduction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["increased survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.","phenotypeText":["slower improvement in Brief Psychiatric Rating Scale (BPRS) scores"]},{"genotypeAnnotationText":"Patients with the rs193922843 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs118192163 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":["changes in mycophenolic acid exposure-related parameters and increased risk of acute allograft rejection"]},{"genotypeAnnotationText":"Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["increased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the GG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival times"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.","phenotypeText":["increased likelihood of discontinuation of methotrexate in people with Arthritis"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *3\/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.","phenotypeText":["poorer improvement in visual acuity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["increased clearance of gemcitabine","decreased severity of Neutropenia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of morphine as compared to patients with the CC genotype, but increased metabolism of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.","phenotypeText":["decreased metabolism of morphine","increased metabolism of morphine"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.","phenotypeText":["increased risk for experiencing side effects"]},{"genotypeAnnotationText":"Patients with the rs186045772 TT genotype (do not have a copy of the CFTR F1074L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.","phenotypeText":["increased response to gemcitabine"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype and depression who are treated with sertraline may have a better response to treatment as compared to other genotypes. However, contradictory findings report no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.","phenotypeText":["increased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the *5\/*5 genotype may have decreased metabolism of lovastatin as compared to patients carrying the *1 or *10 alleles. Other genetic and clinical factors may also influence the metabolism of lovastatin.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype who are treated with nortriptyline may have a decreased likelihood of treatment side effects as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":["decreased likelihood of treatment side effects"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.","phenotypeText":["more likely to discontinue treatment due to toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of zuclopenthixol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and zuclopenthixol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence zuclopenthixol metabolism.","phenotypeText":["metabolism of zuclopenthixol"]},{"genotypeAnnotationText":"Patients with the CYP2D6*14 allele may have decreased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*1 allele. The CYP2D6*14 allele was found to have decreased activity during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased activity of CYP2D6 with n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.","phenotypeText":["increased plasma concentrations of R-methadone"]},{"genotypeAnnotationText":"Patients with the *1 allele in combination with another normal function allele may have increased metabolism of N-desmethylclobazam, the main metabolite of clobazam, as compared to patients with a normal function allele in combination with a no function allele or patients with two no function alleles, while patients with the *1 allele in combination with a no function allele may have increased metabolism of N-desmethylclobazam as compared to patients with two no function alleles. Other genetic and clinical factors may also affect clobazam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clobazam and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of N-desmethylclobazam"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.","phenotypeText":["decreased likelihood of Neurotoxicity"]},{"genotypeAnnotationText":"Patients who carry the *3 allele and have colorectal cancer may have an increased risk for vomiting when treated with TIROX (S-1, irinotecan and oxaliplatin) as compared to patients without the *3 allele. Other genetic and clinical factors may also influence risk for vomiting on TIROX.","phenotypeText":["increased risk for vomiting"]},{"genotypeAnnotationText":"Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.","phenotypeText":["increased severity of pharmacological resistance"]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 1-4 nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.","phenotypeText":["decreased risk of granulocytopenia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.","phenotypeText":["less likely to respond to lithium"]},{"genotypeAnnotationText":"Patients with the UGT1A1 *6\/*6 genotype and chronic myeloid leukemia may have an increased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the *1\/*1, *1\/*6, *1\/*28 or *27\/*28 genotype. Other genetic and clinical factors may also influence risk of hyperbilirubinemia.","phenotypeText":["increased risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the rs1801394 AA genotype may be at a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["decreased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["lower decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.","phenotypeText":["decreased likelihood of toxic liver disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*48 allele may have similar enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*48 allele was found to have similar enzyme activity compared to CYP2D6*1 during in-vitro characterization with bufuralol. Other genetic and clinical factors may also influence the metabolism of bufuralol.","phenotypeText":["similar enzyme activity"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence or heavy smoking"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*12 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.","phenotypeText":["increased risk for nevirapine hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1323040 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements.","phenotypeText":["increased sufentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype and Crohn Disease who are treated with corticosteroids may have a decreased likelihood of responsiveness as compared to patients with AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["decreased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.","phenotypeText":["increased plasma concentrations of cotinine"]},{"genotypeAnnotationText":"Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.","phenotypeText":["less likely to have positive erectile response"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.","phenotypeText":["decreased risk for myalgia"]},{"genotypeAnnotationText":"Patients with genotype CC and hypertension have decreased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.","phenotypeText":["increased risk for cough"]},{"genotypeAnnotationText":"Individuals with the *1\/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1\/*3A or *1\/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.","phenotypeText":["decreased likelihood of fatigue"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*4 diplotype (poor metabolizers) may have reduced clearance of donepezil as compared to patients who are extensive metabolizers (diplotypes *1\/*3, *1\/*4, *1\/*5, *1\/*6, *1\/*1, *4\/*1xN, *6\/*1xN) or ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Poor metabolizers may also be more likely to experience adverse events (though this was not statistically significant). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":["reduced clearance of donepezil"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplant and have have the CYP3A5*3 allele in combination with another no function allele may require a decreased dose of tacrolimus as compared to patients with a no function allele in combination with a normal function allele or two normal function alleles, while patients who have the CYP3A5*3 allele in combination with a normal function allele may require a decreased dose of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.","phenotypeText":["decreased dose requirement of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased nicotine consumption and an increased neural response to nicotine, as measured by MRI, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine.","phenotypeText":["decreased nicotine consumption","increased neural response to nicotine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.","phenotypeText":["no association between the rs6313 GG genotype and response to sertraline"]},{"genotypeAnnotationText":"Patients with the GG genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.","phenotypeText":["increased response to fluoropyrimidine-based chemotherapy"]},{"genotypeAnnotationText":"Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with metastatic stomach cancer and the rs1695 GG genotype may have an increased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function alleles by CPIC. Patients carrying the *3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.","phenotypeText":["decreased risk of cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the CT and TT genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin.","phenotypeText":["increased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2075572 GG genotype and severity of sleep disorders when treated with methadone. However, patients with the CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.","phenotypeText":["decreased exposure to tramadol"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.","phenotypeText":["increased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.","phenotypeText":["no association with response to paroxetine"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.","phenotypeText":["increased risk of myopathy"]},{"genotypeAnnotationText":"Patients with the rs4240803 GG genotype may have a decreased response to gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to gabapentin.","phenotypeText":["decreased response to gabapentin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.","phenotypeText":["increased concentrations of S-EDDP"]},{"genotypeAnnotationText":"\"Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or \"\"clinical benefit\"\" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.\"","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the rs548783838 TT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["less likely to respond to citalopram and fluoxetine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*1xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*1xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*1xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":["increased metabolism of clomipramine"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["higher maintenance dose"]},{"genotypeAnnotationText":"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the GG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or\/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.","phenotypeText":["smaller elevations of fasting glucose concentrations"]},{"genotypeAnnotationText":"Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's risk for bleeding.","phenotypeText":["increased risk for bleeding"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the AA or AG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.","phenotypeText":["overall survival"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["decreased response to treatment with interferons"]},{"genotypeAnnotationText":"Individuals with the AG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GG genotype but may have and an improved response as compared to individuals with the AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1437153 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.","phenotypeText":["decreased response to anastrozole"]},{"genotypeAnnotationText":"Patients with the CYP2D6*43 allele may have decreased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*43 allele was found to have decreased intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["decreased clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Patients with two X-chromosomes and the GG genotype who are treated with risperidone may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.","phenotypeText":["decreased risk of developing metabolic syndrome"]},{"genotypeAnnotationText":"Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.","phenotypeText":["increased risk for conjunctival hemorrhage"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["poorer response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the GGAGTC\/del genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GGAGTC\/GGAGTC genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of three adolescents, one of whom was compound heterozygous for additional variants in NUDT15.","phenotypeText":["higher incidence of toxicity","tolerate lower doses of mercaptopurine"]},{"genotypeAnnotationText":"Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may require decreased doses of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased risk of gastrointestinal side effects"]},{"genotypeAnnotationText":"Patients with the rs7662029 GG genotype who are treated with sublingual buprenorphine\/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.","phenotypeText":["tumor shrinkage"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype may have and increased response to antidepressants as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.","phenotypeText":["lower thioridazine:mesoridazine ratio"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["decreased risk of nonfatal myocardial infarction"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype, or increased severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate.","phenotypeText":["reduced severity of mucositis"]},{"genotypeAnnotationText":"Patients with the CT genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.","phenotypeText":["increased withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the AA genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence.","phenotypeText":["more likely to respond to drugs to treat nicotine dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.","phenotypeText":["decreased likelihood of addiction"]},{"genotypeAnnotationText":"Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/del genotype may have decreased response when treated with enalapril as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the rs12979860 CC genotype and hepatitis C infection may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["higher response rates to triple therapy"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors"]},{"genotypeAnnotationText":"Patient with the CC genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose.","phenotypeText":["increased risk of cardiac arrest or respiratory arrest following overdose"]},{"genotypeAnnotationText":"Patients with hepatitis B and the TT genotype may have an increased response to treatment with peginterferon-alpha 2a and\/or 2b as compared to patients with the CC or CT genotypes. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and\/or 2b","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs671 GG genotype may have decreased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["decreased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Patients with the rs1051266 TT genotype and rheumatoid arthritis may have increased response when treated with methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with the CC genotype and breast or ovarian cancer may have a decreased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.","phenotypeText":["decreased risk for peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased risk for gastrointestinal side effects"]},{"genotypeAnnotationText":"Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["higher decreases in triglyceride levels"]},{"genotypeAnnotationText":"Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["decreased risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.","phenotypeText":["decreased risk for alcoholism"]},{"genotypeAnnotationText":"Patients with the rs45445694 3R\/3R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3) may have decreased progression-free survival when treated with methotrexate chemotherapy regimens compared to patients with the 2R\/2R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.","phenotypeText":["increased concentrations of atazanavir"]},{"genotypeAnnotationText":"Patients with heart failure and the rs1801253 GG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.","phenotypeText":["increased risk of cardiac damage after anthracycline exposure"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.","phenotypeText":["decreased risk for resistance to antiepileptic treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.","phenotypeText":["decreased metabolism of carbamazepine"]},{"genotypeAnnotationText":"Patient harbors the rs144336148 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG\/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia susceptibility"]},{"genotypeAnnotationText":"Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.","phenotypeText":["decreased but not absent risk for endometrial neoplasms"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs55944529 CT genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.","phenotypeText":["decreased plasma concentrations of methadone"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the CYP2D6*2\/*101 genotype may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with genotype CC may have increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CT or TT genotypes. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa\/RBV than those receiving pegIFN-alfa\/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.","phenotypeText":["increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic"]},{"genotypeAnnotationText":"Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Patients with colorectal or breast cancer and the CT genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.","phenotypeText":["improved response to bevacizumab-based treatment regimens"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the AA genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased likelihood of weight gain"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.","phenotypeText":["risk of skin rash"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["increased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.","phenotypeText":["increased sensitivity to antilymphocyte serum"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.","phenotypeText":["risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of fluvoxamine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and fluvoxamine and does not include evidence about clinical outcomes. Be aware that the CPIC guideline for fluvoxamine and CYP2D6 has a \u2018no recommendation\u2019 for ultrarapid metabolizers. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of fluvoxamine.","phenotypeText":["decreased metabolism of fluvoxamine"]},{"genotypeAnnotationText":"People with an ultra-rapid metabolizer genotype (e.g. *17\/*17) may have increased metabolism of 3,4-methylenedioxymethamphetamine compared to people with intermediate metabolizer genotypes. Other clinical and genetic factors may affect response to 3,4-methylenedioxymethamphetamine.","phenotypeText":["increased metabolism of 3,4-methylenedioxymethamphetamine"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased renal clearance and secretion clearance of metformin","decreased renal clearance and secretion clearance of metformin"]},{"genotypeAnnotationText":"Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.","phenotypeText":["less sensitive to Alkylating agents"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*12 allele or one copy of the *12 allele in combination with one copy of the *1 or *9 alleles may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.","phenotypeText":["decreased risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased clearance of mephenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/ A-202A_376G diplotype (homozygous for the A- variant) who are treated with glibenclamide may have an increased risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B\/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.","phenotypeText":["increased risk of hemolysis or hemolytic anemia"]},{"genotypeAnnotationText":"Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.","phenotypeText":["lack of early response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.","phenotypeText":["methotrexate dosage"]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.","phenotypeText":["increased dose of opioids"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.","phenotypeText":["decreased risk for moderate or severe depression"]},{"genotypeAnnotationText":"Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.","phenotypeText":["respond to migalastat"]},{"genotypeAnnotationText":"The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal function allele may have an increased severity of dyspepsia when treated with ketoprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence the severity of dyspepsia.","phenotypeText":["increased severity of dyspepsia"]},{"genotypeAnnotationText":"Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may be at a decreased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *4 allele in combination with a normal function allele may be at an increased risk of developing opioid dependence as a result of taking oxycodone as compared to patients carrying two no function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of developing opioid dependence.","phenotypeText":["decreased risk of developing opioid dependence","increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs4948496 CC genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype may be at an increased risk of developing alcohol dependence as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) or HTTLPR long form (L allele)\/HTTLPR short form (S allele) genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["increased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["decreased time in therapeutic range of INR (TTR)"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.","phenotypeText":["decreased severity of thrombocytopenia","increased likelihood of overall survival"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.","phenotypeText":["lower response to repaglinide"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.","phenotypeText":["lower plasma concentrations of metoprolol and smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.","phenotypeText":["increased dose"]},{"genotypeAnnotationText":"Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.","phenotypeText":["increased risk of edema"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and response to opioids. However, patients with the AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids.","phenotypeText":["decreased response to opioids"]},{"genotypeAnnotationText":"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers","phenotypeText":["smaller tamoxifen-induced decrease in total cholesterol"]},{"genotypeAnnotationText":"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1\/*1 or *1\/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.","phenotypeText":["higher concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the CYP2C9*3\/*3 diplotype may have reduced metabolism of trimipramine as compared to patients with the CYP2C9*1\/*1, CYP2D6*1\/*1 and CYP2C19*1\/*1 combined diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.","phenotypeText":["reduced metabolism of trimipramine"]},{"genotypeAnnotationText":"Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.","phenotypeText":["decreased metabolism of erythromycin"]},{"genotypeAnnotationText":"Patients with the rs780801862 AT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.","phenotypeText":["reduced risk of grade 1-2 neurotoxicity"]},{"genotypeAnnotationText":"Patients with the del\/del genotype were not studied but patients with the GAT\/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT\/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased trough metformin steady-state concentration"]},{"genotypeAnnotationText":"Patients with the rs397508435 CC genotype (two copies of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["increased alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.","phenotypeText":["greater increase in HDL cholesterol"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*34 allele in combination with a normal function allele may require a decreased dose of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. Other genetic and clinical factors may also influence thioguanine dose requirements.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Pediatric patients with the AA genotype who are undergoing hematopoietic stem cell transplantation may have increased clearance of busulfan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence busulfan clearance.","phenotypeText":["increased clearance of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["increased likelihood of remission","increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the rs11615 AG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of diabetes.","phenotypeText":["decreased risk of developing diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CT genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CT or TT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.","phenotypeText":["increased incidence of nausea"]},{"genotypeAnnotationText":"Patients with the CT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.","phenotypeText":["increased concentrations of valproic acid"]},{"genotypeAnnotationText":"Patients with the rs1142345 TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["decreased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.","phenotypeText":["increased clearance of carbamazepine"]},{"genotypeAnnotationText":"Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a\/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN\/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.","phenotypeText":["lower response rates (SVR) to triple therapy"]},{"genotypeAnnotationText":"Patients with the GG genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.","phenotypeText":["decreased severity of nausea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*6 allele and risk of drug toxicity when taking oxycodone. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of drug toxicity when taking oxycodone.","phenotypeText":["no significant association between the CYP2D6*6 allele and risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1556422499 T allele (also known as the 961T allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with streptomycin as compared to patients with a delT+C(n) allele (e.g. CCCCCCC). However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.","phenotypeText":["increased risk of late stage toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.","phenotypeText":["increased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the rs267606617 A allele (also known as the 1555A allele) may have a decreased, but not absent, risk of experiencing hearing loss when treated with isepamicin as compared to patients with the G allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with isepamicin.","phenotypeText":["decreased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the rs1045642 GG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs2239050 CC genotype may have a decreased response to nimodipine as compared to patients with the CG genotype. Other genetic and clinical factors may also affect response to nimodipine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["less likely to have improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype and postoperative pain may require an increased dose when treated with fentanyl as compared to patients with the AG+GG genotype. Other genetic and clinical factors may also influence the required dose of fentanyl.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*35:01 allele may have an increased risk of experiencing nevirapine-related adverse events when treated with the drug as compared to patients with no HLA-B*35:01 alleles or negative for the HLA-B*35:01 test. Other genetic and clinical factors may also influence a patient's risk of nevirapine-induced adverse reactions.","phenotypeText":["increased risk of experiencing nevirapine-related adverse events"]},{"genotypeAnnotationText":"Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.","phenotypeText":["increased exposure to efavirenz"]},{"genotypeAnnotationText":"Patients with the rs376073289 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"Patients with the CYP3A5 *3\/*3 genotype who are administered midazolam may have slower clearance rates, and decreased metabolism of midazolam as compared to patients with the CYP3A5 *1\/*3 or *1\/*1 genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.","phenotypeText":["slower clearance rates and decreased metabolism"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.","phenotypeText":["increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with another no function allele may have increased response to sulfonylureas as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.","phenotypeText":["worse response to lithium"]},{"genotypeAnnotationText":"Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with kidney transplantation and the del\/del genotype may have decreased metabolism of mycophenolic acid as compared to patients with the de\/T or TT genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.","phenotypeText":["decreased metabolism of mycophenolic acid"]},{"genotypeAnnotationText":"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased, but not absent, risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["increased treatment response"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.","phenotypeText":["greater reduction in blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.","phenotypeText":["decreased risk of emergency department visits"]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased response to atenolol"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["increased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the A genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.","phenotypeText":["decreased risk of post anesthesia apnea"]},{"genotypeAnnotationText":"Patients with the AG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.","phenotypeText":["better response to salbutamol"]},{"genotypeAnnotationText":"Patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde.","phenotypeText":["increased concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.","phenotypeText":["decreased likelihood of hypertension"]},{"genotypeAnnotationText":"\"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the \"\"non-responder\"\" phenotype from the \"\"responder\"\" phenotype when using a logistic regression multivariate model.\"","phenotypeText":["improved response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.","phenotypeText":["decreased response to citalopram"]},{"genotypeAnnotationText":"Patients with the rs4633 CT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A\/*1B) may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A\/*1A). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.","phenotypeText":["decreased likelihood of transplant rejection"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype or those who are not taking oral contraceptives and a decreased risk of DVT as compared to patients with the AA genotype. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.","phenotypeText":["increased risk for deep vein thrombosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.","phenotypeText":["increased clozapine plasma concentrations","increased risk for clozapine-induced agranulocytosis or neutropenia"]},{"genotypeAnnotationText":"Patients with the insert\/del genotype and Migraine with Aura or Chronic Migraine may be more likely to use pharmacological prophylaxis as compared to patients with the ins\/ins genotype. No association was seen for patients with Migraine without Aura. Other genetic and clinical factors may also influence a patient's use of pharmacological prophylaxis.","phenotypeText":["more likely to use pharmacological prophylaxis"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.","phenotypeText":["better response to antidepressant treatment"]},{"genotypeAnnotationText":"Individuals who smoke and have the GG genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the AG or AA genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.","phenotypeText":["increased rates of nicotine clearance"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":["decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg"]},{"genotypeAnnotationText":"Patients with one copy of the TPMT*24 allele in combination with a normal function allele may have decreased metabolism of mercaptopurine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and mercaptopurine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mercaptopurine metabolism.","phenotypeText":["decreased metabolism of mercaptopurine"]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may be at a decreased risk of QT prolongation when treated with methadone as compared to patients with two decreased function alleles. Other genetic and clinical factors may also affect a patient's risk of QT prolongation when treated with methadone.","phenotypeText":["decreased risk of QT prolongation"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles or a decreased function allele in combination with a no function allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased inhibition of platelet aggregation","decreased risk of high on-clopidogrel platelet reactivity and poor responder status"]},{"genotypeAnnotationText":"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CC genotype may have an increased response to treatment with either aripiprazole or risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-B*57:01 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.","phenotypeText":["decreased likelihood of gastrointestinal intolerance"]},{"genotypeAnnotationText":"Patients with the rs1603218569 T allele (also known as the 1243T allele) may have a decreased, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the C allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.","phenotypeText":["decreased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.","phenotypeText":["decreased risk of tardive dyskinesia"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response to risperidone"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":["reduced risk of severe ototoxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.","phenotypeText":["decreased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.","phenotypeText":["reduced risk of developing noncirrhotic portal hypertension"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.","phenotypeText":["decreased response","decreased exposure"]},{"genotypeAnnotationText":"Patients with cancer and the AG genotype may have an increased risk of hyperbilirubinemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.","phenotypeText":["risk of hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the CC genotype and increased reduction of diastolic blood pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["decreased reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.","phenotypeText":["no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan"]},{"genotypeAnnotationText":"The CYP2B6*9 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*9 allele in combination with a normal function allele or another decreased function allele may have increased concentrations of sertraline as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence metabolism of sertraline. This annotation only covers the pharmacokinetic relationship between CYP2B6 and sertraline and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of sertraline"]},{"genotypeAnnotationText":"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AG genotypes. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.","phenotypeText":["increased response to cisplatin-based therapy"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*35 allele in combination with one copy of the *17 allele may have decreased metabolism of letrozole as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also affect letrozole metabolism. This annotation only covers the pharmacokinetic relationship between CYP2A6 and letrozole and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of letrozole"]},{"genotypeAnnotationText":"Patients with the del\/del genotype and Coronary Artery Disease may be less likely to benefit from pravastatin treatment as compared to patients with the AA or A\/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["less likely to benefit from pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.","phenotypeText":["decreased risk of developing alcohol dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and colorectal cancer may have increased overall survival time when treated with cetuximab as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence overall survival time.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG or GT genotypes. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["increased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the null\/null (has no copies of the GSTM1 gene) genotype and Tuberculosis may have an increased risk of drug-induced hepatotoxicity when treated with an isoniazid-containing anti-TB drug regimen as compared to patients with the non-null\/ null or the non-null\/ non-null genotype. However, this association is not seen in the majority of studies. Other genetic and clinical factors may also influence a patient's risk of drug-induced liver injury.","phenotypeText":["increased risk of drug-induced hepatotoxicity"]},{"genotypeAnnotationText":"Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.","phenotypeText":["decreased likelihood to be phenobarbital resistant"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["decreased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.","phenotypeText":["increased risk for gingival overgrowth"]},{"genotypeAnnotationText":"Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk for venous thrombosis compared to the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["increased risk of venous thrombosis","decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hypertension who are treated with hydrochlorothiazide may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.","phenotypeText":["decreased risk for diabetes mellitus"]},{"genotypeAnnotationText":"Patients with the CC genotype (CYP3A5 *3\/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1\/*3 or *1\/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.","phenotypeText":["decreased risk for infections"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.","phenotypeText":["increased blood concentrations"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require medication to treat neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.","phenotypeText":["decreased response to platinum compounds"]},{"genotypeAnnotationText":"Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.","phenotypeText":["higher dose of methadone required"]},{"genotypeAnnotationText":"Patients with cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GT or TT genotypes. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.","phenotypeText":["decreased severity of peripheral neuropathy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.","phenotypeText":["higher plasma concentrations and reduced clearance of simvastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":["decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias"]},{"genotypeAnnotationText":"Patients with the rs568724445 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["decreased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.","phenotypeText":["decreased area under the plasma concentration-time curve"]},{"genotypeAnnotationText":"Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.","phenotypeText":["increased risk of developing leukopenia or neutropenia"]},{"genotypeAnnotationText":"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to treatment with ivacaftor\/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor\/lumacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with two copies of the CYP3A4*1 allele may have decreased exposure to quetiapine as compared to patients with two copies of the *20 or *22 alleles or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to quetiapine.","phenotypeText":["decreased exposure to quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors"]},{"genotypeAnnotationText":"Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.","phenotypeText":["decreased risk of bleeding at therapeutic INR"]},{"genotypeAnnotationText":"Patients with the TT genotype and major depression who are treated with nortriptyline may have more improvement in neurovegetative symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["more improvement in neurovegetative symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.","phenotypeText":["better response","reduced response"]},{"genotypeAnnotationText":"Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response.","phenotypeText":["better response to treatment with quetiapine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["increased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with temporomandibular disorder (TMD) and the rs4680 AG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol.","phenotypeText":["decreased response to propranolol"]},{"genotypeAnnotationText":"Patients with the CC genotype (two copies of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype or may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.","phenotypeText":["increased dose of warfarin","decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*1 allele in combination with a decreased function allele may have increased irinotecan dose requirements as compared to patients carrying two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan dose requirements.","phenotypeText":["increased irinotecan dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["decreased residual platelet aggregation to collagen and epinephrine"]},{"genotypeAnnotationText":"Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.","phenotypeText":["increased risk of in-hospital death"]},{"genotypeAnnotationText":"Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements.","phenotypeText":["decreased opioid dose requirements"]},{"genotypeAnnotationText":"Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["decreased event free survival"]},{"genotypeAnnotationText":"Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.","phenotypeText":["increased response to venlafaxine in people with Anxiety Disorder","decreased response to venlafaxine in people with Depressive Disorders"]},{"genotypeAnnotationText":"Patients with the *1\/*1 diplotype may be at a decreased risk of developing rifampin-induced liver injury as compared to patients carrying one or more copies of the *15 allele. Other genetic or clinical factors may also affect a patient's risk of develop rifampin-induced liver injury.","phenotypeText":["decreased risk of developing rifampin-induced liver injury"]},{"genotypeAnnotationText":"Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to hydrochlorothiazide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.","phenotypeText":["increased systolic blood pressure response"]},{"genotypeAnnotationText":"Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.","phenotypeText":["longer overall and event-free survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in disease activity"]},{"genotypeAnnotationText":"Patients with the rs4680 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence.","phenotypeText":["more likely to experience somnolence following fentanyl administration"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["increased platelet reactivity"]},{"genotypeAnnotationText":"Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.","phenotypeText":["lower dose of warfarin"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with the rs3804100 CC genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.","phenotypeText":["decreased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with liver cancer, anti-HCV antibodies and the TT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib.","phenotypeText":["decreased overall survival"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["no significant differences in progression-free survival time","reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*11 allele or one copy of the *11 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for nausea","increased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.","phenotypeText":["increased levels of alcohol consumption"]},{"genotypeAnnotationText":"Patients with the rs536577604 TT genotype may have decreased risk of toxicity when treated with fluorouracil regimens as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk of aspirin-intolerant asthma"]},{"genotypeAnnotationText":"Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.","phenotypeText":["increased response to milnacipran"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.","phenotypeText":["more likely to have relapsed before 52 weeks of nicotine abstinence"]},{"genotypeAnnotationText":"Patients with the CYP2D6*40\/*42 genotype (assigned as poor metabolizer phenotype) may have a decreased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*1\/*1 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the GG genotype may be more likely to experience myopathy when treated with statins as compared to patients with the AA or AG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":["more likely to experience myopathy"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer may have a poorer response to treatment with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["poorer response to treatment with imatinib"]},{"genotypeAnnotationText":"The CYP2C9*11 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *11 allele in combination with a normal, decreased, or no function allele may have decreased metabolism\/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenytoin metabolism.","phenotypeText":["decreased metabolism\/clearance of phenytoin"]},{"genotypeAnnotationText":"Patients with AA genotype may have decreased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.","phenotypeText":["decreased blood pressure response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.","phenotypeText":["increased naltrexone-induced blunting of alcohol stimulation and alcohol craving"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.","phenotypeText":["increased risk of drug-induced torsades de pointes"]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["decreased exposure to imatinib"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C\/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)","phenotypeText":["increased chance of experiencing sensory neuropathy"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["increased levels of O-desmethylnaproxen sulfation"]},{"genotypeAnnotationText":"Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine.","phenotypeText":["increased risk of moderate anemia"]},{"genotypeAnnotationText":"Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.","phenotypeText":["decreased risk of kidney tubular dysfunction"]},{"genotypeAnnotationText":"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.","phenotypeText":["elevated concentrations of lumefantrine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the G\/del genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.","phenotypeText":["increased risk of overall early-onset capecitabine-related toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *6\/*6 diplotype and chronic pain, or cancer may have decreased clearance of ketamine as compared to patients with the CYP2B6 *1\/*6 and *1\/*1 diplotypes. Other clinical and genetic factors may also influence clearance of ketamine.","phenotypeText":["decreased clearance of ketamine"]},{"genotypeAnnotationText":"Patients with a HCV genotype I infection and the rs12979860 TT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.","phenotypeText":["decreased response to treatment with interferons"]},{"genotypeAnnotationText":"Patients with the GG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.","phenotypeText":["increased response to cisplatin"]},{"genotypeAnnotationText":"Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.","phenotypeText":["longer survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.","phenotypeText":["decreased blood concentrations of acetaldehyde"]},{"genotypeAnnotationText":"Female patients with the GG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.","phenotypeText":["decreased prolactin concentrations"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del\/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.","phenotypeText":["decreased likelihood of developing grade 3 hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the rs7662029 AA genotype who are treated with sublingual buprenorphine\/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine \/ naloxone and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma levels of buprenorphine"]},{"genotypeAnnotationText":"Patients with the non-null\/non-null genotype may have an increased risk for neutropenia when treated with clozapine as compared to patients with the null\/null genotype. Other genetic and clinical factors may also influence neutropenia risk.","phenotypeText":["increased risk for neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.","phenotypeText":["increased chance of rehospitalization"]},{"genotypeAnnotationText":"Women with ovarian cancer and the CC genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes.","phenotypeText":["improved response, longer survival times"]},{"genotypeAnnotationText":"Patients with the rs527580106 CC genotype may have increased risk of toxicity phenotype when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity phenotype"]},{"genotypeAnnotationText":"Patients with the rs1800559 CC genotype may have a decreased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["decreased risk for malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.","phenotypeText":["increased sexual side-effects"]},{"genotypeAnnotationText":"Patients with the rs2032582 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the rs2031920 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.","phenotypeText":["decreased mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.","phenotypeText":["decreased risk of progression of disease"]},{"genotypeAnnotationText":"Patients with hypertension and the CC genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.","phenotypeText":["decreased systolic blood pressure response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.","phenotypeText":["increased risk for alcoholism"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":["decreased metabolism of haloperidol","similar metabolism of haloperidol","increased metabolism of haloperidol"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of infection or nausea"]},{"genotypeAnnotationText":"Patients with the rs1800629 AG genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs4728709 AA genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.","phenotypeText":["decreased likelihood of developing asthenia"]},{"genotypeAnnotationText":"Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["decreased risk for adverse cardiovascular events"]},{"genotypeAnnotationText":"Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment.","phenotypeText":["poorer response to metformin"]},{"genotypeAnnotationText":"Patients with the CT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.","phenotypeText":["decreased likelihood of developing opioid dependence"]},{"genotypeAnnotationText":"Patients with the rs1127354 CC genotype and chronic hepatitis C may have an increased risk of anemia as compared to patients with the AA or AC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.","phenotypeText":["increased risk of anemia"]},{"genotypeAnnotationText":"Patients carrying the UGT1A1*28 allele in combination with a normal function allele may have increased severity of diarrhea when treated with irinotecan-based regimens as compared to patients with two normal function alleles but decreased severity of diarrhea compared to patients with two decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan related diarrhea.","phenotypeText":["increased severity of diarrhea"]},{"genotypeAnnotationText":"Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.","phenotypeText":["greater decreases in systolic and diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.","phenotypeText":["decreased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with two copies of the TPMT*34 allele or one copy of the *34 allele in combination with a normal function allele may have decreased metabolism of thioguanine as compared to patients with two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between TPMT and thioguanine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thioguanine metabolism.","phenotypeText":["decreased metabolism of thioguanine"]},{"genotypeAnnotationText":"Patients with the AC genotype and diabetes mellitus may have a worse response to sulfonylureas as compared to the AA and CC genotypes. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.","phenotypeText":["worse response to sulfonylureas"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["average risk for progression"]},{"genotypeAnnotationText":"Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.","phenotypeText":["greater weight gain"]},{"genotypeAnnotationText":"Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["greater improvement in visual acuity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with a normal or no function allele may require a decreased dose of tramadol as compared to patients carrying two no function alleles while patients carrying the *1 allele in combination with a decreased function allele with an activity value of 0.25 may require a decreased dose of tramadol as compared to patients carrying two decreased function alleles with an activity value of 0.25. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence tramadol dosage requirements.","phenotypeText":["decreased dose of tramadol"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs62368105 AG genotype may have a decreased response to buprenorphine therapy as compared to patients GG genotype but an increased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.","phenotypeText":["smaller decrease in glomerular filtration rate (GFR)"]},{"genotypeAnnotationText":"In healthy volunteers the AG genotype may be associated with decreased secretory clearance of metformin and in patients with diabetes mellitus may result in an increase in efficacy (decreased HbA1c levels) as compared to patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.","phenotypeText":["decreased secretory clearance of metformin","increase in efficacy (decreased HbA1c levels)"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP.","phenotypeText":["decreased concentrations of S-EDDP"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.","phenotypeText":["increased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the rs193922876 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*1x2 and *1x\u22653) have been assigned as increased function alleles by CPIC. Patients carrying a CYP2D6*2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a CYP2D6*2xN allele with an activity value of 3 or greater in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a CYP2D6*2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":["increased metabolism of nortriptyline"]},{"genotypeAnnotationText":"Patients with the rs367619008 CT genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["more severe anemia"]},{"genotypeAnnotationText":"Patients with cancer and the rs25487 CC genotype may have increased response when treated with platinum-based therapies as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.","phenotypeText":["decreased risk for weight gain"]},{"genotypeAnnotationText":"Patients with the *2\/*2 diplotype who are administered bupropion may have increased exposure to bupropion as compared to patients with the *1\/*2 and *1\/*1 diplotypes. Other clinical and genetic factors may also influence metabolism of bupropion.","phenotypeText":["increased exposure to bupropion"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.","phenotypeText":["no association with response to venlafaxine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["more improvement in symptoms"]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased clearance of bufuralol or dextromethorphan"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with a normal function allele or an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the TT genotype and colon cancer may have a shorter time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluorouracil.","phenotypeText":["shorter time to tumor recurrence"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["decreased clearance of mephenytoin"]},{"genotypeAnnotationText":"Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response to treatment"]},{"genotypeAnnotationText":"Pregnant patients with malaria and the CT genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the TT genotypes and lower concentrations and worse response to lumefantrine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.","phenotypeText":["increased concentrations and an improved response to lumefantrine"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.","phenotypeText":["more likely to respond to tramadol treatment"]},{"genotypeAnnotationText":"Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.","phenotypeText":["acquired resistance to erlotinib"]},{"genotypeAnnotationText":"Patients with the AA genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["poorer response to pravastatin treatment"]},{"genotypeAnnotationText":"Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.","phenotypeText":["increased dose adjusted trough concentration of tacrolimus"]},{"genotypeAnnotationText":"Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.","phenotypeText":["higher mitotane plasma concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.","phenotypeText":["decreased doses of anti-Parkinsonian drugs","decreased risk of mortality"]},{"genotypeAnnotationText":"Patients with the AA genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.","phenotypeText":["increased risk of hematologic toxicity"]},{"genotypeAnnotationText":"Patients with breast cancer and the rs1695 AA genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.","phenotypeText":["decreased severity of toxicity"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-C*03:02 allele and chronic renal insufficiency who are treated with allopurinol may have an increased risk of simple rash as compared to patients with no HLA-C*03:02 alleles or negative for the HLA-C*03:02 test. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.","phenotypeText":["increased risk of simple rash"]},{"genotypeAnnotationText":"Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.","phenotypeText":["better response to EULAR therapy"]},{"genotypeAnnotationText":"Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience adverse events as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.","phenotypeText":["more likely to experience adverse events"]},{"genotypeAnnotationText":"Patients with the *3\/*3 diplotype may have increased toxicity when treated with indomethacin as compared to patients with *1\/*1 diplotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.","phenotypeText":["increased toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.","phenotypeText":["decreased levels of glucuronidation of morphine"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR long form (L allele) genotype who are treated with escitalopram may have an increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.","phenotypeText":["higher baseline mean arterial blood pressure"]},{"genotypeAnnotationText":"Patients the CC genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival","decreased progression-free survival","increased overall survival","decreased overall survival"]},{"genotypeAnnotationText":"High-risk pediatric patients with acute lymphoblastic leukemia who have the TT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.","phenotypeText":["decreased risk for osteonecrosis"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have decreased metabolism of lornoxicam as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of lornoxicam"]},{"genotypeAnnotationText":"Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.","phenotypeText":["decreased physical responses to smoking"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have decreased severity of nicotine dependence as compared to patients with one copy of the *1 allele in combination with one copy of the *1x2 allele, but increased severity as compared to patients with two copies of the *2 allele or one copy of the *1 allele in combination with one copy of the *2 allele. Other genetic and clinical factors may also influence severity of nicotine dependence.","phenotypeText":["severity of nicotine dependence"]},{"genotypeAnnotationText":"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["decreased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.","phenotypeText":["increased plasma concentrations of triglycerides"]},{"genotypeAnnotationText":"Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["reduced progression-free survival time"]},{"genotypeAnnotationText":"Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.","phenotypeText":["increased chance of disease recurrence"]},{"genotypeAnnotationText":"Patients with the rs121909005 GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.","phenotypeText":["less likely to experience erythema"]},{"genotypeAnnotationText":"Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.","phenotypeText":["increased response to lithium"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to clopidogrel.","phenotypeText":["decreased risk of adverse cardiac events"]},{"genotypeAnnotationText":"Children with the TT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["risk for hearing loss"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.","phenotypeText":["decreased likelihood of smoking abstinence"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs9397685 AG genotype may experience a decreased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl.","phenotypeText":["decreased severity of nausea and vomiting"]},{"genotypeAnnotationText":"African-American patients with the CC genotype (E4\/E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3\/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin.","phenotypeText":["shorter duration to reach stable warfarin dose"]},{"genotypeAnnotationText":"Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.","phenotypeText":["smaller increases in fractional shortening and systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs2108622 TT genotype may have increased warfarin dosage requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements.","phenotypeText":["increased warfarin dosage requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased systolic blood pressure following nimodipine administration as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.","phenotypeText":["decreased systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the CT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*2 allele or one copy of the *2 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.","phenotypeText":["smoking addiction"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased exposure to pitavastatin as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.","phenotypeText":["increased exposure to pitavastatin"]},{"genotypeAnnotationText":"Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose.","phenotypeText":["resistant to warfarin"]},{"genotypeAnnotationText":"Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.","phenotypeText":["decreased clearance of gemcitabine","increased severity of neutropenia"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have increased exposure to imatinib as compared to patients with. the*1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.","phenotypeText":["increased exposure to imatinib"]},{"genotypeAnnotationText":"Healthy males with the del\/del genotype may have an increased response when given bumetanide, furosemide or torasemide as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC\/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide, torasemide.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and pulmonary fibrosis may have increased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine.","phenotypeText":["increased response to N-acetylcysteine"]},{"genotypeAnnotationText":"Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":["improvement in psoriasis area and severity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele in combination with a decreased or uncertain function allele may have decreased clearance of methadone as compared to patients carrying two normal function alleles. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone clearance.","phenotypeText":["decreased clearance of methadone"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype TT or AT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.","phenotypeText":["increased risk of Esophagitis"]},{"genotypeAnnotationText":"Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Individuals with the CC genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.","phenotypeText":["less likely to experience anxiety"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["increased risk for non-response"]},{"genotypeAnnotationText":"Patients with the HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with risperidone may have a reduced, but not absent, risk of side effects as compared to patients with the HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced adverse events.","phenotypeText":["reduced risk of side effects"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or AT. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.","phenotypeText":["decreased likelihood of Osteonecrosis"]},{"genotypeAnnotationText":"Patients with the AA genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.","phenotypeText":["increased risk for methamphetamine psychosis"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele may have decreased metabolism of losartan as compared to patients with the *1 allele. There is currently no evidence to suggest that losartan metabolism is significantly different in patients carrying the * 2 allele in combination with a normal function allele (e.g. *1\/*2) as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.","phenotypeText":["decreased metabolism of losartan"]},{"genotypeAnnotationText":"Cells with the CC genotype may have decreased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CT genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.","phenotypeText":["decreased expression of FKBP5 and NR3C1 genes"]},{"genotypeAnnotationText":"Patients with the AG genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.","phenotypeText":["risk of addiction"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*9 allele or one copy of the *9 allele in combination with one copy of the *1, *4, *4B or *4C alleles may have decreased metabolism of coumarin as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and coumarin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence coumarin metabolism.","phenotypeText":["decreased metabolism of coumarin"]},{"genotypeAnnotationText":"Female patients with the A-202A_376G\/B (reference) diplotype (heterozygous for the G6PD A- variant) who are treated with nitrofurantoin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the A-202A_376G\/A-202A_376G or B\/B diplotype. Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased risk of mortality after myocardial infarction as compared to the CC or CT genotypes (ApoE E2 carriers), which may be mitigated by simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":["decreased risk of mortality after myocardial infarction"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.","phenotypeText":["increased clearance of nevirapine"]},{"genotypeAnnotationText":"Patients with the rs17682789 TT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.","phenotypeText":["increased risk of diarrhea"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*4 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1\/*1 and CYP3A5 *3\/*3). Other genetic and clinical factors may also influence risk for neuropathy.","phenotypeText":["decreased risk for neuropathy"]},{"genotypeAnnotationText":"Patients with the AA genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.","phenotypeText":["similar risk of grade 3-4 neutropenia"]},{"genotypeAnnotationText":"HIV positive patients who are treated with nevirapine and are also carriers of the HLA-C*05:09 allele may have an increased risk of DRESS Syndrome or SJS\/TEN as compared to non-carriers.","phenotypeText":["increased risk of DRESS Syndrome or SJS\/TEN"]},{"genotypeAnnotationText":"Patients with the TT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of gemcitabine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1805087 AA genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.","phenotypeText":["no significant association between the rs1805087 AA genotype and risk of toxicity"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have decreased concentration of lovastatin acid as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentration of lovastatin acid"]},{"genotypeAnnotationText":"Patients with hypertension and the AG genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.","phenotypeText":["decreased response to candesartan"]},{"genotypeAnnotationText":"Patients with the rs121909020 AG genotype (one copy of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.","phenotypeText":["less improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.","phenotypeText":["decreased metabolism of phenylalanine"]},{"genotypeAnnotationText":"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["increased progression-free survival"]},{"genotypeAnnotationText":"Patients with the CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.","phenotypeText":["increased response to fentanyl"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with the TT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.","phenotypeText":["more likely to quit smoking"]},{"genotypeAnnotationText":"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["better response to atorvastatin treatment"]},{"genotypeAnnotationText":"Female children with typhoid fever and the A-202A_376G\/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency) who are treated with chloramphenicol may have an increased risk of hemolysis as compared to children with the wildtype B\/B diplotype (not associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (reference) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":["increased risk of hemolysis"]},{"genotypeAnnotationText":"The SLCO1B1*14 allele (defined as consisting of rs2306283 and rs11045819) is assigned as an increased function allele by CPIC. Patients with the *14 allele in combination with another increased or normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1XN genotype (carriers of more than two functional CYP2D6 alleles) may have a reduced response to dolasetron as compared to patients with the same genotype who were administered granisetron. Other clinical and genetic factors may also influence response to dolasetron in patients with postoperative nausea and vomiting.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*58:01 allele have a decreased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with antiepileptics as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test.","phenotypeText":["decreased risk of Severe Cutaneous Adverse Reactions"]},{"genotypeAnnotationText":"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3\/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1\/*3 or *1\/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.","phenotypeText":["decreased metabolism of cyclosporine resulting in increased exposure"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.","phenotypeText":["decreased serum bicarbonate levels"]},{"genotypeAnnotationText":"Patients with the TT genotype who smoke tobacco may have a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.","phenotypeText":["greater body mass index"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the AG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response","better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["increased likelihood of developing Thrombocytopenia"]},{"genotypeAnnotationText":"Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of PONV.","phenotypeText":["decreased risk for post-operative nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis may have an increased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.","phenotypeText":["risk of bone marrow toxicity"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is not significant association between the CYP3A4*22 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.","phenotypeText":["not significant association"]},{"genotypeAnnotationText":"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":["decreased response to TNF-alpha inhibitors"]},{"genotypeAnnotationText":"Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.","phenotypeText":["increased likelihood of responsiveness"]},{"genotypeAnnotationText":"Patients with the CYP2D6*33 allele may have similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. The CYP2D6*33 allele was found to have similar intrinsic clearance during in-vitro characterization with n-desmethyltamoxifen. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["similar clearance of n-desmethyltamoxifen"]},{"genotypeAnnotationText":"Pediatric patients with the *1\/*1C genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.","phenotypeText":["increased concentrations of tacrolimus"]},{"genotypeAnnotationText":"Patients with the AA genotype and solid tumors, may have increased response to gemcitabine compared to the CC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL\/A or DEL\/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.","phenotypeText":["decreased risk for antipsychotic-induced extrapyramidal symptoms"]},{"genotypeAnnotationText":"Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of cardiovascular disease events"]},{"genotypeAnnotationText":"Patients with the AA genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.","phenotypeText":["decreased chance of response"]},{"genotypeAnnotationText":"Patients with the CC genotype may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.","phenotypeText":["decreased likelihood of Substance-Related Disorders"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["increased risk of myocardial infarction"]},{"genotypeAnnotationText":"Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["better response to treatment"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.","phenotypeText":["decreased clearance of methotrexate"]},{"genotypeAnnotationText":"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.","phenotypeText":["decreased doses of warfarin"]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have improved response to citalopram or escitalopram as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.","phenotypeText":["improved response"]},{"genotypeAnnotationText":"Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.","phenotypeText":["poorer likelihood of abstinence"]},{"genotypeAnnotationText":"Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and heart conditions may have a poorer response to treatment with beta-blockers or antihypertensives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate.","phenotypeText":["no significant association with response to methylphenidate"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of desipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of desipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D6*2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of desipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25.This annotation only covers the pharmacokinetic relationship between CYP2D6 and desipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of desipramine.","phenotypeText":["increased metabolism of desipramine","decreased metabolism of desipramine"]},{"genotypeAnnotationText":"Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms compared to TT carriers, and more likely to have improvement in symptoms as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["less likely to have an improvement in symptoms"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased fluvastatin concentration when treated with fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased fluvastatin concentration"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.","phenotypeText":["better response according to the Positive and Negative Syndrome Scale"]},{"genotypeAnnotationText":"Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"It is currently unclear how the CT genotype affects a patient's risk of developing heroin dependence.","phenotypeText":["risk of developing heroin dependence"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["decreased likelihood of developing Diarrhea"]},{"genotypeAnnotationText":"Patients with the A\/del genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A\/A genotype, but a decreased risk as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.","phenotypeText":["increased risk of developing agranulocytosis"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQB1*02:02 allele who are treated with acetaminophen may have an increased risk of severe cutaneous adverse reactions as compared to patients with no HLA-DQB1*02:02 alleles or negative for the HLA-DQB1*02:02 test. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.","phenotypeText":["increased improvement in forced expiratory volume (FEV)"]},{"genotypeAnnotationText":"Patients with the AA genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.","phenotypeText":["higher frequency of asthma exacerbations"]},{"genotypeAnnotationText":"Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.","phenotypeText":["decreased progression-free survival"]},{"genotypeAnnotationText":"Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.","phenotypeText":["increased dose of acenocoumarol"]},{"genotypeAnnotationText":"Patients with the del\/del genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the C\/del or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.","phenotypeText":["decreased risk of venous thrombosis"]},{"genotypeAnnotationText":"Patients with the rs12471326 CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.","phenotypeText":["increased risk for QTc prolongation"]},{"genotypeAnnotationText":"Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["decreased risk of hypercholesteremia"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of tramadol toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":["decreased likelihood of remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*95 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*95 allele (in this study only defined as R388H not including 100C>T, P34S) was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor\/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor\/tezacaftor.","phenotypeText":["respond to ivacaftor\/tezacaftor treatment"]},{"genotypeAnnotationText":"Patients with cancer and the CT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["increased overall survival time"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.","phenotypeText":["increased conversion of tramadol to O-desmethyltramadol (M1)"]},{"genotypeAnnotationText":"Patients with testicular cancer and the AG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["decreased risk of developing febrile neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype (two copies of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of trimipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of trimipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and trimipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of trimipramine.","phenotypeText":["decreased metabolism","increased metabolism","similar metabolism"]},{"genotypeAnnotationText":"Infants with the rs1799971 AG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["less likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"Patients with the rs10306114 AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to aspirin.","phenotypeText":["decreased risk for non-response"]},{"genotypeAnnotationText":"Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.","phenotypeText":["better chance at achieving remission"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.","phenotypeText":["decreased risk of acetylsalicylic acid-intolerant chronic urticaria"]},{"genotypeAnnotationText":"Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype, but decreased morphine dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements.","phenotypeText":["increased morphine dose requirements"]},{"genotypeAnnotationText":"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.","phenotypeText":["decreased likelihood of headache"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.","phenotypeText":["increased rate of sulfation of morphine"]},{"genotypeAnnotationText":"Patients with the rs118192176 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and\/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.","phenotypeText":["malignant hyperthermia"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":["increased likelihood of methotrexate response"]},{"genotypeAnnotationText":"The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":["increased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.","phenotypeText":["better response to treatment with salvianolate"]},{"genotypeAnnotationText":"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.","phenotypeText":["decreased social and clinical needs"]},{"genotypeAnnotationText":"The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.","phenotypeText":["decreased clearance of midazolam"]},{"genotypeAnnotationText":"Patients with the AC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.","phenotypeText":["higher plasma concentrations of efavirenz"]},{"genotypeAnnotationText":"Patients with the CC genotype who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotypes, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin.","phenotypeText":["increased bioavailability of metformin"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.","phenotypeText":["decreased improvement of depression symptoms"]},{"genotypeAnnotationText":"Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.","phenotypeText":["increased likelihood of survival"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["increased oxycodone dose requirements"]},{"genotypeAnnotationText":"Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.","phenotypeText":["increased response to measles vaccination"]},{"genotypeAnnotationText":"Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the AG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":["increased risk of neurotoxicity"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *4\/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.","phenotypeText":["decreased metabolism of mirtazapine"]},{"genotypeAnnotationText":"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["altered risk of drug toxicity"]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":["worse response","decreased concentrations of deferasirox","increased risk of iron overload"]},{"genotypeAnnotationText":"Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["lower risk of toxicity"]},{"genotypeAnnotationText":"Patients with the *6\/*6 genotype and chronic lymphocytic leukemia may be less likely to achieve a complete response but also less likely to experience drug toxicities when receiving combination cyclophosphamide and fludarabine treatment, as compared to patients with the *1\/*1 genotype. Other genetic and clinical factors may also influence response or drug toxicity when receiving cyclophosphamide and fludarabine treatment.","phenotypeText":["less likely to achieve a complete response but also less likely to experience drug toxicities"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele in combination with a normal function allele and depression may require a higher dose of selective serotonin reuptake inhibitors as compared to patients with two no function alleles. Other genetic and clinical factors may also influence a patient's dose requirement.","phenotypeText":["higher dose requirement of selective serotonin reuptake inhibitors"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*2 allele or one copy of the *2 allele in combination with one copy of the *1 allele may have decreased nicotine consumption as compared to patients with two copies of the *1 allele. Other genetic and clinical factors may also influence nicotine consumption.","phenotypeText":["decreased nicotine consumption"]},{"genotypeAnnotationText":"Patients with the rs1799971 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl.","phenotypeText":["increased analgesic response"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of naproxen as compared to patients with the AT or TT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of naproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.","phenotypeText":["decreased likelihood of cardiotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.","phenotypeText":["increased risk of developing hyperlipidemia"]},{"genotypeAnnotationText":"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.","phenotypeText":["decreased response, specifically mean arterial pressure"]},{"genotypeAnnotationText":"Patients with the rs9923231 TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.","phenotypeText":["increased risk of over-anticoagulation"]},{"genotypeAnnotationText":"Hispanic patients with the AG genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.","phenotypeText":["greater decrease in viral load"]},{"genotypeAnnotationText":"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the rs1799971 AG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements.","phenotypeText":["increased alfentanil dose requirements"]},{"genotypeAnnotationText":"Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["decreased risk of neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence rosuvastatin pharmacokinetics. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and rosuvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased exposure to rosuvastatin"]},{"genotypeAnnotationText":"Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.","phenotypeText":["increased risk of diarrhea or dehydration"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["less severe anemia"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DQA1*02:01 allele have an increased risk of hepatotoxicity when treated with lapatinib as compared to patients with no HLA-DQA1*02:01 alleles or negative for the HLA-DQA1*02:01 test. This allele is in strong linkage disequilibrium with HLA-DRB1*07:01. Other genetic and clinical factors may also influence a patient's risk of lapatinib-induced hepatotoxicity.","phenotypeText":["increased risk of hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype, and an increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer.","phenotypeText":["increased metabolism of temsirolimus","increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.","phenotypeText":["decreased risk for leukopenia"]},{"genotypeAnnotationText":"Postoperative patients with the AG genotype may have higher morphine requirements as compared to patients with the GG genotype, but lower morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements.","phenotypeText":["higher morphine requirements","lower morphine requirements","interaction with ethnicity"]},{"genotypeAnnotationText":"Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.","phenotypeText":["reduced risk of adverse drug reactions"]},{"genotypeAnnotationText":"Patients with the GG genotype and tobacco use disorder may have a decreased risk for nicotine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to nicotine.","phenotypeText":["decreased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with the rs1799971 AA genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements.","phenotypeText":["decreased oxycodone dose requirements"]},{"genotypeAnnotationText":"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.","phenotypeText":["increased doses of tacrolimus"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.","phenotypeText":["decreased sulfation of O-desmethylnaproxen"]},{"genotypeAnnotationText":"Patients with the GG genotype and bladder cancer may have decreased exposure to sirolimus and temsirolimus as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of citalopram as compared to patients with a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2D6 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence citalopram metabolism.","phenotypeText":["increased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.","phenotypeText":["shorter post-transplantation hospital stay"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.","phenotypeText":["increased serum creatine kinase levels"]},{"genotypeAnnotationText":"Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.","phenotypeText":["decreased response to rosuvastatin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.","phenotypeText":["increased risk of nonfatal myocardial infarction"]},{"genotypeAnnotationText":"Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.","phenotypeText":["increased response to treatment with methylphenidate"]},{"genotypeAnnotationText":"Patients with the GG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.","phenotypeText":["decreased severity of Substance-Related Disorders"]},{"genotypeAnnotationText":"People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.","phenotypeText":["decreased exposure"]},{"genotypeAnnotationText":"The TT genotype was not analyzed, but patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.","phenotypeText":["decreased risk for periorbital edema"]},{"genotypeAnnotationText":"Patients with opioid dependence and the CT genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.","phenotypeText":["decreased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the rs2011425 TT genotype may have increased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine.","phenotypeText":["increased serum concentrations of lamotrigine"]},{"genotypeAnnotationText":"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.","phenotypeText":["decreased risk of developing neutropenia"]},{"genotypeAnnotationText":"Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":["less likely to respond to TNF inhibitors"]},{"genotypeAnnotationText":"Patients with cardiovascular disease and the GT genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the TT genotype and a decreased likelihood as compared to the GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.","phenotypeText":["increased likelihood of rhabdomyolysis"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased sensitivity"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk.","phenotypeText":["decreased risk of developing hyperbilirubinemia"]},{"genotypeAnnotationText":"Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.","phenotypeText":["higher plasma concentrations of the drug"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.","phenotypeText":["decreased survival"]},{"genotypeAnnotationText":"Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the response to clodronate.","phenotypeText":["decreased likelihood of resistance"]},{"genotypeAnnotationText":"Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.","phenotypeText":["decreased severity of Diarrhea"]},{"genotypeAnnotationText":"Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CYP2B6 *1\/*4 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6\/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.","phenotypeText":["decreased risk of experiencing weight gain"]},{"genotypeAnnotationText":"Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.","phenotypeText":["increased beta cell function"]},{"genotypeAnnotationText":"Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.","phenotypeText":["reduced response or better response to treatment"]},{"genotypeAnnotationText":"Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.","phenotypeText":["risk for peptic ulcer"]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.","phenotypeText":["increased subjective responses to alcohol"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.","phenotypeText":["decreased response to atorvastatin"]},{"genotypeAnnotationText":"Patients with the AC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.","phenotypeText":["higher platelet aggregation"]},{"genotypeAnnotationText":"Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.","phenotypeText":["decreased dose of phenytoin"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*38:01 allele who are treated with lamotrigine may have an increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) as compared to patients with no HLA-B*38:01 alleles or negative for the HLA-B*38:01 test. Other genetic and clinical factors may also influence a patient's risk of lamotrigine-induced adverse reactions.","phenotypeText":["increased risk of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)"]},{"genotypeAnnotationText":"Patients with heroin dependence and the rs5326 CC genotype may have decreased methadone dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.","phenotypeText":["decreased methadone dose requirements"]},{"genotypeAnnotationText":"Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.","phenotypeText":["increased risk of opioid dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.","phenotypeText":["increased risk of Hypertension and hand-foot skin reactions"]},{"genotypeAnnotationText":"Patients with the CC genotype and cancer may have decreased survival time and a decreased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.","phenotypeText":["decreased survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*10 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT, and increased dose as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.","phenotypeText":["associated with decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.","phenotypeText":["increased risk for Aspirin-Exacerbated Respiratory Disease"]},{"genotypeAnnotationText":"Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.","phenotypeText":["better response to fluvastatin"]},{"genotypeAnnotationText":"Patients with HIV and the CYP3A5 *1\/*7 genotype (designated as intermediate metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1\/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found a lack of association with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.","phenotypeText":["increased plasma concentrations"]},{"genotypeAnnotationText":"Patients with genotype GG and depressive disorder may have increased response to venlafaxine compared to patients with genotype AA or AG. Patients with GG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.","phenotypeText":["increased exposure to SN-38"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*44 allele have an increased likelihood of having a sustained response to interferon-alpha and ribavirin therapy, as compared to patients with no HLA-B*44 alleles or negative for the HLA-B*44 test. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to interferon-alpha and ribavirin therapy. Note that the information in this clinical annotation refers to the presence of any HLA-B*44 allele. This clinical annotation appears on the HLA-B*44:02 allele page because this was the first *44 allele discovered.","phenotypeText":["increased likelihood of having a sustained response to interferon-alpha and ribavirin therapy"]},{"genotypeAnnotationText":"The TPMT*3A allele is assigned as a no function allele by CPIC. Patients with the TPMT*3A allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.","phenotypeText":["increased risk for nicotine dependence"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-B*15:01 allele may have a decreased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-B*15:01 alleles or negative for the HLA-B*15:01 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["decreased risk of oxcarbazepine-induced maculopapular eruption"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["increased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the CYP2D6*41 allele and risk of side effects or intolerance to citalopram. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects or intolerance to citalopram.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs70991108 TGGCGCGTCCCGCCCAGGT\/TGGCGCGTCCCGCCCAGGT genotype may have an increased risk of side effects when treated with methotrexate as compared to patients with TGGCGCGTCCCGCCCAGGT\/del or del\/del genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.","phenotypeText":["increased risk of side effects"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.","phenotypeText":["better response to treatment with imatinib"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.","phenotypeText":["increased risk of developing diarrhea"]},{"genotypeAnnotationText":"Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.","phenotypeText":["poorer response"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs1868089 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.","phenotypeText":["decreased risk of dermatologic toxicity"]},{"genotypeAnnotationText":"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["decreased risk and reduced severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the *4\/*4 genotype and dementia may have increased dose-adjusted plasma concentrations of galantamine as compared to patients with the *1\/*1, *1\/*4, *4\/*41, *1\/*41, *5\/*41, *6\/*41 or *4\/*1XN genotype. Other genetic and clinical factors may also influence dose-adjusted plasma concentrations of galantamine.","phenotypeText":["increased dose-adjusted plasma concentrations"]},{"genotypeAnnotationText":"Patients with the CG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.","phenotypeText":["decreased risk for nausea"]},{"genotypeAnnotationText":"Patients with opioid dependence and the AG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.","phenotypeText":["increased risk of sudden death"]},{"genotypeAnnotationText":"Patients with the AG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.","phenotypeText":["decreased dose requirement"]},{"genotypeAnnotationText":"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.","phenotypeText":["better response to anti-TNF therapy"]},{"genotypeAnnotationText":"Patients with the rs76103438 TT genotype may be at a decreased risk of experiencing adverse events when treated with simvastatin as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.","phenotypeText":["decreased severity of akathisia"]},{"genotypeAnnotationText":"Patients with the CT (CYP2C9 *1\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the GG genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.","phenotypeText":["increased risk of suicidal thoughts"]},{"genotypeAnnotationText":"Patients with the GG genotype may require decreased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose","phenotypeText":["decreased dose of warfarin"]},{"genotypeAnnotationText":"Patients with irritable bowel disorders and the rs2413739 TT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.","phenotypeText":["decreased response to azathioprine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.","phenotypeText":["decreased risk of myocardial infarction"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.","phenotypeText":["decreased analgesic response","similar analgesic response"]},{"genotypeAnnotationText":"Patients with opioid dependence and the rs11265549 GG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.","phenotypeText":["less likely to experience skin irritation"]},{"genotypeAnnotationText":"Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.","phenotypeText":["increased risk of drug-induced liver toxicity"]},{"genotypeAnnotationText":"Genotype TT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir.","phenotypeText":["decreased uptake"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.","phenotypeText":["increased chance of achieving 6 month abstinence"]},{"genotypeAnnotationText":"Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.","phenotypeText":["decreased efflux of rhodamine from CD56+ natural killer cells"]},{"genotypeAnnotationText":"Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT.","phenotypeText":["decreased likelihood of developing new-onset diabetes after transplantation (NODAT)"]},{"genotypeAnnotationText":"Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.","phenotypeText":["decreased risk of developing drug dependence"]},{"genotypeAnnotationText":"People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.","phenotypeText":["increased exposure to sulindac"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AG or GG genotypes. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.","phenotypeText":["increased risk of developing hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Women with intermediate metabolizer genotypes, such as *1\/*3, and epilepsy who are taking valproic acid may have increased risk of becoming overweight compared to patients with normal metabolizer genotypes. However, this result was not found in men or in another study. Other genetic and clinical factors may affect response to valproic acid.","phenotypeText":["increased risk of becoming overweight"]},{"genotypeAnnotationText":"Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype (carriers of E2 or E2\/E2). Other genetic and clinical factors may also influence response to fenofibrate.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs45445694 2R\/2R genotype ((CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2) may have increased response to methotrexate in people with Rheumatoid Arthritis as compared to patients with the 2R\/3R or 3R\/3R genotypes. Other genetic and clinical factors may also influence response to methotrexate.","phenotypeText":["increased response to methotrexate in people with Rheumatoid Arthritis"]},{"genotypeAnnotationText":"Patients with the rs4035887 AA genotype may have an increased risk of toxicity when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of tamoxifen resulting in decreased endoxifen concentrations as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele may achieve therapeutic endoxifen concentrations compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","decreased endoxifen concentrations","therapeutic endoxifen concentrations"]},{"genotypeAnnotationText":"Patients with the CYP2D6*2\/*44 genotype may have a decreased metabolism of dextromethorphan as compared to patients with the CYP2D6*1\/*2 genotype. Finding reported in case study for *2\/*44 subject. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["decreased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with the AA genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.","phenotypeText":["less likely to require a dose reduction of imatinib due to toxicity"]},{"genotypeAnnotationText":"Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CGG genotype may be at an increased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing anemia"]},{"genotypeAnnotationText":"Patients with the CT genotype (one copy of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["respond to ivacaftor treatment"]},{"genotypeAnnotationText":"Patients with the rs2075572 CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":["decreased severity of sleep disorders"]},{"genotypeAnnotationText":"Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.","phenotypeText":["decreased response to anti-CLL treatment"]},{"genotypeAnnotationText":"Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.","phenotypeText":["association with serotonin levels"]},{"genotypeAnnotationText":"Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*90 allele was found to have decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":["decreased clearance of amitriptyline"]},{"genotypeAnnotationText":"Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.","phenotypeText":["increased dose-adjusted serum olanzapine N-oxide concentrations"]},{"genotypeAnnotationText":"Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.","phenotypeText":["decreased risk of developing alcoholism"]},{"genotypeAnnotationText":"Patients with the AA genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.","phenotypeText":["decreased risk of severe cutaneous adverse reactions (SCAR)"]},{"genotypeAnnotationText":"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to peginterferon alpha and ribavirin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the rs538336580 AA genotype may have increased risk of toxicity when treated with fluorouracil regimens as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fluorouracil toxicity.","phenotypeText":["increased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.","phenotypeText":["greater reduction of diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine.","phenotypeText":["increased likelihood of recurrence"]},{"genotypeAnnotationText":"Patients with the rs9606186 CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Individuals with the TC\/TCCTC genotype may have decreased clearance of olanzapine as compared to individuals with the TCCTC\/TCCTC genotype. Other genetic and clinical factors may also influence clearance of olanzapine.","phenotypeText":["decreased clearance of olanzapine"]},{"genotypeAnnotationText":"The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of sertraline as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["increased metabolism","decreased metabolism"]},{"genotypeAnnotationText":"Patients with the GGTCCCACTCTTCCCACA\/GGTCCCACTCTTCCCACA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del\/del genotype. Other genetic and clinical factors may also influence progression-free survival time.","phenotypeText":["longer progression-free survival time"]},{"genotypeAnnotationText":"Patients carrying the CYP3A4*8 allele may have decreased clearance of oxycodone as comapred to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.","phenotypeText":["decreased clearance of oxycodone"]},{"genotypeAnnotationText":"Patients with the rs12885713 TT genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to cyclosporine.","phenotypeText":["increased response to cyclosporine"]},{"genotypeAnnotationText":"The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of tamoxifen resulting in increased endoxifen concentrations as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D6*1 allele in combination with alleles that result in a normal metabolizer phenotype may achieve therapeutic endoxifen concentrations similar to patients with an increased function allele in combination with an increased, normal, decreased or no function allele. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of tamoxifen.","phenotypeText":["increased metabolism of tamoxifen resulting in increased endoxifen concentrations"]},{"genotypeAnnotationText":"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype may have increased activity of DPYD as compared to patients with the AT or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["increased activity of DPYD"]},{"genotypeAnnotationText":"Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.","phenotypeText":["shorter progression-free survival time"]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.","phenotypeText":["decreased severity of opiate withdrawal symptoms"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":["decreased risk of developing nicotine dependence"]},{"genotypeAnnotationText":"Patients with the TT genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.","phenotypeText":["better response to pravastatin treatment"]},{"genotypeAnnotationText":"Patients with the 9,9-repeat genotype (del\/del) may have a decreased response to disulfiram treatment for cocaine dependence. as compared to patients with the 10,10-repeat genotype. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.","phenotypeText":["increased risk for treatment-resistance"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1 allele may have 1) an increased clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*9 or *25 or *26 or *28 or *32 or *39 or *43 or *45 or *48 or *70 allele, 2) similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*22 or *23 or *24 or *27 or *33 or *49 allele, and 3) increased activity of CYP2D6 when assayed with n-desmethyltamoxifen compared to CYP2D6*7 or *10 or *12 or *14A or *14B or *17 or *18 or *29 or *30 or *31 or *36 or *37 or *40 or *46 or *47 or *50 or *51 or *52 or *54 or *55 or *61 or *62 or *63 or *64 or *65 or *71 or *72 or *75 allele. This annotation only covers the pharmacokinetic relationship between CYP2D6 and n-desmethyltamoxifen and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of n-desmethyltamoxifen.","phenotypeText":["increased clearance of n-desmethyltamoxifen","similar clearance of n-desmethyltamoxifen","increased activity of CYP2D6"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.","phenotypeText":["no significant association with methotrexate exposure"]},{"genotypeAnnotationText":"Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.","phenotypeText":["increased area under the curve (AUC) of olanzapine"]},{"genotypeAnnotationText":"Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.","phenotypeText":["more likely to develop colorectal cancer"]},{"genotypeAnnotationText":"The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*29 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.","phenotypeText":["increased risk of experiencing apnea"]},{"genotypeAnnotationText":"Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["increased likelihood of nausea and vomiting","decreased likelihood of nausea and vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.","phenotypeText":["increased AUC of letermovir"]},{"genotypeAnnotationText":"Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.","phenotypeText":["increased metabolism of tegafur"]},{"genotypeAnnotationText":"Patients with the rs61605570 AT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs9679162 GG genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.","phenotypeText":["decreased response to chemotherapy"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":["decreased dose of mercaptopurine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14 allele or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":["greater bone mineral loss"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":["increased metabolism of imatinib","decreased sensitivity to dasatinib, imatinib, or nilotinib"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one copy of the CYP2A6*1 allele in combination with one copy of the *4 or *9 allele may have increased metabolism of nicotine as compared to patients with one copy of the *4 allele in combination with the *9 allele, or patients with two copies of the *9 allele. Patients with two copies of the *1 allele may have increased metabolism of nicotine as compared to patients with one copy of the *1 allele in combination with one copy of the *2, *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *23, *24, *25, *26, *27, *28, *35, *39, *41 or *55 alleles or or patients with two copies of the *4, *7, *9, *10, *11 *12, *13, *15, *17, *19, *20, *24, *27, *28, *35, *39, *41 or *55 alleles or patients with the *4\/*7, *4\/*9 *4\/*17, *9\/*12 *9\/*26 or *17\/*20 diplotypes but may have decreased metabolism as compared to patients with two copies of the *46 allele or one copy of the *1 allele in combination with the *46 or *1x2 alleles. However, conflicting evidence has been reported for *24. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have a decreased response to antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["reduced risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":["decreased metabolism of tramadol","similar metabolism of tramadol","increased metabolism of tramadol"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have an increased response to statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["increased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and carrying one or two copies of the NAT2*1 allele (formerly *12A, B, C) may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of two *5, *6 or *7 suballeles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":["require a decreased dose of antipsychotics"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the CC genotype may have improved response to antidepressants as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["improved response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 CC genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":["increased clearance of mephenytoin"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["increased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["decreased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*14 allele or one copy of the *14 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the rs72547516 AT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir in people with HIV"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with the *6, *7, or *14 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another fast acetylator allele may have increased metabolism of dipyrone as compared to patients carrying the *4 allele in combination with the *6, *7, *14, or *16 allele or patients with the any two *6, *7, *14, or *16 alleles. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of dipyrone"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism","reduced metabolism"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":["increased risk of developing opioid dependence"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*14 allele or one copy of the *14 allele in combination with the *6, *7, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5 allele or one copy of the *5 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 CT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"Patients carrying the NAT2*6 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AG genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele or one copy of the *4 allele (*13A now also mapped under *4) in combination with the *1 allele (formerly *12A, B, C) may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7, *14, or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2306283 GG genotype may have decreased clearance of pravastatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have increased plasma concentrations of aripiprazole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["increased plasma concentrations of aripiprazole"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*41 allele or one copy of the *41 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and carrying one or two copies of the NAT2*4 allele (*13A now also mapped under *4) may have a decreased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with any combination of two *5, *6 or *7 suballeles. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*39 allele or one copy of the *39 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*14 allele or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["better response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 CT genotype may have increased clearance of tenofovir as compared to patients with the TT genotype but decreased clearance compared to the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["increased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 TT genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *6 allele or one copy of the *6 allele in combination with any of the *5, *6, *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"Patients with the rs895819 CC genotype may have increased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["increased risk of severe toxicity"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7 allele or one copy of the *7 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*7 allele or one copy of the *7 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association between the rs2306283 AA genotype and response to pravastatin"]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have an increased response to antidepressants as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*5 allele or one copy of *5 in combination with the *6, *7, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*5 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *5 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":["reduced metabolism of escitalopram","less severe side effects","increased metabolism of escitalopram","more severe side effects"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["greater response to azathiopurine treatment for SLE"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["less likely to have a complete response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure","increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*55 allele or one copy of the *55 allele in combination with one copy of the *1 allele may have decreased metabolism of nicotine as compared to patients with two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP2A6 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":["increased risk of oxcarbazepine-induced maculopapular eruption (MPE)"]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have increased clearance of pravastatin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["decreased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*7 allele or one copy of the *7 allele in combination with the *6, *14, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":["decreased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["increased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*6 allele or one copy of *6 in combination with the *5, *7, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*6 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *6 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of hydralazine","increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs11045819 CC genotype may have a decreased response to statins as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":["increased codeine dose requirements"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 CC genotype may have increased clearance of tenofovir as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["increased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":["increased chance of response to bisphosphonate treatment"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*5 allele or one copy of the *5 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CT genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["increased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"Patients with the rs11045819 AA genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["decreased progression-free survival","decreased overall survival","increased progression-free survival","increased overall survival"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["increased metabolism"]},{"genotypeAnnotationText":"Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["increased plasma concentrations of tenofovir in people with HIV"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele (*13A now also mapped under *4) or one copy of the *4 allele in combination with one copy of any *1 allele (formerly *12A, B, C) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele; any combination of the *5, *6, *7, *14, *16 or *39 allele; two copies of *5, *6, *7, *14, *16 or *39 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6 allele or one copy of the *6 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have an increased response to statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*6 allele or one copy of the *6 allele in combination with the *7, *14, or *16 allele (NAT2 slow acetylators) may have increased likelihood of adverse events when treated with hydralazine as compared to patients identified as NAT2 rapid acetylators. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the rs4149056 TT genotype may have an increased response to simvastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*5 allele or one copy of the *5 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["decreased dose of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":["increased risk for Adenoma"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of myalgia and lower degree of muscle damage"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with HIV and the rs12979860 TT genotype may have decreased clearance of tenofovir as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs12979860 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir clearance.","phenotypeText":["decreased clearance of tenofovir"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*7 allele or one copy of the *7 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["more likely to respond to hydralazine treatment"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *7 allele or one copy of the *7 allele in combination with any of the *5, *6 *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["decreased concentrations of deferasirox"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 GG genotype may be at a decreased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["decreased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":["decreased DPYD activity"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox. This annotation only covers the pharmacokinetic relationship between rs887829 and deferasirox and does not include evidence about clinical outcomes.","phenotypeText":["increased concentrations of deferasirox"]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the AC genotype may have decreased response to antidepressants as compared to patients with the CC genotypes and imporved response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["decreased response to antidepressants","improved response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AA genotype may have a decreased response to metformin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response to metformin"]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*16 allele or one copy of *16 in combination with the *5, *6, or *7 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*16 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *16 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72547516 TT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 CC genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with concentrations of tenofovir"]},{"genotypeAnnotationText":"Patients with the rs895819 CT genotype may have increased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["increased risk of severe toxicity"]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":["decreased metabolism of sertraline"]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7 allele or one copy of the *7 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*7G allele or one copy of the *7G allele in combination with one of the *5, *6, *7, *14, *16 or *39 may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The *7G allele was not transitioned into the PharmVar database and remains with the arylamine N-acetyltransferases (NATs) site.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients with the rs72547516 GG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*14 allele or one copy of the *14 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1128503 AA genotype may have an increased response to antidepressants as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to antidepressants.","phenotypeText":["increased response to antidepressants"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*6 allele or one copy of the *6 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["more likely to respond to hydralazine treatment"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with one copy of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any *5, *6, *7, *14, or *16 allele may be more likely to respond to hydralazine treatment as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy","consume less NRT at 7 days post quit attempt","more likely to adhere to NRT","consume more NRT at 7 days post quit attempt"]},{"genotypeAnnotationText":"Patients with the rs895819 TT genotype may have decreased risk of severe toxicity when treated with fluorouracil or capecitabine regimens as compared to patients with the CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severe fluoropyrimidine toxicity.","phenotypeText":["decreased risk of severe toxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs11045819 AC genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.","phenotypeText":["increased response to statins"]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":["increased risk of developing neutropenia"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism of venlafaxine","similar metabolism of venlafaxine","increased metabolism of venlafaxine"]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response in men","increased response in women"]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6J allele or one copy of the *6J allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The *6J allele was not transitioned into the PharmVar database and remains with the arylamine N-acetyltransferases (NATs) site.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*16 allele (formerly *5A, *5D) in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs2306283 AG genotype and response to statins. However, patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.","phenotypeText":["decreased response to statins"]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation of carvedilol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["decreased atorvastatin lactonization"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":["stronger aggregation","increased risk of non-response"]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*1 allele (formerly *12A, B, C) may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two of the *5, *6, *7, *14, or *16 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*4 allele may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with any combination of the *5, *6, *7, *14 or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*39 allele (formerly *6O) or one copy of the *14 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele may have decreased metabolism of isoniazid as compared to patients with the *1 or *4 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of isoniazid"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*7 allele or one copy of *7 in combination with the *5, *6, or *16 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*7 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of hydralazine","increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1805128 CC genotype may have increased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["increased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["decreased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with tuberculosis and two copies of the NAT2*6 allele or one copy of the *6 allele in combination with any of the *5, *6, *7, *14, or *16 allele may be at an increased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with at least one copy of the *1 or *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs1751034 CT genotype and concentrations of tenofovir. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentrations.","phenotypeText":["no significant association with tenofovir concentrations"]},{"genotypeAnnotationText":"Patients with the rs1805128 TT genotype may have decreased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["decreased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":["decreased risk for hearing loss"]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin serum concentration","decreased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with the rs1803155 AA genotype and tuberculosis may have decreased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["decreased clearance of rifampin"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AA genotype may be at an increased risk of gastrointestinal toxicity when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with metformin.","phenotypeText":["increased risk of gastrointestinal toxicity"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":["decreased clearance of fesoterodine"]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":["less skin redness"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1803155 AG genotype and tuberculosis may have increased clearance of rifampin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4149056 CC genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72547516 AA genotype and may have increased metabolism of clozapine as compared to patients with the AG, AT, TT or GG genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron","no recommendation for CYP2D6 intermediate and poor metabolizers"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.","phenotypeText":["no significant association between the rs2306283 GG genotype and response to pravastatin"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with tuberculosis and with at least one copy of the NAT2*4 allele (*13A now also mapped under *4) may be at a decreased risk of developing toxic liver disease when treated with isoniazid regimens as compared to patients with any two of the *5, *6, *7, *14, or *16 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing toxic liver disease. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased risk of developing toxic liver disease"]},{"genotypeAnnotationText":"The current evidence base suggests that there is no significant association between the rs4363657 TT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.","phenotypeText":["no significant association"]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response and increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["increased severity of thrombocytopenia"]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Patients with the rs72547516 AG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of clozapine"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*1 allele (formerly *12A, B, C) or one copy of the *1 allele in combination with one copy of *4 allele (*13A now also mapped under *4) may have increased metabolism of isoniazid as compared to patients with any of the following genotype combinations: one copy of the *1 or *4 allele in combination with one copy of the *5, *6, *7, *14, *16 or *39 allele; any combination of the *5, *6, *7, *14, *16 or *39 allele; two copies of the *5, *6, *7, *14, *16 or *39 allele. Other genetic and clinical factors may also affect isoniazid metabolism. This annotation only covers the pharmacokinetic relationship between NAT2 and isoniazid and does not include evidence about clinical outcomes. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of isoniazid"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":["decreased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 GG genotype may have an increased response to metformin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["increased response to metformin"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":["decreased clearance of codeine"]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*6 allele or one copy of the *6 allele in combination with one copy of the *5, *6, *7, *14 or *16 alleles may have increased risk of experiencing adverse events when treated with sulfamethoxazole\/trimethoprim as compared to patients with two copies of the *4 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole\/trimethoprim. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Patients with the rs2306283 AG genotype may have increased clearance of pravastatin as compared to patients with the GG genotype but decreased clearance as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance","decreased clearance"]},{"genotypeAnnotationText":"Patients with the rs1128503 AG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations of aripiprazole"]},{"genotypeAnnotationText":"Patients with type II diabetes and the rs628031 AG genotype may have a decreased response to metformin as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["increased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the NAT2*1 allele or one copy of the *1 allele (formerly *12A, B, C) in combination with *4 allele (*13A now also mapped under *4) may be less likely to respond to hydralazine treatment or require a higher dosage as compared to patients with any two *5, *6, *7, *14, or *16 alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["less likely to respond to hydralazine treatment or require a higher dosage"]},{"genotypeAnnotationText":"Patients with the rs1128503 GG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["improved response to the drug"]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *4 allele in combination with the *5, *6, *7, or *16 allele or patients with two of the *5, *6, *7, or *16 alleles. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with co-infection of HIV and tuberculosis and with two copies of the *16 allele (formerly *5A, *5D) or one copy of the *16 allele in combination with any of the *5, *6 *7, or *16 allele may have an increased risk of drug-induced liver injury when treated with a combination of HIV antivirals and anti-TB drugs as compared to patients with at least one copy of the *1 or *4 allele. Other genetic and clinical factors may also affect a patient's risk of drug-induced liver injury. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased risk of drug-induced liver injury"]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":["worse response","increased clearance"]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["better response to metoprolol"]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":["greater decrease in systolic blood pressure"]},{"genotypeAnnotationText":"Patients with the rs1805128 CT genotype may have increased likelihood of Acquired Long QT Syndrome when treated with qt-prolonging drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Acquired Long QT Syndrome.","phenotypeText":["increased likelihood of Acquired Long QT Syndrome"]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with depressive disorder and the AA genotype may have decreased response to antidepressants as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to antidepressants in patients with depressive disorder.","phenotypeText":["decreased response to antidepressants"]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":["increased metabolism of oxycodone"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":["increased concentrations of nicotine"]},{"genotypeAnnotationText":"Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.","phenotypeText":["decreased plasma concentrations"]},{"genotypeAnnotationText":"Patients carrying the NAT2*14 allele in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["decreased metabolism of dipyrone"]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1803155 GG genotype and tuberculosis may have increased clearance of rifampin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rifampin clearance. This annotation only covers the pharmacokinetic relationship between rs1803155 and rifampin and does not include evidence about clinical outcomes.","phenotypeText":["increased clearance of rifampin"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":["increased risk and increased severity of drug toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of flurbiprofen"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["reduced risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":["decreased metabolism"]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":["increased concentrations of methylphenidate and atomoxetine"]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":["increased likelihood of experiencing vomiting"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":["decreased plasma concentrations of 6-thioguanine"]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":["decreased severity of pain"]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":["increased metabolism","reduced metabolism"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":["decreased risk for neutropenia and a decreased likelihood of dose delay"]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":["increased methadone dose requirements"]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of fluvastatin"]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased concentrations of cotinine glucuronide"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":["increased risk of drug resistance"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure","increased likelihood of treatment failure"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":["decreased metabolism and dose requirements of tacrolimus"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":["decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity"]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*7 allele in combination with the *4 allele (assigned as intermediate (or rapid) acetylator phenotype) may have increased metabolism of hydralazine as compared to patients carrying the *7 allele in combination with *6 (assigned as slow acetylator phenotype) and decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype (assigned as rapid acetylator phenotype). Patients carrying the *7 allele in combination with the *6 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4, *4\/*5, *4\/*6, or *4\/*7 genotypes. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["increased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["increased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":["decreased progression-free survival","decreased overall survival","increased progression-free survival","increased overall survival"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":["better response to treatment with buprenorphine"]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":["increased risk of adverse reactions"]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":["decreased exposure to mycophenolic acid"]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["decreased dose requirement of phenprocoumon"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":["increased risk of developing leukopenia"]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":["increased response","decreased risk of myalgia","lower degree of muscle damage"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of efavirenz"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":["increased risk of suicidal ideation"]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response","no association of the genotype with fluvoxamine response","the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response","Other genetic and clinical factors may also influence a patient's response to fluvoxamine"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":["decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c"]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":["increased rate of phenytoin clearance"]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":["more likely to require treatment with morphine for neonatal abstinence syndrome"]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["less likely to respond to treatment"]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":["less likely to adhere to nicotine replacement therapy","consume less NRT at 7 days post quit attempt","more likely to adhere to NRT","consume more NRT at 7 days post quit attempt"]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs114558780 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":["reduced response in men","increased response in women"]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":["increased risk of experiencing sedation"]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism","similar metabolism","increased metabolism"]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":["decreased glucuronidation of carvedilol"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["decreased atorvastatin lactonization"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":["decreased response","increased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":["increased risk of drug-induced rash"]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":["unknown response"]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":["increased plasma drug concentration"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":["increased metabolism of losartan"]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":["increased likelihood of toxicity"]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":["decreased risk of developing phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":["similar response to ondansetron","decreased response to ondansetron","no recommendation for CYP2D6 intermediate and poor metabolizers"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response and an increased likelihood of remission"]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["metabolism of codeine"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":["increased risk of developing psychosis"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":["No information available"]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":["increased risk of severe cutaneous adverse reactions"]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":["increased sensitivity"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":["increased risk of developing alopecia"]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":["decreased metabolism of cyclophosphamide","decreased risk of gastrointestinal toxicity","decreased risk of leukopenia"]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.","phenotypeText":["increased risk for anemia"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*36 allele may have a decreased enzyme activity of CYP2D6 as compared to patients with the CYP2D6*1 allele. The CYP2D6*16 allele was found to have a no enzymatic activity during in in-vitro characterization with bufuralol or dextromethorphan. Other genetic and clinical factors may also influence the metabolism of bufuralol or dextromethorphan.","phenotypeText":["decreased enzyme activity"]},{"genotypeAnnotationText":"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":["increased lipid-lowering response"]},{"genotypeAnnotationText":"Patients with the GG (i.e. UGT1A1 *1\/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6\/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.","phenotypeText":["decreased risk of occurrence of breast cancer"]},{"genotypeAnnotationText":"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":["decreased metabolism of venlafaxine","similar metabolism of venlafaxine","increased metabolism of venlafaxine"]},{"genotypeAnnotationText":"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*97 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.","phenotypeText":["decreased likelihood of dose delay"]},{"genotypeAnnotationText":"The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients carrying SLCO1B1*1 allele in combination with another normal function allele may have a lower risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B (reference)\/ B (reference) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (homozygous or heterozygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","phenotypeText":["longer disease-free survival","shorter disease-free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*4 allele in combination with another no function allele may have increased concentrations of methylphenidate and atomoxetine as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methylphenidate and atomoxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methylphenidate and atomoxetine.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha\/ribavirin as compared to people with with TT\/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha\/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha\/ribavirin-based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of propafenone as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and propafenone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence propafenone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *4 allele in combination with a normal function or a decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients who are recipients of an organ transplant and one copy of the *20 allele in combination with the *1 allele may require a decreased dose of tacrolimus as compared to patients with two copies of the CYP3A4*1 allele. Other genetic and clinical factors may also influence tacrolimus dose.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function alleles by CPIC. Patients carrying the *5 allele in combination with a normal, decreased or no function allele may have decreased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of paroxetine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of paroxetine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for paroxetine and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and paroxetine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence paroxetine metabolism.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*52 allele or one copy of the *52 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*1\/*1 genotype may have an increased metabolism of dextromethorphan (probe drug) as compared to patients with the CYP2D6*40\/*42 or *3\/*4XN or *4XN\/*56 genotype. Other genetic and clinical factors may also influence the metabolism of dextromethorphan.","phenotypeText":["increased metabolism of dextromethorphan"]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.","phenotypeText":["decreased severity of anemia"]},{"genotypeAnnotationText":"Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *2\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds a poorer response to tamoxifen in patients with the *2\/*2 genotype as compared to those with the *1\/*1 or *1\/*2 genotype. One study finds no significant association with response. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.","phenotypeText":["better response"]},{"genotypeAnnotationText":"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *4\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*24 allele may have decreased clearance of codeine or increased clearance of dextromethorphan or similar clearance of n-desmethyltamoxifen as compared to patients with the CYP2D6*1 allele. Other genetic and clinical factors may also influence the metabolism of codeine or dextromethorphan or n-desmethyltamoxifen.","phenotypeText":["decreased clearance of codeine"]},{"genotypeAnnotationText":"The CYP2D6*9 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients carrying the CYP2D6*9 allele in combination with a no or decreased function allele may have decreased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*9 allele in combination with an increased function allele may have increased metabolism of doxepin as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and doxepin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of doxepin.","phenotypeText":["decreased metabolism","increased metabolism"]},{"genotypeAnnotationText":"The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are undergoing kidney transplantation may have a decreased risk for kidney dysfunction as compared to patients with the *1\/*3 and *3\/*3 genotypes. However, one study found that those with the *1\/*1 variant had decreased estimated glomerular filtration rate, or poorer kidney function, as compared to those with the *1\/*3 or *3\/*3 genotypes. Other genetic and clinical factors may also influence kidney dysfunction.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*29\/*29 genotype may have a decreased metabolism of dextromethorphan or debrisoquine compared to patients with the *1\/*1 or *1\/*29 genotype. However the findings for debrisoquine or not consistent. Other genetic and clinical factors may also influence the metabolism of dextromethorphan or debrisoquine.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have decreased concentrations of methadone as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and methadone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with Alzheimer Disease and the *6\/*1XN diplotype (homozygous extensive metabolizers) may have increased clearance of donepezil as compared to patients who are poor metabolizers (*4\/*4, *4\/*5) or may have decreased clearance as compared to patients who are ultrarapid metabolizers (*1\/*1xN, *1XN\/*1XN). Other genetic and clinical factors may also influence donepezil clearance.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["reduced response to metoprolol"]},{"genotypeAnnotationText":"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and ER and\/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN\/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*4 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2B6*4 allele in combination with a normal function allele or another increased function allele may have increased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the B\/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*88 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a no function allele may have decreased metabolism of atomoxetine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence metabolism of atomoxetine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and atomoxetine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*10 allele in combination with another decreased function allele with an activity value of 0.25 may have decreased metabolism of carvedilol as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*6 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *2xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *2xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *10 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *6 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *6 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *7 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note that the *7 allele has only been assessed for this association in combination with other loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.","phenotypeText":[]},{"genotypeAnnotationText":"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one X-chromosome and the A- 202A_376G allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with another deficient class I-III allele who are treated with rasburicase may have an increased risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Patients with two X-chromosomes and the A- 202A_376G allele in combination with a non-deficient allele who are treated with rasburicase have an unknown risk of methemoglobinemia and\/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3\/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1\/*1 and *1\/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.","phenotypeText":["increased risk of experiencing adverse events"]},{"genotypeAnnotationText":"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["increased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.","phenotypeText":["lower chance of eradication failure"]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*24 allele may have decreased enzyme activity of CYP2C19 as compared to patients with the CYP2C19*24 allele. The CYP2C19*24 allele was catalytic inactive toward mephenytoin during in-vitro characterization. No activity for *24 was reported. Other genetic and clinical factors may also influence the metabolism of mephenytoin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2xN alleles (*2x2 and *2x\u22653) are assigned as increased function alleles by CPIC. Patients carrying the *2xN allele in combination with a normal or increased function allele or a decreased function allele with an activity value of 0.5 may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 3 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may also have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *2xN allele with an activity value of 2 in combination with a decreased function allele with an activity value of 0.25 or a no function allele may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.","phenotypeText":["better response and increased likelihood of remission"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and ER and\/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and\/or PR positive breast cancer when exposed to exemestane or anastrazole.","phenotypeText":["increased risk of bone fractures"]},{"genotypeAnnotationText":"The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR short form (S allele)\/HTTLPR short form (S allele) genotype who are treated with sertraline may have increased response as compared to patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Crohn's disease and the TPMT *1\/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1\/*3A or *1\/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10x2 allele is assigned as a decreased function allele with an activity value of 0.5 by CPIC. Patients with breast cancer and carrying the CYP2D6*10x2 allele in combination with a no or decreased function allele may have increased likelihood of recurrence and lower event-free and recurrence-free survival when treated with tamoxifen in an adjuvant setting as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Be aware that the DPWG guideline for tamoxifen and CYP2D6 has a 'no recommendation' for CYP2D6 ultrarapid metabolizers. Other genetic and clinical factors may also influence response to tamoxifen treatment.","phenotypeText":["increased likelihood of recurrence and lower event-free and recurrence-free survival"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased metabolism of oxycodone as compared to patients carrying two normal function alleles or two no function alleles. This annotation only covers the pharmacokinetic relationship between CYP2D6 and oxycodone and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC and DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect oxycodone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased\/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.","phenotypeText":[]},{"genotypeAnnotationText":"The TPMT*4 allele is assigned as a no function allele by CPIC. Patients with the *4 allele, in combination with a normal function allele or a no function allele, may have an increased likelihood of toxicity when treated with mercaptopurine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele may have decreased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of nortriptyline as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of nortriptyline as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and nortriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nortriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients carrying a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C19 and methadone and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of risperidone as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for risperidone and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence risperidone metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.","phenotypeText":["improvement in symptoms"]},{"genotypeAnnotationText":"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *7 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*1xN alleles (*1x2 and *1x\u22653) are assigned as increased function alleles by CPIC. Patients carrying a *1xN allele with an activity value of 3 or greater in combination with a normal, increased, decreased or no function allele may have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying a *1xN allele with an activity value of 2 in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5 may also have an increased risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying a *1xN allele with an activity value of 2 in combination with a no function allele or a decreased function allele with an activity value of 0.25 may have a similar risk of toxicity when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*51 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *1 allele in combination with another normal function allele may have decreased exposure to dabigatran as compared to patients with at least one no function allele. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2A6*1 allele may have increased metabolism of tegafur as compared to patients with one copy of the *1 allele in combination with one copy of the *4, *7, *9 or *10 alleles, patients with two copies of the *4, *9, *11, *18 or *19 alleles, patients with one copy of the *7 allele in combination with one copy of the *4 or *10 alleles, patients with one copy of the *4 allele in combination with one copy of the *11 allele, or patients with one copy of the *9 allele in combination with one copy of the *4 or *7 alleles. Patients with two copies of the *1 may also have decreased metabolism of tegafur as compared to patients with two copies of the *46 allele or patients with one copy of the *46 allele in combination with one copy of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2A6 and tegafur and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tegafur metabolism.","phenotypeText":["increased metabolism","decreased metabolism","conflicting evidence"]},{"genotypeAnnotationText":"Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with schizophrenia who carry the *14 allele may have an increased risk for tardive dyskinesia or parkinsonism when treated with antipsychotics as compared to patients with the *1\/*1 genotype. Note, that the *14 allele has only been assessed for this association in combination with loss-of-function alleles (e.g. *3, *4, *5). Additionally, some studies find no association between loss-of-function alleles and risk for tardive dyskinesia, parkinsonism, or other dystonic disorders. Other genetic and clinical factors may also influence antipsychotic-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.","phenotypeText":["more likely to respond"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased clearance of amitriptyline as compared to patients with the CYP2D6*1 allele. The CYP2D6*93 allele was found to have significantly decreased intrinsic clearance during in-vitro characterization with amitriptyline. This annotation only covers the pharmacokinetic relationship between CYP2D6 and amitriptyline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of amitriptyline.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.","phenotypeText":["decreased risk of developing cocaine dependence"]},{"genotypeAnnotationText":"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of haloperidol as compared to patients with alleles that result in a normal metabolizer phenotype. Be aware that the DPWG guideline for haloperidol and CYP2D6 has a 'no recommendation' for intermediate metabolizers. This annotation only covers the pharmacokinetic relationship between CYP2D6 and haloperidol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence haloperidol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased risk of toxicity when treated with codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased risk of toxicity when treated with codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but a similar risk of toxicity when treated with codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence risk of codeine toxicity.","phenotypeText":["decreased risk of toxicity"]},{"genotypeAnnotationText":"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha\/ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*2 allele is assigned as a normal function allele by CPIC. Patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar response to ondansetron as compared to patients with two decreased or no function alleles or a no function allele in combination with a normal or decreased function allele, while patients carrying the *2 allele in combination with alleles that result in a normal metabolizer phenotype may have a deceased response to ondansetron as compared to patients with two increased function alleles or an increased function allele in combination with a normal function allele or a deceased function allele with an activity value of 0.5 or patients with an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. Be aware that the CPIC guideline for ondansetron and CYP2D6 has a 'no recommendation' for CYP2D6 intermediate and poor metabolizers. Other genetic and clinical factors may also influence response to ondansetron.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*15:02-HLA-DQB1*05:02 haplotype who are treated with allopurinol may have an increased risk of severe cutaneous adverse reactions as compared to patients without this haplotype. Other genetic and clinical factors may also influence a patient's risk of acetaminophen-induced adverse reactions.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 or 2R\/2R genotype may have an increased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/3R or 3R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*16 allele (formerly *5A, *5D) in combination with any other allele may have decreased metabolism of dipyrone as compared to patients with the *4\/*4 genotype. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and dipyrone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence dipyrone metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA (i.e. UGT1A1 *6\/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1\/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have increased metabolism of carvedilol as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and carvedilol and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence carvedilol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with another normal function allele may be at a decreased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying a normal function allele in combination with a no function allele or a decreased function allele with an activity value of 0.25. Patients carrying the CYP2D6*1 allele in combination with a no function allele or a decreased function allele with an activity value of 0.25 may be at an increased risk of experiencing adverse events when treated with gefitinib as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with gefitinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs45445694 (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3\/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 or 3R\/3R genotype may have a decreased response or survival when treated with fluorouracil chemotherapy regimens as compared to patients with the 2R\/2R or 2R\/3R genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.","phenotypeText":["increased prolactin serum concentration","decreased prolactin serum concentration"]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)9 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-na\u00efve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir\/pegintron therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*93 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the *41 allele in combination with a no function or another decreased function allele may have an increased risk of experiencing sedation when treated with postoperative tramadol and ketoprofen as compared to patients with two normal function alleles or a normal function and a decreased function allele. Other genetic and clinical factors may also affect a patient's risk of sedation when treated with tramadol and ketoprofen.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.","phenotypeText":["less likely to respond"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of sertraline as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and sertraline and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of sertraline.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis.","phenotypeText":["reduced risk of requiring a blood transfusion"]},{"genotypeAnnotationText":"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.","phenotypeText":["decreased clearance of metformin"]},{"genotypeAnnotationText":"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":["poorer response to treatment"]},{"genotypeAnnotationText":"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.","phenotypeText":["increased likelihood of remission"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*47 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the del\/del genotype and the 3\/3 genotype at rs45445694 who are treated with methotrexate may have a better response to treatment as compared to patients with the TTAAAGTTA\/TTAAAGTTA OR TTAAAGTTA\/del genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*6 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2B6*6 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of efavirenz as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between CYP2B6 and efavirenz and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with with a decreased, normal or no function allele may have decreased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *4 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of tramadol as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tramadol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *6 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency) who are treated with sulfasalazine may have an increased risk of hemolysis as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *10 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *10 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*4 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*36 allele has been assigned as a no function allele by CPIC. Patients carrying the *36 allele in combination with a decreased, normal or no function allele may have decreased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *36 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *6 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of codeine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and codeine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence codeine metabolism.","phenotypeText":["decreased metabolism of codeine"]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*90 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.","phenotypeText":["decreased risk of phenytoin toxicity"]},{"genotypeAnnotationText":"Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.","phenotypeText":[]},{"genotypeAnnotationText":"Male patients hemizygous for the Mediterranean variant (associated with G6PD deficiency) who are treated with ciprofloxacin may have an increased risk of hemolytic anemia as compared to patients with the wildtype B haplotype (not associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6 *5 genotype who are CYP2C19*1\/*1 carriers and undergoing percutaneous coronary intervention may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CYP2B6 *1 genotype who are CYP2C19*1\/*1 carriers. Other genetic and clinical factors may also influence a patient's response to clopidogrel.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.","phenotypeText":["increased risk of developing diabetes"]},{"genotypeAnnotationText":"The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of citalopram as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and citalopram and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of citalopram.","phenotypeText":["decreased metabolism of citalopram"]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*54 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of voriconazole as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of voriconazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol.","phenotypeText":["smaller decreases in systolic or diastolic blood pressure"]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with sertraline may have decreased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings for either no association or opposite effect have been published for this genotype and response to sertraline. Other genetic and clinical factors may also influence a patient's response to sertraline.","phenotypeText":["decreased response"]},{"genotypeAnnotationText":"Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.","phenotypeText":[]},{"genotypeAnnotationText":"No information available.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, a decreased, or no function allele may have decreased metabolism of fluvastatin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.","phenotypeText":["increased risk for experiencing drug toxicity, particularly hand-foot syndrome"]},{"genotypeAnnotationText":"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*56 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*3 allele in combination with a UGT1A3*1 or a UGT1A3*3 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3\/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the NAT2*4 allele in combination with another *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *4 allele in combination with the *5, *6, *7, or *16 allele or patients with two of the *5, *6, *7, or *16 alleles. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":["increased metabolism of hydralazine"]},{"genotypeAnnotationText":"Patients with the *1\/*2 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*3 allele in combination with a no, decreased or normal function allele may have decreased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of clomipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D6*3 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of clomipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the non-null\/ null genotype (has one copy of the GSTM1 gene) and testicular cancer who are treated with a cisplatin-containing regimen may have an increased risk of hearing impairment as compared to patients with the null\/null genotype. No association was seen with ototoxicity in a separate study of children receiving cisplatin-based chemotherapy for cancer treatment. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying two copies of the NAT2*16 allele or one copy of *16 in combination with the *5, *6, or *7 allele may have decreased metabolism of hydralazine as compared to patients with the *4\/*4 genotype. Patients carrying the NAT2*16 allele in combination with the *4 allele may have increased metabolism of hydralazine as compared to patients carrying the *16 allele in combination with the *5, *6, *7, or *16 allele. This annotation only covers the pharmacokinetic relationship between NAT2 genotypes and hydralazine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence hydralazine metabolism. The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane.","phenotypeText":["less bone mineral loss"]},{"genotypeAnnotationText":"Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.","phenotypeText":["increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites"]},{"genotypeAnnotationText":"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":[]},{"genotypeAnnotationText":"Women with breast cancer and the CYP2C19 *1\/*2 genotype who are treated with tamoxifen may have decreased metabolism of tamoxifen, but an improved response to the drug as compared to those with the *1\/*1 genotype. One study finds an improved response to tamoxifen in patients with the *1\/*2 genotype as compared to those with the *2\/*2 genotype. Other genetic and clinical factors may also influence metabolism of and response to tamoxifen.","phenotypeText":["decreased metabolism of tamoxifen","improved response to the drug"]},{"genotypeAnnotationText":"The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *5 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and venlafaxine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence venlafaxine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D6*5 allele in combination with a no, decreased or normal function allele who are treated with nortriptyline may have an increased likelihood of treatment side effects as compared to patients with alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.","phenotypeText":["decreased severity of neutropenia"]},{"genotypeAnnotationText":"Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.","phenotypeText":["increased risk of experiencing drug toxicity"]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":["decreased likelihood of treatment failure"]},{"genotypeAnnotationText":"The CYP2D6*9 allele has been assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *9 allele in combination with a decreased or no function allele may have decreased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *9 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of metoprolol as compared to patients with alleles that result in a normal metabolizer phenotype. This annotation only covers the pharmacokinetic relationship between CYP2D6 and metoprolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metoprolol metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2B6*28 allele may result in decreased expression and enzymatic activity of CYP2B6 due to protein truncation, as compared to the CYP2B6*1 allele. A patient with the *6\/*28 genotype who was treated with efavirenz was noted to have had a dose reduction\/stoppage of therapy and experienced efavirenz toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.","phenotypeText":["increased risk of hypercholesteremia"]},{"genotypeAnnotationText":"Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.","phenotypeText":["decreased doses of methadone"]},{"genotypeAnnotationText":"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *1\/*1 genotype who are treated with sipoglitazar may have 1) a worse response (as measured by increased HbgA1c) and 2) increased clearance as compared to patients with the *2\/*2 genotype. Other genetic and clinical factors may also influence a patient's response to sipoglitazar treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *22 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine.","phenotypeText":["increased likelihood of adverse events"]},{"genotypeAnnotationText":"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.","phenotypeText":["better response to treatment with photodynamic therapy"]},{"genotypeAnnotationText":"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.","phenotypeText":["increased risk of nephrotoxicity"]},{"genotypeAnnotationText":"Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the SLC6A4 HTTLPR long form (L allele)\/HTTLPR long form (L allele) genotype who are treated with fluvoxamine may have increased response as compared to patients with the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype. However, contradictory findings exist reporting either no association of the genotype with fluvoxamine response or the opposite effect with an association of the SLC6A4 HTTLPR short form (S allele)\/SLC6A4 HTTLPR short form (S allele) genotype and increased response. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with one or two copies of the HLA-DRB1*04:03 allele may have an increased risk of oxcarbazepine-induced maculopapular eruption (MPE) as compared to patients with no HLA-DRB1*04:03 alleles or negative for the HLA-DRB1*04:03 test. Other genetic and clinical factors may also influence a patient's risk of oxcarbazepine-induced MPE.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2D6*89 allele may have decreased metabolism of risperidone as compared to patients with the CYP2D6*1 allele. Note that this allele has been assigned as an uncertain function allele by CPIC. This annotation only covers the pharmacokinetic relationship between CYP2D6 and risperidone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the metabolism of risperidone.","phenotypeText":[]},{"genotypeAnnotationText":"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.","phenotypeText":["increased concentrations of voriconazole"]},{"genotypeAnnotationText":"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*19 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.","phenotypeText":["increased risk of developing thiopurine-related cytopenia"]},{"genotypeAnnotationText":"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine.","phenotypeText":["increased response to fluvoxamine, milnacipran and paroxetine in people with major depression"]},{"genotypeAnnotationText":"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["increased metabolism of nicotine"]},{"genotypeAnnotationText":"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.","phenotypeText":["increased response","decreased response"]},{"genotypeAnnotationText":"The CYP2B6*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2B6*1 allele in combination with another normal function allele may have decreased risk of adverse events (eg. liver toxicity or CNS side effects) when treated with efavirenz as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of efavirenz.","phenotypeText":["decreased risk of adverse events (eg. liver toxicity or CNS side effects)"]},{"genotypeAnnotationText":"Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*36 allele may have a decreased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.","phenotypeText":[]},{"genotypeAnnotationText":"Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1\/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.","phenotypeText":["decreased severity of thrombocytopenia"]},{"genotypeAnnotationText":"Patients with the CYP2C8*1 allele in combination with another *1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.","phenotypeText":["increased response"]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*2 allele in combination with a normal or decreased function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the 10,10-repeat genotype(GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT\/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT) may have an increased response to disulfiram treatment for cocaine dependence. as compared to patients with the 9,9 or 9,10-repeat genotypes. Other genetic and clinical factors may also affect a patient's response to disulfiram.","phenotypeText":["increased response to disulfiram treatment for cocaine dependence"]},{"genotypeAnnotationText":"The rs267606619 C allele (also known as the 1494C allele) is assigned as a MT-RNR1 normal risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the C allele may have a decreased, but not absent, risk of experiencing hearing loss when treated with kanamycin as compared to patients with the 1494T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with kanamycin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*44 allele or one copy of the *44 allele in combination with a no function allele may have decreased metabolism of diclofenac as compared to individuals with two normal function alleles. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":["decreased metabolism of diclofenac"]},{"genotypeAnnotationText":"Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.","phenotypeText":[]},{"genotypeAnnotationText":"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.","phenotypeText":["better response to metoprolol"]},{"genotypeAnnotationText":"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying at least one copy of the *20 allele may have decreased clearance of fesoterodine as compared to patients with the *1\/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*40 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP3A5 *1\/*3 may have an increased metabolism of cilostazol as compared to patients with the CYP3A5 *3\/*3 diplotype and a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1\/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with two copies of the CYP2C9*1 allele may have increased metabolism of diclofenac as compared to individuals with a normal function allele combined with an uncertain, decreased or no function allele or two copies of an uncertain, decreased or no function allele. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*41 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.","phenotypeText":[]},{"genotypeAnnotationText":"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs368234815 G\/TT genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT\/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TTAAAGTTA\/TTAAAGTTA genotype who are treated with methotrexate may have a lower response to treatment as compared to patients with the TTAAAGTTA\/del or del\/del genotypes and the 3\/3 genotype at rs45445694. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.","phenotypeText":["decreased on-treatment platelet reactivity"]},{"genotypeAnnotationText":"Patients with the UGT1A3*1\/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2\/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism.","phenotypeText":["decreased atorvastatin lactonization"]},{"genotypeAnnotationText":"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":["increased risk for hepatotoxicity"]},{"genotypeAnnotationText":"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"The rs267606617 G allele (also known as the 1555G allele) is assigned as a MT-RNR1 increased risk of aminoglycoside-induced hearing loss allele by CPIC. Patients with the G allele may have an increased risk of experiencing hearing loss when treated with gentamicin as compared to patients with the A allele. However, conflicting evidence has been reported. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with gentamicin.","phenotypeText":["increased risk of aminoglycoside-induced hearing loss"]},{"genotypeAnnotationText":"Transplant recipients with the CC (CYP3A4 *1B\/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1\/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.","phenotypeText":["increased dose requirement"]},{"genotypeAnnotationText":"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*23 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.","phenotypeText":["increased risk of neutropenia"]},{"genotypeAnnotationText":"Patients with the *37\/*37 genotype may have decreased plasma level of olmesartan as compared to patients with SLCO1B1 *15\/*15 genotype. Other genetic and clinical factors may also influence the pharmacokinetics of olmesartan. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and olmesartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *2 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *2 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.","phenotypeText":[]},{"genotypeAnnotationText":"Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.","phenotypeText":[]},{"genotypeAnnotationText":"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2B6*6 allele in combination with a normal function, decreased function or a no function allele may have decreased metabolism of bupropion as compared to patients with any of the following allele combinations: two normal function alleles; one normal function allele in combination with an increased function allele; two increased function alleles. Other genetic and clinical factors may also affect bupropion metabolism. This annotation only covers the pharmacokinetic relationship between CYP2B6 and bupropion and does not include evidence about clinical outcomes.","phenotypeText":["decreased metabolism of bupropion"]},{"genotypeAnnotationText":"Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with epilepsy and the *3 allele in combination with another no function allele may have an increased response to clobazam as compared to patients with two normal function alleles or patients with a normal function allele in combination with a no function allele, while patients with the *3 allele in combination with a normal function allele may have an increased response as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's response to clobazam.","phenotypeText":[]},{"genotypeAnnotationText":"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.","phenotypeText":[]},{"genotypeAnnotationText":"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have a higher risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence the toxicity of simvastatin.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs28358571 C allele (also known as the 1189C allele) may have an increased risk of experiencing hearing loss when treated with streptomycin as compared to patients with the T allele. MT-RNR1 is a mitochondrial gene and is inherited as a haploid (i.e. there is only ever one allele present). Other genetic and clinical factors may also influence risk of hearing loss when treated with streptomycin.","phenotypeText":["increased risk of hearing loss"]},{"genotypeAnnotationText":"Patients with the TT (CYP2C9 *2\/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1\/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.","phenotypeText":["decreased metabolism of busulfan"]},{"genotypeAnnotationText":"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.","phenotypeText":[]},{"genotypeAnnotationText":"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.","phenotypeText":["decreased clearance of dicloxacillin"]},{"genotypeAnnotationText":"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a \u201cno recommendation\u201d by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2\/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CYP2C19*14 allele may have decreased enzyme activity of CYP2C19 and decreased clearance of clopidogrel in in-vitro characterization as compared to patients with the CYP2C19*1 allele. Other genetic and clinical factors may also influence the metabolism of clopidogrel. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clopidogrel and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*53 allele may have an increased rate of phenytoin clearance as compared to patients carrying the *1 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the (CCCACCCGA)10\/(CCCACCCGA)10 genotype and depression who are treated with paroxetine may be less likely to respond to treatment as compared to patients with the (CCCACCCGA)12\/(CCCACCCGA)12 genotype. However, a contradictory finding reports no association of the (CCCACCCGA)12 allele and response. Other genetic and clinical factors may also influence a patient's response to treatment.","phenotypeText":[]},{"genotypeAnnotationText":"The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of dexlansoprazole as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and dexlansoprazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of dexlansoprazole.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.","phenotypeText":["decreased metabolism of nicotine"]},{"genotypeAnnotationText":"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the CYP2C9*3 allele in combination with a normal or no function allele may require a decreased dose of phenprocoumon as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.","phenotypeText":["decreased dose requirement of phenprocoumon"]},{"genotypeAnnotationText":"There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.","phenotypeText":[]},{"genotypeAnnotationText":"Female patients with the Mediterranean\/B (reference) genotype (heterozygous for the G6PD Mediterranean variant) who are treated with ciprofloxacin may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolytic anemia as compared to patients with the Mediterranean\/Mediterranean or B\/B genotype. Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.","phenotypeText":[]},{"genotypeAnnotationText":"Patients carrying the UGT1A3*2 allele in combination with a UGT1A3*1 or a UGT1A3*2 allele may have decreased exposure of telmisartan as compared to patients with with two normal function alleles. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between UGT1A3 and telmisartan and does not include evidence about clinical outcomes.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a \u201cno recommendation\u201d by DPWG, as it was determined to be not clinically actionable.","phenotypeText":[]},{"genotypeAnnotationText":"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.","phenotypeText":[]},{"genotypeAnnotationText":"The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic and clinical factors may also influence the pharmacokinetics of pravastatin. This annotation only covers the pharmacokinetic relationship between SLCO1B1 and pravastatin and does not include evidence about clinical outcomes.","phenotypeText":["increased bioavailability of pravastatin"]},{"genotypeAnnotationText":"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate.","phenotypeText":[]}]
\ No newline at end of file